FN Thomson Reuters Web of Science™ VR 1.0 PT J AU Byrd, KK Mehal, JM Schillie, SF Holman, RC Haberling, D Murphy, T AF Byrd, Kathy K. Mehal, Jason M. Schillie, Sarah F. Holman, Robert C. Haberling, Dana Murphy, Trudy TI Chronic Liver Disease-Associated Hospitalizations Among Adults with Diabetes, National Inpatient Sample, 2001-2012 SO PUBLIC HEALTH REPORTS LA English DT Article ID HEPATITIS-C VIRUS; UNITED-STATES; HEPATOCELLULAR-CARCINOMA; HIGH PREVALENCE; MELLITUS; INFECTION; RISK; CIRRHOSIS; METAANALYSIS; INCREASES AB Objective. Many people with diabetes have a variety of diabetes-related complications. Among the variety of conditions associated with diabetes, however, liver diseases are less well recognized. As such, we aimed to describe chronic liver disease (CLD)-associated hospitalization rates among U.S. adults with diabetes from 2001-2012. Methods. We used a nationally representative database of hospitalizations, the National Inpatient Sample, to determine CLD-associated hospitalization rates among U.S. adults aged >= 18 years with and without diabetes, from 2001-2012. Hospitalizations listing an International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) code for CLD on the discharge record were selected for analysis and were further classified by diabetes status based on concurrent presence of a diabetes ICD-9-CM code. We calculated average annual age-adjusted hospitalization rates and 95% confidence intervals (Cis), and conducted a test for trend. Results. For 2001-2012, the total age-adjusted CLD-associated hospitalization rate among adults with diabetes (1,680.9 per 100,000 population; 95% CI 1,577.2, 1,784.6) was approximately four times the rate of adults without diabetes (424.2 per 100,000 population; 95% CI 413.4, 435.1). Total age-adjusted hospitalization rates of adults with and without diabetes increased 59% and 48%, respectively, from 2001-2002 to 2011-2012 (p<0.001). Hepatitis C- and chronic hepatitis and cirrhosis-associated hospitalizations comprised the largest proportion of total CLD-associated hospitalizations among adults with and without diabetes. Conclusion. Providers should be aware of the potential existence of CLD among adults with diabetes and counsel patients on preventive methods to avoid progressive liver damage. C1 [Byrd, Kathy K.; Schillie, Sarah F.; Murphy, Trudy] Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA 30333 USA. [Mehal, Jason M.; Holman, Robert C.; Haberling, Dana] Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Atlanta, GA 30333 USA. RP Byrd, KK (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, 1600 Clifton Rd NE,MS E-45, Atlanta, GA 30333 USA. EM gdn8@cdc.gov NR 39 TC 0 Z9 0 U1 1 U2 1 PU ASSOC SCHOOLS PUBLIC HEALTH PI WASHINGTON PA 1900 M ST NW, STE 710, WASHINGTON, DC 20036 USA SN 0033-3549 J9 PUBLIC HEALTH REP JI Public Health Rep. PD NOV-DEC PY 2015 VL 130 IS 6 BP 693 EP 703 PG 11 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CV8CI UT WOS:000364503700018 PM 26556941 ER PT J AU Mai, CT Correa, A Kirby, RS Rosenberg, D Petros, M Fagen, MC AF Mai, Cara T. Correa, Adolfo Kirby, Russell S. Rosenberg, Deborah Petros, Michael Fagen, Michael C. TI Assessing the Practices of Population-Based Birth Defects Surveillance Programs Using the CDC Strategic Framework, 2012 SO PUBLIC HEALTH REPORTS LA English DT Article AB Objective. We assessed the practices of U.S. population-based birth defects surveillance programs in addressing current and emergent public health needs. Methods. Using the CDC Strategic Framework considerations for public health surveillance (i.e., lexicon and standards, legal authority, technological advances, workforce, and analytic capacity), during 2012 and 2013, we conducted a survey of all U.S. operational birth defects programs (n=43) soliciting information on legal authorities, case definition and clinical information collected, types of data sources, and workforce staffing. In addition, we conducted semi-structured interviews with nine program directors to further understand how programs are addressing current and emergent needs. Results. Three-quarters of birth defects surveillance programs used national guidelines for case definition. Most birth defects surveillance programs (86%) had a legislative mandate to conduct surveillance, and many relied on a range of prenatal, postnatal, public health, and pediatric data sources for case ascertainment. Programs reported that the transition from paper to electronic formats was altering the information collected, offering an opportunity for remote access to improve timeliness for case review and verification. Programs also reported the growth of pooled, multistate data collaborations as a positive development. Needs identified included ongoing workforce development to improve information technology and analytic skills, more emphasis on data utility and birth defects-specific standards for health information exchange, and support to develop channels for sharing ideas on data interpretation and dissemination. Conclusion. The CDC Strategic Framework provided a useful tool to determine the birth defects surveillance areas with positive developments, such as multistate collaborative epidemiologic studies, and areas for improvement, such as preparation for health information exchanges and workforce database and analytic skills. Our findings may inform strategic deliberations for enhancing the effectiveness of birth defects surveillance programs. C1 [Mai, Cara T.] Ctr Dis Control & Prevent, Div Birth Defects & Dev Disabil, Atlanta, GA 30345 USA. [Correa, Adolfo] Univ Mississippi, Med Ctr, Jackson, MS 39216 USA. [Kirby, Russell S.] Univ S Florida, Coll Publ Hlth, Tampa, FL USA. [Rosenberg, Deborah; Petros, Michael] Univ Illinois, Sch Publ Hlth, Chicago, IL USA. [Fagen, Michael C.] Northwestern Univ, Inst Publ Hlth & Med, Feinberg Sch Med, Chicago, IL 60611 USA. RP Mai, CT (reprint author), Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, 4770 Buford Hwy,MS E-86, Atlanta, GA 30345 USA. EM cmai@cdc.gov NR 16 TC 2 Z9 2 U1 0 U2 1 PU ASSOC SCHOOLS PUBLIC HEALTH PI WASHINGTON PA 1900 M ST NW, STE 710, WASHINGTON, DC 20036 USA SN 0033-3549 J9 PUBLIC HEALTH REP JI Public Health Rep. PD NOV-DEC PY 2015 VL 130 IS 6 BP 722 EP 730 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CV8CI UT WOS:000364503700020 PM 26556943 ER PT J AU Morshed, MG Lee, MK Man, S Fernando, K Wong, Q Hojgaard, A Tang, P Mak, S Henry, B Patrick, DM AF Morshed, Muhammad G. Lee, Min-Kuang Man, Stephanie Fernando, Keerthi Wong, Quantine Hojgaard, Andrias Tang, Patrick Mak, Sunny Henry, Bonnie Patrick, David M. TI Surveillance for Borrelia burgdorferi in Ixodes Ticks and Small Rodents in British Columbia SO VECTOR-BORNE AND ZOONOTIC DISEASES LA English DT Article DE Lyme disease; Surveillance; Ticks; Mice; Borrelia burgdorferi; PCR ID LYME-DISEASE; INFECTION; CANADA AB To determine the prevalence of Borrelia burgdorferi in British Columbian ticks, fieldwork was conducted over a 2-year period. In all, 893 ticks (Ixodes pacificus, I. angustus, I. soricis, Ixodes spp., and Dermacentor andersoni) of different life stages were retrieved from 483 small rodents (Peromyscus maniculatus, Perognathus parvus, and Reithrodontomys megalotis). B. burgdorferi DNA was detected in 5 out of 359 tick pools, and 41 out of 483 mice were serologically confirmed to have antibodies against B. burgdorferi. These results were consistent with previous studies, data from passive surveillance in British Columbia, and data from neighboring states in the Pacific Northwest, suggesting a continually low prevalence of B. burgdorferi in British Columbia ticks. C1 [Morshed, Muhammad G.; Lee, Min-Kuang; Man, Stephanie; Fernando, Keerthi; Wong, Quantine; Tang, Patrick] British Columbia Publ Hlth Microbiol & Reference, Vancouver, BC, Canada. [Morshed, Muhammad G.; Tang, Patrick; Henry, Bonnie; Patrick, David M.] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada. [Hojgaard, Andrias] Ctr Dis Control & Prevent, Ft Collins, CO USA. [Mak, Sunny; Patrick, David M.] British Columbia Ctr Dis Control, Vancouver, BC, Canada. [Henry, Bonnie] British Columbia Minist Hlth, Victoria, BC, Canada. RP Morshed, MG (reprint author), Prov Hlth Serv Author, BC Publ Hlth Microbiol & Reference Lab, Zoonot Dis & Emerging Pathogens, 655 West 12th Ave, Vancouver, BC V5Z 4R4, Canada. EM muhammad.morshed@bccdc.ca FU British Columbia Centre for Disease Control Foundation FX The British Columbia Centre for Disease Control Foundation provided funding for this research. Acknowledgments are due to the co-op students (Kristoffer Nyquist Jensen, Brian Kahnamelli, Derek Tam, and Tanya Dhanoa) who worked in the field and laboratory for this study. The authors also like to thank Dr. Robbin Lindsay and Dr. Nick Ogden for their suggestions to standardize field sampling methodology. NR 10 TC 1 Z9 1 U1 2 U2 10 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1530-3667 EI 1557-7759 J9 VECTOR-BORNE ZOONOT JI Vector-Borne Zoonotic Dis. PD NOV 1 PY 2015 VL 15 IS 11 BP 701 EP 705 DI 10.1089/vbz.2015.1854 PG 5 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA CV8NL UT WOS:000364544700010 PM 26502354 ER PT J AU France, AM Grant, J Kammerer, JS Navin, TR AF France, Anne Marie Grant, Juliana Kammerer, J. Steve Navin, Thomas R. TI A Field-Validated Approach Using Surveillance and Genotyping Data to Estimate Tuberculosis Attributable to Recent Transmission in the United States SO AMERICAN JOURNAL OF EPIDEMIOLOGY LA English DT Article DE disease transmission; genotyping; molecular epidemiology; recent transmission; tuberculosis ID MYCOBACTERIUM-TUBERCULOSIS; MOLECULAR EPIDEMIOLOGY; PLEURAL TUBERCULOSIS; POPULATION AB Tuberculosis genotyping data are frequently used to estimate the proportion of tuberculosis cases in a population that are attributable to recent transmission (RT). Multiple factors influence genotype-based estimates of RT and limit the comparison of estimates over time and across geographic units. Additionally, methods used for these estimates have not been validated against field-based epidemiologic assessments of RT. Here we describe a novel genotype-based approach to estimation of RT based on the identification of plausible-source cases, which facilitates systematic comparisons over time and across geographic areas. We compared this and other genotype-based RT estimation approaches with the gold standard of field-based assessment of RT based on epidemiologic investigation in Arkansas, Maryland, and Massachusetts during 1996-2000. We calculated the sensitivity and specificity of each approach for epidemiologic evidence of RT and calculated the accuracy of each approach across a range of hypothetical RT prevalence rates plausible for the United States. The sensitivity, specificity, and accuracy of genotype-based RT estimates varied by approach. At an RT prevalence of 10%, accuracy ranged from 88.5% for state-based clustering to 94.4% with our novel approach. Our novel, field-validated approach allows for systematic assessments over time and across public health jurisdictions of varying geographic size, with an established level of accuracy. C1 [France, Anne Marie; Grant, Juliana; Kammerer, J. Steve; Navin, Thomas R.] Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA 30329 USA. RP France, AM (reprint author), Ctr Dis Control & Prevent, Div TB Eliminat, 1600 Clifton Rd NE,Mail Stop E-10, Atlanta, GA 30329 USA. EM afrance@cdc.gov NR 41 TC 3 Z9 3 U1 1 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0002-9262 EI 1476-6256 J9 AM J EPIDEMIOL JI Am. J. Epidemiol. PD NOV 1 PY 2015 VL 182 IS 9 BP 799 EP 807 DI 10.1093/aje/kwv121 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CV0IX UT WOS:000363935500012 PM 26464470 ER PT J AU Zytnick, D Park, S Onufrak, SJ Kingsley, BS Sherry, B AF Zytnick, Deena Park, Sohyun Onufrak, Stephen J. Kingsley, Beverly S. Sherry, Bettylou TI Knowledge of Sugar Content of Sports Drinks Is Not Associated With Sports Drink Consumption SO AMERICAN JOURNAL OF HEALTH PROMOTION LA English DT Article DE Sugar; Knowledge; Sports Drinks; Sugar-Sweetened Beverage; Consumption; Prevention Research ID SWEETENED BEVERAGES; UNITED-STATES; WEIGHT-GAIN; ENERGY; QUESTIONNAIRE; TELEVISION; BEHAVIORS; OBESITY; ADULTS; HEALTH AB Purpose. To examine U.S. adult knowledge of the sugar content of sports drinks and whether this knowledge and other characteristics are associated with their sports drink consumption. Design. Nonexperimental. Setting. Nationally representative 2011 Summer ConsumerStyles survey data. Subjects. 3929 US. adults. Measures. The outcome variable was sports drink consumption in the past 7 days. The main exposure variable was knowledge about sports drinks containing sugar The covariates were sociodemographic characteristics, physical activity, and weight status. Analysis. Multivariable logistic regression analysis was used to estimate adjusted odds ratios (ORs) for adults consuming sports drinks >= 1 times/wk after controlling for other characteristics. Results. Approximately 22% of adults reported consuming sports drinks >= 1 times/wk. Most adults (71%) agreed that sports drinks contain sugar; however, this agreement was not significantly associated with adults' sports drink consumption. The odds of drinking sports drinks >= 1 times/wk were significantly higher among younger adults aged 18 to 64 years (OR range: 5.46-2.71), males (OR = 2.09), high-school graduates (OR = 1.52), and highly active adults (OR = 2.09). Conclusion. There were disparities in sports drink consumption by sociodemographic characteristics and physical activity level; however, knowledge of sports drinks' sugar content was not associated with consumption. Understanding why some population groups are higher consumers may assist in the development of education, providing those groups with a better understanding of sports drinks' nutritional value and health consequences of excessive sugar consumption in any farm. C1 [Zytnick, Deena; Park, Sohyun; Onufrak, Stephen J.; Kingsley, Beverly S.; Sherry, Bettylou] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Natl Ctr Chron Dis Prevent & Hlth Promot, CDC, Atlanta, GA 30341 USA. [Park, Sohyun; Onufrak, Stephen J.; Kingsley, Beverly S.; Sherry, Bettylou] CDC, Atlanta, GA 30333 USA. RP Onufrak, SJ (reprint author), Ctr Dis Control & Prevent, 4770 Buford Hwy NE,Mail Stop F77, Atlanta, GA 30341 USA. EM seo5@cdc.gov NR 33 TC 0 Z9 0 U1 0 U2 6 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0890-1171 EI 2168-6602 J9 AM J HEALTH PROMOT JI Am. J. Health Promot. PD NOV-DEC PY 2015 VL 30 IS 2 BP 101 EP 108 DI 10.4278/ajhp.130916-QUAN-479 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CV0AM UT WOS:000363909000007 PM 25372240 ER PT J AU Tuot, DS Lin, F Shlipak, MG Grubbs, V Hsu, CY Yee, J Shahinian, V Saran, R Saydah, S Williams, DE Powe, NR AF Tuot, Delphine S. Lin, Feng Shlipak, Michael G. Grubbs, Vanessa Hsu, Chi-yuan Yee, Jerry Shahinian, Vahakn Saran, Rajiv Saydah, Sharon Williams, Desmond E. Powe, Neil R. CA CDC CKD Surveillance Team TI Potential Impact of Prescribing Metformin According to eGFR Rather Than Serum Creatinine SO DIABETES CARE LA English DT Article ID GLOMERULAR-FILTRATION-RATE; CHRONIC KIDNEY-DISEASE; TYPE-2 DIABETIC-PATIENTS; RENAL-DISEASE; COCKCROFT-GAULT; ETHNIC-DIFFERENCES; UNITED-STATES; CYSTATIN C; DIET; EQUATION AB OBJECTIVE Many societies recommend using estimated glomerular filtration rate (eGFR) rather than serum creatinine (sCr) to determine metformin eligibility. We examined the potential impact of these recommendations on metformin eligibility among U.S. adults. RESEARCH DESIGN AND METHODS Metformin eligibility was assessed among 3,902 adults with diabetes who participated in the 1999-2010 National Health and Nutrition Examination Surveys and reported routine access to health care, using conventional sCr thresholds (eligible if <1.4 mg/dL for women and <1.5 mg/dL for men) and eGFR categories: likely safe, >= 45 mL/min/1.73 m(2); contraindicated, <30 mL/min/1.73 m(2); and indeterminate, 30-44 mL/min/1.73 m(2)). Different eGFR equations were used: four-variable MDRD, Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine (CKD-EPIcr), and CKD-EPI cystatin C, as well as Cockcroft-Gault (CG) to estimate creatinine clearance (CrCl). Diabetes was defined by self-report or A1C >= 6.5% (48 mmol/mol). We used logistic regression to identify populations for whom metformin was likely safe adjusted for age, race/ethnicity, and sex. Results were weighted to the U.S. adult population. RESULTS Among adults with sCr above conventional cutoffs, MDRD eGFR mL/min/1.73 m(2) was most common among men (adjusted odds ratio [aOR] 33.3 [95% Cl 7.4-151.5] vs. women) and non-Hispanic Blacks (aOR vs. whites 14.8 [4.27-51.7]). No individuals with sCr below conventional cutoffs had an MDRD eGFR <30 mL/min/1.73 m(2). All estimating equations expanded the population of individuals for whom metformin is likely safe, ranging from 86,900 (CKD-EPIcr) to 834,800 (CG). All equations identified larger populations with eGFR 30-44 mL/min/1.73 m(2), for whom metformin safety is indeterminate, ranging from 784,700 (CKD-EPIcr) to 1,636,000 (CG). CONCLUSIONS The use of eGFR or CrCI to determine metformin eligibility instead of sCr can expand the adult population with diabetes for whom metformin is likely safe, particularly among non-Hispanic blacks and men. C1 [Tuot, Delphine S.; Grubbs, Vanessa; Hsu, Chi-yuan] Univ Calif San Francisco, Div Nephrol, San Francisco, CA 94143 USA. [Tuot, Delphine S.; Grubbs, Vanessa; Powe, Neil R.] San Francisco Gen Hosp, Ctr Vulnerable Populat, San Francisco, CA 94110 USA. [Lin, Feng] Univ Calif San Francisco, Dept Biostat, San Francisco, CA 94143 USA. [Shlipak, Michael G.; Powe, Neil R.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Yee, Jerry] Henry Ford Hosp, Div Nephrol & Hypertens, Detroit, MI 48202 USA. [Shahinian, Vahakn; Saran, Rajiv] Univ Michigan, Dept Med, Div Nephrol, Ann Arbor, MI 48109 USA. [Saydah, Sharon; Williams, Desmond E.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Tuot, DS (reprint author), Univ Calif San Francisco, Div Nephrol, San Francisco, CA 94143 USA. EM delphine.tuot@ucsf.edu FU Centers for Disease Control and Prevention [U58 DP003839]; National Institute of Diabetes and Digestive and Kidney Diseases [K23-DK-094850]; National Center for Advancing Translational Sciences at the National Institutes of Health (UCSF-CTSI) [UL1TR000004] FX This project was supported by Centers for Disease Control and Prevention grant U58 DP003839. Dr. Tuot is supported by National Institute of Diabetes and Digestive and Kidney Diseases grant K23-DK-094850 as well as the National Center for Advancing Translational Sciences at the National Institutes of Health (UCSF-CTSI grant UL1TR000004). NR 47 TC 6 Z9 6 U1 0 U2 1 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 EI 1935-5548 J9 DIABETES CARE JI Diabetes Care PD NOV PY 2015 VL 38 IS 11 BP 2059 EP 2067 DI 10.2337/dc15-0542 PG 9 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA CV5WQ UT WOS:000364342500024 PM 26307607 ER PT J AU Harris, KI AF Harris, Kathleen I. TI The Unexpected Journey Shared by Families: Using Literature to Support and Understand Families Raising a Child with Disabilities SO EARLY CHILDHOOD EDUCATION JOURNAL LA English DT Article DE Teacher educators; Families; Children with disabilities; Literature; Attitudes; Teaching strategies ID SPECIAL-EDUCATION; ATTITUDES; TEACHERS; INCLUSION; PEOPLE; IDEAS; SELF AB In today's global society, it is important for future teacher educators to identify and apply different types of dispositions, attitudes, and skills in order to provide full participation and support to all types of families. Partnerships with families having a child with a disability calls for teacher educators of the general and special education professions to collaborate and to provide a meaningful, engaging environment for children with and without disabilities. As a result, teacher educators must be committed to teaching all children and supporting all families with equal respect, care, and dignity, regardless of the child's ability level. This article addresses how using literature can be a teaching strategy for understanding and supporting families with children with disabilities. The article summarizes future teacher educators' attitudes and perceptions of working with families with children with disabilities after reading a book written by a parent raising a child with a disability. By investigating specific disabilities and reflecting about the personal story each family shares through literature selections, teacher educators may develop and nurture the dispositions to teach with passion, appreciate individual differences, and empower families raising children with disabilities to reach their full potential. C1 Seton Hill Univ, CDC, Greensburg, PA 15601 USA. RP Harris, KI (reprint author), Seton Hill Univ, CDC, One Seton Hill Dr, Greensburg, PA 15601 USA. EM kihaurora@hotmail.com NR 56 TC 0 Z9 0 U1 1 U2 2 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 1082-3301 EI 1573-1707 J9 EARLY CHILD EDUC J JI Early Child. Educ. J. PD NOV PY 2015 VL 43 IS 6 BP 473 EP 484 DI 10.1007/s10643-014-0682-1 PG 12 WC Education & Educational Research SC Education & Educational Research GA CV1GN UT WOS:000364001800004 ER PT J AU Cain, KP Shah, NS AF Cain, Kevin P. Shah, N. Sarita TI (Not) measuring in the dark SO INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE LA English DT Editorial Material C1 [Cain, Kevin P.] US Ctr Dis Control & Prevent, Kisumu, Kenya. [Shah, N. Sarita] US Ctr Dis Control & Prevent, Atlanta, GA USA. RP Cain, KP (reprint author), US Ctr Dis Control & Prevent, Kisumu, Kenya. EM kcain@cdc.gov NR 5 TC 1 Z9 1 U1 0 U2 0 PU INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D) PI PARIS PA 68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE SN 1027-3719 EI 1815-7920 J9 INT J TUBERC LUNG D JI Int. J. Tuberc. Lung Dis. PD NOV PY 2015 VL 19 IS 11 BP 1270 EP 1270 DI 10.5588/ijtld.15.0782 PG 1 WC Infectious Diseases; Respiratory System SC Infectious Diseases; Respiratory System GA CV4XQ UT WOS:000364270200002 PM 26467576 ER PT J AU Sharma, A Musau, S Heilig, CM Okumu, AO Opiyo, EO Basiye, FL Miruka, FO Kioko, JK Sitienei, JK Cain, KP AF Sharma, A. Musau, S. Heilig, C. M. Okumu, A. O. Opiyo, E. O. Basiye, F. L. Miruka, F. O. Kioko, J. K. Sitienei, J. K. Cain, K. P. TI Assessing the effect of decentralisation of laboratory diagnosis for drug-resistant tuberculosis in Kenya SO INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE LA English DT Article DE decentralisation; laboratory testing; drug-resistant tuberculosis AB SETTING: Drug susceptibility testing (DST) is recommended in Kenya to identify multidrug-resistant tuberculosis (MDR-TB) in persons registered for tuberculosis (TB) retreatment. DST is performed at a central laboratory with a two-step growth-based process and a regional laboratory with a simultaneous molecular- and growth-based process. OBJECTIVE: To compare proportions of retreatment cases who underwent DST and turnaround times for hospitals referring to the central vs. regional laboratory. DESIGN: Cases were persons registered for TB retreatment from 1 January 2012 to 31 December 2013. Records of 11 hospitals and 7 hospitals referring patients to the regional and central laboratories, respectively, were reviewed. RESULTS: Respectively 238/432 (55%) and 88/355 (25%) cases from hospitals referring to the regional and central laboratories underwent DST. The mean time from case registration to receipt of DST results and initiation of MDR-TB treatment was quicker in hospitals referring to the regional laboratory. The time required for the transportation of specimens, specimen testing and receipt of DST results at hospitals was shorter for the regional laboratory (P < 0.05). CONCLUSION: Testing was faster and more complete at hospitals referring to the regional laboratory. A comprehensive review of MDR-TB detection in Kenya is required to increase the proportion of cases receiving DST. C1 [Sharma, A.] Ctr Dis Control & Prevent CDC, Epidem Intelligence Serv, Atlanta, GA USA. [Musau, S.; Okumu, A. O.; Opiyo, E. O.] Kenya Govt Med Res Ctr, Kisian, Kenya. [Heilig, C. M.] CDC, Div TB Eliminat, Atlanta, GA 30333 USA. [Basiye, F. L.; Miruka, F. O.] CDC, Div Global HIV AIDS, Kisumu, Kenya. [Kioko, J. K.] Minist Hlth, Div TB & Lung Dis, Nairobi, Kenya. [Sitienei, J. K.] Minist Hlth, Div Communicable Dis Prevent & Control, Nairobi, Kenya. [Cain, K. P.] CDC, Div TB Eliminat, Kisumu, Kenya. RP Sharma, A (reprint author), Ctr Dis Control & Prevent, Div TB Eliminat, Int Res & Programs Branch, 1600 Clifton Rd NE,MS E-10, Atlanta, GA 30329 USA. EM aditya.sharma@cdc.hhs.gov OI Heilig, Charles/0000-0003-1075-1310 FU US Centers for Disease Control and Prevention (CDC) FX This project was supported by the US Centers for Disease Control and Prevention (CDC). Some authors from this publication are employed by the CDC. NR 9 TC 1 Z9 1 U1 0 U2 0 PU INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D) PI PARIS PA 68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE SN 1027-3719 EI 1815-7920 J9 INT J TUBERC LUNG D JI Int. J. Tuberc. Lung Dis. PD NOV PY 2015 VL 19 IS 11 BP 1348 EP 1353 DI 10.5588/ijtld.15.0328 PG 6 WC Infectious Diseases; Respiratory System SC Infectious Diseases; Respiratory System GA CV4XQ UT WOS:000364270200013 PM 26467587 ER PT J AU Sukumaran, L McCarthy, NL Kharbanda, EO Weintraub, ES Vazquez-Benitez, G McNeil, MM Li, RX Klein, NP Hambidge, SJ Naleway, AL Lugg, MM Jackson, ML King, JP DeStefano, F Omer, SB Orenstein, WA AF Sukumaran, Lakshmi McCarthy, Natalie L. Kharbanda, Elyse O. Weintraub, Eric S. Vazquez-Benitez, Gabriela McNeil, Michael M. Li, Rongxia Klein, Nicola P. Hambidge, Simon J. Naleway, Allison L. Lugg, Marlene M. Jackson, Michael L. King, Jennifer P. DeStefano, Frank Omer, Saad B. Orenstein, Walter A. TI Safety of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis and Influenza Vaccinations in Pregnancy SO OBSTETRICS AND GYNECOLOGY LA English DT Article ID VACCINE SAFETY; OBSTETRIC EVENTS; PRETERM BIRTH; OUTCOMES; WOMEN; IMMUNOGENICITY; IMMUNIZATION; DATALINK; RISKS; TDAP AB OBJECTIVE:To evaluate the safety of coadministering tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) and influenza vaccines during pregnancy by comparing adverse events after concomitant and sequential vaccination.METHODS:We conducted a retrospective cohort study of pregnant women aged 14-49 years in the Vaccine Safety Datalink from January 1, 2007, to November 15, 2013. We compared medically attended acute events (fever, any acute reaction) and adverse birth outcomes (preterm delivery, low birth weight, small for gestational age) in women receiving concomitant Tdap and influenza vaccination and women receiving sequential vaccination.RESULTS:Among 36,844 pregnancies in which Tdap and influenza vaccines were administered, the vaccines were administered concomitantly in 8,464 (23%) pregnancies and sequentially in 28,380 (77%) pregnancies. Acute adverse events after vaccination were rare. We found no statistically significant increased risk of fever or any medically attended acute adverse event in pregnant women vaccinated concomitantly compared with sequentially. When analyzing women at 20 weeks of gestation or greater during periods of influenza vaccine administration, there were no differences in preterm delivery, low-birth-weight, or small-for-gestational-age neonates between women vaccinated concomitantly compared with sequentially in pregnancy.CONCLUSION:Concomitant administration of Tdap and influenza vaccines during pregnancy was not associated with a higher risk of medically attended adverse acute outcomes or birth outcomes compared with sequential vaccination.LEVEL OF EVIDENCE:II C1 Ctr Dis Control & Prevent, Immunizat Safety Off, Atlanta, GA USA. Emory Univ, Sch Med, Dept Pediat, Atlanta, GA USA. Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. Emory Univ, Emory Vaccine Ctr, Atlanta, GA 30322 USA. HealthPartners Inst Educ & Res, Minneapolis, MN USA. Kaiser Permanente No Calif, Kaiser Permanente Vaccine Study Ctr, Oakland, CA USA. Kaiser Permanente So Calif, Dept Res & Evaluat, Pasadena, CA 91101 USA. Denver Hlth, Dept Ambulatory Care Serv, Denver, CO USA. Kaiser Permanente Colorado, Inst Hlth Res, Denver, CO USA. Univ Colorado, Dept Pediat, Denver, CO 80202 USA. Kaiser Permanente Northwest, Ctr Hlth Res, Portland, OR USA. Grp Hlth Res Inst, Seattle, WA USA. Marshfield Clin Res Fdn, Marshfield, WI USA. RP Sukumaran, L (reprint author), 1600 Clifton Rd NE,Bldg 16,MS D-26, Atlanta, GA 30333 USA. EM xfq3@cdc.gov FU National Institute of Allergy and Infectious Diseases [T32AI074492]; GlaxoSmithKline; Sanofi Pasteur; Merck Co; Pfizer; Nuron Biotech; MedImmune; Novartis; Protein Science FX Dr. Sukumaran has received research support from award number T32AI074492 from the National Institute of Allergy and Infectious Diseases. Dr. Klein has received research support from GlaxoSmithKline, Sanofi Pasteur, Merck & Co, Pfizer, Nuron Biotech, MedImmune, Novartis, and Protein Science. Dr. Naleway has received research support from GlaxoSmithKline and Pfizer. The other authors did not report any potential conflicts of interest. NR 24 TC 12 Z9 14 U1 1 U2 8 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0029-7844 J9 OBSTET GYNECOL JI Obstet. Gynecol. PD NOV PY 2015 VL 126 IS 5 BP 1069 EP 1074 DI 10.1097/AOG.0000000000001066 PG 6 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA CV0WI UT WOS:000363974000023 PM 26444109 ER PT J AU Lu, PJ Yankey, D Jeyarajah, J O'Halloran, A Elam-Evans, LD Smith, PJ Stokley, S Singleton, JA Dunne, EF AF Lu, Peng-jun Yankey, David Jeyarajah, Jenny O'Halloran, Alissa Elam-Evans, Laurie D. Smith, Philip J. Stokley, Shannon Singleton, James A. Dunne, Eileen F. TI HPV Vaccination Coverage of Male Adolescents in the United States SO PEDIATRICS LA English DT Article ID AGED 13-17 YEARS; HUMAN-PAPILLOMAVIRUS VACCINE; CANCERS; BURDEN; WOMEN; MEN; US AB BACKGROUND: In 2011, the Advisory Committee for Immunization Practices (ACIP) recommended routine use human papillomavirus (HPV) vaccine for male adolescents. METHODS: We used the 2013 National Immunization Survey-Teen data to assess HPV vaccine uptake (>= 1 dose) and series completion (>= 3 doses). Multivariable logistic regression analysis and a predictive marginal model were conducted to identify independent predictors of vaccination among adolescent males aged 13 to 17 years. RESULTS: HPV vaccination coverage with >= 1 dose was 34.6%, and series completion (>= 3 doses) was 13.9%. Coverage was significantly higher among non-Hispanic blacks and Hispanics compared with non-Hispanic white male adolescents. Multivariable logistic regression showed that characteristics independently associated with a higher likelihood of HPV vaccination (>= 1 dose) included being non-Hispanic black race or Hispanic ethnicity; having mothers who were widowed, divorced, or separated; having 1 to 3 physician contacts in the past 12 months; a well-child visit at age 11 to 12 years; having 1 or 2 vaccination providers; living in urban or suburban areas; and receiving vaccinations from >1 type of facility (P<.05). Having mothers with some college or college education, having a higher family income to poverty ratio, living in the South or Midwest, and receiving vaccinations from all sexually transmitted diseases/school/teen clinics or other facilities were independently associated with a lower likelihood of HPV vaccination (P<.05). CONCLUSIONS: Following recommendations for routine HPV vaccination among male adolescents, uptake in 2013 was low in this population. Increased efforts are needed to improve vaccination coverage, especially for those who are least likely to be vaccinated. C1 [Lu, Peng-jun; Yankey, David; Jeyarajah, Jenny; O'Halloran, Alissa; Elam-Evans, Laurie D.; Smith, Philip J.; Stokley, Shannon; Singleton, James A.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Immunizat Serv Div, Atlanta, GA 30333 USA. [Dunne, Eileen F.] Ctr Dis Control & Prevent, Div Sexually Transmitted Dis Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. RP Lu, PJ (reprint author), Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, 1600 Clifton Rd NE,Mail Stop A-19, Atlanta, GA 30333 USA. EM lhp8@cdc.gov NR 33 TC 5 Z9 5 U1 0 U2 6 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 EI 1098-4275 J9 PEDIATRICS JI Pediatrics PD NOV PY 2015 VL 136 IS 5 BP 839 EP 849 DI 10.1542/peds.2015-1631 PG 11 WC Pediatrics SC Pediatrics GA CV0US UT WOS:000363969600048 PM 26504124 ER PT J AU O'Leary, ST Lee, M Lockhart, S Eisert, S Furniss, A Barnard, J Shmueli, D Stokley, S Dickinson, LM Kempe, A AF O'Leary, Sean T. Lee, Michelle Lockhart, Steven Eisert, Sheri Furniss, Anna Barnard, Juliana Shmueli, Doron Stokley, Shannon Dickinson, L. Miriam Kempe, Allison TI Effectiveness and Cost of Bidirectional Text Messaging for Adolescent Vaccines and Well Care SO PEDIATRICS LA English DT Article ID RANDOMIZED-CONTROLLED-TRIAL; INFLUENZA VACCINATION RATES; IMPLEMENTATION INTENTIONS; IMMUNIZATIONS; REMINDERS; DELIVERY; RECALL AB OBJECTIVE: To evaluate the effectiveness and cost of bidirectional short messaging service in increasing rates of vaccination and well child care (WCC) among adolescents. METHODS: We included all adolescents needing a recommended adolescent vaccine (n = 4587) whose parents had a cell-phone number in 5 private and 2 safety-net pediatric practices. Adolescents were randomized to intervention (n = 2228) or control (n = 2359). Parents in the intervention group received up to 3 personalized short messaging services with response options 1 (clinic will call to schedule), 2 (parent will call clinic), or STOP (no further short messaging service). Primary outcomes included completion of all needed services, WCC only, all needed vaccinations, any vaccination, and missed opportunity for vaccination. RESULTS: Intervention patients were more likely to complete all needed services (risk ratio [RR] 1.31, 95% confidence interval [ CI] 1.12-1.53), all needed vaccinations (RR 1.29, 95% CI 1.12-1.50), and any vaccination (RR 1.36, 95% CI 1.20-1.54). Seventy-five percent of control patients had a missed opportunity versus 69% of intervention (P = .002). There was not a significant difference for WCC visits. Responding that the clinic should call to schedule ("1") was associated with the highest effect size for completion of all needed services (RR 1.89, 95% CI 1.41-2.54). Net cost ranged from $855 to $3394 per practice. CONCLUSIONS: Bidirectional short messaging service to parents was effective at improving rates for all adolescent vaccinations and for all needed services, especially among parents who responded they desired a call from the practice. C1 [O'Leary, Sean T.; Kempe, Allison] Univ Colorado, Dept Pediat, Sch Med, Aurora, CO 80045 USA. [O'Leary, Sean T.; Lee, Michelle; Lockhart, Steven; Furniss, Anna; Barnard, Juliana; Shmueli, Doron; Dickinson, L. Miriam; Kempe, Allison] Univ Colorado, Adult & Child Ctr Hlth Outcomes Res & Delivery Sc, Denver, CO 80202 USA. [Eisert, Sheri] Univ S Florida, Coll Publ Hlth, Tampa, FL USA. [Stokley, Shannon] Ctr Dis Control & Prevent, Atlanta, GA USA. [Dickinson, L. Miriam] Univ Colorado, Dept Family Med, Aurora, CO 80045 USA. RP O'Leary, ST (reprint author), Univ Colorado, Dept Pediat, Mail Stop F443,13199 E Montview Blvd,Ste 300, Aurora, CO 80045 USA. EM sean.o'leary@childrenscolorado.org RI Emchi, Karma/Q-1952-2016 FU National Center for Immunization and Respiratory Diseases; Centers for Disease Control and Prevention [5U01IP000310-02] FX This investigation was funded by the National Center for Immunization and Respiratory Diseases and the Centers for Disease Control and Prevention (5U01IP000310-02). The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. NR 27 TC 2 Z9 2 U1 0 U2 4 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 EI 1098-4275 J9 PEDIATRICS JI Pediatrics PD NOV PY 2015 VL 136 IS 5 BP E1220 EP E1227 DI 10.1542/peds.2015-1089 PG 8 WC Pediatrics SC Pediatrics GA CV0US UT WOS:000363969600007 PM 26438703 ER PT J AU Zemel, BS Pipan, M Stallings, VA Hall, W Schadt, K Freedman, DS Thorpe, P AF Zemel, Babette S. Pipan, Mary Stallings, Virginia A. Hall, Waynitra Schadt, Kim Freedman, David S. Thorpe, Phoebe TI Growth Charts for Children With Down Syndrome in the United States SO PEDIATRICS LA English DT Article ID FOR-DISEASE-CONTROL; BIRTH-DEFECTS; AGE; PREVALENCE; PREVENTION; STATURE; OBESITY AB BACKGROUND AND OBJECTIVES: Children with Down syndrome (DS) have lower birth weights and grow more slowly than children without DS. Advances in and increased access to medical care have improved the health and well-being of individuals with DS; however, it is unknown whether their growth has also improved. Our objective was to develop new growth charts for children with DS and compare them to older charts from the United States and more contemporary charts from the United Kingdom. METHODS: The Down Syndrome Growing Up Study (DSGS) enrolled a convenience sample of children with DS up to 20 years of age and followed them longitudinally. Growth parameters were measured by research anthropometrists. Sex-specific growth charts were generated for the age ranges birth to 36 months and 2 to 20 years using the LMS method. Weight-for-length and BMI charts were also generated. Comparisons with other curves were presented graphically. RESULTS: New DSGS growth charts were developed by using 1520 measurements on 637 participants. DSGS growth charts for children,36 months of age showed marked improvements in weight compared with older US charts. DSGS charts for 2- to 20-year-olds showed that contemporary males are taller than previous charts showed. Generally, the DSGS growth charts are similar to the UK charts. CONCLUSIONS: The DSGS growth charts can be used as screening tools to assess growth and nutritional status and to provide indications of how growth of an individual child compares with peers of the same age and sex with DS. C1 [Zemel, Babette S.; Stallings, Virginia A.; Hall, Waynitra] Childrens Hosp Philadelphia, Div Gastroenterol Hepatol & Nutr, Philadelphia, PA 19104 USA. [Pipan, Mary; Schadt, Kim] Childrens Hosp Philadelphia, Div Behavioral Pediat, Philadelphia, PA 19104 USA. [Zemel, Babette S.; Pipan, Mary; Stallings, Virginia A.; Schadt, Kim] Univ Penn, Perelman Sch Med, Dept Pediat, Philadelphia, PA 19104 USA. [Freedman, David S.] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Atlanta, GA USA. [Thorpe, Phoebe] Ctr Dis Control & Prevent, Div Birth Defects & Dev Disabil, Atlanta, GA USA. RP Zemel, BS (reprint author), Childrens Hosp Philadelphia, Div Gastroenterol Hepatol & Nutr, 3535 Market St,Room 1560, Philadelphia, PA 19104 USA. EM zemel@email.chop.edu FU National Center for Research Resources [U01 DD000518, UL1RR024134]; National Center for Advancing Translational Sciences [UL1TR000003] FX Supported by U01 DD000518, UL1RR024134 (National Center for Research Resources), and UL1TR000003 (National Center for Advancing Translational Sciences). NR 31 TC 8 Z9 8 U1 1 U2 8 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 EI 1098-4275 J9 PEDIATRICS JI Pediatrics PD NOV PY 2015 VL 136 IS 5 BP E1204 EP E1211 DI 10.1542/peds.2015-1652 PG 8 WC Pediatrics SC Pediatrics GA CV0US UT WOS:000363969600005 PM 26504127 ER PT J AU McFarlane, M Brookmeyer, K Friedman, A Habel, M Kachur, R Hogben, M AF McFarlane, Mary Brookmeyer, Kathryn Friedman, Allison Habel, Melissa Kachur, Rachel Hogben, Matthew TI GYT: Get Yourself Tested Campaign Awareness: Associations With Sexually Transmitted Disease/HIV Testing and Communication Behaviors Among Youth SO SEXUALLY TRANSMITTED DISEASES LA English DT Article ID UNITED-STATES; CARE; ADOLESCENTS; INFECTIONS; CHILDREN; HEALTH; WOMEN AB Background The GYT: Get Yourself Tested campaign promotes sexually transmitted disease (STD) and HIV testing and communication with partners and providers among youth. We evaluated these behaviors in relation to campaign awareness among youth through a national survey. Methods We collected data from 4017 respondents aged 15 to 25 years through an online panel survey designed to be representative of the US population. The GYT campaign targeted 4 key behaviors: STD testing, HIV testing, talking to partners about testing, and talking to providers about testing. Results Respondents who were aware of the GYT campaign (24.4%) were more likely to report engaging in each of the 4 target behaviors. Associations remained significant when stratified by race and sex and when taking into account sexuality, sexual activity, age, insurance status, and use of campaign partner-provided services. Conclusions Awareness of the GYT campaign is related to the 4 target behaviors promoted by the campaign, suggesting that health promotions campaigns oriented toward youth can be successful in increasing STD-related, health-seeking behavior, including among populations disproportionately affected by STD. C1 [McFarlane, Mary; Brookmeyer, Kathryn; Friedman, Allison; Habel, Melissa; Kachur, Rachel; Hogben, Matthew] US Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA USA. RP McFarlane, M (reprint author), Ctr Dis Control & Prevent, Mail Stop E-27, Atlanta, GA 30333 USA. EM mmcfarlane@cdc.gov NR 17 TC 2 Z9 2 U1 2 U2 7 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD NOV PY 2015 VL 42 IS 11 BP 619 EP 624 DI 10.1097/OLQ.0000000000000361 PG 6 WC Infectious Diseases SC Infectious Diseases GA CV2LY UT WOS:000364089400004 PM 26457487 ER PT J AU Seth, P Figueroa, A Wang, GS Reid, L Belcher, L AF Seth, Puja Figueroa, Argelia Wang, Guoshen Reid, Laurie Belcher, Lisa TI HIV Testing, HIV Positivity, and Linkage and Referral Services in Correctional Facilities in the United States, 2009-2013 SO SEXUALLY TRANSMITTED DISEASES LA English DT Article ID ANTIRETROVIRAL THERAPY; TRANSITIONAL CARE; FORMER INMATES; HEALTH; INCARCERATION; COORDINATION; PREVENTION; HIV/AIDS; RELEASE; PRISON AB Background Because of health disparities, incarcerated persons are at higher risk for multiple health issues, including HIV. Correctional facilities have an opportunity to provide HIV services to an underserved population. This article describes Centers for Disease Control and Prevention (CDC)-funded HIV testing and service delivery in correctional facilities. Methods Data on HIV testing and service delivery were submitted to CDC by 61 health department jurisdictions in 2013. HIV testing, HIV positivity, receipt of test results, linkage, and referral services were described, and differences across demographic characteristics for linkage and referral services were assessed. Finally, trends were examined for HIV testing, HIV positivity, and linkage from 2009 to 2013. Results Of CDC-funded tests in 2013 among persons 18 years and older, 254,719 (7.9%) were conducted in correctional facilities. HIV positivity was 0.9%, and HIV positivity for newly diagnosed persons was 0.3%. Blacks accounted for the highest percentage of HIV-infected persons (1.3%) and newly diagnosed persons (0.5%). Only 37.9% of newly diagnosed persons were linked within 90 days; 67.5% were linked within any time frame; 49.7% were referred to partner services; and 45.2% were referred to HIV prevention services. There was a significant percent increase in HIV testing, overall HIV positivity, and linkage from 2009 to 2013. However, trends were stable for newly diagnosed persons. Conclusions Identification of newly diagnosed persons in correctional facilities has remained stable from 2009 to 2013. Correctional facilities seem to be reaching blacks, likely due to higher incarceration rates. The current findings indicate that improvements are needed in HIV testing strategies, service delivery during incarceration, and linkage to care postrelease. C1 [Seth, Puja; Figueroa, Argelia; Wang, Guoshen; Belcher, Lisa] Ctr Dis Control & Prevent, Program Evaluat Branch, Div HIV AIDS Prevent, Atlanta, GA 30329 USA. [Reid, Laurie] Ctr Dis Control & Prevent, Off Hlth Equ, Div HIV AIDS Prevent, Atlanta, GA 30329 USA. RP Seth, P (reprint author), Ctr Dis Control & Prevent, Program Evaluat Branch, Div HIV AIDS Prevent, 1600 Clifton Rd NE,MS E-59, Atlanta, GA 30329 USA. EM pseth@cdc.gov FU Intramural CDC HHS [CC999999] NR 32 TC 1 Z9 1 U1 1 U2 8 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD NOV PY 2015 VL 42 IS 11 BP 643 EP 649 DI 10.1097/OLQ.0000000000000353 PG 7 WC Infectious Diseases SC Infectious Diseases GA CV2LY UT WOS:000364089400009 PM 26462190 ER PT J AU Amoah, S Cao, WP Ranjan, P Greer, P Shieh, WJ Zaki, SR Katz, JM Sambhara, S Gangappa, S AF Amoah, Samuel Cao, Weiping Ranjan, Priya Greer, Patricia Shieh, Wun-Ju Zaki, Sherif R. Katz, Jacqueline M. Sambhara, Suryaprakash Gangappa, Shivaprakash TI Increased Dietary Salt Intake Does Not Influence Influenza A Virus-Induced Disease Severity in Mice SO VIRAL IMMUNOLOGY LA English DT Article ID INFECTION; RISK; H1N1; HYPERTENSION; BALANCE; CARE AB Influenza viruses are pathogens of significant public health importance. The influence of nutritional status on severity of disease has become increasingly recognized. In particular, high dietary salt intake has been linked to cardiovascular disease, but the effects on infectious diseases have not been studied. This study investigated the impact on influenza-induced morbidity and mortality in mice fed isocaloric diets containing 10-fold increments of sodium by altering the salt levels. Following infection, despite higher levels of IFN-gamma cytokine in the lung as well as virus-neutralizing antibody in the serum of mice fed the lowest salt level, the amounts of dietary salt intake had no substantial impact on the disease severity or the ability to respond immunologically to the infection. C1 [Amoah, Samuel; Cao, Weiping; Ranjan, Priya; Katz, Jacqueline M.; Sambhara, Suryaprakash; Gangappa, Shivaprakash] Ctr Dis Control & Prevent, Immunol & Pathogenesis Branch, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Greer, Patricia; Shieh, Wun-Ju; Zaki, Sherif R.] Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. RP Gangappa, S (reprint author), Ctr Dis Control & Prevent, Immunol & Pathogenesis Branch, Influenza Div, Natl Ctr Immunizat & Resp Dis, 1600 Clifton Rd,Bldg 17 Rm 5205,MS-G16, Atlanta, GA 30333 USA. EM sgangappa@cdc.gov FU CDC; Battelle Memorial Institute, Clairmont Rd, Suite, Atlanta, GA FX We thank members of the Immunology and Pathogenesis Branch in the Influenza Division, Centers for Disease Control and Prevention, for providing constructive comments on this research. This study was supported by CDC intramural funding. SA was supported by Battelle Memorial Institute, 2987 Clairmont Rd, Suite 450, Atlanta, GA 30329. NR 23 TC 0 Z9 0 U1 0 U2 1 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0882-8245 EI 1557-8976 J9 VIRAL IMMUNOL JI Viral Immunol. PD NOV 1 PY 2015 VL 28 IS 9 BP 532 EP 537 DI 10.1089/vim.2015.0037 PG 6 WC Immunology; Virology SC Immunology; Virology GA CV4BN UT WOS:000364210500009 PM 26284685 ER PT J AU Duggal, NK Reisen, WK Fang, Y Newman, RM Yang, X Ebel, GD Brault, AC AF Duggal, Nisha K. Reisen, William K. Fang, Ying Newman, Ruchi M. Yang, Xiao Ebel, Gregory D. Brault, Aaron C. TI Genotype-specific variation in West Nile virus dispersal in California SO VIROLOGY LA English DT Article DE West Nile virus; Arbovirus; Phylogenetics; Evolution ID MIGRATORY BIRDS; UNITED-STATES; NEW-YORK; NORTH-AMERICA; MOSQUITOS; ARBOVIRUSES; POPULATIONS; EVOLUTION; DYNAMICS; STRAIN AB West Nile virus (WNV) is an arbovirus that was first reported in North America in New York in 1999 and, by 2003, had spread more than 4000 km to California. However, variation in viral genetics associated with spread is not well understood. Herein, we report sequences for more than 100 WNV isolates made from mosquito pools that were collected from 2003 to 2011 as part of routine surveillance by the California Mosquito-borne Virus Surveillance System. We performed phylogeographic analyses and demonstrated that 5 independent introductions of WNV (1 WNO2 genotype strain and 4 SW03 genotype strains) occurred in California. The 5W03 genotype of WNV was constrained to the southwestern U.S. and had a more rapid rate of spread. In addition, geographic constraint of WNV strains within a single region for up to 6 years suggest viral maintenance has been driven by resident, rather than migratory, birds and overwintering in mosquitoes. (C) 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license C1 [Duggal, Nisha K.; Brault, Aaron C.] Ctr Dis Control & Prevent, Div Vector Borne Dis, Ft Collins, CO 80521 USA. [Reisen, William K.; Fang, Ying; Ebel, Gregory D.] Univ Calif Davis, Ctr Vectorborne Dis, Davis, CA 95616 USA. [Newman, Ruchi M.; Yang, Xiao] Broad Inst Harvard, Cambridge, MA USA. [Newman, Ruchi M.; Yang, Xiao] MIT, Cambridge, MA 02139 USA. [Ebel, Gregory D.] Colorado State Univ, Dept Microbiol Immunol & Pathol, Ft Collins, CO 80523 USA. RP Brault, AC (reprint author), Ctr Dis Control & Prevent, Div Vector Borne Dis, Ft Collins, CO 80521 USA. EM abrault@cdc.gov RI Ebel, Gregory/D-8324-2017 FU National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services [AI55607, AI067380, HHSN272200900018C]; APHL/CDC Emerging Infectious Diseases postdoctoral fellowship FX This project has been funded in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Grant no. AI55607 (WKR), Grant no. AI067380 (GDE) and Contract no. HHSN272200900018C to the Broad Institute's Genomic Sequencing Center for Infectious Diseases, and by an APHL/CDC Emerging Infectious Diseases postdoctoral fellowship (NKD). NR 38 TC 4 Z9 4 U1 6 U2 24 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0042-6822 J9 VIROLOGY JI Virology PD NOV PY 2015 VL 485 BP 79 EP 85 DI 10.1016/j.virol.2015.07.004 PG 7 WC Virology SC Virology GA CV1DH UT WOS:000363993100007 PM 26210076 ER PT J AU Wilson, JR Guo, Z Tzeng, WP Garten, RJ Xu, XY Blanchard, EG Blanchfield, K Stevens, J Katz, JM York, IA AF Wilson, Jason R. Guo, Zhu Tzeng, Wen-Pin Garten, Rebecca J. Xu Xiyan Blanchard, Elisabeth G. Blanchfield, Kristy Stevens, James Katz, Jacqueline M. York, Ian A. TI Diverse antigenic site targeting of influenza hemagglutinin in the murine antibody recall response to A(H1N1)pdm09 virus SO VIROLOGY LA English DT Article DE Influenza; Monoclonal antibody; Epitope mapping; Antigenic site; Virus neutralization; Antigenic drift; A/H1N1/pdm09 ID NEUTRALIZING MONOCLONAL-ANTIBODIES; RECEPTOR-BINDING SITE; MEMORY B-CELLS; INHIBITING ANTIBODY; SEASONAL INFLUENZA; ESCAPE MUTANTS; GLOBULAR HEAD; PROTECTION; REPERTOIRE; INFECTION AB Here we define the epitopes on HA that are targeted by a group of 9 recombinant monoclonal antibodies (rmAbs) isolated from memory B cells of mice, immunized by infection with A(H1N1)pdm09 virus followed by a seasonal TIV boost. These rmAbs were all reactive against the HA1 region of HA, but display 7 distinct binding footprints, targeting each of the 4 known antigenic sites. Although the rmAbs were not broadly cross-reactive, a group showed subtype-specific cross-reactivity with the HA of A/South Carolina/1/18. Screening these rmAbs with a panel of human A(H1N1)pdm09 virus isolates indicated that naturally-occurring changes in HA could reduce rmAb binding, HI activity, and/or virus neutralization activity by rmAb, without showing changes in recognition by polyclonal antiserum. In some instances, virus neutralization was lost while both ELISA binding and HI activity were retained, demonstrating a discordance between the two serological assays traditionally used to detect antigenic drift. Published by Elsevier Inc. C1 [Wilson, Jason R.; Guo, Zhu; Tzeng, Wen-Pin; Garten, Rebecca J.; Xu Xiyan; Blanchard, Elisabeth G.; Blanchfield, Kristy; Stevens, James; Katz, Jacqueline M.; York, Ian A.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Influenza Div, Atlanta, GA 30333 USA. RP York, IA (reprint author), Influenza Div, MS G-16,1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM ite1@cdc.gov OI York, Ian/0000-0002-3478-3344 FU Centers for Disease Control and Prevention (CDC); Oak Ridge Institute for Science and Education, Oak Ridge, TN FX This work was supported by the Centers for Disease Control and Prevention (CDC).; JRW received financial support for this work from the Oak Ridge Institute for Science and Education, Oak Ridge, TN. NR 40 TC 2 Z9 2 U1 0 U2 1 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0042-6822 J9 VIROLOGY JI Virology PD NOV PY 2015 VL 485 BP 252 EP 262 DI 10.1016/j.virol.2015.08.004 PG 11 WC Virology SC Virology GA CV1DH UT WOS:000363993100026 PM 26318247 ER PT J AU Wilson, MR Shanbhag, NM Reid, MJ Singhal, NS Gelfand, JM Sample, HA Benkli, B O'Donovan, BD Ali, IKM Keating, MK Dunnebacke, TH Wood, MD Bollen, A DeRisi, JL AF Wilson, Michael R. Shanbhag, Niraj M. Reid, Michael J. Singhal, Neel S. Gelfand, Jeffrey M. Sample, Hannah A. Benkli, Barlas O'Donovan, Brian D. Ali, Ibne K. M. Keating, M. Kelly Dunnebacke, Thelma H. Wood, Matthew D. Bollen, Andrew DeRisi, Joseph L. TI Diagnosing Balamuthia mandrillaris Encephalitis With Metagenomic Deep Sequencing SO ANNALS OF NEUROLOGY LA English DT Article ID AMEBIC MENINGOENCEPHALITIS; CD-HIT; AGENT; ANIMALS; HUMANS AB ObjectiveIdentification of a particular cause of meningoencephalitis can be challenging owing to the myriad bacteria, viruses, fungi, and parasites that can produce overlapping clinical phenotypes, frequently delaying diagnosis and therapy. Metagenomic deep sequencing (MDS) approaches to infectious disease diagnostics are known for their ability to identify unusual or novel viruses and thus are well suited for investigating possible etiologies of meningoencephalitis. MethodsWe present the case of a 74-year-old woman with endophthalmitis followed by meningoencephalitis. MDS of her cerebrospinal fluid (CSF) was performed to identify an infectious agent. ResultsSequences aligning to Balamuthia mandrillaris ribosomal RNA genes were identified in the CSF by MDS. Polymerase chain reaction subsequently confirmed the presence of B. mandrillaris in CSF, brain tissue, and vitreous fluid from the patient's infected eye. B. mandrillaris serology and immunohistochemistry for free-living amoebas on the brain biopsy tissue were positive. InterpretationThe diagnosis was made using MDS after the patient had been hospitalized for several weeks and subjected to costly and invasive testing. MDS is a powerful diagnostic tool with the potential for rapid and unbiased pathogen identification leading to early therapeutic targeting. Ann Neurol 2015;78:Ann Neurol 2015;78:679-696 C1 [Wilson, Michael R.; O'Donovan, Brian D.] Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94158 USA. [DeRisi, Joseph L.] Howard Hughes Med Inst, Chevy Chase, MD USA. [Wilson, Michael R.; Shanbhag, Niraj M.; Singhal, Neel S.; Gelfand, Jeffrey M.; Sample, Hannah A.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94158 USA. [Reid, Michael J.] Univ Calif San Francisco, Dept Med, Div Infect Dis, San Francisco, CA 94158 USA. [Benkli, Barlas] Koc Univ, Istanbul, Turkey. [Wood, Matthew D.; Bollen, Andrew] Univ Calif San Francisco, Dept Pathol, Div Neuropathol, San Francisco, CA 94158 USA. [Dunnebacke, Thelma H.] Calif Dept Publ Hlth, Viral & Rickettsial Dis Lab, Richmond, CA USA. [Ali, Ibne K. M.] Ctr Dis Control & Prevent, Free Living & Intestinal Amebas Lab, Atlanta, GA USA. [Keating, M. Kelly] Ctr Dis Control & Prevent, Infect Dis Pathol Branch, Atlanta, GA USA. RP Wilson, MR (reprint author), Univ Calif San Francisco, Dept Neurol, 1500 Owens St, San Francisco, CA 94158 USA. EM michael.wilson@ucsf.edu FU American Brain Foundation Clinical Research Training Fellowship; Howard Hughes Medical Institute; National Center for Advancing Translational Sciences of the NIH [KL2TR000143] FX This work was supported by the American Brain Foundation Clinical Research Training Fellowship (to M.R.W.); Howard Hughes Medical Institute (to J.L.D.); National Center for Advancing Translational Sciences of the NIH (KL2TR000143; to M.R.W. and J.M.G.). The latter's contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH. The findings and conclusions are those of the authors and do not necessarily represent the official position of the U.S. Department of Health and Human Services. NR 24 TC 14 Z9 14 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0364-5134 EI 1531-8249 J9 ANN NEUROL JI Ann. Neurol. PD NOV PY 2015 VL 78 IS 5 BP 722 EP 730 DI 10.1002/ana.24499 PG 9 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA CU7NP UT WOS:000363727900007 PM 26290222 ER PT J AU Weiner, ZP Crew, RM Brandt, KS Ullmann, AJ Schriefer, ME Molins, CR Gilmore, RD AF Weiner, Zachary P. Crew, Rebecca M. Brandt, Kevin S. Ullmann, Amy J. Schriefer, Martin E. Molins, Claudia R. Gilmore, Robert D. TI Evaluation of Selected Borrelia burgdorferi lp54 Plasmid-Encoded Gene Products Expressed during Mammalian Infection as Antigens To Improve Serodiagnostic Testing for Early Lyme Disease SO CLINICAL AND VACCINE IMMUNOLOGY LA English DT Article ID CLINICAL-PRACTICE; SURFACE-PROTEINS; IMMUNO-PCR; DIAGNOSIS; ASSAY; VLSE; IDENTIFICATION; TRANSMISSION; RESISTANCE; EVOLUTION AB Laboratory testing for the diagnosis of Lyme disease is performed primarily by serologic assays and is accurate for detection beyond the acute stage of the infection. Serodiagnostic assays to detect the early stages of infection, however, are limited in their sensitivity, and improvement is warranted. We analyzed a series of Borrelia burgdorferi proteins known to be induced within feeding ticks and/or during mammalian infection for their utility as serodiagnostic markers against a comprehensive panel of Lyme disease patient serum samples. The antigens were assayed for IgM and IgG reactivity in line immunoblots and separately by enzyme-linked immunosorbent assay (ELISA), with a focus on reactivity against early Lyme disease with erythema migrans (EM), early disseminated Lyme neuroborreliosis, and early Lyme carditis patient serum samples. By IgM immunoblotting, we found that recombinant proteins BBA65, BBA70, and BBA73 reacted with early Lyme EM samples at levels comparable to those of the OspC antigen used in the current IgM blotting criteria. Additionally, these proteins reacted with serum samples from patients with early neuroborreliosis and early carditis, suggesting value in detecting early stages of this disease progression. We also found serological reactivity against recombinant proteins BBA69 and BBA73 with early-Lyme-disease samples using IgG immunoblotting and ELISA. Significantly, some samples that had been scored negative by the Centers for Disease Control and Prevention-recommended 2-tiered testing algorithm demonstrated positive reactivity to one or more of the antigens by IgM/IgG immunoblot and ELISA. These results suggest that incorporating additional in vivo-expressed antigens into the current IgM/IgG immunoblotting tier in a recombinant protein platform assay may improve the performance of early-Lyme-disease serologic testing. C1 [Weiner, Zachary P.; Crew, Rebecca M.; Brandt, Kevin S.; Ullmann, Amy J.; Schriefer, Martin E.; Molins, Claudia R.; Gilmore, Robert D.] Ctr Dis Control & Prevent, Div Vector Borne Dis, Ft Collins, CO USA. RP Gilmore, RD (reprint author), Ctr Dis Control & Prevent, Div Vector Borne Dis, Ft Collins, CO USA. EM rbg9@cdc.gov FU American Society for Microbiology/CDC Program in Infectious Disease and Public Health Microbiology; Emerging Infectious Disease Training Fellow through the Association for Public Health Laboratories (APHL); CDC FX Z.P.W. was supported as a fellow through the American Society for Microbiology/CDC Program in Infectious Disease and Public Health Microbiology. R.M.C. was supported as an Emerging Infectious Disease Training Fellow through the Association for Public Health Laboratories (APHL) and CDC. NR 40 TC 1 Z9 1 U1 3 U2 8 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 1556-6811 EI 1556-679X J9 CLIN VACCINE IMMUNOL JI Clin. Vaccine Immunol. PD NOV PY 2015 VL 22 IS 11 BP 1176 EP 1186 DI 10.1128/CVI.00399-15 PG 11 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA CU8SS UT WOS:000363814200006 PM 26376927 ER PT J AU Frieden, TR Damon, IK AF Frieden, Thomas R. Damon, Inger K. TI Ebola in West Africa-CDC's Role in Epidemic Detection, Control, and Prevention SO EMERGING INFECTIOUS DISEASES LA English DT Article ID GLOBAL HEALTH SECURITY; VIRUS DISEASE EPIDEMIC; UNITED-STATES; SEPTEMBER 2014; OUTBREAK; LIBERIA; COUNTY AB Since Ebola virus disease was identified in West Africa on March 23, 2014, the Centers for Disease Control and Prevention (CDC) has undertaken the most intensive response in the agency's history; >3,000 staff have been involved, including >1,200 deployed to West Africa for >50,000 person workdays. Efforts have included supporting incident management systems in affected countries; mobilizing partners; and strengthening laboratory, epidemiology, contact investigation, health care infection control, communication, and border screening in West Africa, Nigeria, Mali, Senegal, and the United States. All efforts were undertaken as part of national and global response activities with many partner organizations. CDC was able to support community, national, and international health and public health staff to prevent an even worse event. The Ebola virus disease epidemic highlights the need to strengthen national and international systems to detect, respond to, and prevent the spread of future health threats. C1 [Frieden, Thomas R.; Damon, Inger K.] Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. RP Frieden, TR (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop D14, Atlanta, GA 30329 USA. EM tfrieden@cdc.gov NR 39 TC 6 Z9 6 U1 4 U2 30 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD NOV PY 2015 VL 21 IS 11 BP 1897 EP 1905 DI 10.3201/eid2111.150949 PG 9 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CU5WA UT WOS:000363601500001 PM 26484940 ER PT J AU Benedict, K Thompson, GR Deresinski, S Chiller, T AF Benedict, Kaitlin Thompson, George R., III Deresinski, Stan Chiller, Tom TI Mycotic Infections Acquired outside Areas of Known Endemicity, United States SO EMERGING INFECTIOUS DISEASES LA English DT Article ID DISSEMINATED HISTOPLASMOSIS; NORTHERN-CALIFORNIA; NONENDEMIC REGIONS; WASHINGTON-STATE; VALLEY FEVER; COCCIDIOIDOMYCOSIS; BLASTOMYCOSIS; EPIDEMIOLOGY; SENSITIVITY; PREVALENCE AB In the United States, endemic mycoses blastomycosis, coccidioidomycosis, and histoplasmosis pose considerable clinical and public health challenges. Although the causative fungi typically exist within broadly defined geographic areas or ecologic niches, some evidence suggests that cases have occurred in humans and animals not exposed to these areas. We describe cases acquired outside regions of traditionally defined endemicity. These patients often have severe disease, but diagnosis may be delayed because of a low index of suspicion for mycotic disease, and many more cases probably go entirely undetected. Increased awareness of these diseases, with a specific focus on their potential occurrence in unusual areas, is needed. Continued interdisciplinary efforts to reevaluate and better describe areas of true endemicity are warranted, along with a more nuanced view of the notion of endemicity. The term "nonendemic" should be used with care; mycoses in such regions might more accurately be considered "not known to be endemic." C1 [Benedict, Kaitlin; Chiller, Tom] Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. [Thompson, George R., III] Univ Calif Davis, Med Ctr, Davis, CA 95616 USA. [Thompson, George R., III] Univ Calif Davis, Davis, CA 95616 USA. [Deresinski, Stan] Stanford Univ, Stanford, CA 94305 USA. RP Benedict, K (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop C09, Atlanta, GA 30329 USA. EM jsy8@cdc.gov NR 39 TC 2 Z9 2 U1 1 U2 5 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD NOV PY 2015 VL 21 IS 11 BP 1935 EP 1941 DI 10.3201/eid2111.141950 PG 7 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CU5WA UT WOS:000363601500006 PM 26485441 ER PT J AU Uejio, CK Mak, S Manangan, A Luber, G Bartlett, KH AF Uejio, Christopher K. Mak, Sunny Manangan, Arie Luber, George Bartlett, Karen H. TI Climatic Influences on Cryptoccoccus gattii Populations, Vancouver Island, Canada, 2002-2004 SO EMERGING INFECTIOUS DISEASES LA English DT Article ID NEOFORMANS VAR. GRUBII; CRYPTOCOCCUS-GATTII; BRITISH-COLUMBIA; PACIFIC-NORTHWEST; NATURAL HABITAT; INDIA; WOOD; SUSCEPTIBILITY; ENVIRONMENT; PREVALENCE AB Vancouver Island, Canada, reports the world's highest incidence of Cryptococcus gattii infection among humans and animals. To identify key biophysical factors modulating environmental concentrations, we evaluated monthly concentrations of C. gatti in air, soil, and trees over a 3-year period. The 2 study datasets were repeatedly measured plots and newly sampled plots. We used hierarchical generalized linear and mixed effect models to determine associations. Climate systematically influenced C. gattii concentrations in all environmental media tested; in soil and on trees, concentrations decreased when temperatures were warmer. Wind may be a key process that transferred C. gattii from soil into air and onto trees. C. gattii results for tree and air samples were more likely to be positive during periods of higher solar radiation. These results improve the understanding of the places and periods with the greatest C. gattii colonization. Refined risk projections may help susceptible persons avoid activities that disturb the topsoil during relatively cool summer days. C1 [Uejio, Christopher K.] Florida State Univ, Tallahassee, FL 32306 USA. [Mak, Sunny] British Columbia Ctr Dis Control, Vancouver, BC, Canada. [Manangan, Arie; Luber, George] Ctr Dis Control & Prevent, Atlanta, GA USA. [Bartlett, Karen H.] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada. RP Uejio, CK (reprint author), Florida State Univ, Dept Geog, Rm 323,Bellamy Bldg,113 Collegiate Loop, Tallahassee, FL 32306 USA. EM cuejio@fsu.edu FU National Center for Atmospheric Research/Centers for Disease Control and Prevention; Florida State University FX This work was supported by the National Center for Atmospheric Research/Centers for Disease Control and Prevention Fellowship Program and the Florida State University First Year Assistant Professor Program. NR 29 TC 2 Z9 2 U1 1 U2 9 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD NOV PY 2015 VL 21 IS 11 BP 1989 EP 1996 DI 10.3201/eid2111.141161 PG 8 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CU5WA UT WOS:000363601500013 PM 26484590 ER PT J AU Wilken, JA Sondermeyer, G Shusterman, D McNary, J Vugia, DJ McDowell, A Borenstein, P Gilliss, D Ancock, B Prudhomme, J Gold, D Windham, GC Lee, L Materna, BL AF Wilken, Jason A. Sondermeyer, Gail Shusterman, Dennis McNary, Jennifer Vugia, Duc J. McDowell, Ann Borenstein, Penny Gilliss, Debra Ancock, Benedict Prudhomme, Janice Gold, Deborah Windham, Gayle C. Lee, Lauren Materna, Barbara L. TI Coccidioidomycosis among Workers Constructing Solar Power Farms, California, USA, 2011-2014 SO EMERGING INFECTIOUS DISEASES LA English DT Article ID UNITED-STATES; OUTBREAK; SURVEILLANCE; ARIZONA AB Coccidioidomycosis is associated with soil-disruptive work in Coccidioides-endemic areas of the southwestern United States. Among 3,572 workers constructing 2 solar power generating facilities in San Luis Obispo County, California, USA, we identified 44 patients with symptom onset during October 2011 April 2014 (attack rate 1.2 cases/100 workers). Of these 44 patients, 20 resided in California outside San Luis Obispo County and 10 resided in another state; 9 were hospitalized (median 3 days), 34 missed work (median 22 days), and 2 had disseminated disease. Of the 25 patients who frequently performed soil-disruptive work, 6 reported frequent use of respiratory protection. As solar farm construction in Coccidioides-endemic areas increases, additional workers will probably be exposed and infected unless awareness is emphasized and effective exposure reduction measures implemented, including limiting dust generation and providing respiratory protection. Medical providers, including those in non Coccidioides-endemic areas, should suspect coccidioidomycosis in workers with compatible illness and report cases to their local health department. C1 [Wilken, Jason A.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Wilken, Jason A.; Sondermeyer, Gail; Shusterman, Dennis; McNary, Jennifer; Vugia, Duc J.; Gilliss, Debra; Ancock, Benedict; Windham, Gayle C.; Lee, Lauren; Materna, Barbara L.] Calif Dept Publ Hlth, Richmond, CA 94804 USA. [McDowell, Ann; Borenstein, Penny] Cty San Luis Obispo Publ Hlth Dept, San Luis Obispo, CA USA. [Prudhomme, Janice; Gold, Deborah] Calif Dept Ind Relat, Oakland, CA USA. RP Wilken, JA (reprint author), Calif Dept Publ Hlth, 850 Marina Bay Pkwy,Bldg P3, Richmond, CA 94804 USA. EM jason.wilken@cdph.ca.gov FU Epidemiology and Laboratory Capacity for Infectious Disease from the Centers for Disease Control and Prevention [3U50CK000410] FX This investigation was supported by the Epidemiology and Laboratory Capacity for Infectious Disease cooperative agreement 3U50CK000410 from the Centers for Disease Control and Prevention. NR 23 TC 0 Z9 0 U1 1 U2 7 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD NOV PY 2015 VL 21 IS 11 BP 1997 EP 2005 DI 10.3201/eid2111.150129 PG 9 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CU5WA UT WOS:000363601500014 PM 26484688 ER PT J AU Dixon, MG Taylor, MM Dee, J Hakim, A Cantey, P Lim, T Bah, H Camara, SM Ndongmo, CB Togba, M Toure, LY Bilivogui, P Sylla, M Kinzer, M Coronado, F Tongren, JE Swaminathan, M Mandigny, L Diallo, B Seyler, T Rondy, M Rodier, G Perea, WA Dahl, B AF Dixon, Meredith G. Taylor, Melanie M. Dee, Jacob Hakim, Avi Cantey, Paul Lim, Travis Bah, Hawa Camara, Sekou Mohamed Ndongmo, Clement B. Togba, Mory Toure, Leonie Yvonne Bilivogui, Pepe Sylla, Mohammed Kinzer, Michael Coronado, Fatima Tongren, Jon Eric Swaminathan, Mahesh Mandigny, Lise Diallo, Boubacar Seyler, Thomas Rondy, Marc Rodier, Guenael Perea, William A. Dahl, Benjamin TI Contact Tracing Activities during the Ebola Virus Disease Epidemic in Kindia and Faranah, Guinea, 2014 SO EMERGING INFECTIOUS DISEASES LA English DT Article ID TRANSMISSION AB The largest recorded Ebola virus disease epidemic began in March 2014; as of July 2015, it continued in 3 principally affected countries: Guinea, Liberia, and Sierra Leone. Control efforts include contact tracing to expedite identification of the virus in suspect case-patients. We examined contact tracing activities during September 20-December 31, 2014, in 2 prefectures of Guinea using national and local data about case-patients and their contacts. Results show less than one third of case-patients (28.3% and 31.1%) were registered as contacts before case identification; approximately two thirds (61.1% and 67.7%) had no registered contacts. Time to isolation of suspected case-patients was not immediate (median 5 and 3 days for Kindia and Faranah, respectively), and secondary attack rates varied by relationships of persons who had contact with the source case-patient and the type of case-patient to which a contact was exposed. More complete contact tracing efforts are needed to augment control of this epidemic. C1 [Dixon, Meredith G.; Taylor, Melanie M.; Dee, Jacob; Hakim, Avi; Cantey, Paul; Lim, Travis; Kinzer, Michael; Coronado, Fatima; Swaminathan, Mahesh; Dahl, Benjamin] US Ctr Dis Control & Prevent, Atlanta, GA USA. [Bah, Hawa; Camara, Sekou Mohamed] WHO, Brazzaville, Congo. [Ndongmo, Clement B.] US Ctr Dis Control & Prevent, Lusaka, Zambia. [Togba, Mory; Toure, Leonie Yvonne; Bilivogui, Pepe; Sylla, Mohammed] Minist Hlth, Conakry, Guinea. [Tongren, Jon Eric] US Ctr Dis Control & Prevent, Kigali, Rwanda. [Mandigny, Lise; Diallo, Boubacar; Rodier, Guenael; Perea, William A.] WHO, CH-1211 Geneva, Switzerland. [Seyler, Thomas; Rondy, Marc] EpiConcept, Paris, France. [Seyler, Thomas; Rondy, Marc] World Hlth Org Ebola Response Team, Conakry, Guinea. RP Dixon, MG (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop E30, Atlanta, GA 30329 USA. EM mgdixon@cdc.gov FU US Centers for Disease Control and Prevention; World Health Organization; Guinea Ministry of Health FX This project was supported by the US Centers for Disease Control and Prevention, World Health Organization, and Guinea Ministry of Health. NR 11 TC 2 Z9 2 U1 0 U2 5 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD NOV PY 2015 VL 21 IS 11 BP 2022 EP 2028 DI 10.3201/eid2111.150684 PG 7 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CU5WA UT WOS:000363601500017 PM 26488116 ER PT J AU Feikin, DR Alraddadi, B Qutub, M Shabouni, O Curns, A Oboho, IK Tomczyk, SM Wolff, B Watson, JT Madani, TA AF Feikin, Daniel R. Alraddadi, Basem Qutub, Mohammed Shabouni, Omaima Curns, Aaron Oboho, Ikwo K. Tomczyk, Sara M. Wolff, Bernard Watson, John T. Madani, Tariq A. TI Association of Higher MERS-CoV Virus Load with Severe Disease and Death, Saudi Arabia, 2014 SO EMERGING INFECTIOUS DISEASES LA English DT Article ID EAST RESPIRATORY SYNDROME; SYNDROME CORONAVIRUS INFECTION; SYNCYTIAL VIRUS; CLINICAL-COURSE; INFLUENZA; OUTCOMES; VALUES AB Middle East respiratory syndrome coronavirus (MERS-CoV) causes a spectrum of illness. We evaluated whether cycle threshold (C-t) values (which are inversely related to virus load) were associated with clinical severity in patients from Saudi Arabia whose nasopharyngeal specimens tested positive for this virus by real-time reverse transcription PCR. Among 102 patients, median C-t of 31.0 for the upstream of the E gene target for 41(40%) patients who died was significantly lower than the median of 33.0 for 61 survivors (p =, 0.0087). In multivariable regression analyses, risk factors for death were age >60 years, underlying illness, and decreasing C-t. Results were similar for a composite severe outcome (death and/or intensive care unit admission). More data are needed to determine whether modulation of virus load by therapeutic agents affects clinical outcomes. C1 [Feikin, Daniel R.; Curns, Aaron; Oboho, Ikwo K.; Tomczyk, Sara M.; Wolff, Bernard; Watson, John T.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Alraddadi, Basem; Qutub, Mohammed; Shabouni, Omaima; Madani, Tariq A.] Minist Hlth, Jeddah, Saudi Arabia. [Alraddadi, Basem; Qutub, Mohammed] King Faisal Specialist Hosp & Res Ctr, Jeddah, Saudi Arabia. [Madani, Tariq A.] King Abdulaziz Univ, Jeddah 21413, Saudi Arabia. RP Madani, TA (reprint author), King Abdulaziz Univ, Fac Med, Dept Med, POB 80215, Jeddah 21589, Saudi Arabia. EM tmadani@kau.edu.sa FU KSA MOH; US Centers for Disease Control and Prevention FX The KSA MOH and the US Centers for Disease Control and Prevention provided funding for this study. NR 28 TC 15 Z9 16 U1 0 U2 8 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD NOV PY 2015 VL 21 IS 11 BP 2029 EP 2035 DI 10.3201/eid2111.150764 PG 7 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CU5WA UT WOS:000363601500018 PM 26488195 ER PT J AU Forrester, JD Kugeler, KJ Perea, AE Pastula, DM Mead, PS AF Forrester, Joseph D. Kugeler, Kiersten J. Perea, Anna E. Pastula, Daniel M. Mead, Paul S. TI No Geographic Correlation between Lyme Disease and Death Due to 4 Neurodegenerative Disorders, United States, 2001-2010 SO EMERGING INFECTIOUS DISEASES LA English DT Article ID AMYOTROPHIC-LATERAL-SCLEROSIS; CENTRAL-NERVOUS-SYSTEM; BORRELIA-BURGDORFERI; ALZHEIMERS-DISEASE; MULTIPLE-SCLEROSIS; NEUROBORRELIOSIS; INFECTION; INVOLVEMENT; DIAGNOSIS; SEROLOGY AB Associations between Lyme disease and certain neurodegenerative diseases have been proposed, but supportive evidence for an association is lacking. Similar geographic distributions would be expected if 2 conditions were etiologically linked. Thus, we compared the distribution of Lyme disease cases in the United States with the distributions of deaths due to Alzheimer disease, amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and Parkinson disease; no geographic correlations were identified. Lyme disease incidence per US state was not correlated with rates of death due to ALS, MS, or Parkinson disease; however, an inverse correlation was detected between Lyme disease and Alzheimer disease. The absence of a positive correlation between the geographic distribution of Lyme disease and the distribution of deaths due to Alzheimer disease, ALS, MS, and Parkinson disease provides further evidence that Lyme disease is not associated with the development of these neurodegenerative conditions. C1 [Forrester, Joseph D.; Kugeler, Kiersten J.; Perea, Anna E.; Pastula, Daniel M.; Mead, Paul S.] Ctr Dis Control & Prevent, Ft Collins, CO USA. [Forrester, Joseph D.; Pastula, Daniel M.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Forrester, JD (reprint author), Stanford Univ, Dept Surg, 300 Pasteur Dr,H3591, Stanford, CA 94305 USA. EM JDForrester84@gmail.com NR 27 TC 2 Z9 2 U1 0 U2 4 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD NOV PY 2015 VL 21 IS 11 BP 2036 EP 2039 DI 10.3201/eid2111.150778 PG 4 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CU5WA UT WOS:000363601500019 PM 26488307 ER PT J AU Ershova, JV Volchenkov, GV Kaminski, DA Somova, TR Kuznetsova, TA Kaunetis, NV Cegielski, JP Kurbatova, EV AF Ershova, Julia V. Volchenkov, Grigory V. Kaminski, Dorothy A. Somova, Tatiana R. Kuznetsova, Tatiana A. Kaunetis, Natalia V. Cegielski, J. Peter Kurbatova, Ekaterina V. TI Epidemiology of Primary Multidrug-Resistant Tuberculosis, Vladimir Region, Russia SO EMERGING INFECTIOUS DISEASES LA English DT Article ID SURVEILLANCE AB We studied the epidemiology of drug-resistant tuberculosis (TB) in Vladimir Region, Russia, in 2012. Most cases of multidrug-resistant TB (MDR TB) were caused by transmission of drug-resistant strains, and >33% were in patients referred for testing after mass radiographic screening. Early diagnosis of drug resistance is essential for preventing transmission of MDR TB. C1 [Ershova, Julia V.; Kaminski, Dorothy A.; Cegielski, J. Peter; Kurbatova, Ekaterina V.] Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. [Volchenkov, Grigory V.; Somova, Tatiana R.; Kuznetsova, Tatiana A.; Kaunetis, Natalia V.] Vladimir Oblast TB Dispensary, Vladimir, Russia. RP Ershova, JV (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop E10, Atlanta, GA 30329 USA. EM jhe3@cdc.gov FU US Agency for International Development FX Funding was provided by the US Agency for International Development. NR 10 TC 2 Z9 2 U1 2 U2 7 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD NOV PY 2015 VL 21 IS 11 BP 2048 EP 2051 DI 10.3201/eid2111.150813 PG 4 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CU5WA UT WOS:000363601500022 PM 26488585 ER PT J AU Roy, S Rungsrisuriyachai, K Esona, MD Boom, JA Sahni, LC Rench, MA Baker, CJ Wikswo, ME Payne, DC Parashar, UD Bowen, MD AF Roy, Sunando Rungsrisuriyachai, Kunchala Esona, Mathew D. Boom, Julie A. Sahni, Leila C. Rench, Marcia A. Baker, Carol J. Wikswo, Mary E. Payne, Daniel C. Parashar, Umesh D. Bowen, Michael D. TI G2P[4]-RotaTeq Reassortant Rotavirus in Vaccinated Child, United States SO EMERGING INFECTIOUS DISEASES LA English DT Letter ID MAXIMUM-LIKELIHOOD; RECOMMENDATIONS; GASTROENTERITIS C1 [Roy, Sunando; Rungsrisuriyachai, Kunchala; Esona, Mathew D.; Wikswo, Mary E.; Payne, Daniel C.; Parashar, Umesh D.; Bowen, Michael D.] Ctr Dis Control & Prevent, Atlanta, GA 30322 USA. [Boom, Julie A.; Sahni, Leila C.; Baker, Carol J.] Texas Childrens Hosp, Houston, TX 77030 USA. [Rench, Marcia A.; Baker, Carol J.] Baylor Coll Med, Houston, TX 77030 USA. RP Roy, S (reprint author), Ctr Dis Control & Prevent, Atlanta, GA 30322 USA. NR 10 TC 0 Z9 0 U1 1 U2 2 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD NOV PY 2015 VL 21 IS 11 BP 2103 EP 2104 DI 10.3201/eid2111.150850 PG 2 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CU5WA UT WOS:000363601500040 PM 26488454 ER PT J AU Breedlove, B M'ikanatha, NM AF Breedlove, Byron M'ikanatha, Nkuchia M. TI Celebrating the Fabric of Commonplace Society SO EMERGING INFECTIOUS DISEASES LA English DT Editorial Material C1 [Breedlove, Byron] Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. [M'ikanatha, Nkuchia M.] Penn Dept Hlth, Harrisburg, PA 17108 USA. RP Breedlove, B (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop C19, Atlanta, GA 30329 USA. EM wbbl@cdc.gov OI Breedlove, Byron/0000-0002-1026-1963 NR 6 TC 0 Z9 0 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD NOV PY 2015 VL 21 IS 11 BP 2110 EP 2111 DI 10.3201/eid2111.AC2111 PG 2 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CU5WA UT WOS:000363601500043 ER PT J AU Pearson, WS Davis, AD Hoover, KW Gift, TL Owusu-Edusei, K Tao, GY AF Pearson, William S. Davis, Anthony D. Hoover, Karen W. Gift, Thomas L. Owusu-Edusei, Kwame Tao, Guoyu TI Demographic and Health Services Characteristics Associated With Testing for Sexually Transmitted Infections Among a Commercially Insured Population of HIV-Positive Patients SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article DE sexually transmitted infections; HIV; testing; privately insured ID DISEASES TREATMENT GUIDELINES; PRIMARY-CARE; EPIDEMIOLOGIC SYNERGY; INSURANCE-COVERAGE; UNITED-STATES; CHLAMYDIA; SYPHILIS; ADULTS; AIDS AB Background:Presence of a sexually transmitted infection (STI) can increase the likelihood of HIV transmission, and current treatment guidelines indicate that HIV-positive persons should be screened yearly for STIs. Therefore, we examined recent insurance claims data to determine whether private insurance beneficiaries who are HIV-positive were receiving recommended STI testing.Methods:We used data from the 2011 and 2012 MarketScan data sets, a longitudinal population-based database that collects claims from commercially insured persons in private insurance and is conducted by Truven Health Analytics. Over a 13-month period, we calculated rates of testing for chlamydia, gonorrhea, and syphilis among an HIV-positive population and determined the factors that contributed to differences in testing rates.Results:Overall testing rates were 22.2% for chlamydia, 21.9% for gonorrhea, and 51.1% for syphilis. Significant predictors of STI testing were sex, age, type of health plan, engagement with the health care system, and geographic location. Most notably, persons receiving viral load testing were more likely to receive testing for chlamydia [odds ratio (OR): 1.72; 95% confidence interval (CI): 1.63 to 1.81], gonorrhea (OR: 1.72; 95% CI: 1.64 to 1.81), and syphilis (OR: 3.38; 95% CI: 3.25 to 3.53) compared with persons not receiving viral load testing.Discussion:Not all commercially insured HIV-positive patients are receiving recommended testing for STIs. Presence of STIs could affect the transmission of HIV and has deleterious effects on health outcomes of the patients. Targeted efforts based on demographics, health plan type, and other quality-of-care measures could help identify populations for whom testing rates for STIs among HIV-positive persons could be improved. C1 [Pearson, William S.; Gift, Thomas L.; Owusu-Edusei, Kwame; Tao, Guoyu] Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Div STD Prevent, Atlanta, GA 30333 USA. [Davis, Anthony D.] Univ Calif San Diego, Dept Family & Prevent Med, San Diego, CA 92103 USA. [Davis, Anthony D.] San Diego State Univ, Grad Sch Publ Hlth, San Diego, CA 92182 USA. [Hoover, Karen W.] Ctr Dis Control & Prevent, Div HIV & AIDS Prevent, Atlanta, GA 30333 USA. RP Pearson, WS (reprint author), Ctr Dis Control & Prevent, Natl Ctr HIV Hepatitis & STD Prevent, Div STD Prevent, Atlanta, GA 30333 USA. EM wpearson@cdc.gov NR 27 TC 1 Z9 1 U1 2 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1525-4135 EI 1077-9450 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD NOV 1 PY 2015 VL 70 IS 3 BP 269 EP 274 DI 10.1097/QAI.0000000000000709 PG 6 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CU6ID UT WOS:000363634600008 PM 26039931 ER PT J AU Byakwaga, H Hunt, PW Laker-Oketta, M Glidden, DV Huang, Y Bwana, BM Mocello, AR Bennett, J Walusansa, V Dollard, SC Bangsberg, DR Mbidde, EK Martin, JN AF Byakwaga, Helen Hunt, Peter W. Laker-Oketta, Miriam Glidden, David V. Huang, Yong Bwana, Bosco M. Mocello, A. Rain Bennett, John Walusansa, Victoria Dollard, Sheila C. Bangsberg, David R. Mbidde, Edward K. Martin, Jeffrey N. TI The Kynurenine Pathway of Tryptophan Catabolism and AIDS-Associated Kaposi Sarcoma in Africa SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article DE tryptophan; kynurenine; indoleamine 2; 3-dioxygenase-1; HIV; Kaposi sarcoma; plasma HIV RNA; Africa ID IMMUNODEFICIENCY-VIRUS TYPE-1; ACTIVE ANTIRETROVIRAL THERAPY; PLASMACYTOID DENDRITIC CELLS; HIV-INFECTED PATIENTS; HERPESVIRUS TYPE 8; T-CELL; INDOLEAMINE 2,3-DIOXYGENASE; HUMAN-HERPESVIRUS-8 INFECTION; HOMOSEXUAL-MEN; GROWTH-FACTOR AB Background:Other than Kaposi sarcoma (KS)-associated herpesvirus and CD4(+) T-cell lymphopenia, the mechanisms responsible for KS in the context of HIV are poorly understood. One recently explored pathway of HIV pathogenesis involves induction of the enzyme indoleamine 2,3-dioxygenase-1 (IDO), which catabolizes tryptophan into kynurenine and several other immunologically active metabolites that suppress T-cell proliferation. We investigated the role of IDO in the development of KS in HIV disease.Methods:In a case-control study among untreated HIV-infected Ugandans, cases were adults with KS and controls were without KS. IDO activity was assessed by the ratio of plasma kynurenine to tryptophan levels (KT ratio), measured by liquid chromatography-tandem mass spectrometry.Results:We studied 631 HIV-infected subjects: 222 KS cases and 409 controls. Non-KS controls had a higher median plasma KT ratio (130, interquartile range: 90 to 190 nM/M) than KS cases (110, interquartile range: 90 to 150 nM/M) (P = 0.004). After adjustment for age, sex, CD4 count, and plasma HIV RNA level, subjects with the highest (fourth quartile) plasma KT ratios had a 59% reduction (95% confidence interval: 27% to 77%) in the odds of KS compared with those with the lowest (first quartile) levels. KS was also independently associated with lower CD4(+) count, higher plasma HIV RNA, and men.Conclusions:Among HIV-infected individuals, greater activity of the kynurenine pathway of tryptophan catabolism, as evidenced by higher levels of plasma KT ratio, was associated with lower occurrence of KS. Some consequences of immune activation in HIV infection might actually suppress certain cancers. C1 [Byakwaga, Helen; Bwana, Bosco M.] Mbarara Univ Sci & Technol, Mbarara, Uganda. [Byakwaga, Helen; Hunt, Peter W.; Laker-Oketta, Miriam; Glidden, David V.; Huang, Yong; Mocello, A. Rain; Bennett, John; Martin, Jeffrey N.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Laker-Oketta, Miriam; Mbidde, Edward K.] Infect Dis Inst, Kampala, Uganda. [Walusansa, Victoria] Uganda Canc Inst, Kampala, Uganda. [Dollard, Sheila C.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Bangsberg, David R.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Global Hlth, Boston, MA USA. [Mbidde, Edward K.] Uganda Virus Res Inst, Entebbe, Uganda. RP Byakwaga, H (reprint author), Mbarara Univ Sci & Technol, POB 1397, Mbarara, Uganda. EM hbyakwaga@gmail.com FU National Institutes of Health (NIH) [D43 CA153717, R01 CA119903, R01 MH054097, U01 CA066529, U01 AI069911, P30 AI027763] FX Supported by National Institutes of Health (NIH) grants D43 CA153717, R01 CA119903, R01 MH054097, U01 CA066529, U01 AI069911, and P30 AI027763. NR 58 TC 3 Z9 3 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1525-4135 EI 1077-9450 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD NOV 1 PY 2015 VL 70 IS 3 BP 296 EP 303 DI 10.1097/QAI.0000000000000747 PG 8 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CU6ID UT WOS:000363634600012 PM 26181812 ER PT J AU Smith, T Samandari, T Abimbola, T Marston, B Sangrujee, N AF Smith, Tyler Samandari, Taraz Abimbola, Taiwo Marston, Barbara Sangrujee, Nalinee TI Cost-Effectiveness of Antiretroviral Therapy and Isoniazid Prophylaxis to Reduce Tuberculosis and Death in People Living With HIV in Botswana SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article DE cost; cost-effectiveness; tuberculosis; HIV infection; antiretroviral therapy; antituberculosis therapy ID PLACEBO-CONTROLLED TRIAL; RIO-DE-JANEIRO; PREVENTIVE THERAPY; INFECTED ADULTS; SOUTH-AFRICA; HIV-1-INFECTED PATIENTS; COLLABORATIVE ANALYSIS; TESTING CENTER; DOUBLE-BLIND; UGANDA AB Objective:In Botswana, a 36-month course of isoniazid treatment of latent tuberculosis (TB) infection [isoniazid preventive therapy (IPT)] was superior to 6-month IPT in reducing TB and death in persons living with HIV (PLHIV), having positive tuberculin skin tests (TSTs) but not in those with negative TST. We examined the cost-effectiveness of IPT in Botswana, where antiretroviral therapy (ART) is widely available.Design:Using a decision-analytic model, we determined the incremental cost-effectiveness of strategies for reducing TB and death in 10,000 PLHIV over 36 months.Methods:IPT for 6 months and provision of ART if CD4(+) lymphocyte count <250 cells per microliter (2011 Botswana policy) was compared with 6 alternative strategies that varied the use of IPT, TST, and ART for CD4(+) count thresholds, including CD4(+) <350 and <500 cells per microliter.Results:Botswana policy, 2011 was dominated by most other strategies. IPT of 36 months for TST-positive PLHIV with ART for CD4(+) <250 cells per microliter resulted in 120 fewer TB cases for an additional cost of $1612 per case averted and resulted in 80 fewer deaths for an additional $2418 per death averted compared with provision of 6-month IPT to TST-positive PLHIV who received ART for CD4(+) <250 cells per microliter, the next most effective strategy. Alternative strategies offered lower incremental effectiveness at higher cost. These findings remained consistent in sensitivity analyses.Conclusions:A strategy of treating PLHIV who have positive TST with 36-month IPT is more cost effective for reducing both TB and death compared with providing IPT without a TST, providing only 6-month IPT, or expanding ART eligibility without IPT. C1 [Smith, Tyler; Abimbola, Taiwo; Marston, Barbara; Sangrujee, Nalinee] US Ctr Dis Control & Prevent CDC, Div Global HIV AIDS, Washington, DC 20009 USA. [Samandari, Taraz] US Ctr Dis Control & Prevent CDC, Div TB Eliminat, Washington, DC 20009 USA. RP Smith, T (reprint author), US Ctr Dis Control & Prevent CDC, Div Global HIV AIDS, 1421 T St NW 8, Washington, DC 20009 USA. EM smitht1@state.gov FU Intramural CDC HHS [CC999999] NR 60 TC 2 Z9 2 U1 1 U2 7 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1525-4135 EI 1077-9450 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD NOV 1 PY 2015 VL 70 IS 3 BP E84 EP E93 DI 10.1097/QAI.0000000000000783 PG 10 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CU6IF UT WOS:000363634800002 PM 26258564 ER PT J AU Romero, LM Middleton, D Mueller, T Avellino, L Hallum-Montes, R AF Romero, Lisa M. Middleton, Dawn Mueller, Trisha Avellino, Lia Hallum-Montes, Rachel TI Improving the Implementation of Evidence-Based Clinical Practices in Adolescent Reproductive Health Care Services SO JOURNAL OF ADOLESCENT HEALTH LA English DT Article DE Teen pregnancy; Adolescent reproductive health services; Evidence-based clinical practices; Youth-friendly reproductive health services ID FAMILY-PLANNING-SERVICES; UNITED-STATES; CONTRACEPTIVE SERVICES; PREVENTIVE SERVICES; POSITION PAPER; YOUNG-ADULTS; WOMEN; PREGNANCY; TRENDS; TEENS AB Purpose: The purposes of the study were to describe baseline data in the implementation of evidence-based clinical practices among health center partners as part of a community-wide teen pregnancy prevention initiative and to identify opportunities for health center improvement. Methods: Health center partner baseline data were collected in the first year (2011) and before program implementation of a 5-year community-wide teen pregnancy prevention initiative. A needs assessment on health center capacity and implementation of evidence-based clinical practices was administered with 51 health centers partners in 10 communities in the United States with high rates of teen pregnancy. Results: Health centers reported inconsistent implementation of evidence-based clinical practices in providing reproductive health services to adolescents. Approximately 94.1% offered same-day appointments, 91.1% had infrastructure to reduce cost barriers, 90.2% offered after-school appointments, and 80.4% prescribed hormonal contraception without prerequisite examinations or testing. Approximately three quarters provided visual and audio privacy in examination rooms (76.5%) and counseling areas (74.5%). Fewer offered a wide range of contraceptive methods (67.8%) and took a sexual health history at every visit (54.9%). Only 45.1% reported Quick Start initiation of hormonal contraception, emergency contraception (43.1%), or intrauterine devices (12.5%) were "always" available to adolescents. Conclusions: The assessment highlighted opportunities for health center improvement. Strategies to build capacity of health center partners to implement evidence-based clinical practices may lead to accessibility and quality of reproductive health services for adolescents in the funded communities. Published by Elsevier Inc. on behalf of Society for Adolescent Health and Medicine. C1 [Romero, Lisa M.; Mueller, Trisha] Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. [Middleton, Dawn; Avellino, Lia; Hallum-Montes, Rachel] Cicatelli Associates Inc, New York, NY USA. RP Romero, LM (reprint author), Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway,NE MS F-74, Atlanta, GA 30341 USA. EM lmromero@cdc.gov FU Intramural CDC HHS [CC999999] NR 44 TC 2 Z9 2 U1 1 U2 10 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1054-139X EI 1879-1972 J9 J ADOLESCENT HEALTH JI J. Adolesc. Health PD NOV PY 2015 VL 57 IS 5 BP 488 EP 495 DI 10.1016/j.jadohealth.2015.07.013 PG 8 WC Psychology, Developmental; Public, Environmental & Occupational Health; Pediatrics SC Psychology; Public, Environmental & Occupational Health; Pediatrics GA CU4IR UT WOS:000363492100008 PM 26381918 ER PT J AU Walker, XJ Barnett, ED Wilson, ME Macleod, WB Jentes, ES Karchmer, AW Hamer, DH Chen, LH AF Walker, Xaviour J. Barnett, Elizabeth D. Wilson, Mary E. Macleod, William B. Jentes, Emily S. Karchmer, Adolf W. Hamer, Davidson H. Chen, Lin H. CA BATMN TI Characteristics of Travelers to Asia Requiring Multidose Vaccine Schedules: Japanese Encephalitis and Rabies Prevention SO JOURNAL OF TRAVEL MEDICINE LA English DT Article ID US INTERNATIONAL TRAVELERS; GLOBAL TRAVEPINET; IMMUNIZATION PRACTICES; ADVISORY-COMMITTEE; UNITED-STATES; HEALTH-CARE; JE VACCINE; IMMUNOGENICITY; RISK; RECOMMENDATIONS AB Background. Japanese encephalitis (JE) and rabies are serious vaccine preventable diseases which are an important consideration for travelers to Asia. Methods. Five Boston-area travel clinics collected demographic data, trip information, and interventions for travelers to Asia seen at pre-travel consultations from March 1, 2008, through July 31, 2010. We evaluated travelers for proportion vaccinated for JE and rabies, those traveling for >1 month, and whether travelers had adequate time to complete the JE series (clinic visit >= 28 days before departure) and rabies pre-exposure prophylaxis (clinic visit >= 21 days before departure). Results. Among 15,440 travelers from five Boston Area Travel Medicine Network travel clinics, Asia was the most common destination region, visited by 5,582 (36%) of travelers. Among these travelers, 4,810 (86%) planned to travel to only one Asian subregion. Median trip duration was 17 days, with more than 20% traveling for >1 month. The most common destinations were South (41%), Southeast (26%), and East (23%) Asia. Of those traveling to South, Southeast, or East Asia, over one-third with trips >1 month had insufficient time to complete a series for either JE or rabies vaccine. Overall, only 10% of travelers were vaccinated (past and pre-travel visit) for either JE or rabies, with lowest percentages among travelers visiting friends and relatives. Most travelers received advice on vector precautions (96%) and rabies prevention, which included avoiding animal contact, washing wounds, and obtaining appropriate post-exposure prophylaxis (88%). Conclusion. Given the insufficient time for completion and relatively low vaccination rates, greater awareness of earlier pre-travel consultations, at least 4-6 weeks before travel, and accurate risk assessment for travelers are important. Effective counseling about vector avoidance, rabies, and animal bite prevention and management remains critical. C1 [Walker, Xaviour J.] Johns Hopkins Bloomberg, Sch Publ Hlth, Baltimore, MD USA. [Barnett, Elizabeth D.] Boston Med Ctr, Sect Pediat Infect Dis, Boston, MA USA. [Barnett, Elizabeth D.] Boston Univ, Sch Med, Boston, MA 02118 USA. [Wilson, Mary E.] Harvard Univ, TH Chan Sch Publ Hlth, Boston, MA 02115 USA. [Macleod, William B.; Hamer, Davidson H.] Boston Univ, Sch Publ Hlth, Ctr Global Hlth & Dev, Boston, MA 02215 USA. [Jentes, Emily S.] Ctr Dis Control & Prevent, Div Global Migrat & Quarantine, Atlanta, GA USA. [Karchmer, Adolf W.] Beth Israel Deaconess Med Ctr, Dept Med, Div Infect Dis, Boston, MA 02215 USA. [Karchmer, Adolf W.; Chen, Lin H.] Harvard Univ, Sch Med, Fac Med, Boston, MA 02115 USA. [Hamer, Davidson H.] Boston Univ, Sch Med, Infect Dis Sect, Boston, MA 02118 USA. [Chen, Lin H.] Mt Auburn Hosp, Dept Med, Cambridge, MA 02138 USA. RP Chen, LH (reprint author), Mt Auburn Hosp, Dept Med, 330 Mt Auburn St, Cambridge, MA 02138 USA. EM lchen@hms.harvard.edu FU Centers for Disease Control and Prevention [1 U19CI000508-01]; Boston Medical Center [1 U19CI000508-01] FX This research was funded by a cooperative agreement (1 U19CI000508-01) between the Centers for Disease Control and Prevention and Boston Medical Center. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. NR 24 TC 1 Z9 1 U1 1 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1195-1982 EI 1708-8305 J9 J TRAVEL MED JI J. Travel Med. PD NOV-DEC PY 2015 VL 22 IS 6 BP 403 EP 409 DI 10.1111/jtm.12237 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA CU6PD UT WOS:000363653700009 PM 26420372 ER PT J AU Desai, AP Sharma, D Crispell, EK Baughman, W Thomas, S Tunali, A Sherwood, L Zmitrovich, A Jerris, R Satola, SW Beall, B Moore, MR Jain, S Farley, MM AF Desai, Ankita P. Sharma, Dolly Crispell, Emily K. Baughman, Wendy Thomas, Stepy Tunali, Amy Sherwood, Logan Zmitrovich, April Jerris, Robert Satola, Sarah W. Beall, Bernard Moore, Matthew R. Jain, Shabnam Farley, Monica M. TI Decline in Pneumococcal Nasopharyngeal Carriage of Vaccine Serotypes After the Introduction of the 13-Valent Pneumococcal Conjugate Vaccine in Children in Atlanta, Georgia SO PEDIATRIC INFECTIOUS DISEASE JOURNAL LA English DT Article DE Streptococcus pneumoniae; pneumococcus; nasopharyngeal carriage; 13-valent pneumococcal conjugate vaccine; vaccine effect ID STREPTOCOCCUS-PNEUMONIAE; UNITED-STATES; DISEASE; ERA; 19A; POPULATION; INFECTIONS; IMPACT AB Background:Streptococcus pneumoniae (SP) serotype distribution among nasopharyngeal (NP) carriage isolates changed significantly after the introduction of the 7-valent pneumococcal conjugate vaccine (PCV7). We evaluated the impact on NP carriage and invasive disease of SP after the introduction of the 13-valent PCV (PCV13) in March 2010. Methods: NP swabs were collected from children 6-59 months of age in an emergency department from July 2010 to June 2013. After broth enrichment, samples were cultured for SP and isolates were serotyped. Clinical and immunization records were reviewed. Findings during 6 sequential 6-month study periods were compared. Surveillance isolates of invasive disease isolates were reviewed. Results: A total of 2048 children were enrolled, and 656 (32%) were SP carriers. Mean age of carriers was 27 months, 54% were males. Carriage was higher among day-care attendees (P < 0.01) and children with respiratory tract illnesses (P < 0.5) and otitis media (P < 0.01). Commonly carried serotypes included 35B (15.2%), 15B/C (14.2%), 19A (9.6%), 11A (8%), 23B (5.6%), 6C (5.3%), 21 (5%), and 15A (5%); 13.9% were PCV13 serotypes. The proportion of children with SP carriage remained stable but the serotype distribution changed during the study period. Among carriers, PCV13 serotypes declined from 29% (36/124) to 3% (3/99; P < 0.0001), predominantly because of decline of serotype 19A from 25.8% (32/124) to 3% (3/99; P < 0.0001); non-PCV13 serotypes (excluding 6C) increased from 68.4% (78/114) to 97% (95/98; P < 0.0001); serotype 35B significantly increased from 8.9% (11/124) to 25.3% (25/99; P < 0.05). Nonsusceptibility to ceftriaxone declined from 22.6% (28/124) to 0% (0/99; P < 0.0001), with a similar decline in penicillin nonsusceptibility. Conclusions: Introduction of PCV13 for universal infant use was associated with significant reductions in nasopharyngeal carriage of PCV13 serotypes and resistant strains. Carriage of non-PCV13 serotypes increased modestly, particularly serotype 35B. Further investigation is warranted to determine whether nonvaccine pneumococcal serotypes carried in the nasopharynx are associated with significant replacement disease. C1 [Desai, Ankita P.; Crispell, Emily K.; Jerris, Robert; Satola, Sarah W.; Jain, Shabnam; Farley, Monica M.] Emory Univ, Sch Med, Atlanta, GA USA. [Desai, Ankita P.; Zmitrovich, April; Jerris, Robert; Jain, Shabnam] Childrens Healthcare Atlanta, Atlanta, GA USA. [Sharma, Dolly] SUNY Buffalo, Women & Childrens Hosp Buffalo, Buffalo, NY 14260 USA. [Crispell, Emily K.; Baughman, Wendy; Thomas, Stepy; Tunali, Amy; Satola, Sarah W.; Farley, Monica M.] Georgia Emerging Infect Program, Atlanta, GA USA. [Crispell, Emily K.; Baughman, Wendy; Thomas, Stepy; Tunali, Amy; Satola, Sarah W.; Farley, Monica M.] Vet Affairs Med Ctr, Atlanta, GA 30033 USA. [Sherwood, Logan; Beall, Bernard; Moore, Matthew R.] CDC, Div Bacterial Dis, Resp Dis Branch, Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Desai, AP (reprint author), 11100 Euclid Ave, Cleveland, OH 44106 USA. EM kita.desai@gmail.com NR 24 TC 17 Z9 17 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0891-3668 EI 1532-0987 J9 PEDIATR INFECT DIS J JI Pediatr. Infect. Dis. J. PD NOV PY 2015 VL 34 IS 11 BP 1168 EP 1174 DI 10.1097/INF.0000000000000849 PG 7 WC Immunology; Infectious Diseases; Pediatrics SC Immunology; Infectious Diseases; Pediatrics GA CU4WF UT WOS:000363530500005 PM 26226445 ER PT J AU Gounder, PP Brewster, M Bruce, MG Bruden, DJT Rudolph, K Hurlburt, DA Hennessy, TW AF Gounder, Prabhu P. Brewster, Melissa Bruce, Michael G. Bruden, Dana J. T. Rudolph, Karen Hurlburt, Debby A. Hennessy, Thomas W. TI Impact of the Pneumococcal Conjugate Vaccine and Antibiotic Use on Nasopharyngeal Colonization by Antibiotic Nonsusceptible Streptococcus pneumoniae, Alaska, 2000-2010 SO PEDIATRIC INFECTIOUS DISEASE JOURNAL LA English DT Article DE Streptococcus pneumonia; pneumococcal conjugate vaccine; antibiotic resistance; epidemiology ID ACUTE OTITIS-MEDIA; ANTIMICROBIAL RESISTANCE; UNITED-STATES; CARRIAGE; CHILDREN; DISEASE; TRIAL; EPIDEMIOLOGY; SECRETIONS; THERAPY AB Background: We describe the relative impact of the heptavalent pneumococcal conjugate vaccine (PCV7, introduced 2001) and antibiotic use on colonization by antibiotic-resistant pneumococci in urban Alaskan children during 2000-2010. Methods: We obtained nasopharyngeal swab specimens from a convenience sample of children aged <5 years at clinics annually during 2000-2004 and 2008-2010. PCV7 status and antibiotic use <90 days before enrollment were determined by interview/medical records review. Pneumococci were characterized by serotype and susceptibility to penicillin (PCN). Isolates with full PCN resistance (PCN-R) or intermediate PCN resistance (PCN-I) were classified as PCN-NS. Results: We recruited 3496 children (median, 452 per year). During 2000-2010, a range of 18-29% per year of children used PCN/amoxicillin (P value for trend = 0.09); the proportion age-appropriately vaccinated with PCV7 increased (090%; P < 0.01). Among pneumococcal isolates, the PCV7-serotype proportion decreased (53-<1%; P < 0.01) and nonPCV7-serotype proportion increased (43-95%; P < 0.01). PCN-R pneumococcal colonization prevalence decreased (23-9%; P < 0.01) and PCN-I pneumococcal colonization prevalence increased (13-24%; P < 0.01); overall PCN-NS pneumococcal colonization prevalence was unchanged. PCN-NS among colonizing PCV7-type and nonPCV7-type pneumococci remained unchanged; a mean of 31% per year of PCV7-type and 10% per year of nonPCV7-type isolates were PCN-R, and 10% per year of PCV7 and 20% per year of nonPCV7-type isolates were PCN-I. Conclusions: Overall, PCN-NS pneumococcal colonization remained unchanged during 2000-2010 because increased colonization by predominantly PCN-I non-PCV7 serotypes offset decreased colonization by predominantly PCN-R PCV7 serotypes. Proportion PCN-NS did not increase within colonizing pneumococcal serotype groups (PCV7 vs. non-PCV7) despite stable PCN use in our population. C1 [Gounder, Prabhu P.; Bruce, Michael G.; Bruden, Dana J. T.; Rudolph, Karen; Hurlburt, Debby A.; Hennessy, Thomas W.] US Ctr Dis Control & Prevent CDC, Arctic Invest Program, Div Preparedness & Emerging Infect, Natl Ctr Emerging & Zoonot Infect Dis, Anchorage, AK USA. [Brewster, Melissa] Alaska Native Tribal Hlth Consortium, Anchorage, AK USA. RP Gounder, PP (reprint author), 4055 Tudor Ctr Dr, Anchorage, AK 99508 USA. EM PGounder@cdc.gov FU Pfizer Vaccines FX This research was supported by an Investigator Initiated Research grant from Wyeth Pharmaceuticals (now Pfizer Vaccines) and in-kind support by the Centers for Disease Control and Prevention. The findings and conclusions in this report are those of the author(s) and do not necessarily represent the official position of the Centers for Disease Control and Prevention. NR 34 TC 1 Z9 1 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0891-3668 EI 1532-0987 J9 PEDIATR INFECT DIS J JI Pediatr. Infect. Dis. J. PD NOV PY 2015 VL 34 IS 11 BP 1223 EP 1229 DI 10.1097/INF.0000000000000856 PG 7 WC Immunology; Infectious Diseases; Pediatrics SC Immunology; Infectious Diseases; Pediatrics GA CU4WF UT WOS:000363530500015 PM 26226443 ER PT J AU Stein, R Shapatava, E Williams, W Griffin, T Bell, K Lyons, B Uhl, G AF Stein, Renee Shapatava, Ekaterine Williams, Weston Griffin, Tanesha Bell, Kelly Lyons, Bridget Uhl, Gary TI Reduced Sexual Risk Behaviors Among Young Men of Color Who Have Sex with Men: Findings from the Community-Based Organization Behavioral Outcomes of Many Men, Many Voices (CBOP-3MV) Project SO PREVENTION SCIENCE LA English DT Article DE Men who have sex with men; Young men of color who have sex with men; MSM; Many Men; Many Voices; 3MV; HIV risk behaviors; Evidenced-based behavioral interventions; Community-based organizations ID PREVENTION INTERVENTION; MODELS AB In 2006, the Centers for Disease Control and Prevention (CDC) funded community-based organizations (CBOs) to deliver Many Men, Many Voices (3MV) to young men of color who have sex with men. Although 3MV, a group-level behavioral intervention designed to reduce human immunodeficiency virus (HIV) risk behaviors of black men who have sex with men (MSM), has shown effectiveness when delivered in a controlled research environment, there is limited evidence that the intervention is associated with similar outcomes in "real world" settings. For the current project, CDC funded three CBOs to conduct outcome monitoring of the 3MV intervention to determine if young MSM of color report changes in HIV risk behaviors postintervention. Using a repeated measures design, risk behaviors were collected at baseline and again at 3 and 6 months postintervention. Changes in risk behaviors were assessed using generalized estimating equations. Participants (n = 337) reported decreases in sexual risk behaviors at both follow-up time points, such as sex without a condom, sex without a condom and multiple partners, and sex without a condom with serodiscordant or status unknown partners. Results suggest that 3MV may be an effective tool for reducing HIV risk behaviors in this critical target population. C1 [Stein, Renee; Shapatava, Ekaterine; Griffin, Tanesha; Lyons, Bridget; Uhl, Gary] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. [Williams, Weston] MANILA Consulting Grp Inc, Mclean, VA USA. RP Stein, R (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, 1600 Clifton Rd,MS E59, Atlanta, GA 30333 USA. EM arf7@cdc.gov NR 18 TC 2 Z9 2 U1 4 U2 8 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1389-4986 EI 1573-6695 J9 PREV SCI JI Prev. Sci. PD NOV PY 2015 VL 16 IS 8 BP 1147 EP 1158 DI 10.1007/s11121-015-0565-8 PG 12 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CU5HF UT WOS:000363562000014 PM 26031542 ER PT J AU Johnson, CY Grajewski, B AF Johnson, Candice Y. Grajewski, Barbara TI Bias from Differential Exposure Measurement Error in a Study of Flight Attendants SO AEROSPACE MEDICINE AND HUMAN PERFORMANCE LA English DT Article DE block hours; exposure assessment; preterm birth AB BACKGROUND: Self-reported occupational exposures are often used in epidemiological studies when actual exposure measurements are unavailable, which could cause measurement error and bias study results. This study provides a numeric example of this potential bias. METHODS: A study of block hours and preterm birth was used as an illustrative example. This study included 577 flight attendants, ages 18-45 yr, who gave birth to a term (37 or greater gestational weeks) or preterm (20-36 gestational weeks) infant between 1992 and 1996. Flight attendants self-reported the number of block hours flown during the first trimester of pregnancy; the number of block hours flown during the first trimester of pregnancy was also calculated from airline records. No adjustment for confounding was performed for this illustrative example. RESULTS: Although flight attendants having term and preterm births self-reported similar hours worked during the first trimester (median 213 vs. 215 block hours), airline records showed that flight attendants having term births worked more hours than those having preterm births (median 146 vs. 104 block hours). Using self-reported block hours, there was no association between block hours and preternn birth; when using airline records, an inverse association was observed. DISCUSSION: In this example, differential measurement error from use of self-reported block hours obscured an inverse association apparent when using airline records, demonstrating the importance of accurate exposure assessment for identifying occupational risk factors for health outcomes. C1 [Johnson, Candice Y.] NIOSH, Ctr Dis Control & Prevent, Cincinnati, OH 45226 USA. Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA. RP Johnson, CY (reprint author), NIOSH, Ctr Dis Control & Prevent, 1090 Tusculum Ave,MS R-15, Cincinnati, OH 45226 USA. EM cyjohnson@cdc.gov FU Federal Aviation Administration (FAA); Department of Defense Women's Health Research Program FX The findings and conclusions of this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention. This work was part of the Intramural Research Program of the National Institute for Occupational Safety and Health (NIOSH). The study was supported, in part, by interagency agreements with the Federal Aviation Administration (FAA) and the Department of Defense Women's Health Research Program. We thank the women who participated in this study. We appreciate the assistance of the study airlines, Airlines for America, the Association of Flight Attendants and its Seattle Local 19, the Association of Professional Flight Attendants and its Miami representatives, and the International Brotherhood of Teamsters, Airline Division, and its Detroit representatives. NR 6 TC 0 Z9 0 U1 0 U2 0 PU AEROSPACE MEDICAL ASSOC PI ALEXANDRIA PA 320 S HENRY ST, ALEXANDRIA, VA 22314-3579 USA SN 2375-6314 EI 2375-6322 J9 AEROSP MED HUM PERF JI Aerosp. Med.Hum. Perform. PD NOV PY 2015 VL 86 IS 11 BP 990 EP 993 DI 10.3357/AMHP.4321.2015 PG 4 WC Biophysics; Public, Environmental & Occupational Health; Medicine, Research & Experimental SC Biophysics; Public, Environmental & Occupational Health; Research & Experimental Medicine GA CU2OA UT WOS:000363361600009 PM 26564765 ER PT J AU Flynn, MA Eggerth, DE Jacobson, CJ AF Flynn, Michael A. Eggerth, Donald E. Jacobson, C. Jeffrey, Jr. TI Undocumented status as a social determinant of occupational safety and health: The workers' perspective SO AMERICAN JOURNAL OF INDUSTRIAL MEDICINE LA English DT Article DE occupational safety and health; immigrant workers; social determinates of health; undocumented status; structural violence; disengagement; latino health; theory of work adjustment; coping strategies ID MEXICAN IMMIGRANT WORKERS; CONSTRUCTION WORKERS; ANTHROPOLOGY; SEARCH; BORDER; RISKS; LABOR AB BackgroundUndocumented immigration to the United States has grown dramatically over the past 25 years. This study explores undocumented status as a social determinant of occupational health by examining its perceived consequences on workplace safety of Latino immigrants. MethodsGuided by the Theory of Work Adjustment, qualitative analysis was conducted on transcripts from focus groups and individual interviews conducted with a convenience sample of Latino immigrant workers. ResultsParticipants reported that unauthorized status negatively impacted their safety at work and resulted in a degree of alienation that exceeded the specific proscriptions of the law. Participants overwhelming used a strategy of disengagement to cope with the challenges they face as undocumented immigrants. ConclusionThis study describes the complex web of consequences resulting from undocumented status and its impact on occupational health. This study presents a framework connecting the daily work experiences of immigrants, the coping strategy of disengagement, and efforts to minimize the impact of structural violence. Am. J. Ind. Med. 58:1127-1137, 2015. (c) 2015 Wiley Periodicals, Inc. C1 [Flynn, Michael A.; Eggerth, Donald E.] NIOSH, Educ & Informat Div, Cincinnati, OH 45226 USA. [Jacobson, C. Jeffrey, Jr.] Univ Cincinnati, Dept Anthropol, Cincinnati, OH USA. [Jacobson, C. Jeffrey, Jr.] Univ Cincinnati, Dept Family & Community Med, Cincinnati, OH USA. RP Flynn, MA (reprint author), NIOSH, CDC, 4676 Columbia Pkwy,M-S C-10, Cincinnati, OH 45226 USA. EM mflynn@cdc.gov FU Intramural CDC HHS [CC999999] NR 48 TC 3 Z9 3 U1 0 U2 9 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0271-3586 EI 1097-0274 J9 AM J IND MED JI Am. J. Ind. Med. PD NOV PY 2015 VL 58 IS 11 BP 1127 EP 1137 DI 10.1002/ajim.22531 PG 11 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CU1ZN UT WOS:000363321000001 PM 26471878 ER PT J AU Lefkowitz, D Pechter, E Fitzsimmons, K Lumia, M Stephens, AC Davis, L Flattery, J Weinberg, J Harrison, RJ Reilly, MJ Filios, MS White, GE Rosenman, KD AF Lefkowitz, Daniel Pechter, Elise Fitzsimmons, Kathleen Lumia, Margaret Stephens, Alicia C. Davis, Letitia Flattery, Jennifer Weinberg, Justine Harrison, Robert J. Reilly, Mary Jo Filios, Margaret S. White, Gretchen E. Rosenman, Kenneth D. TI Isocyanates and work-related asthma: Findings from California, Massachusetts, Michigan, and New Jersey, 1993-2008 SO AMERICAN JOURNAL OF INDUSTRIAL MEDICINE LA English DT Article DE work-related asthma; isocyanates; occupational health surveillance; occupational disease prevention ID METHYLENE DIPHENYL DIISOCYANATE; OCCUPATIONAL ASTHMA; TOLUENE DIISOCYANATE; SKIN EXPOSURE; DYSFUNCTION SYNDROME; SURVEILLANCE DATA; SAMPLING METHODS; BODY REPAIR; INDUSTRY; TDI AB BackgroundIsocyanates remain a leading cause of work-related asthma (WRA). MethodsTwo independent data systems were analyzed for the period 1993-2008: (1) State-based WRA case surveillance data on persons with isocyanate-induced WRA from four states, and (2) Occupational Safety and Health Administration (OSHA) Integrated Management Information System (IMIS) isocyanate air sampling results. ResultsWe identified 368 cases of isocyanate-induced WRA from 32 industries and 678 OSHA isocyanate air samples with detectable levels from 31 industries. Seventeen industries were unique to one or the other dataset. ConclusionIsocyanate-induced WRA continues to occur in a wide variety of industries. Two data systems uncovered industries with isocyanate exposures and/or illness. Improved control measures and standards, including medical surveillance, are needed. More emphasis is needed on task-specific guidance, spill clean-up procedures, skin and respiratory protection, and targeted medical monitoring to mitigate the hazards of isocyanate use. Am. J. Ind. Med. 58:1138-1149, 2015. (c) 2015 Wiley Periodicals, Inc. C1 [Lefkowitz, Daniel; Lumia, Margaret; Stephens, Alicia C.] New Jersey Dept Hlth, Environm & Occupat Hlth Surveillance Program, Trenton, NJ 08625 USA. [Pechter, Elise; Fitzsimmons, Kathleen; Davis, Letitia] Massachusetts Dept Publ Hlth, Occupat Hlth Surveillance Program, Boston, MA USA. [Flattery, Jennifer; Harrison, Robert J.] Calif Dept Publ Hlth, Occupat Hlth Branch, Richmond, CA USA. [Weinberg, Justine] Calif Dept Publ Hlth, Inst Publ Hlth, Richmond, CA USA. [Reilly, Mary Jo; Rosenman, Kenneth D.] Michigan State Univ, Div Occupat & Environm Med, E Lansing, MI 48824 USA. [Filios, Margaret S.; White, Gretchen E.] NIOSH, Div Resp Dis Studies, Ctr Dis Control & Prevent, Morgantown, WV 26505 USA. [White, Gretchen E.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA USA. RP Lefkowitz, D (reprint author), New Jersey Dept Hlth, 135 East State St,POB 369, Trenton, NJ 08625 USA. EM Daniel.Lefkowitz@doh.state.nj.us FU Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health FX Contract grant sponsor: Centers for Disease Control and Prevention; Contract grant sponsor: National Institute for Occupational Safety and Health. NR 78 TC 1 Z9 2 U1 2 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0271-3586 EI 1097-0274 J9 AM J IND MED JI Am. J. Ind. Med. PD NOV PY 2015 VL 58 IS 11 BP 1138 EP 1149 DI 10.1002/ajim.22527 PG 12 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CU1ZN UT WOS:000363321000002 PM 26351141 ER PT J AU McCague, AB Cox-Ganser, JM Harney, JM Alwis, KU Blount, BC Cummings, KJ Edwards, N Kreiss, K AF McCague, Anna-Binney Cox-Ganser, Jean M. Harney, Joshua M. Alwis, K. Udeni Blount, Benjamin C. Cummings, Kristin J. Edwards, Nicole Kreiss, Kathleen TI Styrene-associated health outcomes at a windblade manufacturing plant SO AMERICAN JOURNAL OF INDUSTRIAL MEDICINE LA English DT Article DE styrene; occupational exposure; color vision defects; contrast sensitivity; spirometry ID EXHALED NITRIC-OXIDE; COLOR-VISION TEST; EXPOSED WORKERS; REINFORCED-PLASTICS; MORTALITY; ASTHMA; STANDARDIZATION; INDUSTRY AB BackgroundHealth risks of using styrene to manufacture windblades for the green energy sector are unknown. MethodsUsing data collected from 355 (73%) current windblade workers and regression analysis, we investigated associations between health outcomes and styrene exposure estimates derived from urinary styrene metabolites. ResultsThe median current styrene exposure was 53.6mg/g creatinine (interquartile range: 19.5-94.4). Color blindness in men and women (standardized morbidity ratios 2.3 and 16.6, respectively) was not associated with exposure estimates, but was the type previously reported with styrene. Visual contrast sensitivity decreased and chest tightness increased (odds ratio 2.9) with increasing current exposure. Decreases in spirometric parameters and FeNO, and increases in the odds of wheeze and asthma-like symptoms (odds ratios 1.3 and 1.2, respectively) occurred with increasing cumulative exposure. ConclusionsDespite styrene exposures below the recommended 400mg/g creatinine, visual and respiratory effects indicate the need for additional preventative measures in this industry. Am. J. Ind. Med. 58:1150-1159, 2015. (c) 2015 Wiley Periodicals, Inc. C1 [McCague, Anna-Binney; Cox-Ganser, Jean M.; Cummings, Kristin J.; Edwards, Nicole; Kreiss, Kathleen] NIOSH, Ctr Dis Control & Prevent, Div Resp Dis Studies, Field Studies Branch, Morgantown, WV 26505 USA. [McCague, Anna-Binney] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA. [Harney, Joshua M.] NIOSH, Hazard Evaluat & Tech Assistance Branch, Div Surveillance Hazard Evaluat & Field Studies, Morgantown, WV 26505 USA. [Alwis, K. Udeni; Blount, Benjamin C.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Div Sci Lab, Tobacco & Volatiles Branch, Atlanta, GA USA. RP Cummings, KJ (reprint author), NIOSH, Ctr Dis Control & Prevent, 1095 Willowdale Rd,MS 2800, Morgantown, WV 26505 USA. EM cvx5@cdc.gov FU National Institute for Occupational Safety and Health FX Contract grant sponsor: National Institute for Occupational Safety and Health. NR 47 TC 0 Z9 0 U1 1 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0271-3586 EI 1097-0274 J9 AM J IND MED JI Am. J. Ind. Med. PD NOV PY 2015 VL 58 IS 11 BP 1150 EP 1159 DI 10.1002/ajim.22516 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CU1ZN UT WOS:000363321000003 PM 26305283 ER PT J AU Asfaw, A Pana-Cryan, R Bushnell, T Sauter, S AF Asfaw, Abay Pana-Cryan, Regina Bushnell, Tim Sauter, Steven TI Musculoskeletal disorders and associated healthcare costs among family members of injured workers SO AMERICAN JOURNAL OF INDUSTRIAL MEDICINE LA English DT Article DE occupational injury; family health; musculoskeletal disorders; negative binomial; two-part model ID OCCUPATIONAL INJURY; ECONOMIC CONSEQUENCES; WORKPLACE INJURIES; UNITED-STATES; 2-PART MODEL; ILLNESS AB BackgroundResearch has infrequently looked beyond the injured worker when gauging the burden of occupational injury. ObjectivesWe explored the relationship between occupational injury and musculoskeletal disorders (MSDs) among family members of injured workers. Data and MethodsWe used 2005 and 2006 Truven Health Analytics databases, which contain information on workers' compensation and family healthcare claims. We used descriptive analyses, and negative binomial and two-part models. ResultsFamily members of severely injured workers had a 15% increase in the total number of MSD outpatient claims and a 34% increase in the mean cost of MSD claims compared to family members of non-severely injured workers within 3 months after injury. Extrapolating cost results to the national level implies that severe occupational injury would be associated with between $29 and $33 million additional cost of family member outpatient MSD claims. ConclusionOccupational injury can impose a formerly unrecognized health burden on family members of injured workers. Am. J. Ind. Med. 58:1205-1216, 2015. Published 2015. This article is a U.S. Government work and is in the public domain in the USA. C1 [Asfaw, Abay; Pana-Cryan, Regina] NIOSH, Ctr Dis Control & Prevent, ERSO, Washington, DC USA. [Bushnell, Tim] NIOSH, Ctr Dis Control & Prevent, ERSO, Cincinnati, OH 45226 USA. [Sauter, Steven] No Kentucky Univ, Highland Hts, KY 41076 USA. RP Asfaw, A (reprint author), 395 E St,SW, Washington, DC 20201 USA. EM hqp0@cdc.gov NR 32 TC 0 Z9 0 U1 3 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0271-3586 EI 1097-0274 J9 AM J IND MED JI Am. J. Ind. Med. PD NOV PY 2015 VL 58 IS 11 BP 1205 EP 1216 DI 10.1002/ajim.22500 PG 12 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CU1ZN UT WOS:000363321000008 PM 26331972 ER PT J AU Coleman, K Baker, KC Bloomsmith, MA Fahey, MA Lutz, CK McCowan, B Pierre, PJ Ruiz, CME Weed, JL Worlein, JM AF Coleman, K. Baker, K. C. Bloomsmith, M. A. Fahey, M. A. Lutz, C. K. McCowan, B. Pierre, P. J. Ruiz, C. M. Escabi Weed, J. L. Worlein, J. M. TI ASSESSING ABNORMAL BEHAVIOR: MEASUREMENT SCALES DEVELOPED BY THE BEHAVIORAL MANAGEMENT CONSORTIUM SO AMERICAN JOURNAL OF PRIMATOLOGY LA English DT Meeting Abstract CT 38th Annual Meeting of the American-Society-of-Primatologists CY JUN 18-21, 2015 CL Bend, OR SP Amer Soc Primatologists, Chimps Inc, Primate Conservat Inc, Purina LabDiet, Res Diets Inc, Carter 2 Syst Inc, S Karger Publishers Inc, Cambridge Univ Press, Unifab Corp, Van Hoang Dao C1 [Coleman, K.] Oregon Natl Primate Res Ctr, Beaverton, OR 97006 USA. [Baker, K. C.] Tulane Natl Primate Res Ctr, Covington, LA USA. [Bloomsmith, M. A.] Yerkes Natl Primate Res Ctr, Atlanta, GA USA. [Fahey, M. A.] New England Natl Primate Res Ctr, Atlanta, GA USA. [Lutz, C. K.] Southwest Natl Primate Res Ctr, New York, NY USA. [McCowan, B.] Calif Natl Primate Res Ctr, San Francisco, CA USA. [Pierre, P. J.] Wisconsin Natl Primate Res Ctr, Atlanta, GA USA. [Ruiz, C. M. Escabi] Caribbean Primate Res Ctr, Atlanta, GA USA. [Weed, J. L.] Ctr Dis Control, Atlanta, GA 30333 USA. [Worlein, J. M.] Washington Natl Primate Res Ctr, Washington, DC USA. NR 0 TC 0 Z9 0 U1 2 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0275-2565 EI 1098-2345 J9 AM J PRIMATOL JI Am. J. Primatol. PD NOV PY 2015 VL 77 SU 1 MA 142 BP 94 EP 95 PG 2 WC Zoology SC Zoology GA CU5GQ UT WOS:000363560500114 ER PT J AU Foster, MA Iqbal, J Zhang, CX McHenry, R Cleveland, BE Romero-Herazo, Y Fonnesbeck, C Payne, DC Chappell, JD Halasa, N Gomez-Duarte, OG AF Foster, Monique A. Iqbal, Junaid Zhang, Chengxian McHenry, Rendie Cleveland, Brent E. Romero-Herazo, Yesenia Fonnesbeck, Chris Payne, Daniel C. Chappell, James D. Halasa, Natasha Gomez-Duarte, Oscar G. TI Enteropathogenic and enteroaggregative E. coli in stools of children with acute gastroenteritis in Davidson County, Tennessee SO DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE LA English DT Article DE E coli; diarrhea; children; gastroenteritis; EPEC; EAEC; epidemiology ID DIARRHEAGENIC ESCHERICHIA-COLI; UNITED-STATES; CHILDHOOD DIARRHEA; PHYLOGENETIC ANALYSIS; EMERGENCY-DEPARTMENT; SHIGA-TOXIN; ETIOLOGY; STRAINS; EPIDEMIOLOGY; MULTICENTER AB This prospective acute gastroenteritis (AGE) surveillance was conducted in the inpatient and emergency room settings at a referral pediatric hospital to determine the prevalence of diarrheagenic Escherichia coli (DEC) in children <12 years of age with AGE in Davidson County, Tennessee. Subjects 15 days to 11 years of age, who presented with diarrhea and/or vomiting, were enrolled. Stool specimens were processed for detection of DEC using multiplex polymerase chain reaction. From December 1, 2011, to June 30, 2012, a total of 79 (38%) out of 206 stool specimens from children with AGE tested positive for E. coli. A total of 12 (5.8%) out of 206 stool specimens from children with AGE were positive for a DEC. Eight (67%) out of these 12 were positive for enteropathogenic E. coli, and the remaining 4 were positive for enteroaggregative E. coli. DEC clinical isolates clustered with known E. coli enteropathogens according to multilocus sequencing typing. (C) 2015 Elsevier Inc. All rights reserved. C1 [Foster, Monique A.; Iqbal, Junaid; Zhang, Chengxian; McHenry, Rendie; Cleveland, Brent E.; Romero-Herazo, Yesenia; Fonnesbeck, Chris; Chappell, James D.; Halasa, Natasha; Gomez-Duarte, Oscar G.] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA. [Payne, Daniel C.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Gomez-Duarte, OG (reprint author), Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA. EM Oscar.gomez@vanderbilt.edu FU Department of Pediatrics, Vanderbilt University School of Medicine; T32 fellowship award FX This study was funded in part by funds from the Department of Pediatrics, Vanderbilt University School of Medicine, to O.G.G.-D., and by a T32 fellowship award to M.F. NR 40 TC 3 Z9 3 U1 0 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0732-8893 EI 1879-0070 J9 DIAGN MICR INFEC DIS JI Diagn. Microbiol. Infect. Dis. PD NOV PY 2015 VL 83 IS 3 BP 319 EP 324 DI 10.1016/j.diagmicrobio.2015.07.016 PG 6 WC Infectious Diseases; Microbiology SC Infectious Diseases; Microbiology GA CU2OO UT WOS:000363363000024 PM 26298817 ER PT J AU Zhang, L Yesupriya, A Chang, MH Teshale, E Teo, CG AF Zhang, Lyna Yesupriya, Ajay Chang, Man-Huei Teshale, Eyasu Teo, Chong-Gee TI Apolipoprotein E and protection against hepatitis E viral infection in American non-Hispanic blacks SO HEPATOLOGY LA English DT Article ID HEPARAN-SULFATE PROTEOGLYCANS; E VIRUS; C VIRUS; ALZHEIMERS-DISEASE; TRANSPORT PROTEIN; GENOMIC CONTROL; UNITED-STATES; CHOLESTEROL; VARIANTS; SURFACE AB Hepatitis E viral (HEV) infection imposes a heavy health burden worldwide and is common in the United States. Previous investigations of risks addressed environmental and host behavioral/lifestyle factors, but host genetic factors have not been examined. We assessed strength of associations between antibody to HEV (anti-HEV) immunoglobulin G seropositivity indicating past or recent HEV infection and human genetic variants among three major racial/ethnic populations in the United States, involving 2434 non-Hispanic whites, 1919 non-Hispanic blacks, and 1919 Mexican Americans from the Third National Health and Nutrition Examination Survey, 1991-1994. We studied 497 single-nucleotide polymorphisms across 190 genes (particularly those associated with lipid metabolism). The genomic control method was used to adjust for potential population stratification. Non-Hispanic blacks had the lowest seroprevalence of anti-HEV immunoglobulin G (15.3%, 95% confidence interval [CI] 12.3%-19.0%) compared with non-Hispanic whites (22.3%, 95% CI 19.1%-25.7%) and Mexican Americans (21.8%, 95% CI 19.0%-25.3%; P<0.01). Non-Hispanic blacks were the only population that showed association between anti-HEV seropositivity and functional epsilon 3 and epsilon 4 alleles of the apolipoprotein E (APOE) gene, encoding the apolipoprotein E protein that mediates lipoprotein metabolism. Seropositivity was significantly lower in participants carrying APOE epsilon 4 (odds ratio=0.5, 95% CI 0.4-0.7; P=0.00004) and epsilon 3 (odds ratio=0.6, 95% CI 0.4-0.8; P=0.001) compared to those carrying APOE epsilon 2. No significant associations were observed between other single-nucleotide polymorphisms and anti-HEV seropositivity in non-Hispanic blacks or between any single-nucleotide polymorphisms and anti-HEV seropositivity in non-Hispanic whites or Mexican Americans. Conclusion: Both APOE epsilon 3 and epsilon 4 are significantly associated with protection against HEV infection in non-Hispanic blacks; additional studies are needed to understand the basis of protection so that preventive services can be targeted to at-risk persons. (Hepatology 2015;62:1346-1352) C1 [Zhang, Lyna; Teshale, Eyasu; Teo, Chong-Gee] Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Div Viral Hepatitis, Atlanta, GA 30329 USA. [Yesupriya, Ajay] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Res Data Ctr, Atlanta, GA 30329 USA. [Chang, Man-Huei] Ctr Dis Control & Prevent, Off Directors, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30329 USA. RP Zhang, L (reprint author), Ctr Dis Control & Prevent, Off Publ Hlth Sci Serv, Ctr Surveillance Epidemiol & Lab Serv, Div Lab Syst, 1600 Clifton Rd NE,MS G23, Atlanta, GA 30329 USA. EM chn6@cdc.gov FU Centers for Disease Control and Prevention (Atlanta, GA) FX Supported by the Centers for Disease Control and Prevention (Atlanta, GA). The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention. NR 41 TC 7 Z9 7 U1 0 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD NOV PY 2015 VL 62 IS 5 BP 1346 EP 1352 DI 10.1002/hep.27938 PG 7 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA CU1EZ UT WOS:000363264100006 PM 26096528 ER PT J AU Edlin, BR Eckhardt, BJ Shu, MA Holmberg, SD Swan, T AF Edlin, Brian R. Eckhardt, Benjamin J. Shu, Marla A. Holmberg, Scott D. Swan, Tracy TI Toward a more accurate estimate of the prevalence of hepatitis C in the United States SO HEPATOLOGY LA English DT Article ID INJECTION-DRUG USE; HUMAN-IMMUNODEFICIENCY-VIRUS; NEW-YORK-CITY; VIRAL-HEPATITIS; HIV-INFECTION; CORRECTIONAL FACILITIES; HOMELESS MEN; RISK-FACTORS; US MILITARY; B-VIRUS AB Data from the 2003-2010 National Health and Nutrition Examination Survey (NHANES) indicate that about 3.6 million people in the United States have antibodies to the hepatitis C virus, of whom 2.7 million are currently infected. NHANES, however, excludes several high-risk populations from its sampling frame, including people who are incarcerated, homeless, or hospitalized; nursing home residents; active-duty military personnel; and people living on Indian reservations. We undertook a systematic review of peer-reviewed literature and sought out unpublished presentations and data to estimate the prevalence of hepatitis C in these excluded populations and in turn improve the estimate of the number of people with hepatitis C in the United States. The available data do not support a precise result, but we estimated that 1.0 million (range 0.4 million-1.8 million) persons excluded from the NHANES sampling frame have hepatitis C virus antibody, including 500,000 incarcerated people, 220,000 homeless people, 120,000 people living on Indian reservations, and 75,000 people in hospitals. Most are men. An estimated 0.8 million (range 0.3 million-1.5 million) are currently infected. Several additional sources of underestimation, including nonresponse bias and the underrepresentation of other groups at increased risk of hepatitis C that are not excluded from the NHANES sampling frame, were not addressed in this study. Conclusion: The number of US residents who have been infected with hepatitis C is unknown but is probably at least 4.6 million (range 3.4 million-6.0 million), and of these, at least 3.5 million (range 2.5 million-4.7 million) are currently infected; additional sources of potential underestimation suggest that the true prevalence could well be higher. (Hepatology 2015;62:1353-1363) C1 [Edlin, Brian R.; Eckhardt, Benjamin J.] Weill Cornell Med Coll, Dept Med, New York, NY USA. [Edlin, Brian R.] Natl Dev & Res Inst, Inst Infect Dis Res, New York, NY USA. [Shu, Marla A.] Beth Israel Deaconess Med Ctr, Dept Psychiat, New York, NY 10003 USA. [Holmberg, Scott D.] Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA USA. [Swan, Tracy] Treatment Act Grp, New York, NY USA. RP Edlin, BR (reprint author), 71 West 23rd St,4th floor, New York, NY 10010 USA. EM bredlin.nyc@gmail.com OI Eckhardt, Benjamin/0000-0002-2846-9762 FU NIDA NIH HHS [R01 DA021550, R01 DA016159, R01 DA029512] NR 96 TC 42 Z9 42 U1 6 U2 18 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD NOV PY 2015 VL 62 IS 5 BP 1353 EP 1363 DI 10.1002/hep.27978 PG 11 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA CU1EZ UT WOS:000363264100007 PM 26171595 ER PT J AU Chapko, MK Dufour, DR Hatia, RI Drobeniuc, J Ward, JW Teo, CG AF Chapko, Michael K. Dufour, D. Robert Hatia, Rikita I. Drobeniuc, Jan Ward, John W. Teo, Chong-Gee TI Cost-effectiveness of strategies for testing current hepatitis C virus infection SO HEPATOLOGY LA English DT Article ID POINT-OF-CARE; UNITED-STATES; HCV; ANTIBODY; POPULATIONS; MORTALITY; SETTINGS; OUTBREAK; SEROLOGY; OUTCOMES AB Six strategies for identifying hepatitis C virus (HCV) viremia, involving testing for HCV antibody (HCVAb) followed by a nucleic acid test (NAT) for HCV RNA when the antibody test is positive, are compared. Decision analysis was used to determine mean relative cost per person tested and outcomes of HCV viremia detection. Parameters included proportions of test population with HCVAb and viremia plus specificity, sensitivity, and cost of individual tests. For testing a population with an HCVAb seroprevalence of 3.25%, all strategies when adopting quantitative NAT vary little in cost (range, $29.50-$30.70) and are highly viremia specific (0.9997). Four of the strategies using venipuncture blood for HCVAb testing (whether laboratory conducted or employing a rapid, point-of-care assay) and for NAT (whether done by reflex or using separately drawn blood) achieve the highest viremia sensitivities (range, 0.9950-0.9954). Point-of-care HCVAb testing in fingerstick blood followed by NAT in venipuncture blood yields relatively lower viremia sensitivity (0.9301). The strategy that requires returning for NAT is even less viremia sensitive (<0.9000) because of follow-up loss. Strategies adopting qualitative rather than quantitative NAT are slightly cheaper (range, $28.90-$29.99), similarly viremia specific (0.9997), but less viremia sensitive (0.9456). Viremia sensitivity and specificity remain the same regardless of the proportion of HCVAb-seropositive persons in the cohort being tested. Conclusions: Strategies involving HCVAb testing in venipuncture blood, whether laboratory conducted or using a point-of-care assay, when followed by quantitative NAT done reflexively or in separately drawn blood, are comparably economical and suitably viremia sensitive. Less cost-effective is point-of-care HCVAb testing in fingerstick blood followed by NAT in venipuncture blood. Least cost-effective is the strategy requiring the tested person to return for NAT. (Hepatology 2015;62:1396-1404) C1 [Chapko, Michael K.] Vet Affairs Paget Sound Hlth Care Syst, Seattle, WA USA. [Chapko, Michael K.] Univ Washington, Seattle, WA 98195 USA. [Dufour, D. Robert] Vet Affairs Med Ctr, Washington, DC 20422 USA. [Hatia, Rikita I.; Drobeniuc, Jan; Ward, John W.; Teo, Chong-Gee] Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA USA. RP Chapko, MK (reprint author), VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev 152, 1660 S Columbian Way, Seattle, WA 98108 USA. EM michael.chapko@va.gov NR 27 TC 3 Z9 3 U1 0 U2 8 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD NOV PY 2015 VL 62 IS 5 BP 1396 EP 1404 DI 10.1002/hep.27966 PG 9 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA CU1EZ UT WOS:000363264100011 PM 26126725 ER PT J AU Gumbe, A McLellan-Lemal, E Gust, DA Pals, SL Gray, KM Ndivo, R Chen, RT Mills, LA Thomas, TK AF Gumbe, Anne McLellan-Lemal, Eleanor Gust, Deborah A. Pals, Sherri L. Gray, Kristen Mahle Ndivo, Richard Chen, Robert T. Mills, Lisa A. Thomas, Timothy K. CA KiCoS Study Team TI Correlates of prevalent HIV infection among adults and adolescents in the Kisumu incidence cohort study, Kisumu, Kenya SO INTERNATIONAL JOURNAL OF STD & AIDS LA English DT Article DE HIV; AIDS; epidemiology; prevalence; sexually transmitted infection; herpes simplex virus type 2 infection; male circumcision; gender disparities; Kenya ID SEXUALLY-TRANSMITTED INFECTIONS; SUB-SAHARAN AFRICA; IMMUNODEFICIENCY-VIRUS TYPE-1; HORMONAL CONTRACEPTIVE USE; MALE CIRCUMCISION; RISK-FACTORS; CONDOM USE; CONTROLLED-TRIAL; BEHAVIOR-CHANGE; WESTERN KENYA AB We estimated HIV prevalence and identified correlates of HIV infection among 1106 men and women aged 16-34 years residing in Kisumu, Kenya. Demographic, sexual, and other behavioural data were collected using audio computer-assisted self-interview in conjunction with a medical examination, real-time parallel rapid HIV testing, and laboratory testing for pregnancy, gonorrhoea, chlamydia, syphilis, and herpes simplex virus type 2. Multivariate logistic regression was used to identify variables associated with prevalent HIV infection by gender. Overall HIV prevalence was 12.1%. HIV prevalence among women (17.1%) was approximately two-and-one-half times the prevalence among men (6.6%). Odds of HIV infection in men increased with age (aOR associated with one-year increase in age=1.21, CI=1.07-1.35) and were greater among those who were uncircumcised (aOR=4.42, CI=1.41-13.89) and those who had an herpes simplex virus type 2-positive (aOR=3.13, CI=1.12-8.73) test result. Odds of prevalent HIV infection among women also increased with age (aOR associated with one-year increase in age=1.16, CI=1.04-1.29). Women who tested herpes simplex virus type 2 positive had more than three times the odds (aOR=3.85, CI=1.38-10.46) of prevalent HIV infection compared with those who tested herpes simplex virus type 2 negative. Tailored sexual health interventions and programs may help mitigate HIV age and gender disparities. C1 [Gumbe, Anne; Ndivo, Richard; KiCoS Study Team] Kenya Govt Med Res Ctr, Kisumu, Kenya. [McLellan-Lemal, Eleanor; Gust, Deborah A.; Pals, Sherri L.; Gray, Kristen Mahle; Chen, Robert T.] Natl Ctr HIV AIDS, Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Viral Hepatitis STD & TB Prevent, Atlanta, GA USA. [Mills, Lisa A.; Thomas, Timothy K.] Ctr Dis Control & Prevent, HIV Res Branch, Kisumu, Kenya. RP Gumbe, A (reprint author), Int AIDS Vaccine Initiat, ABC Pl Bldg 2,3rd Fl Waiyaki Way,POB 340 KNH, Nairobi, Kenya. EM agumbe@iavi.org FU Centers for Disease Control and Prevention (CDC), Atlanta, GA, USA FX The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Funding for this study was provided by the Centers for Disease Control and Prevention (CDC), Atlanta, GA, USA. NR 54 TC 2 Z9 2 U1 0 U2 4 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0956-4624 EI 1758-1052 J9 INT J STD AIDS JI Int. J. STD AIDS PD NOV PY 2015 VL 26 IS 13 BP 929 EP 940 DI 10.1177/0956462414563625 PG 12 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CU2CY UT WOS:000363331400003 PM 25505039 ER PT J AU Cherry, C Buttke, D Wong, D Wild, MA AF Cherry, Cara Buttke, Danielle Wong, David Wild, Margaret A. TI Freshwater harmful algal blooms and cyanotoxin poisoning in domestic dogs SO JAVMA-JOURNAL OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION LA English DT Letter C1 [Cherry, Cara] CDC, Div Sci Educ & Profess Dev, Biol Resources Div, Wildlife Hlth Branch,Off Publ Hlth,Natl Pk Serv, Ft Collins, CO 80521 USA. [Buttke, Danielle] Natl Pk Serv, US Publ Hlth Serv, Biol Resources Div, Wildlife Hlth Branch,Off Publ Hlth, Ft Collins, CO USA. [Wong, David] Natl Pk Serv, Epidemiol Branch, Off Publ Hlth, Albuquerque, NM USA. [Wild, Margaret A.] Natl Pk Serv, Biol Resources Div, Wildlife Hlth Branch, Ft Collins, CO USA. RP Cherry, C (reprint author), CDC, Div Sci Educ & Profess Dev, Biol Resources Div, Wildlife Hlth Branch,Off Publ Hlth,Natl Pk Serv, Ft Collins, CO 80521 USA. NR 7 TC 0 Z9 0 U1 1 U2 3 PU AMER VETERINARY MEDICAL ASSOC PI SCHAUMBURG PA 1931 N MEACHAM RD SUITE 100, SCHAUMBURG, IL 60173-4360 USA SN 0003-1488 EI 1943-569X J9 JAVMA-J AM VET MED A JI JAVMA-J. Am. Vet. Med. Assoc. PD NOV 1 PY 2015 VL 247 IS 9 BP 1004 EP 1005 PG 2 WC Veterinary Sciences SC Veterinary Sciences GA CU2DQ UT WOS:000363333400015 PM 26767217 ER PT J AU Just, AC Miller, RL Perzanowski, MS Rundle, AG Chen, QX Jung, KH Hoepner, L Camann, DE Calafat, AM Perera, FP Whyatt, RM AF Just, Allan C. Miller, Rachel L. Perzanowski, Matthew S. Rundle, Andrew G. Chen, Qixuan Jung, Kyung Hwa Hoepner, Lori Camann, David E. Calafat, Antonia M. Perera, Frederica P. Whyatt, Robin M. TI Vinyl flooring in the home is associated with children's airborne butylbenzyl phthalate and urinary metabolite concentrations SO JOURNAL OF EXPOSURE SCIENCE AND ENVIRONMENTAL EPIDEMIOLOGY LA English DT Article DE indoor air; phthalates; urine; vinyl flooring ID POLYCYCLIC AROMATIC-HYDROCARBONS; ENDOCRINE-DISRUPTING COMPOUNDS; DAY-CARE-CENTERS; INDOOR AIR; YOUNG-CHILDREN; EXPOSURE; DUST; VARIABILITY; ASTHMA; COHORT AB Prior studies have shown that vinyl flooring as well as the vinyl-softening plasticizers butylbenzyl phthalate (BBzP) and di(2-ethylhexyl) phthalate (DEHP) are associated with asthma and airway inflammation. Although DEHP exposure is primarily dietary, whether home vinyl flooring contributes to indoor air and urinary metabolite concentrations for these two phthalates is unclear. Exposures to BBzP and DEHP were examined in a prospective birth cohort of New York City children (n=239) using: (i) visual observation of potential phthalate containing flooring, (ii) a 2-week home indoor air sample, and (iii) concurrent urinary metabolites in a subset (n=193). The category "vinyl or linoleum" flooring was observed in 135 (56%) of monitored rooms; these rooms had statistically significantly higher indoor air geometric mean concentrations of BBzP (23.9 ng/m(3)) than rooms with wood or carpet flooring (10.6 ng/m(3)). Children from homes with "vinyl or linoleum" flooring also had significantly higher urinary BBzP metabolite concentrations than other children. Indoor air BBzP and urinary metabolite concentrations were correlated positively (Spearman's rho 0.40). By contrast, indoor air DEHP was not associated with flooring type nor with its urinary metabolite concentrations. Vinyl flooring in the home may be an important source of children's exposure to BBzP via indoor air. C1 [Just, Allan C.] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, HSPH EOME, Boston, MA 02215 USA. [Miller, Rachel L.; Perzanowski, Matthew S.; Rundle, Andrew G.; Hoepner, Lori; Perera, Frederica P.; Whyatt, Robin M.] Columbia Univ, Columbia Ctr Childrens Environm Hlth, New York, NY USA. [Miller, Rachel L.; Jung, Kyung Hwa] Columbia Univ, Coll Phys & Surg, Dept Med, Divi Pulm Allergy Crit Care, New York, NY USA. [Miller, Rachel L.] Columbia Univ, Coll Phys & Surg, Div Rheumatol Allergy & Immunol, Dept Pediat, New York, NY USA. [Rundle, Andrew G.] Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY USA. [Chen, Qixuan] Columbia Univ, Mailman Sch Publ Hlth, Dept Biostat, New York, NY USA. [Camann, David E.] Southwest Res Inst, San Antonio, TX USA. [Calafat, Antonia M.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA USA. RP Just, AC (reprint author), Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, HSPH EOME, 401 Pk Dr,Landmark Ctr,3rd Floor East,111 WS 12, Boston, MA 02215 USA. EM acjust@hsph.harvard.edu RI Rundle, Andrew/A-5282-2009; OI Rundle, Andrew/0000-0003-0211-7707; Just, Allan/0000-0003-4312-5957 FU National Institute of Environmental Health Sciences [R01 ES014393, R01 ES013163, P01 ES09600, R01 ES008977, P30 ES009089, T32 ES007069, K99 ES023450]; U.S. Environmental Protection Agency [R827027, RD832141, RD834509]; EPA STAR graduate fellowship [FP-91712001]; John and Wendy Neu Family Foundation; Blanchette Hooker Rockefeller Fund; New York Community Trust FX Supported by the National Institute of Environmental Health Sciences grants R01 ES014393, R01 ES013163, P01 ES09600, R01 ES008977, P30 ES009089, T32 ES007069 and K99 ES023450; the U.S. Environmental Protection Agency grants R827027, RD832141, RD834509, and EPA STAR graduate fellowship FP-91712001 (ACJ); the John and Wendy Neu Family Foundation; Blanchette Hooker Rockefeller Fund; and the New York Community Trust. We gratefully acknowledge the technical assistance of M. Silva, E. Samandar, J. Preau, and L. Jia in measuring the urinary concentrations of phthalate metabolites. NR 38 TC 0 Z9 0 U1 5 U2 12 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1559-0631 EI 1559-064X J9 J EXPO SCI ENV EPID JI J. Expo. Sci. Environ. Epidemiol. PD NOV-DEC PY 2015 VL 25 IS 6 BP 574 EP 579 DI 10.1038/jes.2015.4 PG 6 WC Environmental Sciences; Public, Environmental & Occupational Health; Toxicology SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology GA CU0QX UT WOS:000363224900005 PM 25690585 ER PT J AU Nkengasong, JN Skaggs, BA AF Nkengasong, John N. Skaggs, Beth A. TI Are post-Ebola reconstruction efforts neglecting public health laboratory systems? SO LANCET GLOBAL HEALTH LA English DT Letter C1 [Nkengasong, John N.; Skaggs, Beth A.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Nkengasong, JN (reprint author), Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. EM jcn5@cdc.gov FU Intramural CDC HHS [CC999999] NR 6 TC 4 Z9 4 U1 0 U2 3 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 2214-109X J9 LANCET GLOB HEALTH JI Lancet Glob. Health PD NOV PY 2015 VL 3 IS 11 BP E678 EP E678 PG 1 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CU1FI UT WOS:000363265000016 PM 26475013 ER PT J AU O'Ryan, M Bandyopadhyay, AS Villena, R Espinoza, M Novoa, J Weldon, WC Oberste, MS Self, S Borate, BR Asturias, EJ Clemens, R Orenstein, W Jimeno, J Ruttimann, R Clemens, SAC AF O'Ryan, Miguel Bandyopadhyay, Ananda S. Villena, Rodolfo Espinoza, Monica Novoa, Jose Weldon, William C. Oberste, M. Steven Self, Steve Borate, Bhavesh R. Asturias, Edwin J. Clemens, Ralf Orenstein, Walter Jimeno, Jose Ruettimann, Ricardo Costa Clemens, Sue Ann CA Chilean IPV bOPV Study Grp TI Inactivated poliovirus vaccine given alone or in a sequential schedule with bivalent oral poliovirus vaccine in Chilean infants: a randomised, controlled, open-label, phase 4, non-inferiority study SO LANCET INFECTIOUS DISEASES LA English DT Article ID INTESTINAL IMMUNITY; CLINICAL-TRIAL; POLIOMYELITIS; CHILDREN AB Background Bivalent oral poliovirus vaccine (bOPV; types 1 and 3) is expected to replace trivalent OPV (tOPV) globally by April, 2016, preceded by the introduction of at least one dose of inactivated poliovirus vaccine (IPV) in routine immunisation programmes to eliminate vaccine-associated or vaccine-derived poliomyelitis from serotype 2 poliovirus. Because data are needed on sequential IPV bOPV schedules, we assessed the immunogenicity of two different IPV bOPV schedules compared with an all-IPV schedule in infants. Methods We did a randomised, controlled, open-label, non-inferiority trial with healthy, full-term (>2.5 kg birthweight) infants aged 8 weeks (+/- 7 days) at six well-child clinics in Santiago, Chile. We used supplied lists to randomly assign infants (1:1:1) to receive three polio vaccinations (IPV by injection or bOPV as oral drops) at age 8,16, and 24 weeks in one of three sequential schedules: IPV bOPV bOPV, IPV IPV bOPV, or IPV IPV IPV. We did the randomisation with blocks of 12 stratified by study site. All analyses were done in a masked manner. Co-primary outcomes were non-inferiority of the bOPV-containing schedules compared with the all-IPV schedule for seroconversion (within a 10% margin) and antibody titres (within two-thirds log(2) titres) to poliovirus serotypes land 3 at age 28 weeks, analysed in the per-protocol population. Secondary outcomes were seroconversion and titres to serotype 2 and faecal shedding for 4 weeks after a monovalent OPV type 2 challenge at age 28 weeks. Safety analyses were done in the intention-to-treat population. This trial is registered with ClinicalTrials.gov, number NCT01841671, and is dosed to new participants. Findings Between April 25 and August 1,2013, we assigned 570 infants to treatment: 190 to IPV bOPV bOPV, 192 to IPV IPV bOPV, and 188 to IPV IPV IPV. 564 (99%) were vaccinated and included in the intention-to-treat cohort, and 537 (94%) in the per-protocol analyses. In the IPV bOPV bOPV, IPV IPV bOPV, and IPV IPV IPV groups, respectively, the proportions of children with seroconversion to type 1 poliovirus were 166 (98.8%) of 168,95% CI 95-8-99.7; 178 (100%), 97.9-100-0; and 175 (100%), 97.9-100.0. Proportions with seroconvsion to type 3 poliovirus were 163 (98.2%) of 166,94.8-99.4; 177(100%), 97.9-100-0, and 172(98.9%) of 174,95.9-99.7. Non-inferiority was thus shown for the bOPV-containing schedules compared with the all-IPV schedule, with no significant differences between groups. In the IPV bOPV bOPV, IPV IPV bOPV, and IPV IPV IPV groups, respectively, the proportions of children with seroprotective antibody titres to type 1 poliovirus were 168 (98-8%) of 170, 95% CI 95-8-99.7; 181 (100%), 97.9-100.0; and 177 (100%), 97.9-100.0. Proportions to type 3 poliovirus were 166 (98-2%) of 169, 94.9-99.4; 180 (100%), 97-9400.0; and 174 (98.9%) of 176,96.0-99.7. Non-inferiority comparisons could not be done for this outcome because median litres for the groups receiving OPV were greater than the assay's upper limit of detection (log2 titres >10.5). The proportions of children seroconverting to type 2 poliovirus in the IPV bOPV bOPV, IPV IPV bOPV, and IPV IPV IPV groups, respectively, were 130 (77.4%) of 168, 95% CI 70.5-83.0; 169 (96.0%) of 176,92.0-98.0; and 175 (100%), 97.8-100. IPV bOPV schedules resulted in almost a 0.3 log reduction of type 2 faecal shedding compared with the IPV-only schedule. No participants died during the trial; 81 serious adverse events were reported, of which one was thought to be possibly vaccine-related (intestinal intussusception). Interpretation Seroconversion rates against polioviruses types 1 and 3 were non-inferior in sequential schedules containing IPV and bOPV, compared with an all-IPV schedule, and proportions of infants with protective antibodies were high after all three schedules. One or two doses of bOPV after IPV boosted intestinal immunity for poliovirus type 2, suggesting possible cross protection. Additionally, there was evidence of humoral priming for type 2 from one dose of IPV. Our findings could give policy makers flexibility when choosing a vaccination schedule, especially when trying to eliminate vaccine-associated and vaccine-derived poliomyelitis. C1 [O'Ryan, Miguel; Villena, Rodolfo; Espinoza, Monica] Univ Chile, Fac Med, Santiago 1027, Chile. [Bandyopadhyay, Ananda S.] Bill & Melinda Gates Fdn, Seattle, WA USA. [Novoa, Jose] Univ Desarrollo, Fac Med, Santiago, Chile. [Weldon, William C.; Oberste, M. Steven] Ctr Dis Control & Prevent, Atlanta, GA USA. [Self, Steve; Borate, Bhavesh R.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. [Asturias, Edwin J.] Univ Colorado, Sch Med, Aurora, CO USA. [Asturias, Edwin J.] Colorado Sch Publ Hlth, Aurora, CO USA. [Clemens, Ralf] Global Res Infect Dis, Rio De Janeiro, Brazil. [Orenstein, Walter] Emory Vaccine Ctr, Atlanta, GA USA. [Jimeno, Jose] Vaxtrials, Panama City, Panama. [Ruettimann, Ricardo] Fighting Infect Dis Emerging Countries, Miami, FL USA. [Costa Clemens, Sue Ann] Inst Pos Grad Carlos Chagas, Rio De Janeiro, Brazil. RP O'Ryan, M (reprint author), Univ Chile, Inst Biomed Sci, Microbiol & Mycol Program, Fac Med, Ave Independencia, Santiago 1027, Chile. EM moryan@med.uchile.cl OI Bandyopadhyay, Ananda/0000-0002-8395-2001 NR 20 TC 9 Z9 9 U1 1 U2 12 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1473-3099 EI 1474-4457 J9 LANCET INFECT DIS JI Lancet Infect. Dis. PD NOV PY 2015 VL 15 IS 11 BP 1273 EP 1282 DI 10.1016/S1473-3099(15)00219-4 PG 10 WC Infectious Diseases SC Infectious Diseases GA CU2OD UT WOS:000363361900027 PM 26318714 ER PT J AU O'Malley, AJ Zelevinsky, K He, YL Busch, AB AF O'Malley, Alistair J. Zelevinsky, Katya He, Yulei Busch, Alisa B. TI Do Patients at Sites With High RCT Enrollment Propensity Have Better Outcomes? SO MEDICAL CARE LA English DT Article DE bipolar disorder; effect modification; generalizability; mixed-effects model; STEP-BD ID TREATMENT ENHANCEMENT PROGRAM; BIPOLAR DEPRESSION; TRIALS; RATIONALE; INTERVIEW AB Background:Concerns about randomized controlled trial (RCT) generalizability typically center on characteristics of RCT patient participants. Possibly there are RCT site characteristics that distinguish RCT outcomes from those that can be expected in non-RCT settings.Objectives:To examine whether site propensity toward RCT enrollment is associated with recovery outcomes for patients and whether the association differs between patients who participate in a RCT compared with those who remain in an observational (OBS) treatment environment.Data:Study participants with acute bipolar depression from The Systematic Treatment Enhancing Program for Bipolar Disorder acute depression pharmacotherapy RCT (N=337) and OBS treatment arm (N=1581).Methods:A longitudinal OBS study comparing the likelihood of recovery in the RCT to the OBS arm, allowing effect modification by site high RCT enrollment propensity (defined as >the median) and other predictors over a 6-month follow-up period.Results:Non-RCT participants who received care in sites with high RCT enrollment propensity had a higher probability of recovering from their bipolar-depression episode compared with participants from low propensity sites [odds ratio (95% confidence interval)=2.13 (1.28-3.55)]. RCT enrollment propensity was not associated with recovery outcomes for RCT participants [1.03 (0.35-3.03)].Conclusions:Sites with high propensity to enroll patients in RCTs appear to have unobserved characteristics, which play a significant role in outcomes for non-RCT patients. For RCT participants in low-enrollment sites, possibly RCT protocols, which proscribe care delivery and monitoring, attenuate this effect. These results have implications for future research to improve outcomes in nonresearch care settings. C1 [O'Malley, Alistair J.] Geisel Sch Med Dartmouth, Dept Biomed Data Sci, Lebanon, NH 03766 USA. [O'Malley, Alistair J.] Geisel Sch Med Dartmouth, Dartmouth Inst Hlth Policy & Clin Practice, Lebanon, NH 03766 USA. [Zelevinsky, Katya; Busch, Alisa B.] Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA USA. [He, Yulei] Ctr Dis Control & Prevent, Off Res & Methodol, Natl Ctr Hlth Stat, Hyattsville, MD USA. [Busch, Alisa B.] McLean Hosp, Belmont, MA 02178 USA. [Busch, Alisa B.] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA USA. RP O'Malley, AJ (reprint author), Geisel Sch Med Dartmouth, Dept Biomed Data Sci, 35 Centerra Pkwy, Lebanon, NH 03766 USA. EM james.omalley@dartmouth.edu FU NIMH [RC4 MH092717, K01 MH071714] FX Supported by the NIMH: RC4 MH092717 (A.J.O.'M. and co-authors) and K01 MH071714 (A.B.B.). NR 15 TC 0 Z9 0 U1 2 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0025-7079 EI 1537-1948 J9 MED CARE JI Med. Care PD NOV PY 2015 VL 53 IS 11 BP 989 EP 995 DI 10.1097/MLR.0000000000000429 PG 7 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA CU2TL UT WOS:000363376400012 PM 26465127 ER PT J AU Frank, EA Birch, ME Yadav, JS AF Frank, Evan A. Birch, M. Eileen Yadav, Jagjit S. TI MyD88 mediates in vivo effector functions of alveolar macrophages in acute lung inflammatory responses to carbon nanotube exposure SO TOXICOLOGY AND APPLIED PHARMACOLOGY LA English DT Article DE Nanotoxicology; Particle toxicology; Molecular toxicology; Carbon nanotubes; Macrophage depletion ID ULTRAFINE PARTICLES; TOXICITY; INJURY; ACTIVATION; EXPRESSION; CELLS; MICE; INITIATION; INNATE; TLR4 AB Carbon nanotubes (CNTs) are rapidly emerging as high-priority occupational toxicants. CNT powders contain fibrous particles that aerosolize readily in places of manufacture and handling, posing an inhalation risk for workers. Studies using animal models indicate that lung exposure to CNTs causes prolonged inflammatory responses and diffuse alveolar injury. The mechanisms governing CNT-induced lung inflammation are not fully understood but have been suggested to involve alveolar macrophages (AMs). In the current study, we sought to systematically assess the effector role of AMs in vivo in the induction of lung inflammatory responses to CNT exposures and investigate their cell type-specific mechanisms. Multi-wall CNTs characterized for various physicochemical attributes were used as the CNT type. Using an AM-specific depletion and repopulation approach in a mouse model, we unambiguously demonstrated that AMs are major effector cells necessary for the in vivo elaboration of CNT-induced lung inflammation. We further investigated in vitro AM responses and identified molecular targets which proved critical to pro-inflammatory responses in this model, namely MyD88 as well as MAPKs and Ca2+/CamKII. We further demonstrated that MyD88 inhibition in donor AMs abrogated their capacity to reconstitute CNT-induced inflammation when adoptively transferred into AM-depleted mice. Taken together, this is the first in vivo demonstration that AMs act as critical effector cell types in CNT-induced lung inflammation and that MyD88 is required for this in vivo effector function. AMs and their cell type-specific mechanisms may therefore represent potential targets for future therapeutic intervention of CNT-related lung injury. (C) 2015 Elsevier Inc. All rights reserved. C1 [Frank, Evan A.; Yadav, Jagjit S.] Univ Cincinnati, Coll Med, Dept Environm Hlth, Div Environm Genet & Mol Toxicol, Cincinnati, OH 45267 USA. [Birch, M. Eileen] NIOSH, Cincinnati, OH 45213 USA. RP Yadav, JS (reprint author), Univ Cincinnati, Coll Med, Dept Environm Hlth, Kettering Lab Complex,160 Panzeca Way, Cincinnati, OH 45267 USA. EM Jagjit.Yadav@uc.edu FU National Institutes of Health/National Institute for Environmental Health Sciences Center for Environmental Genetics (CEG) funds [2P30ES006096-16A1]; Gene-Environment Interactions Training Program (GEITP) fellowship [T32ES016646]; National Institute of Occupational Safety and Health/Education and Research Center (ERC) [T42OH008432-07]; University of Cincinnati resources FX The authors would like to acknowledge Dr. Marepalli B. Rao (University of Cincinnati) for his expert assistance in the selection and application of statistical methods in this study. This work was supported by the National Institutes of Health/National Institute for Environmental Health Sciences Center for Environmental Genetics (CEG) funds [2P30ES006096-16A1 to JSY], Gene-Environment Interactions Training Program (GEITP) fellowship [T32ES016646 to EAF], and National Institute of Occupational Safety and Health/Education and Research Center (ERC) funding [T42OH008432-07 to EAF], and the University of Cincinnati resources (to JSY). NR 41 TC 7 Z9 8 U1 1 U2 13 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0041-008X EI 1096-0333 J9 TOXICOL APPL PHARM JI Toxicol. Appl. Pharmacol. PD NOV 1 PY 2015 VL 288 IS 3 BP 322 EP 329 DI 10.1016/j.taap.2015.08.004 PG 8 WC Pharmacology & Pharmacy; Toxicology SC Pharmacology & Pharmacy; Toxicology GA CT8RL UT WOS:000363083600005 PM 26272622 ER PT J AU Brown, KK Robinson, K AF Brown, Kenneth K. Robinson, Keisha TI High-Performance Liquid Chromatography Identification, Quantification, and Fractionation of a Suspect Allergen, 4-Chloro-3-methylphenol, in an LLNA-Positive Metalworking Fluid SO TRIBOLOGY & LUBRICATION TECHNOLOGY LA English DT Article DE Metalworking Fluids; Maintenance; Safety: Toxicology; Biocides; Hygiene; Lubricant Microbial Decomposition; Chemical Conatmination; Cleanliness; Liquid Chromatography; Gas Chromatography; Spectroscopy ID EXPOSURE AB A metalworking fluid (MWF) was obtained that produced an allergic reaction in the local lymph node assay (LLNA) with asn EC3 = 4%, the EC3 being the estimated concentration needed to provoke a 3-fold allergy responce. High-performance liquid chromatography (HPLC) was used to separate, identify and isolate the suspected allergen. The biocide, 4-chloro-3-methylphenol, was detected in the MWF as a chromatographic peak matching the retention time of a external standard. The technique of standard addition was used to quantify and confirm the presence of 4-chloro-3-methylphenol at about 1% (w/W). Preparative HPLC was used to fractionate 1 gram of MWF separating the 4-chloro-3-methylphenol fraction from the remaining MWF. The two mobile-phase solution were concentrated back into an MWF and a 4-chloro-3-methylphenol fraction. The original MWF and the reconstituted 4-chloro-3-methylphenol and MWF fraction were also analyzed by gas chromatography-mass spectrometry to confirm the isolation of the biocide. C1 [Brown, Kenneth K.] NIOSH, Div Appl Res & Technol, Cincinnati, OH 45226 USA. [Robinson, Keisha] Howard Univ, Dept Biol, Washington, DC 20059 USA. RP Brown, KK (reprint author), NIOSH, Div Appl Res & Technol, Cincinnati, OH 45226 USA. NR 12 TC 0 Z9 0 U1 2 U2 2 PU SOC TRIBOLOGISTS & LUBRICATION ENGINEERS PI PARK RIDGE PA 840 BUSSE HIGHWAY, PARK RIDGE, IL 60068 USA SN 1545-858X J9 TRIBOL LUBR TECHNOL JI Tribol. Lubr. Technol. PD NOV PY 2015 VL 71 IS 11 BP 97 EP + PG 7 WC Engineering, Mechanical SC Engineering GA CU5UH UT WOS:000363597000022 ER PT J AU Mowery, PD Dube, SR Thorne, SL Garrett, BE Homa, DM Henderson, PN AF Mowery, Paul D. Dube, Shanta R. Thorne, Stacy L. Garrett, Bridgette E. Homa, David M. Henderson, Patricia Nez TI Disparities in Smoking-Related Mortality Among American Indians/Alaska Natives SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID DISEASE RISK-FACTORS; ALASKA NATIVES; ATTRIBUTABLE MORTALITY; CARDIOVASCULAR-DISEASE; UNITED-STATES; LUNG-CANCER; CIGARETTE-SMOKING; TOBACCO USE; HEALTH; IMPACT AB Introduction: Smoking-related disparities continue to be a public health problem among American Indian/Alaska Native (AI/AN) population groups and data documenting the health burden of smoking in this population are sparse. The purpose of this study was to assess mortality attributable to cigarette smoking among AI/AN adults relative to non-Hispanic white adults (whites) by calculating and comparing smoking-attributable fractions and mortality. Methods: Smoking-attributable fractions and mortality among AI/ANs (n=1.63 million AI/ANs) and whites were calculated for people living in 637 Indian Health Service Contract Health Service Delivery Area counties in the U.S., from mortality data collected during 2001-2009. Differences in smoking-attributable mortality between AI/ANs and whites for five major causes of smoking-related deaths were examined. All data analyses were carried out in 2013-2014. Results: Overall, from 2001 to 2009, age-adjusted death rates, smoking-attributable fractions, and smoking-attributable mortality for all-cause mortality were higher among AI/ANs than among whites for adult men and women aged >= 35 years. Smoking caused 21% of ischemic heart disease, 15% of other heart disease, and 17% of stroke deaths in AI/AN men, compared with 15%, 10%, and 9%, respectively, for white men. Among AI/AN women, smoking caused 18% of ischemic heart disease deaths, 13% of other heart diseases deaths, and 20% of stroke deaths, compared with 9%, 7%, and 10%, respectively, among white women. Conclusions: These findings underscore the need for comprehensive tobacco control and prevention efforts that can effectively reach and impact the AI/AN population to prevent and reduce smoking. (C) 2015 American Journal of Preventive Medicine. All rights reserved. C1 [Mowery, Paul D.] Biostatistics Inc, Sarasota, FL 34239 USA. [Dube, Shanta R.] Georgia State Univ, Sch Publ Hlth, Div Epidemiol & Biostat, Atlanta, GA 30303 USA. [Thorne, Stacy L.; Garrett, Bridgette E.; Homa, David M.] CDC, Off Smoking & Hlth, Atlanta, GA 30333 USA. [Henderson, Patricia Nez] Black Hills Ctr Amer Indian Hlth, Rapid City, SD USA. RP Mowery, PD (reprint author), Biostatistics Inc, 1738 Illehaw Dr, Sarasota, FL 34239 USA. EM pzm4@cdc.gov FU CDC FX This work was funded by CDC. The authors thank David Espey and Melissa Jim, CDC Division of Cancer Prevention and Control, for providing the population and mortality data for Contract Health Services Delivery Area counties and for their help with the analyses. We also thank Nat Cobb, Division of Epidemiology and Disease Prevention, Indian Health Service, for reviewing the manuscript. NR 40 TC 2 Z9 2 U1 1 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD NOV PY 2015 VL 49 IS 5 BP 738 EP 744 DI 10.1016/j.amepre.2015.05.002 PG 7 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA CT7MK UT WOS:000362998600009 PM 26163166 ER PT J AU Owusu-Edusei, K Carroll, DS Gift, TL AF Owusu-Edusei, Kwame, Jr. Carroll, Danya S. Gift, Thomas L. TI Examining Fluoroquinolone Claims Among Gonorrhea-Associated Prescription Drug Claims, 2000-2010 SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID DISEASES-TREATMENT-GUIDELINES; SEXUALLY-TRANSMITTED INFECTIONS; UNITED-STATES; GONOCOCCAL INFECTIONS; INSURED POPULATION; MEDICAL COST; WOMEN; US AB Introduction: After the release of CDC's revised gonorrhea treatment guidelines in April 2007, a study reported the declining use of fluoroquinolones to treat gonorrhea among health departments participating in the Sexually Transmitted Disease Surveillance Network. In this study, we examine the proportion of fluoroquinolone claims among gonorrhea-associated prescription drug claims from a large insurance database from 2000 through 2010. Methods: We extracted drug claims associated with gonorrhea diagnosis claims from the Market Scan database for 2000-2010 and calculated the proportion of the drug claims for fluoroquinolones on a monthly basis. We then used an interrupted time series analysis to investigate trend characteristics of fluoroquinolone claims before and after the gonorrhea treatment guidelines were revised in April 2007. Results: Although there was a monthly decline in the proportion of fluoroquinolone claims before April 2007 (-0.11 percentage points, P < 0.01), results indicate a sevenfold (-0.78 percentage points, P<0.01) increase in the rate of decline after the revised guidelines were released in April 2007. We did not find any sudden drop (immediate or delayed) in the proportion of fluoroquinolones after April 2007, implying a gradual permanent decline over the analytic period. Conclusions: Our results are consistent with the findings of the previous study and indicate a gradual and permanent decline (over the analytic period) in the proportion of fluoroquinolone claims among gonorrhea-associated prescription drug claims. However, because this is a convenience sample of claims data, these findings cannot be generalized to the entire privately insured population in the U.S. Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine C1 [Owusu-Edusei, Kwame, Jr.; Carroll, Danya S.; Gift, Thomas L.] CDC, Div STD Prevent, Atlanta, GA 30333 USA. RP Owusu-Edusei, K (reprint author), CDC, Div STD Prevent, 1600 Clifton Rd MS E-80, Atlanta, GA 30333 USA. EM kowusuedusei@cdc.gov NR 18 TC 0 Z9 0 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD NOV PY 2015 VL 49 IS 5 BP 761 EP 764 DI 10.1016/j.amepre.2015.04.031 PG 4 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA CT7MK UT WOS:000362998600013 PM 26190198 ER PT J AU Jacob, V Chattopadhyay, SK Thota, AB Proia, KK Njie, G Hopkins, DP Finnie, RKC Pronk, NP Kottke, TE AF Jacob, Verughese Chattopadhyay, Sajal K. Thota, Anilkrishna B. Proia, Krista K. Njie, Gibril Hopkins, David P. Finnie, Ramona K. C. Pronk, Nicolaas P. Kottke, Thomas E. CA Community Preventive Serv Task TI Economics of Team-based Care in Controlling Blood Pressure A Community Guide Systematic Review SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID RANDOMIZED-CONTROLLED-TRIAL; CORONARY-HEART-DISEASE; COST-EFFECTIVENESS; HEALTH-CARE; CARDIOVASCULAR-DISEASE; HYPERTENSION TREATMENT; CLINICAL PHARMACIST; SELF-MANAGEMENT; RISK ENGINE; PROGRAM AB Context: High blood pressure is an important risk factor for cardiovascular disease and stroke, the leading cause of death in the U.S., and a substantial national burden through lost productivity and medical care. A recent Community Guide systematic review found strong evidence of effectiveness of team-based care in improving blood pressure control. The objective of the present review is to determine from the economic literature whether team-based care for blood pressure control is cost beneficial or cost effective. Evidence acquisition: Electronic databases of papers published January 1980 May 2012 were searched to find economic evaluations of team-based care interventions to improve blood pressure outcomes, yielding 31 studies for inclusion. Evidence synthesis: In analyses conducted in 2012, intervention cost, healthcare cost averted, benefit-to-cost ratios, and cost effectiveness were abstracted from the studies. The quality of estimates for intervention and healthcare cost from each study were assessed using three elements: intervention focus on blood pressure control, incremental estimates in the intervention group relative to a control group, and inclusion of major cost-driving elements in estimates. Intervention cost per unit reduction in systolic blood pressure was converted to lifetime intervention cost per quality-adjusted life-year (QALY) saved using algorithms from published trials. Conclusions: Team-based care to improve blood pressure control is cost effective based on evidence that 26 of 28 estimates of $/QALY gained from ten studies were below a conservative threshold of $50,000. This finding is salient to recent U.S. healthcare reforms and coordinated patient-centered care through formation of Accountable Care Organizations. Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine C1 [Jacob, Verughese; Chattopadhyay, Sajal K.; Thota, Anilkrishna B.; Proia, Krista K.; Njie, Gibril; Hopkins, David P.; Finnie, Ramona K. C.; Community Preventive Serv Task] CDC, Community Guide Branch, Div Publ Hlth Informat, Ctr Surveillance Epidemiol & Lab Serv, Atlanta, GA 30329 USA. [Pronk, Nicolaas P.; Kottke, Thomas E.] HealthPartners, Minneapolis, MN USA. RP Jacob, V (reprint author), CDC, Community Guide Branch, 1600 Clifton Rd, Atlanta, GA 30329 USA. EM hir0@cdc.gov OI Jacob, Verughese/0000-0001-6833-6588 FU Oak Ridge Institute for Scientific Education FX The work of Krista Proia, Gibril Njie, and Ramona Finnie was supported with funds from the Oak Ridge Institute for Scientific Education. NR 52 TC 3 Z9 3 U1 0 U2 10 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD NOV PY 2015 VL 49 IS 5 BP 772 EP 783 DI 10.1016/j.amepre.2015.04.003 PG 12 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA CT7MK UT WOS:000362998600015 PM 26477804 ER PT J AU Njie, GJ Proia, KK Thota, AB Finnie, RKC Hopkins, DP Banks, SM Callahan, DB Pronk, NP Rask, KJ Lackland, DT Kottke, TE AF Njie, Gibril J. Proia, Krista K. Thota, Anilkrishna B. Finnie, Ramona K. C. Hopkins, David P. Banks, Starr M. Callahan, David B. Pronk, Nicolaas P. Rask, Kimberly J. Lackland, Daniel T. Kottke, Thomas E. CA Community Preventive Serv Task TI Clinical Decision Support Systems and Prevention A Community Guide Cardiovascular Disease Systematic Review SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID RANDOMIZED-CONTROLLED-TRIAL; HEALTH INFORMATION-TECHNOLOGY; COMPUTER-GENERATED PHYSICIAN; PRIMARY-CARE PRACTICE; QUALITY-OF-CARE; BLOOD-PRESSURE; DIABETES CARE; PRESCRIBING BEHAVIOR; LIPID MANAGEMENT; TASK DELEGATION AB Context: Clinical decision support systems (CDSSs) can help clinicians assess cardiovascular disease (CVD) risk and manage CVD risk factors by providing tailored assessments and treatment recommendations based on individual patient data. The goal of this systematic review was to examine the effectiveness of CDSSs in improving screening for CVD risk factors, practices for CVD-related preventive care services such as clinical tests and prescribed treatments, and management of CVD risk factors. Evidence acquisition: An existing systematic review (search period, January 1975 January 2011) of CDSSs for any condition was initially identified. Studies of CDSSs that focused on CVD prevention in that review were combined with studies identified through an updated search (January 2011 October 2012). Data analysis was conducted in 2013. Evidence synthesis: A total of 45 studies qualified for inclusion in the review. Improvements were seen for recommended screening and other preventive care services completed by clinicians, recommended clinical tests completed by clinicians, and recommended treatments prescribed by clinicians (median increases of 3.8, 4.0, and 2.0 percentage points, respectively). Results were inconsistent for changes in CVD risk factors such as systolic and diastolic blood pressure, total and low-density lipoprotein cholesterol, and hemoglobin A1C levels. Conclusions: CDSSs are effective in improving clinician practices related to screening and other preventive care services, clinical tests, and treatments. However, more evidence is needed from implementation of CDSSs within the broad context of comprehensive service delivery aimed at reducing CVD risk and CVD-related morbidity and mortality. C1 [Njie, Gibril J.; Proia, Krista K.; Thota, Anilkrishna B.; Finnie, Ramona K. C.; Hopkins, David P.; Banks, Starr M.] CDC, Community Guide Branch, Div Publ Hlth Informat Disseminat, Ctr Surveillance Epidemiol & Lab Serv, Atlanta, GA 30329 USA. [Callahan, David B.] CDC, Div Heart Dis & Stroke Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30329 USA. [Pronk, Nicolaas P.; Kottke, Thomas E.] HealthPartners, Minneapolis, MN USA. [Rask, Kimberly J.] Emory Univ, Georgia Med Care Fdn, Atlanta, GA 30322 USA. [Lackland, Daniel T.] Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA. RP Hopkins, DP (reprint author), CDC, Community Guide Branch, Div Epidemiol Anal & Lib Serv, Ctr Surveillance Epidemiol & Lab Serv, 1600 Clifton Rd,Mailstop E-69, Atlanta, GA 30329 USA. EM dhh4@cdc.gov RI rask, kimberly/M-8001-2016 FU Oak Ridge Institute for Scientific Education FX The work of Gibril Njie and Ramona Finnie was supported with funds from the Oak Ridge Institute for Scientific Education. NR 103 TC 1 Z9 1 U1 4 U2 7 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD NOV PY 2015 VL 49 IS 5 BP 784 EP 795 DI 10.1016/j.amepre.2015.04.006 PG 12 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA CT7MK UT WOS:000362998600016 PM 26477805 ER PT J CA Community Preventive Serv Task TI Clinical Decision Support Systems Recommended to Prevent Cardiovascular Disease Community Preventive Services Task Force SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article RP Care off Hopkins DP, CDC, Community Guide Branch, Div Epidemiol Anal & Lib Serv,Ctr Surveillance Ep, 1600 Clifton Rd,Mailstop E-69, Atlanta, GA 30329 USA. NR 10 TC 0 Z9 0 U1 1 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD NOV PY 2015 VL 49 IS 5 BP 796 EP 799 DI 10.1016/j.amepre.2015.03.041 PG 4 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA CT7MK UT WOS:000362998600017 ER PT J AU Contreary, KA Chattopadhyay, SK Hopkins, DP Chaloupka, FJ Forster, JL Grimshaw, V Holmes, CB Goetzel, RZ Fielding, JE AF Contreary, Kara A. Chattopadhyay, Sajal K. Hopkins, David P. Chaloupka, Frank J. Forster, Jean L. Grimshaw, Victoria Holmes, Carissa B. Goetzel, Ron Z. Fielding, Jonathan E. CA Community Preventive Serv Task TI Economic Impact of Tobacco Price Increases Through Taxation A Community Guide Systematic Review SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID CIGARETTE-SMOKING; PUBLIC-HEALTH; UNITED-STATES; TAXES; PRODUCTIVITY; SIMULATION; COST AB Context: Tobacco use is a leading cause of preventable death in the U.S. and around the world. Increasing tobacco price through higher taxes is an effective intervention both to reduce tobacco use in the population and generate government revenues. The goal of this paper is to review evidence on the economic impact of tobacco price increases through taxation with a focus on the likely healthcare cost savings and improvements in employee productivity. Evidence acquisition: The search covered studies published in English from January 2000 to July 2012 and included evaluations of national, state, and local policies to increase the price of any type of tobacco product by raising taxes in high-income countries. Economic review methods developed for The Guide to Community Preventive Services were used to screen and abstract included studies. Economic impact estimates were standardized to summarize the available evidence. Analyses were conducted in 2012. Evidence synthesis: The review included eight modeling studies, with seven providing estimates of the impact on healthcare costs and three providing estimates of the value of productivity gains. Only one study provided an estimate of intervention costs. The economic merit of tobacco product price increases through taxation was determined from the overall body of evidence on per capita annual cost savings from a conservative 20% price increase. Conclusions: The evidence indicates that interventions that raise the unit price of tobacco products through taxes generate substantial healthcare cost savings and can generate additional gains from improved productivity in the workplace. C1 [Contreary, Kara A.; Chattopadhyay, Sajal K.; Hopkins, David P.] CDC, Community Guide Branch, Ctr Surveillance Epidemiol & Lab Serv, Atlanta, GA 30329 USA. [Chaloupka, Frank J.] Univ Illinois, Inst Hlth Res & Policy, Chicago, IL USA. [Forster, Jean L.] Univ Minnesota, Sch Publ Hlth, Div Epidemiol & Community Hlth, Minneapolis, MN USA. [Grimshaw, Victoria] Bur Chron Dis Prevent & Tobacco Control, New York City Dept Hlth & Mental Hyg, New York, NY USA. [Holmes, Carissa B.] CDC, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. [Goetzel, Ron Z.] Johns Hopkins Bloomberg Sch Publ Hlth, Inst Hlth & Prod Studies, Bethesda, MD USA. [Fielding, Jonathan E.] Los Angeles Cty Dept Publ Hlth, Los Angeles, CA USA. RP Chattopadhyay, SK (reprint author), CDC, Community Guide Branch, Ctr Surveillance Epidemiol & Lab Serv, 1600 Clifton Rd NE,MS E-69, Atlanta, GA 30329 USA. EM skc9@cdc.gov NR 29 TC 6 Z9 6 U1 1 U2 10 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD NOV PY 2015 VL 49 IS 5 BP 800 EP 808 DI 10.1016/j.amepre.2015.04.026 PG 9 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA CT7MK UT WOS:000362998600018 PM 26188686 ER PT J AU Jani, AA Trask, J Ali, A AF Jani, Asim A. Trask, Jennifer Ali, Ather TI Integrative Medicine in Preventive Medicine Education Competency and Curriculum Development for Preventive Medicine and Other Specialty Residency Programs SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID HEALTH-CARE; TRANSFORMATION; FRAMEWORK AB During 2012, the USDHHS's Health Resources and Services Administration funded 12 accredited preventive medicine residencies to incorporate an evidence-based integrative medicine curriculum into their training programs. It also funded a national coordinating center at the American College of Preventive Medicine, known as the Integrative Medicine in Preventive Medicine Education (IMPriME) Center, to provide technical assistance to the 12 grantees. To help with this task, the IMPriME Center established a multidisciplinary steering committee, versed in integrative medicine, whose primary aim was to develop integrative medicine core competencies for incorporation into preventive medicine graduate medical education training. The competency development process was informed by central integrative medicine definitions and principles, preventive medicine's dual role in clinical and population-based prevention, and the burgeoning evidence base of integrative medicine. The steering committee considered an interdisciplinary integrative medicine contextual framework guided by several themes related to workforce development and population health. A list of nine competencies, mapped to the six general domains of competence approved by the Accreditation Council of Graduate Medical Education, was operationalized through an iterative exercise with the 12 grantees in a process that included mapping each site's competency and curriculum products to the core competencies. The competencies, along with central curricular components informed by grantees' work presented elsewhere in this supplement, are outlined as a roadmap for residency programs aiming to incorporate integrative medicine content into their curricula. This set of competencies adds to the larger efforts of the IMPriME initiative to facilitate and enhance further curriculum development and implementation by not only the current grantees but other stakeholders in graduate medical education around integrative medicine training. Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine. C1 [Jani, Asim A.] CDC, Atlanta, GA 30333 USA. [Trask, Jennifer] Amer Coll Prevent Med, Washington, DC USA. [Ali, Ather] Yale Univ, Sch Med, Dept Pediat, New Haven, CT 06510 USA. RP Jani, AA (reprint author), CDC, MS E-92,1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM ajani@cdc.gov RI Timmers, Gabrielle/O-6505-2016 FU Health Resources and Services Administration [HRSA-12-182]; Health Resources and Services Administration (HRSA) of the USDHHS [UE1HP25094]; National Center for Complementary and Integrative Health (NCCIH) at NIH [K23AT006703] FX Publication of this article was supported by the Health Resources and Services Administration (HRSA-12-182).; The project was supported by the Health Resources and Services Administration (HRSA) of the USDHHS under grant UE1HP25094 and from the National Center for Complementary and Integrative Health (NCCIH) at NIH under grant K23AT006703. This information or content and conclusions are those of the authors and should not be construed as the official position or policy of, nor should any endorsements be inferred by HRSA, NCCIH, DHHS, or the U.S. Government. NR 29 TC 1 Z9 1 U1 3 U2 7 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD NOV PY 2015 VL 49 IS 5 SU 3 BP S222 EP S229 DI 10.1016/j.amepre.2015.08.019 PG 8 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA CT7ML UT WOS:000362998700002 PM 26477897 ER PT J AU Lasker, BA Bell, M Klenk, HP Schumann, P Brown, JM AF Lasker, Brent A. Bell, Melissa Klenk, Hans-Peter Schumann, Peter Brown, June M. TI Nocardia arizonensis sp nov., obtained from human respiratory specimens SO ANTONIE VAN LEEUWENHOEK INTERNATIONAL JOURNAL OF GENERAL AND MOLECULAR MICROBIOLOGY LA English DT Article DE Nocardia arizonensis; Polyphasic analysis; 16S rRNA gene; Actinomycetes ID MAXIMUM-LIKELIHOOD; ACID; CLASSIFICATION; IDENTIFICATION; SEQUENCES; DISTANCE; TREES AB In 2008, three clinical isolates (W9405(T), W9409 and W9575) were obtained from bronchial wash or sputum specimens from patients from the state of Arizona and characterised by polyphasic analysis. All three clinical isolates 16S rRNA gene sequences were found to be 100 % identical to each other and showed the strains belong in the genus Nocardia. BLASTn searches in the GenBank database of near full-length 16S rRNA gene sequences showed the highest sequence similarities to the type strains of Nocardia takedensis (98.3 %, sequence similarity), Nocardia lijiangensis (97.4 %), Nocardia harenae (97.4 %), and Nocardia xishanensis (97.1 %). The DNA-DNA relatedness between isolate W9405(T) and the type strain of N. takedensis is 26.0 +/- 2.4 % when measured in silico using genomic DNA sequences. The G+C content of isolate W9405(T) is 68.6 mol%. Chemotaxonomic analyses of the clinical isolates were consistent with their assignment to the genus Nocardia: whole cell hydrolysates contain meso-diaminopimelic acid as the diagnostic diamino acid of peptidoglycan; the whole-cell sugars are arabinose and galactose; the predominant phospholipids include diphosphatidylglycerol, phosphatidylethanolamine and phosphatidylinositol; MK-8-(H-4) (omega-cyc) as the major menaquinone; mycolic acids ranging from 38 to 62 carbon atoms; and palmitic acid, tuberculostearic acid, palmitelaidic acid and oleic acid are the major fatty acids. Genus and species specific profiles were obtained following analysis by matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) mass spectra of the clinical isolates. All isolates were found to be intermediately resistant or resistant to minocycline and resistant to ciprofloxacin but were susceptible to amikacin, imipenem and linezolid. Our polyphasic analysis suggest the three clinical isolates obtained from patients in Arizona represent a novel species of Nocardia for which we propose the name Nocardia arizonensis, with strain W9405(T) (=DSM 45748(T) = CCUG 62754(T) = NBRC 108935(T)) as the type strain. C1 [Lasker, Brent A.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Lasker, Brent A.; Bell, Melissa; Brown, June M.] Ctr Dis Control & Prevent, Bacterial Special Pathogens Branch, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Klenk, Hans-Peter] Newcastle Univ, Sch Biol, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England. [Schumann, Peter] German Collect Microorganisms & Cell Cultures, Leibniz Inst DSMZ, D-38124 Braunschweig, Germany. RP Lasker, BA (reprint author), Ctr Dis Control & Prevent, Bldg 17,Room 2025,Mailstop G-11,1600 Clifton Rd, Atlanta, GA 30333 USA. EM blasker@cdc.gov NR 33 TC 0 Z9 0 U1 1 U2 7 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0003-6072 EI 1572-9699 J9 ANTON LEEUW INT J G JI Antonie Van Leeuwenhoek PD NOV PY 2015 VL 108 IS 5 BP 1129 EP 1137 DI 10.1007/s10482-015-0566-4 PG 9 WC Microbiology SC Microbiology GA CT5WI UT WOS:000362881400011 PM 26427857 ER PT J AU Choi, MJ Torremorell, M Bender, JB Smith, K Boxrud, D Ertl, JR Yang, M Suwannakarn, K Her, D Nguyen, J Uyeki, TM Levine, M Lindstrom, S Katz, JM Jhung, M Vetter, S Wong, KK Sreevatsan, S Lynfield, R AF Choi, Mary J. Torremorell, Montserrat Bender, Jeff B. Smith, Kirk Boxrud, David Ertl, Jon R. Yang, My Suwannakarn, Kamol Her, Duachi Nguyen, Jennifer Uyeki, Timothy M. Levine, Min Lindstrom, Stephen Katz, Jacqueline M. Jhung, Michael Vetter, Sara Wong, Karen K. Sreevatsan, Srinand Lynfield, Ruth TI Live Animal Markets in Minnesota: A Potential Source for Emergence of Novel Influenza A Viruses and Interspecies Transmission SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE influenza; human; swine; live animal markets ID AGRICULTURAL FAIR; H7N9 VIRUS; SWINE; INFECTION; VARIANT; PIGS; OUTBREAK; HUMANS; CHINA; BIRDS AB Background. Live animal markets have been implicated in transmission of influenza A viruses (IAVs) from animals to people. We sought to characterize IAVs at 2 live animal markets in Minnesota to assess potential routes of occupational exposure and risk for interspecies transmission. Methods. We implemented surveillance for IAVs among employees, swine, and environment (air and surfaces) during a 12-week period (October 2012-January 2013) at 2 markets epidemiologically associated with persons with swine-origin IAV (variant) infections. Real-time reverse transcription polymerase chain reaction (rRT-PCR), viral culture, and whole-genome sequencing were performed on respiratory and environmental specimens, and serology on sera from employees at beginning and end of surveillance. Results. Nasal swabs from 11 of 17 (65%) employees tested positive for IAVs by rRT-PCR; 7 employees tested positive on multiple occasions and 1 employee reported influenza-like illness. Eleven of 15 (73%) employees had baseline hemagglutination inhibition antibody titers >= 40 to swine-origin IAVs, but only 1 demonstrated a 4-fold titer increase to both swine-origin and pandemic A/Mexico/4108/2009 IAVs. IAVs were isolated from swine (72/84), air (30/45), and pen railings (5/21). Whole-genome sequencing of 122 IAVs isolated from swine and environmental specimens revealed multiple strains and subtype codetections. Multiple gene segment exchanges among and within subtypes were observed, resulting in new genetic constellations and reassortant viruses. Genetic sequence similarities of 99%-100% among IAVs of 1 market customer and swine indicated interspecies transmission. Conclusions. At markets where swine and persons are in close contact, swine-origin IAVs are prevalent and potentially provide conditions for novel IAV emergence. C1 [Choi, Mary J.; Uyeki, Timothy M.; Levine, Min; Lindstrom, Stephen; Katz, Jacqueline M.; Jhung, Michael; Wong, Karen K.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Torremorell, Montserrat; Bender, Jeff B.; Ertl, Jon R.; Yang, My; Suwannakarn, Kamol; Sreevatsan, Srinand] Univ Minnesota, Minnesota Ctr Excellence Influenza Res & Surveill, Coll Vet Med, Minneapolis, MN 55455 USA. [Smith, Kirk; Boxrud, David; Her, Duachi; Nguyen, Jennifer; Vetter, Sara; Lynfield, Ruth] Minnesota Dept Hlth, St Paul, MN USA. RP Torremorell, M (reprint author), Minnesota Ctr Excellence Influenza Res & Surveill, 1988 Fitch Ave, St Paul, MN 55108 USA. EM torr0033@umn.edu OI Sreevatsan, Srinand/0000-0002-5162-2403 FU National Institutes of Health, US Department of Health and Human Services [HHSN266200700007C]; CDC [U38HM000414] FX This work was supported by the National Institutes of Health, US Department of Health and Human Services (grant number HHSN266200700007C) and by the CDC (cooperative agreement U38HM000414). NR 26 TC 11 Z9 11 U1 3 U2 15 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD NOV 1 PY 2015 VL 61 IS 9 BP 1355 EP 1362 DI 10.1093/cid/civ618 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA CT6XI UT WOS:000362956000001 PM 26223994 ER PT J AU Koepke, R Bartholomew, ML Eickhoff, JC Ayele, RA Rodd, D Kuennen, J Rosekrans, J Warshauer, DM Conway, JH Davis, JP AF Koepke, Ruth Bartholomew, Michael L. Eickhoff, Jens C. Ayele, Roman A. Rodd, Diane Kuennen, Joan Rosekrans, Jean Warshauer, David M. Conway, James H. Davis, Jeffrey P. TI Widespread Bordetella parapertussis Infections-Wisconsin, 2011-2012: Clinical and Epidemiologic Features and Antibiotic Use for Treatment and Prevention SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE Bordetella parapertussis; Bordetella pertussis; epidemiology ID UNITED-STATES; PERTUSSIS VACCINES; SYMPTOMS; OUTBREAK; INFANTS; DIAGNOSTICS; CHILDREN; EFFICACY; HOLMESII; ILLNESS AB Background. During October 2011-December 2012, concurrent with a statewide pertussis outbreak, 443 Bordetella parapertussis infections were reported among Wisconsin residents. We examined clinical features of patients with parapertussis and the effect of antibiotic use for treatment and prevention. Methods. Patients with polymerase chain reaction results positive for B. parapertussis reported during October 2011-May 2012 were interviewed regarding presence and durations of pertussis-like symptoms and receipt of azithromycin treatment. Data regarding acute cough illnesses and receipt of azithromycin prophylaxis among parapertussis patient household members (HHMs) were also collected. Using multivariate repeated measures log-binomial regression analysis, we examined associations of treatment receipt by the HHM with the earliest illness onset and prophylaxis receipt among other HHMs with the presence of any secondary cough illnesses in the household. Results. Among 218 patients with parapertussis, pertussis-like symptoms were frequently reported. Illness durations were significantly shorter among patients with treatment initiated 0-6 days after cough onset, compared with nonrecipients (median durations: 10 vs 19 days, P = .002). Among 361 HHMs from 120 households, compared with nonrecipients, prompt prophylaxis of HHMs was associated with no secondary cough illnesses (relative risk: 0.16; 95% confidence interval, .04-.69). Conclusions. Bordetella parapertussis infection causes pertussis-like illness that might be misclassified as pertussis if B. parapertussis testing is not performed. Prompt treatment might shorten illness duration, and prompt HHM prophylaxis might prevent secondary illnesses. Further study is needed to evaluate antibiotic effectiveness for preventing parapertussis and to determine risks and benefits of antibiotic use. C1 [Koepke, Ruth; Bartholomew, Michael L.; Ayele, Roman A.; Davis, Jeffrey P.] Wisconsin Dept Hlth Serv, Div Publ Hlth, Madison, WI 53702 USA. [Koepke, Ruth; Ayele, Roman A.; Conway, James H.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Pediat, Madison, WI 53706 USA. [Bartholomew, Michael L.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Ctr Surveillance Epidemiol & Lab Serv, Atlanta, GA USA. [Eickhoff, Jens C.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Biostat & Med Informat, Madison, WI 53706 USA. [Rodd, Diane; Kuennen, Joan; Rosekrans, Jean] Wood Cty Hlth Dept, Wisconsin Rapids, WI USA. [Warshauer, David M.] Univ Wisconsin, Wisconsin State Lab Hyg, Madison, WI 53706 USA. RP Koepke, R (reprint author), Wisconsin Dept Hlth Serv, Div Publ Hlth, 1 W Wilson St, Madison, WI 53702 USA. EM ruth.koepke@wisconsin.gov FU Sanofi Pasteur, Swiftwater, Pennsylvania [IND 8502] FX This work was partially supported by funding from Sanofi Pasteur, Swiftwater, Pennsylvania (grant IND 8502, study M5A16). NR 34 TC 1 Z9 1 U1 0 U2 3 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD NOV 1 PY 2015 VL 61 IS 9 BP 1421 EP 1431 DI 10.1093/cid/civ514 PG 11 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA CT6XI UT WOS:000362956000011 PM 26113655 ER PT J AU Garrison, LE Lucas, CE Demirjian, A Sonel, AF Hicks, LA AF Garrison, Laurel E. Lucas, Claressa E. Demirjian, Alicia Sonel, Ali F. Hicks, Lauri A. TI The Case for Routine Environmental Testing for Legionella Bacteria in Healthcare Facility Water Distribution Systems-Reconciling CDC Position and Guidance Regarding Risk Reply SO CLINICAL INFECTIOUS DISEASES LA English DT Letter C1 [Garrison, Laurel E.; Lucas, Claressa E.; Demirjian, Alicia; Hicks, Lauri A.] Natl Ctr Immunizat & Resp Dis, Div Bacterial Dis, Atlanta, GA USA. [Demirjian, Alicia] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA 30329 USA. [Sonel, Ali F.] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Sonel, Ali F.] Univ Pittsburgh, Sch Med, Pittsburgh, PA 15260 USA. RP Garrison, LE (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,MS C-25, Atlanta, GA 30329 USA. EM lee5@cdc.gov NR 2 TC 1 Z9 1 U1 2 U2 3 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD NOV 1 PY 2015 VL 61 IS 9 BP 1488 EP 1488 DI 10.1093/cid/civ591 PG 1 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA CT6XI UT WOS:000362956000022 PM 26195018 ER PT J AU Keddy, KH Sooka, A Musekiwa, A Smith, AM Ismail, H Tau, NP Crowther-Gibson, P Angulo, FJ Klugman, KP AF Keddy, Karen H. Sooka, Arvinda Musekiwa, Alfred Smith, Anthony M. Ismail, Husna Tau, Nomsa P. Crowther-Gibson, Penny Angulo, Frederick J. Klugman, Keith P. CA Grp Enteric Resp Meningeal Dis Sur TI Clinical and Microbiological Features of Salmonella Meningitis in a South African Population, 2003-2013 SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE Salmonella; meningitis; HIV; Salmonella Typhimurium ST313 ID HUMAN-IMMUNODEFICIENCY-VIRUS; ENTERICA SEROVAR TYPHIMURIUM; SYSTEMIC-LUPUS-ERYTHEMATOSUS; BACTERIAL-MENINGITIS; OPPORTUNISTIC INFECTIONS; ANTIRETROVIRAL THERAPY; NEONATAL MENINGITIS; MALAWIAN CHILDREN; NORTH-AMERICA; HIV AB Background. The clinical and microbiological characteristics of nontyphoidal Salmonella (NTS) meningitis in South Africa, where human immunodeficiency virus (HIV) prevalence is high (approximately 15% in persons >= 15 years of age), were reviewed. Methods. From 2003 through 2013, 278 cases were identified through national laboratory-based surveillance. Clinical information (age, sex, outcome, Glasgow Coma Scale [GCS], and HIV status) was ascertained at selected sites. Isolates were serotyped; susceptibility testing and multilocus sequence typing on Salmonella enterica serovar Typhimurium isolates was performed. Multivariable logistic regression was used to determine factors associated with mortality outcome, using Stata software, version 13. Results. Where age was ascertained, 139 of 256 (54.3%) patients were <15 years. Males represented 151 of 267 (56.6%). Mortality outcome was recorded for 112 of 146 (76.7%) enhanced surveillance patients; 53 of 112 (47.3%) died. Death was associated with GCS <= 13 (adjusted odds ratio [OR], 18.7; 95% confidence interval [CI], 3.0-118.5; P=.002) on multivariable analysis. Where data were available, all 45 patients aged >15 years were HIV infected, compared with 24 of 46 (52.2%) patients aged <5 years. Neonates were less likely to be HIV infected than infants aged 2-12 months (OR, 4.8; 95% CI, 1.1-21.1; P=.039). Salmonella Typhimurium represented 106 of 238 (44.5%) serotyped isolates: 65 of 95 (68.4%) were ST313 vs ST19, respectively, and significantly associated with HIV-infected patients (P=.03) and multidrug resistance (OR, 6.6; 95% CI, 2.5-17.2; P<.001). Conclusions. NTS meningitis in South Africa is highly associated with HIV in adults, with neonates (irrespective of HIV status), and with Salmonella Typhimurium ST313. GCS is the best predictor of mortality: early diagnosis and treatment are critical. Focused prevention requires further studies to understand the sources and transmission routes. C1 [Keddy, Karen H.; Sooka, Arvinda; Smith, Anthony M.; Ismail, Husna; Tau, Nomsa P.] Univ Witwatersrand, Natl Inst Communicable Dis, Ctr Enter Dis, Johannesburg, South Africa. [Keddy, Karen H.; Smith, Anthony M.; Klugman, Keith P.] Univ Witwatersrand, Fac Hlth Sci, Johannesburg, South Africa. [Musekiwa, Alfred] Ctr Dis Control & Prevent, South Africa Global Dis Detect Ctr, Int Emerging Infect Programme, Pretoria, South Africa. [Crowther-Gibson, Penny] Natl Inst Communicable Dis, Div Publ Hlth Surveillance & Response, Johannesburg, South Africa. [Angulo, Frederick J.] Emory Univ, Ctr Dis Control & Prevent, Ctr Global Hlth, Div Global Hlth Protect, Atlanta, GA 30322 USA. [Klugman, Keith P.] Emory Univ, Rollins Sch Publ Hlth, Hubert Dept Global Hlth, Atlanta, GA 30322 USA. [Klugman, Keith P.] Emory Univ, Sch Med, Div Infect Dis, Atlanta, GA 30322 USA. RP Keddy, KH (reprint author), Natl Inst Communicable Dis, Ctr Enter Dis, Private Bag X4, ZA-2131 Johannesburg, South Africa. EM karenk@nicd.ac.za FU Bill & Melinda Gates Foundation [OPP1125993]; NICD/NHLS; President's Emergency Plan for AIDS Relief through CDC [5U2GPS001328]; US Agency for International Development Antimicrobial Resistance Initiative from CDC [U60/CCU022088]; STD, and TB Prevention, Global AIDS Program Cooperative Agreement [U62/PSO022901]; CDC, National Center for HIV/AIDS, Viral Hepatitis FX This publication was made possible by a grant from the Bill & Melinda Gates Foundation (OPP1125993). This research has been supported by the NICD/NHLS and the President's Emergency Plan for AIDS Relief through the CDC (5U2GPS001328) and, in part, for 2003-2006 by funds from the US Agency for International Development Antimicrobial Resistance Initiative, transferred via a cooperative agreement (number U60/CCU022088) from the CDC. For 2007-2009, it was supported by the CDC, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Global AIDS Program Cooperative Agreement (U62/PSO022901). K. H. K., A. S., A. M. S., H. I., and N. P. T. are permanent employees of the NHLS and receive no additional funding from other institutions resulting in a conflict of interest. A. M. is employed through the Global Disease Detection Program of the CDC, Pretoria, South Africa. P. C.-G. is funded through 5U2GPS001328, F. J. A. is staff at the CDC, and K. P. K. is employed by the Bill & Melinda Gates Foundation. NR 45 TC 5 Z9 6 U1 1 U2 3 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD NOV 1 PY 2015 VL 61 SU 4 BP S272 EP S282 DI 10.1093/cid/civ685 PG 11 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA CT6WZ UT WOS:000362955100006 PM 26449942 ER PT J AU Oneko, M Kariuki, S Muturi-Kioi, V Otieno, K Otieno, VO Williamson, JM Folster, J Parsons, MB Slutsker, L Mahon, BE Hamel, MJ AF Oneko, Martina Kariuki, Simon Muturi-Kioi, Vincent Otieno, Kephas Otieno, Vincent O. Williamson, John M. Folster, Jason Parsons, Michele B. Slutsker, Laurence Mahon, Barbara E. Hamel, Mary J. TI Emergence of Community-Acquired, Multidrug-Resistant Invasive Nontyphoidal Salmonella Disease in Rural Western Kenya, 2009-2013 SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE invasive; multidrug resistant; nontyphoidal Salmonella; malaria; HIV ID BLOOD-STREAM INFECTIONS; SUB-SAHARAN AFRICA; TRIMETHOPRIM-SULFAMETHOXAZOLE; FALCIPARUM-MALARIA; CHILDREN; BACTEREMIA; MALAWI AB Background. Nontyphoidal Salmonella (NTS), mainly serotypes Typhimurium and Enteritidis, cause invasive infections with high mortality in children in sub-Saharan Africa. Multidrug resistance is common, and resistance to third-generation cephalosporins has emerged. Methods. We reviewed clinical features, outcomes, and antimicrobial resistance patterns in invasive NTS infections among children aged 6 weeks to 5 years participating in malaria vaccine studies in an area of high malaria and human immunodeficiency virus (HIV) transmission in Siaya, western Kenya. Blood culture was performed in hospitalized children and pediatric outpatients with prolonged fever. Results. From July 2009 to December 2013, 1696 children aged 6 weeks to 17 months were enrolled into vaccine trials and followed for up to 53 months. We obtained 1692 blood cultures from 847 children. Of 134 bacterial pathogens isolated, 102 (76.1%) were Salmonella serogroup B or D. Invasive NTS disease occurred in 94 (5.5%) children, with an incidence of 1870, 4134, and 6510 episodes per 100 000 person-years overall, in infants, and in HIV-infected children, respectively. Malaria infection within the past 2 weeks occurred in 18.8% (3/16) of invasive NTS episodes in HIV-infected and 66.2% (53/80) in HIV-uninfected children. Case fatality rate was 3.1%. Salmonella group B resistant to ceftriaxone emerged in 2009 and 2010 (6.2% [2/32 isolates]), rising to 56.5% (13/23 isolates) in 2012 and 2013. Conclusions. Incidence of invasive NTS disease was high in this area of high malaria and HIV transmission, especially in HIV-infected children. Rapidly emerging resistance against ceftriaxone requires urgent reevaluation of antibiotic recommendations and primary prevention of exposure to Salmonella. C1 [Oneko, Martina; Kariuki, Simon; Muturi-Kioi, Vincent; Otieno, Kephas; Otieno, Vincent O.] Kenya Govt Med Res Ctr, Ctr Global Hlth Res, Kisumu 40100, Kenya. [Williamson, John M.; Folster, Jason; Parsons, Michele B.; Slutsker, Laurence; Mahon, Barbara E.; Hamel, Mary J.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Oneko, M (reprint author), Kenya Govt Med Res Ctr, POB 1578, Kisumu 40100, Kenya. EM moneko@kemricdc.org OI Muturi-Kioi, Vincent/0000-0003-1620-3999 FU Bill & Melinda Gates Foundation [OPP1125993] FX This publication was made possible by a grant from the Bill & Melinda Gates Foundation (OPP1125993). NR 31 TC 5 Z9 5 U1 4 U2 13 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD NOV 1 PY 2015 VL 61 SU 4 BP S310 EP S316 DI 10.1093/cid/civ674 PG 7 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA CT6WZ UT WOS:000362955100010 PM 26449946 ER PT J AU Verani, JR Toroitich, S Auko, J Kiplang'at, S Cosmas, L Audi, A Mogeni, OD Aol, G Oketch, D Odiembo, H Katieno, J Wamola, N Onyango, CO Juma, BW Fields, BS Bigogo, G Montgomery, JM AF Verani, Jennifer R. Toroitich, Samuel Auko, Joshua Kiplang'at, Samuel Cosmas, Leonard Audi, Allan Mogeni, Ondari D. Aol, George Oketch, Dismas Odiembo, Herine Katieno, Jim Wamola, Newton Onyango, Clayton O. Juma, Bonventure W. Fields, Barry S. Bigogo, Godfrey Montgomery, Joel M. TI Burden of Invasive Nontyphoidal Salmonella Disease in a Rural and Urban Site in Kenya, 2009-2014 SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE salmonellosis; nontyphoidal Salmonella; invasive NTS ID WESTERN KENYA; CHILDREN; BACTEREMIA; MALARIA; AFRICA; PREVALENCE AB Background. Invasive infections with nontyphoidal Salmonella (NTS) lead to bacteremia in children and adults and are an important cause of illness in Africa; however, few data on the burden of NTS bacteremia are available. We sought to determine the burden of invasive NTS disease in a rural and urban setting in Kenya. Methods. We conducted the study in a population-based surveillance platform in a rural setting in western Kenya (Lwak), and an informal urban settlement in Nairobi (Kibera) from 2009 to 2014. We obtained blood culture specimens from participants presenting with acute lower respiratory tract illness or acute febrile illness to a designated outpatient facility in each site, or any hospital admission for a potentially infectious cause (rural site only). Incidence was calculated using a defined catchment population and adjusting for specimen collection and healthcare-seeking practices. Results. A total of 12 683 and 9524 blood cultures were analyzed from Lwak and Kibera, respectively. Of these, 428 (3.4%) and 533 (5.6%) grew a pathogen; among those, 208 (48.6%) and 70 (13.1%) were positive for NTS in Lwak and Kibera, respectively. Overall, the adjusted incidence of invasive NTS disease was higher in Lwak (839.4 per 100 000 person-years of observation [PYO]) than in Kibera (202.5 per 100 000 PYO). The highest adjusted incidences were observed in children <5 years of age (Lwak 3914.3 per 100 000 PYO and Kibera 997.9 per 100 000 PYO). The highest adjusted annual incidence was 1927.3 per 100 000 PYO (in 2010) in Lwak and 220.5 per 100 000 PYO (in 2011) in Kibera; the lowest incidences were 303.3 and 62.5 per 100 000 PYO, respectively (in 2012). In both sites, invasive NTS disease incidence generally declined over the study period. Conclusions. We observed an extremely high burden of invasive NTS disease in a rural area of Kenya and a lesser, but still substantial, burden in an urban slum. Although the incidences in both sites declined during the study period, invasive NTS infections remain an important cause of morbidity in these settings, particularly among children <5 years old. C1 [Verani, Jennifer R.; Cosmas, Leonard; Onyango, Clayton O.; Juma, Bonventure W.; Fields, Barry S.; Montgomery, Joel M.] Ctr Dis Control & Prevent, Atlanta, GA 30341 USA. [Toroitich, Samuel; Auko, Joshua; Kiplang'at, Samuel; Audi, Allan; Mogeni, Ondari D.; Aol, George; Oketch, Dismas; Odiembo, Herine; Katieno, Jim; Wamola, Newton; Bigogo, Godfrey] Kenya Govt Med Res Ctr, Nairobi, Kenya. RP Montgomery, JM (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE, Atlanta, GA 30341 USA. EM ztq9@cdc.gov FU CDC; Bill & Melinda Gates Foundation [OPP1125993] FX This work was supported by the CDC. This publication was made possible by a grant from the Bill & Melinda Gates Foundation (OPP1125993). NR 25 TC 6 Z9 6 U1 0 U2 6 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD NOV 1 PY 2015 VL 61 SU 4 BP S302 EP S309 DI 10.1093/cid/civ728 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA CT6WZ UT WOS:000362955100009 PM 26449945 ER PT J AU Routh, JA Pringle, J Mohr, M Bidol, S Arends, K Adams-Cameron, M Hancock, WT Kissler, B Rickert, R Folster, J Tolar, B Bosch, S Behravesh, CB Williams, IT Gieraltowski, L AF Routh, J. A. Pringle, J. Mohr, M. Bidol, S. Arends, K. Adams-Cameron, M. Hancock, W. T. Kissler, B. Rickert, R. Folster, J. Tolar, B. Bosch, S. Behravesh, C. Barton Williams, I. T. Gieraltowski, L. TI Nationwide outbreak of multidrug-resistant Salmonella Heidelberg infections associated with ground turkey: United States, 2011 SO EPIDEMIOLOGY AND INFECTION LA English DT Article DE Food-borne infections; food safety; outbreaks; Salmonella; salmonellosis ID ENTERICA SEROVAR HEIDELBERG; ANTIMICROBIAL RESISTANCE; FOOD ANIMALS; RETAIL MEAT; PATHOGENS; SEROTYPE; HEALTH AB On 23 May 2011, CDC identified a multistate cluster of Salmonella Heidelberg infections and two multidrug-resistant (MDR) isolates from ground turkey retail samples with indistinguishable pulsed-field gel electrophoresis patterns. We defined cases as isolation of outbreak strains in persons with illness onset between 27 February 2011 and 10 November 2011. Investigators collected hypothesis-generating questionnaires and shopper-card information. Food samples from homes and retail outlets were collected and cultured. We identified 136 cases of S. Heidelberg infection in 34 states. Shopper-card information, leftover ground turkey from a patient's home containing the outbreak strain and identical antimicrobial resistance profiles of clinical and retail samples pointed to plant A as the source. On 3 August, plant A recalled 36 million pounds of ground turkey. This outbreak increased consumer interest in MDR Salmonella infections acquired through United States-produced poultry and played a vital role in strengthening food safety policies related to Salmonella and raw ground poultry. C1 [Routh, J. A.; Pringle, J.; Hancock, W. T.; Bosch, S.; Behravesh, C. Barton; Williams, I. T.; Gieraltowski, L.] Ctr Dis Control & Prevent, Outbreak Response & Prevent Branch, Atlanta, GA 30333 USA. [Mohr, M.] Ohio Dept Hlth, Columbus, OH 43266 USA. [Bidol, S.; Arends, K.] Michigan Dept Community Hlth, Lansing, MI USA. [Adams-Cameron, M.] New Mexico Dept Hlth, Albuquerque, NM USA. [Kissler, B.] USDA FSIS, Atlanta, GA USA. [Rickert, R.; Folster, J.] CDC, Natl Antimicrobial Resistance Monitoring Syst, Atlanta, GA 30333 USA. [Tolar, B.] CDC, Enter Dis Lab Branch, Atlanta, GA 30333 USA. RP Routh, JA (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE MS C-09, Atlanta, GA 30333 USA. EM iyp1@cdc.gov NR 29 TC 4 Z9 5 U1 1 U2 20 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0950-2688 EI 1469-4409 J9 EPIDEMIOL INFECT JI Epidemiol. Infect. PD NOV PY 2015 VL 143 IS 15 BP 3227 EP 3234 DI 10.1017/S0950268815000497 PG 8 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA CT6WR UT WOS:000362954200009 PM 25865382 ER PT J AU Aungkulanon, S Cheng, PY Kusreesakul, K Bundhamcharoen, K Chittaganpitch, M Margaret, M Olsen, S AF Aungkulanon, Suchunya Cheng, Po-Yung Kusreesakul, Khanitta Bundhamcharoen, Kanitta Chittaganpitch, Malinee Margaret, McCarron Olsen, Sonja TI Influenza-associated mortality in Thailand, 2006-2011 SO INFLUENZA AND OTHER RESPIRATORY VIRUSES LA English DT Article DE Influenza; mortality; Thailand; tropical ID UNITED-STATES; HOSPITAL ADMISSIONS; SEASONAL INFLUENZA; INFECTIONS; BURDEN; VIRUS AB Background Influenza-associated mortality in subtropical or tropical regions, particularly in developing countries, remains poorly quantified and often underestimated. We analyzed data in Thailand, a middle-income tropical country with good vital statistics and influenza surveillance data. Methods We obtained weekly mortality data for all-cause and three underlying causes of death (circulatory and respiratory diseases, and pneumonia and influenza), and weekly influenza virus data, from 2006 to 2011. A negative binomial regression model was used to estimate deaths attributable to influenza in two age groups (< 65 and >= 65 years) by incorporating influenza viral data as covariates in the model. Results From 2006 to 2011, the average annual influenzaassociated mortality per 100 000 persons was 4>0 (95% CI: -18 to 26). Eighty-three percent of influenza-associated deaths occurred among persons aged 65 years. The average annual rate of influenza-associated deaths was 0.7 (95% CI: -8.2 to 10) per 100 000 population for person aged < 65 years and 42 (95% CI: similar to 137 to 216) for person aged >= 65 years. Discussion In Thailand, estimated excess mortality associated with influenza was considerable even during non-pandemic years. These data provide support for Thailand's seasonal influenza vaccination campaign. Continued monitoring of mortality data is important to assess impact. C1 [Aungkulanon, Suchunya; Kusreesakul, Khanitta; Bundhamcharoen, Kanitta] Minist Publ Hlth, Int Hlth Policy Program, Nonthaburi 11000, Thailand. [Cheng, Po-Yung; Margaret, McCarron; Olsen, Sonja] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. [Chittaganpitch, Malinee] Natl Inst Hlth, Nonthaburi, Thailand. [Olsen, Sonja] Thailand Minist Publ Hlth US Ctr Dis Control & Pr, Nonthaburi, Thailand. RP Aungkulanon, S (reprint author), Minist Publ Hlth, Int Hlth Policy Program, Tiwanon Rd, Nonthaburi 11000, Thailand. EM suchunya@ihpp.thaigov.net NR 22 TC 2 Z9 2 U1 1 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1750-2640 EI 1750-2659 J9 INFLUENZA OTHER RESP JI Influenza Other Respir. Viruses PD NOV PY 2015 VL 9 IS 6 BP 298 EP 304 DI 10.1111/irv.12344 PG 7 WC Infectious Diseases; Virology SC Infectious Diseases; Virology GA CT6ID UT WOS:000362915800004 ER PT J AU Brown, LM Laco, CDRJ AF Brown, Lisa M. Laco, C. D. R. Joe TI Rodent Control and Public Health: A Description of Local Rodent Control Programs SO JOURNAL OF ENVIRONMENTAL HEALTH LA English DT Editorial Material C1 [Brown, Lisa M.] NACCHO, Washington, DC 20036 USA. [Laco, C. D. R. Joe] CDC, Atlanta, GA 30333 USA. [Laco, C. D. R. Joe] EHSB, Div Emergency Environm Hlth Serv, Atlanta, GA USA. RP Brown, LM (reprint author), NACCHO, 1100 17th St NW,Seventh Floor, Washington, DC 20036 USA. EM Ibrown@naccho.org NR 6 TC 0 Z9 0 U1 2 U2 2 PU NATL ENVIRON HEALTH ASSOC PI DENVER PA 720 S COLORADO BLVD SUITE 970, SOUTH TOWER, DENVER, CO 80246 USA SN 0022-0892 J9 J ENVIRON HEALTH JI J. Environ. Health PD NOV PY 2015 VL 78 IS 4 BP 28 EP 29 PG 2 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA CT7MO UT WOS:000362999000007 PM 26638674 ER PT J AU Rutledge, G Ayers, DR MacGowan, C Murphy, P AF Rutledge, Gia Ayers, Diane Roberts MacGowan, Carol Murphy, Paulette TI An Overview of the CDC's Community-Based Breastfeeding Supplemental Cooperative Agreement SO JOURNAL OF HUMAN LACTATION LA English DT Editorial Material ID INITIATION; RATES; SCALE C1 [Rutledge, Gia; Ayers, Diane Roberts; MacGowan, Carol; Murphy, Paulette] Natl Ctr Chron Dis Prevent & Hlth Promot, Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Atlanta, GA 30341 USA. RP Rutledge, G (reprint author), Natl Ctr Chron Dis Prevent & Hlth Promot, Ctr Dis Control & Prevent, 4770 Buford Highway,Mailstop F77, Atlanta, GA 30341 USA. EM GRutledge@cdc.gov NR 18 TC 1 Z9 1 U1 1 U2 2 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0890-3344 EI 1552-5732 J9 J HUM LACT JI J. Hum. Lact. PD NOV PY 2015 VL 31 IS 4 SI SI BP 571 EP 576 DI 10.1177/0890334415599779 PG 6 WC Nursing; Obstetrics & Gynecology; Pediatrics SC Nursing; Obstetrics & Gynecology; Pediatrics GA CT3DD UT WOS:000362686100001 PM 26303879 ER PT J AU Hudson, IJ Rutledge, G Ayers, DR AF Hudson, Iris J. Rutledge, Gia Ayers, Diane Roberts TI A Case Study of Michigan's Breastfeeding Initiative: The Role of Coalitions in Community-Based Breastfeeding Support SO JOURNAL OF HUMAN LACTATION LA English DT Article DE breastfeeding; breastfeeding support; coalitions; community-based AB The Michigan Department of Community Health (MDCH) funded 9 local breastfeeding coalitions to implement breastfeeding support groups and to develop breastfeeding resources for mothers and health professionals. The authors conducted qualitative analyses of reports, success stories, and MDCH grantees' interview responses (via follow-up call with 3 coalitions) to assess key barriers, facilitators, and lessons learned for coalitions implementing breastfeeding support groups. Coalitions noted implementation barriers related to their organizational structure and to recruiting mothers and finding meeting locations. Facilitators to implementing breastfeeding support groups included referrals, expertise, resources, and incentives. The following themes emerged from the reports analysis regarding how to implement breastfeeding support groups: meet moms where they are, build community partnerships, and leverage in-kind and financial resources to sustain breastfeeding support groups. C1 [Hudson, Iris J.; Rutledge, Gia; Ayers, Diane Roberts] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Nutr Phys Act & Obes, Atlanta, GA 30341 USA. RP Hudson, IJ (reprint author), Ctr Dis Control & Prevent, Mail Stop F-77,4770 Buford Highway NE, Atlanta, GA 30341 USA. EM ihudson@cdc.gov FU US Department of Health and Human Services, Centers for Disease Control and Prevention [CDC-RFA-DP08-8050501PPHF12] FX The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: US Department of Health and Human Services, Centers for Disease Control and Prevention CDC-RFA-DP08-8050501PPHF12. NR 5 TC 0 Z9 0 U1 2 U2 4 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0890-3344 EI 1552-5732 J9 J HUM LACT JI J. Hum. Lact. PD NOV PY 2015 VL 31 IS 4 SI SI BP 611 EP 613 DI 10.1177/0890334415601358 PG 3 WC Nursing; Obstetrics & Gynecology; Pediatrics SC Nursing; Obstetrics & Gynecology; Pediatrics GA CT3DD UT WOS:000362686100009 PM 26286470 ER PT J AU Lilleston, P Nhim, K Rutledge, G AF Lilleston, Pamela Nhim, Kunthea Rutledge, Gia TI An Evaluation of the CDC's Community-Based Breastfeeding Supplemental Cooperative Agreement: Reach, Strategies, Barriers, Facilitators, and Lessons Learned SO JOURNAL OF HUMAN LACTATION LA English DT Article DE breastfeeding; breastfeeding support; community-based; community support; process evaluation; program evaluation ID INITIATION; DURATION; WOMEN AB Background: Community-based organizations (CBOs) have an important role to play in promoting breastfeeding continuation among mothers. The Centers for Disease Control and Prevention's Nutrition, Physical Activity, and Obesity Program's Cooperative Agreement Breastfeeding Supplement funded 6 state health departments to support CBOs to implement community-based breastfeeding support activities. Objectives: Study objectives were to (1) describe the reach of the Cooperative Agreement, (2) describe breastfeeding support strategies implemented by state health departments and CBOs, and (3) understand the barriers and facilitators to implementing community-based breastfeeding support strategies. Methods: Qualitative and quantitative data were abstracted from state health departments' final evaluation reports. Qualitative data were analyzed for common themes using deductive and inductive approaches. Results: Within the 6 states funded by the Cooperative Agreement, 66 primary CBOs implemented breastfeeding support strategies and reported 59256 contacts with mothers. Support strategies included incorporating lactation services into community-based programs, training staff, providing walk-in locations for lactation support, connecting breastfeeding mothers to resources, and providing services that reflect community-specific culture. Community partnerships, network building, stakeholders' commitment, and programmatic and policy environments were key facilitators of program success. Conclusion: Key lessons learned include the importance of time in creating lasting organizational change, use of data for program improvement, choosing the right partners, taking a collective approach, and leveraging resources. C1 [Lilleston, Pamela] Natl Ctr Chron Dis Prevent & Hlth Promot, Ctr Dis Control & Prevent, Div Populat Hlth, Atlanta, GA 30341 USA. [Nhim, Kunthea] Natl Ctr Chron Dis Prevent & Hlth Promot, Ctr Dis Control & Prevent, Div Diabet Translat, Atlanta, GA 30341 USA. [Rutledge, Gia] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Nutr Phys Act & Obes, Atlanta, GA 30341 USA. RP Lilleston, P (reprint author), Natl Ctr Chron Dis Prevent & Hlth Promot, Ctr Dis Control & Prevent, 4770 Buford Highway,NE,Mailstop F-78, Atlanta, GA 30341 USA. EM plilleston@gmail.com FU Centers for Disease Control and Prevention (CDC) Nutrition, Physical Activity, and Obesity Program's Cooperative Agreement (Breastfeeding Supplement) [CDC-RFA-DP08-050501PPHF12] FX The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The programs included in the evaluation findings were supported by the Centers for Disease Control and Prevention (CDC) Nutrition, Physical Activity, and Obesity Program's Cooperative Agreement (Breastfeeding Supplement), CDC-RFA-DP08-050501PPHF12. NR 20 TC 3 Z9 3 U1 4 U2 10 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0890-3344 EI 1552-5732 J9 J HUM LACT JI J. Hum. Lact. PD NOV PY 2015 VL 31 IS 4 SI SI BP 614 EP 622 DI 10.1177/0890334415597904 PG 9 WC Nursing; Obstetrics & Gynecology; Pediatrics SC Nursing; Obstetrics & Gynecology; Pediatrics GA CT3DD UT WOS:000362686100010 PM 26261226 ER PT J AU Gaskins, AJ Rich-Edwards, JW Lawson, CC Schernhammer, ES Missmer, SA Chavarro, JE AF Gaskins, Audrey J. Rich-Edwards, Janet W. Lawson, Christina C. Schernhammer, Eva S. Missmer, Stacey A. Chavarro, Jorge E. TI Work schedule and physical factors in relation to fecundity in nurses SO OCCUPATIONAL AND ENVIRONMENTAL MEDICINE LA English DT Article ID CURRENT-DURATION APPROACH; SHIFT WORK; REGISTERED NURSES; DEMANDING WORK; UNITED-STATES; WHITEHALL II; HEALTH-CARE; SUBFECUNDITY; PREGNANCY; LONG AB Objectives To evaluate the association of work schedule and physical factors with fecundity. Methods Women currently employed outside the home and trying to get pregnant (n=1739) in the Nurses' Health Study 3 cohort (2010-2014) were included in this analysis. Work schedule and physical labour were self-reported on the baseline questionnaire, and every 6 months thereafter the women reported the duration of their ongoing pregnancy attempt. Multivariable accelerated failure time models were used to estimate time ratios (TR) and 95% CIs. Results Among the 1739 women (median age=33 years, 93% Caucasian) the estimated proportions of women not pregnant after 12 and 24 months were 16% and 5%, respectively. None of the various shift work patterns were associated with duration of pregnancy attempt (as a surrogate for fecundity). However, women working >40 h/week had a 20% (95% CI 7 to 35%) longer median duration of pregnancy attempt compared to women working 21-40 h/week (p-trend=0.005). Women whose work entailed heavy lifting or moving (ie, 25+ pounds) >15 times/day also had a longer median duration of pregnancy attempt (adjusted TR=1.49; 95% CI 1.20 to 1.85) compared to women who never lifted or moved heavy loads (p-trend=0.002). The association between heavy moving and lifting and duration of pregnancy attempt was more pronounced among overweight or obese women (body mass index, BMI<25: TR=1.17; 95% CI 0.88 to 1.56; BMI >= 25: TR=2.03, 95% CI 1.48 to 2.79; p-interaction=0.007). Conclusions Working greater than 40 h per week and greater frequency of lifting or moving a heavy load were associated with reduced fecundity in a cohort of nurses planning pregnancy. C1 [Gaskins, Audrey J.; Chavarro, Jorge E.] Harvard Univ, TH Chan Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA. [Gaskins, Audrey J.; Rich-Edwards, Janet W.; Schernhammer, Eva S.; Missmer, Stacey A.; Chavarro, Jorge E.] Harvard Univ, TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA. [Rich-Edwards, Janet W.; Schernhammer, Eva S.; Missmer, Stacey A.; Chavarro, Jorge E.] Brigham & Womens Hosp, Dept Med, Channing Div Network Med, Boston, MA 02115 USA. [Rich-Edwards, Janet W.; Schernhammer, Eva S.; Missmer, Stacey A.; Chavarro, Jorge E.] Harvard Univ, Sch Med, Boston, MA 02115 USA. [Rich-Edwards, Janet W.] Brigham & Womens Hosp, Dept Med, Connors Ctr Womens Hlth & Gender Biol, Boston, MA 02115 USA. [Lawson, Christina C.] NIOSH, Ctr Dis Control & Prevent, Cincinnati, OH 45226 USA. [Missmer, Stacey A.] Brigham & Womens Hosp, Dept Obstet Gynecol & Reprod Biol, Boston, MA 02115 USA. RP Gaskins, AJ (reprint author), Harvard Univ, TH Chan Sch Publ Hlth, Dept Nutr, Bldg 2 3rd Floor,655 Huntington Ave, Boston, MA 02115 USA. EM ajg219@mail.harvard.edu FU NIH [T32HD060454, T32DK007703]; CDC/NIOSH [200-2013-M-54978]; Breast Cancer Research Foundation FX The authors are supported by NIH grant T32HD060454, T32DK007703, contract 200-2013-M-54978 from CDC/NIOSH, and a grant from the Breast Cancer Research Foundation. The funding sources had no influence on the study design, data analysis, writing of the report, or the decision to submit the findings of the present study for publication. NR 43 TC 4 Z9 4 U1 0 U2 3 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1351-0711 EI 1470-7926 J9 OCCUP ENVIRON MED JI Occup. Environ. Med. PD NOV PY 2015 VL 72 IS 11 BP 777 EP 783 DI 10.1136/oemed-2015-103026 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CT6GA UT WOS:000362909900005 PM 26251064 ER PT J AU Landgren, O Shim, YK Michalek, J Costello, R Burton, D Ketchum, N Calvo, KR Caporaso, N Raveche, E Middleton, D Marti, G Vogt, RF AF Landgren, Ola Shim, Youn K. Michalek, Joel Costello, Rene Burton, Debra Ketchum, Norma Calvo, Katherine R. Caporaso, Neil Raveche, Elizabeth Middleton, Dan Marti, Gerald Vogt, Robert F., Jr. TI Agent Orange Exposure and Monoclonal Gammopathy of Undetermined Significance An Operation Ranch Hand Veteran Cohort Study SO JAMA ONCOLOGY LA English DT Article ID EARLY TREATMENT STRATEGIES; PRECEDES MULTIPLE-MYELOMA; AGRICULTURAL-WORKERS; BIOLOGICAL INSIGHTS; PESTICIDE EXPOSURE; SIGNIFICANCE MGUS; CANCER INCIDENCE; UNITED-STATES; LIGHT-CHAINS; IOWA FARMERS AB IMPORTANCE Multiple myeloma has been classified as exhibiting "limited or suggestive evidence" of an association with exposure to herbicides in Vietnam War veterans. Occupational studies have shown that other pesticides (ie, insecticides, herbicides, fungicides) are associated with excess risk of multiple myeloma and its precursor state, monoclonal gammopathy of undetermined significance (MGUS); however, to our knowledge, no studies have uncovered such an association in Vietnam War veterans. OBJECTIVE To examine the relationship between MGUS and exposure to Agent Orange, including its contaminant 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), in Vietnam War veterans. DESIGN, SETTING, AND PARTICIPANTS This was a prospective cohort study conducted in 2013 to 2014, testing for MGUS in serum specimens collected and stored in 2002 by the Air Force Health Study (AFHS). The relevant exposure data collected by the AFHS was also used. We tested all specimens in 2013 without knowledge of the exposure status. The AFHS included former US Air Force personnel who participated in Operation Ranch Hand (Ranch Hand veterans) and other US Air Force personnel who had similar duties in Southeast Asia during the same time period (1962 to 1971) but were not involved in herbicide spray missions (comparison veterans). Agent Orange was used by the US Air Force personnel who conducted aerial spray missions of herbicides (Operation Ranch Hand) in Vietnam from 1962 to 1971. We included 479 Ranch Hand veterans and 479 comparison veterans who participated in the 2002 follow-up examination of AFHS. EXPOSURES Agent Orange and TCDD. Serum TCDD levels were measured in 1987, 1992, 1997, and 2002. MAIN OUTCOMES AND MEASURES Risk of MGUS measured by prevalence, odds ratios (ORs), and 95% CIs. RESULTS The 479 Ranch Hand veterans and 479 comparison veterans had similar demographic and lifestyle characteristics and medical histories. The crude prevalence of overall MGUS was 7.1%(34 of 479) in Ranch Hand veterans and 3.1% (15 of 479) in comparison veterans. This translated into a 2.4-fold increased risk for MGUS in Ranch Hand veterans than comparison veterans after adjusting for age, race, BMI in 2002, and the change in BMI between 2002 and the time of blood draw for TCDD measurement (adjusted OR, 2.37; 95% CI, 1.27-4.44; P =.007). CONCLUSIONS AND RELEVANCE Operation Ranch Hand veterans have a significantly increased risk of MGUS, supporting an association between Agent Orange exposure and multiple myeloma. C1 [Landgren, Ola; Costello, Rene; Burton, Debra; Caporaso, Neil] NCI, NIH, Bethesda, MD 20892 USA. [Landgren, Ola] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Shim, Youn K.; Middleton, Dan] Agcy Tox Subst & Dis Registry, Atlanta, GA USA. [Michalek, Joel; Ketchum, Norma] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA. [Calvo, Katherine R.] NIH, Ctr Clin, Bethesda, MD 20892 USA. [Raveche, Elizabeth] Rutgers New Jersey Med Sch, Dept Pathol & Lab Med, Newark, NJ USA. [Marti, Gerald] US FDA, Ctr Devices & Radiol Hlth, Silver Spring, MD USA. [Vogt, Robert F., Jr.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA USA. RP Landgren, O (reprint author), Mem Sloan Kettering Canc Ctr, Myeloma Serv, 1275 York Ave, New York, NY 10065 USA. EM landgrec@mskcc.org FU Intramural Program at the Agency for Toxic Substances and Disease Registry; Intramural Program at the National Cancer Institute; Air Force Health Study (AFHS) Assets Research Program at the Institute of Medicine FX This study was supported by the Intramural Program at the Agency for Toxic Substances and Disease Registry, the Intramural Program at the National Cancer Institute, and the Air Force Health Study (AFHS) Assets Research Program at the Institute of Medicine through an award to the Centers for Disease Control and Prevention (CDC) Foundation. NR 50 TC 4 Z9 5 U1 0 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2374-2445 J9 JAMA ONCOL JI JAMA Oncol. PD NOV PY 2015 VL 1 IS 8 BP 1061 EP 1068 DI 10.1001/jamaoncol.2015.2938 PG 8 WC Oncology SC Oncology GA DW5IO UT WOS:000383677700010 PM 26335650 ER PT J AU Ekwueme, D Guy, G Rim, SH White, A Dean, H AF Ekwueme, D. Guy, G. Rim, S. H. White, A. Dean, H. TI HEALTH AND ECONOMIC BURDEN OF BREAST CANCER MORTALITY IN YOUNGER WOMEN AGED 18-44 YEARS IN THE UNITED STATES, 1970-2012 SO VALUE IN HEALTH LA English DT Meeting Abstract C1 [Ekwueme, D.; Guy, G.; Rim, S. H.; White, A.; Dean, H.] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1098-3015 EI 1524-4733 J9 VALUE HEALTH JI Value Health PD NOV PY 2015 VL 18 IS 7 MA PCN116 BP A450 EP A450 PG 1 WC Economics; Health Care Sciences & Services; Health Policy & Services SC Business & Economics; Health Care Sciences & Services GA DX3DD UT WOS:000384252400633 PM 26532534 ER PT J AU Said, MA German, D Flynn, C Linton, SL Blythe, D Cooley, LA Balaji, AB Oster, AM AF Said, Maria A. German, Danielle Flynn, Colin Linton, Sabriya L. Blythe, David Cooley, Laura A. Balaji, Alexandra B. Oster, Alexandra M. TI Uptake of Testing for HIV and Syphilis Among Men Who Have Sex with Men in Baltimore, Maryland: 2004-2011 SO AIDS AND BEHAVIOR LA English DT Article DE HIV infections/diagnosis; HIV infections/epidemiology; Homosexuality; Male; Baltimore ID BEHAVIORAL SURVEILLANCE SYSTEM; HEALTH-CARE SETTINGS; NEW-YORK-CITY; UNITED-STATES; MISSED OPPORTUNITIES; RISK BEHAVIORS; INFECTION; PREVENTION; US; RECOMMENDATIONS AB Men who have sex with men (MSM) in Baltimore are at disproportionately high risk for HIV and syphilis infection. Testing and diagnosis are important first steps in receiving treatment and reducing transmission. We analyzed cross-sectional data collected in 2004-2005, 2008, and 2011 among MSM not reporting a previous positive HIV test (n = 1268) in Baltimore, Maryland as part of the National HIV Behavioral Surveillance System to determine the proportion of men tested for HIV and/or syphilis within the previous 12 months and examine the extent to which opportunities for testing were being missed in health care settings. Within the previous 12 months, 54 % of men had received an HIV test; 31 % had received a syphilis test; and only 23 % of men had received testing for both. Among 979 men who did not receive both tests, 72 % had seen a health care provider in the past year, suggesting missed testing opportunities. C1 [Said, Maria A.; Cooley, Laura A.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA 30322 USA. [German, Danielle; Linton, Sabriya L.] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA. [Said, Maria A.; Flynn, Colin; Blythe, David] Maryland Dept Hlth & Mental Hyg, Baltimore, MD USA. [Cooley, Laura A.; Balaji, Alexandra B.; Oster, Alexandra M.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. RP Said, MA (reprint author), Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA 30322 USA. EM said.maria@gmail.com FU Centers for Disease Control and Prevention; Maryland Department of Health and Mental Hygiene FX The National HIV Behavioral Surveillance System is funded by the Centers for Disease Control and Prevention. Baltimore activities are funded through a cooperative agreement with the Maryland Department of Health and Mental Hygiene, who contracts with the Johns Hopkins Bloomberg School of Public Health. NR 41 TC 3 Z9 3 U1 1 U2 5 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1090-7165 EI 1573-3254 J9 AIDS BEHAV JI AIDS Behav. PD NOV PY 2015 VL 19 IS 11 BP 2036 EP 2043 DI 10.1007/s10461-015-1106-y PG 8 WC Public, Environmental & Occupational Health; Social Sciences, Biomedical SC Public, Environmental & Occupational Health; Biomedical Social Sciences GA CT2TQ UT WOS:000362657300008 PM 26078117 ER PT J AU Lewallen, TC Hunt, H Potts-Datema, W Zaza, S Giles, W AF Lewallen, Theresa C. Hunt, Holly Potts-Datema, William Zaza, Stephanie Giles, Wayne TI The Whole School, Whole Community, Whole Child Model: A New Approach for Improving Educational Attainment and Healthy Development for Students SO JOURNAL OF SCHOOL HEALTH LA English DT Article DE school health; coordinated school health; whole child; health and academics ID PHYSICAL-ACTIVITY; ACADEMIC-PERFORMANCE; BREAKFAST; METAANALYSIS; ACHIEVEMENT; ADOLESCENTS; OUTCOMES; SMOKING; PROGRAM AB BACKGROUNDThe Whole Child approach and the coordinated school health (CSH) approach both address the physical and emotional needs of students. However, a unified approach acceptable to both the health and education communities is needed to assure that students are healthy and ready to learn. METHODSDuring spring 2013, the ASCD (formerly known as the Association for Supervision and Curriculum Development) and the US Centers for Disease Control and Prevention (CDC) convened experts from the field of education and health to discuss lessons learned from implementation of the CSH and Whole Child approaches and to explore the development of a new model that would incorporate the knowledge gained through implementation to date. RESULTSAs a result of multiple discussions and review, the Whole School, Whole Community, Whole Child (WSCC) approach was developed. The WSCC approach builds upon the traditional CSH model and ASCD's Whole Child approach to learning and promotes greater alignment between health and educational outcomes. CONCLUSIONBy focusing on children and youth as students, addressing critical education and health outcomes, organizing collaborative actions and initiatives that support students, and strongly engaging community resources, the WSCC approach offers important opportunities that will improve educational attainment and healthy development for students. C1 [Lewallen, Theresa C.] ASCD, Constituent Serv, Alexandria, VA 22311 USA. [Hunt, Holly] Ctr Dis Control & Prevent, Sch Hlth Branch, Div Populat Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. [Potts-Datema, William] Ctr Dis Control & Prevent, Program Dev & Serv Branch, Div Adolescent & Sch Hlth, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30329 USA. [Zaza, Stephanie] Ctr Dis Control & Prevent, Div Adolescent & Sch Hlth, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30329 USA. [Giles, Wayne] Ctr Dis Control & Prevent, Div Populat Hlth, Natl Ctr Chron Dis Prevent and Hlth Promot, Atlanta, GA 30341 USA. RP Lewallen, TC (reprint author), ASCD, 1703 N Beauregard St, Alexandria, VA 22311 USA. EM tlewalle@ascd.org; HHunt@cdc.gov; wpottsdatema@cdc.gov; szaza@cdc.gov; HGiles@cdc.gov NR 58 TC 13 Z9 13 U1 4 U2 18 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0022-4391 EI 1746-1561 J9 J SCHOOL HEALTH JI J. Sch. Health PD NOV PY 2015 VL 85 IS 11 SI SI BP 729 EP 739 DI 10.1111/josh.12310 PG 11 WC Education & Educational Research; Education, Scientific Disciplines; Health Care Sciences & Services; Public, Environmental & Occupational Health SC Education & Educational Research; Health Care Sciences & Services; Public, Environmental & Occupational Health GA CT0PN UT WOS:000362498700001 PM 26440815 ER PT J AU Michael, SL Merlo, CL Basch, CE Wentzel, KR Wechsler, H AF Michael, Shannon L. Merlo, Caitlin L. Basch, Charles E. Wentzel, Kathryn R. Wechsler, Howell TI Critical Connections: Health and Academics SO JOURNAL OF SCHOOL HEALTH LA English DT Article DE child and adolescent health; health behaviors; academic achievement; school health programs; Whole School; Whole Community; Whole Child model ID URBAN MINORITY YOUTH; OF-THE-LITERATURE; SCHOOL CLIMATE RESEARCH; PHYSICAL-ACTIVITY; ACHIEVEMENT GAP; STUDENT PERFORMANCE; PARENTAL INVOLVEMENT; COMPREHENSIVE SCHOOL; ADOLESCENT HEALTH; PROMOTION PROGRAM AB BACKGROUNDWhile it is a national priority to support the health and education of students, these sectors must better align, integrate, and collaborate to achieve this priority. This article summarizes the literature on the connection between health and academic achievement using the Whole School, Whole Community, and Whole Child (WSCC) framework as a way to address health-related barriers to learning. METHODSA literature review was conducted on the association between student health and academic achievement. RESULTSMost of the evidence examined the association between student health behaviors and academic achievement, with physical activity having the most published studies and consistent findings. The evidence supports the need for school health services by demonstrating the association between chronic conditions and decreased achievement. Safe and positive school environments were associated with improved health behaviors and achievement. Engaging families and community members in schools also had a positive effect on students' health and achievement. CONCLUSIONSSchools can improve the health and learning of students by supporting opportunities to learn about and practice healthy behaviors, providing school health services, creating safe and positive school environments, and engaging families and community. This evidence supports WSCC as a potential framework for achieving national educational and health goals. C1 [Michael, Shannon L.; Merlo, Caitlin L.] Ctr Dis Control & Prevent, Div Populat Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. [Basch, Charles E.] Columbia Univ, Hlth & Educ, Teachers Coll, New York, NY 10027 USA. [Wentzel, Kathryn R.] Univ Maryland, Dept Human Dev, Coll Educ, College Pk, MD 20742 USA. [Wechsler, Howell] Clinton Fdn, Alliance Healthier Generat, New York, NY 10020 USA. RP Michael, SL (reprint author), Ctr Dis Control & Prevent, Div Populat Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway NE Mailstop F-78, Atlanta, GA 30341 USA. EM sot2@cdc.gov; cmerlo@cdc.gov; ceb35@columbia.edu; wentzel@umd.edu; howell.wechsler@healthiergeneration.org NR 112 TC 6 Z9 6 U1 3 U2 14 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0022-4391 EI 1746-1561 J9 J SCHOOL HEALTH JI J. Sch. Health PD NOV PY 2015 VL 85 IS 11 SI SI BP 740 EP 758 DI 10.1111/josh.12309 PG 19 WC Education & Educational Research; Education, Scientific Disciplines; Health Care Sciences & Services; Public, Environmental & Occupational Health SC Education & Educational Research; Health Care Sciences & Services; Public, Environmental & Occupational Health GA CT0PN UT WOS:000362498700002 PM 26440816 ER PT J AU Rasberry, CN Slade, S Lohrmann, DK Valois, RF AF Rasberry, Catherine N. Slade, Sean Lohrmann, David K. Valois, Robert F. TI Lessons Learned From the Whole Child and Coordinated School Health Approaches SO JOURNAL OF SCHOOL HEALTH LA English DT Article DE coordinated school health; whole child; education outcomes; child health; health outcomes; Whole School; Whole Community; Whole Child (WSCC) model ID COMPLEMENTARY ECOLOGICAL MODEL; PHYSICAL-ACTIVITY; LEADERSHIP-INSTITUTE; PROGRAM; PROJECT; ACHIEVEMENT; INTERVENTION; BEHAVIORS; IMPACT AB BACKGROUNDThe new Whole School, Whole Community, Whole Child (WSCC) model, designed to depict links between health and learning, is founded on concepts of coordinated school health (CSH) and a whole child approach to education. METHODSThe existing literature, including scientific articles and key publications from national agencies and organizations, was reviewed and synthesized to describe (1) the historical context for CSH and a whole child approach, and (2) lessons learned from the implementation and evaluation of these approaches. RESULTSThe literature revealed that interventions conducted in the context of CSH can improve health-related and academic outcomes, as well as policies, programs, or partnerships. Several structural elements and processes have proved useful for implementing CSH and a whole child approach in schools, including use of school health coordinators, school-level and district-level councils or teams; systematic assessment and planning; strong leadership and administrative support, particularly from school principals; integration of health-related goals into school improvement plans; and strong community collaborations. CONCLUSIONSLessons learned from years of experience with CSH and the whole child approaches have applicability for developing a better understanding of the WSCC model as well as maximizing and documenting its potential for impacting both health and education outcomes. C1 [Rasberry, Catherine N.] Ctr Dis Control & Prevent, Div Adolescent Hlth, Natl Ctr HIV AIDS Viral Hepatitis STD TB Prevent, Atlanta, GA 30329 USA. [Slade, Sean] ASCD, Alexandria, VA 22311 USA. [Lohrmann, David K.] Indiana Univ, Sch Publ Health Bloomington, Dept Appl Hlth Sci, Bloomington, IN 47405 USA. [Valois, Robert F.] Univ S Carolina, Dept Hlth Promot Educ & Behav, Arnold Sch Publ Hlth, Columbia, SC 29208 USA. RP Rasberry, CN (reprint author), Ctr Dis Control & Prevent, Div Adolescent Hlth, Natl Ctr HIV AIDS Viral Hepatitis STD TB Prevent, 1600 Clifton Rd ,MS E-75, Atlanta, GA 30329 USA. EM CRasberry@cdc.gov; sslade@ascd.org; dlohrman@indiana.edu; RFValois@sc.edu RI Rasberry, Catherine/P-1984-2016 OI Rasberry, Catherine/0000-0001-8256-6961 FU Intramural CDC HHS [CC999999] NR 45 TC 0 Z9 0 U1 3 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0022-4391 EI 1746-1561 J9 J SCHOOL HEALTH JI J. Sch. Health PD NOV PY 2015 VL 85 IS 11 SI SI BP 759 EP 765 DI 10.1111/josh.12307 PG 7 WC Education & Educational Research; Education, Scientific Disciplines; Health Care Sciences & Services; Public, Environmental & Occupational Health SC Education & Educational Research; Health Care Sciences & Services; Public, Environmental & Occupational Health GA CT0PN UT WOS:000362498700003 PM 26440817 ER PT J AU Kolbe, LJ Allensworth, DD Potts-Datema, W White, DR AF Kolbe, Lloyd J. Allensworth, Diane D. Potts-Datema, William White, Douglas R. TI What Have We Learned From Collaborative Partnerships to Concomitantly Improve Both Education and Health? SO JOURNAL OF SCHOOL HEALTH LA English DT Article DE coordinated school health programs; healthy schools; health-promoting schools; collaborative partnerships; Whole School; Whole Community; Whole Child model ID UNITED-STATES; ACHIEVEMENT; SCHOOLS; CANCER AB BACKGROUNDCollaborative partnerships are an essential means to concomitantly improve both education outcomes and health outcomes among K-12 students. METHODSWe describe examples of contemporaneous, interactive, and evolving partnerships that have been implemented, respectively, by a national governmental health organization, national nongovernmental education and health organizations, a state governmental education organization, and a local nongovernmental health organization that serves partner schools. RESULTSEach of these partnerships strategically built operational infrastructures that enabled partners to efficiently combine their resources to improve student education and health. CONCLUSIONSTo implement a Whole School, Whole Community, Whole Child Framework, we need to purposefully strengthen, expand, and interconnect national, state, and local collaborative partnerships and supporting infrastructures that concomitantly can improve both education and health. C1 [Kolbe, Lloyd J.] Indiana Univ, Appl Hlth Sci, Sch Publ Hlth, Bloomington, IN 47405 USA. [Allensworth, Diane D.] Kent State Univ, Sch Hlth Sci, Kent, OH 44240 USA. [Potts-Datema, William] Ctr Dis Control & Prevent, Program Dev & Serv Branch, Div Adolescent & Sch Hlth, Natl Ctr HIV Viral Hepatitis STD & TB Prevent, Atlanta, GA 30329 USA. [White, Douglas R.] Wisconsin Dept Publ Instruct, Student Serv Prevent & Wellness, Madison, WI 53707 USA. RP Kolbe, LJ (reprint author), Indiana Univ, Appl Hlth Sci, Sch Publ Hlth, Bloomington, IN 47405 USA. EM lkolbe@indiana.edu; dallensw@kent.edu; wpottsdatema@cdc.gov; douglas.white@dpi.wi.gov NR 52 TC 4 Z9 4 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0022-4391 EI 1746-1561 J9 J SCHOOL HEALTH JI J. Sch. Health PD NOV PY 2015 VL 85 IS 11 SI SI BP 766 EP 774 DI 10.1111/josh.12312 PG 9 WC Education & Educational Research; Education, Scientific Disciplines; Health Care Sciences & Services; Public, Environmental & Occupational Health SC Education & Educational Research; Health Care Sciences & Services; Public, Environmental & Occupational Health GA CT0PN UT WOS:000362498700004 PM 26440818 ER PT J AU Murray, SD Hurley, J Ahmed, SR AF Murray, Sharon D. Hurley, James Ahmed, Shannon R. TI Supporting the Whole Child Through Coordinated Policies, Processes, and Practices SO JOURNAL OF SCHOOL HEALTH LA English DT Article DE school health; health and academics; Whole School; Whole Community; Whole Child (WSCC) model AB BACKGROUNDThe Whole School, Whole Community, Whole Child (WSCC) model provides a framework for promoting greater alignment, integration, and collaboration between health and education across the school setting and improving students' cognitive, physical, social, and emotional development. By providing a learning environment that ensures each student is emotionally and physically healthy, safe, actively engaged, supported, and challenged, the WSCC model presents a framework for school systems to evaluate, streamline, implement, and sustain policies, processes, and practices. METHODSThis article examines the essential roles of the school district and of schools in aligning, developing, and implementing policy, processes, and practices to create optimal learning environments that support the whole child. RESULTSThree key factors advance efforts to align policies, processes, and practices. These include hiring a coordinator at the district and school levels, having collaborative teams address health and learning at the district and school levels, and using data to make decisions and build health outcomes into school and district accountability systems. CONCLUSIONSThese key factors provide a road map for successfully implementing WSCC. More research is needed to determine the extent that coordinators, collaborative teams, and the inclusion of health indicators in accountability systems impact student health and learning. C1 [Murray, Sharon D.; Hurley, James] RMC Hlth, Lakewood, CO 80214 USA. [Ahmed, Shannon R.] Ctr Dis Control & Prevent, Div Populat Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. RP Murray, SD (reprint author), RMC Hlth, 7525 W 10th Ave, Lakewood, CO 80214 USA. EM sharonm@rmc.org; jamesh@rmc.org; kbx4@cdc.gov NR 20 TC 0 Z9 0 U1 3 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0022-4391 EI 1746-1561 J9 J SCHOOL HEALTH JI J. Sch. Health PD NOV PY 2015 VL 85 IS 11 SI SI BP 795 EP 801 DI 10.1111/josh.12306 PG 7 WC Education & Educational Research; Education, Scientific Disciplines; Health Care Sciences & Services; Public, Environmental & Occupational Health SC Education & Educational Research; Health Care Sciences & Services; Public, Environmental & Occupational Health GA CT0PN UT WOS:000362498700007 PM 26440821 ER PT J AU Hunt, P Barrios, L Telljohann, SK Mazyck, D AF Hunt, Pete Barrios, Lisa Telljohann, Susan K. Mazyck, Donna TI A Whole School Approach: Collaborative Development of School Health Policies, Processes, and Practices SO JOURNAL OF SCHOOL HEALTH LA English DT Article DE coordinated school health; whole child; academic achievement; health outcomes; Whole School; Whole Community; Whole Child (WSCC) model ID ACHIEVEMENT; EDUCATION; STUDENTS AB BACKGROUNDThe Whole School, Whole Community, Whole Child (WSCC) model shows the interrelationship between health and learning and the potential for improving educational outcomes by improving health outcomes. However, current descriptions do not explain how to implement the model. METHODSThe existing literature, including scientific articles, programmatic guidance, and publications by national agencies and organizations, was reviewed and synthesized to describe an overview of interrelatedness of learning and health and the 10 components of the WSCC model. RESULTSThe literature suggests potential benefits of applying the WSCC model at the district and school level. But, the model lacks specific guidance as to how this might be made actionable. A collaborative approach to health and learning is suggested, including a 10-step systematic process to help schools and districts develop an action plan for improving health and education outcomes. Essential preliminary actions are suggested to minimize the impact of the challenges that commonly derail systematic planning processes and program implementation, such as lack of readiness, personnel shortages, insufficient resources, and competing priorities. CONCLUSIONSAll new models require testing and evidence to confirm their value. District and schools will need to test this model and put plans into action to show that significant, substantial, and sustainable health and academic outcomes can be achieved. C1 [Hunt, Pete; Barrios, Lisa] Ctr Dis Control & Prevent, Res Applicat & Evaluat Branch, Div Adolescent & Sch Hlth, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30329 USA. [Telljohann, Susan K.] Univ Toledo, Dept Hlth & Recreat Profess, Toledo, OH 43606 USA. [Mazyck, Donna] Natl Assoc Sch Nurses, Washington, DC 20036 USA. RP Hunt, P (reprint author), Ctr Dis Control & Prevent, Res Applicat & Evaluat Branch, Div Adolescent & Sch Hlth, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, 1600 Clifton Rd NE,MS E-75, Atlanta, GA 30329 USA. EM phunt@cdc.gov; lbarrios@cdc.gov; susan.telljohann@utdedo.edu; dmazyck@nasn.org NR 18 TC 3 Z9 3 U1 2 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0022-4391 EI 1746-1561 J9 J SCHOOL HEALTH JI J. Sch. Health PD NOV PY 2015 VL 85 IS 11 SI SI BP 802 EP 809 DI 10.1111/josh.12305 PG 8 WC Education & Educational Research; Education, Scientific Disciplines; Health Care Sciences & Services; Public, Environmental & Occupational Health SC Education & Educational Research; Health Care Sciences & Services; Public, Environmental & Occupational Health GA CT0PN UT WOS:000362498700008 PM 26440822 ER PT J AU Quick, H Carlin, BP Banerjee, S AF Quick, Harrison Carlin, Bradley P. Banerjee, Sudipto TI Heteroscedastic conditional auto-regression models for areally referenced temporal processes for analysing California asthma hospitalization data SO JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES C-APPLIED STATISTICS LA English DT Article DE Bayesian methods; Gaussian process; Gradients; Markov chain Monte Carlo methods; Spatial process models AB Often in regionally aggregated spatiotemporal models, a single variance parameter is used to capture variability in the spatial structure of the model, ignoring the effect that spatially varying factors may have on the variability in the underlying process. We extend existing methodologies to allow for region-specific variance components in our analysis of monthly asthma hospitalization rates in California counties, introducing a heteroscedastic conditional auto-regression model that can greatly improve the fit of our spatiotemporal process. After demonstrating the effectiveness of our new model via simulation, we reanalyse the asthma hospitalization data and note some important findings. C1 [Quick, Harrison] Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. [Carlin, Bradley P.] Univ Minnesota, Minneapolis, MN USA. [Banerjee, Sudipto] Univ Calif Los Angeles, Los Angeles, CA 90024 USA. RP Quick, H (reprint author), Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, Atlanta, GA 30329 USA. EM HQuick@cdc.gov FU NIGMS NIH HHS [RC1 GM092400] NR 18 TC 0 Z9 0 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0035-9254 EI 1467-9876 J9 J R STAT SOC C-APPL JI J. R. Stat. Soc. Ser. C-Appl. Stat. PD NOV PY 2015 VL 64 IS 5 BP 799 EP 813 DI 10.1111/rssc.12106 PG 15 WC Statistics & Probability SC Mathematics GA CT3FL UT WOS:000362692500005 PM 26692587 ER PT J AU Tong, X Spradling, PR AF Tong, X. Spradling, P. R. TI Increase in nonhepatic diagnoses among persons with hepatitis C hospitalized for any cause, United States, 2004-2011 SO JOURNAL OF VIRAL HEPATITIS LA English DT Article DE healthcare cost and utilization project; international classification of diseases; 9th revision; clinical modification; morbidity; nationwide inpatient sample; treatment guidelines ID VIRUS-INFECTION; THERAPY; HEALTH; HCV; METAANALYSIS; SOFOSBUVIR; DISEASE; BURDEN AB Although persons with hepatitis C virus (HCV) infection may experience nonhepatic illnesses, little is known about the frequency of and trends in such conditions in a population-based sample of HCV-infected persons. Using hospitalization data collected during 2004-2011 from the Nationwide Inpatient Sample of the Healthcare Cost and Utilization Project, we examined trends in comorbidities among all hospitalizations that included either a principal or secondary HCV diagnostic code (i.e., HCV was not necessarily the cause for hospitalization). We also compared comorbidities among all persons aged 45-64years hospitalized with and without principal or secondary HCV diagnostic codes. The estimated number of hospitalizations among persons with HCV infection increased from 850490 in 2004-2005 to 1178633 in 2010-2011; mean age at hospitalization was 50years in 2004-2005 and 52.5years in 2010-2011. There were significant increases in the prevalence of most medical and psychiatric comorbidities; the largest were for lipid disorders, chronic kidney disease and obesity. Among HCV-infected aged 45-64 persons hospitalized for any cause, the prevalence of alcohol /substance abuse, mental disorders, chronic kidney disease, pneumonia, hepatitis B virus infection and HIV infection were significantly higher than those aged 45-64 persons hospitalized without HCV infection (P<0.001 for all). The prevalence of cryoglobulinaemia, vasculitis, nephrotic syndrome or membranoproliferative glomerulonephritis and porphyria cutanea tarda among hospitalizations with HCV infection was consistently low during the study period (i.e., <0.5%). The increase we observed in nonhepatic comorbidities associated with a high risk of HCV-related complications has important implications for the current HCV treatment recommendations in a greatly expanded treatment population. C1 [Tong, X.; Spradling, P. R.] Div Viral Hepatitis, Centers Dis Control & Prevent, Atlanta, GA USA. [Tong, X.; Spradling, P. R.] Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA USA. RP Spradling, PR (reprint author), Mailstop G37,1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM pspradling@cdc.gov NR 26 TC 2 Z9 2 U1 1 U2 8 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1352-0504 EI 1365-2893 J9 J VIRAL HEPATITIS JI J. Viral Hepatitis PD NOV PY 2015 VL 22 IS 11 BP 906 EP 913 DI 10.1111/jvh.12414 PG 8 WC Gastroenterology & Hepatology; Infectious Diseases; Virology SC Gastroenterology & Hepatology; Infectious Diseases; Virology GA CS9YR UT WOS:000362450600006 PM 25894392 ER PT J AU Haque, F Banu, SS Ara, K Chowdhury, IA Chowdhury, SA Kamili, S Rahman, M Luby, SP AF Haque, F. Banu, S. S. Ara, K. Chowdhury, I. A. Chowdhury, S. A. Kamili, S. Rahman, M. Luby, S. P. TI An outbreak of hepatitis E in an urban area of Bangladesh SO JOURNAL OF VIRAL HEPATITIS LA English DT Article DE hepatitis E; outbreak investigation; risk factors; serology; urban Bangladesh ID E VIRUS-INFECTIONS; IMMUNOGLOBULIN-M; RURAL BANGLADESH; WATER-QUALITY; ANTIBODIES; ASSAYS; SEROPREVALENCE; EPIDEMIOLOGY; POPULATION; HOUSEHOLD AB We investigated an outbreak of jaundice in urban Bangladesh in 2010 to examine the cause and risk factors and assess the diagnostic utility of commercial assays. We classified municipal residents reporting jaundice during the preceding 4weeks as probable hepatitis E cases and their neighbours without jaundice in the previous 6months as probable controls. We tested the sera collected from probable cases and probable controls for IgM anti-hepatitis E virus (HEV), and the IgM-negative sera for IgG anti-HEV using a commercial assay locally. We retested the IgM-positive sera for both IgM and IgG anti-HEV using another assay at the Centre for Disease Control and Prevention (CDC), USA. Probable cases positive for IgM anti-HEV were confirmed cases; probable controls negative for both IgM and IgG anti-HEV were confirmed controls. We explored the local water supply and sanitation infrastructure and tested for bacterial concentration of water samples. Probable cases were more likely than probable controls to drink tap water (adjusted odds ratio: 3.4; 95% CI: 1.2-9.2). Fifty-eight percentage (36/62) of the case sera were IgM anti-HEV positive; and 75% of the IgM-positive samples were confirmed positive on retesting with another assay at CDC. Compared to confirmed controls, cases confirmed using either or both assays also identified drinking tap water as the risk factor. Two tap water samples had detectable thermotolerant coliforms. Research exploring decentralized water treatment technologies for sustainable safe water might prevent HEV transmission in resource-poor cities. Detection of serological markers in a majority of probable cases implied that available diagnostic assays could adequately identify HEV infection during outbreaks. C1 [Haque, F.; Luby, S. P.] Icddr B, Ctr Communicable Dis, Dhaka 1212, Bangladesh. [Haque, F.; Banu, S. S.; Ara, K.; Chowdhury, I. A.; Chowdhury, S. A.; Rahman, M.] IEDCR, Dhaka, Bangladesh. [Kamili, S.] CDC, Div Viral Hepatitis, Atlanta, GA 30333 USA. [Luby, S. P.] CDC, Global Dis Detect Program, Atlanta, GA 30333 USA. RP Haque, F (reprint author), Icddr B, Ctr Communicable Dis, Dhaka 1212, Bangladesh. EM farhanahaque@icddrb.org OI Luby, Stephen/0000-0001-5385-899X FU Centers for Disease Control and Prevention (CDC), Atlanta; Government of the People's Republic of Bangladesh (GoB) FX The authors would like to thank all the study participants for their contributions. We are also grateful to the Chief Medical Officer of Rajshahi City Corporation. Ms. Dorothy Southern and Ms Meghan Scott deserve special thanks for their contributions in reviewing the manuscript. This research activity was funded by the Centers for Disease Control and Prevention (CDC), Atlanta, and the Government of the People's Republic of Bangladesh (GoB). icddr,b is thankful to the Governments of Australia, Bangladesh, Canada, Sweden and the UK for providing core/unrestricted support. NR 30 TC 1 Z9 1 U1 2 U2 8 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1352-0504 EI 1365-2893 J9 J VIRAL HEPATITIS JI J. Viral Hepatitis PD NOV PY 2015 VL 22 IS 11 BP 948 EP 956 DI 10.1111/jvh.12407 PG 9 WC Gastroenterology & Hepatology; Infectious Diseases; Virology SC Gastroenterology & Hepatology; Infectious Diseases; Virology GA CS9YR UT WOS:000362450600010 PM 25817821 ER PT J AU Callahan, T Stampfel, C Cornell, A Diop, H Barnes-Josiah, D Kane, D Mccracken, S McKane, P Phillips, G Theall, K Pies, C Sappenfield, W AF Callahan, Tegan Stampfel, Caroline Cornell, Andria Diop, Hafsatou Barnes-Josiah, Debora Kane, Debra Mccracken, Sarah McKane, Patricia Phillips, Ghasi Theall, Katherine Pies, Cheri Sappenfield, William TI From Theory to Measurement: Recommended State MCH Life Course Indicators SO MATERNAL AND CHILD HEALTH JOURNAL LA English DT Article DE Health indicators; Life course; Public health surveillance; Maternal and child health; Reproductive health ID ADULT DISEASE; HEALTH; LIFECOURSE; FRAMEWORK AB In May 2012, the Association of Maternal and Child Health (MCH) Programs initiated a project to develop indicators for use at a state or community level to assess, monitor, and evaluate the application of life course principles to public health. Using a developmental framework established by a national expert panel, teams of program leaders, epidemiologists, and academicians from seven states proposed indicators for initial consideration. More than 400 indicators were initially proposed, 102 were selected for full assessment and review, and 59 were selected for final recommendation as Maternal and Child Health (MCH) life course indicators. Each indicator was assessed on five core features of a life course approach: equity, resource realignment, impact, intergenerational wellness, and life course evidence. Indicators were also assessed on three data criteria: quality, availability, and simplicity. These indicators represent a major step toward the translation of the life course perspective from theory to application. MCH programs implementing program and policy changes guided by the life course framework can use these initial measures to assess and influence their approaches. C1 [Callahan, Tegan] Ctr Dis Control & Prevent, Field Serv Off, Off State Tribal Local & Territorial Support, DeKalb, GA 30341 USA. [Stampfel, Caroline; Cornell, Andria] Assoc Maternal & Child Hlth Programs, Washington, DC USA. [Diop, Hafsatou] Off Data Translat, Bur Family Hlth & Nutr, Massachusetts Dept Publ Hlth, Boston, MA USA. [Barnes-Josiah, Debora] Nebraska Dept Hlth & Human Serv, Lifespan Hlth Serv Unit, Lincoln, NE USA. [Kane, Debra; Phillips, Ghasi] Natl Ctr Chron Dis Prevent & Hlth Promot, Field Support Branch, Div Reprod Hlth, Ctr Dis Control & Prevent, DeKalb, GA USA. [Kane, Debra] Iowa Dept Publ Hlth, Bur Family Hlth, Div Hlth Promot & Chron Dis Prevent, Des Moines, IA 50319 USA. [Mccracken, Sarah] North Carolina Dept Hlth & Human Serv, Womens & Childrens Hlth Sect, Div Publ Hlth, Raleigh, NC USA. [McKane, Patricia] Michigan Dept Community Hlth, Maternal Child Hlth Epidemiol Unit, Lifecourse Epidemiol & Genom Div, Lansing, MI USA. [Phillips, Ghasi] Florida Dept Hlth, Div Community Hlth Promot, Tallahassee, FL USA. [Theall, Katherine] Tulane Univ, Dept Global Community Hlth & Behav Sci, Sch Publ Hlth & Trop Med, New Orleans, LA USA. [Pies, Cheri] Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA. [Sappenfield, William] Univ S Florida, Coll Publ Hlth, Tampa, FL USA. RP Callahan, T (reprint author), Ctr Dis Control & Prevent, Field Serv Off, Off State Tribal Local & Territorial Support, DeKalb, GA 30341 USA. EM tegan.callahan@gmail.com RI Barnes-Josiah, Debora/E-2832-2017 OI Barnes-Josiah, Debora/0000-0002-1783-105X FU W.K. Kellogg Foundation FX This work was funded by a grant from W.K. Kellogg Foundation. We would also like to acknowledge all of the members of the national expert panel and each member of the state teams that participated in the Life Course Metrics Project. Members of Life Course Metrics Project state teams are listed below. Florida Cheryl Clark, DrPH, RHIA, Florida Department of Health; Kris-Tena Albers, CNM, MN, Florida Department of Health; Trina Thompson, MA, Florida Department of Health; Carol Brady, MANE, Florida Healthy Start Coalition; Leisa Stanley, PhD, Healthy Start Coalition of Hillsborough County; Isaac Eberstein, PhD, Florida State University; Javier Vazquez, MPH, Florida Department of Health; Kelli Stannard, RN, BSN, Florida Department of Health; Susan Redmon, RN, MPH, Florida Department of Health; Shairi R. Turner, MD, MPH, Florida Department of Health. Iowa: Gretchen Hageman, MA, Iowa Department of Public Health; Kimberly Noble Piper, BS, RN, CPH, CPHG, Iowa Department of Public Health; Debra Waldron, MD, MPH, FAAP, Child Health Specialty Clinics; Mary Mincer-Hansen, PhD, RN, Des Moines University; DeAnn Decker, Iowa Department of Public Health; Dawn Gentsch, Iowa Primary Care Association; Denise Wheeler CNM, MS, ARNP, Iowa Department of Public Health; Abby Kremer, MPH, Iowa Department of Public Health. Massachusetts Karin Downs, RN, MPH, Massachusetts Department of Public Health; Suzanne H. Gottlieb, Massachusetts Department of Public Health; Deborah Allen, ScD, Boston Public Health Commission; Eugene Declercq, PhD, Boston University School of Public Health; Candice Belanoff, ScD, MPH, Boston University School of Public Health; Milton Kotelchuck, PhD, MPH, Massachusetts General Hospital Center for Child & Adolescent Health Research and Policy and Harvard Medical School; Olivia Sappenfield, MPH, Massachusetts Department of Public Health; Susan E. Manning, MD, MPH, Massachusetts Department of Public Health; Emily Lu, MPH, Massachusetts Department of Public Health; Jill Clark, MPH, Massachusetts Department of Public Health; John A. Zdanowicz, DMD, MPH, Harvard School of Dental Medicine. Michigan Brenda Fink, MSW, ACSW, Michigan Department of Community Health; Kevin Dombkowski, DrPH, MS, University of Michigan; Chris Fussman, MS, Michigan Department of Community Health; Julia Heany, PhD, Michigan Public Health Institute; Monica Kwasnik, MA, Michigan Department of Community Health; Cassandre Larrieux, MPH, Ingham County Health Department; Mary Ludtke, MA, Department of Community Health; Nancy Peeler, EdM, Michigan Department of Community Health; Carrie Tarry, MPH, Michigan Department of Community Health. Nebraska Paula Eurek, Nebraska Department of Health and Human Services; Jennifer Severe-Oforah, MCRP, Nebraska Department of Health and Human Services; Mary Balluf, MS, RD, LMNT, Douglas County Health Department; Cathy Dillon, MA, Nebraska Department of Health and Human Services; Holly Dingman, MS, Nebraska Department of Health and Human Services; Rosa Gofin, MD, MPH, College of Public Health, University of Nebraska Medical Center; Mihaela Johnson, PhD, Nebraska Department of Health and Human Services; Colleen Svoboda, MPH, Nebraska Department of Health and Human Services; Shirley Terry, RN, BSN, Lincoln-Lancaster County Health Department.; North Carolina Alvina Long Valentin, RN, MPH, North Carolina Women's and Children's Health Section; Deborah Carroll, North Carolina Women's and Children's Health Section; Najmul Chowdhury, MB, BS, MPH, North Carolina Women's and Children's Health Section; Julie De Clerque, DrPH, MPH, Sheps Center for Health Services Research; Kathleen Jones-Vessey, MS, North Carolina State Center for Health Statistics; Kathy Lamb, MS, RD, North Carolina Women's and Children's Health Section; Debbie Mason, MPH, Forsyth County Department of Public Health; Judy Ruffin, MPA, North Carolina Women's and Children's Health Section. Louisiana Amy Zapata, MPH, Louisiana Office of Public Health; Geoff Nagle, PhD, MPH, MSW, LCSW, Louisiana's Early Childhood Advisory Council; Michelle Alletto, MPA, Louisiana Birth Outcomes Initiative; Nicole Richmond, MS, Louisiana Office of Public Health; Nkenge H. Jones-Jack, MPH, Louisiana Office of Health and Hospitals; Allen Schulenberg, MPA, Louisiana Department of Education; Petrice Abiodun-Sams, PhD, Lindy Boggs National Center for Community Literacy; Allison Plyer, MBA, ScD, Nonprofit Knowledge Works Greater New Orleans Community Data Center; Monisha Shah, MPH, Tulane University; Shokufeh Ramirez, MPH, Tulane University; Rebecca Gurvich, MPH, Tulane University; Lisanne Brown, PhD, Louisiana Public Health Institute; Janna Knight, MPH, Louisiana Public Health Institute; David Kulick, MPH, Louisiana Public Health Institute; Snigdha Mukherjee, MPH, Louisiana Public Health Institute. NR 13 TC 2 Z9 2 U1 0 U2 4 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1092-7875 EI 1573-6628 J9 MATERN CHILD HLTH J JI Matern. Child Health J. PD NOV PY 2015 VL 19 IS 11 BP 2336 EP 2347 DI 10.1007/s10995-015-1767-1 PG 12 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CT1QY UT WOS:000362576800003 PM 26122251 ER PT J AU Mann, JR Royer, JA McDermott, S Hardin, JW Ozturk, O Street, N AF Mann, Joshua R. Royer, Julie A. McDermott, Suzanne Hardin, James W. Ozturk, Orgul Street, Natalie TI Hospitalizations and emergency room visits for adolescents and young adults with muscular dystrophy living in South Carolina SO MUSCLE & NERVE LA English DT Article DE ambulatory care-sensitive conditions; emergency department; hospitalizations; muscular dystrophy; transition ID HEALTH-CARE UTILIZATION; SPINA-BIFIDA; TRANSITION; SERVICES; CHILDREN; EXPENDITURES; SURVIVAL; SYSTEMS; DISEASE; NEEDS AB Introduction: Transitioning from adolescence to adulthood can be problematic for individuals with rare disabilities such as muscular dystrophy (MD). Methods: We identified a cohort of 220 individuals with MD and 440 matched comparison individuals and measured emergency room (ER) and inpatient (IP) encounters for the years 2000 through 2010, using all-payer hospital discharge uniform billing data. We compared ER and IP use rates for people with and without MD, and for 15-19-year-olds with MD to 20-24-year-olds with MD. Results: ER and IP use rates were significantly higher among individuals with MD than the comparison group. In addition, ER and IP use rates were significantly higher in the 20-24-year age group than in the 15-19-year group. Conclusions: Additional research is needed to determine whether increased ER and IP use in young adults is attributable to difficulties in healthcare transition versus increased disease severity. Muscle Nerve 52: 714-721, 2015 C1 [Mann, Joshua R.] Univ S Carolina, Dept Family & Prevent Med, Sch Med, Columbia, SC 29201 USA. [Royer, Julie A.] South Carolina Revenue & Fiscal Affairs Off, Hlth & Demog Sect, Columbia, SC USA. [McDermott, Suzanne; Hardin, James W.] Univ S Carolina, Dept Epidemiol & Biostat, Arnold Sch Publ Hlth, Columbia, SC 29201 USA. [Ozturk, Orgul] Univ S Carolina, Dept Econ, Moore Sch Business, Columbia, SC 29201 USA. [Street, Natalie] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. RP Mann, JR (reprint author), Univ S Carolina, Dept Family & Prevent Med, Sch Med, 3209 Colonial Dr, Columbia, SC 29201 USA. EM johua.mann@uscmed.sc.edu RI Hardin, James/Q-7617-2016 OI Hardin, James/0000-0003-0506-5500 FU U.S. Centers for Disease Control and Prevention [1U01DD000776-01] FX Contract grant sponsor: This study was funded by a grant from the U.S. Centers for Disease Control and Prevention; contract grant number: 1U01DD000776-01. NR 29 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0148-639X EI 1097-4598 J9 MUSCLE NERVE JI Muscle Nerve PD NOV PY 2015 VL 52 IS 5 BP 714 EP 721 DI 10.1002/mus.24599 PG 8 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA CT1HO UT WOS:000362549500004 PM 25665090 ER PT J AU England, LJ Bulkley, JE Pazol, K Bruce, FC Kimes, T Berg, CJ Hornbrook, MC Callaghan, WM AF England, Lucinda J. Bulkley, Joanna E. Pazol, Karen Bruce, F. Carol Kimes, Terry Berg, Cynthia J. Hornbrook, Mark C. Callaghan, William M. TI Investigating Implausible Gestational Age and High Birthweight Combinations SO PAEDIATRIC AND PERINATAL EPIDEMIOLOGY LA English DT Article DE preterm delivery; gestational age; clinical estimate; misclassification ID PRETERM DELIVERY RATES; LAST MENSTRUAL PERIOD; UNITED-STATES; TRENDS; TERM; RACE AB BackgroundBirth certificate data overestimate national preterm births because a high percentage of last menstrual period (LMP) dates have errors. Study goals were to determine: (i) To what extent errors in transfer of birthweight and LMP date from medical records to birth certificates contribute to implausibly high birthweight-for-gestational-age births; (ii) What percentage of implausible births would be resolved if the clinical estimate (CE) from birth certificates were used instead of LMP-based gestational age, and with what degree of certainty; and (iii) Of those not resolved, what percentage had a medical explanation. MethodsMedical records and birth certificates for all singleton infants with implausibly high birthweight-for-gestational-age based on LMP delivered in the Kaiser Permanente Northwest system in Oregon during 1998-2007 were examined. Percentages of implausible records resolved under various scenarios were calculated. ResultsA total of 100 births with implausibly high birthweight-for-gestational age combinations were identified. When LMP date and birthweight from medical records were used instead of from birth certificates, 31% of births with implausible combinations were resolved. Substituting the CE on the birth certificate for the LMP date resolved 92%. Of the latter, the clinician's gestational age estimate in the medical record was obtained in early pregnancy in 72%. Five of the eight births with unresolved implausible combinations were to mothers with diabetes; the remaining three had no documented medical explanation. ConclusionsIn this study, use of the birth certificate CE rather than the LMP resulted in a clinically reliable reclassification for the majority of implausible birthweight-for-gestational age deliveries. C1 [England, Lucinda J.; Pazol, Karen; Bruce, F. Carol; Berg, Cynthia J.; Callaghan, William M.] Ctr Dis Control & Prevent, Atlanta, GA 30341 USA. [Bulkley, Joanna E.; Kimes, Terry; Hornbrook, Mark C.] Kaiser Permanente Ctr Hlth Res, Portland, OR USA. RP England, LJ (reprint author), Ctr Dis Control & Prevent, 4770 Buford Highway NE,MS F-79, Atlanta, GA 30341 USA. EM lbe9@cdc.gov FU Centers for Disease Control and Prevention [200-2009-31663] FX Funded by contract # 200-2009-31663, 'Extent of Maternal Morbidity in a Managed Care Setting' from the Centers for Disease Control and Prevention. NR 15 TC 0 Z9 0 U1 1 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0269-5022 EI 1365-3016 J9 PAEDIATR PERINAT EP JI Paediatr. Perinat. Epidemiol. PD NOV PY 2015 VL 29 IS 6 BP 562 EP 566 DI 10.1111/ppe.12243 PG 5 WC Public, Environmental & Occupational Health; Obstetrics & Gynecology; Pediatrics SC Public, Environmental & Occupational Health; Obstetrics & Gynecology; Pediatrics GA CT3RG UT WOS:000362723900012 PM 26367856 ER PT J AU Thai, PK Li, Z Sjodin, A Fox, A Diep, NB Binh, TT Mueller, JF AF Thai, Phong K. Li, Zheng Sjoedin, Andreas Fox, Annette Nguyen Bich Diep Ta Thi Binh Mueller, Jochen F. TI Biomonitoring of polycyclic aromatic hydrocarbons exposure in small groups of residents in Brisbane, Australia and Hanoi, Vietnam, and those travelling between the two cities SO CHEMOSPHERE LA English DT Article DE OH-PAHs; PAH exposure; Air pollution ID AIR-POLLUTION; PARTICULATE MATTER; METABOLITES; PAHS; 1-HYDROXYPYRENE; POPULATION; URINE; RISK; 2-NAPHTHOL; CREATININE AB Exposure to polycyclic aromatic hydrocarbons (PAHs) has been associated with adverse health outcomes. Concentrations of urinary PAH metabolites (OH-PAHs) provide an integrated measure of human exposure to PAHs but measurement of urinary OH-PAHs has not been done in Australia and rarely in Vietnam, where air pollution is of concern. In this study, we assessed exposure to PAHs in 16 participants living in Brisbane, Australia and Hanoi, Vietnam, with 4 participants travelling between the two cities during the monitoring period. A total of 312 first morning urine samples were collected over 10 weeks and were analysed for nine OH-PAHs. Concentrations of the urinary OH-PAHs were 2-10 times higher in participants from Hanoi than those from Brisbane. For example, the median concentrations of 1-hydroxypyrene were 292 pg/mL in Hanoi, compared to 64 pg/mL in Brisbane. For participants travelling from Brisbane to Hanoi and back, differences in exposure to PAHs in these two cities resulted in corresponding changes of urinary OH-PAN concentrations, demonstrating that the more polluted environment in Hanoi was likely the source for higher PAR exposure there. (C) 2015 Elsevier Ltd. All rights reserved. C1 [Thai, Phong K.; Mueller, Jochen F.] Univ Queensland, Natl Res Ctr Environm Toxicol Entox, Brisbane, Qld 4072, Australia. [Thai, Phong K.] Queensland Univ Technol, Int Lab Air Qual & Hlth, Brisbane, Qld, Australia. [Li, Zheng; Sjoedin, Andreas] Ctr Dis Control & Prevent, Atlanta, GA USA. [Fox, Annette] Univ Oxford, Clin Res Unit, Ho Chi Minh City, Vietnam. [Fox, Annette] Univ Oxford, Wellcome Trust Major Overseas Programme, Ho Chi Minh City, Vietnam. [Nguyen Bich Diep; Ta Thi Binh] Natl Inst Occupat & Environm Hlth, Hanoi, Vietnam. RP Thai, PK (reprint author), Univ Queensland, Natl Res Ctr Environm Toxicol Entox, Brisbane, Qld 4072, Australia. EM phong.thai@qut.edu.au RI Mueller, Jochen/C-6241-2008; Thai, Phong/A-3998-2011; OI Thai, Phong/0000-0003-0042-3057; Fox, Annette/0000-0002-0565-7146; Mueller, Jochen/0000-0002-0000-1973 FU UQ Postdoctoral Fellowship; ARC [FT120100546] FX We would like to thank the participants for their time and devotion. The co-authors of this manuscript do not have any financial conflict of interest. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. PT is partly funded by a UQ Postdoctoral Fellowship. JFM is funded by an ARC Future Fellowship (FT120100546). Entox is a joint venture of the University of Queensland and the Queensland Department of Health. NR 41 TC 3 Z9 3 U1 0 U2 16 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0045-6535 EI 1879-1298 J9 CHEMOSPHERE JI Chemosphere PD NOV PY 2015 VL 139 BP 358 EP 364 DI 10.1016/j.chemosphere.2015.07.004 PG 7 WC Environmental Sciences SC Environmental Sciences & Ecology GA CS1ZQ UT WOS:000361868000047 PM 26184100 ER PT J AU Starling, AP Engel, LS Calafat, AM Koutros, S Satagopan, JM Yang, G Matthews, CE Cai, QY Buckley, JP Ji, BT Cai, H Chow, WH Zheng, W Gao, YT Rothman, N Xiang, YB Shu, XO AF Starling, Anne P. Engel, Lawrence S. Calafat, Antonia M. Koutros, Stella Satagopan, Jaya M. Yang, Gong Matthews, Charles E. Cai, Qiuyin Buckley, Jessie P. Ji, Bu-Tian Cai, Hui Chow, Wong-Ho Zheng, Wei Gao, Yu-Tang Rothman, Nathaniel Xiang, Yong-Bing Shu, Xiao-Ou TI Predictors and long-term reproducibility of urinary phthalate metabolites in middle-aged men and women living in urban Shanghai SO ENVIRONMENT INTERNATIONAL LA English DT Article DE Phthalates; Reproducibility; Predictors; Food contaminants; Personal care products ID NUTRITION EXAMINATION SURVEY; HUMAN EXPOSURE; BISPHENOL-A; TEMPORAL VARIABILITY; NATIONAL-HEALTH; US POPULATION; UNITED-STATES; CHINA; ESTERS; MEDICATIONS AB Phthalate esters are man-made chemicals commonly used as plasticizers and solvents, and humans may be exposed through ingestion, inhalation, and dermal absorption. Little is known about predictors of phthalate exposure, particularly in Asian countries. Because phthalates are rapidly metabolized and excreted from the body following exposure, it is important to evaluate whether phthalate metabolites measured at a single point in time can reliably rank exposures to phthalates over a period of time. We examined the concentrations and predictors of phthalate metabolite concentrations among 50 middle-aged women and 50 men from two Shanghai cohorts, enrolled in 1997-2000 and 2002-2006, respectively. We assessed the reproducibility of urinary concentrations of phthalate metabolites in three spot samples per participant taken several years apart (mean interval between first and third sample was 7.5 years [women] or 2.9 years [men]), using Spearman's rank correlation coefficients and intra-class correlation coefficients. We detected ten phthalate metabolites in at least 50% of individuals for two or more samples. Participant sex, age, menopausal status, education, income, body mass index, consumption of bottled water, recent intake of medication, and time of day of collection of the urine sample were associated with concentrations of certain phthalate metabolites. The reproducibility of an individual's urinary concentration of phthalate metabolites across several years was low, with all intra-class correlation coefficients and most Spearman rank correlation coefficients <= 03. Only mono(2-ethylhexyl) phthalate, a metabolite of di(2-ethylhexyl) phthalate, had a Spearman rank correlation coefficient >= 0.4 among men, suggesting moderate reproducibility. These findings suggest that a single spot urine sample is not sufficient to rank exposures to phthalates over several years in an adult urban Chinese population. Published by Elsevier Ltd. C1 [Starling, Anne P.; Engel, Lawrence S.; Buckley, Jessie P.] Univ N Carolina, Dept Epidemiol, Gillings Sch Global Publ Hlth, Chapel Hill, NC USA. [Calafat, Antonia M.] Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA USA. [Koutros, Stella; Matthews, Charles E.; Ji, Bu-Tian; Chow, Wong-Ho; Rothman, Nathaniel] NCI, Div Canc Epidemiol & Genet, NIH, US Dept HHS, Bethesda, MD 20892 USA. [Satagopan, Jaya M.] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA. [Yang, Gong; Cai, Qiuyin; Cai, Hui; Zheng, Wei; Shu, Xiao-Ou] Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Div Epidemiol,Dept Med,Vanderbilt Epidemiol Ctr, Nashville, TN 37212 USA. [Gao, Yu-Tang] Shanghai Jiao Tong Univ, Shanghai Canc Inst, Dept Epidemiol, Shanghai 200030, Peoples R China. [Xiang, Yong-Bing] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Shanghai Canc Inst, Shanghai 200030, Peoples R China. RP Starling, AP (reprint author), Univ Colorado, Dept Epidemiol, Colorado Sch Publ Hlth, Anschutz Med Campus,Campus Box F426,12474 E 19th, Aurora, CO 80045 USA. EM Anne.Starling@ucdenver.edu OI Satagopan, Jaya/0000-0001-7102-5633; Engel, Lawrence/0000-0001-9268-4830 FU National Institutes of Health; National Cancer Institute Division of Cancer Epidemiology and Genetics; National Cancer Institute [R37 CA070867, UM1182910, UM1 CA173640, NO2-CP11010-66]; National Institutes of Health from National Cancer Institute [R01CA137420]; Cancer Center Core Grant from the National Cancer Institute [P30CA008748]; Clinical and Translational Science Center at Weill Cornell Medical College, New York, USA [UL1RR024996] FX Funding sources: The study was funded in part by the Intramural Research Program of the National Institutes of Health and the National Cancer Institute Division of Cancer Epidemiology and Genetics. Support for the Shanghai Women's Health Study (R37 CA070867, UM1182910, PI: Zheng), the Shanghai Men's Health Study (UM1 CA173640, PI: Shu) and the physical activity substudy (NO2-CP11010-66, PI: Shu) was provided by grants from the National Cancer Institute. Dr. Satagopan was supported by the following grants from the National Institutes of Health: R01CA137420, Cancer Center Core Grant P30CA008748 from the National Cancer Institute, and UL1RR024996 from the Clinical and Translational Science Center at Weill Cornell Medical College, New York, USA NR 46 TC 4 Z9 4 U1 5 U2 20 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0160-4120 EI 1873-6750 J9 ENVIRON INT JI Environ. Int. PD NOV PY 2015 VL 84 BP 94 EP 106 DI 10.1016/j.envint.2015.07.003 PG 13 WC Environmental Sciences SC Environmental Sciences & Ecology GA CS5UK UT WOS:000362143600011 PM 26255822 ER PT J AU Wolff, MS Teitelbaum, SL McGovern, K Pinney, SM Windham, GC Galvez, M Pajak, A Rybak, M Calafat, AM Kushi, LH Biro, FM AF Wolff, Mary S. Teitelbaum, Susan L. McGovern, Kathleen Pinney, Susan M. Windham, Gayle C. Galvez, Maida Pajak, Ashley Rybak, Michael Calafat, Antonia M. Kushi, Lawrence H. Biro, Frank M. CA Breast Canc Environm Res Program TI Environmental phenols and pubertal development in girls SO ENVIRONMENT INTERNATIONAL LA English DT Article DE Phenols; Breast development; Puberty; Environment ID ENDOCRINE-DISRUPTING CHEMICALS; LONGITUDINAL COHORT; BREAST DEVELOPMENT; EXPOSURE; PARABENS; BIOMARKERS; CHILDREN; VARIABILITY; CANCER; SIZE AB Environmental exposures to many phenols are documented worldwide and exposures can be quite high (>1 mu M of urine metabolites). Phenols have a range of hormonal activity, but knowledge of effects on child reproductive development is limited, coming mostly from cross-sectional studies. We undertook a prospective study of pubertal development among 1239 girls recruited at three U.S. sites when they were 6-8 years old and were followed annually for 7 years to determine age at first breast or pubic hair development. Ten phenols were measured in urine collected at enrollment (benzophenone-3, enterolactone, bisphenol A, three parabens (methyl-, ethyl-, propyl-), 2,5-dichlorophenol, triclosan, genistein, daidzein). We used multivariable adjusted Cox proportional hazards ratios (HR (95% confidence intervals)) and Kaplan-Meier survival analyses to estimate relative risk of earlier or later age at puberty associated with phenol exposures. For enterolactone and benzophenone-3, girls experienced breast development 5-6 months later, adjusted HR 0.79 (0.64-0.98) and HR 0.80 (0.65-0.98) respectively for the 5th vs 1st quintiles of urinary biomarkers (mu g/g-creatinine). Earlier breast development was seen for triclosan and 2,5-dichlorophenol: 4-9 months sooner for 5th vs 1st quintiles of urinary concentrations (HR 1.17 (0.96-1.43) and HR 137 (1.09-1.72), respectively). Association of breast development with enterolactone, but not the other three phenols, was mediated by body size. These phenols may be antiadipogens (benzophenone-3 and enterolactone) or thyroid agonists (triclosan and 2,5-dichlorophenol), and their ubiquity and relatively high levels in children would benefit from further investigation to confirm these findings and to establish whether there are certain windows of susceptibility during which exposure can affect pubertal development. (C) 2015 Elsevier Ltd. All rights reserved. C1 [Wolff, Mary S.; Teitelbaum, Susan L.; McGovern, Kathleen; Galvez, Maida; Pajak, Ashley] Icahn Sch Med Mt Sinai, Dept Prevent Med, New York, NY 10029 USA. [Pinney, Susan M.] Univ Cincinnati, Dept Environm Hlth, Coll Med, Cincinnati, OH 45267 USA. [Windham, Gayle C.] Calif Dept Publ Hlth, Div Environm & Occupat Dis Control, Richmond, CA 94804 USA. [Rybak, Michael; Calafat, Antonia M.] Ctr Dis Control & Prevent, Atlanta, GA 30341 USA. [Kushi, Lawrence H.] Kaiser Permanente, Div Res, Oakland, CA 94612 USA. [Biro, Frank M.] Cincinnati Childrens Hosp Med Ctr, Div Adolescent Med, Cincinnati, OH 45229 USA. [Breast Canc Environm Res Program] Breast Canc & Environm Res Program, Madison, WI USA. RP Wolff, MS (reprint author), Icahn Sch Med Mt Sinai, Dept Prevent Med, 1 Gustave L Levy Pl Box 1057, New York, NY 10029 USA. EM mary.wolff@mssm.edu; susan.teitelbaum@mssm.edu; kathleen.mcgovern@mssm.edu; pinneysm@ucmail.uc.edu; gayle.windham@cdph.ca.gov; maida.galvez@mssm.edu; ashley.pajak7@mssm.edu; szr8@cdc.gov; aic7@cdc.gov; lariy.kushi@kp.org; frank.biro@cchmc.org OI Rybak, Michael/0000-0003-1650-8581 FU Breast Cancer and the Environment Research Program (BCERP) from the National Institute of Environmental Health Sciences (NIEHS) [U01ES012770, U01ES012771, U01ES012800, U01ES012801, U01ES019435, U01ES019453, U01ES019454, U01ES019457, R827039, P01ES009584, P30ES006096, P30ES023515]; National Cancer Institute (NCI); EPA; NIH; DHHS; NYS Empire Clinical Research Investigator Program; Pediatric Environmental Health Fellowship [HD049311]; Avon Foundation; [CSTA-UL1RR029887] FX We gratefully acknowledge our collaborators at the centers involved in this research including Jessica Montana, Nancy Mervish, Cheryl Stein, Rochelle Osborne, Lisa Boguski, Joel Forman, and Barbara Brenner (MSSM); Gayle Greenberg, Peggy Monroe, Bob Bornschein (Cincinnati); Robert Hiatt, Louise Greenspan, Julie Deardorff, Janice Barlow (Kaiser Permanente). We also thank Daniel L. Parker, Xiaoyun Ye, Amber Bishop, and Tao Jia for measurement of the phenol metabolites. This research was supported by the Breast Cancer and the Environment Research Program (BCERP) award numbers U01ES012770, U01ES012771, U01ES012800, U01ES012801, U01ES019435, U01ES019453, U01ES019454, U01ES019457, R827039 and P01ES009584,P30ES006096, P30ES023515 from the National Institute of Environmental Health Sciences (NIEHS), the National Cancer Institute (NCI), EPA, NIH, DHHS, CSTA-UL1RR029887, NYS Empire Clinical Research Investigator Program, Pediatric Environmental Health Fellowship HD049311, and the Avon Foundation. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIEHS or NCI, the National Institutes of Health, the Centers for Disease Control and Prevention, or the California Department of Public Health. NR 31 TC 10 Z9 11 U1 7 U2 28 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0160-4120 EI 1873-6750 J9 ENVIRON INT JI Environ. Int. PD NOV PY 2015 VL 84 BP 174 EP 180 DI 10.1016/j.envint.2015.08.008 PG 7 WC Environmental Sciences SC Environmental Sciences & Ecology GA CS5UK UT WOS:000362143600018 PM 26335517 ER PT J AU Pereira, TA Syn, WK Machado, MV Vidigal, PV Resende, V Voieta, I Xie, GH Otoni, A Souza, MM Santos, ET Chan, IS Trindade, GVM Choi, SS Witek, RP Pereira, FE Secor, WE Andrade, ZA Lambertucci, JR Diehl, AM AF Pereira, Thiago A. Syn, Wing-Kin Machado, Mariana V. Vidigal, Paula V. Resende, Vivian Voieta, Izabela Xie, Guanhua Otoni, Alba Souza, Marcia M. Santos, Elisangela T. Chan, Isaac S. Trindade, Guilherme V. M. Choi, Steve S. Witek, Rafal P. Pereira, Fausto E. Secor, William E. Andrade, Zilton A. Lambertucci, Jose Roberto Diehl, Anna Mae TI Schistosome-induced cholangiocyte proliferation and osteopontin secretion correlate with fibrosis and portal hypertension in human and murine schistosomiasis mansoni SO CLINICAL SCIENCE LA English DT Article DE cholangiocyte; ductular proliferation; osteopontin; portal hypertension; Schistosomiasis mansoni; Symmers' fibrosis ID JAPONICUM-INFECTED MICE; BILE-DUCT CHANGES; HEDGEHOG; ACTIVATION; CHEMOTHERAPY; FIBROGENESIS; INFLAMMATION; PATHWAY AB Schistosomiasis is a major cause of portal hypertension worldwide. It associates with portal fibrosis that develops during chronic infection. The mechanisms by which the pathogen evokes these host responses remain unclear. We evaluated the hypothesis that schistosome eggs release factors that directly stimulate liver cells to produce osteopontin (OPN), a pro-fibrogenic protein that stimulates hepatic stellate cells to become myofibroblasts. We also investigated the utility of OPN as a biomarker of fibrosis and/or severity of portal hypertension. Cultured cholangiocytes, Kupffer cells and hepatic stellate cells were treated with soluble egg antigen (SEA); OPN production was quantified by quantitative reverse transcriptase polymerase chain reaction (qRTPCR) and ELISA; cell proliferation was assessed by BrdU (5-bromo-2'-deoxyuridine). Mice were infected with Schistosoma mansoni for 6 or 16 weeks to cause early or advanced fibrosis. Liver OPN was evaluated by qRTPCR and immunohistochemistry (IHC) and correlated with liver fibrosis and serum OPN. Livers from patients with schistosomiasis mansoni (early fibrosis n=15; advanced fibrosis n=72) or healthy adults (n=22) were immunostained for OPN and fibrosis markers. Results were correlated with plasma OPN levels and splenic vein pressures. SEA-induced cholangiocyte proliferation and OPN secretion (P<0.001 compared with controls). Cholangiocytes were OPN (+) in Schistosoma-infected mice and humans. Liver and serum OPN levels correlated with fibrosis stage (mice: r = 0.861; uman r = 0.672, P=0.0001) and myofibroblast accumulation (mice: r = 0.800; human: r = 0.761, P=0.0001). Numbers of OPN (+) bile ductules strongly correlated with splenic vein pressure (r = 0.778; P=0.001). S. mansoni egg antigens stimulate cholangiocyte proliferation and OPN secretion. OPN levels in liver and blood correlate with fibrosis stage and portal hypertension severity. C1 [Pereira, Thiago A.; Machado, Mariana V.; Xie, Guanhua; Chan, Isaac S.; Choi, Steve S.; Diehl, Anna Mae] Duke Univ, Div Gastroenterol, Dept Med, Med Ctr, Durham, NC 27710 USA. [Pereira, Thiago A.; Souza, Marcia M.; Santos, Elisangela T.; Andrade, Zilton A.] Fiocruz MS, Ctr Pesquisas Goncalo Moniz, Lab Patol Expt, BR-40296710 Salvador, BA, Brazil. [Syn, Wing-Kin] Fdn Liver Res, Inst Hepatol, Liver Regenerat & Repair Res Grp, London WC1E 6HX, England. [Syn, Wing-Kin] Loyola Univ, Dept Surg, Chicago, IL 60153 USA. [Vidigal, Paula V.; Resende, Vivian; Voieta, Izabela; Otoni, Alba; Trindade, Guilherme V. M.; Lambertucci, Jose Roberto] Univ Fed Minas Gerais, Fac Med, BR-30130100 Belo Horizonte, MG, Brazil. [Witek, Rafal P.] Life Technol, Frederick, MD 21704 USA. [Pereira, Fausto E.] Univ Fed Espirito Santo, Nucleo Doencas Infecciosas, BR-29040091 Vitoria, ES, Brazil. [Secor, William E.] Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. RP Diehl, AM (reprint author), Duke Univ, Div Gastroenterol, Dept Med, Med Ctr, Durham, NC 27710 USA. EM diehl004@mc.duke.edu OI Resende, Vivian/0000-0003-4400-0427 FU National Institutes of Health [R01-DK-077794]; Duke University Endowment; Federal Council for Research and Development; Fundacao de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG) FX This work was support by the National Institutes of Health [grant number R01-DK-077794 (to A.M.D.)]; the Duke University Endowment [the Florence McAlister Professorship (to A.M.D.)]; the Federal Council for Research and Development (to F.E.P., J.R.L., T.A.P. and Z.A.A.); and the Fundacao de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG) (to J.R.L.). NR 30 TC 6 Z9 6 U1 1 U2 11 PU PORTLAND PRESS LTD PI LONDON PA CHARLES DARWIN HOUSE, 12 ROGER STREET, LONDON WC1N 2JU, ENGLAND SN 0143-5221 EI 1470-8736 J9 CLIN SCI JI Clin. Sci. PD NOV 1 PY 2015 VL 129 IS 10 BP 875 EP 883 DI 10.1042/CS20150117 PG 9 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA CR0YF UT WOS:000361048900004 PM 26201095 ER PT J AU Evans, KA Rich, DQ Weinberger, B Vetrano, AM Valentin-Blasini, L Strickland, PO Blount, BC AF Evans, Kristin A. Rich, David Q. Weinberger, Barry Vetrano, Anna M. Valentin-Blasini, Liza Strickland, Pamela Ohman Blount, Benjamin C. TI Association of prenatal perchlorate, thiocyanate, and nitrate exposure with neonatal size and gestational age SO REPRODUCTIVE TOXICOLOGY LA English DT Article DE Perchlorate; Thiocyanate; Nitrate; NIS inhibitors; Prenatal; Birth weight ID THYROID-STIMULATING HORMONE; SODIUM-IODIDE SYMPORTER; DRINKING-WATER; CONGENITAL HYPOTHYROIDISM; FETAL-GROWTH; MATERNAL HYPOTHYROIDISM; URINARY PERCHLORATE; PREGNANCY OUTCOMES; MEDITERRANEAN DIET; UNITED-STATES AB Background: Perchlorate and similar anions compete with iodine for uptake into the thyroid by the sodium iodide symporter (NIS). This may restrict fetal growth via impaired thyroid hormone production. Methods: We collected urine samples from 107 pregnant women and used linear regression to estimate differences in newborn size and gestational age associated with increases in perchlorate, thiocyanate, nitrate, and perchlorate equivalence concentrations (PEC; measure of total NIS inhibitor exposure). Results: NIS inhibitor concentrations were not associated with newborn weight, length, or gestational age. Each 2.62 ng/mu g creatinine increase in perchlorate was associated with smaller head circumference (0.32 cm; 95% CI: -0.66, 0.01), but each 3.38 ng/mu g increase in PEC was associated with larger head circumference (0.48 cm; -0.01, 0.97). Conclusions: These anions may have effects on fetal development (e.g. neurocognitive) that are not reflected in gross measures. Future research should focus on other abnormalities in neonates exposed to NIS inhibitors. (C) 2015 Elsevier Inc. All rights reserved. C1 [Evans, Kristin A.; Rich, David Q.] Univ Rochester, Sch Med & Dent, Dept Publ Hlth Sci, Rochester, NY 14642 USA. [Weinberger, Barry; Vetrano, Anna M.] Rutgers State Univ, Robert Wood Johnson Med Sch, Div Neonatol, New Brunswick, NJ 08903 USA. [Valentin-Blasini, Liza; Blount, Benjamin C.] Ctr Dis Control & Prevent, Div Sci Lab, Atlanta, GA USA. [Strickland, Pamela Ohman] Rutgers State Univ, Dept Biostat, Sch Publ Hlth, Piscataway, NJ USA. RP Evans, KA (reprint author), Univ Rochester, Sch Med & Dent, Dept Publ Hlth Sci, 265 Crittenden Blvd,CU 420644, Rochester, NY 14642 USA. EM Kristin_Evans@urmc.rochester.edu FU New jersey Department of Environmental Protection [P30ES005022]; National Institutes of Health [R21HD058019, 5T32HL66988] FX This work has been supported by grants from the New jersey Department of Environmental Protection (P30ES005022) and the National Institutes of Health (R21HD058019 and 5T32HL66988). NR 41 TC 3 Z9 4 U1 1 U2 16 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0890-6238 J9 REPROD TOXICOL JI Reprod. Toxicol. PD NOV PY 2015 VL 57 BP 183 EP 189 DI 10.1016/j.reprotox.2015.07.069 PG 7 WC Reproductive Biology; Toxicology SC Reproductive Biology; Toxicology GA CQ0XQ UT WOS:000360322300021 PM 26169551 ER PT J AU Toscano, CM Zhuo, XH Imai, K Duncan, BB Polanczyk, CA Zhang, P Engelgau, M Schmidt, MI AF Toscano, Cristiana M. Zhuo, Xiaohui Imai, Kumiko Duncan, Bruce B. Polanczyk, Carisi A. Zhang, Ping Engelgau, Michael Schmidt, Maria Ines CA CNDDM Working Grp TI Cost-effectiveness of a national population-based screening program for type 2 diabetes: the Brazil experience SO DIABETOLOGY & METABOLIC SYNDROME LA English DT Article ID INTENSIVE GLYCEMIC CONTROL; BLOOD-PRESSURE CONTROL; CARDIOVASCULAR-DISEASE; RANDOMIZED-TRIAL; GLUCOSE CONTROL; FOLLOW-UP; MELLITUS; COMPLICATIONS; HYPERTENSION; COMMUNITY AB Background: The cost-effectiveness of screening for type 2 diabetes mellitus (DM2) in developing countries remains unknown. The Brazilian government conducted a nationwide population screening program for type 2 diabetes mellitus (BNDSP) in which 22 million capillary glucose tests were performed in individuals aged 40 years and older. The objective of this study was to evaluate the life-time cost-effectiveness of a national population-based screening program for DM2 conducted in Brazil. Methods: We used a Markov-based cost-effectiveness model to simulate the long-term costs and benefits of screening for DM2, compared to no screening program. The analysis was conducted from a public health care system perspective. Sensitivity analyses were conducted to examine the robustness of results to key model parameters. Results: Brazilian National diabetes screening program will yield a large health benefit and higher costs. Compared with no screening, screen detection of undiagnosed diabetes resulted in US$ 31,147 per QALY gained. Results from sensitivity analyses found that screening targeted at hypertensive individuals would cost US$ 22,695/ QALY. When benefits from early glycemic control on cardiovascular outcomes were considered, the cost per QALY gained would reduce significantly. Conclusions: In the base case analysis, not considering the intangible benefit of transferring diabetes management to primary care nor the benefit of using statin to treat eligible diabetic patients, CE ratios were not cost-effective considering thresholds proposed by the World Health Organization. However, significant uncertainty was demonstrated in sensitivity analysis. Our results indicate that policy-makers should carefully balance the benefit and cost of the program while considering using a population-based approach to screen for diabetes. C1 [Toscano, Cristiana M.; Duncan, Bruce B.; Polanczyk, Carisi A.; Schmidt, Maria Ines] Univ Fed Rio Grande do Sul, Porto Alegre, RS, Brazil. [Zhuo, Xiaohui; Imai, Kumiko; Zhang, Ping; Engelgau, Michael] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Toscano, CM (reprint author), Univ Fed Rio Grande do Sul, Porto Alegre, RS, Brazil. EM ctoscano@terra.com.br FU Brazilian Ministry of Health; Pan American Health Organization FX Funding for this study was provided by the Brazilian Ministry of Health with the support of the Pan American Health Organization. The cost-effectiveness model was developed by the Centers for Disease Control and Prevention and RTI International, Triangle Park, and the, Atlanta, GA. NR 52 TC 1 Z9 1 U1 0 U2 4 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1758-5996 J9 DIABETOL METAB SYNDR JI Diabetol. Metab. Syndr. PD OCT 31 PY 2015 VL 7 AR 95 DI 10.1186/s13098-015-0090-8 PG 11 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA CU9AH UT WOS:000363834700001 PM 26523154 ER PT J AU Ng, J Ye, F Roth, L Sobel, K Byron, S Barton, M Lindley, M Stokley, S AF Ng, Judy Ye, Faye Roth, Lindsey Sobel, Katherine Byron, Sepheen Barton, Mary Lindley, Megan Stokley, Shannon TI Human Papillomavirus Vaccination Coverage Among Female Adolescents in Managed Care Plans - United States, 2013 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Ng, Judy; Ye, Faye; Roth, Lindsey; Sobel, Katherine; Byron, Sepheen; Barton, Mary] Natl Comm Qual Assurance, Washington, DC USA. [Ng, Judy] Princeton Univ, Woodrow Wilson Sch Publ & Int Affairs, Princeton, NJ 08544 USA. [Lindley, Megan; Stokley, Shannon] CDC, Natl Ctr Immunizat & Resp Dis, Immunizat Serv Div, Atlanta, GA 30333 USA. RP Stokley, S (reprint author), CDC, Natl Ctr Immunizat & Resp Dis, Immunizat Serv Div, Atlanta, GA 30333 USA. EM sstokley@cdc.gov NR 10 TC 4 Z9 4 U1 1 U2 1 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD OCT 30 PY 2015 VL 64 IS 42 BP 1185 EP 1189 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CW4RQ UT WOS:000364980200001 PM 26513219 ER PT J AU Dooling, KL Toews, KA Hicks, LA Garrison, LE Bachaus, B Zansky, S Carpenter, LR Schaffner, B Parker, E Petit, S Thomas, A Thomas, S Mansmann, R Morin, C White, B Langley, GE AF Dooling, Kathleen L. Toews, Karrie-Ann Hicks, Lauri A. Garrison, Laurel E. Bachaus, Brian Zansky, Shelley Carpenter, L. Rand Schaffner, Bill Parker, Erin Petit, Susan Thomas, Ann Thomas, Stephanie Mansmann, Robert Morin, Craig White, Benjamin Langley, Gayle E. TI Active Bacterial Core Surveillance for Legionellosis - United States, 2011-2013 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID LEGIONNAIRES-DISEASE; MORTALITY; DIAGNOSIS C1 [Dooling, Kathleen L.; Toews, Karrie-Ann; Hicks, Lauri A.; Garrison, Laurel E.; Langley, Gayle E.] CDC, Div Bacterial Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Dooling, Kathleen L.] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Bachaus, Brian] Maryland Dept Hlth & Mental Hyg, Baltimore, MD 21201 USA. [Zansky, Shelley] New York State Dept Hlth, Albany, NY 12237 USA. [Carpenter, L. Rand] Tennessee Dept Hlth, Nashville, TN USA. [Schaffner, Bill] Vanderbilt Univ, Sch Med, Nashville, TN 37235 USA. [Parker, Erin] Calif Emerging Infect Program, Atlanta, GA USA. [Petit, Susan] Connecticut Dept Publ Hlth, Hartford, CT USA. [Thomas, Ann] Oregon Publ Hlth Div, Portland, OR USA. [Thomas, Stephanie] Georgia Emerging Infect Program, Atlanta, GA USA. [Morin, Craig] Minnesota Dept Hlth, Minneapolis, MN 55414 USA. [White, Benjamin] Colorado Dept Publ Hlth & Environm, Denver, CO USA. RP Langley, GE (reprint author), CDC, Div Bacterial Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. EM glangley@cdc.gov NR 10 TC 5 Z9 5 U1 2 U2 3 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD OCT 30 PY 2015 VL 64 IS 42 BP 1190 EP 1193 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CW4RQ UT WOS:000364980200002 PM 26513329 ER PT J AU Singleterry, J Jump, Z DiGiulio, A Babb, S Sneegas, K MacNeil, A Zhang, L Williams, KAS AF Singleterry, Jennifer Jump, Zach DiGiulio, Anne Babb, Stephen Sneegas, Karla MacNeil, Allison Zhang, Lei Williams, Kisha-Ann S. TI State Medicaid Coverage for Tobacco Cessation Treatments and Barriers to Coverage - United States, 2014-2015 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID AFFORDABLE CARE ACT; DEPENDENCE TREATMENT; SMOKING; IMPACT C1 [Singleterry, Jennifer; Jump, Zach; DiGiulio, Anne] Amer Lung Assoc, New York, NY 10019 USA. [Babb, Stephen; Sneegas, Karla; MacNeil, Allison; Zhang, Lei; Williams, Kisha-Ann S.] CDC, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. RP Babb, S (reprint author), CDC, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. EM sbabb@cdc.gov NR 10 TC 6 Z9 6 U1 0 U2 1 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD OCT 30 PY 2015 VL 64 IS 42 BP 1194 EP 1199 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CW4RQ UT WOS:000364980200003 PM 26513425 ER PT J AU McCotter, OZ Smith, RM Westercamp, M Kerkering, TM Malani, AN Latham, R Peglow, SL Mody, RK Pappas, PG Chiller, TM AF McCotter, Orion Z. Smith, Rachel M. Westercamp, Mathew Kerkering, Thomas M. Malani, Anurag N. Latham, Robert Peglow, Sheree L. Mody, Rajal K. Pappas, Peter G. Chiller, Tom M. TI Update on Multistate Outbreak of Fungal Infections Associated with Contaminated Methylprednisolone Injections, 2012-2014 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID MENINGITIS C1 [McCotter, Orion Z.; Smith, Rachel M.; Westercamp, Mathew; Mody, Rajal K.; Chiller, Tom M.] CDC, Mycot Dis Branch, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Div, Atlanta, GA 30333 USA. [Kerkering, Thomas M.] Virginia Tech, Carillon Sch Med, Roanolce, VA USA. [Malani, Anurag N.] St Joseph Mercy Hosp, Ann Arbor, MI 48104 USA. [Latham, Robert] St Thomas Hosp, Nashville, TN USA. [Peglow, Sheree L.] Elkhart Gen Hosp, Elkhart, IN USA. [Pappas, Peter G.] Univ Alabama Birmingham, Mycoses Study Grp, Birmingham, AL USA. RP Chiller, TM (reprint author), CDC, Mycot Dis Branch, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Div, Atlanta, GA 30333 USA. EM tnc3@cdc.gov NR 3 TC 3 Z9 3 U1 0 U2 1 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD OCT 30 PY 2015 VL 64 IS 42 BP 1200 EP 1201 PG 2 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CW4RQ UT WOS:000364980200004 PM 26513534 ER PT J AU Curran, K Heiman, KE Singh, T Doobovsky, Z Hensley, J Melius, B Burnworth, L Williams, I Nichols, M AF Curran, Kathryn Heiman, Katherine E. Singh, Tushar Doobovsky, Zachary Hensley, Joni Melius, Beth Burnworth, Laura Williams, Ian Nichols, Megin TI Outbreak of Escherichia coli O157:H7 Infections Associated with Dairy Education Event Attendance -Whatcom County, Washington, 2015 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Curran, Kathryn; Singh, Tushar] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Curran, Kathryn; Heiman, Katherine E.; Burnworth, Laura; Williams, Ian; Nichols, Megin] CDC, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Singh, Tushar] CDC, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. [Doobovsky, Zachary; Hensley, Joni] Whatcom Cty Hlth Dept, Bellingham, WA USA. [Melius, Beth] Washington State Dept Hlth, Olympia, WA USA. RP Curran, K (reprint author), CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. EM ydh9@cdc.gov NR 2 TC 1 Z9 1 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD OCT 30 PY 2015 VL 64 IS 42 BP 1202 EP 1203 PG 2 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CW4RQ UT WOS:000364980200005 PM 26513638 ER PT J AU Amer, S Abd El Wahab, T Metwaly, A Feng, YY Xiao, LH AF Amer, Said Abd El Wahab, Taher Metwaly, Abd El Naby Feng, Yaoyu Xiao, Lihua TI Morphologic and Genotypic Characterization of Psoroptes Mites from Water Buffaloes in Egypt SO PLOS ONE LA English DT Article ID MANGE MITES; SHEEP SCAB; OVIS INFESTATION; BUBALUS-BUBALIS; GREAT-BRITAIN; RESPONSES; CUNICULI; RABBITS; ACARI; POPULATIONS AB Species delimitation of Psoroptes spp. and identity of the parasite in water buffaloes remain poorly defined. In this study, Psoroptes infestation on three water buffalo farms in Egypt was examined based on morphometric characteristics, especially the opisthosomal setae of adult male mites. Clinical investigations showed that 28% (196/700) of the sampled animals had mange infestation. Microscopic examinations of 80 skin scrapings indicated the occurrence of Psoroptes mites in 17 (21.3%) samples, Sarcoptes mites in 27 (33.7%) samples, and the concurrence of both in 36 (45.0%) samples. Morphologically, the Psoroptes parasite was identified as Psoroptes natalensis. DNA sequence analysis of the second internal transcribed spacer (ITS2) in 11 representative samples confirmed the diagnosis and suggested the presence of a distinct variety of Psoroptes natalensis in Egypt. C1 [Amer, Said; Xiao, Lihua] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Div Foodborne Waterborne & Environm Dis, Atlanta, GA USA. [Amer, Said] Kafr El sheikh Univ, Fac Sci, Dept Zool, Kafr Al Sheikh, Egypt. [Abd El Wahab, Taher; Metwaly, Abd El Naby] Anim Hlth Res Inst, Kafr El Sheikh Provis Lab, Kafr Al Sheikh, Egypt. [Feng, Yaoyu] E China Univ Sci & Technol, Sch Resources & Environm Engn, State Environm Protect Key Lab Environm Risk Asse, Shanghai 200237, Peoples R China. RP Feng, YY (reprint author), E China Univ Sci & Technol, Sch Resources & Environm Engn, State Environm Protect Key Lab Environm Risk Asse, Shanghai 200237, Peoples R China. EM yyfeng@ecust.edu.cn; lxiao@cdc.gov RI Xiao, Lihua/B-1704-2013; Feng, Yaoyu/B-3076-2014 OI Xiao, Lihua/0000-0001-8532-2727; FU Arab Fund for Economic & Social Development "Zamalat Program"; National Natural Science Foundation of China [31110103901] FX This study was supported in part by the Arab Fund for Economic & Social Development "Zamalat Program" and the National Natural Science Foundation of China (Project No. 31110103901). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 47 TC 1 Z9 1 U1 2 U2 7 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD OCT 30 PY 2015 VL 10 IS 10 AR e0141554 DI 10.1371/journal.pone.0141554 PG 11 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CV0EH UT WOS:000363920800053 PM 26517834 ER PT J AU Hanson, C Waiswa, P Marchant, T Marx, M Manzi, F Mbaruku, G Rowe, A Tomson, G Schellenberg, J Peterson, S AF Hanson, Claudia Waiswa, Peter Marchant, Tanya Marx, Michael Manzi, Fatuma Mbaruku, Godfrey Rowe, Alex Tomson, Goran Schellenberg, Joanna Peterson, Stefan CA EQUIP Study Team TI Expanded Quality Management Using Information Power (EQUIP): protocol for a quasi-experimental study to improve maternal and newborn health in Tanzania and Uganda (vol 9, 41, 2014) SO IMPLEMENTATION SCIENCE LA English DT Correction C1 [Hanson, Claudia; Waiswa, Peter; Tomson, Goran; Peterson, Stefan] Karolinska Inst, Dept Publ Hlth Sci, Stockholm, Sweden. [Hanson, Claudia; Marchant, Tanya; Schellenberg, Joanna] London Sch Hyg & Trop Med, Dept Dis Control, London WC1, England. [Waiswa, Peter; Peterson, Stefan] Makerere Univ, Coll Hlth Sci, Sch Publ Hlth, Kampala, Uganda. [Marx, Michael] Heidelberg Univ, Evaplan GmbH, Heidelberg, Germany. [Hanson, Claudia; Manzi, Fatuma; Mbaruku, Godfrey] Ifakara Hlth Inst, Dar Es Salaam, Tanzania. [Rowe, Alex] Ctr Dis Control & Prevent, Malaria Branch, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA USA. [Tomson, Goran] Karolinska Inst, Dept Learning Informat Management Eth, Stockholm, Sweden. [Peterson, Stefan] Uppsala Univ, Dept Womens & Childrens Hlth, Int Maternal & Child Hlth Unit, Uppsala, Sweden. RP Hanson, C (reprint author), Karolinska Inst, Dept Publ Hlth Sci, Stockholm, Sweden. EM claudia.hanson@ki.se FU Medical Research Council [MR/K012126/1] NR 1 TC 0 Z9 0 U1 0 U2 0 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1748-5908 J9 IMPLEMENT SCI JI Implement. Sci. PD OCT 29 PY 2015 VL 10 AR 152 DI 10.1186/s13012-015-0343-9 PG 1 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA CV1GR UT WOS:000364002200002 PM 26515014 ER PT J AU Yoon, A Yi, KS Chang, SY Kim, SH Song, M Choi, JA Bourgeois, M Hossain, MJ Chen, LM Donis, RO Kim, H Lee, Y Hwang, DB Min, JY Chang, SJ Chung, J AF Yoon, Aerin Yi, Kye Sook Chang, So Young Kim, Sung Hwan Song, Manki Choi, Jung Ah Bourgeois, Melissa Hossain, M. Jaber Chen, Li-Mei Donis, Ruben O. Kim, Hyori Lee, Yujean Hwang, Do Been Min, Ji-Young Chang, Shin Jae Chung, Junho TI An Anti-Influenza Virus Antibody Inhibits Viral Infection by Reducing Nucleus Entry of Influenza Nucleoprotein SO PLOS ONE LA English DT Article ID NEUTRALIZING ANTIBODY; RECEPTOR-BINDING; A VIRUSES; HEMAGGLUTININ; EPITOPE; CELLS; NEURAMINIDASE; TRANSCRIPTION; PROTECTION; CHALLENGE AB To date, four main mechanisms mediating inhibition of influenza infection by anti-hemagglutinin antibodies have been reported. Anti-globular-head-domain antibodies block either influenza virus receptor binding to the host cell or progeny virion release from the host cell. Anti-stem region antibodies hinder the membrane fusion process or induce antibody-dependent cytotoxicity to infected cells. In this study we identified a human monoclonal IgG1 antibody (CT302), which does not inhibit both the receptor binding and the membrane fusion process but efficiently reduced the nucleus entry of viral nucleoprotein suggesting a novel inhibition mechanism of viral infection by antibody. This antibody binds to the subtype-H3 hemagglutinin globular head domain of group-2 influenza viruses circulating throughout the population between 1997 and 2007. C1 [Yoon, Aerin; Kim, Hyori; Lee, Yujean; Hwang, Do Been; Chung, Junho] Seoul Natl Univ, Coll Med, Dept Biochem & Mol Biol, Seoul, South Korea. [Yoon, Aerin; Kim, Hyori; Lee, Yujean; Hwang, Do Been; Chung, Junho] Seoul Natl Univ, Coll Med, Canc Res Inst, Seoul, South Korea. [Yi, Kye Sook; Kim, Sung Hwan; Chang, Shin Jae] Celltrion Inc, Biotechnol Res Inst, Inchon, South Korea. [Chang, So Young; Min, Ji-Young] Inst Pasteur Korea, Songnam, Gyeonggi Do, South Korea. [Song, Manki; Choi, Jung Ah] Int Vaccine Inst, Seoul, South Korea. [Bourgeois, Melissa; Hossain, M. Jaber; Chen, Li-Mei; Donis, Ruben O.] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. RP Chung, J (reprint author), Seoul Natl Univ, Coll Med, Dept Biochem & Mol Biol, Seoul, South Korea. EM jiyoung.min@ip-korea.org; ShinJae.Chang@celltrion.com; jjhchung@snu.ac.kr FU Korea Healthcare Technology R&D Project, Ministry of Health & Welfare, Republic of Korea [A103001]; National Research Foundation of Korea (NRF) - Korea government (MSIP) [2012R1A5A2A44671346] FX This study was supported in part by a grant from the Korea Healthcare Technology R&D Project, Ministry of Health & Welfare, Republic of Korea (Grant No.: A103001). Additional funding was provided by a National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIP) (No. 2012R1A5A2A44671346). NR 40 TC 1 Z9 1 U1 2 U2 6 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD OCT 29 PY 2015 VL 10 IS 10 AR e0141312 DI 10.1371/journal.pone.0141312 PG 18 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CV0ED UT WOS:000363920300027 PM 26512723 ER PT J AU Ghersi, BM Jia, HW Aiewsakun, P Katzourakis, A Mendoza, P Bausch, DG Kasper, MR Montgomery, JM Switzer, WM AF Ghersi, Bruno M. Jia, Hongwei Aiewsakun, Pakorn Katzourakis, Aris Mendoza, Patricia Bausch, Daniel G. Kasper, Matthew R. Montgomery, Joel M. Switzer, William M. TI Wide distribution and ancient evolutionary history of simian foamy viruses in New World primates SO RETROVIROLOGY LA English DT Article DE Retrovirus; Simian foamy virus; Co-evolution; Co-speciation; Nonhuman primates; South America; Peru; Neotropical ID INFECTION; TRANSMISSION; IDENTIFICATION; PREVALENCE; DIVERSITY; HUNTERS; MONKEYS; APOBEC3; HUMANS; COLONY AB Background: Although simian foamy viruses (SFV) are the only exogenous retroviruses to infect New World monkeys (NWMs), little is known about their evolutionary history and epidemiology. Previous reports show distinct SFVs among NWMs but were limited to small numbers of captive or wild monkeys from five (Cebus, Saimiri, Ateles, Alouatta, and Callithrix) of the 15 NWM genera. Other studies also used only PCR testing or serological assays with limited validation and may have missed infection in some species. We developed and validated new serological and PCR assays to determine the prevalence of SFV in blood specimens from a large number of captive NWMs in the US (n = 274) and in captive and wild-caught NWMs (n = 236) in Peruvian zoos, rescue centers, and illegal trade markets. Phylogenetic and co-speciation reconciliation analyses of new SFV polymerase (pol) and host mitochondrial cytochrome B sequences, were performed to infer SFV and host co-evolutionary histories. Results: 124/274 (45.2 %) of NWMs captive in the US and 59/157 (37.5 %) of captive and wild-caught NWMs in Peru were SFV WB-positive representing 11 different genera (Alouatta, Aotus, Ateles, Cacajao, Callithrix, Cebus, Lagothrix, Leontopithecus, Pithecia, Saguinus and Saimiri). Seroprevalences were lower at rescue centers (10/53, 18.9 %) compared to zoos (46/97, 47.4 %) and illegal trade markets (3/7, 8/19, 42.9 %) in Peru. Analyses showed that the trees of NWM hosts and SFVs have remarkably similar topologies at the level of species and sub-populations suggestive of co-speciation. Phylogenetic reconciliation confirmed 12 co-speciation events (p < 0.002) which was further supported by obtaining highly similar divergence dates for SFV and host genera and correlated SFV-host branch times. However, four ancient cross-genus transmission events were also inferred for Pitheciinae to Atelidae, Cacajao to ancestral Callithrix or Cebus monkeys, between Callithrix and Cebus monkeys, and Lagothrix to Alouatta. Conclusions: We demonstrate a broad distribution and stable co-speciation history of SFV in NWMs at the species level. Additional studies are necessary to further explore the epidemiology and natural history of SFV infection of NWMs and to determine the zoonotic potential for persons exposed to infected monkeys in captivity and in the wild. C1 [Ghersi, Bruno M.; Bausch, Daniel G.; Kasper, Matthew R.; Montgomery, Joel M.] US Naval Med Res Unit 6, Lima, Peru. [Jia, Hongwei; Switzer, William M.] Ctr Dis Control & Prevent, Natl Ctr HIV AIDS, Div HIV AIDS Prevent, Branch Lab,Viral Hepatitis STD & TB Prevent, Atlanta, GA 30329 USA. [Aiewsakun, Pakorn; Katzourakis, Aris] Univ Oxford, Dept Zool, Oxford OX1 3PS, England. [Mendoza, Patricia] Wildlife Conservat Soc, Lima, Peru. [Bausch, Daniel G.] Tulane Sch Publ Hlth & Trop Hyg, New Orleans, LA USA. [Montgomery, Joel M.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Ghersi, BM (reprint author), US Naval Med Res Unit 6, Lima, Peru. EM bghersi@tulane.edu FU US Department of Defense; Global Emerging Infections Surveillance and Response System; US Centers for Disease Control and Prevention; United States Agency for International Development (USAID) Emerging Pandemic Threats PREDICT; Royal Thai Government; Royal Society FX We are thankful for the authorization for collection, exportation and processing of samples from the Peruvian Ministry of Agriculture (RD N 0363-2010-AG-DGFFS-DGEFFS and RD N 411-2010-AG-DGFFS-DGEFFS; export permit N 001312, Access to genetic material contract 0016-2014-MINAGRI-DGFFS/DGEFFS). We also thank the staff at all the Peru and US zoos, rescue centers and research institutions that provided the archived and opportunistic blood specimens. This work would not be possible without the collaborations of Marieke Rosenbaum, Nancy Cavero, Tatiana Quevedo, Catalina Hermoza, Milagros Ramos, Helene Collongues and Raul Bello. Use of trade names is for identification only and does not imply endorsement by the US Department of Health and Human Services, the Public Health Service, or the Centers for Disease Control and Prevention. This work was supported by the US Department of Defense, Global Emerging Infections Surveillance and Response System, the US Centers for Disease Control and Prevention and the United States Agency for International Development (USAID) Emerging Pandemic Threats PREDICT. P. A. is funded by the Royal Thai Government. A. K. is funded by the Royal Society. The findings and conclusions in the report are those of the authors and do not necessarily reflect the official policy or position of the Department of the Navy, Department of Defense, the Centers for Disease Control and Prevention, or the US Government. NR 50 TC 1 Z9 1 U1 6 U2 18 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1742-4690 J9 RETROVIROLOGY JI Retrovirology PD OCT 29 PY 2015 VL 12 AR 89 DI 10.1186/s12977-015-0214-0 PG 19 WC Virology SC Virology GA CU9BG UT WOS:000363837200002 PM 26514626 ER PT J AU Frieden, TR AF Frieden, Thomas R. TI The Future of Public Health SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID UNITED-STATES; UNDIAGNOSED HYPERTENSION; BLOOD-PRESSURE; CARE; TUBERCULOSIS; PREVALENCE; MANAGEMENT; CHILDHOOD; AWARENESS; PROGRESS AB The field of public health aims to improve the health of as many people as possible as rapidly as possible. Since 1900, the average life span in the United States has increased by more than 30 years; 25 years of this gain have been attributed to public health advances.(1,2) Globally, life expectancy doubled during the 20th century,(3) largely as a result of reductions in child mortality attributable to expanded immunization coverage, clean water, sanitation, and other child-survival programs.(4) Public health focuses on denominators - what proportion of all people who can benefit from an intervention actually benefit. Maximizing health requires contributions from many sectors of society, including broad social, economic, environmental, transportation, and other policies in which government plays key roles; involvement of civil society; innovation by the public and private sectors; and health care and public health action. Although there has sometimes been distrust and disrespect between the health care and public health fields, 5 they are inevitably and increasingly interdependent; maximizing potential health gains is a defining challenge for both fields. C1 Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Frieden, TR (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd, Atlanta, GA 30333 USA. EM tfrieden@cdc.gov NR 49 TC 13 Z9 13 U1 8 U2 16 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 EI 1533-4406 J9 NEW ENGL J MED JI N. Engl. J. Med. PD OCT 29 PY 2015 VL 373 IS 18 BP 1748 EP 1754 DI 10.1056/NEJMsa1511248 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA CU4QH UT WOS:000363514100010 PM 26510022 ER PT J AU Burton, DC Bigogo, GM Audi, AO Williamson, J Munge, K Wafula, J Ouma, D Khagayi, S Mugoya, I Mburu, J Muema, S Bauni, E Bwanaali, T Feikin, DR Ochieng, PM Mogeni, OD Otieno, GA Olack, B Kamau, T Van Dyke, MK Chen, R Farrington, P Montgomery, JM Breiman, RF Scott, JAG Laserson, KF AF Burton, Deron C. Bigogo, Godfrey M. Audi, Allan O. Williamson, John Munge, Kenneth Wafula, Jackline Ouma, Dominic Khagayi, Sammy Mugoya, Isaac Mburu, James Muema, Shadrack Bauni, Evasius Bwanaali, Tahreni Feikin, Daniel R. Ochieng, Peter M. Mogeni, Ondari D. Otieno, George A. Olack, Beatrice Kamau, Tatu Van Dyke, Melissa K. Chen, Robert Farrington, Paddy Montgomery, Joel M. Breiman, Robert F. Scott, J. Anthony G. Laserson, Kayla F. TI Risk of Injection-Site Abscess among Infants Receiving a Preservative-Free, Two-Dose Vial Formulation of Pneumococcal Conjugate Vaccine in Kenya SO PLOS ONE LA English DT Article ID IMMUNIZATION; CHILDREN; HEALTH AB There is a theoretical risk of adverse events following immunization with a preservative-free, 2-dose vial formulation of 10-valent-pneumococcal conjugate vaccine (PCV10). We set out to measure this risk. Four population-based surveillance sites in Kenya (total annual birth cohort of 11,500 infants) were used to conduct a 2-year post-introduction vaccine safety study of PCV10. Injection-site abscesses occurring within 7 days following vaccine administration were clinically diagnosed in all study sites (passive facility-based surveillance) and, also, detected by caregiver-reported symptoms of swelling plus discharge in two sites (active household-based surveillance). Abscess risk was expressed as the number of abscesses per 100,000 injections and was compared for the second vs first vial dose of PCV10 and for PCV10 vs pentavalent vaccine (comparator). A total of 58,288 PCV10 injections were recorded, including 24,054 and 19,702 identified as first and second vial doses, respectively (14,532 unknown vial dose). The risk ratio for abscess following injection with the second (41 per 100,000) vs first (33 per 100,000) vial dose of PCV10 was 1.22 (95% confidence interval [CI] 0.37-4.06). The comparator vaccine was changed from a 2-dose to 10-dose presentation midway through the study. The matched odds ratios for abscess following PCV10 were 1.00 (95% CI 0.12-8.56) and 0.27 (95% CI 0.14-0.54) when compared to the 2-dose and 10-dose pentavalent vaccine presentations, respectively. In Kenya immunization with PCV10 was not associated with an increased risk of injection site abscess, providing confidence that the vaccine may be safely used in Africa. The relatively higher risk of abscess following the 10-dose presentation of pentavalent vaccine merits further study. C1 [Burton, Deron C.; Bigogo, Godfrey M.; Audi, Allan O.; Williamson, John; Ouma, Dominic; Khagayi, Sammy; Muema, Shadrack; Feikin, Daniel R.; Ochieng, Peter M.; Mogeni, Ondari D.; Otieno, George A.; Olack, Beatrice; Montgomery, Joel M.; Laserson, Kayla F.] CDC Res & Publ Hlth Collaborat, Ctr Dis Control & Prevent, Kenya Med Res Inst KEMRI, Nairobi, Kenya. [Burton, Deron C.; Bigogo, Godfrey M.; Audi, Allan O.; Ouma, Dominic; Muema, Shadrack; Feikin, Daniel R.; Ochieng, Peter M.; Mogeni, Ondari D.; Otieno, George A.; Olack, Beatrice; Montgomery, Joel M.; Breiman, Robert F.] CDC, Global Dis Detect Response Ctr, Int Emerging Infect Program, Nairobi, Kenya. [Munge, Kenneth; Wafula, Jackline; Mburu, James; Bauni, Evasius; Bwanaali, Tahreni; Scott, J. Anthony G.] KEMRI Wellcome Trust Res Programme, Kilifi, Kenya. [Williamson, John; Breiman, Robert F.; Laserson, Kayla F.] CDC, Ctr Global Hlth, Atlanta, GA 30333 USA. [Mugoya, Isaac; Kamau, Tatu] Minist Publ Hlth & Sanitat, Div Vaccines & Immunizat, Nairobi, Kenya. [Van Dyke, Melissa K.] GlaxoSmithKline Vaccines, Wavre, Belgium. [Chen, Robert] CDC, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. [Farrington, Paddy] Open Univ, Milton Keynes, Bucks, England. [Scott, J. Anthony G.] London Sch Hyg & Trop Med, London WC1, England. RP Burton, DC (reprint author), CDC Res & Publ Hlth Collaborat, Ctr Dis Control & Prevent, Kenya Med Res Inst KEMRI, Nairobi, Kenya. EM DBurton@cdc.gov FU GlaxoSmithKline Vaccines; Centers for Disease Control and Prevention; Wellcome Trust [098532] FX This work was supported by GlaxoSmithKline Vaccines (http://www.gsk.com/), the Centers for Disease Control and Prevention (http://www.cdc.gov/), and the Wellcome Trust (http://www.wellcome.ac.uk/). JAGS is funded by a fellowship from the Wellcome Trust (098532). Employees of the CDC participated in study design, data collection and analysis, decision to publish, and preparation of the manuscript. Wellcome Trust-supported co-authors participated in study design, data collection and analysis, decision to publish, and preparation of the manuscript. The GSK-employed co-author participated in study design, data analysis, and preparation of the manuscript. GSK and the GSK-employed co-author had no role in data collection or decision to publish. NR 12 TC 1 Z9 1 U1 0 U2 0 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD OCT 28 PY 2015 VL 10 IS 10 AR e0141896 DI 10.1371/journal.pone.0141896 PG 18 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CV0DL UT WOS:000363918100140 PM 26509274 ER PT J AU Freedman, DS Kit, BK Ford, ES AF Freedman, David S. Kit, Brian K. Ford, Earl S. TI Are the Recent Secular Increases in Waist Circumference among Children and Adolescents Independent of Changes in BMI? SO PLOS ONE LA English DT Article ID BODY-MASS INDEX; TO-HEIGHT RATIO; X-RAY ABSORPTIOMETRY; ABDOMINAL OBESITY; CARDIOVASCULAR-DISEASE; CARDIOMETABOLIC RISK; US CHILDREN; VISCERAL FAT; TRENDS; ADIPOSITY AB Background Several studies have shown that the waist circumference of children and adolescents has increased over the last 25 years. However, given the strong correlation between waist circumference and BMI, it is uncertain if the secular trends in waist circumference are independent of those in BMI. Methods We analyzed data from 6- to 19-year-olds who participated in the 1988-1994 through 2011-2012 cycles of the National Health and Nutrition Examination Survey to assess whether the trends in waist circumference were independent of changes in BMI, race-ethnicity and age. Results Mean, unadjusted levels of waist circumference increased by 3.7 cm (boys) and 6.0 cm (girls) from 1988-94 through 2011-12, while mean BMI levels increased by 1.1 kg/m(2) (boys) and 1.6 kg/m(2) (girls). Overall, the proportional changes in mean levels of both waist circumference and BMI were fairly similar among boys (5.3%, waist vs. 5.6%, BMI) and girls (8.7%, waist vs. 7.7%, BMI). As assessed by the area under the curve, adjustment for BMI reduced the secular increases in waist circumference by about 75% (boys) and 50% (girls) beyond that attributable to age and race-ethnicity. There was also a race-ethnicity interaction (p < 0.001). Adjustment for BMI reduced the secular trend in waist circumference among non-Hispanic (NH) black children (boys and girls) to a greater extent (about 90%) than among other children. Conclusions Our results indicate that among children in the U.S., about 75% (boys) and 50% (girls) of the secular increases in waist circumference since 1988-94 can be accounted for by changes in BMI. The reasons for the larger independent effects among girls and among NH blacks are uncertain. C1 [Freedman, David S.] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Atlanta, GA USA. [Kit, Brian K.] Ctr Dis Control & Prevent, Div Hlth & Nutr Examinat Surveys, Natl Ctr Hlth Stat, Hyattsville, MD USA. [Ford, Earl S.] Ctr Dis Control & Prevent, Div Populat Hlth, Atlanta, GA USA. RP Freedman, DS (reprint author), Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Atlanta, GA USA. EM dxf1@cdc.gov NR 53 TC 0 Z9 0 U1 0 U2 0 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD OCT 27 PY 2015 VL 10 IS 10 AR e0141056 DI 10.1371/journal.pone.0141056 PG 12 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CU8PC UT WOS:000363804200027 PM 26506450 ER PT J AU Tempia, S Wolter, N Cohen, C Walaza, S von Mollendorf, C Cohen, AL Moyes, J de Gouveia, L Nzenze, S Treurnicht, F Venter, M Groome, MJ Madhi, SA von Gottberg, A AF Tempia, Stefano Wolter, Nicole Cohen, Cheryl Walaza, Sibongile von Mollendorf, Claire Cohen, Adam L. Moyes, Jocelyn de Gouveia, Linda Nzenze, Susan Treurnicht, Florette Venter, Marietjie Groome, Michelle J. Madhi, Shabir A. von Gottberg, Anne TI Assessing the impact of pneumococcal conjugate vaccines on invasive pneumococcal disease using polymerase chain reaction-based surveillance: an experience from South Africa SO BMC INFECTIOUS DISEASES LA English DT Article DE Pneumococcus; Conjugate vaccine; lytA; Molecular serotyping; South Africa ID STREPTOCOCCUS-PNEUMONIAE; MULTIPLEX PCR; CHILDREN; HIV; INFECTION; EPIDEMIOLOGY; VACCINATION; SEROTYPE; CULTURE; ERA AB Background: The use of molecular diagnostic techniques for the evaluation of the impact of pneumococcal conjugate vaccines (PCVs) has not been documented. We aimed to evaluate the impact of PCVs on invasive pneumococcal disease (IPD) using polymerase chain reaction (PCR)-based techniques and compare with results obtained from culture-based methods. Methods: We implemented two independent surveillance programs for IPD among individuals hospitalized at one large surveillance site in Soweto, South Africa during 2009-2012: (i) PCR-based (targeting the lytA gene) syndromic pneumonia surveillance; and (ii) culture-based laboratory surveillance. Positive samples were serotyped. The molecular serotyping assay included targets for 42 serotypes including all serotypes/serogroups included in the 7-valent (PCV-7) and 13-valent (PCV-13) PCV. The Quellung reaction was used for serotyping of culture-positive cases. We calculated the change in rates of IPD (lytA-or culture-positive) among HIV-uninfected children aged <2 years from the year of PCV-7 introduction (2009) to the post-vaccine years (2011 or 2012). Results: During the study period there were 607 lytA-positive and 1,197 culture-positive cases that were serotyped. Samples with lytA cycle threshold (Ct)-values >= 35 (30.2 %; 123/407) were significantly less likely to have a serotype/serogroup detected for serotypes included in the molecular serotyping assay than those with Ct-values <35 (78.0 %; 156/200) (p < 0.001). From 2009 to 2012 rates of PCV-7 serotypes/serogroups decreased -63.8 % (95 % CI: -79.3 % to -39.1 %) among lytA-positive cases and -91.7 % (95 % CI: -98.8 % to -73.6 %) among culture-positive cases. Rates of lytA-positive non-vaccine serotypes/serogroups also significantly decreased (-71.7 %; 95 % CI: -81.1 % to -58.5 %) over the same period. Such decline was not observed among the culture-positive non-vaccine serotypes (1.2 %; 95 % CI: -96.7 % to 58.4 %). Conclusions: Significant downward trends in IPD PCV-7 serotype-associated rates were observed among patients tested by PCR or culture methods; however trends of non-vaccine serotypes/serogroups differed between the two groups. Misclassifications of serotypes/serogroups, affecting the use of non-vaccine serotypes as a control group, may have occurred due to the low performance of the serotyping assay among lytA-positive cases with high Ct-values. Until PCR methods improve further, culture methods should continue to be used to monitor the effects of PCV vaccination programs on IPD incidence. C1 [Tempia, Stefano; Cohen, Adam L.] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. [Tempia, Stefano; Cohen, Adam L.] Ctr Dis Control & Prevent, Influenza Program, Pretoria, South Africa. [Tempia, Stefano; Wolter, Nicole; Cohen, Cheryl; Walaza, Sibongile; von Mollendorf, Claire; Moyes, Jocelyn; de Gouveia, Linda; Treurnicht, Florette; Madhi, Shabir A.; von Gottberg, Anne] Natl Hlth Lab Serv, Natl Inst Communicable Dis, Ctr Resp Dis & Meningitis, Johannesburg, South Africa. [Wolter, Nicole; von Gottberg, Anne] Univ Witwatersrand, Sch Pathol, Fac Hlth Sci, Johannesburg, South Africa. [Cohen, Cheryl; Walaza, Sibongile; von Mollendorf, Claire; Moyes, Jocelyn; Nzenze, Susan] Univ Witwatersrand, Sch Publ Hlth, Fac Hlth Sci, Johannesburg, South Africa. [Nzenze, Susan; Groome, Michelle J.; Madhi, Shabir A.] Univ Witwatersrand, MRC, Resp & Meningeal Pathogens Res Unit, Johannesburg, South Africa. [Venter, Marietjie] Ctr Dis Control & Prevent, Div Global Hlth Protect, Pretoria, South Africa. [Groome, Michelle J.; Madhi, Shabir A.] Univ Witwatersrand, Dept Sci & Technol, Natl Res Fdn Vaccine Preventable Dis, Johannesburg, South Africa. RP Tempia, S (reprint author), Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. EM stefanot@nicd.ac.za; annev@nicd.ac.za RI Venter, Marietjie/P-9604-2016; OI Venter, Marietjie/0000-0003-2696-824X; Tempia, Stefano/0000-0003-4395-347X FU Pfizer South Africa [WS1167521]; US Centers for Disease Control and Prevention [5U51IP000155] FX This work was supported by Pfizer South Africa (investigator-initiated research agreement number: WS1167521) and the US Centers for Disease Control and Prevention (co-operative agreement number: 5U51IP000155). NR 25 TC 4 Z9 4 U1 2 U2 2 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2334 J9 BMC INFECT DIS JI BMC Infect. Dis. PD OCT 26 PY 2015 VL 15 AR 450 DI 10.1186/s12879-015-1198-z PG 13 WC Infectious Diseases SC Infectious Diseases GA CV6HH UT WOS:000364370800001 PM 26496761 ER PT J AU Krishnan, A Amarchand, R Gupta, V Lafond, KE Suliankatchi, RA Saha, S Rai, S Misra, P Purakayastha, DR Wahi, A Sreenivas, V Kapil, A Dawood, F Pandav, CS Broor, S Kapoor, SK Lal, R Widdowson, MA AF Krishnan, Anand Amarchand, Ritvik Gupta, Vivek Lafond, Kathryn E. Suliankatchi, Rizwan Abdulkader Saha, Siddhartha Rai, Sanjay Misra, Puneet Purakayastha, Debjani Ram Wahi, Abhishek Sreenivas, Vishnubhatla Kapil, Arti Dawood, Fatimah Pandav, Chandrakant S. Broor, Shobha Kapoor, Suresh K. Lal, Renu Widdowson, Marc-Alain TI Epidemiology of acute respiratory infections in children - preliminary results of a cohort in a rural north Indian community SO BMC INFECTIOUS DISEASES LA English DT Article DE Acute respiratory infections; Burden; Children; Cohort; Developing countries; Epidemiology; Pneumonia ID CHILDHOOD PNEUMONIA; SYSTEMATIC ANALYSIS; YOUNG-CHILDREN; MORTALITY; BURDEN; SLUM; STRATEGIES; MORBIDITY; COST AB Background: Despite acute respiratory infections being a major cause of death among children in developing countries including India, there is a lack of community-based studies that document its burden and aetiology. Methods: A dynamic cohort of children aged 0-10 years was established in four villages in a north Indian state of Haryana from August 2012 onwards. Trained health workers conducted weekly home visits to screen children for acute respiratory infection (ARI) defined as one of the following: cough, sore throat, nasal congestion, earache/discharge, or breathing difficulty. Nurses clinically assessed these children to grade disease severity based on standard age-specific guidelines into acute upper or lower respiratory infection (AURI or ALRI) and collected nasal/throat swabs for pathogen testing. Results: Our first year results show that ARI incidence in 0-10 years of age was 5.9 (5.8-6.0) per child-year with minimal gender difference, the ALRI incidence in the under-five age group was higher among boys (0.43; 0.39-0.49) as compared to girls (0.31; 0.26-0.35) per child year. Boys had 2.4 times higher ARI-related hospitalization rate as compared to girls. Conclusion: ARI impose a significant burden on the children of this cohort. This study platform aims to provide better evidence for prevention and control of pneumonia in developing countries. C1 [Krishnan, Anand; Rai, Sanjay; Misra, Puneet; Purakayastha, Debjani Ram; Wahi, Abhishek; Pandav, Chandrakant S.] All India Inst Med Sci, Ctr Community Med, New Delhi 110029, India. [Amarchand, Ritvik; Gupta, Vivek; Broor, Shobha; Kapoor, Suresh K.] INCLEN Trust Int, New Delhi 110020, India. [Lafond, Kathryn E.; Saha, Siddhartha; Dawood, Fatimah; Lal, Renu; Widdowson, Marc-Alain] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Suliankatchi, Rizwan Abdulkader] Velammal Med Coll Hosp & Res Inst, Dept Community Med, Madurai 625009, Tamil Nadu, India. [Sreenivas, Vishnubhatla] All India Inst Med Sci, Dept Biostat, New Delhi 110029, India. [Kapil, Arti] All India Inst Med Sci, Dept Microbiol, New Delhi 110029, India. RP Krishnan, A (reprint author), All India Inst Med Sci, Ctr Community Med, New Delhi 110029, India. EM anand.drk@gmail.com RI S A, Rizwan/F-5289-2014 OI S A, Rizwan/0000-0002-3140-2614 FU United States Centers for Disease Control and Prevention [U01 IP000492] FX We are indebted to the villagers of the study area for their support and patience despite repeated visits during the study. The excellent teamwork and dedication of the entire team from health workers, supervisors, and nurses to doctors is singularly responsible for the smooth execution of this study. This work was supported by the United States Centers for Disease Control and Prevention [U01 IP000492]. NR 36 TC 1 Z9 1 U1 1 U2 1 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2334 J9 BMC INFECT DIS JI BMC Infect. Dis. PD OCT 26 PY 2015 VL 15 AR 462 DI 10.1186/s12879-015-1188-1 PG 10 WC Infectious Diseases SC Infectious Diseases GA CU4NH UT WOS:000363506100012 PM 26502931 ER PT J AU Hofstetter, AM DuRivage, N Vargas, CY Camargo, S Vawdrey, DK Fisher, A Stockwell, MS AF Hofstetter, Annika M. DuRivage, Nathalie Vargas, Celibell Y. Camargo, Stewin Vawdrey, David K. Fisher, Allison Stockwell, Melissa S. TI Text message reminders for timely routine MMR vaccination: A randomized controlled trial SO VACCINE LA English DT Article DE Measles; MMR; Text message; Reminder; Vaccination; Children ID UNITED-STATES; CHILDHOOD VACCINATIONS; MEASLES-VACCINE; CHILDREN; IMMUNIZATION; RUBELLA; MUMPS; RISK; AGE; POPULATION AB Objective: Measles-mumps-rubella (MMR) vaccination is important for preventing disease outbreaks, yet pockets of under-vaccination persist. Text message reminders have been employed successfully for other pediatric vaccines, but studies examining their use for MMR vaccination are limited. This study assessed the impact of text message reminders on timely MMR vaccination. Study design: Parents (n = 2054) of 9.5-10.5-month-old children from four urban academically-affiliated pediatric clinics were randomized to scheduling plus appointment text message reminders, appointment text message reminder-only, or usual care. The former included up to three text reminders to schedule the one-year preventive care visit. Both text messaging arms included a text reminder sent 2 days before that visit. Outcomes included appointment scheduling, appointment attendance, and MMR vaccination by age 13 months, the standard of care at study sites. Results: Children of parents in the scheduling plus appointment text message reminders arm were more likely to have a scheduled one-year visit than those in the other arms (71.9% vs. 67.4%, relative risk ratio (RRR) 1.07 [95% CI 1.005-1.13]), particularly if no appointment was scheduled before randomization (i.e., no baseline appointment) (62.1% vs. 54.7%, RRR 1.14 [95% CI 1.04-1.24]). One-year visit attendance and timely MMR vaccination were similar between arms. However, among children without a baseline appointment, those with parents in the scheduling plus appointment text message reminders arm were more likely to undergo timely MMR vaccination (61.1% vs. 55.1%, RRR 1.11 [95% CI 1.01-1.21]). Conclusion: Text message reminders improved timely MMR vaccination of high-risk children without a baseline one-year visit. (C) 2015 Published by Elsevier Ltd. C1 [Hofstetter, Annika M.; DuRivage, Nathalie; Vargas, Celibell Y.; Camargo, Stewin; Stockwell, Melissa S.] Columbia Univ, Dept Pediat, New York, NY 10032 USA. [Hofstetter, Annika M.; Vawdrey, David K.; Stockwell, Melissa S.] NewYork Presbyterian Hosp, New York, NY USA. [Vawdrey, David K.] Columbia Univ, Dept Biomed Informat, New York, NY 10032 USA. [Fisher, Allison] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [Stockwell, Melissa S.] Columbia Univ, Mailman Sch Publ Hlth, Dept Populat & Family Hlth, New York, NY 10032 USA. RP Stockwell, MS (reprint author), Columbia Univ, Dept Pediat, 622W 168th St,VC 417, New York, NY 10032 USA. EM annika.hofstetter@seattlechildrens.org; DurivageN@chop.edu; cv2211@cumc.columbia.edu; sc2689@cumc.columbia.edu; dkv2101@cumc.columbia.edu; ark2@cdc.gov; mss2112@cumc.columbia.edu FU Pfizer Medical Education Group; Investigator-Initiated Studies Program of Merck Sharp Dohme Corp. FX Dr. Hofstetter receives research support for an investigator-initiated study funded by the Pfizer Medical Education Group. Dr. Stockwell is an unfunded co-investigator on this study. Dr. Hofstetter previously received research support from the Investigator-Initiated Studies Program of Merck Sharp & Dohme Corp. The other authors have no financial disclosures to report. NR 30 TC 4 Z9 4 U1 0 U2 6 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD OCT 26 PY 2015 VL 33 IS 43 BP 5741 EP 5746 DI 10.1016/j.vaccine.2015.09.042 PG 6 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA CU8WK UT WOS:000363824600003 PM 26424607 ER PT J AU Stewart, AM Lindley, MC Cox, MA AF Stewart, Alexandra M. Lindley, Megan C. Cox, Marisa A. TI Medicaid provider reimbursement policy for adult immunizations SO VACCINE LA English DT Article DE Adult vaccination; Immunizations; Medicaid; Provider reimbursement AB Background: State Medicaid programs establish provider reimbursement policy for adult immunizations based on: costs, private insurance payments, and percentage of Medicare payments for equivalent services. Each program determines provider eligibility, payment amount, and permissible settings for administration. Total reimbursement consists of different combinations of Current Procedural Terminology codes: vaccine, vaccine administration, and visit. Objective: Determine how Medicaid programs in the 50 states and the District of Columbia approach provider reimbursement for adult immunizations. Design: Observational analysis using document review and a survey. Setting and participants: Medicaid administrators in 50 states and the District of Columbia. Measurements: Whether fee-for-service programs reimburse providers for: vaccines; their administration; and/or office visits when provided to adult enrollees. We assessed whether adult vaccination services are reimbursed when administered by a wide range of providers in a wide range of settings. Results: Medicaid programs use one of 4 payment methods for adults: (1) a vaccine and an administration code; (2) a vaccine and visit code; (3) a vaccine code; and (4) a vaccine, visit, and administration code. Limitations: Study results do not reflect any changes related to implementation of national health reform. Nine of fifty one programs did not respond to the survey or declined to participate, limiting the information available to researchers. Conclusions: Medicaid reimbursernent policy for adult vaccines impacts provider participation and enrollee access and uptake. While programs have generally increased reimbursement levels since 2003, each program could assess whether current policies reflect the most effective approach to encourage providers to increase vaccination services. (C) 2015 Elsevier Ltd. All rights reserved. C1 [Stewart, Alexandra M.; Cox, Marisa A.] George Washington Univ, Sch Publ Hlth, Milken Inst, Washington, DC 20052 USA. [Lindley, Megan C.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. RP Stewart, AM (reprint author), George Washington Univ, Sch Publ Hlth, Milken Inst, 2nd Floor,950 New Hampshire Ave, Washington, DC 20052 USA. EM stewarta@gwu.edu; cvx9@cdc.gov; mcox@gwu.edu FU National Center for Immunization and Respiratory Diseases Immunization Services Division of the Centers for Disease Control and Prevention FX The National Center for Immunization and Respiratory Diseases Immunization Services Division of the Centers for Disease Control and Prevention. NR 12 TC 1 Z9 1 U1 1 U2 1 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD OCT 26 PY 2015 VL 33 IS 43 BP 5801 EP 5808 DI 10.1016/j.vaccine.2015.09.014 PG 8 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA CU8WK UT WOS:000363824600011 PM 26403369 ER PT J AU Marcone, DN Durand, LO Azziz-Baumgartner, E Vidaurreta, S Ekstrom, J Carballal, G Echavarria, M AF Marcone, Debora Natalia Durand, Lizette O. Azziz-Baumgartner, Eduardo Vidaurreta, Santiago Ekstrom, Jorge Carballal, Guadalupe Echavarria, Marcela TI Incidence of viral respiratory infections in a prospective cohort of outpatient and hospitalized children aged <= 5 years and its associated cost in Buenos Aires, Argentina SO BMC INFECTIOUS DISEASES LA English DT Article DE Incidence; Children; Rhinovirus; Respiratory syncytial virus; Influenza; Hospitalized and outpatients; Charges ID YOUNG-CHILDREN; INFLUENZA; RHINOVIRUS; BANGLADESH; BURDEN; VIRUS; PCR AB Background: Although information about the incidence of viral respiratory illnesses and their associated cost can help health officials explore the value of interventions, data are limited from middle-income countries. Methods: During 2008-2010, we conducted a prospective cohort study and followed similar to 1,800 Argentinian children aged <= 5 years to identify those children who were hospitalized or who sought care at an emergency room with any acute respiratory infection sign or symptom (e.g., rhinorrhea, cough, wheezing, tachypnea, retractions, or cyanosis). Respiratory samples were obtained for respiratory syncytial virus, influenza, parainfluenza, adenovirus, and metapneumovirus testing by immunofluorescence and for rhinovirus by real-time reverse transcription polymerase chain reaction. Results: The incidence of respiratory syncytial virus (24/1000 children-years), human metapneumovirus (8/1000 children-years), and influenza (8/1000 children-years) illnesses was highest among hospitalized children aged < 6 months and decreased among older children. In contrast, the incidence of rhinovirus was highest (12/1000 children-years) among those aged 6-23 months. In the emergency room, the incidence of rhinovirus was 459; respiratory syncytial virus 352; influenza 185; parainfluenza 177; metapneumovirus 130; and adenovirus 73/1,000 children-years. The total cost of hospitalization was a median of US$529 (Interquartile range, US$ 362-789). Conclusions: Our findings indicate that respiratory viruses, in particular rhinovirus, respiratory syncytial virus, metapneumovirus, and influenza may be associated with severe illness causing substantial economic burden. C1 [Marcone, Debora Natalia; Carballal, Guadalupe; Echavarria, Marcela] CEMIC, Virol Unit, RA-1431 Buenos Aires, DF, Argentina. [Marcone, Debora Natalia; Carballal, Guadalupe; Echavarria, Marcela] CEMIC, Clin Virol Lab, RA-1431 Buenos Aires, DF, Argentina. [Marcone, Debora Natalia; Carballal, Guadalupe; Echavarria, Marcela] Consejo Nacl Invest Cient & Tecn, RA-1431 Buenos Aires, DF, Argentina. [Durand, Lizette O.; Azziz-Baumgartner, Eduardo] Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. [Vidaurreta, Santiago; Ekstrom, Jorge] CEMIC, Dept Pediat, Buenos Aires, DF, Argentina. RP Azziz-Baumgartner, E (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,MS A32, Atlanta, GA 30329 USA. EM eha9@cdc.gov; mechavarria@cemic.edu.ar FU Agencia Nacional de Promocion Cientifica y Tecnologica, Argentina [PICT 2006-650]; Centers for Disease Control and Prevention (an agency of the U.S. Department of Health and Human Services) FX This study has been funded through a grant awarded to Dr. Echavarria from the Agencia Nacional de Promocion Cientifica y Tecnologica (PICT 2006-650), Argentina and a grant from the Centers for Disease Control and Prevention (an agency of the U.S. Department of Health and Human Services), which is administered from an Interagency Agreement between U.S. CDC, U.S. Naval Medical Research Unit Number-6 and CEMIC). None of the coauthors have any conflicts of interest to declare. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or other institutions with which the authors are affiliated. NR 21 TC 2 Z9 2 U1 0 U2 2 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2334 J9 BMC INFECT DIS JI BMC Infect. Dis. PD OCT 24 PY 2015 VL 15 AR 447 DI 10.1186/s12879-015-1213-4 PG 9 WC Infectious Diseases SC Infectious Diseases GA CU4ND UT WOS:000363505700002 PM 26497393 ER PT J AU Nelson, JAE Fokar, A Hudgens, MG Compliment, KJ Hawkins, JT Tegha, G Kamwendo, DD Kayira, D Mofolo, IA Kourtis, AP Jamieson, DJ Van Der Horst, CM Fiscus, SA AF Nelson, Julie A. E. Fokar, Ali Hudgens, Michael G. Compliment, Kara J. Hawkins, Justin Tyler Tegha, Gerald Kamwendo, Deborah D. Kayira, Dumbani Mofolo, Innocent A. Kourtis, Athena P. Jamieson, Denise J. Van Der Horst, Charles M. Fiscus, Susan A. TI Frequent nevirapine resistance in infants infected by HIV-1 via breastfeeding while on nevirapine prophylaxis SO AIDS LA English DT Article DE antiretroviral; breastfeeding; HIV transmission; nevirapine resistance; prevention of mother-to-child transmission ID RANDOMIZED CONTROLLED-TRIAL; TO-CHILD TRANSMISSION; ANTIRETROVIRAL DRUGS; EXTENDED NEVIRAPINE; CLINICAL-TRIAL; FOLLOW-UP; PREVENTION; SINGLE; MALAWI; ZIDOVUDINE AB Objective:The objective of this study is to assess nevirapine (NVP) resistance in infants who became infected in the three arms of the Breastfeeding, Antiretrovirals and Nutrition (BAN) study: daily infant NVP prophylaxis, triple maternal antiretrovirals or no extra intervention for 28 weeks of breastfeeding. Design:A prospective cohort study. Methods:The latest available plasma or dried blood spot specimen was tested from infants who became HIV-positive between 3 and 48 weeks of age. Population sequencing was used to detect mutations associated with reverse transcriptase inhibitor resistance. Sequences were obtained from 22 out of 25 transmissions in the infant-NVP arm, 23 out of 30 transmissions in the maternal-antiretroviral arm and 33 out of 38 transmissions in the control arm. Results:HIV-infected infants in the infant-NVP arm were significantly more likely to have NVP resistance than infected infants in the other two arms of the trial, especially during breastfeeding through 28 weeks of age (56% in infant-NVP arm vs. 6% in maternal-antiretroviral arm and 11% in control arm, P=0.004). There was a nonsignificant trend, suggesting that infants with NVP resistance tended to be infected earlier and exposed to NVP while infected for a greater duration than infants without resistance. Conclusion:Infants on NVP prophylaxis during breastfeeding are at a reduced risk of acquiring HIV, but are at an increased risk of NVP resistance if they do become infected. These findings point to the need for frequent HIV testing of infants while on NVP prophylaxis, and for the availability of antiretroviral regimens excluding NVP for treating infants who become infected while on such a prophylactic regimen. Copyright (C) 2015 Wolters Kluwer Health, Inc. All rights reserved. C1 [Nelson, Julie A. E.; Hudgens, Michael G.; Compliment, Kara J.; Hawkins, Justin Tyler; Fiscus, Susan A.] Univ N Carolina, UNC Ctr AIDS Res, Chapel Hill, NC 27599 USA. [Nelson, Julie A. E.; Hawkins, Justin Tyler; Fiscus, Susan A.] Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA. [Fokar, Ali; Van Der Horst, Charles M.] Univ N Carolina, Dept Med, Sch Med, Chapel Hill, NC 27599 USA. [Hudgens, Michael G.] Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Biostat, Chapel Hill, NC 27599 USA. [Tegha, Gerald; Kamwendo, Deborah D.; Kayira, Dumbani; Mofolo, Innocent A.] Univ North Carolina Project, Lilongwe, Malawi. [Kourtis, Athena P.; Jamieson, Denise J.] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA USA. RP Nelson, JAE (reprint author), Univ N Carolina, CB 7295, Chapel Hill, NC 27599 USA. EM jnelson@med.unc.edu FU Prevention Research Centers Special Interest Project of the Centers for Disease Control and Prevention [SIP13-01 U48-CCU409660-09]; IMPAACT Network through UNC IMPAACT Specialty Laboratory [U01-AI068632]; NIH Fogarty AIDS International Training and Research Programme [DHHS/NIH/FIC 2-D43 TW01039-06]; UNC Center for AIDS Research [P30-AI50410]; Fogarty International Clinical Research Scholars Programme [R24 TW007988]; Elizabeth Glaser Pediatric AIDS Foundation; United Nations Children's Fund; World Food Programme; Malawi Ministry of Health and Population; U.S. Agency for International Development; Johnson Johnson FX No conflicts of interest were declared by any of the authors. This project was supported by a grant from the Prevention Research Centers Special Interest Project of the Centers for Disease Control and Prevention (SIP13-01 U48-CCU409660-09), the IMPAACT Network (U01-AI068632) through the UNC IMPAACT Specialty Laboratory, the NIH Fogarty AIDS International Training and Research Programme (DHHS/NIH/FIC 2-D43 TW01039-06), the Fogarty International Clinical Research Scholars Programme (R24 TW007988) and the UNC Center for AIDS Research (P30-AI50410). The antiretrovirals used in the BAN study were donated by Abbott Laboratories, GlaxoSmithKline, Boehringer Ingelheim, Roche Pharmaceuticals and Bristol-Myers Squibb. The Call to Action PMTCT programme was supported by the Elizabeth Glaser Pediatric AIDS Foundation, the United Nations Children's Fund, the World Food Programme, the Malawi Ministry of Health and Population, Johnson & Johnson and the U.S. Agency for International Development. NR 17 TC 1 Z9 1 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0269-9370 EI 1473-5571 J9 AIDS JI Aids PD OCT 23 PY 2015 VL 29 IS 16 BP 2131 EP 2138 DI 10.1097/QAD.0000000000000814 PG 8 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA DB4IQ UT WOS:000368477100001 PM 26186128 ER PT J AU Conley, LJ Bush, TJ Rupert, AW Sereti, I Patel, P Brooks, JT Baker, JV AF Conley, Lois J. Bush, Timothy J. Rupert, Adam W. Sereti, Irini Patel, Pragna Brooks, John T. Baker, Jason V. CA SUN Study Understand Nat Hist HIV TI Obesity is associated with greater inflammation and monocyte activation among HIV-infected adults receiving antiretroviral therapy SO AIDS LA English DT Article DE contemporary antiretroviral therapy; HIV; monocyte activation; obesity; systemic inflammation ID ACQUIRED-IMMUNODEFICIENCY-SYNDROME; T-CELL-ACTIVATION; VIRUS-INFECTION; AIDS; COAGULATION; MORTALITY; RISK; INDIVIDUALS; PREVALENCE; DISEASE AB Objectives:Among virally suppressed HIV-infected persons, we examined the relationship between obesity and alterations in key clinical markers of immune activation and inflammation. These markers have also been associated with excess HIV-related cardiovascular disease and mortality. Methods:We evaluated data from virally suppressed participants in the Study to Understand the Natural History of HIV/AIDS in the Era of Effective Therapy, including inflammatory biomarkers (interleukin-6 and highly sensitive C-reactive protein), monocyte biomarkers [soluble CD163 (sCD163), sCD14], and monocyte immunophenotypes. We assessed associations with these immunologic measures and obesity, via logistic regression preadjustment and postadjustment for demographic and clinical factors, homeostatic model assessment of insulin resistance, and leptin levels. Results:Among 452 evaluable participants, median (interquartile range) age was 41 (36-48) years, CD4(+) cell count was 475 (308-697)cells/l, and 21% were obese (BMI 30kg/m(2)). In univariable models, obesity, smoking, and lower CD4(+) cell count were associated with higher measures of inflammation and monocyte activation. After adjustment, obesity remained independently associated with elevated levels (highest vs. lower two tertiles) of interleukin-6 [odds ratio (OR) 1.96; P = 0.02], highly sensitive C-reactive protein (OR 2.79; P<0.001) and sCD163 (OR 1.94; P=0.02), and elevated frequency of CD14(+)CD16(+) (OR 1.77; P=0.03) and CD14(dim)CD16(+) (OR 1.97; P=0.01). Adjusting for homeostatic model assessment of insulin resistance and leptin modestly affected associations for obesity with inflammation and monocyte activation. Conclusion:Obesity was prevalent and independently associated with greater monocyte activation and systemic inflammation. Research is needed to determine how adipose tissue excess is functionally related to persistent immunologic abnormalities among HIV-infected persons with viral suppression. Copyright (C) 2015 Wolters Kluwer Health, Inc. All rights reserved. C1 [Conley, Lois J.; Bush, Timothy J.; Patel, Pragna; Brooks, John T.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. [Rupert, Adam W.] Frederick Natl Lab Canc Res, Leidos Biomed Res Inc, AIDS Monitoring Lab, Frederick, MD USA. [Sereti, Irini] NIAID, NIH, Bethesda, MD 20892 USA. [Baker, Jason V.] Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA. [Baker, Jason V.] Hennepin Cty Med Ctr, Div Infect Dis, Minneapolis, MN 55415 USA. RP Conley, LJ (reprint author), Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. EM ljc2@cdc.gov FU Intramural Research Program of NIAID/NIH; Leidos Biomedical Research, Inc. [HHSN261200800001E]; US Centers for Disease Control and Prevention [200-2002-00610, 200-2002-00611, 200-2002-00612, 200-2002-00613, 200-2007-23633, 200-2007-23634, 200-2007-23635, 200-2007-23636]; CDC; SUN Study Principal Investigator at Hennepin County Medical Center FX Financial support was provided by the Intramural Research Program of NIAID/NIH, Leidos Biomedical Research, Inc., contract number HHSN261200800001E, and the US Centers for Disease Control and Prevention contract numbers: 200-2002-00610, 200-2002-00611, 200-2002-00612, 200-2002-00613, 200-2007-23633, 200-2007-23634, 200-2007-23635, and 200-2007-23636. As the SUN Study sponsor, the CDC, along with the SUN Study Principal Investigator at Hennepin County Medical Center, and the lead investigator at the National Institute of Allergy and Infectious Disease, were the primary investigators involved with this analysis. They provided the study design, collection, analysis, and interpretation of data, writing of the report, and decision to submit the manuscript for publication at The Lancet HIV. NR 32 TC 8 Z9 8 U1 1 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0269-9370 EI 1473-5571 J9 AIDS JI Aids PD OCT 23 PY 2015 VL 29 IS 16 BP 2201 EP 2207 DI 10.1097/QAD.0000000000000817 PG 7 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA DB4IW UT WOS:000368477700003 PM 26544583 ER PT J AU de Martel, C Shiels, MS Franceschi, S Simard, EP Vignat, J Hall, HI Engels, EA Plummer, M AF de Martel, Catherine Shiels, Meredith S. Franceschi, Silvia Simard, Edgar P. Vignat, Jerome Hall, H. Irene Engels, Eric A. Plummer, Martyn TI Cancers attributable to infections among adults with HIV in the United States SO AIDS LA English DT Article DE AIDS; attributable fraction; cancer; HIV; infection; United States ID ACTIVE ANTIRETROVIRAL THERAPY; HUMAN-IMMUNODEFICIENCY-VIRUS; HEPATOCELLULAR-CARCINOMA; HUMAN-PAPILLOMAVIRUS; RISK-FACTORS; ANAL CANCER; COHORT; POPULATION; WOMEN; METAANALYSIS AB Objective:HIV-infected people are at increased risk of cancers of infectious origin. We estimated the burden of cancer attributable to infections among HIV-infected people in the United States in 2008.Design:Incidence rates for cancer sites associated with infections were estimated from record linkage between HIV/AIDS registries and cancer registries.Methods:Rates were applied to estimates of the population living with diagnosed HIV in the United States in 2008 to obtain the number of incident cancer cases. Site-specific attributable fractions and corresponding 95% confidence intervals (CIs) were estimated from infection prevalence among cancer cases. Infection prevalence data were derived from literature review of case series.Results:Of an estimated 6200 incident cancer cases (95% CI 6000-6500), 2500 (95% CI 2400-2700) were attributable to infection (attributable fraction = 40%, 95% CI 39-42). The most important infections were Kaposi sarcoma herpes virus, Epstein-Barr virus, and human papillomavirus, which together were responsible for 2200 new cancer cases (95% CI 2100-2400), mainly Kaposi sarcoma, lymphomas, and ano-genital cancers. The attributable fraction in HIV-infected people was highest in the age group 20-29 years (69%, 95% CI 65-72). MSM were the HIV transmission group with the highest attributable fraction (48%, 95% CI 46-50), due to the high incidence of both Kaposi sarcoma and anal cancer.Conclusion:The very high fraction of cancer attributable to infection in HIV-infected people points to special opportunities to prevent these cancers, that is, avoidance, detection, and early treatment of cancer-associated infections, and universal early detection and uninterrupted treatment of HIV infection to avoid immunosuppression. C1 [de Martel, Catherine; Franceschi, Silvia; Vignat, Jerome; Plummer, Martyn] Int Agcy Res Canc, F-69372 Lyon 08, France. [Shiels, Meredith S.; Engels, Eric A.] NCI, Rockville, MD USA. [Simard, Edgar P.] Amer Canc Soc, Atlanta, GA 30329 USA. [Hall, H. Irene] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Plummer, M (reprint author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon 08, France. EM plummerm@iarc.fr FU Fondation de France [00039621]; Intramural Research Program of the National Cancer Institute, NCI; Bill & Melinda Gates Foundation [OPP1053353] FX The present study was supported by a grant from the Fondation de France (Grant number: 00039621) and by the Intramural Research Program of the National Cancer Institute, NCI. C.deM. was partly supported by a grant from the Bill & Melinda Gates Foundation (OPP1053353). NR 34 TC 8 Z9 8 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0269-9370 EI 1473-5571 J9 AIDS JI Aids PD OCT 23 PY 2015 VL 29 IS 16 BP 2173 EP 2181 DI 10.1097/QAD.0000000000000808 PG 9 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA DB4IU UT WOS:000368477500001 PM 26182198 ER PT J AU Hopkins, DR Ruiz-Tiben, E Eberhard, ML Roy, SL AF Hopkins, Donald R. Ruiz-Tiben, Ernesto Eberhard, Mark L. Roy, Sharon L. TI Progress Toward Global Eradication of Dracunculiasis, January 2014-June 2015 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Editorial Material ID CHAD C1 [Hopkins, Donald R.; Ruiz-Tiben, Ernesto] Emory Univ, Carter Ctr, Atlanta, GA 30322 USA. [Eberhard, Mark L.] CDC, Ctr Global Hlth, Div Parasit Dis & Malaria, Atlanta, GA 30333 USA. [Roy, Sharon L.] Natl Ctr Emerging & Zoonot Infect Dis, Div Foodborne Waterborne & Environm Dis, Atlanta, GA 30333 USA. [Roy, Sharon L.] WHO, Collaborating Ctr Res Training & Eradicat Dracunc, CDC, Geneva, Switzerland. RP Roy, SL (reprint author), Natl Ctr Emerging & Zoonot Infect Dis, Div Foodborne Waterborne & Environm Dis, Atlanta, GA 30333 USA. EM slroy@cdc.gov NR 8 TC 3 Z9 3 U1 5 U2 16 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD OCT 23 PY 2015 VL 64 IS 41 BP 1161 EP 1165 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DA5CN UT WOS:000367819800001 PM 26492134 ER PT J AU Mbaeyi, C Saatcioglu, A Tangermann, RH Hadler, S Ehrhardt, D AF Mbaeyi, Chukwuma Saatcioglu, Akif Tangermann, Rudolf H. Hadler, Stephen Ehrhardt, Derek TI Progress Toward Poliomyelitis Eradication - Afghanistan, January 2014-August 2015 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Editorial Material ID POLIO ERADICATION; WORLDWIDE C1 [Mbaeyi, Chukwuma; Ehrhardt, Derek] WHO, Ctr Global Hlth, CDC, Global Immunizat Div, Geneva, Switzerland. [Saatcioglu, Akif; Tangermann, Rudolf H.] WHO, Polio Eradicat Dept, Geneva, Switzerland. [Hadler, Stephen] CDC, Natl Ctr Immunizat & Resp Dis, Div Bacterial Dis, Atlanta, GA 30333 USA. RP Mbaeyi, C (reprint author), WHO, Ctr Global Hlth, CDC, Global Immunizat Div, Geneva, Switzerland. EM cmbaeyi@cdc.gov NR 10 TC 6 Z9 6 U1 0 U2 2 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD OCT 23 PY 2015 VL 64 IS 41 BP 1166 EP 1170 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DA5CN UT WOS:000367819800002 PM 26492280 ER PT J AU MacNeil, JR Rubin, L Folaranmi, T Ortega-Sanchez, IR Patel, M Martin, SW AF MacNeil, Jessica R. Rubin, Lorry Folaranmi, Temitope Ortega-Sanchez, Ismael R. Patel, Manisha Martin, Stacey W. TI Use of Serogroup B Meningococcal Vaccines in Adolescents and Young Adults: Recommendations of the Advisory Committee on Immunization Practices, 2015 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Editorial Material ID HEALTHY ADOLESCENTS; OBSERVER-BLIND; TRIAL; IMMUNOGENICITY; TOLERABILITY; RECOMBINANT; RESPONSES; 4CMENB C1 [MacNeil, Jessica R.; Folaranmi, Temitope; Patel, Manisha; Martin, Stacey W.] CDC, Natl Ctr Immunizat & Resp Dis, Div Bacterial Dis, Meningitis & Vaccine Preventable Dis Branch, Hempstead, NY 11552 USA. [Rubin, Lorry] New York & Hofstra North Shore LIJ Sch Med, Advisory Comm Immunizat Practices Meningococcal V, Steven & Alexandra Cohen Childrens Med Ctr New Yo, New Hyde Pk, Hempstead, NY USA. [Folaranmi, Temitope] CDC, Epidem Intelligence Serv, Hempstead, NY USA. [Ortega-Sanchez, Ismael R.] CDC, Natl Ctr Immunizat & Resp Dis, Div Viral Dis, Hempstead, NY USA. RP MacNeil, JR (reprint author), CDC, Natl Ctr Immunizat & Resp Dis, Div Bacterial Dis, Meningitis & Vaccine Preventable Dis Branch, Hempstead, NY 11552 USA. EM jmacneil@cdc.gov NR 19 TC 32 Z9 32 U1 2 U2 2 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD OCT 23 PY 2015 VL 64 IS 41 BP 1171 EP 1176 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DA5CN UT WOS:000367819800003 PM 26492381 ER PT J AU Edens, C Liebich, L Halpin, AL Moulton-Meissner, H Eitniear, S Zgodzinski, E Vasko, L Grossman, D Perz, JF Mohr, MC AF Edens, Chris Liebich, Lauren Halpin, Alison Laufer Moulton-Meissner, Heather Eitniear, Samantha Zgodzinski, Eric Vasko, Larry Grossman, David Perz, Joseph F. Mohr, Marika C. TI Mycobacterium chelonae Eye Infections Associated with Humidifier Use in an Outpatient LASIK Clinic - Ohio, 2015 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID SURGERY C1 [Edens, Chris; Halpin, Alison Laufer; Moulton-Meissner, Heather; Perz, Joseph F.] CDC, Natl Ctr Emerging & Zoonot Infect Dis, Div Healthcare Qual Promot, Atlanta, GA 30333 USA. [Edens, Chris] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Liebich, Lauren; Eitniear, Samantha; Zgodzinski, Eric; Vasko, Larry; Grossman, David] Toledo Lucas Cty Dept Publ Hlth, Toledo, OH USA. [Mohr, Marika C.] Ohio Dept Publ Health, Toledo, OH USA. RP Edens, C (reprint author), CDC, Natl Ctr Emerging & Zoonot Infect Dis, Div Healthcare Qual Promot, Atlanta, GA 30333 USA. EM wedens@cdc.gov RI Laufer Halpin, Alison/E-5453-2015 OI Edens, William/0000-0002-7563-6201; Laufer Halpin, Alison/0000-0003-1643-1617 NR 6 TC 3 Z9 3 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD OCT 23 PY 2015 VL 64 IS 41 BP 1177 EP 1177 PG 1 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DA5CN UT WOS:000367819800004 PM 26492452 ER PT J AU Kalb, SR Baudys, J Barr, JR AF Kalb, Suzanne R. Baudys, Jakub Barr, John R. TI Detection of the HA-33 protein in botulinum neurotoxin type G complex by mass spectrometry SO BMC MICROBIOLOGY LA English DT Article DE Botulinum neurotoxin; Botulism; Mass spectrometry ID NEUROTRANSMITTER RELEASE; MOLECULAR COMPOSITION; PROGENITOR TOXINS; SEROTYPE-A; SNAP-25; CLEAVES; GENES; BOND; VAMP/SYNAPTOBREVIN; IDENTIFICATION AB Background: The disease botulism is caused by intoxication with botulinum neurotoxins (BoNTs), extremely toxic proteins which cause paralysis. This neurotoxin is produced by some members of the Clostridium botulinum and closely related species, and is produced as a protein complex consisting of the neurotoxin and neurotoxin-associated proteins (NAPs). There are seven known serotypes of BoNT, A-G, and the composition of the NAPs can differ between these serotypes. It was previously published that the BoNT/G complex consisted of BoNT/G, nontoxic-nonhemagglutinin (NTNH), Hemagglutinin 70 (HA-70), and HA-17, but that HA-33, a component of the protein complex of other serotypes of BoNT, was not found. Methods: Components of the BoNT/G complex were first separated by SDS-PAGE, and bands corresponding to components of the complex were digested and analyzed by LC-MS/MS. Results: Gel bands were identified with sequence coverages of 91 % for BoNT/G, 91 % for NTNH, 89 % for HA-70, and 88 % for HA-17. Notably, one gel band was also clearly identified as HA-33 with 93 % sequence coverage. Conclusions: The BoNT/G complex consists of BoNT/G, NTNH, HA-70, HA-17, and HA-33. These proteins form the progenitor form of BoNT/G, similar to all other HA positive progenitor toxin complexes. C1 [Kalb, Suzanne R.; Baudys, Jakub; Barr, John R.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Div Sci Lab, Atlanta, GA 30341 USA. RP Barr, JR (reprint author), Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Div Sci Lab, 4770 Buford Hwy NE, Atlanta, GA 30341 USA. EM jbarr@cdc.gov FU Office of Public Health Preparedness and Response, Centers for Disease Control and Prevention FX The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. Funding for this work was provided by the Office of Public Health Preparedness and Response, Centers for Disease Control and Prevention. NR 31 TC 0 Z9 0 U1 2 U2 5 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2180 J9 BMC MICROBIOL JI BMC Microbiol. PD OCT 23 PY 2015 VL 15 AR 227 DI 10.1186/s12866-015-0567-5 PG 5 WC Microbiology SC Microbiology GA CU2VO UT WOS:000363381900003 PM 26494251 ER PT J AU Malvagia, S Haynes, CA Grisotto, L Ombrone, D Funghini, S Moretti, E McGreevy, KS Biggeri, A Guerrini, R Yahyaoui, R Garg, U Seeterlin, M Chace, D De Jesus, VR la Marca, G AF Malvagia, Sabrina Haynes, Christopher A. Grisotto, Laura Ombrone, Daniela Funghini, Silvia Moretti, Elisa McGreevy, Kathleen S. Biggeri, Annibale Guerrini, Renzo Yahyaoui, Raquel Garg, Uttam Seeterlin, Mary Chace, Donald De Jesus, Victor R. la Marca, Giancarlo TI Heptadecanoylcarnitine (C17) a novel candidate biomarker for newborn screening of propionic and methylmalonic acidemias SO CLINICA CHIMICA ACTA LA English DT Article DE Propionic acidemia; Methylmalonic acidemia; Expanded newborn screening; Acylcarnitine; Heptadecanoylcarnitine; Propionylcarnitine ID TANDEM MASS-SPECTROMETRY; DRIED BLOOD SPOTS; CHAIN FATTY-ACIDS; INBORN-ERRORS; METABOLISM; DIAGNOSIS; ACIDURIA; PROPIONYLCARNITINE; VITAMIN-B-12; DEFICIENCY AB Background: 3-Hydroxypalmitoleoyl-carnitine (C16:1-OH) has recently been reported to be elevated in acylcarnitine profiles of patients with propionic acidemia (PA) or methylmalonic acidemia (MMA) during expanded newborn screening (NBS). High levels of C16:1-OH, combined with other hydroxylated long chain acylcamitines are related to long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency (LCHADD) and trifunctional protein (TFP) deficiency. Methods: The acylcarnitine profile of two LCHADD patients was evaluated using liquid chromatography-tandem mass spectrometric method. A specific retention time was determined for each hydroxylated long chain acylcarnitine. The same method was applied to some neonatal dried blood spots (DBSs) from PA and MMA patients presenting abnormal C16:1-OH concentrations. Results: The retention time of the peak corresponding to C16:1-OH in LCHADD patients differed from those in MMA and PA patients. Heptadecanoylcarnitine (C17) has been identified as the novel biomarker specific for PA and MMA patients through high resolution mass spectrometry (Orbitrap) experiments. We found that 21 out of 23 neonates (22 MMA, and IPA) diagnosed through the Tuscany region NBS program exhibited significantly higher levels of C17 compared to controls. Twenty-three maternal deficiency (21 vitamin B12 deficiency, 1 homocystinuria and 1 gastrin deficiency) samples and 82 false positive for elevated propionylcarnitine (C3) were also analyzed. Conclusions: We have characterized a novel biomarker able to detect propionate disorders during expanded newborn screening (NBS). The use of this new biomarker may improve the analytical performances of NBS programs especially in laboratories where second tier tests are not performed. (C) 2015 Elsevier B.V. All rights reserved. C1 [Malvagia, Sabrina; Ombrone, Daniela; Funghini, Silvia; la Marca, Giancarlo] Meyer Childrens Univ Hosp, Pediat Neurol Unit & Labs, Newborn Screening Biochem & Pharmacol Lab, I-50139 Florence, Italy. [Haynes, Christopher A.; De Jesus, Victor R.] Ctr Dis Control & Prevent, Newborn Screening & Mol Biol Branch, Atlanta, GA USA. [Grisotto, Laura; Biggeri, Annibale] Univ Florence, Dept Stat Comp Sci & Applicat G Parenti, Florence, Italy. [Moretti, Elisa] Chiesi Farmaceut SPA, Analyt & Early Formulat Dept, Parma, Italy. [McGreevy, Kathleen S.] Meyer Childrens Univ Hosp, Res Innovat & Int Relat Off, I-50139 Florence, Italy. [Guerrini, Renzo] Meyer Childrens Univ Hosp, Pediat Neurol Unit & Labs, I-50139 Florence, Italy. [Yahyaoui, Raquel] Malaga Reg Hosp, Newborn Screening & Clin Lab, Malaga, Spain. [Garg, Uttam] Childrens Mercy Hosp, Dept Pathol & Lab Med, Kansas City, MO 64108 USA. [Seeterlin, Mary] Bur Labs Chem & Toxicol, Newborn Screening Sect, Michigan Dept Community Hlth, Lansing, MI USA. [Chace, Donald] Pediatrix Ctr Res Educ & Qual Pediatrix Med Grp, Concord Terrace Sunrise, FL USA. RP la Marca, G (reprint author), Meyer Childrens Univ Hosp, Pediat Neurol Unit & Labs, Newborn Screening Biochem & Pharmacol Lab, Viale Pieraccini 24, I-50139 Florence, Italy. EM g.lamarca@meyer.it OI Yahyaoui, Raquel/0000-0001-6789-1563; la marca, giancarlo/0000-0003-3319-7260 NR 23 TC 3 Z9 3 U1 2 U2 6 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0009-8981 EI 1873-3492 J9 CLIN CHIM ACTA JI Clin. Chim. Acta PD OCT 23 PY 2015 VL 450 BP 342 EP 348 DI 10.1016/j.cca.2015.09.012 PG 7 WC Medical Laboratory Technology SC Medical Laboratory Technology GA CV4TN UT WOS:000364259500055 PM 26368264 ER PT J AU Mues, KE Lammie, PJ Klein, M Kleinbaum, DG Addiss, D Fox, LM AF Mues, Katherine E. Lammie, Patrick J. Klein, Mitchel Kleinbaum, David G. Addiss, David Fox, LeAnne M. TI Changes in Antibody Levels during and following an Episode of Acute Adenolymphangitis (ADL) among Lymphedema Patients in Leogane, Haiti SO PLOS ONE LA English DT Article ID ELIMINATE LYMPHATIC FILARIASIS; PAPUA-NEW-GUINEA; BANCROFTIAN FILARIASIS; ENDEMIC COMMUNITY; IMMUNE-RESPONSE; MASS TREATMENT; BRUGIA-MALAYI; INFECTION; AREA; FREQUENCY AB Introduction Episodes of acute adenolymphangitis (ADL) are often the first clinical sign of lymphatic filariasis (LF). They are often accompanied by swelling of the affected limb, inflammation, fever, and general malaise and lead to the progression of lymphedema. Although ADL episodes have been studied for a century or more, questions still remain as to their etiology. We quantified antibody levels to pathogens that potentially contribute to ADL episodes during and after an episode among lymphedema patients in Leogane, Haiti. We estimated the proportion of ADL episodes hypothesized to be attributed to specific pathogens. Methods We measured antibody levels to specific pathogens during and following an ADL episode among 41 lymphedema patients enrolled in a cohort study in Leogane, Haiti. We calculated the absolute and relative changes in antibody levels between the ADL and convalescent time points. We calculated the proportion of episodes that demonstrated a two-fold increase in antibody level for several bacterial, fungal, and filarial pathogens. Results Our results showed the greatest proportion of two-fold changes in antibody levels for the carbohydrate antigen Streptococcus group A, followed by IgG2 responses to a soluble filarial antigen (BpG2), Streptococcal Pyrogenic Exotoxin B, and an antigen for the fungal pathogen Candida. When comparing the median antibody level during the ADL episode to the median antibody level at the convalescent time point, only the antigens for Pseudomonas species (P-value = 0.0351) and Streptolysin O (P-value = 0.0074) showed a significant result. Conclusion Although our results are limited by the lack of a control group and few antibody responses, they provide some evidence for infection with Streptococcus A as a potential contributing factor to ADL episodes. Our results add to the current evidence and illustrate the importance of determining the causal role of bacterial and fungal pathogens and immunological antifilarial response in ADL episodes. C1 [Mues, Katherine E.; Klein, Mitchel; Kleinbaum, David G.] Emory Univ, Dept Epidemiol, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. [Mues, Katherine E.; Klein, Mitchel; Kleinbaum, David G.] Emory Univ, Laney Grad Sch, Atlanta, GA 30322 USA. [Lammie, Patrick J.; Fox, LeAnne M.] Ctr Dis Control & Prevent, Parasit Dis Branch, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA USA. [Addiss, David] Task Force Global Hlth, Decatur, GA USA. RP Mues, KE (reprint author), Emory Univ, Dept Epidemiol, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. EM Katie.mues@gmail.com FU Office of Women's Health, U.S. Centers for Disease Control and Prevention, Atlanta, Georgia; WHO/UNDP/World Bank Special Programme for Research and Training in Tropical Diseases (Filariasis Operational Research Project) [950568]; Emory University, Laney Graduate School FX This study was funded by grants from the Office of Women's Health (http://www.cdc.gov/women/), U.S. Centers for Disease Control and Prevention, Atlanta, Georgia; and the WHO/UNDP/World Bank Special Programme for Research and Training in Tropical Diseases (Filariasis Operational Research Project No. 950568) (http://apps.who.int/tdr/index.html). KEM was supported in part by Emory University, Laney Graduate School. The content is solely the responsibility of the authors and does not necessarily represent the official views of the Centers for Disease Control and Prevention. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 38 TC 0 Z9 0 U1 0 U2 1 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD OCT 22 PY 2015 VL 10 IS 10 AR e0141047 DI 10.1371/journal.pone.0141047 PG 13 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CU0ZU UT WOS:000363249300025 PM 26492462 ER PT J AU Mirabelli, MC Beavers, SF Shepler, SH Chatterjee, AB AF Mirabelli, Maria C. Beavers, Suzanne F. Shepler, Samantha H. Chatterjee, Arjun B. TI Age at asthma onset and asthma self-management education among adults in the United States SO JOURNAL OF ASTHMA LA English DT Article DE Behavior; epidemiology; health; prevention; respiratory; surveillance ID OLDER-ADULTS; ACTIVE ASTHMA; ADHERENCE; OUTCOMES; SURVEILLANCE; CHILDREN; PROGRAM; TRIAL AB Objective: Asthma self-management education improves asthma-related outcomes. We conducted this analysis to evaluate variation in the percentages of adults with active asthma reporting components of asthma self-management education by age at asthma onset. Methods: Data from 2011 to 2012 Asthma Call-back Surveys were used to estimate percentages of adults with active asthma reporting six components of asthma self-management education. Components of asthma self-management education include having been taught to what to do during an asthma attack and receiving an asthma action plan. Differences in the percentages of adults reporting each component and the average number of components reported across categories of age at asthma onset were estimated using linear regression, adjusted for age, education, race/ethnicity, sex, smoking status, and years since asthma onset. Results: Overall, an estimated 76.4% of adults with active asthma were taught what to do during an asthma attack and 28.7% reported receiving an asthma action plan. Percentages reporting each asthma self-management education component declined with increasing age at asthma onset. Compared with the referent group of adults whose asthma onset occurred at 5-14 years of age, the percentage of adults reporting being taught what to do during an asthma attack was 10% lower among those whose asthma onset occurred at 65-93 years of age (95% CI: -18.0, -2.5) and the average number of components reported decreased monotonically across categories of age at asthma onset of 35 years and older. Conclusions: Among adults with active asthma, reports of asthma self-management education decline with increasing age at asthma onset. C1 [Mirabelli, Maria C.; Beavers, Suzanne F.] Ctr Dis Control & Prevent, Air Pollut & Resp Hlth Branch, Div Environm Hazards & Hlth Effects, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA. [Shepler, Samantha H.] Emory Univ, Dept Biostat, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. [Chatterjee, Arjun B.] Wake Forest Sch Med, Sect Pulm Crit Care Allergy & Immunol Dis, Dept Internal Med, Winston Salem, NC USA. RP Mirabelli, MC (reprint author), Ctr Dis Control & Prevent, Air Pollut & Resp Hlth Branch, Natl Ctr Environm Hlth, 4770 Buford Hwy,NE Mailstop F-60, Atlanta, GA 30341 USA. EM zif7@cdc.gov FU Intramural CDC HHS [CC999999] NR 26 TC 0 Z9 0 U1 0 U2 2 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 0277-0903 EI 1532-4303 J9 J ASTHMA JI J. Asthma PD OCT 21 PY 2015 VL 52 IS 9 BP 974 EP 980 DI 10.3109/02770903.2015.1020389 PG 7 WC Allergy; Respiratory System SC Allergy; Respiratory System GA CY2NU UT WOS:000366246200017 PM 26291134 ER PT J AU Zitomer, N Rybak, ME Li, Z Walters, MJ Holman, MR AF Zitomer, Nicholas Rybak, Michael E. Li, Zhong Walters, Matthew J. Holman, Matthew R. TI Determination of Aflatoxin B-1 in Smokeless Tobacco Products by Use of UHPLC-MS/MS SO JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY LA English DT Article DE aflatoxins; smokeless tobacco; chewing tobacco; UHPLC-MS/MS; immunoaffinity column chromatography ID CHROMATOGRAPHY/TANDEM MASS-SPECTROMETRY; SOLID-PHASE EXTRACTION; LIQUID-CHROMATOGRAPHY; ISOTOPE-DILUTION; CLEANUP AB This work developed a UHPLC-MS/MS method for the detection and quantitation of aflatoxins in smokeless tobacco products, which was then used to determine aflatoxin B-1 concentrations in 32 smokeless tobacco products commercially available in the United States. Smokeless tobacco products were dried, milled, and amended with C-13(17)-labeled internal standards, extracted in water/methanol solution in the presence of a surfactant, isolated through use of immunoaffinity column chromatography, and reconstituted in mobile phase prior to UHPLC-MS/MS analysis. The method was capable of baseline separation of aflatoxins B-1, B-2, G(1), and G(2) in a 2.5 min run by use of a fused core C-18 column and a water/methanol gradient. MS/MS transition (m/z) 313.3 -> 241.2 was used for aflatoxin B-1 quantitation, with 313.3 -> 285.1 used for confirmation. The limit of detection (LOD) for aflatoxin B-1 was 0.007 parts per billion (ppb). Method imprecision for aflatoxin B1 (expressed as coefficient of variation) ranged from 5.5 to 9.4%. Spike recoveries were 105-111%. Aflatoxin B-1, concentrations in the smokeless tobacco products analyzed ranged from = 18 years hospitalized with an acute respiratory infection (ARI). Results Among 1595 adults admitted with ARI, 1363 (82%) had either urine testing (n = 1286) or blood culture (n = 338) performed. Of these, 188 (14%) had pneumococcal pneumonia, including 173 detected by urine only, 8 by blood culture only, and 7 by both methods. Incidence rates increased with age, with the lowest rate among 18-24 year-olds (2.75/100,000) and the highest among >= 65 year-olds (31.3/100,000). The adjusted incidence of hospitalized pneumococcal pneumonia was 18.6/100,000 overall, with in-hospital mortality of 5%. Conclusions An important burden of hospitalized pneumococcal pneumonia in adults was described, particularly for the elderly. However, even adjusted rates likely underestimate the true burden of pneumococcal pneumonia in the community. These data provide a baseline against which to measure the indirect effects of the 2013 introduction of the pneumococcal conjugate vaccine in children in Guatemala. C1 [Contreras, Carmen Luca; Lopez, Maria Renee; Bernart, Chris; Moscoso, Fabiola; Roldan, Aleida; McCracken, John P.] Univ Valle Guatemala, Ctr Hlth Studies, Guatemala City, Guatemala. [Verani, Jennifer R.] Ctr Dis Control & Prevent CDC, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [Paredes, Antonio] Minist Publ Hlth & Social Welf MSPAS, Natl Ctr Epidemiol, Guatemala City, Guatemala. [Arvelo, Wences; Lindblade, Kim A.] Ctr Dis Control & Prevent CDC, Div Global Dis Detect & Emergency Response, Atlanta, GA USA. RP Contreras, CL (reprint author), Univ Valle Guatemala, Ctr Hlth Studies, Guatemala City, Guatemala. EM ccontreras@ces.uvg.edu.gt FU US Centers for Disease Control and Prevention (CDC) [1U01GH000028] FX This work was supported by Cooperative Agreement Number 1U01GH000028 from the US Centers for Disease Control and Prevention (CDC). The CDC participated in all aspects of study design, data collection, data analysis and manuscript preparation. NR 54 TC 1 Z9 1 U1 0 U2 4 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD OCT 21 PY 2015 VL 10 IS 10 AR e0140939 DI 10.1371/journal.pone.0140939 PG 14 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CU0ZM UT WOS:000363248400083 PM 26488871 ER PT J AU Zuo, HJ Chen, XR Cai, Y Wang, JW Hong, YL Ma, JX AF Zuo, Huijuan Chen, Xiaorong Cai, Ying Wang, Jinwen Hong, Yuling Ma, Jixiang TI Analysis on home blood pressure monitoring and blood pressure control among patients with hypertension in part of urban and rural areas in China SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Meeting Abstract CT 26th Great Wall International Congress of Cardiology (GW-ICC) / Asia Pacific Heart Congress (APHC) / International Congress of Cardiovascular Prevention and Rehabilitation (ICCPR) CY OCT 29-NOV 01, 2015 CL Beijing, PEOPLES R CHINA C1 [Zuo, Huijuan; Wang, Jinwen] Capital Univ Med Sci, Beijing Anzhen Hosp, Beijing Inst Heart Lung & Blood Vessel Dis, Beijing, Peoples R China. [Chen, Xiaorong; Ma, Jixiang] Chinese Ctr Dis Control & Prevent, Beijing, Peoples R China. [Cai, Ying; Hong, Yuling] US Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 EI 1558-3597 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD OCT 20 PY 2015 VL 66 IS 16 SU S MA GW26-e1828 BP C123 EP C123 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA CY3LC UT WOS:000366310000443 ER PT J AU Richardson, DB Cardis, E Daniels, RD Gillies, M O'Hagan, JA Hamra, GB Haylock, R Laurier, D Leuraud, K Moissonnier, M Schubauer-Berigan, MK Thierry-Chef, I Kesminiene, A AF Richardson, David B. Cardis, Elisabeth Daniels, Robert D. Gillies, Michael O'Hagan, Jacqueline A. Hamra, Ghassan B. Haylock, Richard Laurier, Dominique Leuraud, Klervi Moissonnier, Monika Schubauer-Berigan, Mary K. Thierry-Chef, Isabelle Kesminiene, Ausrele TI Risk of cancer from occupational exposure to ionising radiation: retrospective cohort study of workers in France, the United Kingdom, and the United States (INWORKS) SO BMJ-BRITISH MEDICAL JOURNAL LA English DT Article ID ATOMIC-BOMB SURVIVORS; COMBINED MORTALITY DATA; NUCLEAR-FUELS PLC; HANFORD SITE; NATIONAL-REGISTRY; WEAPONS-PLANT; SOLID CANCER; CHILDHOOD; ENERGY; IRRADIATION AB STUDY QUESTION Is protracted exposure to low doses of ionising radiation associated with an increased risk of solid cancer? METHODS In this cohort study, 308 297 workers in the nuclear industry from France, the United Kingdom, and the United States with detailed monitoring data for external exposure to ionising radiation were linked to death registries. Excess relative rate per Gy of radiation dose for mortality from cancer was estimated. Follow-up encompassed 8.2 million person years. Of 66 632 known deaths by the end of follow-up, 17 957 were due to solid cancers. STUDY ANSWER AND LIMITATIONS Results suggest a linear increase in the rate of cancer with increasing radiation exposure. The average cumulative colon dose estimated among exposed workers was 20.9 mGy (median 4.1 mGy). The estimated rate of mortality from all cancers excluding leukaemia increased with cumulative dose by 48% per Gy (90% confidence interval 20% to 79%), lagged by 10 years. Similar associations were seen for mortality from all solid cancers (47% (18% to 79%)), and within each country. The estimated association over the dose range of 0-100 mGy was similar in magnitude to that obtained over the entire dose range but less precise. Smoking and occupational asbestos exposure are potential confounders; however, exclusion of deaths from lung cancer and pleural cancer did not affect the estimated association. Despite substantial efforts to characterise the performance of the radiation dosimeters used, the possibility of measurement error remains. WHAT THIS STUDY ADDS The study provides a direct estimate of the association between protracted low dose exposure to ionising radiation and solid cancer mortality. Although high dose rate exposures are thought to be more dangerous than low dose rate exposures, the risk per unit of radiation dose for cancer among radiation workers was similar to estimates derived from studies of Japanese atomic bomb survivors. Quantifying the cancer risks associated with protracted radiation exposures can help strengthen the foundation for radiation protection standards. FUNDING, COMPETING INTERESTS, DATA SHARING Support from the US Centers for Disease Control and Prevention; Ministry of Health, Labour and Welfare of Japan; Institut de Radioprotection et de Surete Nucleaire; AREVA; Electricite de France; US National Institute for Occupational Safety and Health; US Department of Energy; and Public Health England. Data are maintained and kept at the International Agency for Research on Cancer. C1 [Richardson, David B.] Univ N Carolina, Sch Publ Hlth, Dept Epidemiol, Chapel Hill, NC 27599 USA. [Cardis, Elisabeth] Ctr Res Environm Epidemiol, Barcelona, Spain. [Cardis, Elisabeth] Univ Pompeu Fabra, Barcelona, Spain. [Cardis, Elisabeth] CIBER Epidemiol & Salud Publ, Madrid, Spain. [Daniels, Robert D.; Schubauer-Berigan, Mary K.] NIOSH, Cincinnati, OH 45226 USA. [Gillies, Michael; O'Hagan, Jacqueline A.; Haylock, Richard] Publ Hlth England, Ctr Radiat Chem & Environm Hazards, Chilton, England. [Hamra, Ghassan B.] Drexel Univ, Sch Publ Hlth, Dept Environm & Occupat Hlth, Philadelphia, PA 19104 USA. [Laurier, Dominique; Leuraud, Klervi] Inst Radioprotect & Surete Nucl, Fontenay Aux Roses, France. [Moissonnier, Monika; Thierry-Chef, Isabelle; Kesminiene, Ausrele] Int Agcy Res Canc, F-69372 Lyon, France. RP Richardson, DB (reprint author), Univ N Carolina, Sch Publ Hlth, Dept Epidemiol, Chapel Hill, NC 27599 USA. EM david.richardson@unc.edu RI Cardis, Elisabeth/C-3904-2017 FU US Centers for Disease Control and Prevention [5RO3 OH010056-02]; Ministry of Health, Labour and Welfare of Japan [2012-02-21-01]; AREVA; EDF; National Institute for Occupational Safety and Health; US Department of Energy; US Department of Health and Human Services; University of North Carolina from the National Institute for Occupational Safety and Health [R03 OH-010056] FX This work was partly funded by the US Centers for Disease Control and Prevention (5RO3 OH010056-02) and Ministry of Health, Labour and Welfare of Japan (GA No 2012-02-21-01). The French cohort was coordinated by IRSN, with part funding from AREVA and EDF. US funding was provided by the National Institute for Occupational Safety and Health, US Department of Energy through an agreement with the US Department of Health and Human Services and a grant received by the University of North Carolina from the National Institute for Occupational Safety and Health (R03 OH-010056). The UK cohort was coordinated by Public Health England who operates the UK's National Registry for Radiation Workers. The sponsors had no role in the study design, the data analysis, and interpretation, or the writing of the report. NR 48 TC 22 Z9 24 U1 1 U2 10 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1756-1833 J9 BMJ-BRIT MED J JI BMJ-British Medical Journal PD OCT 20 PY 2015 VL 351 AR h5359 DI 10.1136/bmj.h5359 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA CV3FJ UT WOS:000364143900006 PM 26487649 ER PT J AU Wei, BN Wang, LQ Blount, BC AF Wei, Binnian Wang, Lanqing Blount, Benjamin C. TI Analysis of Cannabinoids and Their Metabolites in Human Urine SO ANALYTICAL CHEMISTRY LA English DT Article ID TANDEM MASS-SPECTROMETRY; GLUCURONIDATED CANNABINOIDS; PLASMA; STABILITY; MARIJUANA AB Biologically monitoring marijuana exposure from active and passive use requires both a wide linear range and sensitive detection. We have developed and validated a multifunctional method using ultrahigh performance liquid chromatography coupled with tandem mass spectrometry (UHPLC-MS/MS) for analysis of urinary Delta 9-tetrahydrocannabinol (THC), cannabidiol and cannabinol, and two major metabolites of THC, 11-nor-9-carboxy-THC and 11-hydroxy-THC, in active users and particularly in people exposed to secondhand marijuana smoke (SHMS). The method used positive electrospray ionization (ESI) mode to reach the sensitivity needed to detect trace SHMS exposure with limits of detection (LOD) ranging from 0.002 to 0.008 nanograms per milliliter (ng/mL) and 0.005 to 0.017 ng/mL for "free" (unconjugated forms) and "total" (unconjugated plus conjugated forms) measurements, respectively. These LODs were approximately 10-100 times more sensitive than those reported in the literature. To reduce or avoid time-consuming repetitive sample preparation and analysis, the method simultaneously monitored multiple reaction monitoring transitions in negative ESI mode to quantify high analyte levels typically found in the urine of active marijuana users (linear dynamic range of 12.5-800 ng/mL). The validation results indicated this method was accurate (average inter/intra-day bias, <10%), precise (inter/intra-day imprecision, <10%), and fast (6 min run time). In addition, sample preparation throughput was greatly improved using an automation liquid-handling system, meeting the needs for potential largescale population studies. C1 [Wei, Binnian; Wang, Lanqing; Blount, Benjamin C.] Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA 30041 USA. RP Wei, BN (reprint author), Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, 4770 Buford Highway,NE Rd,Mail Stop F44, Atlanta, GA 30041 USA. EM bwei@cdc.gov OI Wei, Binnian/0000-0003-0465-9964 FU Intramural CDC HHS [CC999999] NR 15 TC 5 Z9 5 U1 9 U2 35 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 0003-2700 EI 1520-6882 J9 ANAL CHEM JI Anal. Chem. PD OCT 20 PY 2015 VL 87 IS 20 BP 10183 EP 10187 DI 10.1021/acs.analchem.5b02603 PG 5 WC Chemistry, Analytical SC Chemistry GA CU2IX UT WOS:000363348300005 PM 26411292 ER PT J AU Chacon, R Clara, AW Jara, J Armero, J Lozano, C El Omeiri, N Widdowson, MA Azziz-Baumgartner, E AF Chacon, Rafael Wilfrido Clara, Alexey Jara, Jorge Armero, Julio Lozano, Celina El Omeiri, Nathalie Widdowson, Marc-Alain Azziz-Baumgartner, Eduardo TI Influenza Illness among Case-Patients Hospitalized for Suspected Dengue, El Salvador, 2012 SO PLOS ONE LA English DT Article ID VIRUS AB We estimate the proportion of patients hospitalized for suspected dengue that tested positive for influenza virus in El Salvador during the 2012 influenza season. We tested specimens from 321 hospitalized patients: 198 patients with SARI and 123 patients with suspected dengue. Among 121 hospitalized suspected dengue (two co-infected excluded) patients, 28% tested positive for dengue and 19% positive for influenza; among 35 with suspected dengue and respiratory symptoms, 14% were positive for dengue and 39% positive for influenza. One percent presented co-infection between influenza and dengue. Clinicians should consider the diagnosis of influenza among patients with suspected dengue during the influenza season. C1 [Chacon, Rafael; Jara, Jorge] Univ Valley Guatemala, Influenza Unit, Guatemala City, Guatemala. [Wilfrido Clara, Alexey] Centers Dis Control & Prevent Cent Amer Reg, Influenza Program, Guatemala City, Guatemala. [Armero, Julio] Minist Hlth El Salvador, Hlth Surveillance Directorate, San Salvador, El Salvador. [Lozano, Celina] Minist Hlth El Salvador, Natl Influenza Ctr, San Salvador, El Salvador. [El Omeiri, Nathalie] Training Programs Epidemiol & Publ Hlth Intervent, Influenza Unit, Guatemala City, Guatemala. [Widdowson, Marc-Alain; Azziz-Baumgartner, Eduardo] Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. RP Chacon, R (reprint author), Univ Valley Guatemala, Influenza Unit, Guatemala City, Guatemala. EM rchaconf@gmail.com FU U.S. Centers for Disease Control and Prevention [1U01GH000028-03] FX This study was supported by the Cooperative Agreement No. 1U01GH000028-03 from the U.S. Centers for Disease Control and Prevention. None of the coauthors have any conflicts of interest to declare. The findings and conclusions in this report are those of the authors and do not necessarily reflect the official position of the Centers for Disease Control and Prevention or the institutions with which the authors are affiliated. NR 18 TC 1 Z9 1 U1 0 U2 0 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD OCT 20 PY 2015 VL 10 IS 10 AR e0140890 DI 10.1371/journal.pone.0140890 PG 7 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CT7XI UT WOS:000363028100086 PM 26485296 ER PT J AU Jones, RT Borchert, J Eisen, R MacMillan, K Boegler, K Gage, KL AF Jones, Ryan Thomas Borchert, Jeff Eisen, Rebecca MacMillan, Katherine Boegler, Karen Gage, Kenneth L. TI Flea-Associated Bacterial Communities across an Environmental Transect in a Plague-Endemic Region of Uganda SO PLOS ONE LA English DT Article ID MICROBIAL COMMUNITIES; RICKETTSIA-FELIS; WOLBACHIA ENDOSYMBIONTS; YERSINIA-PESTIS; UNITED-STATES; NEW-MEXICO; CAT FLEAS; DIVERSITY; TRANSMISSION; SIPHONAPTERA AB The vast majority of human plague cases currently occur in sub-Saharan Africa. The primary route of transmission of Yersinia pestis, the causative agent of plague, is via flea bites. Non-pathogenic flea-associated bacteria may interact with Y. pestis within fleas and it is important to understand what factors govern flea-associated bacterial assemblages. Six species of fleas were collected from nine rodent species from ten Ugandan villages between October 2010 and March 2011. A total of 660,345 16S rRNA gene DNA sequences were used to characterize bacterial communities of 332 individual fleas. The DNA sequences were binned into 421 Operational Taxonomic Units (OTUs) based on 97% sequence similarity. We used beta diversity metrics to assess the effects of flea species, flea sex, rodent host species, site (i.e. village), collection date, elevation, mean annual precipitation, average monthly precipitation, and average monthly temperature on bacterial community structure. Flea species had the greatest effect on bacterial community structure with each flea species harboring unique bacterial lineages. The site (i.e. village), rodent host, flea sex, elevation, precipitation, and temperature also significantly affected bacterial community composition. Some bacterial lineages were widespread among flea species (e.g. Bartonella spp. and Wolbachia spp.), but each flea species also harbored unique bacterial lineages. Some of these lineages are not closely related to known bacterial diversity and likely represent newly discovered lineages of insect symbionts. Our finding that flea species has the greatest effect on bacterial community composition may help future investigations between Yersinia pestis and non-pathogenic flea-associated bacteria. Characterizing bacterial communities of fleas during a plague epizootic event in the future would be helpful. C1 [Jones, Ryan Thomas] Montana State Univ, Dept Microbiol & Immunol, Bozeman, MT 59717 USA. [Jones, Ryan Thomas] Montana State Univ, Montana Inst Ecosyst, Bozeman, MT 59717 USA. [Borchert, Jeff; Eisen, Rebecca; MacMillan, Katherine; Boegler, Karen; Gage, Kenneth L.] Ctr Dis Control & Prevent, Div Vector Borne Dis, Ft Collins, CO USA. RP Jones, RT (reprint author), Montana State Univ, Dept Microbiol & Immunol, Bozeman, MT 59717 USA. EM DrRyanJones@gmail.com FU Centers for Disease Control and Prevention FX Funding was provided by the Centers for Disease Control and Prevention. NR 55 TC 2 Z9 2 U1 1 U2 8 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD OCT 20 PY 2015 VL 10 IS 10 AR e0141057 DI 10.1371/journal.pone.0141057 PG 14 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CT7XI UT WOS:000363028100107 PM 26485147 ER PT J AU Klangthong, K Promsthaporn, S Leepitakrat, S Schuster, AL McCardle, PW Kosoy, M Takhampunya, R AF Klangthong, Kewalin Promsthaporn, Sommai Leepitakrat, Surachai Schuster, Anthony L. McCardle, Patrick W. Kosoy, Michael Takhampunya, Ratree TI The Distribution and Diversity of Bartonella Species in Rodents and Their Ectoparasites across Thailand SO PLOS ONE LA English DT Article ID MOLECULAR-DETECTION; ANIMAL RESERVOIRS; MAMMALIAN HOSTS; SPP.; INFECTIONS; PREVALENCE; DNA; DIFFERENTIATION; IDENTIFICATION; PATHOGENICITY AB Our study highlights the surveillance of Bartonella species among rodents and their associated ectoparasites (ticks, fleas, lice, and mites) in several regions across Thailand. A total of 619 rodents and 554 pooled ectoparasites (287 mite pools, 62 flea pools, 35 louse pools, and 170 tick pools) were collected from 8 provinces within 4 regions of Thailand. Bandicota indica (279), Rattus rattus (163), and R. exulans (96) were the most prevalent species of rats collected in this study. Real-time PCR assay targeting Bartonella-specific ssrA gene was used for screening and each positive sample was confirmed by PCR using nuoG gene. The prevalence of Bartonella DNA in rodent (around 17%) was recorded in all regions. The highest prevalence of Bartonella species was found in B. savilei and R. rattus with the rate of 35.7% (5/14) and 32.5%(53/163), respectively. High prevalence of Bartonella-positive rodent was also found in B. indica (15.1%, 42/279), and R. norvegicus (12.5%, 5/40). In contrast, the prevalence of Bartonella species in ectoparasites collected from the rats varied significantly according to types of ectoparasites. A high prevalence of Bartonella DNA was found in louse pools (Polyplax spp. and Hoplopleura spp., 57.1%) and flea pools (Xenopsylla cheopis, 25.8%), while a low prevalence was found in pools of mites (Leptotrombidium spp. and Ascoschoengastia spp., 1.7%) and ticks (Haemaphysalis spp., 3.5%). Prevalence of Bartonella DNA in ectoparasites collected from Bartonella-positive rodents (19.4%) was significantly higher comparing to ectoparasites from Bartonella-negative rodents (8.7%). The phylogenetic analysis of 41 gltA sequences of 16 Bartonella isolates from rodent blood and 25 Bartonella-positive ectoparasites revealed a wide range of diversity among Bartonella species with a majority of sequences (61.0%) belonging to Bartonella elizabethae complex (11 rodents, 1 mite pool, and 5 louse pools), while the remaining sequences were identical to B. phoceensis (17.1%, 1 mite pool, 5 louse pools, and 1 tick pool), B. coopersplainensis (19.5%, 5 rodents, 1 louse pool, and 2 tick pools), and one previously unidentified Bartonella species (2.4%, 1 louse pool). C1 [Klangthong, Kewalin; Promsthaporn, Sommai; Leepitakrat, Surachai; Schuster, Anthony L.; McCardle, Patrick W.; Takhampunya, Ratree] Armed Forces Res Inst Med Sci, US Army Med Directorate, Dept Entomol, Bangkok 10400, Thailand. [Kosoy, Michael] Ctr Dis Control & Prevent, Div Vector Borne Dis, Ft Collins, CO USA. RP Takhampunya, R (reprint author), Armed Forces Res Inst Med Sci, US Army Med Directorate, Dept Entomol, Bangkok 10400, Thailand. EM RatreeT.fsn@afrims.org FU Department of Defense Global Emerging Infections Surveillance and Response System (GEIS) FX This work has been supported by the Department of Defense Global Emerging Infections Surveillance and Response System (GEIS, https://www.afhsc.mil/Home/Divisions/GEIS). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 38 TC 2 Z9 2 U1 2 U2 7 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD OCT 20 PY 2015 VL 10 IS 10 AR e0140856 DI 10.1371/journal.pone.0140856 PG 16 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CT7XI UT WOS:000363028100080 PM 26484537 ER PT J AU Sukumaran, L McCarthy, NL Kharbanda, EO McNeil, MM Naleway, AL Klein, NP Jackson, ML Hambidge, SJ Lugg, MM Li, RX Weintraub, ES Bednarczyk, RA King, JP DeStefano, F Orenstein, WA Omer, SB AF Sukumaran, Lakshmi McCarthy, Natalie L. Kharbanda, Elyse O. McNeil, Michael M. Naleway, Allison L. Klein, Nicola P. Jackson, Michael L. Hambidge, Simon J. Lugg, Marlene M. Li, Rongxia Weintraub, Eric S. Bednarczyk, Robert A. King, Jennifer P. DeStefano, Frank Orenstein, Walter A. Omer, Saad B. TI Association of Tdap Vaccination With Acute Events and Adverse Birth Outcomes Among Pregnant Women With Prior Tetanus-Containing Immunizations SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Article ID ACELLULAR PERTUSSIS-VACCINE; INACTIVATED INFLUENZA VACCINE; SAFETY DATALINK; ADVISORY-COMMITTEE; OBSTETRIC EVENTS; PRACTICES ACIP; DIPHTHERIA; RECOMMENDATIONS; EPIDEMIC; INFANTS AB IMPORTANCE The Advisory Committee on Immunization Practices (ACIP) recommends the tetanus, diphtheria, and acellular pertussis (Tdap) vaccine for pregnant women during each pregnancy, regardless of prior immunization status. However, safety data on repeated Tdap vaccination in pregnancy is lacking. OBJECTIVE To determine whether receipt of Tdap vaccine during pregnancy administered in close intervals from prior tetanus-containing vaccinations is associated with acute adverse events in mothers and adverse birth outcomes in neonates. DESIGN, SETTING, ANDPARTICIPANTS A retrospective cohort study in 29 155 pregnant women aged 14 through 49 years from January 1, 2007, through November 15, 2013, using data from 7 Vaccine Safety Datalink sites in California, Colorado, Minnesota, Oregon, Washington, and Wisconsin. EXPOSURES Women who received Tdap in pregnancy following a prior tetanus-containing vaccine less than 2 years before, 2 to 5 years before, and more than 5 years before. MAIN OUTCOMES AND MEASURES Acute adverse events (fever, allergy, and local reactions) and adverse birth outcomes (small for gestational age, preterm delivery, and low birth weight) were evaluated. Women who were vaccinated with Tdap in pregnancy and had a prior tetanus-containing vaccine more than 5 years before served as controls. RESULTS There were no statistically significant differences in rates of medically attended acute adverse events or adverse birth outcomes related to timing since prior tetanus-containing vaccination. [GRAPHCIS] CONCLUSIONS AND RELEVANCE Among women who received Tdap vaccination during pregnancy, there was no increased risk of acute adverse events or adverse birth outcomes for those who had been previously vaccinated less than 2 years before or 2 to 5 years before compared with those who had been vaccinated more than 5 years before. These findings suggest that relatively recent receipt of a prior tetanus-containing vaccination does not increase risk after Tdap vaccination in pregnancy. C1 [Sukumaran, Lakshmi; McCarthy, Natalie L.; McNeil, Michael M.; Li, Rongxia; Weintraub, Eric S.; DeStefano, Frank] Ctr Dis Control & Prevent, Immunizat Safety Off, Atlanta, GA 30333 USA. [Sukumaran, Lakshmi] Emory Univ, Sch Med, Dept Pediat, Atlanta, GA USA. [Kharbanda, Elyse O.] HealthPartners Inst Educ & Res, Minneapolis, MN USA. [Naleway, Allison L.] Kaiser Permanente Northwest, Ctr Hlth Res, Portland, OR USA. [Klein, Nicola P.] Kaiser Permanente, Vaccine Study Ctr, Oakland, CA USA. [Jackson, Michael L.] Grp Hlth Res Inst, Seattle, WA USA. [Hambidge, Simon J.] Denver Hlth, Dept Ambulatory Care Serv, Denver, CO USA. [Hambidge, Simon J.] Kaiser Permanente Colorado, Inst Hlth Res, Denver, CO USA. [Hambidge, Simon J.] Univ Colorado, Dept Pediat, Denver, CO 80202 USA. [Lugg, Marlene M.] Kaiser Permanente So Calif, Dept Res & Evaluat, Pasadena, CA 91101 USA. [Bednarczyk, Robert A.; Omer, Saad B.] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. [King, Jennifer P.] Marshfield Clin Res Fdn, Marshfield, WI USA. [Orenstein, Walter A.; Omer, Saad B.] Emory Univ, Emory Vaccine Ctr, Atlanta, GA 30322 USA. RP Sukumaran, L (reprint author), Ctr Dis Control & Prevent, Immunizat Safety Off, 1600 Clifton Rd NE,Bldg 16,MS D-26, Atlanta, GA 30333 USA. EM xfq3@cdc.gov FU Centers for Disease Control and Prevention; National Institute of Allergy and Infectious Diseases [T32AI074492] FX This work was supported by the Centers for Disease Control and Prevention and grant T32AI074492 from the National Institute of Allergy and Infectious Diseases (Dr Sukumaran). NR 22 TC 15 Z9 17 U1 0 U2 7 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD OCT 20 PY 2015 VL 314 IS 15 BP 1581 EP 1587 DI 10.1001/jama.2015.12790 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA CT7XK UT WOS:000363028500018 PM 26501534 ER PT J AU Liou, SH Tsai, CSJ Pelclova, D Schubauer-Berigan, MK Schulte, PA AF Liou, Saou-Hsing Tsai, Candace S. J. Pelclova, Daniela Schubauer-Berigan, Mary K. Schulte, Paul A. TI Assessing the first wave of epidemiological studies of nanomaterial workers SO JOURNAL OF NANOPARTICLE RESEARCH LA English DT Review DE Epidemiological studies; Nanomaterial workers; Biological markers; Cross-sectional study; Longitudinal panel study; Sample size; Nanoparticle exposure ID HANDLING ENGINEERED NANOMATERIALS; OCCUPATIONAL-EXPOSURE ASSESSMENT; CARBON NANOTUBE; HEALTH SURVEILLANCE; SECONDARY MANUFACTURERS; NANOPARTICLE EXPOSURES; MYOCARDIAL-INFARCTION; NANOFIBER PRIMARY; TITANIUM-DIOXIDE; SELECTION BIAS AB The results of early animal studies of engineered nanomaterials (ENMs) and air pollution epidemiology suggest that it is important to assess the health of ENM workers. Initial epidemiological studies of workers' exposure to ENMs (<100 nm) are reviewed and characterized for their study designs, findings, and limitations. Of the 15 studies, 11 were cross-sectional, 4 were longitudinal (1 was both cross-sectional and longitudinal in design), and 1 was a descriptive pilot study. Generally, the studies used biologic markers as the dependent variables. All 11 cross-sectional studies showed a positive relationship between various biomarkers and ENM exposures. Three of the four longitudinal studies showed a negative relationship; the fourth showed positive findings after a 1-year follow-up. Each study considered exposure to ENMs as the independent variable. Exposure was assessed by mass concentration in 10 studies and by particle count in six studies. Six of them assessed both mass and particle concentrations. Some of the studies had limited exposure data because of inadequate exposure assessment. Generally, exposure levels were not very high in comparison to those in human inhalation chamber studies, but there were some exceptions. Most studies involved a small sample size, from 2 to 258 exposed workers. These studies represent the first wave of epidemiological studies of ENM workers. They are limited by small numbers of participants, inconsistent (and in some cases inadequate) exposure assessments, generally low exposures, and short intervals between exposure and effect. Still, these studies are a foundation for future work; they provide insight into where ENM workers are experiencing potentially adverse effects that might be related to ENM exposures. C1 [Liou, Saou-Hsing] Natl Hlth Res Inst, Natl Inst Environm Hlth Sci, Zhunan 35053, Miaoli County, Taiwan. [Liou, Saou-Hsing] Acad Sinica, Grad Inst Life Sci, Natl Def Med Ctr, Taipei 115, Taiwan. [Liou, Saou-Hsing] Natl Hlth Res Inst, Taipei, Taiwan. [Tsai, Candace S. J.] Colorado State Univ, Dept Environm & Radiol Hlth Sci, Ft Collins, CO 80523 USA. [Tsai, Candace S. J.] Purdue Univ, Birck Nanotechnol Ctr, Discovery Pk, IN USA. [Pelclova, Daniela] Charles Univ Prague, Dept Occupat Med, Fac Med 1, Prague, Czech Republic. [Schubauer-Berigan, Mary K.; Schulte, Paul A.] NIOSH, Cincinnati, OH 45226 USA. RP Liou, SH (reprint author), Natl Hlth Res Inst, Natl Inst Environm Hlth Sci, 35 Keyan Rd, Zhunan 35053, Miaoli County, Taiwan. EM shliou@nhri.org.tw RI Pelclova, Daniela/C-8885-2017; OI Pelclova, Daniela/0000-0002-0240-5146 FU National Health Research Institutes of Taiwan [01A1-EOSP03-014]; Institute of Occupational Safety and Health, Taiwan [IOSH101-M323]; Charles University in Prague, Czech Republic [P25/1LF/2, P28/1LF/6] FX This study was partly supported by the National Health Research Institutes of Taiwan (Grants 01A1-EOSP03-014) and the Institute of Occupational Safety and Health, Taiwan (Grants IOSH101-M323). The authors also thank project teams P25/1LF/2 and P28/1LF/6, of the Charles University in Prague, Czech Republic, which supported this work. NR 51 TC 15 Z9 15 U1 2 U2 21 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 1388-0764 EI 1572-896X J9 J NANOPART RES JI J. Nanopart. Res. PD OCT 19 PY 2015 VL 17 IS 10 AR 413 DI 10.1007/s11051-015-3219-7 PG 19 WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials Science, Multidisciplinary SC Chemistry; Science & Technology - Other Topics; Materials Science GA CU1CH UT WOS:000363256400001 PM 26635494 ER PT J AU Paulozzi, LJ Strickler, GK Kreiner, PW Koris, CM AF Paulozzi, Leonard J. Strickler, Gail K. Kreiner, Peter W. Koris, Caitlin M. TI Controlled Substance Prescribing Patterns Prescription Behavior Surveillance System, Eight States, 2013 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID OPIOID SHOPPING BEHAVIOR; UNITED-STATES; MONITORING PROGRAMS; OVERDOSE DEATHS; DRUG OVERDOSE; LEGAL STATUS; PREVALENCE; ABUSE; STIMULANTS; PHYSICIANS AB Problem/Condition: Drug overdose is the leading cause of injury death in the United States. The death rate from drug overdose in the United States more than doubled during 1999-2013, from 6.0 per 100,000 population in 1999 to 13.8 in 2013. The increase in drug overdoses is attributable primarily to the misuse and abuse of prescription drugs, especially opioid analgesics, sedatives/tranquilizers, and stimulants. Such drugs are prescribed widely in the United States, with substantial variation by state. Certain patients obtain drugs for nonmedical use or resale by obtaining overlapping prescriptions from multiple prescribers. The risk for overdose is directly associated with the use of multiple prescribers and daily dosages of >100 morphine milligram equivalents (MMEs) per day. Period Covered: 2013. Description of System: The Prescription Behavior Surveillance System (PBSS) is a public health surveillance system that allows public health authorities to characterize and quantify the use and misuse of prescribed controlled substances. PBSS began collecting data in 2012 and is funded by CDC and the Food and Drug Administration. PBSS uses standard metrics to measure prescribing rates per 1,000 state residents by demographic variables, drug type, daily dose, and source of payment. Data from the system can be used to calculate rates of misuse by certain behavioral measures such as use of multiple prescribers and pharmacies within specified time periods. This report is based on 2013 de-identified data (most recent available) that represent approximately one fourth of the U.S. population. Data were submitted quarterly by prescription drug monitoring programs (PDMPs) in eight states (California, Delaware, Florida, Idaho, Louisiana, Maine, Ohio, and West Virginia) that routinely collect data on every prescription for a controlled substance to help law enforcement and health care providers identify misuse or abuse of such drugs. Results: In all eight states, opioid analgesics were prescribed approximately twice as often as stimulants or benzodiazepines. Prescribing rates by drug class varied widely by state: twofold for opioids, fourfold for stimulants, almost twofold for benzodiazepines, and eightfold for carisoprodol, a muscle relaxant. Rates for opioids and benzodiazepines were substantially higher for females than for males in all states. In most states, opioid prescribing rates peaked in either the 45-54 years or the 55-64 years age group. Benzodiazepine prescribing rates increased with age. Louisiana ranked first in opioid prescribing, and Delaware and Maine had relatively high rates of use of long-acting (LA) or extended-release (ER) opioids. Delaware and Maine ranked highest in both mean daily opioid dosage and in the percentage of opioid prescriptions written for >100 MMEs per day. The top 1% of prescribers wrote one in four opioid prescriptions in Delaware, compared with one in eight in Maine. For the five states whose PDMPs collected the method of payment, the percentage of controlled substance prescriptions paid for in cash varied almost threefold, and the percentage paid by Medicaid varied sixfold. In West Virginia, for 1 of every 5 days of treatment with an opioid, the patient also was taking a benzodiazepine. Multiple-provider episode rates were highest in Ohio and lowest in Louisiana. Interpretation: This report presents rates of population-based prescribing and behavioral measures of drug misuse in the general population that have not been available previously for comparison among demographic groups and states. The higher prescribing rates for opioids among women compared with men are consistent with a higher self-reported prevalence of certain common types of pain, such as lower back pain among women. The trend in opioid prescribing rates with age is consistent with an increase in the prevalence of chronic pain with age, but the increasing prescribing rates of benzodiazepines with age is not consistent with the fact that anxiety is most common among persons aged 30 44 years. The variation among states in the type of opioid or benzodiazepine of choice is unexplained. Most opioid prescribing occurs among a small minority of prescribers. Most of the prescriptions by top-decile prescribers probably are written by general, family medicine, internal medicine, and midlevel practitioners. The source of payment varied by state, for reasons that are unclear. Persons who are prescribed opioids also are commonly prescribed benzodiazepine sedatives despite the risk for additive depressant effects. Public Health Actions: States can use their prescription drug monitoring programs to generate population-based measures for the prescribing of controlled substances and for behaviors that suggest their misuse. Comparing data with other states and tracking changes in these measures over time can be useful in measuring the effect of policies designed to reduce prescription drug misuse. C1 [Paulozzi, Leonard J.; Koris, Caitlin M.] CDC, Div Unintent Injury Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA. [Strickler, Gail K.; Kreiner, Peter W.] Brandeis Univ, Prescript Drug Monitoring Program, Ctr Excellence, Waltham, MA 02254 USA. RP Paulozzi, LJ (reprint author), CDC, Div Unintent Injury Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA. EM Lbp4@cdc.gov NR 41 TC 0 Z9 0 U1 4 U2 5 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD OCT 16 PY 2015 VL 64 IS 9 SU S BP 1 EP 14 PG 14 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CW4RT UT WOS:000364980500001 ER PT J AU Paulozzi, LJ Strickler, GK Kreiner, PW Koris, CM AF Paulozzi, Leonard J. Strickler, Gail K. Kreiner, Peter W. Koris, Caitlin M. TI Controlled Substance Prescribing Patterns - Prescription Behavior Surveillance System, Eight States, 2013 SO MMWR SURVEILLANCE SUMMARIES LA English DT Article ID OPIOID SHOPPING BEHAVIOR; UNITED-STATES; MONITORING PROGRAMS; OVERDOSE DEATHS; DRUG OVERDOSE; LEGAL STATUS; PREVALENCE; ABUSE; STIMULANTS; PHYSICIANS AB Problem/Condition: Drug overdose is the leading cause of injury death in the United States. The death rate from drug overdose in the United States more than doubled during 1999-2013, from 6.0 per 100,000 population in 1999 to 13.8 in 2013. The increase in drug overdoses is attributable primarily to the misuse and abuse of prescription drugs, especially opioid analgesics, sedatives/tranquilizers, and stimulants. Such drugs are prescribed widely in the United States, with substantial variation by state. Certain patients obtain drugs for nonmedical use or resale by obtaining overlapping prescriptions from multiple prescribers. The risk for overdose is directly associated with the use of multiple prescribers and daily dosages of >100 morphine milligram equivalents (MMEs) per day. Period Covered: 2013. Description of System: The Prescription Behavior Surveillance System (PBSS) is a public health surveillance system that allows public health authorities to characterize and quantify the use and misuse of prescribed controlled substances. PBSS began collecting data in 2012 and is funded by CDC and the Food and Drug Administration. PBSS uses standard metrics to measure prescribing rates per 1,000 state residents by demographic variables, drug type, daily dose, and source of payment. Data from the system can be used to calculate rates of misuse by certain behavioral measures such as use of multiple prescribers and pharmacies within specified time periods. This report is based on 2013 de-identified data (most recent available) that represent approximately one fourth of the U.S. population. Data were submitted quarterly by prescription drug monitoring programs (PDMPs) in eight states (California, Delaware, Florida, Idaho, Louisiana, Maine, Ohio, and West Virginia) that routinely collect data on every prescription for a controlled substance to help law enforcement and health care providers identify misuse or abuse of such drugs. Results: In all eight states, opioid analgesics were prescribed approximately twice as often as stimulants or benzodiazepines. Prescribing rates by drug class varied widely by state: twofold for opioids, fourfold for stimulants, almost twofold for benzodiazepines, and eightfold for carisoprodol, a muscle relaxant. Rates for opioids and benzodiazepines were substantially higher for females than for males in all states. In most states, opioid prescribing rates peaked in either the 45-54 years or the 55-64 years age group. Benzodiazepine prescribing rates increased with age. Louisiana ranked first in opioid prescribing, and Delaware and Maine had relatively high rates of use of long-acting (LA) or extended-release (ER) opioids. Delaware and Maine ranked highest in both mean daily opioid dosage and in the percentage of opioid prescriptions written for >100 MMEs per day. The top 1% of prescribers wrote one in four opioid prescriptions in Delaware, compared with one in eight in Maine. For the five states whose PDMPs collected the method of payment, the percentage of controlled substance prescriptions paid for in cash varied almost threefold, and the percentage paid by Medicaid varied sixfold. In West Virginia, for 1 of every 5 days of treatment with an opioid, the patient also was taking a benzodiazepine. Multiple-provider episode rates were highest in Ohio and lowest in Louisiana. Interpretation: This report presents rates of population-based prescribing and behavioral measures of drug misuse in the general population that have not been available previously for comparison among demographic groups and states. The higher prescribing rates for opioids among women compared with men are consistent with a higher self-reported prevalence of certain common types of pain, such as lower back pain among women. The trend in opioid prescribing rates with age is consistent with an increase in the prevalence of chronic pain with age, but the increasing prescribing rates of benzodiazepines with age is not consistent with the fact that anxiety is most common among persons aged 30-44 years. The variation among states in the type of opioid or benzodiazepine of choice is unexplained. Most opioid prescribing occurs among a small minority of prescribers. Most of the prescriptions by top-decile prescribers probably are written by general, family medicine, internal medicine, and midlevel practitioners. The source of payment varied by state, for reasons that are unclear. Persons who are prescribed opioids also are commonly prescribed benzodiazepine sedatives despite the risk for additive depressant effects. Public Health Actions: States can use their prescription drug monitoring programs to generate population-based measures for the prescribing of controlled substances and for behaviors that suggest their misuse. Comparing data with other states and tracking changes in these measures over time can be useful in measuring the effect of policies designed to reduce prescription drug misuse. C1 [Paulozzi, Leonard J.; Koris, Caitlin M.] CDC, Div Unintent Injury Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA. [Strickler, Gail K.; Kreiner, Peter W.] Brandeis Univ, Prescript Drug Monitoring Program Ctr Excellence, Waltham, MA 02254 USA. RP Paulozzi, LJ (reprint author), CDC, Div Unintent Injury Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA. EM Lbp4@cdc.gov NR 39 TC 16 Z9 16 U1 3 U2 6 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-8636 J9 MMWR SURVEILL SUMM JI MMWR Surv. Summ. PD OCT 16 PY 2015 VL 64 IS 9 BP 1 EP 14 PG 14 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CV6NP UT WOS:000364387200001 PM 26469747 ER PT J AU Lavinghouze, SR Malarcher, A Jama, A Neff, L Debrot, K Whalen, L AF Lavinghouze, S. Rene Malarcher, Ann Jama, Amal Neff, Linda Debrot, Karen Whalen, Laura TI Trends in Quit Attempts Among Adult Cigarette Smokers - United States, 2001-2013 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID FACTOR SURVEILLANCE SYSTEM; PREVALENCE; SMOKING C1 [Lavinghouze, S. Rene; Malarcher, Ann; Neff, Linda; Debrot, Karen; Whalen, Laura] CDC, Natl Ctr Chron Dis Prevent & Hlth Promot, Off Smoking & Hlth, Atlanta, GA 30333 USA. [Jama, Amal] DB Consulting Grp Inc, Silver Spring, MD USA. RP Lavinghouze, SR (reprint author), CDC, Natl Ctr Chron Dis Prevent & Hlth Promot, Off Smoking & Hlth, Atlanta, GA 30333 USA. EM rlavinghouze@cdc.gov NR 10 TC 1 Z9 1 U1 0 U2 1 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD OCT 16 PY 2015 VL 64 IS 40 BP 1129 EP 1135 PN 2 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CU2OY UT WOS:000363364000001 PM 26468619 ER PT J AU Rolle, IV Kennedy, SM Agaku, I Jones, SE Bunnell, R Carabalio, R Xu, X Schauer, G McAfee, T AF Rolle, Italia V. Kennedy, Sara M. Agaku, Israel Jones, Sherry Everett Bunnell, Rebecca Carabalio, Ralph Xu, Xin Schauer, Gillian McAfee, Tim TI Cigarette, Cigar, and Marijuana Use Among High School Students - United States, 1997-2013 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID CANNABIS; SENIORS; TOBACCO C1 [Rolle, Italia V.; Kennedy, Sara M.; Agaku, Israel; Bunnell, Rebecca; Carabalio, Ralph; Xu, Xin; Schauer, Gillian; McAfee, Tim] CDC, Natl Ctr Chron Dis Prevent & Hlth Promot, Off Smoking & Hlth, Atlanta, GA 30333 USA. [Jones, Sherry Everett] CDC, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Div Adolescent, Atlanta, GA 30333 USA. [Jones, Sherry Everett] CDC, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Sch Hlth, Atlanta, GA 30333 USA. RP Rolle, IV (reprint author), CDC, Natl Ctr Chron Dis Prevent & Hlth Promot, Off Smoking & Hlth, Atlanta, GA 30333 USA. EM itr2@cdc.gov NR 10 TC 5 Z9 5 U1 1 U2 3 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD OCT 16 PY 2015 VL 64 IS 40 BP 1136 EP 1141 PN 2 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CU2OY UT WOS:000363364000002 PM 26468662 ER PT J AU Sunshine, G Pepin, D Cetron, M Penn, M AF Sunshine, Gregory Pepin, Dawn Cetron, Many Penn, Matthew TI State and Territorial Ebola Screening, Monitoring, and Movement Policy Statements - United States, August 31, 2015 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Sunshine, Gregory; Pepin, Dawn; Penn, Matthew] CDC, Off State Tribal Local & Territorial Support, Publ Hlth Law Program, Atlanta, GA 30333 USA. [Cetron, Many] CDC, Natl Ctr Emerging & Zoonot Infect Dis, Div Global Migrat & Quarantine, Atlanta, GA 30333 USA. RP Sunshine, G (reprint author), CDC, Off State Tribal Local & Territorial Support, Publ Hlth Law Program, Atlanta, GA 30333 USA. EM gsunshine@cdc.gov NR 4 TC 3 Z9 3 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD OCT 16 PY 2015 VL 64 IS 40 BP 1145 EP 1146 PN 2 PG 2 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CU2OY UT WOS:000363364000004 PM 26468902 ER PT J AU Raesima, MM Forhan, SE Voetsch, AC Hewitt, S Hariri, S Wang, SA Pelletier, AR Letebele, M Pheto, T Ramogola-Masire, D El-Halabi, S AF Raesima, Mmakgomo Mimi Forhan, Sara E. Voetsch, Andrew C. Hewitt, Shannon Hariri, Susan Wang, Susan A. Pelletier, Andrew R. Letebele, Mpho Pheto, Tlhomamo Ramogola-Masire, Doreen El-Halabi, Shenaaz TI Human Papillomavirus Vaccination Coverage Among School Girls in a Demonstration Project - Botswana, 2013 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID VACCINES; TRIALS C1 [Raesima, Mmakgomo Mimi; Pheto, Tlhomamo; El-Halabi, Shenaaz] CDC, Botswana Minist Hlth, Atlanta, GA 30333 USA. [Forhan, Sara E.; Voetsch, Andrew C.; Pelletier, Andrew R.; Letebele, Mpho] CDC, Ctr Global Hlth, Div Global HIV AIDS, Atlanta, GA 30333 USA. [Hewitt, Shannon] CDC, United States Peace Corps, Atlanta, GA 30333 USA. [Hariri, Susan] CDC, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Div STD Prevent, Atlanta, GA 30333 USA. [Wang, Susan A.] CDC, Ctr Global Hlth, Global Immunizat Div, Atlanta, GA 30333 USA. [Ramogola-Masire, Doreen] Botswana Univ Pennsylvania Partnership, Gaborone, Botswana. [Ramogola-Masire, Doreen] Univ Botswana, Dept Med, Gaborone, Botswana. RP Forhan, SE (reprint author), CDC, Ctr Global Hlth, Div Global HIV AIDS, Atlanta, GA 30333 USA. EM ggt1@cdc.gov NR 10 TC 4 Z9 4 U1 0 U2 2 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD OCT 16 PY 2015 VL 64 IS 40 BP 1147 EP 1149 PN 2 PG 3 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CU2OY UT WOS:000363364000005 PM 26468997 ER PT J AU Woolston, S Cohen, SE Fanfair, RN Lewis, SC Marra, CM Golden, MR AF Woolston, Sophie Cohen, Stephanie E. Fanfair, Robyn Neblett Lewis, Sarah C. Marra, Christina M. Golden, Matthew R. TI A Cluster of Ocular Syphilis Cases - Seattle, Washington, and San Francisco, California, 2014-2015 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Woolston, Sophie; Golden, Matthew R.] Univ Washington, Dept Med, Div Allergy & Infect Dis, Seattle, WA 98195 USA. [Cohen, Stephanie E.] Univ Calif San Francisco, San Francisco Dept Publ Hlth, San Francisco, CA 94143 USA. [Cohen, Stephanie E.; Lewis, Sarah C.] Univ Calif San Francisco, Div Infect Dis, San Francisco, CA 94143 USA. [Fanfair, Robyn Neblett] CDC, Div STD Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. [Marra, Christina M.] Univ Washington, Dept Neurol, Seattle, WA 98195 USA. [Golden, Matthew R.] Publ Hlth Seattle & King Cty, HIV STD Control Program, Seattle, WA USA. RP Fanfair, RN (reprint author), CDC, Div STD Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. EM iyo5@cdc.gov FU NIAID NIH HHS [T32 AI007641] NR 6 TC 9 Z9 9 U1 1 U2 1 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD OCT 16 PY 2015 VL 64 IS 40 BP 1150 EP 1151 PN 2 PG 2 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CU2OY UT WOS:000363364000006 PM 26469141 ER PT J AU Monto, AS Petrie, JG Cross, RT Johnson, E Liu, M Zhong, WM Levine, M Katz, JM Ohmit, SE AF Monto, Arnold S. Petrie, Joshua G. Cross, Rachel T. Johnson, Emileigh Liu, Merry Zhong, Weimin Levine, Min Katz, Jacqueline M. Ohmit, Suzanne E. TI Antibody to Influenza Virus Neuraminidase: An Independent Correlate of Protection SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE influenza; serologic assays; hemagglutinin; neuraminidase; clinical trial; influenza vaccine; vaccine response; immune correlates ID SEROLOGIC ASSAYS; VACCINES; INFECTION; SERUM; EFFICACY; IMMUNITY AB Background. Laboratory correlates of influenza vaccine protection can best be identified by examining people who are infected despite vaccination. While the importance of antibody to viral hemagglutinin (HA) has long been recognized, the level of protection contributed independently by antibody to viral neuraminidase (NA) has not been determined. Methods. Sera from a controlled trial of the efficacies of inactivated influenza vaccine (IIV) and live attenuated influenza vaccine (LAIV) were tested by hemagglutination inhibition (HAI) assay, microneutralization (MN) assay, and a newly standardized lectin-based neuraminidase inhibition (NAI) assay. Results. The NAI assay detected a vaccine response in 37% of IIV recipients, compared with 77% and 67% of participants in whom responses were detected by the HAI and MN assays, respectively. For LAIV recipients, the NAI, HAI, and MN assays detected responses in 6%, 21%, and 17%, respectively. In IIV recipients, as NAI assay titers rose, the frequency of infection fell, similar to patterns seen with HAI and MN assays. HAI and MN assay titers were highly correlated, but NAI assay titers exhibited less of a correlation. Analyses suggested an independent role for NAI antibody in protection, which was similar in the IIV, LAIV, and placebo groups. Conclusions. While NAI antibody is not produced to a large extent in response to current IIV, it appears to have an independent role in protection. As new influenza vaccines are developed, NA content should be considered. C1 [Monto, Arnold S.; Petrie, Joshua G.; Cross, Rachel T.; Johnson, Emileigh; Ohmit, Suzanne E.] Univ Michigan, Sch Publ Hlth, Dept Epidemiol, Ann Arbor, MI 48109 USA. [Liu, Merry; Zhong, Weimin; Levine, Min; Katz, Jacqueline M.] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. RP Petrie, JG (reprint author), Univ Michigan, Sch Publ Hlth, 1415 Washington Hts, Ann Arbor, MI 48109 USA. EM jpetrie@umich.edu FU Sanofi-Pasteur FX This work was supported by Sanofi-Pasteur (unrestricted grant). NR 23 TC 18 Z9 18 U1 0 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD OCT 15 PY 2015 VL 212 IS 8 BP 1191 EP 1199 DI 10.1093/infdis/jiv195 PG 9 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA CU0GY UT WOS:000363195400004 PM 25858957 ER PT J AU Arriola, CS Anderson, EJ Baumbach, J Bennett, N Bohm, S Hill, M Lindegren, ML Lung, K Meek, J Mermel, E Miller, L Monroe, ML Morin, C Oni, O Reingold, A Schaffner, W Thomas, A Zansky, SM Finelli, L Chaves, SS AF Arriola, Carmen S. Anderson, Evan J. Baumbach, Joan Bennett, Nancy Bohm, Susan Hill, Mary Lindegren, Mary Lou Lung, Krista Meek, James Mermel, Elizabeth Miller, Lisa Monroe, Maya L. Morin, Craig Oni, Oluwakemi Reingold, Arthur Schaffner, William Thomas, Ann Zansky, Shelley M. Finelli, Lyn Chaves, Sandra S. TI Does Influenza Vaccination Modify Influenza Severity? Data on Older Adults Hospitalized With Influenza During the 2012-2013 Season in the United States SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE influenza; influenza vaccine; adults; severe illness ID LABORATORY-CONFIRMED INFLUENZA; RESPIRATORY SYNCYTIAL VIRUS; CHARLSON COMORBIDITY INDEX; MORTALITY BENEFITS; PROPENSITY SCORES; DIAGNOSTIC-TESTS; DISEASE; OSELTAMIVIR; OUTCOMES; RISK AB Background. Some studies suggest that influenza vaccination might be protective against severe influenza outcomes in vaccinated persons who become infected. We used data from a large surveillance network to further investigate the effect of influenza vaccination on influenza severity in adults aged >= 50 years who were hospitalized with laboratory-confirmed influenza. Methods. We analyzed influenza vaccination and influenza severity using Influenza Hospitalization Surveillance Network (FluSurv-NET) data for the 2012-2013 influenza season. Intensive care unit (ICU) admission, death, diagnosis of pneumonia, and hospital and ICU lengths of stay served as measures of disease severity. Data were analyzed by multivariable logistic regression, parametric survival models, and propensity score matching (PSM). Results. Overall, no differences in severity were observed in the multivariable logistic regression model. Using PSM, adults aged 50-64 years (but not other age groups) who were vaccinated against influenza had a shorter length of ICU stay than those who were unvaccinated (hazard ratio for discharge, 1.84; 95% confidence interval, 1.12-3.01). Conclusions. Our findings show a modest effect of influenza vaccination on disease severity. Analysis of data from seasons with different predominant strains and higher estimates of vaccine effectiveness are needed. C1 [Arriola, Carmen S.] Emory Univ, Sch Med, Epidem Intelligence Serv Program, Atlanta, GA 30322 USA. [Arriola, Carmen S.; Finelli, Lyn; Chaves, Sandra S.] Emory Univ, Sch Med, Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA 30322 USA. [Anderson, Evan J.] Emory Univ, Sch Med, Dept Med, Atlanta, GA 30322 USA. [Anderson, Evan J.] Atlanta Vet Affairs Med Ctr, Atlanta, GA USA. [Baumbach, Joan] New Mexico Dept Hlth, Santa Fe, NM USA. [Bennett, Nancy] Univ Rochester, Sch Med & Dent, Dept Med, Albany, NY USA. [Zansky, Shelley M.] New York State Dept Hlth, Emerging Infect Program, Albany, NY USA. [Bohm, Susan] Michigan Dept Community Hlth, Lansing, MI USA. [Hill, Mary] Salt Lake City Cty Hlth Dept, Salt Lake City, UT USA. [Lindegren, Mary Lou] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA. [Lung, Krista] Ohio Dept Hlth, Columbus, OH 43266 USA. [Meek, James] Yale Univ, Sch Publ Hlth, Connecticut Emerging Infect Program, New Haven, CT USA. [Mermel, Elizabeth] Rhode Isl Dept Hlth, Providence, RI 02908 USA. [Miller, Lisa] Colorado Dept Publ Hlth & Environm, Denver, CO USA. [Monroe, Maya L.] Maryland Dept Hlth & Mental Hyg, Baltimore, MD USA. [Morin, Craig] Minnesota Dept Hlth, St Paul, MN USA. [Oni, Oluwakemi] Iowa Dept Publ Hlth, Des Moines, IA 50319 USA. [Reingold, Arthur] Calif Emerging Infect Program, Oakland, CA USA. [Thomas, Ann] Oregon Publ Hlth Div, Portland, OR USA. RP Arriola, CS (reprint author), Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Influenza Div, 1600 Clifton Rd,MS A-32, Atlanta, GA 30333 USA. EM wus3@cdc.gov FU CDC [CDC-RFA-CK12-1202, 5U38HM000414] FX This work was supported by the CDC (cooperative agreements CDC-RFA-CK12-1202 and 5U38HM000414). NR 49 TC 9 Z9 9 U1 0 U2 5 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD OCT 15 PY 2015 VL 212 IS 8 BP 1200 EP 1208 DI 10.1093/infdis/jiv200 PG 9 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA CU0GY UT WOS:000363195400005 PM 25821227 ER PT J AU Tamura, D DeBiasi, RL Okomo-Adhiambo, M Mishin, VP Campbell, AP Loechelt, B Wiedermann, BL Fry, AM Gubareva, LV AF Tamura, Daisuke DeBiasi, Roberta L. Okomo-Adhiambo, Margaret Mishin, Vasiliy P. Campbell, Angela P. Loechelt, Brett Wiedermann, Bernhard L. Fry, Alicia M. Gubareva, Larisa V. TI Emergence of Multidrug-Resistant Influenza A(H1N1)pdm09 Virus Variants in an Immunocompromised Child Treated With Oseltamivir and Zanamivir SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE neuraminidase; drug resistance; pyrosequencing; oseltamivir; zanamivir ID NEURAMINIDASE INHIBITORS; A H1N1; MUTATIONS; RECOVERY AB Prolonged treatment of an immunocompromised child with oseltamivir and zanamivir for A(H1N1) pdm09 virus infection led to the emergence of viruses carrying H275Y and/or E119G in the neuraminidase (NA). When phenotypically evaluated by NA inhibition, the dual H275Y-E119G substitution caused highly reduced inhibition by 4 NA inhibitors: oseltamivir, zanamivir, peramivir, and laninamivir. C1 [Tamura, Daisuke; Okomo-Adhiambo, Margaret; Mishin, Vasiliy P.; Campbell, Angela P.; Fry, Alicia M.; Gubareva, Larisa V.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp, Influenza Div, Atlanta, GA USA. [DeBiasi, Roberta L.; Wiedermann, Bernhard L.] George Washington Univ, Sch Med, Div Pediat Infect Dis, Washington, DC USA. [Loechelt, Brett] George Washington Univ, Sch Med, Childrens Natl Med Ctr, Div Blood & Marrow Transplantat, Washington, DC USA. [DeBiasi, Roberta L.; Loechelt, Brett; Wiedermann, Bernhard L.] George Washington Univ, Sch Med, Dept Pediat, Washington, DC USA. [DeBiasi, Roberta L.] George Washington Univ, Sch Med, Div Microbiol, Div Immunol & Trop Med, Washington, DC USA. RP Gubareva, LV (reprint author), Mail Stop G-16,1600 Clifton Rd, Atlanta, GA 30333 USA. EM lgubareva@cdc.gov FU Oak Ridge Institute for Science and Education, Oak Ridge, Tennessee FX This work was supported by the Oak Ridge Institute for Science and Education, Oak Ridge, Tennessee (D. T.). NR 15 TC 8 Z9 8 U1 0 U2 6 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD OCT 15 PY 2015 VL 212 IS 8 BP 1209 EP 1213 DI 10.1093/infdis/jiv245 PG 5 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA CU0GY UT WOS:000363195400006 PM 25943200 ER PT J AU Tseng, HF Lewin, B Hales, CM Sy, LS Harpaz, R Bialek, S Luo, Y Jacobsen, SJ Reddy, K Huang, PY Zhang, J Anand, S Bauer, EM Chang, J Tartof, SY AF Tseng, Hung Fu Lewin, Bruno Hales, Craig M. Sy, Lina S. Harpaz, Rafael Bialek, Stephanie Luo, Yi Jacobsen, Steven J. Reddy, Kavya Huang, Po-yin Zhang, Jeff Anand, Sean Bauer, Erin Mary Chang, Jennifer Tartof, Sara Y. TI Zoster Vaccine and the Risk of Postherpetic Neuralgia in Patients Who Developed Herpes Zoster Despite Having Received the Zoster Vaccine SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE herpes zoster; post-herpetic neuralgia; adult vaccination; shingles; varicella zoster virus ID OLDER-ADULTS; PREVENTION; EXPERIENCE; PAINFUL; QUALITY AB Background. Although it is evident that zoster vaccination reduces postherpetic neuralgia (PHN) risk by reducing herpes zoster (HZ) occurrence, it is less clear whether the vaccine protects against PHN among patients who develop HZ despite previous vaccination. Methods. This cohort study included immunocompetent patients with HZ. The vaccinated cohort included 1155 individuals who were vaccinated against HZ at age >= 60 years and had an HZ episode after vaccination. Vaccinated patients were matched 1: 1 by sex and age with unvaccinated patients. Trained medical residents reviewed the full medical record to determine the presence of HZ-related pain at 1, 2, 3, and 6 months after HZ diagnosis. The incidence of PHN was compared between vaccinated and unvaccinated -patients. Results. Thirty vaccinated women (4.2%) experienced PHN, compared with 75 unvaccinated women (10.4%), with an adjusted relative risk of 0.41 (95% confidence interval, .26-.64). PHN occurred in 26 vaccinated men (6.0%) versus 25 unvaccinated men (5.8%), with an adjusted relative risk of 1.06 (.58-1.94). These associations did not differ significantly by age. Conclusions. Among persons experiencing HZ, prior HZ vaccination is associated with a lower risk of PHN in women but not in men. This sex-related difference may reflect differences in healthcare-seeking patterns and deserve further investigation. C1 [Tseng, Hung Fu; Sy, Lina S.; Luo, Yi; Jacobsen, Steven J.; Anand, Sean; Tartof, Sara Y.] Kaiser Permanente So Calif, Dept Res & Evaluat, Pasadena, CA 91101 USA. [Lewin, Bruno; Huang, Po-yin; Chang, Jennifer] Kaiser Permanente So Calif, Dept Res & Evaluat, Pasadena, CA 91101 USA. [Reddy, Kavya; Bauer, Erin Mary] Kaiser Permanente So Calif, Dept Internal Med, Pasadena, CA 91101 USA. [Hales, Craig M.; Harpaz, Rafael; Bialek, Stephanie] Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA USA. RP Tseng, HF (reprint author), Kaiser Permanente, So Calif Permanente Med Grp, Dept Res & Evaluat, 100 S Los Robles Ave, Pasadena, CA 91101 USA. EM hung-fu.x.tseng@kp.org OI Jacobsen, Steven/0000-0002-8174-8533 FU CDC [00HCVGEB-2014-6638] FX This work was supported by the CDC (grant 00HCVGEB-2014-6638). NR 22 TC 6 Z9 6 U1 1 U2 7 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD OCT 15 PY 2015 VL 212 IS 8 BP 1222 EP 1231 DI 10.1093/infdis/jiv244 PG 10 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA CU0GY UT WOS:000363195400008 PM 26038400 ER PT J AU Najarro, K Nguyen, H Chen, GB Xu, M Alcorta, S Yao, X Zukley, L Metter, EJ Truong, T Lin, Y Li, HF Oelke, M Xu, XY Ling, SM Longo, DL Schneck, J Leng, S Ferrucci, L Weng, NP AF Najarro, Kevin Huy Nguyen Chen, Guobing Xu, Mai Alcorta, Sandy Yao, Xu Zukley, Linda Metter, E. Jeffrey Thai Truong Lin, Yun Li, Huifen Oelke, Mathias Xu, Xiyan Ling, Shari M. Longo, Dan L. Schneck, Jonathan Leng, Sean Ferrucci, Luigi Weng, Nan-ping TI Telomere Length as an Indicator of the Robustness of B- and T-Cell Response to Influenza in Older Adults SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE telomere; influenza vaccine; CD8 T cells; antibody; CMV; CD28(-) T cells ID STEM-CELLS; DYSKERATOSIS-CONGENITA; SHORTENED TELOMERES; ELDERLY INDIVIDUALS; LYMPHOCYTE SUBSETS; INTRINSIC DEFECTS; HUMAN FIBROBLASTS; IN-VIVO; INFECTION; IMMUNOSENESCENCE AB Background. Telomeres provide a key mechanism for protecting the integrity of chromosomes and their attrition after cell division and during aging are evident in lymphocytes. However, the significance of telomere shortening in age-associated decline of immune function is unknown. Methods. We selected 22 HLA-A2-positive healthy older adults who have relatively short or long telomere lengths to compare their antibody response against the influenza vaccine, and their CD8(+) T-cell response against an influenza antigen. Results. B cells from individuals with a robust antibody response to the influenza vaccine had significantly longer telomeres than those with a poor antibody response. Monocyte-derived antigen-presenting cells of both short and long telomere groups induced similar expansions of influenza M1-specific CD8(+) T cells. Vaccination did not increase M1-specific CD8(+) T cells in blood, but M1-specific CD8(+) T cells from the long telomere group exhibited significantly greater expansion in vitro than those from the short telomere group. Finally, M1-specific CD8(+) T cells that underwent more expansions had significantly longer telomeres than cells with fewer divisions. Conclusions. Telomere length is positively associated with a robust lymphocyte response, and telomere attrition may contribute to the age-associated decline of adaptive immunity. C1 [Najarro, Kevin; Huy Nguyen; Chen, Guobing; Xu, Mai; Thai Truong; Lin, Yun; Weng, Nan-ping] Johns Hopkins Univ, Sch Med, Lab Mol Biol & Immunol, Baltimore, MD USA. [Alcorta, Sandy; Zukley, Linda; Metter, E. Jeffrey; Li, Huifen; Ling, Shari M.; Ferrucci, Luigi] Johns Hopkins Univ, Sch Med, Translat Gerontol Branch, Baltimore, MD USA. [Yao, Xu; Li, Huifen; Leng, Sean] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA. [Oelke, Mathias; Schneck, Jonathan] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA. [Xu, Xiyan] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. [Longo, Dan L.] NIA, Genet Lab, NIH, Baltimore, MD 21224 USA. RP Weng, NP (reprint author), NIH, 251 Bayview Blvd,Ste 100, Baltimore, MD 21224 USA. EM Wengn@mail.nih.gov RI Chen, Guobing/D-9572-2012 OI Chen, Guobing/0000-0002-2401-6168 FU National Institute on Aging; Radiation and Nuclear Countermeasures Program of the National Institute of Allergy and Infectious Diseases, National Institutes of Health FX This research was supported by the Intramural Research Program of the National Institute on Aging and the Radiation and Nuclear Countermeasures Program of the National Institute of Allergy and Infectious Diseases, National Institutes of Health. NR 45 TC 6 Z9 6 U1 1 U2 7 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD OCT 15 PY 2015 VL 212 IS 8 BP 1261 EP 1269 DI 10.1093/infdis/jiv202 PG 9 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA CU0GY UT WOS:000363195400013 PM 25828247 ER PT J AU Ali, O Aseffa, A Bedru, A Lema, T Moti, T Tekletsion, Y Worku, A Xabher, HG Yamuah, L Boukary, RM Collard, JM Dano, ID Habiboulaye, I Issaka, B Jusot, JF Ousmane, S Rabe, I Daugla, DM Gami, JP Gamougam, K Mbainadji, L Naibei, N Narbe, M Toralta, J Berthe, A Diallo, K Keita, M Onwuchekwa, U Sow, SO Tamboura, B Traore, A Toure, A Clark, T Mayer, L Amodu, M Beida, O Gadzama, G Omotara, B Sambo, Z Yahya, S Chandramohan, D Greenwood, BM Hassan-King, M Manigart, O Nascimento, M Stuart, JM Woukeu, A Basta, NE Bai, XL Borrow, R Findlow, H Alavo, S Bassene, H Diallo, A Dieng, M Doucoure, S Gomis, JF Ndiaye, A Sokhna, C Trape, JF Akalifa, B Forgor, A Hodgson, A Osei, I Quaye, SL Williams, J Wontuo, P Irving, T Trotter, CL Bennett, J Hill, D Harrison, O Maiden, MC Rebbetts, L Watkins, E AF Ali, Oumer Aseffa, Abraham Bedru, Ahmed Lema, Tsehaynesh Moti, Tesfaye Tekletsion, Yenenesh Worku, Alemayehu Xabher, Haimanot Guebre Yamuah, Lawrence Boukary, Rahamatou Moustapha Collard (PI), Jean-Marc Dano, Ibrahim Dan Habiboulaye, Ibrahim Issaka, Bassira Jusot, Jean-Francois Ousmane, Sani Rabe, Issoufa Daugla (PI), Doumagoum Moto Gami, Jean Pierre Gamougam, Kadidja Mbainadji, Lodoum Naibei, Nathan Narbe, Maxime Toralta, Jacques Berthe, Abdoulaye Diallo, Kanny Keita, Mahamadou Onwuchekwa, Uma Sow (PI), Samba O. Tamboura, Boubou Traore, Awa Toure, Alou Clark, Tom Mayer, Leonard Amodu, Mary Beida, Omeiza Gadzama, Galadima Omotara (PI), Babatunji Sambo, Zailani Yahya, Shuaibu Chandramohan, Daniel Greenwood (PI), Brian M. Hassan-King, Musa Manigart, Olivier Nascimento, Maria Stuart, James M. Woukeu, Arouna Basta, Nicole E. Bai, Xilian Borrow, Ray Findlow, Helen Alavo, Serge Bassene, Hubert Diallo (PI), Aldiouma Dieng, Marietou Doucoure, Souleymane Gomis, Jules Francois Ndiaye, Assane Sokhna, Cheikh Trape, Jean Francois Akalifa, Bugri Forgor, Abudulai Hodgson (PI), Abraham Osei, Isaac Quaye, Stephen L. Williams, John Wontuo, Peter Irving, Thomas Trotter, Caroline L. Bennett, Julia Hill, Dorothea Harrison, Odile Maiden, Martin C. Rebbetts, Lisa Watkins, Eleanor CA MenAfriCar Consortium TI The Diversity of Meningococcal Carriage Across the African Meningitis Belt and the Impact of Vaccination With a Group A Meningococcal Conjugate Vaccine SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE Africa; meningitis; meningococcus; Neisseria meningitidis; carriage ID NEISSERIA-MENINGITIDIS; BURKINA-FASO; SEROGROUP; IMMUNITY AB Background. Study of meningococcal carriage is essential to understanding the epidemiology of Neisseria meningitidis infection. Methods. Twenty cross-sectional carriage surveys were conducted in 7 countries in the African meningitis belt; 5 surveys were conducted after introduction of a new serogroup A meningococcal conjugate vaccine (MenAfriVac). Pharyngeal swab specimens were collected, and Neisseria species were identified by microbiological and molecular techniques. Results. A total of 1687 of 48 490 participants (3.4%; 95% confidence interval [CI], 3.2%-3.6%) carried meningococci. Carriage was more frequent in individuals aged 5-14 years, relative to those aged 15-29 years (adjusted odds ratio [OR], 1.41; 95% CI, 1.25-1.60); in males, relative to females (adjusted OR, 1.17; 95% CI, 1.10-1.24); in individuals in rural areas, relative to those in urban areas (adjusted OR, 1.44; 95% CI, 1.28-1.63); and in the dry season, relative to the rainy season (adjusted OR, 1.54; 95% CI, 1.37-1.75). Forty-eight percent of isolates had genes encoding disease-associated polysaccharide capsules; genogroup W predominated, and genogroup A was rare. Strain diversity was lower in countries in the center of the meningitis belt than in Senegal or Ethiopia. The prevalence of genogroup A fell from 0.7% to 0.02% in Chad following mass vaccination with MenAfriVac. Conclusions. The prevalence of meningococcal carriage in the African meningitis belt is lower than in industrialized countries and is very diverse and dynamic, even in the absence of vaccination. C1 [Ali, Oumer; Aseffa, Abraham; Bedru, Ahmed; Lema, Tsehaynesh; Moti, Tesfaye; Tekletsion, Yenenesh; Worku, Alemayehu; Xabher, Haimanot Guebre; Yamuah, Lawrence] Armauer Hansen Res Inst, Addis Ababa, Ethiopia. [Boukary, Rahamatou Moustapha; Collard (PI), Jean-Marc; Dano, Ibrahim Dan; Habiboulaye, Ibrahim; Issaka, Bassira; Jusot, Jean-Francois; Ousmane, Sani; Rabe, Issoufa] Ctr Rech Med & Sanit, Niamey, Niger. [Daugla (PI), Doumagoum Moto; Gami, Jean Pierre; Gamougam, Kadidja; Mbainadji, Lodoum; Naibei, Nathan; Narbe, Maxime; Toralta, Jacques] Ctr Support Sante Int, Ndjamena, Chad. [Berthe, Abdoulaye; Diallo, Kanny; Keita, Mahamadou; Onwuchekwa, Uma; Sow (PI), Samba O.; Tamboura, Boubou; Traore, Awa; Toure, Alou] Ctr Vaccins Dev, Bamako, Mali. [Clark, Tom; Mayer, Leonard] Ctr Dis Control & Prevent, Atlanta, GA USA. [Amodu, Mary; Beida, Omeiza; Gadzama, Galadima; Omotara (PI), Babatunji; Sambo, Zailani; Yahya, Shuaibu] Univ Maiduguri, Dept Community Med, Maiduguri, Nigeria. [Chandramohan, Daniel; Greenwood (PI), Brian M.; Hassan-King, Musa; Manigart, Olivier; Nascimento, Maria; Stuart, James M.; Woukeu, Arouna] London Sch Hyg & Trop Med, Fac Infect Dis, London, England. [Basta, Nicole E.] Princeton Univ, Princeton, NJ 08544 USA. [Bai, Xilian; Borrow, Ray; Findlow, Helen] Publ Hlth England Vaccine Evaluat Unit, Manchester, Lancs, England. [Alavo, Serge; Bassene, Hubert; Diallo (PI), Aldiouma; Dieng, Marietou; Doucoure, Souleymane; Gomis, Jules Francois; Ndiaye, Assane; Sokhna, Cheikh; Trape, Jean Francois] Inst Rech Dev, Dakar, Senegal. [Akalifa, Bugri; Forgor, Abudulai; Hodgson (PI), Abraham; Osei, Isaac; Quaye, Stephen L.; Williams, John; Wontuo, Peter] Navrongo Hlth Res Ctr, Accra, Ghana. [Irving, Thomas; Bennett, Julia; Hill, Dorothea; Harrison, Odile; Maiden, Martin C.; Rebbetts, Lisa; Watkins, Eleanor] Univ Bristol, Bristol BS8 1TH, Avon, England. [Bennett, Julia; Hill, Dorothea; Harrison, Odile; Maiden, Martin C.; Rebbetts, Lisa; Watkins, Eleanor] Univ Cambridge, Cambridge CB2 1TN, England. [Bennett, Julia; Hill, Dorothea; Harrison, Odile; Maiden, Martin C.; Rebbetts, Lisa; Watkins, Eleanor] Univ Oxford, Oxford OX1 2JD, England. RP Greenwood, BM (reprint author), London Sch Hyg & Trop Med, Fac Infect & Trop Dis, Keppel St, London WC1E 7HT, England. EM brian.greenwood@lshtm.ac.uk RI Aseffa, Abraham/J-3248-2016; OI Aseffa, Abraham/0000-0002-8028-1150; Ibrahim, Dan Dano/0000-0003-3281-2452; Trotter, Caroline/0000-0003-4000-2708; Maiden, Martin/0000-0001-6321-5138 FU Bill and Melinda Gates Foundation; Wellcome Trust; National Institutes of Health [DP5OD009162] FX This work was supported by the Bill and Melinda Gates Foundation (to the MenAfriCar Consortium), the Wellcome Trust (to the MenAfriCar Consortium), and the National Institutes of Health (grant DP5OD009162 to N. B.). NR 27 TC 11 Z9 11 U1 0 U2 4 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD OCT 15 PY 2015 VL 212 IS 8 BP 1298 EP 1307 DI 10.1093/infdis/jiv211 PG 10 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA CU0GY UT WOS:000363195400017 ER PT J AU Nicol, MP Gnanashanmugam, D Browning, R Click, ES Cuevas, LE Detjen, A Graham, SM Levin, M Makhene, M Nahid, P Perez-Velez, CM Reither, K Song, R Spiegel, HML Worrell, C Zar, HJ Walzl, G AF Nicol, Mark Patrick Gnanashanmugam, Devasena Browning, Renee Click, Eleanor S. Cuevas, Luis E. Detjen, Anne Graham, Steve M. Levin, Michael Makhene, Mamodikoe Nahid, Payam Perez-Velez, Carlos M. Reither, Klaus Song, Rinn Spiegel, Hans M. L. Worrell, Carol Zar, Heather J. Walzl, Gerhard TI A Blueprint to Address Research Gaps in the Development of Biomarkers for Pediatric Tuberculosis SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE tuberculosis; children; diagnosis; biomarker; blueprint ID XPERT MTB/RIF ASSAY; PULMONARY TUBERCULOSIS; INTRATHORACIC TUBERCULOSIS; CHILDHOOD TUBERCULOSIS; RAPID DIAGNOSIS; STOOL SAMPLES; CHILDREN; AFRICA; URINE; DNA AB Childhood tuberculosis contributes significantly to the global tuberculosis disease burden but remains challenging to diagnose due to inadequate methods of pathogen detection in paucibacillary pediatric samples and lack of a child-specific host biomarker to identify disease. Accurately diagnosing tuberculosis in children is required to improve case detection, surveillance, healthcare delivery, and effective advocacy. In May 2014, the National Institutes of Health convened a workshop including researchers in the field to delineate priorities to address this research gap. This blueprint describes the consensus from the workshop, identifies critical research steps to advance this field, and aims to catalyze efforts toward harmonization and collaboration in this area. C1 [Nicol, Mark Patrick] Univ Cape Town, Div Med Microbiol, ZA-7700 Rondebosch, South Africa. [Nicol, Mark Patrick] Univ Cape Town, Inst Infect Dis & Mol Med, ZA-7700 Rondebosch, South Africa. [Nicol, Mark Patrick] Natl Hlth Lab Serv, Cape Town, South Africa. [Gnanashanmugam, Devasena; Browning, Renee; Makhene, Mamodikoe; Worrell, Carol] NIAID, Bethesda, MD 20892 USA. [Click, Eleanor S.] Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA USA. [Cuevas, Luis E.] Univ Liverpool Liverpool Sch Trop Med, Dept Clin Sci, Liverpool, Merseyside, England. [Detjen, Anne; Graham, Steve M.] Int Union TB & Lung Dis, Paris, France. [Graham, Steve M.] Univ Melbourne, Ctr Int Child Hlth, Melbourne, Vic, Australia. [Graham, Steve M.] Royal Childrens Hosp, Dept Paediat, Melbourne, Vic, Australia. [Graham, Steve M.] Royal Childrens Hosp, Murdoch Childrens Res Inst, Melbourne, Vic, Australia. [Graham, Steve M.] Burnet Inst, Melbourne, Vic, Australia. [Levin, Michael] Univ London Imperial Coll Sci Technol & Med, Dept Pediat, London, England. [Nahid, Payam] Univ Calif San Francisco, Pulm & Crit Care Med, San Francisco, CA 94143 USA. [Perez-Velez, Carlos M.] Univ Arizona, Banner Univ, Coll Med, Div Infect Dis,Med Ctr Phoenix, Tucson, AZ 85721 USA. [Reither, Klaus] Univ Basel, Swiss Trop & Publ Hlth Inst, CH-4003 Basel, Switzerland. [Song, Rinn] Childrens Hosp, Div Infect Dis, Boston, MA 02115 USA. [Song, Rinn] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA. [Spiegel, Hans M. L.] NIAID, HJF DAIDS, Div Henry M Jackson Fdn, Adv Mil Med Inc,NIH, Bethesda, MD 20892 USA. [Zar, Heather J.] Univ Cape Town, Red Cross Childrens Hosp, Dept Paediat & Child Hlth, ZA-7700 Rondebosch, South Africa. [Zar, Heather J.] Univ Cape Town, Med Res Council, Unit Child & Adolescent Hlth, ZA-7700 Rondebosch, South Africa. [Walzl, Gerhard] Univ Stellenbosch, Dept Sci & Technol, ZA-7600 Stellenbosch, South Africa. [Walzl, Gerhard] Univ Stellenbosch, Ctr Excellence Biomed TB Res, Natl Res Fdn,Div Mol Biol & Human Genet, Med Res Council,Ctr TB Res,Fac Med & Hlth Sci, ZA-7600 Stellenbosch, South Africa. RP Nicol, MP (reprint author), Fac Hlth Sci, Anzio Rd, ZA-7925 Cape Town, South Africa. EM mark.nicol@uct.ac.za OI Nicol, Mark/0000-0002-1366-4805; Walzl, Gerhard/0000-0003-2487-125X; Cuevas, Luis E./0000-0002-6581-0587 FU NIAID/NIH; Eunice Kennedy Shriver NICHD; US Department of Health and Human Services [HHSN272200800014C] FX This work was supported by NIAID/NIH and the Eunice Kennedy Shriver NICHD. This project has also been supported in part with federal funds from the NIAID/NIH, US Department of Health and Human Services (contract no. HHSN272200800014C). NR 30 TC 4 Z9 4 U1 2 U2 3 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD OCT 15 PY 2015 VL 61 SU 3 BP S164 EP S172 DI 10.1093/cid/civ613 PG 9 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA CT6WG UT WOS:000362952900010 PM 26409279 ER PT J AU Starks, AM Aviles, E Cirillo, DM Denkinger, CM Dolinger, DL Emerson, C Gallarda, J Hanna, D Kim, PS Liwski, R Miotto, P Schito, M Zignol, M AF Starks, Angela M. Aviles, Enrique Cirillo, Daniela M. Denkinger, Claudia M. Dolinger, David L. Emerson, Claudia Gallarda, Jim Hanna, Debra Kim, Peter S. Liwski, Richard Miotto, Paolo Schito, Marco Zignol, Matteo TI Collaborative Effort for a Centralized Worldwide Tuberculosis Relational Sequencing Data Platform SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE Mycobacterium tuberculosis; drug resistance; database ID DRUG-RESISTANT TUBERCULOSIS; MYCOBACTERIUM-TUBERCULOSIS AB Continued progress in addressing challenges associated with detection and management of tuberculosis requires new diagnostic tools. These tools must be able to provide rapid and accurate information for detecting resistance to guide selection of the treatment regimen for each patient. To achieve this goal, globally representative genotypic, phenotypic, and clinical data are needed in a standardized and curated data platform. A global partnership of academic institutions, public health agencies, and nongovernmental organizations has been established to develop a tuberculosis relational sequencing data platform (ReSeqTB) that seeks to increase understanding of the genetic basis of resistance by correlating molecular data with results from drug susceptibility testing and, optimally, associated patient outcomes. These data will inform development of new diagnostics, facilitate clinical decision making, and improve surveillance for drug resistance. ReSeqTB offers an opportunity for collaboration to achieve improved patient outcomes and to advance efforts to prevent and control this devastating disease. C1 [Starks, Angela M.] Ctr Dis Control & Prevent, Div TB Eliminat, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30329 USA. [Aviles, Enrique; Hanna, Debra; Liwski, Richard; Schito, Marco] Crit Path Inst, Tucson, AZ USA. [Cirillo, Daniela M.; Miotto, Paolo] Ist Sci San Raffaele, Ist Ricovero & Cura Carattere Sci, I-20132 Milan, Italy. [Denkinger, Claudia M.; Dolinger, David L.] Fdn Innovat New Diagnost, Geneva, Switzerland. [Emerson, Claudia] St Michaels Hosp, Li Ka Shing Knowledge Inst, Ctr Eth Social & Cultural Risk, Toronto, ON M5B 1W8, Canada. [Gallarda, Jim] Bill & Melinda Gates Fdn, Seattle, WA USA. [Kim, Peter S.] NIAID, Div AIDS, NIH, Bethesda, MD 20892 USA. [Zignol, Matteo] WHO, TB Monitoring & Evaluat, Global TB Programme, CH-1211 Geneva, Switzerland. RP Starks, AM (reprint author), Ctr Dis Control & Prevent, Div TB Eliminat, 1600 Clifton Rd NE,Bldg 17,Rm 4040,MS F08, Atlanta, GA 30329 USA. EM astarks@cdc.gov RI Miotto, Paolo/E-3940-2017 OI Miotto, Paolo/0000-0003-4610-2427 FU Bill & Melinda Gates Foundation [OPP1115209]; Critical Path Institute [OPP1115887] FX This work was supported by the Bill & Melinda Gates Foundation to Foundation for Innovative New Diagnostics (FIND) (grant number OPP1115209) and the Critical Path Institute (grant number OPP1115887). NR 27 TC 9 Z9 9 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD OCT 15 PY 2015 VL 61 SU 3 BP S141 EP S146 DI 10.1093/cid/civ610 PG 6 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA CT6WG UT WOS:000362952900006 PM 26409275 ER PT J AU Geller, AI Shehab, N Weidle, NJ Lovegrove, MC Wolpert, BJ Timbo, BB Mozersky, RP Budnitz, DS AF Geller, Andrew I. Shehab, Nadine Weidle, Nina J. Lovegrove, Maribeth C. Wolpert, Beverly J. Timbo, Babgaleh B. Mozersky, Robert P. Budnitz, Daniel S. TI Emergency Department Visits for Adverse Events Related to Dietary Supplements SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID HERBAL MEDICINES; UNITED-STATES; SURVEILLANCE; MEDICATIONS; SYSTEM; HEALTH AB BACKGROUND Dietary supplements, such as herbal or complementary nutritional products and micronutrients (vitamins and minerals), are commonly used in the United States, yet national data on adverse effects are limited. METHODS We used nationally representative surveillance data from 63 emergency departments obtained from 2004 through 2013 to describe visits to U.S. emergency departments because of adverse events related to dietary supplements. RESULTS On the basis of 3667 cases, we estimated that 23,005 (95% confidence interval [CI], 18,611 to 27,398) emergency department visits per year were attributed to adverse events related to dietary supplements. These visits resulted in an estimated 2154 hospitalizations (95% CI, 1342 to 2967) annually. Such visits frequently involved young adults between the ages of 20 and 34 years (28.0% of visits; 95% CI, 25.1 to 30.8) and unsupervised children (21.2% of visits; 95% CI, 18.4 to 24.0). After the exclusion of unsupervised ingestion of dietary supplements by children, 65.9% (95% CI, 63.2 to 68.5) of emergency department visits for single-supplement-related adverse events involved herbal or complementary nutritional products; 31.8% (95% CI, 29.2 to 34.3) involved micronutrients. Herbal or complementary nutritional products for weight loss (25.5%; 95% CI, 23.1 to 27.9) and increased energy (10.0%; 95% CI, 8.0 to 11.9) were commonly implicated. Weight-loss or energy products caused 71.8% (95% CI, 67.6 to 76.1) of supplement-related adverse events involving palpitations, chest pain, or tachycardia, and 58.0% (95% CI, 52.2 to 63.7) involved persons 20 to 34 years of age. Among adults 65 years of age or older, choking or pill-induced dysphagia or globus caused 37.6% (95% CI, 29.1 to 46.2) of all emergency department visits for supplement-related adverse events; micronutrients were implicated in 83.1% (95% CI, 73.3 to 92.9) of these visits. CONCLUSIONS An estimated 23,000 emergency department visits in the United States every year are attributed to adverse events related to dietary supplements. Such visits commonly involve cardiovascular manifestations from weight-loss or energy products among young adults and swallowing problems, often associated with micronutrients, among older adults. C1 [Geller, Andrew I.; Shehab, Nadine; Lovegrove, Maribeth C.; Budnitz, Daniel S.] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA USA. [Weidle, Nina J.] Chenega Govt Consulting, Atlanta, GA USA. [Wolpert, Beverly J.; Timbo, Babgaleh B.] US FDA, Ctr Food Safety & Appl Nutr, College Pk, MD USA. [Wolpert, Beverly J.; Timbo, Babgaleh B.] US FDA, Div Publ Hlth Informat & Analyt, College Pk, MD USA. [Mozersky, Robert P.] US FDA, Div Dietary Supplement Programs, College Pk, MD USA. RP Geller, AI (reprint author), CDC, Div Healthcare Qual Promot, 1825 Century Blvd NE,Mailstop D-26, Atlanta, GA 30345 USA. EM ageller@cdc.gov FU Department of Health and Human Services FX Funded by the Department of Health and Human Services. NR 32 TC 32 Z9 34 U1 4 U2 18 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 EI 1533-4406 J9 NEW ENGL J MED JI N. Engl. J. Med. PD OCT 15 PY 2015 VL 373 IS 16 BP 1531 EP 1540 DI 10.1056/NEJMsa1504267 PG 10 WC Medicine, General & Internal SC General & Internal Medicine GA CT5VX UT WOS:000362880300009 PM 26465986 ER PT J AU Grayzel, SE Bender, JB Glore, RP Gumley, N Sykes, JE Whichard, JM Papich, MG Watts, JL Barlam, TF Murphy, MJ Hoang, C AF Grayzel, Sharon E. Bender, Jeff B. Glore, Reilly P. Gumley, Nigel Sykes, Jane E. Whichard, Jean M. Papich, Mark G. Watts, Jeffrey L. Barlam, Tamar F. Murphy, Michael J. Hoang, Christine CA AVMA Task Force Antimicrobial Stew TI Understanding companion animal practitioners' attitudes toward antimicrobial stewardship SO JAVMA-JOURNAL OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION LA English DT Editorial Material ID DRUG-USE; GUIDELINES; DOGS C1 [Grayzel, Sharon E.] Columbia Vet Ctr, Vancouver, WA 98665 USA. [Bender, Jeff B.] Univ Minnesota, Coll Vet Med, Dept Vet Populat Med, St Paul, MN 55108 USA. [Glore, Reilly P.] Brady Vet Hosp, Montesano, WA 98563 USA. [Gumley, Nigel] Canadian Vet Med Assoc, Ottawa, ON K1R 7K1, Canada. [Sykes, Jane E.] Univ Calif Davis, Sch Vet Med, Dept Med & Epidemiol, Davis, CA 95616 USA. [Whichard, Jean M.] CDC, Atlanta, GA 30329 USA. [Papich, Mark G.] N Carolina State Univ, Coll Vet Med, Dept Mol Biomed Sci, Raleigh, NC 27607 USA. [Watts, Jeffrey L.] Anti Infect Res VMRD, Kalamazoo, MI 49009 USA. [Barlam, Tamar F.] Boston Med Ctr, Infect Dis Sect, Boston, MA 02118 USA. [Murphy, Michael J.] US FDA, Ctr Vet Med, Rockville, MD 20855 USA. [Hoang, Christine] AVMA, Schaumburg, IL 60173 USA. RP Grayzel, SE (reprint author), Columbia Vet Ctr, 5106 NE 78th St, Vancouver, WA 98665 USA. EM sgrayzel@comcast.net NR 6 TC 0 Z9 0 U1 4 U2 6 PU AMER VETERINARY MEDICAL ASSOC PI SCHAUMBURG PA 1931 N MEACHAM RD SUITE 100, SCHAUMBURG, IL 60173-4360 USA SN 0003-1488 EI 1943-569X J9 JAVMA-J AM VET MED A JI JAVMA-J. Am. Vet. Med. Assoc. PD OCT 15 PY 2015 VL 247 IS 8 BP 883 EP 884 PG 2 WC Veterinary Sciences SC Veterinary Sciences GA CS6QY UT WOS:000362207300036 ER PT J AU Nett, RJ Witte, TK Holzbauer, SM Elchos, BL Campagnolo, ER Musgrave, KJ Carter, KK Kurkjian, KM Vanicek, CF O'Leary, DR Pride, KR Funk, RH AF Nett, Randall J. Witte, Tracy K. Holzbauer, Stacy M. Elchos, Brigid L. Campagnolo, Enzo R. Musgrave, Karl J. Carter, Kris K. Kurkjian, Katie M. Vanicek, Cole F. O'Leary, Daniel R. Pride, Kerry R. Funk, Renee H. TI Risk factors for suicide, attitudes toward mental illness, and practice-related stressors among US veterinarians SO JAVMA-JOURNAL OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION LA English DT Article ID UNITED-STATES; COMPLETED SUICIDE; HEALTH; DEPRESSION; IDEATION; STUDENTS; BURNOUT; ANXIETY; SURVEILLANCE; POPULATION AB Objective-To evaluate the prevalence of suicide risk factors, attitudes toward mental illness, and practice-related stressors among US veterinarians. Design-Cross-sectional survey. Sample-11,627 US veterinarians. Procedures-Between July 1 and October 20, 2014, a Web-based questionnaire was made available through the Veterinary Information Network (VIN), VIN News Service, JAVMA News, and email messages to US veterinarians sent by a veterinary medical association, agriculture or livestock department, or health department of each state (except Maine) and Puerto Rico. Results-Of 11,627 respondents, 3,628 (31%) were male. Modal age category was 30 to 39 years, and modal range for years practicing veterinary medicine was 10 to 19 years. There were 7,460 (64%) respondents who primarily practiced small animal medicine, and 4,224 (36%) who were practice owners. There were 1,077 (9%) respondents with current serious psychological distress. Since leaving veterinary school, 3,655 (31%) respondents experienced depressive episodes, 1,952 (17%) experienced suicidal ideation, and 157 (1%) attempted suicide. Currently, 2,228 (19%) respondents were receiving treatment for a mental health condition. Only 3,250 of 10,220 (32%) respondents somewhat or strongly agreed that people are sympathetic toward persons with mental illness. The most commonly reported practice-related stressor was demands of practice. Conclusions and Clinical Relevance-In this survey, approximately 1 in 11 veterinarians had serious psychological distress and 1 in 6 experienced suicidal ideation since leaving veterinary school. Implementing measures to help veterinarians cope with practice-related stressors and reducing barriers veterinarians face in seeking mental health treatment might reduce the risk for suicide among veterinarians. C1 [Nett, Randall J.; Holzbauer, Stacy M.; Campagnolo, Enzo R.; Kurkjian, Katie M.; O'Leary, Daniel R.] CDC, Off Publ Hlth Preparedness & Response, Atlanta, GA 30329 USA. [Funk, Renee H.] CDC, NIOSH, Atlanta, GA 30329 USA. [Nett, Randall J.; Pride, Kerry R.] Montana Dept Publ Hlth & Human Serv, Helena, MT 59620 USA. [Witte, Tracy K.] Auburn Univ, Coll Liberal Arts, Dept Psychol, Auburn, AL 36849 USA. [Holzbauer, Stacy M.] Minnesota Dept Hlth, St Paul, MN 55164 USA. [Elchos, Brigid L.] Mississippi Board Anim Hlth, Jackson, MS 39201 USA. [Campagnolo, Enzo R.] Penn Dept Hlth, Harrisburg, PA 17120 USA. [Musgrave, Karl J.; O'Leary, Daniel R.] Wyoming Dept Hlth, Cheyenne, WY 82002 USA. [Carter, Kris K.] Idaho Dept Hlth & Welf, Boise, ID 83702 USA. [Kurkjian, Katie M.] Virginia Dept Hlth, Richmond, VA 23218 USA. [Vanicek, Cole F.] Nebraska Dept Hlth & Human Serv, Lincoln, NE 68508 USA. RP Nett, RJ (reprint author), CDC, 1095 Willowdale Rd,MS-2800, Morgantown, WV 26505 USA. EM rnett@cdc.gov NR 43 TC 14 Z9 14 U1 15 U2 31 PU AMER VETERINARY MEDICAL ASSOC PI SCHAUMBURG PA 1931 N MEACHAM RD SUITE 100, SCHAUMBURG, IL 60173-4360 USA SN 0003-1488 EI 1943-569X J9 JAVMA-J AM VET MED A JI JAVMA-J. Am. Vet. Med. Assoc. PD OCT 15 PY 2015 VL 247 IS 8 BP 945 EP 955 PG 11 WC Veterinary Sciences SC Veterinary Sciences GA CS6QY UT WOS:000362207300047 PM 26421408 ER PT J AU O'Halloran, AC Lu, PJ Pilishvili, T AF O'Halloran, Alissa C. Lu, Peng-jun Pilishvili, Tamara TI Pneumococcal vaccination coverage among persons >= 65 years-United States, 2013 SO VACCINE LA English DT Article DE Pneumococcal vaccination ID INFLUENZA VACCINATION; POLYSACCHARIDE VACCINE; ADULTS; DISPARITIES; RECOMMENDATIONS; PREVENTION; CARE AB Background: Invasive pneumococcal disease is a major cause of illness in the United States, and rates are higher among persons >= 65 years. Pneumococcal vaccination has been recommended to adults >= 65 years since 1997. Methods: Data from the 2005-2013 Behavioral Risk Factor Surveillance System were analyzed. Weighted estimates of pneumococcal vaccination coverage were calculated by state and race/ethnicity and tests for linear trend were performed. Results: In 2013, the median state vaccination coverage among adults >= 65 years was 69.5%, and coverage ranged from 61.9% in New Jersey to 75.6% in Oregon. Coverage overall among non-Hispanic whites (71.1%) was higher than coverage for non-Hispanic blacks (57.7%), Hispanics (51.9%), and non-Hispanic persons of other race (65.4%). Coverage increased from 2005 to 2013 overall and by racial/ethnic subgroups. Conclusion: Although pneumococcal vaccination coverage has improved in the past several years, coverage remains below the Healthy People 2020 target of 90% and racial/ethnic disparities exist. (C) 2015 Elsevier Ltd. All rights reserved. C1 [O'Halloran, Alissa C.; Lu, Peng-jun] CDC, Natl Ctr Immunizat & Resp Dis, Immunizat Serv Div, Atlanta, GA 30329 USA. [Pilishvili, Tamara] CDC, Natl Ctr Immunizat & Resp Dis, Div Bacterial Dis, Atlanta, GA 30329 USA. RP O'Halloran, AC (reprint author), CDC, Natl Ctr Immunizat & Resp Dis, Immunizat Serv Div, 1600 Clifton Rd NE,Mail Stop A19, Atlanta, GA 30329 USA. EM idg3@cdc.gov NR 22 TC 2 Z9 2 U1 0 U2 0 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD OCT 13 PY 2015 VL 33 IS 42 BP 5503 EP 5506 DI 10.1016/j.vaccine.2015.09.002 PG 4 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA CV4WZ UT WOS:000364268500008 PM 26372859 ER PT J AU Guh, AY Bulens, SN Mu, Y Jacob, JT Reno, J Scott, J Wilson, LE Vaeth, E Lynfield, R Shaw, KM Vagnone, PMS Bamberg, WM Janelle, SJ Dumyati, G Concannon, C Beldavs, Z Cunningham, M Cassidy, PM Phipps, EC Kenslow, N Travis, T Lonsway, D Rasheed, JK Limbago, BM Kallen, AJ AF Guh, Alice Y. Bulens, Sandra N. Mu, Yi Jacob, Jesse T. Reno, Jessica Scott, Janine Wilson, Lucy E. Vaeth, Elisabeth Lynfield, Ruth Shaw, Kristin M. Vagnone, Paula M. Snippes Bamberg, Wendy M. Janelle, Sarah J. Dumyati, Ghinwa Concannon, Cathleen Beldavs, Zintars Cunningham, Margaret Cassidy, P. Maureen Phipps, Erin C. Kenslow, Nicole Travis, Tatiana Lonsway, David Rasheed, J. Kamile Limbago, Brandi M. Kallen, Alexander J. TI Epidemiology of Carbapenem-Resistant Enterobacteriaceae in 7 US Communities, 2012-2013 SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Article ID ESCHERICHIA-COLI INFECTION; SPECTRUM BETA-LACTAMASE; TERM-CARE FACILITIES; KLEBSIELLA-PNEUMONIAE; UNITED-STATES; ACTIVE SURVEILLANCE; PREVENTION; EMERGENCE; BURDEN AB IMPORTANCE Carbapenem-resistant Enterobacteriaceae (CRE) are increasingly reported worldwide as a cause of infections with high-mortality rates. Assessment of the US epidemiology of CRE is needed to inform national prevention efforts. OBJECTIVE To determine the population-based CRE incidence and describe the characteristics and resistance mechanism associated with isolates from 7 US geographical areas. DESIGN, SETTING, AND PARTICIPANTS Population-and laboratory-based active surveillance of CRE conducted among individuals living in 1 of 7 US metropolitan areas in Colorado, Georgia, Maryland, Minnesota, New Mexico, New York, and Oregon. Cases of CRE were defined as carbapenem-nonsusceptible (excluding ertapenem) and extended-spectrum cephalosporin-resistant Escherichia coli, Enterobacter aerogenes, Enterobacter cloacae complex, Klebsiella pneumoniae, or Klebsiella oxytoca that were recovered from sterile-site or urine cultures during 2012-2013. Case records were reviewed and molecular typing for common carbapenemases was performed. EXPOSURES Demographics, comorbidities, health care exposures, and culture source and location. MAIN OUTCOMES AND MEASURES Population-based CRE incidence, site-specific standardized incidence ratios (adjusted for age and race), and clinical and microbiological characteristics. RESULTS Among 599 CRE cases in 481 individuals, 520 (86.8%; 95% CI, 84.1%-89.5%) were isolated from urine and 68 (11.4%; 95% CI, 8.8%-13.9%) from blood. The median age was 66 years (95% CI, 62.1-65.4 years) and 284 (59.0%; 95% CI, 54.6%-63.5%) were female. The overall annual CRE incidence rate per 100 000 population was 2.93 (95% CI, 2.65-3.23). The CRE standardized incidence ratio was significantly higher than predicted for the sites in Georgia (1.65 [95% CI, 1.20-2.25]; P < .001), Maryland (1.44 [95% CI, 1.06-1.96]; P = .001), and New York (1.42 [95% CI, 1.05-1.92]; P = .048), and significantly lower than predicted for the sites in Colorado (0.53 [95% CI, 0.39-0.71]; P < .001), New Mexico (0.41 [95% CI, 0.30-0.55]; P = .01), and Oregon (0.28 [95% CI, 0.21-0.38]; P < .001). Most cases occurred in individuals with prior hospitalizations (399/531 [75.1%; 95% CI, 71.4%-78.8%]) or indwelling devices (382/525 [72.8%; 95% CI, 68.9%-76.6%]); 180 of 322 (55.9%; 95% CI, 50.0%-60.8%) admitted cases resulted in a discharge to a long-term care setting. Death occurred in 51 (9.0%; 95% CI, 6.6%-11.4%) cases, including in 25 of 91 cases (27.5%; 95% CI, 18.1%-36.8%) with CRE isolated from normally sterile sites. Of 188 isolates tested, 90 (47.9%; 95% CI, 40.6%-55.1%) produced a carbapenemase. CONCLUSIONS AND RELEVANCE In this population-and laboratory-based active surveillance system in 7 states, the incidence of CRE was 2.93 per 100 000 population. Most CRE cases were isolated from a urine source, and were associated with high prevalence of prior hospitalizations or indwelling devices, and discharge to long-term care settings. C1 [Guh, Alice Y.; Bulens, Sandra N.; Mu, Yi; Travis, Tatiana; Lonsway, David; Rasheed, J. Kamile; Limbago, Brandi M.; Kallen, Alexander J.] US Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA 30329 USA. [Jacob, Jesse T.] Emory Univ, Sch Med, Atlanta, GA USA. [Jacob, Jesse T.; Reno, Jessica; Scott, Janine] Georgia Emerging Infect Program, Decatur, GA USA. [Reno, Jessica; Scott, Janine] Atlanta Res & Educ Fdn, Decatur, GA USA. [Reno, Jessica; Scott, Janine] Atlanta Vet Affairs Med Ctr, Atlanta, GA USA. [Wilson, Lucy E.; Vaeth, Elisabeth] Maryland Dept Hlth & Mental Hyg, Baltimore, MD USA. [Lynfield, Ruth; Shaw, Kristin M.; Vagnone, Paula M. Snippes] Minnesota Dept Hlth, St Paul, MN USA. [Bamberg, Wendy M.; Janelle, Sarah J.] Colorado Dept Publ Hlth & Environm, Denver, CO USA. [Dumyati, Ghinwa; Concannon, Cathleen] New York Emerging Infect Program, Rochester, NY USA. [Dumyati, Ghinwa; Concannon, Cathleen] Univ Rochester, Med Ctr, Rochester, NY 14627 USA. [Beldavs, Zintars; Cunningham, Margaret; Cassidy, P. Maureen] Oregon Hlth Author, Portland, OR USA. [Phipps, Erin C.; Kenslow, Nicole] Univ New Mexico, Albuquerque, NM 87131 USA. RP Kallen, AJ (reprint author), US Ctr Dis Control & Prevent, Div Healthcare Qual Promot, 1600 Clifton Rd,MS A-31, Atlanta, GA 30329 USA. EM akallen@cdc.gov RI Jacob, Jesse/A-8836-2009 FU Emerging Infections Program; National Center for Emerging and Zoonotic Infectious Diseases at the US Centers for Disease Control and Prevention FX This work was supported by the Emerging Infections Program and the National Center for Emerging and Zoonotic Infectious Diseases at the US Centers for Disease Control and Prevention. NR 29 TC 32 Z9 32 U1 1 U2 4 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD OCT 13 PY 2015 VL 314 IS 14 BP 1479 EP 1487 DI 10.1001/jama.2015.12480 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA CT2QI UT WOS:000362647800015 PM 26436831 ER PT J AU Grijalva, CG Zhu, YW Williams, DJ Self, WH Ampofo, K Pavia, AT Stockmann, CR McCullers, J Arnold, SR Wunderink, RG Anderson, EJ Lindstrom, S Fry, AM Foppa, IM Finelli, L Bramley, AM Jain, S Griffin, MR Edwards, KM AF Grijalva, Carlos G. Zhu, Yuwei Williams, Derek J. Self, Wesley H. Ampofo, Krow Pavia, Andrew T. Stockmann, Chris R. McCullers, Jonathan Arnold, Sandra R. Wunderink, Richard G. Anderson, Evan J. Lindstrom, Stephen Fry, Alicia M. Foppa, Ivo M. Finelli, Lyn Bramley, Anna M. Jain, Seema Griffin, Marie R. Edwards, Kathryn M. TI Association Between Hospitalization With Community-Acquired Laboratory-Confirmed Influenza Pneumonia and Prior Receipt of Influenza Vaccination SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Article ID IMMUNIZATION PRACTICES ACIP; TEST-NEGATIVE DESIGN; SEASONAL INFLUENZA; REQUIRING HOSPITALIZATION; VACCINES RECOMMENDATIONS; ADVISORY-COMMITTEE; YOUNG-CHILDREN; UNITED-STATES; US CHILDREN; ADULTS AB IMPORTANCE Few studies have evaluated the relationship between influenza vaccination and pneumonia, a serious complication of influenza infection. OBJECTIVE To assess the association between influenza vaccination status and hospitalization for community-acquired laboratory-confirmed influenza pneumonia. DESIGN, SETTING, AND PARTICIPANTS The Etiology of Pneumonia in the Community (EPIC) study was a prospective observational multicenter study of hospitalizations for community-acquired pneumonia conducted from January 2010 through June 2012 at 4 US sites. In this case-control study, we used EPIC data from patients 6 months or older with laboratory-confirmed influenza infection and verified vaccination status during the influenza seasons and excluded patients with recent hospitalization, from chronic care residential facilities, and with severe immunosuppression. Logistic regression was used to calculate odds ratios, comparing the odds of vaccination between influenza-positive (case) and influenza-negative (control) patients with pneumonia, controlling for demographics, comorbidities, season, study site, and timing of disease onset. Vaccine effectiveness was estimated as (1 - adjusted odds ratio) x 100%. EXPOSURE Influenza vaccination, verified through record review. MAIN OUTCOMES AND MEASURES Influenza pneumonia, confirmed by real-time reverse-transcription polymerase chain reaction performed on nasal/oropharyngeal swabs. RESULTS Overall, 2767 patients hospitalized for pneumonia were eligible for the study; 162 (5.9%) had laboratory-confirmed influenza. Twenty-eight of 162 cases (17%) with influenza-associated pneumonia and 766 of 2605 controls (29%) with influenza-negative pneumonia had been vaccinated. The adjusted odds ratio of prior influenza vaccination between cases and controls was 0.43 (95% CI, 0.28-0.68; estimated vaccine effectiveness, 56.7%; 95% CI, 31.9%-72.5%). CONCLUSIONS AND RELEVANCE Among children and adults hospitalized with community-acquired pneumonia, those with laboratory-confirmed influenza-associated pneumonia, compared with those with pneumonia not associated with influenza, had lower odds of having received influenza vaccination. C1 [Grijalva, Carlos G.; Zhu, Yuwei; Williams, Derek J.; Self, Wesley H.; Griffin, Marie R.; Edwards, Kathryn M.] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA. [Grijalva, Carlos G.; Griffin, Marie R.] VA Tennessee Valley, Geriatr Res Educ Clin Ctr, Nashville, TN USA. [Ampofo, Krow; Pavia, Andrew T.; Stockmann, Chris R.] Univ Utah, Sch Med, Salt Lake City, UT USA. [McCullers, Jonathan; Arnold, Sandra R.] Univ Tennessee, Sch Med, Memphis, TN USA. [Wunderink, Richard G.] Northwestern Univ, Sch Med, Chicago, IL USA. [Anderson, Evan J.] Emory Univ, Sch Med, Atlanta, GA USA. [Lindstrom, Stephen; Fry, Alicia M.; Foppa, Ivo M.; Finelli, Lyn; Bramley, Anna M.; Jain, Seema] Ctr Dis Control & Prevent, Atlanta, GA USA. [Foppa, Ivo M.] Battelle Mem Inst, Atlanta, GA USA. RP Grijalva, CG (reprint author), Vanderbilt Univ, Sch Med, Dept Hlth Policy, 1500 21st Ave S,Village Vanderbilt Ste 2600, Nashville, TN 37212 USA. EM carlos.grijalva@vanderbilt.edu OI Wunderink, Richard/0000-0002-8527-4195 FU Influenza Division in the National Center for Immunization and Respiratory Diseases at the Centers for Disease Control and Prevention (CDC) FX This study was funded by the Influenza Division in the National Center for Immunization and Respiratory Diseases at the Centers for Disease Control and Prevention (CDC). NR 40 TC 4 Z9 5 U1 1 U2 6 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD OCT 13 PY 2015 VL 314 IS 14 BP 1488 EP 1497 DI 10.1001/jama.2015.12160 PG 10 WC Medicine, General & Internal SC General & Internal Medicine GA CT2QI UT WOS:000362647800016 PM 26436611 ER PT J AU Eisenberg, Y Rimmer, JH Mehta, T Fox, MH AF Eisenberg, Yochai Rimmer, James H. Mehta, Tapan Fox, Michael H. TI Development of a community health inclusion index: an evaluation tool for improving inclusion of people with disabilities in community health initiatives SO BMC PUBLIC HEALTH LA English DT Article DE Physical activity; Nutrition; Obesity; Disability; Community health; Accessibility; Built environment ID PHYSICAL-ACTIVITY; UNITED-STATES; ENVIRONMENT INSTRUMENTS; SECONDARY CONDITIONS; BUILT ENVIRONMENT; PREVENTION; BARRIERS; OBESITY; ADULTS; PROMOTION AB Background: Community health initiatives often do not provide enough supports for people with disabilities to fully participate in healthy, active living opportunities. The purpose of this study was to design an instrument that focused on integrating disability-related items into a multi-level survey tool that assessed healthy, active living initiatives. Methods: The development and testing of the Community Health Inclusion Index (CHII) involved four components: (a) literature review of studies that examined barriers and facilitators to healthy, active living; (b) focus groups with persons with disabilities and professionals living in geographically diverse settings; (c) expert panel to establish a final set of critical items; and (d) field testing the CHII in 164 sites across 15 communities in 5 states to assess the instrument's reliability. Results: Results from initial analysis of these data indicated that the CHII has good reliability. Depending on the subscale, Cronbach's alpha ranged from 0.700 to 0.965. The CHII's inter-rater agreement showed that 14 of the 15 venues for physical activity or healthy eating throughout a community had strong agreement (0.81 - 1.00), while one venue had substantial agreement (0.61 - 0.80). Conclusion: The CHII is the first instrument to operationalize community health inclusion into a comprehensive assessment tool that can be used by public health professionals and community coalitions to examine the critical supports needed for improving healthy, active living among people with disabilities. C1 [Eisenberg, Yochai] Inst Disabil & Human Dev, Chicago, IL 60608 USA. [Rimmer, James H.; Mehta, Tapan] Univ Alabama Birmingham, Lakeshore Fdn Res Collaborat, Birmingham, AL 35209 USA. [Fox, Michael H.] Ctr Dis Control & Prevent, Div Human Dev & Disabil, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. RP Eisenberg, Y (reprint author), Inst Disabil & Human Dev, 1640 W Roosevelt Rd M-C 626, Chicago, IL 60608 USA. EM yeisen2@uic.edu FU Centers for Disease Control and Prevention [BAA 2011-N-13396] FX The contents of this article were developed through a cooperative agreement from the Centers for Disease Control and Prevention Grant # BAA 2011-N-13396. However, the findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. NR 36 TC 2 Z9 2 U1 6 U2 13 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2458 J9 BMC PUBLIC HEALTH JI BMC Public Health PD OCT 13 PY 2015 VL 15 AR 1050 DI 10.1186/s12889-015-2381-2 PG 11 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CU2WX UT WOS:000363385500001 PM 26462917 ER PT J AU Edison, L Beaudoin, A Goh, L Introcaso, CE Martin, D Dubray, C Marrone, J Van Beneden, C AF Edison, Laura Beaudoin, Amanda Goh, Lucy Introcaso, Camille E. Martin, Diana Dubray, Christine Marrone, James Van Beneden, Chris TI Scabies and Bacterial Superinfection among American Samoan Children, 2011-2012 SO PLOS ONE LA English DT Article ID PARASITIC SKIN DISEASES; SARCOPTES-SCABIEI; RURAL-COMMUNITY; GLOBAL CONTROL; MANAGEMENT; MORBIDITY; EPIDEMIOLOGY; IVERMECTIN; SURVIVAL; BRAZIL AB Background Scabies, a highly pruritic and contagious mite infestation of the skin, is endemic among tropical regions and causes a substantial proportion of skin disease among lower-income countries. Delayed treatment can lead to bacterial superinfection, and treatment of close contacts is necessary to prevent reinfestation. We describe scabies incidence and superinfection among children in American Samoa (AS) to support scabies control recommendations. Methodology/Principal Findings We reviewed 2011-2012 pharmacy records from the only AS pharmacy to identify children aged <= 14 years with filled prescriptions for permethrin, the only scabicide available in AS. Medical records of identified children were reviewed for physician-diagnosed scabies during January 1, 2011-December 31, 2012. We calculated scabies incidence, bacterial superinfection prevalence, and reinfestation prevalence during 14-365 days after first diagnosis. We used log binomial regression to calculate incidence ratios for scabies by age, sex, and county. Medical record review identified 1,139 children with scabies (incidence 29.3/1,000 children aged <= 14 years); 604 (53%) had a bacterial superinfection. Of 613 children who received a scabies diagnosis during 2011, 94 (15.3%) had one or more reinfestation. Scabies incidence varied significantly among the nine counties (range 14.8-48.9/1,000 children). Children aged < 1 year had the highest incidence (99.9/1,000 children). Children aged 0-4 years were 4.9 times more likely and those aged 5-9 years were 2.2 times more likely to have received a scabies diagnosis than children aged 10-14 years. Conclusions/Significance Scabies and its sequelae cause substantial morbidity among AS children. Bacterial superinfection prevalence and frequent reinfestations highlight the importance of diagnosing scabies and early treatment of patients and close contacts. Investigating why certain AS counties have a lower scabies incidence might help guide recommendations for improving scabies control among counties with a higher incidence. We recommend interventions targeting infants and young children who have frequent close family contact. C1 [Edison, Laura; Beaudoin, Amanda] Ctr Dis Control & Prevent, Epidemiol Workforce Branch, Atlanta, GA USA. [Goh, Lucy; Marrone, James] Lyndon B Johnson Trop Med Ctr, Dept Pediat, Pago Pago, GA USA. [Introcaso, Camille E.] Penn Ctr Dermatol, Philadelphia, PA USA. [Martin, Diana; Dubray, Christine] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Atlanta, GA USA. [Van Beneden, Chris] Ctr Dis Control & Prevent, Resp Dis Branch, Atlanta, GA USA. RP Edison, L (reprint author), Georgia Dept Publ Hlth, Epidemiol, 2 Peachtree St NW,Suite 14-232, Atlanta, GA 30303 USA. EM kgq2@cdc.gov NR 32 TC 0 Z9 0 U1 2 U2 3 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD OCT 12 PY 2015 VL 10 IS 10 AR e0139336 DI 10.1371/journal.pone.0139336 PG 10 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CT6YZ UT WOS:000362961100010 PM 26458270 ER PT J AU Landman, KZ Jean, SE Existe, A Akom, EE Chang, MA Lemoine, JF Mace, KE AF Landman, Keren Z. Jean, Samuel E. Existe, Alexandre Akom, Eniko E. Chang, Michelle A. Lemoine, Jean Frantz Mace, Kimberly E. TI Evaluation of case management of uncomplicated malaria in Haiti: a national health facility survey, 2012 SO MALARIA JOURNAL LA English DT Article DE Malaria; Plasmodium falciparum; Haiti; Case management; Diagnostic tests; Routine; Guideline adherence AB Background: Malaria is a public health concern in Haiti, although there are limited data on its burden and case management. National malaria guidelines updated in 2012 recommend treatment with chloroquine and primaquine. In December 2012, a nationally-representative cross-sectional survey of health facilities (HFs) was conducted to determine malaria prevalence among febrile outpatients and malaria case management quality at baseline before scale-up of diagnostics and case management training. Methods: Among all 833 HFs nationwide, 30 were selected randomly, in proportion to total HFs per region, for 2-day evaluations. Survey teams inventoried HF material and human resources. Outpatients of all ages were screened for temperature >37.5 degrees C or history of fever; those without severe symptoms were consented and enrolled. Providers evaluated and treated enrolled patients according to HF standards; the survey teams documented provider-ordered diagnostic tests and treatment decisions. Facility-based test results [microscopy and malaria rapid diagnostic tests (RDTs)] were collected from HF laboratories. Blood smears for gold-standard microscopy, and dried blood spots for polymerase chain reaction (PCR) were obtained. Results: Malaria diagnostic capacity, defined as completing a test for an enrolled patient or having adequate resources for RDTs or microscopy, was present in 11 (37 %) HFs. Among 459 outpatients screened, 257 (56 %) were febrile, of which 193 (75 %) were eligible, and 153 (80 %) were enrolled. Among 39 patients with facility-level malaria test results available on the survey day, 11 (28 %) were positive, of whom 6 (55 %) were treated with an anti-malarial. Twenty-seven (95 %) of the 28 patients testing negative were not treated with an anti-malarial. Of 114 patients without test results available, 35 (31 %) were presumptively treated for malaria. Altogether, 42 patients were treated with an anti-malarial, one (2 %) according to Haiti's 2012 guidelines. Of 140 gold-standard smears, none were positive, although one patient tested positive by PCR, a more sensitive technique. The national prevalence of malaria among febrile outpatients is estimated to be 0.5 % (95 % confidence interval 0-1.7 %). Conclusions: Malaria is an uncommon cause of fever in Haitian outpatients, and limited, often inaccurate, diagnostic capacity at baseline contributes to over diagnosis. Scale-up of diagnostics and training on new guidelines should improve malaria diagnosis and treatment in Haiti. C1 [Landman, Keren Z.; Chang, Michelle A.; Mace, Kimberly E.] US Ctr Dis Control & Prevent, Malaria Branch, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA 30333 USA. [Jean, Samuel E.; Akom, Eniko E.] Populat Serv Int Org Haitienne Mkt Social Sante, Port Au Prince, Haiti. [Existe, Alexandre] MSPP, Lab Natl Sante Publ, Port Au Prince, Haiti. [Lemoine, Jean Frantz] MSPP, Programme Natl Controle Malaria, Port Au Prince, Haiti. RP Mace, KE (reprint author), US Ctr Dis Control & Prevent, Malaria Branch, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA 30333 USA. EM kmace@cdc.gov NR 21 TC 0 Z9 0 U1 1 U2 1 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1475-2875 J9 MALARIA J JI Malar. J. PD OCT 9 PY 2015 VL 14 AR 394 DI 10.1186/s12936-015-0901-2 PG 12 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA CT2KO UT WOS:000362630600001 PM 26450272 ER PT J AU Gray, KM Valverde, EE Tang, T Siddiqi, AEA Hall, HI AF Gray, Kristen Mahle Valverde, Eduardo E. Tang, Tian Siddiqi, Azfar-e-Alam Hall, H. Irene TI Diagnoses and Prevalence of HIV Infection Among Hispanics or Latinos - United States, 2008-2013 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID PUERTO-RICO C1 [Gray, Kristen Mahle; Valverde, Eduardo E.; Siddiqi, Azfar-e-Alam; Hall, H. Irene] CDC, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Div HIV AIDS Prevent, Atlanta, GA 30333 USA. [Tang, Tian] ICF Int, Atlanta, GA USA. RP Gray, KM (reprint author), CDC, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Div HIV AIDS Prevent, Atlanta, GA 30333 USA. EM kgray1@cdc.gov NR 10 TC 1 Z9 1 U1 0 U2 3 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD OCT 9 PY 2015 VL 64 IS 39 BP 1097 EP 1103 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CT1JM UT WOS:000362554600002 PM 26448539 ER PT J AU Simeone, RM Feldkamp, ML Reefhuis, J Mitchell, AA Gilboa, SM Honein, MA Iskander, J AF Simeone, Regina M. Feldkamp, Marcia L. Reefhuis, Jennita Mitchell, Allen A. Gilboa, Suzanne M. Honein, Margaret A. Iskander, John TI CDC Grand Rounds: Understanding the Causes of Major Birth Defects - Steps to Prevention SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID NEURAL-TUBE DEFECTS; H1N1 INFLUENZA VACCINE; PRETERM DELIVERY; GESTATIONAL-AGE; UNITED-STATES; FOLIC-ACID; PREVALENCE; MORTALITY; INFANTS; SAFETY C1 [Simeone, Regina M.; Reefhuis, Jennita; Gilboa, Suzanne M.; Honein, Margaret A.] CDC, Natl Ctr Birth Defects & Dev Disabil, Div Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. [Feldkamp, Marcia L.] Univ Utah, Sch Med, Dept Pediat, Div Med Genet, Salt Lake City, UT 84112 USA. [Mitchell, Allen A.] Boston Univ, Slone Epidemiol Ctr, Boston, MA 02215 USA. [Iskander, John] CDC, Off Associate Director Sci, Atlanta, GA 30333 USA. RP Simeone, RM (reprint author), CDC, Natl Ctr Birth Defects & Dev Disabil, Div Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. EM uzx8@cdc.gov NR 17 TC 0 Z9 0 U1 2 U2 10 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD OCT 9 PY 2015 VL 64 IS 39 BP 1104 EP 1107 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CT1JM UT WOS:000362554600003 PM 26447345 ER PT J AU Gleason, B Redd, J Kilmarx, P Sesay, T Bayor, F Mozalevskis, A Connolly, A Akpablie, J Prybylski, D Moffett, D King, M Bass, M Joseph, K Jones, J Ocen, F AF Gleason, Brigette Redd, John Kilmarx, Peter Sesay, Tom Bayor, Francis Mozalevskis, Antons Connolly, Allison Akpablie, James Prybylski, Dimitri Moffett, Daphne King, Michael Bass, Micah Joseph, Kristy Jones, Jefferson Ocen, Francis TI Establishment of an Ebola Treatment Unit and Laboratory - Bombali District, Sierra Leone, July 2014-January 2015 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID WEST-AFRICA C1 [Gleason, Brigette; Jones, Jefferson] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Redd, John] CDC, Off Publ Hlth Preparedness & Response, Atlanta, GA 30333 USA. [Kilmarx, Peter; Prybylski, Dimitri; Moffett, Daphne; Joseph, Kristy] CDC, Ctr Global Hlth, Atlanta, GA 30333 USA. [Kilmarx, Peter] CDC Zimbabwe, Atlanta, GA USA. [Sesay, Tom; Bayor, Francis] Sierra Leone Minist Hlth & Sanitat, Bombali Dist, Sierra Leone. [Mozalevskis, Antons; Connolly, Allison; Akpablie, James] WHO, Ebola Response Bombali Dist, Bombali, Sierra Leone. [Prybylski, Dimitri] CDC Namibia, Windhoek, Namibia. [Moffett, Daphne] CDC Tanzania, Dar Es Salaam, Tanzania. [King, Michael] CDC, Ctr Surveillance Epidemiol & Lab Serv, Atlanta, GA 30333 USA. [Bass, Micah] CDC, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Ocen, Francis] African Union, Addis Ababa, Ethiopia. RP Gleason, B (reprint author), CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. EM yer7@cdc.gov NR 10 TC 3 Z9 3 U1 0 U2 1 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD OCT 9 PY 2015 VL 64 IS 39 BP 1108 EP 1111 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CT1JM UT WOS:000362554600004 PM 26447483 ER PT J AU Perrine, CG Galuska, DA Dohack, JL Shealy, KR Murphy, PE Grummer-Strawn, LM Scanlon, KS AF Perrine, Cria G. Galuska, Deborah A. Dohack, Jaime L. Shealy, Katherine R. Murphy, Paulette E. Grummer-Strawn, Laurence M. Scanlon, Kelley S. TI Vital Signs: Improvements in Maternity Care Policies and Practices That Support Breastfeeding - United States, 2007-2013 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID HOSPITAL PRACTICES; COST-ANALYSIS; RISK-FACTORS; LACTATION; DISEASE AB Background: Although 80% of U.S. mothers begin breastfeeding their infants, many do not continue breastfeeding as long as they would like to. Experiences during the birth hospitalization affect a mother's ability to establish and maintain breastfeeding. The Baby-Friendly Hospital Initiative is a global program launched by the World Health Organization and the United Nations Children's Fund, and has at its core the Ten Steps to Successful Breastfeeding (Ten Steps), which describe evidence-based hospital policies and practices that have been shown to improve breastfeeding outcomes. Methods: Since 2007, CDC has conducted the biennial Maternity Practices in Infant Nutrition and Care (mPINC) survey among all birth facilities in all states, the District of Columbia, and territories. CDC analyzed data from 2007 (baseline), 2009, 2011, and 2013 to describe trends in the prevalence of facilities using maternity care policies and practices that are consistent with the Ten Steps to Successful Breastfeeding. Results: The percentage of hospitals that reported providing prenatal breastfeeding education (range=91.1%-92.8%) and teaching mothers breastfeeding techniques (range=87.8%-92.2%)was high at baseline and across all survey years. Implementation of the other eight steps was lower at baseline. From 2007 to 2013, six of these steps increased by 10-21 percentage points, although limiting non-breast milk feeding of breastfed infants and fostering post-discharge support only increased by 5-6 percentage points. Nationally, hospitals implementing more than half of the Ten Steps increased from 28.7% in 2007 to 53.9% in 2013. Conclusions: Maternity care policies and practices supportive of breastfeeding are improving nationally; however, more work is needed to ensure all women receive optimal breastfeeding support during the birth hospitalization. Implications for Public Health Practice: Because of the documented benefits of breastfeeding to both mothers and children, and because experiences in the first hours and days after birth help determine later breastfeeding outcomes, improved hospital policies and practices could increase rates of breastfeeding nationwide, contributing to improved child health. C1 [Perrine, Cria G.; Galuska, Deborah A.; Shealy, Katherine R.; Murphy, Paulette E.; Scanlon, Kelley S.] CDC, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Nutr Phys Act & Obes, Atlanta, GA 30333 USA. [Dohack, Jaime L.] Battelle Mem Inst, Columbus, OH USA. [Grummer-Strawn, Laurence M.] WHO, Dept Nutr Hlth & Dev, Geneva, Switzerland. RP Perrine, CG (reprint author), CDC, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Nutr Phys Act & Obes, Atlanta, GA 30333 USA. EM cperrine@cdc.gov NR 16 TC 7 Z9 7 U1 1 U2 13 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD OCT 9 PY 2015 VL 64 IS 39 BP 1112 EP 1117 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CT1JM UT WOS:000362554600005 PM 26447527 ER PT J AU Schillie, S Murphy, TV Fenlon, N Ko, S Ward, JW AF Schillie, Sarah Murphy, Trudy V. Fenlon, Nancy Ko, Stephen Ward, John W. TI Update: Shortened Interval for Postvaccination Serologic Testing of Infants Born to Hepatitis B-Infected Mothers SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID ANTIGEN-POSITIVE WOMEN C1 [Schillie, Sarah; Murphy, Trudy V.; Ward, John W.] CDC, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Div Viral Hepatitis, Atlanta, GA 30333 USA. [Fenlon, Nancy] CDC, Natl Ctr Immunizat & Resp Dis, Immunizat Serv Div, Atlanta, GA 30333 USA. [Ko, Stephen] Boston Univ, Sch Publ Hlth, Boston, MA 02215 USA. [Ko, Stephen] Boston Univ, Sch Med, Boston, MA 02215 USA. RP Schillie, S (reprint author), CDC, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Div Viral Hepatitis, Atlanta, GA 30333 USA. EM sschillie@cdc.gov NR 9 TC 3 Z9 3 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD OCT 9 PY 2015 VL 64 IS 39 BP 1118 EP 1120 PG 3 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CT1JM UT WOS:000362554600006 PM 26447601 ER PT J AU Kasper, AM Ridpath, AD Arnold, JK Chatham-Stephens, K Morrison, M Olayinka, O Parker, C Galli, R Cox, R Preacely, N Anderson, J Kyle, PB Gerona, R Martin, C Schier, J Wolkin, A Dobbs, T AF Kasper, Amelia M. Ridpath, Alison D. Arnold, Justin K. Chatham-Stephens, Kevin Morrison, Melissa Olayinka, Olaniyi Parker, Christina Galli, Robert Cox, Robert Preacely, Nykiconia Anderson, Jannifer Kyle, Patrick B. Gerona, Roy Martin, Colleen Schier, Josh Wolkin, Amy Dobbs, Thomas TI Severe Illness Associated with Reported Use of Synthetic Cannabinoids - Mississippi, April 2015 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID STATES C1 [Kasper, Amelia M.; Chatham-Stephens, Kevin; Olayinka, Olaniyi] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Kasper, Amelia M.; Ridpath, Alison D.; Chatham-Stephens, Kevin; Olayinka, Olaniyi; Martin, Colleen; Schier, Josh; Wolkin, Amy] CDC, Natl Ctr Environm Hlth, Div Environm Hazards & Hlth Effects, Atlanta, GA 30333 USA. [Arnold, Justin K.] Georgia Poison Ctr, Atlanta, GA USA. [Morrison, Melissa; Preacely, Nykiconia] CDC, Atlanta, GA 30333 USA. [Parker, Christina; Cox, Robert] Mississippi Poison Ctr, Jackson, MS USA. [Galli, Robert; Kyle, Patrick B.] Univ Mississippi, Med Ctr, University, MS 38677 USA. [Preacely, Nykiconia; Anderson, Jannifer; Dobbs, Thomas] Mississippi Dept Hlth, Biloxi, MS USA. [Gerona, Roy] Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA. RP Kasper, AM (reprint author), CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. EM akasper@cdc.gov NR 4 TC 6 Z9 6 U1 0 U2 1 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD OCT 9 PY 2015 VL 64 IS 39 BP 1121 EP 1122 PG 2 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CT1JM UT WOS:000362554600007 PM 26447715 ER PT J AU Kamali, A Bagchi, CP Mendoza, E Wilson, D Schwartz, B Mascola, L AF Kamali, Amanda Bagchi, Chhandasi P. Mendoza, Emmanuel Wilson, Dulmini Schwartz, Benjamin Mascola, Laurene TI Measles in a Patient with Presumed Immunity - Los Angeles County, 2015 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Kamali, Amanda] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Kamali, Amanda; Schwartz, Benjamin; Mascola, Laurene] Los Angeles Cty Dept Publ Hlth, Acute Communicable Dis Control, Los Angeles, CA USA. [Bagchi, Chhandasi P.; Mendoza, Emmanuel; Wilson, Dulmini] Los Angeles Cty Dept Publ Hlth, Immunizat Program, Los Angeles, CA USA. RP Kamali, A (reprint author), CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. EM ydh3@cdc.gov NR 5 TC 0 Z9 0 U1 0 U2 2 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD OCT 9 PY 2015 VL 64 IS 39 BP 1123 EP 1123 PG 1 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CT1JM UT WOS:000362554600008 PM 26447803 ER PT J AU Zhou, Y Li, CY Huijbregts, MAJ Mumtaz, MM AF Zhou, Ying Li, Chaoyang Huijbregts, Mark A. J. Mumtaz, M. Moiz TI Carcinogenic Air Toxics Exposure and Their Cancer-Related Health Impacts in the United States SO PLOS ONE LA English DT Article ID CHEMICAL-MIXTURES; SYSTEMATIC ANALYSIS; RISK-ASSESSMENT; GLOBAL BURDEN; 21 REGIONS; POLLUTION; DISEASE AB Public health protection from air pollution can be achieved more effectively by shifting from a single-pollutant approach to a multi-pollutant approach. To develop such multi-pollutant approaches, identifying which air pollutants are present most frequently is essential. This study aims to determine the frequently found carcinogenic air toxics or hazardous air pollutants (HAPs) combinations across the United States as well as to analyze the health impacts of developing cancer due to exposure to these HAPs. To identify the most commonly found carcinogenic air toxics combinations, we first identified HAPs with cancer risk greater than one in a million in more than 5% of the census tracts across the United States, based on the National-Scale Air Toxics Assessment (NATA) by the U.S. EPA for year 2005. We then calculated the frequencies of their two-component (binary), and three-component (ternary) combinations. To quantify the cancer-related health impacts, we focused on the 10 most frequently found HAPs with national average cancer risk greater than one in a million. Their cancer-related health impacts were calculated by converting lifetime cancer risk reported in NATA 2005 to years of healthy life lost or Disability-Adjusted Life Years (DALYs). We found that the most frequently found air toxics with cancer risk greater than one in a million are formaldehyde, carbon tetrachloride, acetaldehyde, and benzene. The most frequently occurring binary pairs and ternary mixtures are the various combinations of these four air toxics. Analysis of urban and rural HAPs did not reveal significant differences in the top combinations of these chemicals. The cumulative annual cancer-related health impacts of inhaling the top 10 carcinogenic air toxics included was about 1,600 DALYs in the United States or 0.6 DALYs per 100,000 people. Formaldehyde and benzene together contribute nearly 60 percent of the total cancer-related health impacts. Our study shows that although there are many carcinogenic air toxics, only a few of them affect public health significantly at the national level in the United States, based on the frequency of occurrence of air toxics mixtures and cancer-related public health impacts. Future research is needed on their joint toxicity and cumulative health impacts. C1 [Zhou, Ying; Li, Chaoyang] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Environm Hlth Tracking Branch, Div Environm Hazards & Hlth Effects, Atlanta, GA 30322 USA. [Huijbregts, Mark A. J.] Radboud Univ Nijmegen, Inst Water & Wetland Res, Dept Environm Sci, NL-6500 GL Nijmegen, Netherlands. [Mumtaz, M. Moiz] Ctr Dis Control & Prevent, Agcy Tox Subst & Dis Registry, Div Toxicol & Human Hlth Sci, Computat Toxicol Lab, Atlanta, GA USA. RP Zhou, Y (reprint author), Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Environm Hlth Tracking Branch, Div Environm Hazards & Hlth Effects, Atlanta, GA 30322 USA. EM yzhou2@cdc.gov RI Huijbregts, Mark/B-8971-2011 NR 32 TC 2 Z9 2 U1 5 U2 14 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD OCT 7 PY 2015 VL 10 IS 10 AR e0140013 DI 10.1371/journal.pone.0140013 PG 15 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CT0TS UT WOS:000362510600120 PM 26444872 ER PT J AU Ye, XY Wong, LY Kramer, J Zhou, XL Jia, T Calafat, AM AF Ye, Xiaoyun Wong, Lee-Yang Kramer, Josh Zhou, Xiaoliu Jia, Tao Calafat, Antonia M. TI Urinary Concentrations of Bisphenol A and Three Other Bisphenols in Convenience Samples of US Adults during 2000-2014 SO ENVIRONMENTAL SCIENCE & TECHNOLOGY LA English DT Article ID UNITED-STATES; PAPER PRODUCTS; HUMAN EXPOSURE; ANALOGS AB Because of regulatory actions and public concerns, the use of bisphenol A (BPA) may decrease, while the use of BPA alternatives may increase. Although BPA alternatives are considered safer than BPA, their effects on health are still largely unknown. For risk assessment, understanding exposure to these chemicals is necessary. We measured the urinary concentrations of BPA and three bisphenol analogs, bisphenol S (BPS), bisphenol F (BPF), and bisphenol AF (BPAF), in 616 archived samples collected from convenience samplings of U.S. adults at eight time points between 2000 and 2014. We detected BPA at the highest frequency and geometric mean (GM) concentrations (74-99%, 0.36-2.07 mu g/L), followed by BPF (42-88%, 0.15-0.54 mu g/L) and BPS (19-74%, < 0.1-0.25 mu g/L); BPAF was rarely detected (<3% of all samples). Although concentrations of BPF were generally lower than for other bisphenols, the 95th percentile concentration of BPF was often comparable or higher than that of BPA. We did not observe obvious exposure trends for BPF. However, the significant changes in GM concentrations of BPA and BPS suggest that exposures may be declining (BPA) or on the rise (BPS). Nationally representative data will be useful to confirm these findings and to allow monitoring future exposure trends to BPA and some of its bisphenol alternatives. C1 [Ye, Xiaoyun; Wong, Lee-Yang; Kramer, Josh; Zhou, Xiaoliu; Jia, Tao; Calafat, Antonia M.] Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA. RP Ye, XY (reprint author), Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA. EM xay5@cdc.gov FU Centers for Disease Control and Prevention (CDC) FX This work was supported in part by the appointment of J.K. to the Research Participation Program at the Centers for Disease Control and Prevention (CDC), administered by the Oak Ridge Institute for Science and Education through an interagency agreement between the U.S. Department of Energy and the CDC. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the CDC. The authors complied with all needed research requirements regarding human subjects. NR 36 TC 14 Z9 15 U1 9 U2 33 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 0013-936X EI 1520-5851 J9 ENVIRON SCI TECHNOL JI Environ. Sci. Technol. PD OCT 6 PY 2015 VL 49 IS 19 BP 11834 EP 11839 DI 10.1021/acs.est.5b02135 PG 6 WC Engineering, Environmental; Environmental Sciences SC Engineering; Environmental Sciences & Ecology GA CT2JZ UT WOS:000362629100067 PM 26360019 ER PT J AU Sagiv, SK Rifas-Shiman, SL Webster, TF Mora, AM Harris, MH Calafat, AM Ye, XY Gillman, MW Oken, E AF Sagiv, Sharon K. Rifas-Shiman, Sheryl L. Webster, Thomas F. Maria Mora, Ana Harris, Maria H. Calafat, Antonia M. Ye, Xiaoyun Gillman, Matthew W. Oken, Emily TI Sociodemographic and Perinatal Predictors of Early Pregnancy Per- and Polyfluoroalkyl Substance (PFAS) Concentrations SO ENVIRONMENTAL SCIENCE & TECHNOLOGY LA English DT Article ID POLYFLUORINATED COMPOUNDS; PERFLUOROALKYL ACIDS; SERUM CONCENTRATIONS; PERFLUORINATED CHEMICALS; PLASMA-CONCENTRATIONS; NHANES 1999-2000; NORWEGIAN WOMEN; NATIONAL-HEALTH; TEMPORAL TRENDS; MATERNAL SERUM AB Per- and polyfluoroalkyl substances (PFASs), used in food packaging and stain-resistant coatings, are suspected developmental toxicants that are ubiquitous and persistent in the environment. We measured plasma PFAS concentrations during early pregnancy (median = 9.7 weeks gestation) among 1645 women in the Boston-area Project Viva cohort, recruited during 1999-2002. We used multivariable linear regression to estimate associations of sociodemographic and perinatal predictors, including measures of pregnancy physiology (albumin, glomerular filtration rate (GFR)), with log-transformed plasma PFAS concentrations. Geometric mean concentrations for the four main PFASs, perfluorooctanesulfonate (PFOS), perfluorooctanoate (PFOA), perfluorohexanesulfonate (PFHxS) and perfluorononanoate (PFNA) were 25.4, 5.7, 2.5, and 0.6 ng/mL, respectively, comparable with general U.S. population concentrations during those years. Higher early pregnancy PFAS concentrations were associated with younger age (except PFNA), less educational attainment, nulliparity, no history of breastfeeding and higher prepregnancy body mass index in adjusted models. In addition, lower GFR was associated with 3-4% higher PFAS concentrations and higher albumin was associated with 4-6% higher PFAS concentrations. Our results show associations consistent (parity and breastfeeding) and less consistent (age and education) with previous studies. We also report associations with GFR and albumin, which were strongly related to PFAS concentrations and thus could confound estimates of PFAS-outcome associations in epidemiologic studies. C1 [Sagiv, Sharon K.] Univ Calif Berkeley, Div Epidemiol, Berkeley, CA 94720 USA. [Sagiv, Sharon K.; Webster, Thomas F.; Maria Mora, Ana; Harris, Maria H.] Boston Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02118 USA. [Rifas-Shiman, Sheryl L.; Gillman, Matthew W.; Oken, Emily] Harvard Univ, Sch Med, Dept Populat Med, Obes Prevent Program, Boston, MA 02215 USA. [Rifas-Shiman, Sheryl L.; Gillman, Matthew W.; Oken, Emily] Harvard Univ, Pilgrim Hlth Care Inst, Boston, MA 02215 USA. [Maria Mora, Ana] Univ Nacl, Cent Amer Inst Studies Tox Subst, Heredia, Costa Rica. [Calafat, Antonia M.; Ye, Xiaoyun] Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA 30329 USA. [Gillman, Matthew W.; Oken, Emily] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA. RP Sagiv, SK (reprint author), Univ Calif Berkeley, Div Epidemiol, Berkeley, CA 94720 USA. EM sagiv@berkeley.edu FU NIH [R01 ES021447, K24 HD069408, P30 DK092924, R37 HD034568] FX Work was supported by NIH grants R01 ES021447, K24 HD069408, P30 DK092924, and R37 HD034568. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. The authors declare they have no competing financial interests. NR 34 TC 8 Z9 8 U1 3 U2 19 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 0013-936X EI 1520-5851 J9 ENVIRON SCI TECHNOL JI Environ. Sci. Technol. PD OCT 6 PY 2015 VL 49 IS 19 BP 11849 EP 11858 DI 10.1021/acs.est.5b02489 PG 10 WC Engineering, Environmental; Environmental Sciences SC Engineering; Environmental Sciences & Ecology GA CT2JZ UT WOS:000362629100069 PM 26333069 ER PT J AU Twomey, PS Smith, BL McDermott, C Novitt-Moreno, A McCarthy, W Kachur, SP Arguin, PM AF Twomey, Patrick S. Smith, Bryan L. McDermott, Cathy Novitt-Moreno, Anne McCarthy, William Kachur, S. Patrick Arguin, Paul M. TI Intravenous Artesunate for the Treatment of Severe and Complicated Malaria in the United States: Clinical Use Under an Investigational New Drug Protocol SO ANNALS OF INTERNAL MEDICINE LA English DT Article ID SEVERE FALCIPARUM-MALARIA; INTENSIVE-CARE-UNIT; PLASMODIUM-FALCIPARUM; RANDOMIZED-TRIAL; QUINIDINE; QUININE; ADULTS; RISK; ARTEMISININ; MANAGEMENT AB Background: Quinidine gluconate, the only U.S. Food and Drug Administration-approved treatment for life-threatening malaria in the United States, has a problematic safety profile and is often unavailable in hospitals. Objective: To assess the safety and clinical benefit of intravenous artesunate as an alternative to quinidine. Design: Retrospective case series. Setting: U.S. hospitals. Patients: 102 patients aged 1 to 72 years (90% adults; 61% men) with severe and complicated malaria. Patients received 4 weight-based doses of intravenous artesunate (2.4 mg/kg) under a treatment protocol implemented by the Centers for Disease Control and Prevention between January 2007 and December 2010. At baseline, 35% had evidence of cerebral malaria, and 17% had severe hepatic impairment. Eligibility required the presence of microscopically confirmed malaria, need for intravenous treatment, and an impediment to quinidine. Measurements: Clinical and laboratory data from each patient's hospital records were abstracted retrospectively, including information from baseline through a maximum 7-day follow-up, and presented before a physician committee to evaluate safety and clinical benefit outcomes. Results: 7 patients died (mortality rate, 6.9%). The most frequent adverse events were anemia (65%) and elevated hepatic enzyme levels (49%). All deaths and most adverse events were attributed to the severity of malaria. Patients' symptoms generally improved or resolved within 3 days, and the median time to discharge from the intensive care unit was 4 days, even for patients with severe liver disease or cerebral malaria. More than 100 concomitant medications were used, with no documented drug-drug interactions. Limitation: Potential late-presenting safety issues might occur outside the 7-day follow-up. Conclusion: Artesunate was a safe and clinically beneficial alternative to quinidine. C1 [Twomey, Patrick S.] US Army Med Mat Dev Act, Ft Detrick, MD 21702 USA. Fast Track Drugs & Biol, North Potomac, MD USA. Ctr Dis Control & Prevent, Bethesda, MD USA. RP Twomey, PS (reprint author), US Army Med Mat Dev Act, 1430 Vet Dr, Ft Detrick, MD 21702 USA. EM patrick.s.twomey.mil@mail.mil FU Office of the Surgeon General, Department of the U.S. Army FX Office of the Surgeon General, Department of the U.S. Army. NR 44 TC 5 Z9 5 U1 2 U2 11 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD OCT 6 PY 2015 VL 163 IS 7 BP 498 EP + DI 10.7326/M15-0910 PG 11 WC Medicine, General & Internal SC General & Internal Medicine GA CT0OQ UT WOS:000362496400003 PM 26301474 ER PT J AU Silverberg, MJ Lau, B Achenbach, CJ Jing, YZ Althoff, KN D'Souza, G Engels, EA Hessol, NA Brooks, JT Burchell, AN Gill, MJ Goedert, JJ Hogg, R Horberg, MA Kirk, GD Kitahata, MM Korthuis, PT Mathews, WC Mayor, A Modur, SP Napravnik, S Novak, RM Patel, P Rachlis, AR Sterling, TR Willig, JH Justice, AC Moore, RD Dubrow, R AF Silverberg, Michael J. Lau, Bryan Achenbach, Chad J. Jing, Yuezhou Althoff, Keri N. D'Souza, Gypsyamber Engels, Eric A. Hessol, Nancy A. Brooks, John T. Burchell, Ann N. Gill, M. John Goedert, James J. Hogg, Robert Horberg, Michael A. Kirk, Gregory D. Kitahata, Mari M. Korthuis, Philip T. Mathews, William C. Mayor, Angel Modur, Sharada P. Napravnik, Sonia Novak, Richard M. Patel, Pragna Rachlis, Anita R. Sterling, Timothy R. Willig, James H. Justice, Amy C. Moore, Richard D. Dubrow, Robert CA Int Epidemiologic Databases TI Cumulative Incidence of Cancer Among Persons With HIV in North America A Cohort Study SO ANNALS OF INTERNAL MEDICINE LA English DT Article ID COMBINATION ANTIRETROVIRAL THERAPY; AIDS-DEFINING MALIGNANCIES; ACQUIRED-IMMUNODEFICIENCY-SYNDROME; FORCE RECOMMENDATION STATEMENT; HUMAN-PAPILLOMAVIRUS VACCINE; UNITED-STATES; INFECTED INDIVIDUALS; HIV-1-INFECTED PATIENTS; LUNG-CANCER; ANAL CANCER AB Background: Cancer is increasingly common among persons with HIV. Objective: To examine calendar trends in cumulative cancer incidence and hazard rate by HIV status. Design: Cohort study. Setting: North American AIDS Cohort Collaboration on Research and Design during 1996 to 2009. Participants: 86 620 persons with HIV and 196 987 uninfected adults. Measurements: Cancer type-specific cumulative incidence by age 75 years and calendar trends in cumulative incidence and hazard rates, each by HIV status. Results: Cumulative incidences of cancer by age 75 years for persons with and without HIV, respectively, were as follows: Kaposi sarcoma, 4.4% and 0.01%; non-Hodgkin lymphoma, 4.5% and 0.7%; lung cancer, 3.4% and 2.8%; anal cancer, 1.5% and 0.05%; colorectal cancer, 1.0% and 1.5%; liver cancer, 1.1% and 0.4%; Hodgkin lymphoma, 0.9% and 0.09%; melanoma, 0.5% and 0.6%; and oral cavity/pharyngeal cancer, 0.8% and 0.8%. Among persons with HIV, calendar trends in cumulative incidence and hazard rate decreased for Kaposi sarcoma and non-Hodgkin lymphoma. For anal, colorectal, and liver cancer, increasing cumulative incidence, but not hazard rate trends, were due to the decreasing mortality rate trend (-9% per year), allowing greater opportunity to be diagnosed. Despite decreasing hazard rate trends for lung cancer, Hodgkin lymphoma, and melanoma, cumulative incidence trends were not seen because of the compensating effect of the declining mortality rate. Limitation: Secular trends in screening, smoking, and viral co-infections were not evaluated. Conclusion: Cumulative cancer incidence by age 75 years, approximating lifetime risk in persons with HIV, may have clinical utility in this population. The high cumulative incidences by age 75 years for Kaposi sarcoma, non- Hodgkin lymphoma, and lung cancer support early and sustained antiretroviral therapy and smoking cessation. C1 Kaiser Permanente No Calif, Oakland, CA USA. Johns Hopkins Sch Med, Baltimore, MD USA. Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA. Northwestern Univ, Feinberg Sch Med, Ctr Global Hlth, Lurie Canc Ctr, Chicago, IL 60611 USA. Univ Illinois, Coll Med, Chicago, IL USA. NCI, NIH, Bethesda, MD 20892 USA. Univ Calif San Francisco, San Francisco, CA 94143 USA. Ctr Dis Control & Prevent, Atlanta, GA USA. Univ Toronto, Ontario HIV Treatment Network, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada. Univ Toronto, Sunnybrook Hlth Sci Ctr, Toronto, ON, Canada. Univ Calgary, Calgary, AB, Canada. British Columbia Ctr Excellence HIV AIDS, Vancouver, BC, Canada. Simon Fraser Univ, Fac Hlth Sci, Burnaby, BC V5A 1S6, Canada. Kaiser Permanente, Midatlantic Permanente Res Inst, Rockville, MD USA. Univ Washington, Seattle, WA 98195 USA. Oregon Hlth & Sci Univ, Portland, OR 97201 USA. Univ Calif San Diego, San Diego, CA 92103 USA. Univ Cent Caribe, Sch Med, Retrovirus Res Ctr, Bayamon, PR USA. Univ N Carolina, Sch Med, Chapel Hill, NC USA. Vanderbilt Univ, Nashville, TN 37235 USA. Univ Alabama Birmingham, Birmingham, AL USA. Vet Affairs Connecticut Healthcare Syst, New Haven, CT USA. Yale Univ, Sch Med, New Haven, CT USA. Yale Univ, Sch Publ Hlth, New Haven, CT USA. RP Silverberg, MJ (reprint author), Kaiser Permanente, Div Res, 2000 Broadway,2nd Floor, Oakland, CA 94612 USA. EM Michael.J.Silverberg@kp.org RI Gill, John/G-7083-2016; OI Gill, John/0000-0002-8546-8790; Mayor, Angel M./0000-0002-7705-837X; Hogg, Robert/0000-0003-3463-5488; Justice, Amy/0000-0003-0139-5502 FU National Institutes of Health FX National Institutes of Health. NR 74 TC 29 Z9 30 U1 2 U2 13 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD OCT 6 PY 2015 VL 163 IS 7 BP 507 EP + DI 10.7326/M14-2768 PG 18 WC Medicine, General & Internal SC General & Internal Medicine GA CT0OQ UT WOS:000362496400004 PM 26436616 ER PT J AU Peng, H Brimijoin, S Hrabovska, A Targosova, K Krejci, E Blake, TA Johnson, RC Masson, P Lockridge, O AF Peng, Hong Brimijoin, Stephen Hrabovska, Anna Targosova, Katarina Krejci, Eric Blake, Thomas A. Johnson, Rudolph C. Masson, Patrick Lockridge, Oksana TI Comparison of 5 monoclonal antibodies for immunopurification of human butyrylcholinesterase on Dynabeads: K-D values, binding pairs, and amino acid sequences SO CHEMICO-BIOLOGICAL INTERACTIONS LA English DT Article DE Butyrylcholinesterase; ELISA; Biacore; Octet; Dynabeads; Monoclonal antibody ID HUMAN SERUM BUTYRYLCHOLINESTERASE; MASS-SPECTROMETRY; HUMAN PLASMA; EXPOSURE; ADDUCTS; ACETYLCHOLINESTERASE; CHOLINESTERASE; QUANTIFICATION; CHLORPYRIFOS; BIOSCAVENGER AB Human butyrylcholinesterase (HuBChE) is a stoichiometric bioscavenger of nerve agents and organophosphorus pesticides. Mass spectrometry methods detect stable nerve agent adducts on the active site serine of HuBChE. The first step in sample preparation is immunopurification of HuBChE from plasma. Our goal was to identify monoclonal antibodies that could be used to immunopurify HuBChE on Dynabeads Protein G. Mouse anti-HuBChE monoclonal antibodies were obtained in the form of ascites fluid, dead hybridoma cells stored frozen at -80 degrees C for 30 years, or recently frozen hybridoma cells. RNA from 4 hybridoma cell lines was amplified by PCR for determination of their nucleotide and amino acid sequences. Full-length light and heavy chains were expressed, and the antibodies purified from culture medium. A fifth monoclonal was purchased. The 5 monoclonal antibodies were compared for ability to capture HuBChE from human plasma on Dynabeads Protein G. In addition, they were evaluated for binding affinity by Biacore and ELISA. Epitope mapping by pairing analysis was performed on the Octet Red96 instrument. The 5 monoclonal antibodies, B2 12-1, B2 18-5, 3E8, mAb2, and 11D8, had similar K-D values of 10(-9) M for HuBChE. Monoclonal 82 18-5 outperformed the others in the Dynabeads Protein G assay where it captured 97% of the HuBChE in 0.5 ml plasma. Pairing analysis showed that 3E8 and B2 121 share the same epitope, 11D8 and B2 18-5 share the same epitope, but mAb2 and B2 12-1 or mAb2 and 3E8 bind to different epitopes on HuBChE. B2 18-5 was selected for establishment of a stable CHO cell line for production of mouse anti-HuBChE monoclonal. (C) 2015 Elsevier Ireland Ltd. All rights reserved. C1 [Peng, Hong; Masson, Patrick; Lockridge, Oksana] Univ Nebraska, Med Ctr, Eppley Inst, Omaha, NE 68182 USA. [Brimijoin, Stephen] Mayo Clin, Dept Mol Pharmacol & Expt Therapeut, Rochester, MN 55905 USA. [Hrabovska, Anna; Targosova, Katarina] Comenius Univ, Fac Pharm, Dept Pharmacol & Toxicol, Bratislava 83232, Slovakia. [Krejci, Eric] Univ Paris 05, CNRS UMR 8194, F-75006 Paris, France. [Blake, Thomas A.; Johnson, Rudolph C.] Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA. RP Lockridge, O (reprint author), Univ Nebraska, Med Ctr, Eppley Inst, Omaha, NE 68182 USA. EM hong.peng@unmc.edu; brimijoi@mayo.edu; anna.hrabovska@gmail.com; mrvova.kaja@gmail.com; eric.krejci@parisdescartes.fr; fsi3@cdc.gov; rmj6@cdc.gov; pmasson@unmc.edu; olockrid@unmc.edu RI Masson, Patrick/J-3964-2013 OI Masson, Patrick/0000-0002-7837-3662 FU DLS/NCEH/CDC [200-2012-M-53381, 200-2013-57169]; Minnesota Partnership for Biotechnology and Medical Genomics; APVV grants [SK-FR- 0031-09/Stefanik, SK-FR-0048-11/Stefanik]; Association Francaise contre les Myopathies; Universite Paris Descartes collaborative grant; Centers for Disease Control and Prevention; Defense Threat Reduction Agency [11-005-12430]; Office of Public Health Preparedness and Response; [VEGA 1/1139/12] FX Supported by DLS/NCEH/CDC contracts 200-2012-M-53381 and 200-2013-57169 (to OL), a grant from the Minnesota Partnership for Biotechnology and Medical Genomics (to SB), grant VEGA 1/1139/12 (to AH), APVV grants SK-FR- 0031-09/Stefanik (to AH and Eric Krejci), SK-FR-0048-11/Stefanik (to AH and Eric Krejci), Association Francaise contre les Myopathies (to Eric Krejci and AH), and a Universite Paris Descartes collaborative grant (to Eric Krejci), the Centers for Disease Control and Prevention, Office of Public Health Preparedness and Response, and the Defense Threat Reduction Agency (11-005-12430) (to TAB and RCJ). NR 27 TC 4 Z9 4 U1 1 U2 9 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0009-2797 EI 1872-7786 J9 CHEM-BIOL INTERACT JI Chem.-Biol. Interact. PD OCT 5 PY 2015 VL 240 BP 336 EP 345 DI 10.1016/j.cbi.2015.08.024 PG 10 WC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Toxicology SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Toxicology GA CZ2QT UT WOS:000366950400032 PM 26343001 ER PT J AU Lewis, JV Abramowitz, S Koenig, LJ Chandwani, S Orban, L AF Lewis, Jennifer V. Abramowitz, Susan Koenig, Linda J. Chandwani, Sulachni Orban, Lisa TI Negative life events and depression in adolescents with HIV: a stress and coping analysis SO AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV LA English DT Article DE negative life events; HIV; youth; depression; coping; social support ID HUMAN-IMMUNODEFICIENCY-VIRUS; INFECTED YOUTH; SOCIAL SUPPORT; RISK BEHAVIOR; STRATEGIES; RUMINATION; ADHERENCE; SYMPTOMS; ADJUSTMENT; DISORDERS AB The prevalence of negative life events (NLE) and daily hassles, and their direct and moderated associations with depression, were examined among HIV-infected adolescents. Specifically, we examined whether the negative association with depression of NLE, daily hassles, and/or passive coping were moderated by social support or active coping strategies. Demographic characteristics, depression, coping, social support, NLE, and daily hassles were collected at baseline as part of the Adolescent Impact intervention via face-to-face and computer-assisted interviews. Of 166 HIV-infected adolescents, 53% were female, 72.9% black, 59.6% with perinatally acquired HIV (PIY), the most commonly reported NLE were death in family (81%), violence exposure (68%), school relocation (67%), and hospitalization (61%); and for daily hassles not having enough money (65%). Behaviorally infected youth (BIY - acquired HIV later in life) were significantly more likely to experience extensive (14-21) lifetime NLE (38.8% vs. 16.3%, p<.012) than PIY. In multiple stepwise regression analysis, the model accounting for the greatest variability in depression scores (32%) included (in order of entry): daily hassles, low social support, behaviorally acquired HIV, minority sexual orientation, and passive coping. A significant passive coping-by-social support interaction revealed that the association between passive coping and depression was exacerbated when social support was low. Social support moderated the effect of NLE, such that NLE were associated with greater depression when social support was low, although the effect did not remain statistically significant when main effects of other variables were accounted for. Daily hassles, poor coping, and limited social support can adversely affect the psychological well-being of HIV-infected adolescents, particularly sexual minority youth with behaviorally acquired HIV. Multimodal interventions that enhance social support and teach adaptive coping skills may help youth cope with environmental stresses and improve mental health outcomes. C1 [Lewis, Jennifer V.; Abramowitz, Susan; Chandwani, Sulachni; Orban, Lisa] NYU, Langone Med Ctr, Dept Pediat Infect Dis, New York, NY 10010 USA. [Koenig, Linda J.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. RP Lewis, JV (reprint author), NYU, Langone Med Ctr, Dept Pediat Infect Dis, New York, NY 10010 USA. EM jennifer.lewis@nyumc.org OI Lewis, Jennifer V./0000-0002-3573-5125 FU Centers for Disease Control & Prevention through NYU School of Medicine [U64CCU219448]; Children's National Medical Center [U64CCU319459]; University of Maryland School of Medicine [U64CCU319455] FX This work was supported by the Centers for Disease Control & Prevention through cooperative agreements with NYU School of Medicine [grant number U64CCU219448]; Children's National Medical Center [grant number U64CCU319459]; University of Maryland School of Medicine [grant number U64CCU319455]. NR 38 TC 1 Z9 1 U1 5 U2 13 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 0954-0121 EI 1360-0451 J9 AIDS CARE JI Aids Care-Psychol. Socio-Med. Asp. Aids-Hiv PD OCT 3 PY 2015 VL 27 IS 10 BP 1265 EP 1274 DI 10.1080/09540121.2015.1050984 PG 10 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychology, Multidisciplinary; Respiratory System; Social Sciences, Biomedical SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychology; Respiratory System; Biomedical Social Sciences GA CT5VP UT WOS:000362879500009 PM 26313848 ER PT J AU AbouZahr, C De Savigny, D Mikkelsen, L Setel, PW Lozano, R Nichols, E Notzon, F Lopez, AD AF AbouZahr, Carla De Savigny, Don Mikkelsen, Lene Setel, Philip W. Lozano, Rafael Nichols, Erin Notzon, Francis Lopez, Alan D. TI Civil registration and vital statistics: progress in the data revolution for counting and accountability SO LANCET LA English DT Article ID MATERNAL MORTALITY; DEATH; BIRTHS; SYSTEM; RISK; LIFE AB New momentum for civil registration and vital statistics (CRVS) is building, driven by the confluence of growing demands for accountability and results in health, improved equity, and rights-based approaches to development challenges, and by the immense potential of innovation and new technologies to accelerate CRVS improvement. Examples of country successes in strengthening of hitherto weak systems are emerging. The key to success has been to build collaborative partnerships involving local ownership by several sectors that span registration, justice, health, statistics, and civil society. Regional partners can be important to raise awareness, set regional goals and targets, foster country-to-country exchange and mutual learning, and build high-level political commitment. These regional partners continue to provide a platform through which country stakeholders, development partners, and technical experts can share experiences, develop and document good practices, and propose innovative approaches to tackle CRVS challenges. This country and regional momentum would benefit from global leadership, commitment, and support. C1 [AbouZahr, Carla] CAZ Consulting, CH-1218 Geneva, Switzerland. [De Savigny, Don] Univ Basel, Swiss Trop & Publ Hlth Inst, Basel, Switzerland. [Mikkelsen, Lene] LM Consulting, Brisbane, Qld, Australia. [Setel, Philip W.] Union North Amer, New York, NY USA. [Lozano, Rafael] Natl Inst Publ Hlth, Mexico City, DF, Mexico. [Nichols, Erin; Notzon, Francis] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. [Lopez, Alan D.] Univ Melbourne, Sch Populat & Global Hlth, Melbourne, Vic, Australia. RP AbouZahr, C (reprint author), CAZ Consulting, CH-1218 Geneva, Switzerland. EM abouzahr.carla@gmail.com NR 112 TC 18 Z9 19 U1 5 U2 8 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0140-6736 EI 1474-547X J9 LANCET JI Lancet PD OCT 3 PY 2015 VL 386 IS 10001 BP 1373 EP 1385 DI 10.1016/S0140-6736(15)60173-8 PG 13 WC Medicine, General & Internal SC General & Internal Medicine GA CS8DP UT WOS:000362316200031 PM 25971224 ER PT J AU Ceballos, D King, B Beaucham, C Brueck, SE AF Ceballos, Diana King, Bradley Beaucham, Catherine Brueck, Scott E. TI Comparison of a Wipe Method With and Without a Rinse to Recover Wall Losses in Closed Face 37-mm Cassettes used for Sampling Lead Dust Particulates SO JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL HYGIENE LA English DT Article ID INTERNAL CAPSULES; FILTER; DEPOSITS; METALS AB Closed-face 37-mm polystyrene cassettes are often used for exposure monitoring of metal particulates. Several methods have been proposed to account for the wall loss in air sampling cassettes, including rinsing, wiping, within-cassette dissolution, and an internal capsule fused to the filter that could be digested with the filter. Until internal capsules replace filters, other methods for assessing wall losses may be considered. To determine if rinsing and wiping or wiping alone is adequate to determine wall losses on cassettes, we collected 54 full-shift area air samples at a battery recycling facility. We collected six replicate samples at three locations within the facility for three consecutive days. The wall losses of three replicate cassettes from each day-location were analyzed following a rinse and two consecutive wipes. The wall losses of the other three replicates from each day-location were analyzed following two consecutive wipes only. Mixed-cellulose ester membrane filter, rinse, and wipes were analyzed separately following NIOSH Method 7303. We found an average of 29% (range: 8-54%) recovered lead from the cassette walls for all samples. We also found that rinsing prior to wiping the interior cassette walls did not substantially improve recovery of wall losses compared to wiping alone. A rinse plus one wipe recovered on average 23% (range: 13-33%) of the lead, while one wipe alone recovered on average 21% (range: 16-22%). Similarly, we determined that a second wipe did not provide substantial additional recovery of lead (average: 4%, range: 0.4-19%) compared to the first wipe disregarding the rinse (average: 18%, range: 4-39%). We concluded that when an internal capsule is not used, wall losses of lead dust in air sampling cassettes can be adequately recovered by wiping the internal wall surfaces of the cassette with a single wipe. C1 [Ceballos, Diana; King, Bradley; Beaucham, Catherine; Brueck, Scott E.] NIOSH, Cincinnati, OH 45226 USA. RP Ceballos, D (reprint author), NIOSH, 1090 Tusculum Ave,MS 11, Cincinnati, OH 45226 USA. EM DCeballos@cdc.gov NR 21 TC 0 Z9 0 U1 0 U2 0 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 1545-9624 EI 1545-9632 J9 J OCCUP ENVIRON HYG JI J. Occup. Environ. Hyg. PD OCT 3 PY 2015 VL 12 IS 10 BP D225 EP D231 DI 10.1080/15459624.2015.1009991 PG 7 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA CQ2IP UT WOS:000360423700001 ER PT J AU Sauber-Schatz, EK Thomas, AM Cook, LJ AF Sauber-Schatz, Erin K. Thomas, Andrea M. Cook, Lawrence J. TI Motor Vehicle Crashes, Medical Outcomes, and Hospital Charges Among Children Aged 1-12 Years - Crash Outcome Data Evaluation System, 11 States, 2005-2008 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID PASSENGER SAFETY; UNITED-STATES; LINKAGE; SEATS AB Problem: Motor vehicle crashes are a leading cause of death among children. Age- and size-appropriate restraint use is an effective way to prevent motor vehicle related injuries and deaths. However, children are not always properly restrained while riding in a motor vehicle, and some are not restrained at all, which increases their risk for injury and death in a crash. Reporting Period: 2005-2008. Description of the System: The Crash Outcome Data Evaluation System (CODES) is a multistate program facilitated by the National Highway Traffic Safety Administration to probabilistically link police crash reports and hospital databases for traffic safety analyses. Eleven participating states (Connecticut, Georgia, Kentucky, Maryland, Minnesota, Missouri, Nebraska, New York, Ohio, South Carolina, and Utah) submitted data to CODES during the reporting period. Descriptive analysis was used to describe drivers and child passengers involved in motor vehicle crashes and to summarize crash and medical outcomes. Odds ratios and 95% confidence intervals were used to compare a child passenger's likelihood of sustaining specific types of injuries by restraint status (optimal, suboptimal, or unrestrained) and seating location (front or back seat). Because of data constraints, optimal restraint use was defined as car seat or booster seat use for children aged 1-7 years and seat belt use for children aged 8-12 years. Suboptimal restraint use was defined as seat belt use for children aged 1-7 years. Unrestrained was defined as no use of car a seat, booster seat, or seat belt for children aged 1-12 years. Results: Optimal restraint use in the back seat declined with child's age (1 year: 95.9%, 5 years: 95.4%, 7 years: 94.7%, 8 years: 77.4%, 10 years: 67.5%, 12 years: 54.7%). Child restraint use was associated with driver restraint use; 41.3% of children riding with unrestrained drivers also were unrestrained compared with 2.2% of children riding with restrained drivers. Child restraint use also was associated with impaired driving due to alcohol or drug use; 16.4% children riding with drivers suspected of alcohol or drug use were unrestrained compared with 2.9% of children riding with drivers not suspected of such use. Optimally restrained and suboptimally restrained children were less likely to sustain a traumatic brain injury than unrestrained children. The 90th percentile hospital charges for children aged 4-7 years who were in motor vehicle crashes were $1,630.00 and $1,958.00 for those optimally restrained in a back seat and front seat, respectively; $2,035.91 and $3,696.00 for those suboptimally restrained in a back seat and front seat, respectively; and $9,956.60 and $11,143.85 for those unrestrained in a back seat and front seat, respectively. Interpretation: Proper car seat, booster seat, and seat belt use among children in the back seat prevents injuries and deaths, as well as averts hospital charges. However, the number, severity, and cost of injuries among children in crashes who were not optimally restrained or who were seated in a front seat indicates the need for improvements in proper use of age- and size-appropriate car seats, booster seats, and seat belts in the back seat. Public Health Actions: Effective interventions for increasing proper child restraint use could be universally implemented by states and communities to prevent motor vehicle related injuries among children and their resulting costs. C1 [Sauber-Schatz, Erin K.] CDC, Natl Ctr Injury Prevent & Control, Div Unintent Injury Prevent, Atlanta, GA 30333 USA. [Sauber-Schatz, Erin K.] Univ Utah, US Publ Hlth Serv, Salt Lake City, UT USA. [Thomas, Andrea M.; Cook, Lawrence J.] Univ Utah, Dept Pediat, Salt Lake City, UT USA. RP Sauber-Schatz, EK (reprint author), CDC, Natl Ctr Injury Prevent & Control, Div Unintent Injury Prevent, Atlanta, GA 30333 USA. EM esauberschatz@cdc.gov NR 26 TC 0 Z9 0 U1 1 U2 1 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD OCT 2 PY 2015 VL 64 IS 8 SU S BP 1 EP 32 PG 32 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CW4RS UT WOS:000364980400001 ER PT J AU Sauber-Schatz, EK Thomas, AM Cook, LJ AF Sauber-Schatz, Erin K. Thomas, Andrea M. Cook, Lawrence J. TI Motor Vehicle Crashes, Medical Outcomes, and Hospital Charges Among Children Aged 1-12 Years - Crash Outcome Data Evaluation System, 11 States, 2005-2008 SO MMWR SURVEILLANCE SUMMARIES LA English DT Article ID PASSENGER SAFETY; UNITED-STATES; LINKAGE; SEATS AB Problem: Motor vehicle crashes are a leading cause of death among children. Age-and size-appropriate restraint use is an effective way to prevent motor vehicle-related injuries and deaths. However, children are not always properly restrained while riding in a motor vehicle, and some are not restrained at all, which increases their risk for injury and death in a crash. Reporting Period: 2005-2008. Description of the System: The Crash Outcome Data Evaluation System (CODES) is a multistate program facilitated by the National Highway Traffic Safety Administration to probabilistically link police crash reports and hospital databases for traffic safety analyses. Eleven participating states (Connecticut, Georgia, Kentucky, Maryland, Minnesota, Missouri, Nebraska, New York, Ohio, South Carolina, and Utah) submitted data to CODES during the reporting period. Descriptive analysis was used to describe drivers and child passengers involved in motor vehicle crashes and to summarize crash and medical outcomes. Odds ratios and 95% confidence intervals were used to compare a child passenger's likelihood of sustaining specific types of injuries by restraint status (optimal, suboptimal, or unrestrained) and seating location (front or back seat). Because of data constraints, optimal restraint use was defined as car seat or booster seat use for children aged 1-7 years and seat belt use for children aged 8-12 years. Suboptimal restraint use was defined as seat belt use for children aged 1-7 years. Unrestrained was defined as no use of car a seat, booster seat, or seat belt for children aged 1-12 years. Results: Optimal restraint use in the back seat declined with child's age (1 year: 95.9%, 5 years: 95.4%, 7 years: 94.7%, 8 years: 77.4%, 10 years: 67.5%, 12 years: 54.7%). Child restraint use was associated with driver restraint use; 41.3% of children riding with unrestrained drivers also were unrestrained compared with 2.2% of children riding with restrained drivers. Child restraint use also was associated with impaired driving due to alcohol or drug use; 16.4% children riding with drivers suspected of alcohol or drug use were unrestrained compared with 2.9% of children riding with drivers not suspected of such use. Optimally restrained and suboptimally restrained children were less likely to sustain a traumatic brain injury than unrestrained children. The 90th percentile hospital charges for children aged 4-7 years who were in motor vehicle crashes were $1,630.00 and $1,958.00 for those optimally restrained in a back seat and front seat, respectively; $2,035.91 and $3,696.00 for those suboptimally restrained in a back seat and front seat, respectively; and $9,956.60 and $11,143.85 for those unrestrained in a back seat and front seat, respectively. Interpretation: Proper car seat, booster seat, and seat belt use among children in the back seat prevents injuries and deaths, as well as averts hospital charges. However, the number, severity, and cost of injuries among children in crashes who were not optimally restrained or who were seated in a front seat indicates the need for improvements in proper use of age-and size-appropriate car seats, booster seats, and seat belts in the back seat. Public Health Actions: Effective interventions for increasing proper child restraint use could be universally implemented by states and communities to prevent motor vehicle-related injuries among children and their resulting costs. C1 [Sauber-Schatz, Erin K.] CDC, Div Unintent Injury Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA. [Sauber-Schatz, Erin K.] US PHS, Washington, DC 20201 USA. [Thomas, Andrea M.; Cook, Lawrence J.] Univ Utah, Dept Pediat, Salt Lake City, UT USA. RP Sauber-Schatz, EK (reprint author), CDC, Div Unintent Injury Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA. EM esauberschatz@cdc.gov NR 26 TC 2 Z9 2 U1 0 U2 3 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-8636 J9 MMWR SURVEILL SUMM JI MMWR Surv. Summ. PD OCT 2 PY 2015 VL 64 IS 8 BP 1 EP 32 PG 32 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CV6NL UT WOS:000364386800001 PM 26426527 ER PT J AU Neff, LJ Arrazola, RA Caraballo, RS Corey, CG Cox, S King, BA Choiniere, CJ Husten, CG AF Neff, Linda J. Arrazola, Rene A. Caraballo, Ralph S. Corey, Catherine G. Cox, Shanna King, Brian A. Choiniere, Conrad J. Husten, Corinne G. TI Frequency of Tobacco Use Among Middle and High School Students - United States, 2014 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID NICOTINE DEPENDENCE; ONSET; RISK C1 [Neff, Linda J.; Arrazola, Rene A.; Caraballo, Ralph S.; Cox, Shanna; King, Brian A.] CDC, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. [Corey, Catherine G.; Choiniere, Conrad J.; Husten, Corinne G.] US FDA, Ctr Tobacco Prod, Rockville, MD 20857 USA. RP Neff, LJ (reprint author), CDC, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. EM len2@cdc.gov NR 8 TC 7 Z9 7 U1 0 U2 3 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD OCT 2 PY 2015 VL 64 IS 38 BP 1061 EP 1065 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CS5DF UT WOS:000362095900001 PM 26422781 ER PT J AU Corey, CG Ambrose, BK Apelberg, BJ King, BA AF Corey, Catherine G. Ambrose, Bridget K. Apelberg, Benjamin J. King, Brian A. TI Flavored Tobacco Product Use Among Middle and High School Students - United States, 2014 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID YOUTH C1 [Corey, Catherine G.; Ambrose, Bridget K.; Apelberg, Benjamin J.] US FDA, Ctr Tobacco Prod, Rockville, MD 20857 USA. [King, Brian A.] CDC, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. RP Corey, CG (reprint author), US FDA, Ctr Tobacco Prod, Rockville, MD 20857 USA. EM catherine.corey@fda.hhs.gov NR 9 TC 11 Z9 11 U1 1 U2 6 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD OCT 2 PY 2015 VL 64 IS 38 BP 1066 EP 1070 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CS5DF UT WOS:000362095900002 PM 26421418 ER PT J AU Robyn, MP Newman, AP Amato, M Walawander, M Kothe, C Nerone, JD Pomerantz, C Behravesh, CB Biggs, HM Dahlgren, FS Pieracci, EG Whitfield, Y Sider, D Ozaldin, O Berger, L Buck, PA Downing, M Blog, D AF Robyn, Misha P. Newman, Alexandra P. Amato, Michael Walawander, Mary Kothe, Cynthia Nerone, James D. Pomerantz, Cynthia Behravesh, Casey Barton Biggs, Holly M. Dahlgren, F. Scott Pieracci, Emily G. Whitfield, Yvonne Sider, Doug Ozaldin, Omar Berger, Lisa Buck, Peter A. Downing, Mark Blog, Debra TI Fever Outbreak Among Travelers to Germany Who Received Live Cell Therapy - United States and Canada, 2014 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Robyn, Misha P.; Biggs, Holly M.; Pieracci, Emily G.] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Robyn, Misha P.; Newman, Alexandra P.; Blog, Debra] New York State Dept Hlth, Albany, NY 12237 USA. [Amato, Michael; Walawander, Mary] Erie Cty Dept Hlth, Buffalo, NY USA. [Behravesh, Casey Barton; Biggs, Holly M.; Dahlgren, F. Scott; Pieracci, Emily G.] CDC, Div Vector Borne Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Whitfield, Yvonne; Sider, Doug] Publ Hlth Ontario, Windsor, ON, Canada. [Ozaldin, Omar; Berger, Lisa] Toronto Publ Hlth, Toronto, ON, Canada. [Buck, Peter A.] Publ Hlth Agcy Canada, Ctr Foodborne Environm & Zoonot Infect Dis, Toronto, ON, Canada. [Downing, Mark] St Josephs Hlth Ctr, Toronto, ON, Canada. [Downing, Mark] Univ Toronto, Dept Med, Toronto, ON M5S 1A1, Canada. RP Robyn, MP (reprint author), CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. EM mrobyn@cdc.gov NR 8 TC 3 Z9 3 U1 0 U2 2 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD OCT 2 PY 2015 VL 64 IS 38 BP 1071 EP 1073 PG 3 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CS5DF UT WOS:000362095900003 PM 26421460 ER PT J AU Florence, C Simon, T Haegerich, T Luo, FJ Zhou, C AF Florence, Curtis Simon, Thomas Haegerich, Tamara Luo, Feijun Zhou, Chao TI Estimated Lifetime Medical and Work-Loss Costs of Fatal Injuries - United States, 2013 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID US C1 [Florence, Curtis; Luo, Feijun; Zhou, Chao] CDC, Div Anal Res & Practice Integrat, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA. [Simon, Thomas] CDC, Div Violence Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA. [Haegerich, Tamara] CDC, Div Unintent Injury Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA. RP Florence, C (reprint author), CDC, Div Anal Res & Practice Integrat, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA. EM cflorence@cdc.gov NR 9 TC 6 Z9 6 U1 1 U2 3 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD OCT 2 PY 2015 VL 64 IS 38 BP 1074 EP 1077 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CS5DF UT WOS:000362095900004 PM 26421530 ER PT J AU Florence, C Haegerich, T Simon, T Zhou, C Luo, FJ AF Florence, Curtis Haegerich, Tamara Simon, Thomas Zhou, Chao Luo, Feijun TI Estimated Lifetime Medical and Work-Loss Costs of Emergency Department-Treated Nonfatal Injuries - United States, 2013 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Florence, Curtis; Zhou, Chao; Luo, Feijun] CDC, Div Anal Res & Practice Integrat, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA. [Haegerich, Tamara] CDC, Div Violence Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA. [Simon, Thomas] CDC, Div Unintent Injury Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA. RP Florence, C (reprint author), CDC, Div Anal Res & Practice Integrat, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA. EM cflorence@cdc.gov NR 9 TC 4 Z9 4 U1 0 U2 1 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD OCT 2 PY 2015 VL 64 IS 38 BP 1078 EP 1082 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CS5DF UT WOS:000362095900005 PM 26421663 ER PT J AU Grinnell, M Dixon, MG Patton, M Fitter, D Bilivogui, P Johnson, C Dotson, E Diallo, B Rodier, G Raghunathan, P AF Grinnell, Margaret Dixon, Meredith G. Patton, Monica Fitter, David Bilivogui, Pepe Johnson, Candice Dotson, Ellen Diallo, Boubacar Rodier, Guenael Raghunathan, Pratima TI Ebola Virus Disease in Health Care Workers - Guinea, 2014 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Grinnell, Margaret] CDC, Div Populat Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. [Dixon, Meredith G.; Raghunathan, Pratima] CDC, Div Global HIV AIDS, Ctr Global Hlth, Atlanta, GA 30333 USA. [Patton, Monica] CDC, Div STD Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. [Fitter, David] CDC, Div Global Hlth Protect, Ctr Global Hlth, Atlanta, GA 30333 USA. [Johnson, Candice] CDC, Div Surveillance Hazard Evaluat & Field Studies, Natl Ctr Occupat Safety & Hlth, Atlanta, GA 30333 USA. [Dotson, Ellen] CDC, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA 30333 USA. [Diallo, Boubacar; Rodier, Guenael] WHO, Conakry, Guinea. RP Grinnell, M (reprint author), CDC, Div Populat Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. EM mhgrinnell@gmail.com NR 7 TC 4 Z9 4 U1 0 U2 3 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD OCT 2 PY 2015 VL 64 IS 38 BP 1083 EP 1087 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CS5DF UT WOS:000362095900006 PM 26421761 ER PT J AU Breakwell, L Moturi, E Helgenberger, L Gopalani, SV Hales, C Lam, E Sharapov, U Larzelere, M Johnson, E Masao, C Setik, E Barrow, L Dolan, S Chen, TH Patel, M Rota, P Hickman, C Bellini, W Seward, J Wallace, G Papania, M AF Breakwell, Lucy Moturi, Edna Helgenberger, Louisa Gopalani, Sameer V. Hales, Craig Lam, Eugene Sharapov, Umid Larzelere, Maribeth Johnson, Eliaser Masao, Carolee Setik, Eleanor Barrow, Lisa Dolan, Samantha Chen, Tai-Ho Patel, Minal Rota, Paul Hickman, Carole Bellini, William Seward, Jane Wallace, Greg Papania, Mark TI Measles Outbreak Associated with Vaccine Failure in Adults - Federated States of Micronesia, February-August 2014 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Breakwell, Lucy] CDC, Div Bacterial Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Moturi, Edna; Lam, Eugene; Sharapov, Umid; Dolan, Samantha; Patel, Minal] CDC, Global Immunizat Div, Ctr Global Hlth, Atlanta, GA 30333 USA. [Hales, Craig; Larzelere, Maribeth; Rota, Paul; Hickman, Carole; Bellini, William; Seward, Jane; Wallace, Greg; Papania, Mark] CDC, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Chen, Tai-Ho] CDC, Div Global Migrat & Quarantine, Natl Ctr Emerging & Zoonot Infect, Atlanta, GA 30333 USA. RP Papania, M (reprint author), CDC, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. EM mpapania@cdc.gov RI Moturi, Edna/P-2835-2015 OI Moturi, Edna/0000-0002-1694-1476 NR 10 TC 5 Z9 6 U1 1 U2 6 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD OCT 2 PY 2015 VL 64 IS 38 BP 1088 EP 1092 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CS5DF UT WOS:000362095900007 PM 26421903 ER PT J AU Ekwueme, DU Allaire, BT Guy, G Arnold, S Trogdon, JG AF Ekwueme, Donatus U. Allaire, Benjamin T. Guy, Gery Arnold, Sarah Trogdon, Justin G. TI Treatment costs of breast cancer among younger women aged 19 to 44 years enrolled in Medicaid. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Breast Cancer Symposium of the American-Society-of-Clinical-Oncology (ASCO) CY SEP 25-27, 2015 CL San Francisco, CA SP Amer Soc Clin Oncol C1 Ctr Dis Control & Prevent, Atlanta, GA USA. RTI Int, Res Triangle Pk, NC USA. Univ N Carolina, Chapel Hill, NC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD OCT 1 PY 2015 VL 33 IS 28 SU S MA 74 PG 1 WC Oncology SC Oncology GA DO9HV UT WOS:000378097000073 ER PT J AU Leffert, LR Clancy, CR Bateman, BT Cox, M Schulte, PJ Smith, EE Fonarow, GC Schwamm, LH Kuklina, EV George, MG AF Leffert, Lisa R. Clancy, Caitlin R. Bateman, Brian T. Cox, Margueritte Schulte, Phillip J. Smith, Eric E. Fonarow, Gregg C. Schwamm, Lee H. Kuklina, Elena V. George, Mary G. TI Patient Characteristics and Outcomes After Hemorrhagic Stroke in Pregnancy SO CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES LA English DT Article DE pregnancy; pre-eclampsia; stroke; epidemiology; hemorrhage ID RISK-FACTORS; INTRACEREBRAL HEMORRHAGE; TRENDS; GUIDELINES; PUERPERIUM; FREQUENCY; MORTALITY; JAPAN; CARE AB Background- Hospitalizations for pregnancy-related stroke are rare but increasing. Hemorrhagic stroke (HS), ie, subarachnoid hemorrhage and intracerebral hemorrhage, is more common than ischemic stroke in pregnant versus nonpregnant women, reflecting different phenotypes or risk factors. We compared stroke risk factors and outcomes in pregnant versus nonpregnant HS in the Get With The Guidelines-Stroke Registry. Methods and Results- Using medical history or International Classification of Diseases-Ninth Revision codes, we identified 330 pregnant and 10 562 nonpregnant female patients aged 18 to 44 years with HS in Get With The Guidelines-Stroke (2008-2014). Differences in patient and care characteristics were compared by chi(2) or Fisher exact test (categorical variables) or Wilcoxon rank-sum (continuous variables) tests. Conditional logistic regression assessed the association of pregnancy with outcomes conditional on categorical age and further adjusted for patient and hospital characteristics. Pregnant versus nonpregnant HS patients were younger with fewer pre-existing stroke risk factors and medications. Pregnant versus nonpregnant subarachnoid hemorrhage patients were less impaired at arrival, and less than half met blood pressure criteria for severe preeclampsia. In-hospital mortality was lower in pregnant versus nonpregnant HS patients: adjusted odds ratios (95% CI) for subarachnoid hemorrhage 0.17 (0.06-0.45) and intracerebral hemorrhage 0.57 (0.34-0.94). Pregnant subarachnoid hemorrhage patients also had a higher likelihood of home discharge (2.60 [1.67-4.06]) and independent ambulation at discharge (2.40 [1.56-3.70]). Conclusions- Pregnant HS patients are younger and have fewer risk factors than their nonpregnant counterparts, and risk-adjusted in-hospital mortality is lower. Our findings suggest possible differences in underlying disease pathophysiology and challenges to identifying at-risk patients. C1 [Leffert, Lisa R.; Clancy, Caitlin R.; Bateman, Brian T.] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, 55 Fruit St, Boston, MA 02114 USA. [Schwamm, Lee H.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. [Schulte, Phillip J.] Duke Clin Res Inst, Clin Trials Stat Grp, Durham, NC USA. [Cox, Margueritte] Duke Clin Res Inst, Outcomes Res & Assessment Grp, Durham, NC USA. [Smith, Eric E.] Univ Calgary, Dept Clin Neurosci, Calgary, AB, Canada. [Smith, Eric E.] Univ Calgary, Hotchkiss Brain Inst, Calgary, AB, Canada. [Fonarow, Gregg C.] Univ Calif Los Angeles, Med Ctr, Ahmanson, Dept Med,Cardiomyopathy Ctr, Los Angeles, CA 90024 USA. [Kuklina, Elena V.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Reprod Hlth, Atlanta, GA USA. [George, Mary G.] Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, Atlanta, GA USA. RP Leffert, LR (reprint author), Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, 55 Fruit St, Boston, MA 02114 USA. EM lleffert@mgh.harvard.edu FU Get With The Guidelines (GWTG)-Stroke Young Investigator Database Research Seed Grant; Medtronic; Boeringher-Ingelheim; Merck; Bristol-Myers Squib/Sanofi Pharmaceutical Partnership; Janseen Pharmaceutical Companies of Johnson Johnson; AHA Pharmaceutical Roundtable FX This project was funded by a Get With The Guidelines (GWTG)-Stroke Young Investigator Database Research Seed Grant. The GWTG-Stroke program is provided by the American Heart Association (AHA)/American Stroke Association. GWTG-Stroke is sponsored, in part, by Medtronic and has been funded in the past through support from Boeringher-Ingelheim, Merck, Bristol-Myers Squib/Sanofi Pharmaceutical Partnership, Janseen Pharmaceutical Companies of Johnson & Johnson and the AHA Pharmaceutical Roundtable. NR 21 TC 3 Z9 4 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1941-7705 EI 1941-7713 J9 CIRC-CARDIOVASC QUAL JI Circ.-Cardiovasc. Qual. Outcomes PD OCT PY 2015 VL 8 IS 6 SU 3 BP S170 EP S178 DI 10.1161/CIRCOUTCOMES.115.002242 PG 9 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA DF4QD UT WOS:000371333600016 PM 26515206 ER PT J AU Schieb, LJ Casper, ML George, MG AF Schieb, Linda J. Casper, Michele L. George, Mary G. TI Mapping Primary and Comprehensive Stroke Centers by Certification Organization SO CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES LA English DT Editorial Material DE stroke; geographic mapping; health services accessibility ID RECOMMENDATIONS; MORTALITY C1 [Schieb, Linda J.; Casper, Michele L.; George, Mary G.] Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, Atlanta, GA USA. RP Schieb, LJ (reprint author), 4770 Buford Hwy,NE,Mailstop F-77, Chamblee, GA 30341 USA. EM lschieb@cdc.gov FU Intramural CDC HHS [CC999999] NR 5 TC 1 Z9 1 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1941-7705 EI 1941-7713 J9 CIRC-CARDIOVASC QUAL JI Circ.-Cardiovasc. Qual. Outcomes PD OCT PY 2015 VL 8 IS 6 SU 3 BP S193 EP S194 DI 10.1161/CIRCOUTCOMES.115.002082 PG 2 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA DF4QD UT WOS:000371333600019 PM 26515209 ER PT J AU Hootman, JM Helmick, CG Golightly, YM AF Hootman, Jennifer M. Helmick, Charles G. Golightly, Yvonne M. TI Trends in Prevalence of Knee Pain Among US Adults, National Health Interview Survey, 2002-2010 SO ARTHRITIS & RHEUMATOLOGY LA English DT Meeting Abstract C1 [Hootman, Jennifer M.] Ctr Dis Control & Prevent, Div Populat Hlth, Atlanta, GA USA. [Helmick, Charles G.] Ctr Dis Control & Prevent, Arthrit Program, Atlanta, GA USA. [Golightly, Yvonne M.] Univ N Carolina, Epidemiol, Chapel Hill, NC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2326-5191 EI 2326-5205 J9 ARTHRITIS RHEUMATOL JI Arthritis Rheumatol. PD OCT PY 2015 VL 67 SU 10 MA 3269 PG 2 WC Rheumatology SC Rheumatology GA DE8BG UT WOS:000370860204817 ER PT J AU Izmirly, PM Wan, I Sahl, S Buyon, JP Belmont, HM Salmon, JE Bathon, JM Askanase, A Geraldino-Pardilla, L Ali, Y Ginzler, EM Putterman, C Gordon, C Helmick, CG Parton, H AF Izmirly, Peter M. Wan, Isabella Sahl, Sara Buyon, Jill P. Belmont, H. Michael Salmon, Jane E. Bathon, Joan M. Askanase, Anca Geraldino-Pardilla, Laura Ali, Yousaf Ginzler, Ellen M. Putterman, Chaim Gordon, Caroline Helmick, Charles G. Parton, Hilary TI Preliminary Population-Based Incidence and Prevalence Estimates of Systemic Lupus Erythematous from the Manhattan Lupus Surveillance Program SO ARTHRITIS & RHEUMATOLOGY LA English DT Meeting Abstract C1 [Izmirly, Peter M.; Sahl, Sara] NYU, Sch Med, Div Rheumatol, Med, New York, NY USA. [Wan, Isabella] NYU, Sch Med, Rheumatol, New York, NY USA. [Buyon, Jill P.] NYU, Sch Med, Dept Med, Div Rheumatol, New York, NY USA. [Belmont, H. Michael] NYU, Sch Med, New York, NY USA. [Salmon, Jane E.] Hosp Special Surg, Weill Cornell Med Coll, Dept Med, New York, NY 10021 USA. [Salmon, Jane E.] Hosp Special Surg, Rheumatol, New York, NY 10021 USA. [Bathon, Joan M.] Columbia Univ Coll Phys & Surg, Rheumatol, New York, NY 10032 USA. [Askanase, Anca] Columbia Univ Coll Phys & Surg, New York, NY 10032 USA. [Geraldino-Pardilla, Laura] Columbia Univ Coll Phys & Surg, Div Rheumatol, New York, NY 10032 USA. [Ali, Yousaf] Icahn Sch Med Mt Sinai, New York, NY 10029 USA. [Ginzler, Ellen M.] SUNY Downstate, Med, Brooklyn, NY USA. [Putterman, Chaim] Albert Einstein Coll Med, Div Rheumatol, Bronx, NY 10467 USA. [Gordon, Caroline] Univ Birmingham, Coll Med & Dent Sci, Sch Immun & Infect, Birmingham, W Midlands, England. [Helmick, Charles G.] Ctr Dis Control & Prevent, Arthrit Program, Atlanta, GA USA. [Parton, Hilary] New York City Dept Hlth & Mental Hyg, Bur Epidemiol Serv, Long Isl City, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2326-5191 EI 2326-5205 J9 ARTHRITIS RHEUMATOL JI Arthritis Rheumatol. PD OCT PY 2015 VL 67 SU 10 MA 2943 PG 2 WC Rheumatology SC Rheumatology GA DE8BG UT WOS:000370860204493 ER PT J AU Jetha, A Theis, K Boring, MA AF Jetha, Arif Theis, Kristina Boring, Michael Alden TI Does Arthritis in the Young Adult Life Phase Impact Involvement in Transitional Social Roles? SO ARTHRITIS & RHEUMATOLOGY LA English DT Meeting Abstract C1 [Jetha, Arif] Liberty Mutual Res Inst Safety, Ctr Disabil Res, Hopkinton, MA USA. [Jetha, Arif] Inst Work & Hlth, Toronto, ON, Canada. [Theis, Kristina; Boring, Michael Alden] Ctr Dis Control & Prevent, Arthrit Program, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2326-5191 EI 2326-5205 J9 ARTHRITIS RHEUMATOL JI Arthritis Rheumatol. PD OCT PY 2015 VL 67 SU 10 MA 2271 PG 2 WC Rheumatology SC Rheumatology GA DE8BG UT WOS:000370860203676 ER PT J AU Murphy, L Cisternas, MG Brady, TJ AF Murphy, Louise Cisternas, Miriam G. Brady, Teresa J. TI Current and Lifetime Smoking Among US Adults with Arthritis: A Serious Clinical and Public Health Issue SO ARTHRITIS & RHEUMATOLOGY LA English DT Meeting Abstract C1 [Murphy, Louise; Brady, Teresa J.] Ctr Dis Control & Prevent, Arthrit Program, Atlanta, GA USA. [Cisternas, Miriam G.] MGC Data Serv, Carlsbad, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2326-5191 EI 2326-5205 J9 ARTHRITIS RHEUMATOL JI Arthritis Rheumatol. PD OCT PY 2015 VL 67 SU 10 MA 2283 PG 2 WC Rheumatology SC Rheumatology GA DE8BG UT WOS:000370860203687 ER PT J AU Qin, J Barbour, KE Murphy, L Helmick, CG Baker, NA Theis, K Schwartz, T Renner, JB Nelson, A Allen, K Jordan, JM AF Qin, Jin Barbour, Kamil E. Murphy, Louise Helmick, Charles G. Baker, Nancy A. Theis, Kristina Schwartz, Todd Renner, Jordan B. Nelson, Amanda Allen, Kelli Jordan, Joanne M. TI Lifetime Risk of Symptomatic Hand Osteoarthritis: The Johnston County Osteoarthritis Project SO ARTHRITIS & RHEUMATOLOGY LA English DT Meeting Abstract C1 [Qin, Jin; Barbour, Kamil E.; Murphy, Louise; Helmick, Charles G.; Theis, Kristina] Ctr Dis Control & Prevent, Arthrit Program, Atlanta, GA USA. [Baker, Nancy A.] Univ Pittsburgh, Pittsburgh, PA USA. [Schwartz, Todd] Univ N Carolina, Biostat, Chapel Hill, NC USA. [Schwartz, Todd; Nelson, Amanda; Jordan, Joanne M.] Univ N Carolina, Thurston Arthrit Res Ctr, Chapel Hill, NC USA. [Renner, Jordan B.] Univ N Carolina, UNC Sch Med, Chapel Hill, NC USA. [Nelson, Amanda] Univ N Carolina, Div Rheumatol Allergy & Immunol, Chapel Hill, NC USA. [Allen, Kelli] Univ N Carolina, Chapel Hill, NC USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2326-5191 EI 2326-5205 J9 ARTHRITIS RHEUMATOL JI Arthritis Rheumatol. PD OCT PY 2015 VL 67 SU 10 MA 334 PG 2 WC Rheumatology SC Rheumatology GA DE8BG UT WOS:000370860201329 ER PT J AU Theis, KA Boring, M AF Theis, Kristina A. Boring, Michael TI Impacts on Work: Arthritis Vs Chronic Joint Symptoms without Arthritis SO ARTHRITIS & RHEUMATOLOGY LA English DT Meeting Abstract C1 [Theis, Kristina A.; Boring, Michael] Ctr Dis Control & Prevent, Arthrit Program, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2326-5191 EI 2326-5205 J9 ARTHRITIS RHEUMATOL JI Arthritis Rheumatol. PD OCT PY 2015 VL 67 SU 10 MA 2279 PG 2 WC Rheumatology SC Rheumatology GA DE8BG UT WOS:000370860203684 ER PT J AU Syamlal, G Mazurek, JM Storey, E Dube, SR AF Syamlal, Girija Mazurek, Jacek M. Storey, Eileen Dube, Shanta R. TI Cigarette Smoking Prevalence Among Adults Working in the Health Care and Social Assistance Sector, 2008 to 2012 SO JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE LA English DT Article ID NURSES; CESSATION; GENDER AB Objective: The primary objective of this study was to estimate current smoking among workers in the health care and social assistance sector. Methods: We analyzed the 2008 to 2012 National Health Interview Survey data for adults (age 18 years or more) working in health care and social assistance sector who reported current cigarette smoking. Results: Of the approximately 18.9 million health care and social assistance workers, 16.0% were current cigarette smokers. Smoking prevalence was highest in women (16.9%) and among workers: age 25 to 44 years (17.7%); with a high school education or less (24.4%); with income less than $ 35,000 (19.5%); with no health insurance (28.5%); in the nursing and residential care facilities (26.9%) industry; and in the material recording, scheduling, dispatching, and distributing (34.7%) occupations. Conclusions: These findings suggest that specific group of workers in the health care and social assistance sector might particularly benefit from cessation programs and incentives to quit smoking. C1 [Syamlal, Girija; Mazurek, Jacek M.; Storey, Eileen] NIOSH, Div Resp Dis Studies, Ctr Dis Control & Prevent, Morgantown, WV 26505 USA. [Dube, Shanta R.] Georgia State Univ, Sch Publ Hlth, Div Epidemiol & Biostat, Atlanta, GA 30303 USA. RP Syamlal, G (reprint author), 1095 Willowdale Rd,Mail Stop HG 900-2, Morgantown, WV 26505 USA. EM gsyamlal@cdc.gov FU Intramural CDC HHS [CC999999] NR 22 TC 0 Z9 0 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1076-2752 EI 1536-5948 J9 J OCCUP ENVIRON MED JI J. Occup. Environ. Med. PD OCT PY 2015 VL 57 IS 10 BP 1107 EP 1112 DI 10.1097/JOM.0000000000000529 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DD0UG UT WOS:000369634900016 PM 26461866 ER PT J AU Leung, J Lopez, AS Blostein, J Thayer, N Zipprich, J Clayton, A Buttery, V Andersen, J Thomas, CA del Rosario, M Seetoo, K Woodall, T Wiseman, R Bialek, SR AF Leung, Jessica Lopez, Adriana S. Blostein, Joel Thayer, Nancy Zipprich, Jennifer Clayton, Anna Buttery, Vicki Andersen, Jannifer Thomas, Carrie A. del Rosario, Maria Seetoo, Kurt Woodall, Tracy Wiseman, Rachel Bialek, Stephanie R. TI Impact of the US Two-dose Varicella Vaccination Program on the Epidemiology of Varicella Outbreaks Data from Nine States, 2005-2012 SO PEDIATRIC INFECTIOUS DISEASE JOURNAL LA English DT Article DE varicella; chickenpox; outbreaks; surveillance; varicella vaccination ID UNITED-STATES; CHILDREN; COVERAGE; HOSPITALIZATIONS; IMMUNIZATION; CHALLENGES; PREVENTION; RATES; ERA AB Background: A routine 2-dose varicella vaccination program was adopted in 2007 in the US to help further decrease varicella disease and prevent varicella outbreaks. We describe trends and characteristics of varicella outbreaks reported to the Centers for Disease Control and Prevention (CDC) during 2005-2012 from 9 states. Methods: Data on varicella outbreaks collected by 9 state health departments were submitted to CDC using the CDC outbreak reporting worksheet. Information was collected on dates of the outbreak, outbreak setting and number of cases by outbreak; aggregate data were provided on the numbers of outbreak-related cases by age group, vaccination status and laboratory confirmation. Results: Nine hundred and twenty-nine outbreaks were reported from the 6 states, which provided data for each year during 2005-2012. Based on data from these 6 states, the number of outbreaks declined by 78%, decreasing from 147 in 2005 to 33 outbreaks in 2012 (P = 0.0001). There were a total of 1015 varicella outbreaks involving 13,595 cases reported by the 9 states from 2005 to 2012. The size and duration of outbreaks declined significantly over time (P < 0.001). The median size of outbreaks was 12, 9 and 7 cases and median duration of outbreaks was 38, 35 and 26 days during 2005-2006, 2007-2009 and 2010-2012, respectively. Majority of outbreaks (95%) were reported from schools, declining from 97% in 2005-2006 to 89% in 2010-2012. Sixty-five percent of outbreak-related cases occurred among 5-year to 9-year olds, with the proportion declining from 76% in 2005-2006 to 45% during 2010-2012. Conclusions: The routine 2-dose varicella vaccination program appears to have significantly reduced the number, size and duration of varicella outbreaks in the US. C1 [Leung, Jessica; Lopez, Adriana S.; Bialek, Stephanie R.] Ctr Dis Control & Prevent, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Blostein, Joel] Michigan Dept Community Hlth, Div Immunizat, Lansing, MI USA. [Thayer, Nancy] Vermont Dept Hlth, Burlington, VT 05402 USA. [Zipprich, Jennifer; Clayton, Anna] Calif Dept Publ Hlth, Immunizat Branch, Richmond, CA USA. [Buttery, Vicki] Minnesota Dept Hlth, Vaccine Preventable Dis Unit, St Paul, MN USA. [Andersen, Jannifer] Mississippi Dept Hlth, Off Epidemiol, Jackson, MS USA. [Thomas, Carrie A.; del Rosario, Maria] West Virginia Dept Hlth & Human Resources, Charleston, WV USA. [Seetoo, Kurt] Maryland Dept Hlth & Mental Hyg, Infect Dis Epidemiol & Outbreak Response Bur, Ctr Immunizat, Baltimore, MD USA. [Woodall, Tracy] Colorado Dept Publ Hlth & Environm, Dis Control & Environm Epidemiol Div, Denver, CO USA. [Wiseman, Rachel] Texas Dept State Hlth Serv, Infect Dis Control Unit, Austin, TX USA. RP Leung, J (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,MS A-34, Atlanta, GA 30333 USA. EM JLeung@cdc.gov FU Federal 317 Immunization Grant Program; Epidemiology and Laboratory Capacity (ELC) grant from CDC; American Recovery and Reinvestment Act (ARRA) FX The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention, US Department of Health and Human Services. T.W. was funded in part by the Federal 317 Immunization Grant Program. V.B. was funded in part by an Epidemiology and Laboratory Capacity (ELC) grant from CDC. C.T. and M.D.R. were funded in part by American Recovery and Reinvestment Act (ARRA) funding. For the remaining others, no sources of funding were declared. There were no conflicts of interest declared. NR 22 TC 3 Z9 4 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0891-3668 EI 1532-0987 J9 PEDIATR INFECT DIS J JI Pediatr. Infect. Dis. J. PD OCT PY 2015 VL 34 IS 10 BP 1105 EP 1109 DI 10.1097/INF.0000000000000821 PG 5 WC Immunology; Infectious Diseases; Pediatrics SC Immunology; Infectious Diseases; Pediatrics GA DD0CD UT WOS:000369587000019 PM 26186103 ER PT J AU Vinekar, K Schaad, N Lucien, MAB Leshem, E Oboho, IK Joseph, G Juin, S Dawood, FS Parashar, U Katz, MA Tohme, RA AF Vinekar, Kavita Schaad, Nicolas Lucien, Mentor Ali Ber Leshem, Eyal Oboho, Ikwo K. Joseph, Gerard Juin, Stanley Dawood, Fatimah S. Parashar, Umesh Katz, Mark A. Tohme, Rania A. TI Hospitalizations and Deaths Because of Respiratory and Diarrheal Diseases Among Haitian Children Under Five Years of Age, 2011-2013 SO PEDIATRIC INFECTIOUS DISEASE JOURNAL LA English DT Article DE hospitalizations; diarrheal disease; respiratory disease; children; Haiti; deaths ID INVASIVE PNEUMOCOCCAL DISEASE; CHILDHOOD PNEUMONIA; ROTAVIRUS VACCINE; SEASONAL PATTERNS; 4 HOSPITALS; MORTALITY; BURDEN; MORBIDITY; YOUNGER; AFRICA AB Background: Respiratory and diarrheal diseases are leading causes of morbidity and mortality among children younger than 5 years in developing countries. Data on the burden of these diseases in Haiti are scarce. Methods: We conducted a retrospective review of hospital admission registries during January 1, 2011-December 31, 2013 for children younger than 5 years in 6 hospitals in Haiti. We recorded the number of all-cause, respiratory and diarrheal disease admissions and deaths by epidemiologic week and age. Results: A total of 31,565 hospital admissions and 1763 deaths were recorded among children aged <5 years during the study period. Respiratory diseases accounted for 9183 (29%) hospitalizations and 301 (17%) deaths. Children aged 6-23 months had the highest percentage of hospitalizations attributable to respiratory diseases (38%), whereas children aged 36-47 months had the highest proportion of deaths attributable to respiratory diseases (37%). Respiratory disease hospitalizations followed a bimodal seasonal pattern, with peaks during May-June and October-December. Diarrheal diseases accounted for 8063 (26%) hospitalizations and 224 (13%) deaths. Children aged 6-11 months had the highest percentage of diarrhea-associated hospitalizations (39%) and deaths (29%). Diarrheal disease admissions peaked in January-April before the rainy season. Conclusions: Respiratory and diarrheal diseases contributed to more than half of hospitalizations and almost a third of deaths in children younger than 5 years in Haiti. These data are essential to assess the impact of pneumococcal and rotavirus vaccines and other interventions in Haiti. C1 [Vinekar, Kavita] Ctr Dis Control & Prevent, Hubert Global Hlth Fellowship, Atlanta, GA 30329 USA. [Schaad, Nicolas] Ctr Dis Control & Prevent, Div Global Hlth Protect, Atlanta, GA 30329 USA. [Lucien, Mentor Ali Ber; Joseph, Gerard] Minist Publ Hlth & Populat, Lab Natl Sante Publ, Port Au Prince, Haiti. [Leshem, Eyal; Oboho, Ikwo K.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA 30329 USA. [Leshem, Eyal; Parashar, Umesh] Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA 30329 USA. [Oboho, Ikwo K.; Dawood, Fatimah S.] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA 30329 USA. [Juin, Stanley; Katz, Mark A.] Ctr Dis Control & Prevent, Surveillance & Epidem Prone Dis, Port Au Prince, Haiti. [Tohme, Rania A.] Ctr Dis Control & Prevent, Global Immunizat Div, Atlanta, GA 30329 USA. RP Tohme, RA (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop E 98, Atlanta, GA 30329 USA. EM rtohme@cdc.gov OI Leshem, Eyal/0000-0003-1267-6131 FU Centers for Disease Control and Prevention FX This study was supported by the Centers for Disease Control and Prevention. NR 28 TC 0 Z9 0 U1 1 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0891-3668 EI 1532-0987 J9 PEDIATR INFECT DIS J JI Pediatr. Infect. Dis. J. PD OCT PY 2015 VL 34 IS 10 BP E238 EP E243 DI 10.1097/INF.0000000000000805 PG 6 WC Immunology; Infectious Diseases; Pediatrics SC Immunology; Infectious Diseases; Pediatrics GA DD0CD UT WOS:000369587000002 PM 26244833 ER PT J AU Zhang, J Duan, ZJ Payne, DC Yen, C Pan, XP Chang, ZR Liu, N Ye, JL Ren, X Tate, JE Jiang, BM Parashar, UD AF Zhang, Jing Duan, Zhaojun Payne, Daniel C. Yen, Catherine Pan, Xiaoping Chang, Zhaorui Liu, Na Ye, Jianli Ren, Xiang Tate, Jacqueline E. Jiang, Baoming Parashar, Umesh D. TI Rotavirus-specific and Overall Diarrhea Mortality in Chinese Children Younger than 5 Years 2003 to 2012 SO PEDIATRIC INFECTIOUS DISEASE JOURNAL LA English DT Article DE all-cause diarrhea death; rotavirus-specific diarrhea death; mortality; children; China ID REPUBLIC-OF-CHINA; SURVEILLANCE; DEATHS; DISEASE AB Background: During the past decade, substantial declines in overall childhood mortality from diarrhea have been documented among Chinese children, but the last detailed assessment of rotavirus-specific mortality in China was conducted in 2002. To provide policy makers with up-to-date information, we examined rotavirus-related mortality in children <5 years of age in China during 2003-2012. Methods: We obtained mortality rates for children <5 years of age from the Chinese Health Statistic Yearbook; these figures were multiplied by the proportion of deaths in this age group attributable to diarrhea from the Chinese Maternal and Child Mortality Surveillance to obtain estimates of diarrhea deaths in children <5 years of age. To estimate rotavirus deaths, diarrhea death estimates were multiplied by the detection rate of rotavirus in children hospitalized with diarrhea from the Viral Diarrhea Surveillance System in China and from peer-reviewed literature. Results: From 2003 to 2012, a total of 127,539 deaths from diarrhea were reported among Chinese children <5 years of age, of which an estimated 53,559 (42%) had illness attributable to rotavirus. Comparing 2003 to 2012, the annual number of deaths from rotavirus diarrhea decreased by 74% (from 10,531 to 2,791, respectively) and the mortality rate fell 74% (from 0.66 to 0.17 deaths per 1000 live births, respectively). Ninety-three percent of all rotavirus deaths occurred in rural areas, where mortality rates (0.33 deaths per 1000 live births in 2012) were 11 times greater than in urban areas (0.03 deaths per 1000 live births in 2012). Conclusions: Rotavirus diarrhea mortality has substantially declined in the past decade in Chinese children. The vast majority of rotavirus deaths occurred in rural areas. There is potential value in using rotavirus vaccine interventions in rural areas to further reduce mortality from this disease. C1 [Zhang, Jing; Chang, Zhaorui; Ren, Xiang] Chinese Ctr Dis Control & Prevent, Div Infect Dis, Key Lab Surveillance & Early Warning Infect Dis, Beijing 102206, Peoples R China. [Duan, Zhaojun; Liu, Na] Chinese Ctr Dis Control & Prevent, Natl Inst Viral Dis Control & Prevent, Beijing 102206, Peoples R China. [Payne, Daniel C.; Yen, Catherine; Tate, Jacqueline E.; Jiang, Baoming; Parashar, Umesh D.] US Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Div Viral Dis, Atlanta, GA USA. [Pan, Xiaoping; Ye, Jianli] Chinese Ctr Dis Control & Prevent, Natl Ctr Women & Childrens Hlth, Beijing 102206, Peoples R China. RP Zhang, J (reprint author), Chinese Ctr Dis Control & Prevent, Div Infect Dis, Beijing 102206, Peoples R China. EM zhangjing@chinacdc.cn; uap2@cdc.gov OI ren, xiang/0000-0001-5020-5838 FU Intramural CDC HHS [CC999999] NR 24 TC 4 Z9 4 U1 2 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0891-3668 EI 1532-0987 J9 PEDIATR INFECT DIS J JI Pediatr. Infect. Dis. J. PD OCT PY 2015 VL 34 IS 10 BP E233 EP E237 DI 10.1097/INF.0000000000000799 PG 5 WC Immunology; Infectious Diseases; Pediatrics SC Immunology; Infectious Diseases; Pediatrics GA DD0CD UT WOS:000369587000001 PM 26083587 ER PT J AU Freudenberg, N Franzosa, E Sohler, N Li, R Devlin, H Albu, J AF Freudenberg, Nicholas Franzosa, Emily Sohler, Nancy Li, Rui Devlin, Heather Albu, Jeanine TI The State of Evaluation Research on Food Policies to Reduce Obesity and Diabetes Among Adults in the United States, 2000-2011 SO PREVENTING CHRONIC DISEASE LA English DT Review ID PUBLIC-HEALTH; PREVENTION; INTERVENTIONS; CHILDREN; PROMOTE; RECOMMENDATIONS; DISEASES; MODEL AB Introduction Improvements in diet can prevent obesity and type 2 diabetes. Although policy changes provide a foundation for improvement at the population level, evidence for the effectiveness of such changes is slim. This study summarizes the literature on recent efforts in the United States to change food-related policies to prevent obesity and diabetes among adults. Methods We conducted a systematic review of evidence of the impact of food policies. Websites of government, academic, and nonprofit organizations were scanned to generate a typology of food-related policies, which we classified into 18 categories. A key-word search and a search of policy reports identified empirical evaluation studies of these categories. Analyses were limited to strategies with 10 or more reports. Of 422 articles identified, 94 met these criteria. Using publication date, study design, study quality, and dietary outcomes assessed, we evaluated the strength of evidence for each strategy in 3 assessment categories: time period, quality, and study design. Results Five strategies yielded 10 or more reports. Only 2 of the 5 strategies, menu labeling and taxes on unhealthy foods, had 50% or more studies with positive findings in at least 2 of 3 assessment categories. Most studies used methods that were rated medium quality. Although the number of published studies increased over 11 years, study quality did not show any clear trend nor did it vary by strategy. Conclusion Researchers and policy makers can improve the quality and rigor of policy evaluations to synthesize existing evidence and develop better methods for gleaning policy guidance from the ample but imperfect data available. C1 [Freudenberg, Nicholas; Franzosa, Emily; Sohler, Nancy] CUNY, Sch Publ Hlth, Silberman Bldg,2180 Third Ave, New York, NY 10035 USA. [Li, Rui; Devlin, Heather] Ctr Dis Control & Prevent, Atlanta, GA USA. [Albu, Jeanine] St Lukes Roosevelt Hosp, Obes Res Ctr, New York, NY USA. RP Freudenberg, N (reprint author), CUNY, Sch Publ Hlth, Silberman Bldg,2180 Third Ave, New York, NY 10035 USA. EM nfreuden@hunter.cuny.edu FU CDC's Natural Experiments for Translation in Diabetes (NEXT-D) Study FX This work was supported by CDC's Natural Experiments for Translation in Diabetes (NEXT-D) Study, of which Dr Albu at St Luke's Roosevelt Hospital Center, Obesity Research Center is the New York Principal Investigator. The authors gratefully acknowledge the many helpful suggestions for improving this manuscript by the Next-D Policy Frameworks Group and CDC internal reviewers and thank Amy Freeman for her assistance in compiling the literature that was reviewed. NR 35 TC 1 Z9 1 U1 6 U2 8 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD OCT PY 2015 VL 12 AR E182 DI 10.5888/pcd12.150237 PG 12 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DB6ZY UT WOS:000368665400020 PM 26513438 ER PT J AU Holt, JB AF Holt, James B. TI Technology and Data Collection in Chronic Disease Epidemiology SO PREVENTING CHRONIC DISEASE LA English DT Editorial Material ID PHYSICAL-ACTIVITY; HEALTH RESEARCH; ENVIRONMENT; APP C1 [Holt, James B.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Populat Hlth, 4770 Buford Hwy NE,Mail Stop F-78, Atlanta, GA 30341 USA. RP Holt, JB (reprint author), Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Populat Hlth, 4770 Buford Hwy NE,Mail Stop F-78, Atlanta, GA 30341 USA. EM jgh4@cdc.gov NR 16 TC 0 Z9 0 U1 0 U2 2 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD OCT PY 2015 VL 12 AR 150400 DI 10.5888/pcd12.150400 PG 3 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DB6ZY UT WOS:000368665400025 ER PT J AU Marshall, LL Kuiper, NM Lavinghouze, SR AF Marshall, LaTisha L. Kuiper, Nicole M. Lavinghouze, S. Rene TI Strategies to Support Tobacco Cessation and Tobacco-Free Environments in Mental Health and Substance Abuse Facilities SO PREVENTING CHRONIC DISEASE LA English DT Article AB We identified and described strategies for promoting smoking cessation and smoke-free environments that were implemented in Oregon and Utah in treatment centers for mental illness and substance abuse. We reviewed final evaluation reports submitted by state tobacco control programs (TCPs) to the Centers for Disease Control and Prevention and transcripts from a call study evaluation. The TCPs described factors that assisted in implementing strategies: being ready for opportunity, having a sound infrastructure, and having a branded initiative. These strategies could be used by other programs serving high-need populations for whom evidence-based interventions are still being developed. C1 [Marshall, LaTisha L.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Off Smoking & Hlth, 4770 Buford Hwy F-79, Atlanta, GA 30341 USA. [Kuiper, Nicole M.; Lavinghouze, S. Rene] Ctr Dis Control & Prevent, Off Smoking & Hlth, Atlanta, GA 30341 USA. RP Marshall, LL (reprint author), Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Off Smoking & Hlth, 4770 Buford Hwy F-79, Atlanta, GA 30341 USA. EM lmarshall@cdc.gov FU CDC FX The authors acknowledge Kimberly Snyder, MPH, ICF International, and the Utah (http://recoveryplus.utah.gov/) and Oregon (http://www.oregon.gov/oha/amh/Pages/tobacco.aspx) state tobacco control programs. Ms Snyder was supported under contract by funding through CDC. Funding for the call study evaluation noted in this article and State Tobacco Control and Prevention Program funding was provided by CDC. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of CDC. NR 8 TC 2 Z9 2 U1 0 U2 4 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD OCT PY 2015 VL 12 AR E167 DI 10.5888/pcd12.140585 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DB6ZY UT WOS:000368665400005 PM 26425871 ER PT J AU Crump, JA Sjolund-Karlsson, M Gordon, MA Parry, CM AF Crump, John A. Sjoelund-Karlsson, Maria Gordon, Melita A. Parry, Christopher M. TI Epidemiology, Clinical Presentation, Laboratory Diagnosis, Antimicrobial Resistance, and Antimicrobial Management of Invasive Salmonella Infections SO CLINICAL MICROBIOLOGY REVIEWS LA English DT Review ID ENTERICA SEROVAR-TYPHI; NON-TYPHOIDAL SALMONELLA; POLYMERASE-CHAIN-REACTION; BLOOD-STREAM INFECTIONS; MEDIATED QUINOLONE RESISTANCE; RANDOMIZED CONTROLLED-TRIAL; TRANSMEMBRANE CONDUCTANCE REGULATOR; COMMUNITY-ACQUIRED BACTEREMIA; LINKED-IMMUNOSORBENT-ASSAY; BONE-MARROW CULTURES AB Salmonella enterica infections are common causes of bloodstream infection in low-resource areas, where they may be difficult to distinguish from other febrile illnesses and may be associated with a high case fatality ratio. Microbiologic culture of blood or bone marrow remains the mainstay of laboratory diagnosis. Antimicrobial resistance has emerged in Salmonella enterica, initially to the traditional first-line drugs chloramphenicol, ampicillin, and trimethoprim-sulfamethoxazole. Decreased fluoroquinolone susceptibility and then fluoroquinolone resistance have developed in association with chromosomal mutations in the quinolone resistance-determining region of genes encoding DNA gyrase and topoisomerase IV and also by plasmid-mediated resistance mechanisms. Resistance to extended-spectrum cephalosporins has occurred more often in nontyphoidal than in typhoidal Salmonella strains. Azithromycin is effective for the management of uncomplicated typhoid fever and may serve as an alternative oral drug in areas where fluoroquinolone resistance is common. In 2013, CLSI lowered the ciprofloxacin susceptibility breakpoints to account for accumulating clinical, microbiologic, and pharmacokinetic-pharmacodynamic data suggesting that revision was needed for contemporary invasive Salmonella infections. Newly established CLSI guidelines for azithromycin and Salmonella enterica serovar Typhi were published in CLSI document M100 in 2015. C1 [Crump, John A.] Univ Otago, Ctr Int Hlth, Dunedin, Otago, New Zealand. [Crump, John A.; Sjoelund-Karlsson, Maria] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. [Gordon, Melita A.] Univ Liverpool, Inst Infect & Global Hlth, Dept Clin Infect Microbiol & Immunol, Liverpool L69 3BX, Merseyside, England. [Gordon, Melita A.] Malawi Liverpool Wellcome Trust Clin Res Programm, Blantyre, Malawi. [Parry, Christopher M.] Nagasaki Univ, Sch Trop Med & Global Hlth, Nagasaki 852, Japan. [Parry, Christopher M.] Univ London London Sch Hyg & Trop Med, Dept Clin Res, London WC1E 7HT, England. [Parry, Christopher M.] Univ Liverpool, Liverpool Sch Trop Med, Dept Clin Sci, Liverpool L3 5QA, Merseyside, England. RP Crump, JA (reprint author), Univ Otago, Ctr Int Hlth, Dunedin, Otago, New Zealand. EM john.crump@otago.ac.nz FU joint U.S. National Institutes of Health-National Science Foundation Ecology and Evolution of Infectious Disease program [R01 TW009237]; United Kingdom Biotechnology and Biological Sciences Research Council (BBSRC) [BB/J010367/1]; United Kingdom BBSRC Zoonoses in Emerging Livestock Systems [BB/L017679, BB/L018926, BB/L018845]; EU-FP7 R-Gnosis program; OSEO-Nosobio; EU-FP7 EvoTAR program FX J.A.C. is supported by the joint U.S. National Institutes of Health-National Science Foundation Ecology and Evolution of Infectious Disease program (R01 TW009237), by the United Kingdom Biotechnology and Biological Sciences Research Council (BBSRC) (BB/J010367/1), and by United Kingdom BBSRC Zoonoses in Emerging Livestock Systems awards BB/L017679, BB/L018926, and BB/L018845. This work was supported in part by EU-FP7 R-Gnosis and EvoTAR programs and by OSEO-Nosobio. NR 604 TC 32 Z9 32 U1 15 U2 36 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0893-8512 EI 1098-6618 J9 CLIN MICROBIOL REV JI Clin. Microbiol. Rev. PD OCT PY 2015 VL 28 IS 4 BP 901 EP 937 DI 10.1128/CMR.00002-15 PG 37 WC Microbiology SC Microbiology GA DB2KR UT WOS:000368337800003 PM 26180063 ER PT J AU Teshale, EH Xing, J Moorman, AC Holmberg, SD Gordon, SC Rupp, LB Lu, M Spradling, PR Boscarino, JA Trinacty, CM Schmidt, MA Xu, FJ AF Teshale, Eyasu H. Xing, Jian Moorman, Anne C. Holmberg, Scott D. Gordon, Stuart C. Rupp, Loralee B. Lu, Mei Spradling, Philip R. Boscarino, Joseph A. Trinacty, Connie M. Schmidt, Mark A. Xu, Fujie TI Effect of HCV treatment outcome on hospitalization rate: Chronic Hepatitis Cohort Study (CHeCS) SO HEPATOLOGY LA English DT Meeting Abstract CT 66th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 13-17, 2015 CL San Francisco, CA SP Amer Assoc Study Liver Dis C1 [Teshale, Eyasu H.; Xing, Jian; Moorman, Anne C.; Holmberg, Scott D.; Spradling, Philip R.; Xu, Fujie] CDC, Atlanta, GA 30333 USA. [Gordon, Stuart C.; Rupp, Loralee B.; Lu, Mei] Henry Ford Hlth Syst, Detroit, MI USA. [Boscarino, Joseph A.] Geisinger Hlth Syst, Danville, PA USA. [Trinacty, Connie M.] Kaiser Permanente Hawaii, Honolulu, HI USA. [Schmidt, Mark A.] Kaiser Permanente Northwest, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2015 VL 62 SU 1 SI SI MA 15 BP 215A EP 215A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DB2YA UT WOS:000368375400016 ER PT J AU Gounder, PP Bulkow, L Snowball, M Negus, S Spradling, PR McMahon, BJ AF Gounder, Prabhu P. Bulkow, Lisa Snowball, Mary Negus, Susan Spradling, Philip R. McMahon, Brian J. TI Hepatocellular Carcinoma (HCC) Risk Among Alaska Native (AN) Persons After Resolving Hepatitis B Virus (HBV) Infection: A Nested Case-Control Study SO HEPATOLOGY LA English DT Meeting Abstract CT 66th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 13-17, 2015 CL San Francisco, CA SP Amer Assoc Study Liver Dis C1 [Gounder, Prabhu P.; Bulkow, Lisa] Ctr Dis Control & Prevent, Arctic Invest Program, Anchorage, AK USA. [Snowball, Mary; Negus, Susan; McMahon, Brian J.] Alaska Native Tribal Hlth Consortium, Liver Dis & Hepatitis Program, Anchorage, AK USA. [Spradling, Philip R.] Ctr Dis Control & Prevent, Div Viral Hepatitis, Anchorage, AK USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2015 VL 62 SU 1 SI SI MA 125 BP 272A EP 273A PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DB2YA UT WOS:000368375401010 ER PT J AU Boscarino, JA Rupp, LB Moorman, AC Zhou, YR Lu, M Gordon, SC Spradling, PR Teshale, EH Schmidt, MA Trinacty, CM Xu, FJ Holmberg, SD Holtzman, D AF Boscarino, Joseph A. Rupp, Loralee B. Moorman, Anne C. Zhou, Yueren Lu, Mei Gordon, Stuart C. Spradling, Philip R. Teshale, Eyasu H. Schmidt, Mark A. Trinacty, Connie M. Xu, Fujie Holmberg, Scott D. Holtzman, Deborah TI Depression and Alcohol Misuse among Patients in the Chronic Hepatitis Cohort Study (CHeCS): Comparison of PHQ-8 and Audit-C Instruments vs. ICD-9 Codes SO HEPATOLOGY LA English DT Meeting Abstract CT 66th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 13-17, 2015 CL San Francisco, CA SP Amer Assoc Study Liver Dis C1 [Boscarino, Joseph A.] Weis Ctr Res, Geisinger Clin, Ctr Hlth Res, Danville, PA 17822 USA. [Rupp, Loralee B.; Zhou, Yueren; Lu, Mei; Gordon, Stuart C.] Henry Ford Hlth Syst, Detroit, MI USA. [Moorman, Anne C.; Spradling, Philip R.; Teshale, Eyasu H.; Xu, Fujie; Holmberg, Scott D.; Holtzman, Deborah] Ctr Dis Control & Prevent, Div Viral Hepatitis, Natl Ctr HIV Hepatitis STD & TB Prevent, Atlanta, GA USA. [Schmidt, Mark A.] Kaiser Permanente Northwest, Portland, OR USA. [Trinacty, Connie M.] Kaiser Permanente Hawaii, Honolulu, HI USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2015 VL 62 SU 1 SI SI MA 525 BP 471A EP 471A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DB2YA UT WOS:000368375401408 ER PT J AU Cui, QW Zubkova, I Murphy, T Schillie, SF Major, ME AF Cui, Qingwen Zubkova, Iryna Murphy, Trudy Schillie, Sarah F. Major, Marian E. TI Assessing the impact of hepatitis B immune globulin (HBIG) on responses to the hepatitis B vaccine during co-administration SO HEPATOLOGY LA English DT Meeting Abstract CT 66th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 13-17, 2015 CL San Francisco, CA SP Amer Assoc Study Liver Dis C1 [Cui, Qingwen; Zubkova, Iryna; Major, Marian E.] US FDA, CBER, Alexandria, VA USA. [Murphy, Trudy; Schillie, Sarah F.] Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2015 VL 62 SU 1 SI SI MA 1546 BP 964A EP 964A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DB2YA UT WOS:000368375403338 ER PT J AU Harris, AM Schoenbachler, B Ramirez, G Vellozzi, C Beckett, G AF Harris, Aaron M. Schoenbachler, Ben Ramirez, Gilberto Vellozzi, Claudia Beckett, Geoff TI Collaborative Public Health Efforts to Test and Link Foreign-Born Persons with Chronic Hepatitis B Virus Infection to Care SO HEPATOLOGY LA English DT Meeting Abstract CT 66th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 13-17, 2015 CL San Francisco, CA SP Amer Assoc Study Liver Dis C1 [Harris, Aaron M.; Schoenbachler, Ben; Ramirez, Gilberto; Vellozzi, Claudia; Beckett, Geoff] Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2015 VL 62 SU 1 SI SI MA 1574 BP 978A EP 978A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DB2YA UT WOS:000368375403366 ER PT J AU Vellozzi, C Patel, R Schoenbachler, B Hariri, S AF Vellozzi, Claudia Patel, Rajiv Schoenbachler, Ben Hariri, Susan TI Hepatitis C Birth-Cohort Testing and Linkage to Care, Selected US Sites, 2012-2014 SO HEPATOLOGY LA English DT Meeting Abstract CT 66th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 13-17, 2015 CL San Francisco, CA SP Amer Assoc Study Liver Dis C1 [Vellozzi, Claudia; Hariri, Susan] CDC, Atlanta, GA 30333 USA. [Patel, Rajiv; Schoenbachler, Ben] ORISE, Oak Ridge, TN USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2015 VL 62 SU 1 SI SI MA 1787 BP 1079A EP 1079A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DB2YA UT WOS:000368375404034 ER PT J AU Bruden, DJ Townshend-Bulson, LJ Gove, JE Plotnik, JN Homan, CE Hewitt, A Bruce, M Gounder, PP Barbour, Y Simons-Petrusa, B McMahon, BJ AF Bruden, Dana J. Townshend-Bulson, Lisa J. Gove, James E. Plotnik, Julia N. Homan, Chriss E. Hewitt, Annette Bruce, Michael Gounder, Prabhu P. Barbour, Youssef Simons-Petrusa, Brenna McMahon, Brian J. TI Development of End Stage Liver Disease, Hepatocellular Carcinoma and Liver-Related Death According to Biopsy-Confirmed Ishak Fibrosis Stage in the Hepatitis C Alaska Cohort Study (AK-HepC) SO HEPATOLOGY LA English DT Meeting Abstract CT 66th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 13-17, 2015 CL San Francisco, CA SP Amer Assoc Study Liver Dis C1 [Bruden, Dana J.; Bruce, Michael; Gounder, Prabhu P.; McMahon, Brian J.] Ctr Dis Control & Prevent, Arctic Invest Program, Div Preparedness & Emerging Infect, Anchorage, AK USA. [Townshend-Bulson, Lisa J.; Gove, James E.; Plotnik, Julia N.; Homan, Chriss E.; Hewitt, Annette; Barbour, Youssef; Simons-Petrusa, Brenna; McMahon, Brian J.] Alaska Native Tribal Hlth Consortium, Liver Dis & Hepatitis Program, Anchorage, AK USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2015 VL 62 SU 1 SI SI MA 1790 BP 1080A EP 1080A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DB2YA UT WOS:000368375404037 ER PT J AU Xu, FJ Xing, J Moorman, AC Rupp, LB Gordon, SC Lu, M Teshale, EH Spradling, PR Boscarino, JA Trinacty, CM Schmidt, MA Holmberg, SD AF Xu, Fujie Xing, Jian Moorman, Anne C. Rupp, Loralee B. Gordon, Stuart C. Lu, Mei Teshale, Eyasu H. Spradling, Philip R. Boscarino, Joseph A. Trinacty, Connie M. Schmidt, Mark A. Holmberg, Scott D. TI Cause of death in HCV patients who achieved sustained virologic response: Chronic Hepatitis Cohort Study (CHeCS), 2006-2012 SO HEPATOLOGY LA English DT Meeting Abstract CT 66th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 13-17, 2015 CL San Francisco, CA SP Amer Assoc Study Liver Dis C1 [Xu, Fujie; Xing, Jian; Moorman, Anne C.; Teshale, Eyasu H.; Spradling, Philip R.; Holmberg, Scott D.] CDC, Div Viral Hepatitis, Atlanta, GA 30333 USA. [Rupp, Loralee B.; Gordon, Stuart C.; Lu, Mei] Henry Ford Hlth Syst, Detroit, MI USA. [Boscarino, Joseph A.] Geisinger Hlth Syst, Danville, PA USA. [Trinacty, Connie M.] Kaiser Permanente Hawaii, Honolulu, HI USA. [Schmidt, Mark A.] Kaiser Permanente Northwest, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2015 VL 62 SU 1 SI SI MA 1789 BP 1080A EP 1080A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DB2YA UT WOS:000368375404036 ER PT J AU Brady, JE Liffmann, D Yartel, AK Kil, NB Federman, AD Jordan, CE Massoud, OI Nerenz, DR Brown, KA Smith, B Vellozzi, C Rein, DB AF Brady, Joanne E. Liffmann, Danielle Yartel, Anthony K. Kil, Natalie B. Federman, Alex D. Jordan, Cynthia E. Massoud, Omar I. Nerenz, David R. Brown, Kimberly Ann Smith, Bryce Vellozzi, Claudia Rein, David B. TI Characteristics of Patients Tested for Hepatitis C and Intervention Costs in the BEST-C Study SO HEPATOLOGY LA English DT Meeting Abstract CT 66th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 13-17, 2015 CL San Francisco, CA SP Amer Assoc Study Liver Dis C1 [Brady, Joanne E.; Liffmann, Danielle; Rein, David B.] Univ Chicago, NORC, Publ Hlth, Bethesda, MD USA. [Yartel, Anthony K.; Vellozzi, Claudia] US Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA USA. [Kil, Natalie B.; Federman, Alex D.] Mt Sinai Sch Med, Div Gen Internal Med, New York, NY USA. [Jordan, Cynthia E.; Massoud, Omar I.] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA. [Nerenz, David R.; Brown, Kimberly Ann] Henry Ford Hosp, Dept Med, Detroit, MI 48202 USA. [Smith, Bryce] US Ctr Dis Control & Prevent, Div Diabet Translat, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2015 VL 62 SU 1 SI SI MA 1792 BP 1081A EP 1082A PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DB2YA UT WOS:000368375404039 ER PT J AU McMahon, BJ Bruden, DJ Townshend-Bulson, LJ Livingston, S Gove, JE Hewitt, A Plotnik, JN Homan, CE Espera, HG Negus, S Snowball, M Barbour, Y Bruce, M Spradling, PR Gounder, PP AF McMahon, Brian J. Bruden, Dana J. Townshend-Bulson, Lisa J. Livingston, Stephen Gove, James E. Hewitt, Annette Plotnik, Julia N. Homan, Chriss E. Espera, Hannah G. Negus, Susan Snowball, Mary Barbour, Youssef Bruce, Michael Spradling, Philip R. Gounder, Prabhu P. TI Hepatitis C Virus (HCV) Genotype 3 is an Independent Risk Factor for Advanced Fibrosis, End Stage Liver Disease (ESLD), Hepatocellular Carcinoma (HCC), and Liver Related Death (LRD): Alaska Hepatitis C Cohort Study (AK-HepC) SO HEPATOLOGY LA English DT Meeting Abstract CT 66th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 13-17, 2015 CL San Francisco, CA SP Amer Assoc Study Liver Dis C1 [McMahon, Brian J.; Townshend-Bulson, Lisa J.; Livingston, Stephen; Gove, James E.; Hewitt, Annette; Plotnik, Julia N.; Homan, Chriss E.; Espera, Hannah G.; Negus, Susan; Snowball, Mary; Barbour, Youssef] Alaska Native Med Ctr, Liver Dis & Hepatitis, Anchorage, AK USA. [Bruden, Dana J.; Bruce, Michael; Gounder, Prabhu P.] Ctr Dis Control & Prevent, Arctic Invest Program, Anchorage, AK USA. [Spradling, Philip R.] CDC, Div Viral Hepatitis, Atlanta, GA 30333 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2015 VL 62 SU 1 SI SI MA 1798 BP 1084A EP 1085A PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DB2YA UT WOS:000368375404045 ER PT J AU Moorman, AC Zhou, YR Rupp, LB Boscarino, JA Trinacty, CM Holmberg, SD AF Moorman, Anne C. Zhou, Yueren Rupp, Loralee B. Boscarino, Joseph A. Trinacty, Connie M. Holmberg, Scott D. TI The Utility and Limitations of Electronic Medical Records: Predictive Values of ICD9 Codes indicating Chronic HCV Infection SO HEPATOLOGY LA English DT Meeting Abstract CT 66th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 13-17, 2015 CL San Francisco, CA SP Amer Assoc Study Liver Dis C1 [Moorman, Anne C.; Holmberg, Scott D.] CDC, Div Viral Hepatitis, Atlanta, GA 30333 USA. [Zhou, Yueren; Rupp, Loralee B.] Henry Ford Hlth Syst, Detroit, MI USA. [Boscarino, Joseph A.] Geaisinger Hlth Syst, Danville, PA USA. [Trinacty, Connie M.] Kaiser Permanente Hawaii, Honolulu, HI USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2015 VL 62 SU 1 SI SI MA 1799 BP 1085A EP 1085A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DB2YA UT WOS:000368375404046 ER PT J AU Xu, FJ Xing, J Moorman, AC Gordon, SC Rupp, LB Lu, M Spradling, PR Teshale, EH Boscarino, JA Schmidt, MA Trinacty, CM Holmberg, SD AF Xu, Fujie Xing, Jian Moorman, Anne C. Gordon, Stuart C. Rupp, Loralee B. Lu, Mei Spradling, Philip R. Teshale, Eyasu H. Boscarino, Joseph A. Schmidt, Mark A. Trinacty, Connie M. Holmberg, Scott D. TI Liver fibrosis stage and comorbidities in persons with diagnosed hepatitis C infection, Chronic Hepatitis Cohort Study (CHeCS) SO HEPATOLOGY LA English DT Meeting Abstract CT 66th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 13-17, 2015 CL San Francisco, CA SP Amer Assoc Study Liver Dis C1 [Xu, Fujie; Xing, Jian; Moorman, Anne C.; Spradling, Philip R.; Teshale, Eyasu H.; Holmberg, Scott D.] Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA USA. [Gordon, Stuart C.; Rupp, Loralee B.; Lu, Mei] Henry Ford Hlth Syst, Detroit, MI USA. [Boscarino, Joseph A.] Geisinger Hlth Syst, Danville, PA USA. [Schmidt, Mark A.] Kaiser Permanente Northwest, Portland, OR USA. [Trinacty, Connie M.] Kaiser Permanente Hawaii, Honolulu, HI USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2015 VL 62 SU 1 SI SI MA 1800 BP 1085A EP 1086A PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DB2YA UT WOS:000368375404047 ER PT J AU Townshend-Bulson, LJ Bruden, DJ McMahon, BJ Livingston, S Simons-Petrusa, B Homan, CE Gove, JE Plotnik, JN Negus, S Snowball, M Espera, HG Gounder, PP Hewitt, A Barbour, Y AF Townshend-Bulson, Lisa J. Bruden, Dana J. McMahon, Brian J. Livingston, Stephen Simons-Petrusa, Brenna Homan, Chriss E. Gove, James E. Plotnik, Julia N. Negus, Susan Snowball, Mary Espera, Hannah G. Gounder, Prabhu P. Hewitt, Annette Barbour, Youssef TI Impact of Hepatitis C (HCV) Treatment on the Risk for End Stage Liver Disease (ESLD) and Hepatocellular Carcinoma (HCC) in Alaska Native/American Indian (AN/AI) People - The Alaska Hepatitis C Cohort (AK-HepC), 1994-2012 SO HEPATOLOGY LA English DT Meeting Abstract CT 66th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 13-17, 2015 CL San Francisco, CA SP Amer Assoc Study Liver Dis C1 [Townshend-Bulson, Lisa J.; McMahon, Brian J.; Livingston, Stephen; Simons-Petrusa, Brenna; Homan, Chriss E.; Gove, James E.; Plotnik, Julia N.; Negus, Susan; Snowball, Mary; Espera, Hannah G.; Hewitt, Annette; Barbour, Youssef] ANTHC, Liver Dis & Hepatitis Program, Anchorage, AK USA. [Townshend-Bulson, Lisa J.; Gounder, Prabhu P.] US PHS, Bethesda, MD USA. [Bruden, Dana J.; Gounder, Prabhu P.] CDC, Arctic Invest Program, Anchorage, AK USA. NR 0 TC 0 Z9 0 U1 2 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2015 VL 62 SU 1 SI SI MA 1807 BP 1089A EP 1090A PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DB2YA UT WOS:000368375404054 ER PT J AU Rein, DB Liffmann, D Brunner, J Wievel, E Scott, G Raymond, D Danelski, L Stokes, S Brady, JE Zibbell, JE AF Rein, David B. Liffmann, Danielle Brunner, Jim Wievel, Emily Scott, Gregory Raymond, Daniel Danelski, Lisa Stokes, Scott Brady, Joanne E. Zibbell, Jon E. TI Factors Associated with Hepatitis C Virus Infection among Persons Ages 18 to 29 who Inject Drugs in Suburban and Rural Wisconsin SO HEPATOLOGY LA English DT Meeting Abstract CT 66th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 13-17, 2015 CL San Francisco, CA SP Amer Assoc Study Liver Dis C1 [Rein, David B.; Liffmann, Danielle; Brady, Joanne E.] Univ Chicago, NORC, Atlanta, GA USA. [Brunner, Jim; Wievel, Emily; Danelski, Lisa; Stokes, Scott] AIDS Resource Ctr Wisconsin, Green Bay, WI USA. [Scott, Gregory] Depaul Univ, Sociol, Chicago, IL 60604 USA. [Raymond, Daniel] Harm Reduct Coalit, New York, NY USA. [Zibbell, Jon E.] CDC, Div Viral Hepatitis, Atlanta, GA 30333 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2015 VL 62 SU 1 SI SI MA 1839 BP 1105A EP 1105A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DB2YA UT WOS:000368375404085 ER PT J AU Choi, Y Zhang, XG Skinner, B Teo, CG AF Choi, Youkyung Zhang, Xiugen Skinner, Brianna Teo, Chong-Gee TI Upregulated hepatic expression of pattern recognition receptors and Th1 type cytokine genes are associated with clearance of HEV in genotype 1 infected rhesus macaques SO HEPATOLOGY LA English DT Meeting Abstract CT 66th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 13-17, 2015 CL San Francisco, CA SP Amer Assoc Study Liver Dis C1 [Choi, Youkyung; Zhang, Xiugen; Skinner, Brianna; Teo, Chong-Gee] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2015 VL 62 SU 1 SI SI MA 2126 BP 1243A EP 1243A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DB2YA UT WOS:000368375404368 ER PT J AU Clair, HB Falkner, KC Prough, RA Pinkston, C Brock, GN Pavuk, M Dutton, N Cave, MC AF Clair, Heather B. Falkner, Keith C. Prough, Russell A. Pinkston, Christina Brock, Guy N. Pavuk, Marian Dutton, N. Cave, Matthew C. TI Polychlorinated biphenyl exposure in Anniston, Alabama is associated with elevated prevalence of liver disease SO HEPATOLOGY LA English DT Meeting Abstract CT 66th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 13-17, 2015 CL San Francisco, CA SP Amer Assoc Study Liver Dis C1 [Clair, Heather B.; Falkner, Keith C.; Pinkston, Christina; Brock, Guy N.; Cave, Matthew C.] Univ Louisville, Dept Med GI, Louisville, KY 40292 USA. [Prough, Russell A.] Univ Louisville, Biochem, Louisville, KY 40292 USA. [Pavuk, Marian; Dutton, N.] CDC, Atlanta, GA 30333 USA. [Cave, Matthew C.] Robley Rex VAMC, Louisville, KY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2015 VL 62 SU 1 SI SI MA 2233 BP 1295A EP 1296A PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DB2YA UT WOS:000368375404473 ER PT J AU Plucinski, MM Morton, L Bushman, M Dimbu, PR Udhayakumar, V AF Plucinski, Mateusz M. Morton, Lindsay Bushman, Mary Dimbu, Pedro Rafael Udhayakumar, Venkatachalam TI Robust Algorithm for Systematic Classification of Malaria Late Treatment Failures as Recrudescence or Reinfection Using Microsatellite Genotyping SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY LA English DT Article ID ANTIMALARIAL CLINICAL-TRIALS; PLASMODIUM-FALCIPARUM; INFECTIONS; RESISTANCE; EFFICACY; MARKERS; IMPACT AB Routine therapeutic efficacy monitoring to measure the response to antimalarial treatment is a cornerstone of malaria control. To correctly measure drug efficacy, therapeutic efficacy studies require genotyping parasites from late treatment failures to differentiate between recrudescent infections and reinfections. However, there is a lack of statistical methods to systematically classify late treatment failures from genotyping data. A Bayesian algorithm was developed to estimate the posterior probability of late treatment failure being the result of a recrudescent infection from microsatellite genotyping data. The algorithm was implemented using a Monte Carlo Markov chain approach and was used to classify late treatment failures using published microsatellite data from therapeutic efficacy studies in Ethiopia and Angola. The algorithm classified 85% of the Ethiopian and 95% of the Angolan late treatment failures as either likely reinfection or likely recrudescence, defined as a posterior probability of recrudescence of <0.1 or >0.9, respectively. The adjusted efficacies calculated using the new algorithm differed from efficacies estimated using commonly used methods for differentiating recrudescence from reinfection. In a high-transmission setting such as Angola, as few as 15 samples needed to be genotyped in order to have enough power to correctly classify treatment failures. Analysis of microsatellite genotyping data for differentiating between recrudescence and reinfection benefits from an approach that both systematically classifies late treatment failures and estimates the uncertainty of these classifications. Researchers analyzing genotyping data from antimalarial therapeutic efficacy monitoring are urged to publish their raw genetic data and to estimate the uncertainty around their classification. C1 [Plucinski, Mateusz M.; Morton, Lindsay; Bushman, Mary; Udhayakumar, Venkatachalam] Ctr Dis Control & Prevent, Malaria Branch, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA 30322 USA. [Plucinski, Mateusz M.] Presidents Malaria Initiat, Atlanta, GA USA. [Bushman, Mary] Emory Univ, Grad Program Populat Biol Ecol & Evolut, Atlanta, GA 30322 USA. [Dimbu, Pedro Rafael] Minist Hlth, Natl Malaria Control Program, Luanda, Angola. RP Plucinski, MM (reprint author), Ctr Dis Control & Prevent, Malaria Branch, Div Parasit Dis & Malaria, Ctr Global Hlth, 4770 Buford Highway,Mail Stop F-12, Atlanta, GA 30322 USA. EM mplucinski@cdc.gov FU Centers for Disease Control and Prevention; President's Malaria Initiative FX This work was supported by the Centers for Disease Control and Prevention and the President's Malaria Initiative. NR 17 TC 1 Z9 1 U1 0 U2 1 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0066-4804 EI 1098-6596 J9 ANTIMICROB AGENTS CH JI Antimicrob. Agents Chemother. PD OCT PY 2015 VL 59 IS 10 BP 6096 EP 6100 DI 10.1128/AAC.00072-15 PG 5 WC Microbiology; Pharmacology & Pharmacy SC Microbiology; Pharmacology & Pharmacy GA DA1YJ UT WOS:000367591800028 PM 26195521 ER PT J AU Sanchez, GV Fleming-Dutra, KE Hicks, LA AF Sanchez, Guillermo V. Fleming-Dutra, Katherine E. Hicks, Lauri A. TI Minimizing Antibiotic Misuse through Evidence-Based Management of Outpatient Acute Respiratory Infections SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY LA English DT Letter C1 [Sanchez, Guillermo V.; Fleming-Dutra, Katherine E.; Hicks, Lauri A.] Ctr Dis Control & Prevent, Get Smart Know Antibiot Work Program, Atlanta, GA 30329 USA. RP Sanchez, GV (reprint author), Ctr Dis Control & Prevent, Get Smart Know Antibiot Work Program, Atlanta, GA 30329 USA. EM gsanchez@cdc.gov NR 5 TC 1 Z9 1 U1 1 U2 1 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0066-4804 EI 1098-6596 J9 ANTIMICROB AGENTS CH JI Antimicrob. Agents Chemother. PD OCT PY 2015 VL 59 IS 10 BP 6673 EP 6673 DI 10.1128/AAC.01709-15 PG 1 WC Microbiology; Pharmacology & Pharmacy SC Microbiology; Pharmacology & Pharmacy GA DA1YJ UT WOS:000367591800109 PM 26386030 ER PT J AU Zinski, A Westfall, AO Gardner, LI Giordano, TP Wilson, TE Drainoni, ML Keruly, JC Rodriguez, AE Malitz, F Batey, DS Mugavero, MJ AF Zinski, Anne Westfall, Andrew O. Gardner, Lytt I. Giordano, Thomas P. Wilson, Tracey E. Drainoni, Mari-Lynn Keruly, Jeanne C. Rodriguez, Allan E. Malitz, Faye Batey, D. Scott Mugavero, Michael J. TI The Contribution of Missed Clinic Visits to Disparities in HIV Viral Load Outcomes SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID INJECTION-DRUG USERS; HEALTH-CARE UTILIZATION; UNITED-STATES; MEDICAL-CARE; SELF-MANAGEMENT; ANTIRETROVIRAL THERAPY; MEASURING RETENTION; RACIAL DISPARITIES; INFECTED PERSONS; AFRICAN-AMERICAN AB Objectives. We explored the contribution of missed primary HIV care visits ("no-show") to observed disparities in virological failure (VF) among Black persons and persons with injection drug use (IDU) history. Methods. We used patient-level data from 6 academic clinics, before the Centers for Disease Control and Prevention and Health Resources and Services Administration Retention in Care intervention. We employed staged multivariable logistic regression and multivariable models stratified by no-show visit frequency to evaluate the association of sociodemographic factors with VF. We used multiple imputations to assign missing viral load values. Results. Among 10 053 patients (mean age = 46 years; 35% female; 64% Black; 15% with IDU history), 31% experienced VF. Although Black patients and patients with IDU history were significantly more likely to experience VF in initial analyses, race and IDU parameter estimates were attenuated after sequential addition of no-show frequency. In stratified models, race and IDU were not statistically significantly associated with VF at any no-show level. Conclusions. Because missed clinic visits contributed to observed differences in viral load outcomes among Black and IDU patients, achieving an improved understanding of differential visit attendance is imperative to reducing disparities in HIV. C1 [Zinski, Anne; Westfall, Andrew O.; Batey, D. Scott; Mugavero, Michael J.] Univ Alabama Birmingham, Dept Med, Div Infect Dis, Birmingham, AL 35294 USA. [Gardner, Lytt I.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. [Giordano, Thomas P.] Baylor Coll Med, Dept Med, Infect Dis Sect, Houston, TX 77030 USA. [Wilson, Tracey E.] Suny Downstate Med Ctr, Dept Community Hlth Sci, Brooklyn, NY 11203 USA. [Drainoni, Mari-Lynn] Boston Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA USA. [Keruly, Jeanne C.] Johns Hopkins Univ, Sch Med, Div Infect Dis, Baltimore, MD 21205 USA. [Rodriguez, Allan E.] Univ Miami, Miller Sch Med, Div Infect Dis, Coral Gables, FL 33124 USA. [Malitz, Faye] Hlth Resources & Serv Adm, HIV AIDS Bur, Rockville, MD USA. RP Zinski, A (reprint author), Univ Alabama Birmingham, 845 19th St S,BBRB 206B, Birmingham, AL 35294 USA. EM azinski@uab.edu FU Centers for Disease Control and Prevention; Health Resources and Services Administration [CDCHRSA9272007] FX The Retention in Care (RIC) Intervention study was funded by the Centers for Disease Control and Prevention and Health Resources and Services Administration (ClinicalTrials.gov: CDCHRSA9272007). NR 55 TC 1 Z9 1 U1 0 U2 0 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 EI 1541-0048 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD OCT PY 2015 VL 105 IS 10 BP 2068 EP 2075 DI 10.2105/AJPH.2015.302695 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CZ9UC UT WOS:000367441500036 PM 26270301 ER PT J AU Windham, GC Pinney, SM Voss, RW Sjodin, A Biro, FM Greenspan, LC Stewart, S Hiatt, RA Kushi, LH AF Windham, Gayle C. Pinney, Susan M. Voss, Robert W. Sjoedin, Andreas Biro, Frank M. Greenspan, Louise C. Stewart, Susan Hiatt, Robert A. Kushi, Lawrence H. TI Brominated Flame Retardants and Other Persistent Organohalogenated Compounds in Relation to Timing of Puberty in a Longitudinal Study of Girls SO ENVIRONMENTAL HEALTH PERSPECTIVES LA English DT Article ID POLYBROMINATED DIPHENYL ETHERS; POLYCHLORINATED-BIPHENYLS; PRENATAL EXPOSURE; NATIONAL-HEALTH; MENSTRUAL-CYCLE; RUSSIAN BOYS; HUMAN SERUM; AGE; MENARCHE; ONSET AB BACKGROUND: Exposure to hormonally active chemicals could plausibly affect pubertal timing, so we are investigating this in the Breast Cancer and the Environment Research Program. OBJECTIVES: Our goal was to examine persistent organic pollutants (POPs) in relation to pubertal onset. METHODS: Ethnically diverse cohorts of 6- to 8-year-old girls (n = 645) provided serum for measure of polybrominated diphenyl ethers (PBDEs), polychlorinated biphenyls (PCBs), organochlorine pesticides (OCPs), and lipids. Tanner stages [breast (B) and pubic hair (PH)], and body mass index (BMI) were measured at up to seven annual clinic visits. Using accelerated failure time models, we calculated time ratios (TRs) for age at Tanner stages 2 or higher (2+) and POPs quartiles (Q1-4), adjusting for confounders (race/ethnicity, site, caregiver education, and income). We also calculated prevalence ratios (PRs) of Tanner stages 2+ at time of blood sampling. RESULTS: Cross-sectionally, the prevalence of B2+ and PH2+ was inversely related to chemical serum concentrations; but after adjustment for confounders, only the associations with B2+, not PH2+, were statistically significant. Longitudinally, the age at pubertal transition was consistently older with greater chemical concentrations; for example: adjusted TR for B2+ and Q4 for Sigma PBDE = 1.05; 95% CI: 1.02, 1.08, for Sigma PCB = 1.05; 95% CI: 1.01, 1.08, and for Sigma OCP = 1.10; 95% CI: 1.06, 1.14, indicating median ages of about 6 and 11 months older than least exposed, and with similar effect estimates for PH2+. Adjusting for BMI attenuated associations for PCBs and OCPs but not for PBDEs. CONCLUSIONS: This first longitudinal study of puberty in girls with serum POPs measurements (to our knowledge) reveals a delay in onset with higher concentrations. C1 [Windham, Gayle C.] Calif Dept Publ Hlth, Richmond, CA USA. [Pinney, Susan M.; Biro, Frank M.] Univ Cincinnati, Coll Med, Cincinnati, OH USA. [Voss, Robert W.] Impact Assessment Inc, La Jolla, CA USA. [Sjoedin, Andreas] Ctr Dis Control & Prevent, Atlanta, GA USA. [Greenspan, Louise C.] Kaiser Permanente, San Francisco, CA USA. [Stewart, Susan] Univ Calif Davis, Dept Publ Hlth Sci, Davis, CA 95616 USA. [Hiatt, Robert A.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Kushi, Lawrence H.] Kaiser Permanente, Div Res, Oakland, CA USA. RP Windham, GC (reprint author), EHIB CDPH, 850 Marina Bay Pkwy,Bldg P, Richmond, CA 94804 USA. EM gayle.windham@cdph.ca.gov FU National Institutes of Health (NIH)/National Institute of Environmental Health Sciences (NIEHS); National Cancer Institute (NCI) [U01 ES012801]; University of Cincinnati/Cincinnati Children's Hospital Medical Center [U01 ES12770]; University of Cincinnati Center for Environmental Genetics [P30-ES006096]; CDPH; NIH/National Center for Research Resources [UL1 RR024131] FX This work was funded by the National Institutes of Health (NIH)/National Institute of Environmental Health Sciences (NIEHS) and the National Cancer Institute (NCI) to the Breast Cancer & the Environment Research Centers at the University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center (U01 ES012801), and the University of Cincinnati/Cincinnati Children's Hospital Medical Center (U01 ES12770), with support from the University of Cincinnati Center for Environmental Genetics (P30-ES006096), the CDPH, and the NIH/National Center for Research Resources-sponsored University of California, San Francisco Center for Translational Science Institute (UL1 RR024131). NR 35 TC 11 Z9 12 U1 5 U2 28 PU US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE PI RES TRIANGLE PK PA NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA SN 0091-6765 EI 1552-9924 J9 ENVIRON HEALTH PERSP JI Environ. Health Perspect. PD OCT PY 2015 VL 123 IS 10 BP 1046 EP 1052 DI 10.1289/ehp.1408778 PG 7 WC Environmental Sciences; Public, Environmental & Occupational Health; Toxicology SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology GA CY8ZW UT WOS:000366698200027 PM 25956003 ER PT J AU Vuong, AM Webster, GM Romano, ME Braun, JM Zoeller, RT Hoofnagle, AN Sjodin, A Yolton, K Lanphear, BP Chen, AM AF Vuong, Ann M. Webster, Glenys M. Romano, Megan E. Braun, Joseph M. Zoeller, R. Thomas Hoofnagle, Andrew N. Sjoedin, Andreas Yolton, Kimberly Lanphear, Bruce P. Chen, Aimin TI Maternal Polybrominated Diphenyl Ether (PBDE) Exposure and Thyroid Hormones in Maternal and Cord Sera: The HOME Study, Cincinnati, USA SO ENVIRONMENTAL HEALTH PERSPECTIVES LA English DT Article ID BROMINATED FLAME RETARDANTS; POLYCHLORINATED-BIPHENYLS; IN-VITRO; PREGNANCY; BLOOD; ASSOCIATIONS; DISRUPTION; WOMEN; HYPOTHYROXINEMIA; PARAMETERS AB BACKGROUND: Polybrominated diphenyl ethers (PBDEs) reduce blood concentrations of thyroid hormones in laboratory animals, but it is unclear whether PBDEs disrupt thyroid hormones in pregnant women or newborn infants. OBJECTIVES: We investigated the relationship between maternal PBDE levels and thyroid hormone concentrations in maternal and cord sera. METHODS: We used data from the Health Outcomes and Measures of the Environment (HOME) Study, a prospective birth cohort of 389 pregnant women in Cincinnati, Ohio, who were enrolled from 2003 through 2006 and delivered singleton infants. Maternal serum PBDE concentrations were measured at enrollment (16 +/- 3 weeks of gestation). Thyroid hormone concentrations were measured in maternal serum at enrollment (n = 187) and in cord serum samples (n = 256). RESULTS: Median maternal serum concentrations of BDEs 28 and 47 were 1.0 and 19.1 ng/g lipid, respectively. A 10-fold increase in BDEs 28 and 47 concentrations was associated with a 0.85-mu g/dL [95% confidence interval (CI): 0.05, 1.64] and 0.82-mu g/dL (95% CI: 0.12, 1.51) increase in maternal total thyroxine concentrations (TT4), respectively. Both congeners were also positively associated with maternal free thyroxine (FT4). We also observed positive associations between BDE-47 and maternal total and free triiodothyronine (TT3 and FT3). A 10-fold increase in BDE-28 was associated with elevated FT3 concentrations (beta = 0.14 pg/mL; 95% CI: 0.02, 0.26). In contrast, maternal PBDE levels were not associated with thyroid hormone concentrations in cord serum. CONCLUSIONS: These findings suggest that maternal PBDE exposure, particularly BDEs 28 and 47, are associated with maternal concentrations of T-4 and T-3 during pregnancy. C1 [Vuong, Ann M.; Chen, Aimin] Univ Cincinnati, Coll Med, Dept Environm Hlth, Div Epidemiol, Cincinnati, OH 45267 USA. [Webster, Glenys M.; Lanphear, Bruce P.] Simon Fraser Univ, BC Childrens & Womens Hosp, Child & Family Res Inst, Vancouver, BC, Canada. [Webster, Glenys M.; Lanphear, Bruce P.] Simon Fraser Univ, Fac Hlth Sci, Vancouver, BC, Canada. [Romano, Megan E.; Braun, Joseph M.] Brown Univ, Sch Publ Hlth, Dept Epidemiol, Providence, RI 02912 USA. [Zoeller, R. Thomas] Univ Massachusetts, Dept Biol, Amherst, MA 01003 USA. [Hoofnagle, Andrew N.] Univ Washington, Dept Lab Med, Seattle, WA 98195 USA. [Sjoedin, Andreas] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Div Sci Lab, Atlanta, GA USA. [Yolton, Kimberly] Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Div Gen & Community Pediat, Cincinnati, OH 45229 USA. RP Chen, AM (reprint author), Univ Cincinnati, Coll Med, Dept Environm Hlth, Div Epidemiol, POB 670056, Cincinnati, OH 45267 USA. EM aimin.chen@uc.edu RI Braun, Joseph/H-8649-2014 FU National Institute of Environmental Health Sciences, National Institutes of Health (NIEHS/NIH) [P01 ES11261, R01 ES014575, R01 ES020349, R00 ES020349] FX This work was supported by grants from the National Institute of Environmental Health Sciences, National Institutes of Health (NIEHS/NIH; P01 ES11261, R01 ES014575, R01 ES020349, and R00 ES020349). NR 45 TC 8 Z9 9 U1 7 U2 18 PU US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE PI RES TRIANGLE PK PA NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA SN 0091-6765 EI 1552-9924 J9 ENVIRON HEALTH PERSP JI Environ. Health Perspect. PD OCT PY 2015 VL 123 IS 10 BP 1079 EP 1085 DI 10.1289/ehp.1408996 PG 7 WC Environmental Sciences; Public, Environmental & Occupational Health; Toxicology SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology GA CY8ZW UT WOS:000366698200032 PM 25893858 ER PT J AU Huang, YLA Frazier, EL Sansom, SL Farnham, PG Shrestha, RK Hutchinson, AB Fagan, JL Viall, AH Skarbinski, J AF Huang, Ya-Lin A. Frazier, Emma L. Sansom, Stephanie L. Farnham, Paul G. Shrestha, Ram K. Hutchinson, Angela B. Fagan, Jennifer L. Viall, Abigail H. Skarbinski, Jacek TI Nearly Half Of US Adults Living With HIV Received Federal Disability Benefits In 2009 SO HEALTH AFFAIRS LA English DT Article ID ANTIRETROVIRAL THERAPY; UNITED-STATES; POPULATION; INFECTION; TRANSMISSION; EMPLOYMENT; COHORT; CARE; MEN AB The effects of HIV infection on national labor-force participation have not been rigorously evaluated. Using data from the Medical Monitoring Project and the National Health Interview Survey, we present nationally representative estimates of the receipt of disability benefits by adults living with HIV receiving care compared with the general US adult population. We found that in 2009, adults living with HIV were nine times more likely than adults in the general population to receive disability benefits. The risk of being on disability is also greater for younger and more educated adults living with HIV compared to the general population, which suggests that productivity losses can result from HIV infection. To prevent disability, early diagnosis and treatment of HIV are essential. This study offers a baseline against which to measure the impacts of recently proposed or enacted changes to Medicaid and private insurance markets, including the Affordable Care Act and proposed revisions to the Social Security Administration's HIV Infection Listings. C1 [Huang, Ya-Lin A.] Ctr Dis Control & Prevent CDC, Div HIV AIDS Prevent, Atlanta, GA 30333 USA. [Frazier, Emma L.; Sansom, Stephanie L.; Farnham, Paul G.; Shrestha, Ram K.; Hutchinson, Angela B.; Fagan, Jennifer L.; Viall, Abigail H.; Skarbinski, Jacek] CDC, Div HIV AIDS Prevent, Atlanta, GA 30333 USA. RP Huang, YLA (reprint author), Ctr Dis Control & Prevent CDC, Div HIV AIDS Prevent, Atlanta, GA 30333 USA. EM yhuang@cdc.gov NR 32 TC 3 Z9 3 U1 0 U2 2 PU PROJECT HOPE PI BETHESDA PA 7500 OLD GEORGETOWN RD, STE 600, BETHESDA, MD 20814-6133 USA SN 0278-2715 J9 HEALTH AFFAIR JI Health Aff. PD OCT PY 2015 VL 34 IS 10 BP 1657 EP 1665 DI 10.1377/hlthaff.2015.0249 PG 9 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA CY9JR UT WOS:000366723700011 PM 26438741 ER PT J AU Mustapha, MM Marsha, JW Krauland, MG Fernandez, JO de Lemos, APS Hotopp, JCD Wang, X Mayer, LW Lawrence, JG Hiller, NL Harrison, LH AF Mustapha, Mustapha M. Marsha, Jane W. Krauland, Mary G. Fernandez, Jorge O. de Lemos, Ana Paula S. Hotopp, Julie C. Dunning Wang, Xin Mayer, Leonard W. Lawrence, Jeffrey G. Hiller, N. Luisa Harrison, Lee H. TI Genomic Epidemiology of Hypervirulent Serogroup W, ST-11 Neisseria meningitidis SO EBIOMEDICINE LA English DT Article DE Hajj clone; Invasive meningococcal disease; W135; Whole genome sequencing; Virulence factors; FHbp ID W135 MENINGOCOCCAL DISEASE; BINDING PROTEIN; PHYLOGENETIC NETWORKS; POPULATION-STRUCTURE; MAXIMUM-LIKELIHOOD; SEQUENCE DIVERSITY; BURKINA-FASO; EMERGENCE; INCREASE; OUTBREAK AB Neisseria meningitidis is a leading bacterial cause of sepsis and meningitis globally with dynamic strain distribution over time. Beginning with an epidemic among Hajj pilgrims in 2000, serogroup W (W) sequence type (ST) 11 emerged as a leading cause of epidemic meningitis in the African 'meningitis belt' and endemic cases in South America, Europe, Middle East and China. Previous genotyping studies were unable to reliably discriminate sporadic W ST-11 strains in circulation since 1970 from the Hajj outbreak strain (Hajj clone). It is also unclear what proportion of more recent W ST-11 disease clusters are caused by direct descendants of the Hajj clone. Whole genome sequences of 270 meningococcal strains isolated from patients with invasive meningococcal disease globally from 1970 to 2013 were compared using whole genome phylogenetic and major antigen-encoding gene sequence analyses. We found that all W ST-11 strains were descendants of an ancestral strain that had undergone unique capsular switching events. The Hajj clone and its descendants were distinct from other W ST-11 strains in that they shared a common antigen gene profile and had undergone recombination involving virulence genes encoding factor H binding protein, nitric oxide reductase, and nitrite reductase. These data demonstrate that recent acquisition of a distinct antigen-encoding gene profile and variations in meningococcal virulence genes was associated with the emergence of the Hajj clone. Importantly, W ST-11 strains unrelated to the Hajj outbreak contribute a significant proportion of W ST-11 cases globally. This study helps illuminate genomic factors associated with meningococcal strain emergence and evolution. (C) 2015 The Authors. Published by Elsevier B.V. C1 [Mustapha, Mustapha M.; Marsha, Jane W.; Harrison, Lee H.] Univ Pittsburgh, Infect Dis Epidemiol Res Unit, Pittsburgh, PA 15261 USA. [Fernandez, Jorge O.] Publ Hlth Inst Chile, Mol Genet Lab, Santiago, Chile. [de Lemos, Ana Paula S.] Adolfo Lutz Inst, Dept Bacteriol, Sao Paulo, Brazil. [Hotopp, Julie C. Dunning] Univ Maryland, Sch Med, Inst Genome Sci, Baltimore, MD 21201 USA. [Wang, Xin; Mayer, Leonard W.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Div Bacterial Dis, Meningitis & Vaccine Preventable Dis Branch, Atlanta, GA USA. [Lawrence, Jeffrey G.] Univ Pittsburgh, Dept Biol Sci, Pittsburgh, PA 15260 USA. [Hiller, N. Luisa] Carnegie Mellon Univ, Dept Biol Sci, Pittsburgh, PA 15213 USA. [Krauland, Mary G.] Univ Pittsburgh, Grad Sch Publ Hlth, Publ Hlth Dynam Lab, Pittsburgh, PA 15260 USA. RP Mustapha, MM (reprint author), Univ Pittsburgh, Infect Dis Epidemiol Res Unit, Pittsburgh, PA 15261 USA. EM mmm147@pitt.edu RI Hiller, N. Luisa/A-3739-2016; Mustapha, Mustapha/I-1348-2016 OI Hiller, N. Luisa/0000-0001-6572-1368; Mustapha, Mustapha/0000-0002-4102-2965 FU NIAID NIH HHS [HHSN272200900018C, K24 AI052788] NR 58 TC 9 Z9 9 U1 2 U2 4 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 2352-3964 J9 EBIOMEDICINE JI EBioMedicine PD OCT PY 2015 VL 2 IS 10 BP 1447 EP 1455 DI 10.1016/j.ebiom.2015.09.007 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA CX8ND UT WOS:000365959700043 PM 26629539 ER PT J AU Leeb, RT Fluke, JD AF Leeb, Rebecca T. Fluke, John D. TI Child maltreatment surveillance: enumeration, monitoring, evaluation and insight SO HEALTH PROMOTION AND CHRONIC DISEASE PREVENTION IN CANADA-RESEARCH POLICY AND PRACTICE LA English DT Editorial Material ID VIOLENCE C1 [Leeb, Rebecca T.] Ctr Dis Control & Prevent, Div Human Dev & Disabil, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30341 USA. [Fluke, John D.] Univ Colorado, Kempe Ctr Prevent & Treatment Child Abuse & Negle, Dept Pediat, Sch Med, Aurora, CO USA. RP Leeb, RT (reprint author), Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, 4700 Buford Hwy,Mailstop E-88, Atlanta, GA 30341 USA. EM RLeeb@CDC.gov FU Intramural CDC HHS [CC999999] NR 22 TC 1 Z9 1 U1 0 U2 0 PU PUBLIC HEALTH AGENCY CANADA PI OTTAWA PA 130 COLONNADE RD, ADDRESS LOCATOR 6501G, OTTAWA, ONTARIO K1A 0K9, CANADA SN 2368-738X J9 HEALTH PROMOT CHRON JI Health Promot. Chronic Dis. Prev. Can.-Res. Policy Pract. PD OCT-NOV PY 2015 VL 35 IS 8-9 SI SI BP 138 EP 140 PG 3 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CX8WK UT WOS:000365984900004 PM 26605561 ER PT J AU Lau, R Cunanan, M Jackson, J Ali, IKM Chong-Kit, A Gasgas, J Tian, JF Ralevski, F Boggild, AK AF Lau, Rachel Cunanan, Marlou Jackson, Jonathan Ali, Ibne Karim M. Chong-Kit, Ann Gasgas, Jason Tian, Jinfang Ralevski, Filip Boggild, Andrea K. TI Reevaluation of an Acanthamoeba Molecular Diagnostic Algorithm following an Atypical Case of Amoebic Keratitis SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID CLINICAL SPECIMENS; HUMANS; SPP.; PCR AB Amoebic keratitis (AK) is a potentially blinding infection, the prompt diagnosis of which is essential for limiting ocular morbidity. We undertook a quality improvement initiative with respect to the molecular detection of acanthamoebae in our laboratory because of an unusual case of discordance. Nine ATCC strains of Acanthamoeba and 40 delinked, biobanked, surplus corneal scraping specimens were analyzed for the presence of acanthamoebae with four separate real-time PCR assays. The assay used by the Free-Living and Intestinal Amebas Laboratory of the CDC was considered the reference standard, and the performance characteristics of each individual assay and pairs of assays were calculated. Outcome measures were sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV). Of 49 included specimens, 14 (28.6%) were positive by the gold standard assay, and 35 (71.4%) were negative. The sensitivities of the individual assays ranged from 64.3% to 92.9%, compared to the gold standard, while the specificities ranged from 88.6% to 91.4%. The PPVs and NPVs ranged from 69.2% to 78.6% and from 86.1% to 96.9%, respectively. Combinations of assay pairs led to improved performance, with sensitivities ranging from 92.9% to 100% and specificities ranging from 97.1% to 100%. ATCC and clinical strains of Acanthamoeba that failed to be detected by certain individual assays included Acanthamoeba castellanii, Acanthamoeba culbertsoni, and Acanthamoeba lenticulata. For three clinical specimens, false negativity of the gold standard assay could not be excluded. Molecular diagnostic approaches, especially combinations of highly sensitive and specific assays, offer a reasonably performing, operator-independent, rapid strategy for the detection of acanthamoebae in clinical specimens and are likely to be more practical than either culture or direct microscopic detection. C1 [Lau, Rachel; Cunanan, Marlou; Chong-Kit, Ann; Gasgas, Jason; Tian, Jinfang; Ralevski, Filip; Boggild, Andrea K.] Publ Hlth Ontario, Publ Hlth Ontario Labs, Toronto, ON, Canada. [Jackson, Jonathan; Ali, Ibne Karim M.] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, Free Living & Intestinal Amebas Lab,Waterborne Di, Atlanta, GA USA. [Boggild, Andrea K.] Toronto Gen Hosp, Trop Dis Unit, Toronto, ON, Canada. [Boggild, Andrea K.] Univ Toronto, Dept Med, Toronto, ON, Canada. RP Boggild, AK (reprint author), Publ Hlth Ontario, Publ Hlth Ontario Labs, Toronto, ON, Canada. EM andrea.boggild@utoronto.ca FU Public Health Ontario FX This work was funded by Public Health Ontario. NR 13 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 EI 1098-660X J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD OCT PY 2015 VL 53 IS 10 BP 3213 EP 3218 DI 10.1128/JCM.01607-15 PG 6 WC Microbiology SC Microbiology GA CX3UQ UT WOS:000365625300015 PM 26202123 ER PT J AU Pham, CD Purfield, AE Fader, R Pascoe, N Lockhart, SR AF Pham, Cau D. Purfield, Anne E. Fader, Robert Pascoe, Neil Lockhart, Shawn R. TI Development of a Multilocus Sequence Typing System for Medically Relevant Bipolaris Species SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID CONTAMINATED METHYLPREDNISOLONE INJECTIONS; MELANIN BIOSYNTHESIS; CANDIDA-GLABRATA; DNA; INFECTIONS; FUNGI; DIVERSITY; IDENTIFICATION; DATABASE; COMPLEX AB Multilocus sequence typing (MLST) is the gold standard genotyping technique for many microorganisms. This classification approach satisfies the requirements for a high-resolution, standardized, and archivable taxonomic system. Here, we describe the development of a novel MLST system to assist with the investigation of an unusual cluster of surgical site infections caused by Bipolaris spp. in postoperative cardiothoracic surgery (POCS) patients during January 2008 to December 2013 in the southeastern United States. We also used the same MLST system to perform a retrospective analysis on isolates from a 2012 Bipolaris endophthalmitis outbreak caused by a contaminated product. This MLST system showed high intraspecies discriminatory power for Bipolaris spicifera, B. hawaiiensis, and B. australiensis. Based on the relatedness of the isolates, the MLST data supported the hypothesis that infections in the POCS cluster were from different environmental sources while confirming that the endophthalmitis outbreak resulted from a point source, which was a contaminated medication. C1 [Pham, Cau D.; Purfield, Anne E.; Lockhart, Shawn R.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Fader, Robert] Scott & White Hosp, Temple, TX USA. [Pascoe, Neil] Texas Dept State Hlth Serv, Austin, TX USA. RP Lockhart, SR (reprint author), Ctr Dis Control & Prevent, Atlanta, GA USA. EM gyi2@cdc.gov NR 28 TC 1 Z9 1 U1 0 U2 1 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 EI 1098-660X J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD OCT PY 2015 VL 53 IS 10 BP 3239 EP 3246 DI 10.1128/JCM.01546-15 PG 8 WC Microbiology SC Microbiology GA CX3UQ UT WOS:000365625300019 PM 26202112 ER PT J AU Dykes, JK Luquez, C Raphael, BH McCroskey, L Maslanka, SE AF Dykes, Janet K. Luquez, Carolina Raphael, Brian H. McCroskey, Loretta Maslanka, Susan E. TI Laboratory Investigation of the First Case of Botulism Caused by Clostridium butyricum Type E Toxin in the United States SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID INFANT BOTULISM; STRAINS AB We report here the laboratory investigation of the first known case of botulism in the United States caused by Clostridium butyricum type E. This investigation demonstrates the importance of extensive microbiological examination of specimens, which resulted in the isolation of this organism. C1 [Dykes, Janet K.; Luquez, Carolina; Raphael, Brian H.; McCroskey, Loretta; Maslanka, Susan E.] Ctr Dis Control & Prevent, Enter Dis Lab Branch, Atlanta, GA USA. RP Dykes, JK (reprint author), Ctr Dis Control & Prevent, Enter Dis Lab Branch, Atlanta, GA USA. EM jdykes@cdc.gov OI Raphael, Brian/0000-0003-2778-2623 FU Centers for Disease Control and Prevention, Office of Public Health Preparedness and Response FX This publication was supported by funds made available from the Centers for Disease Control and Prevention, Office of Public Health Preparedness and Response. NR 15 TC 2 Z9 2 U1 1 U2 5 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 EI 1098-660X J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD OCT PY 2015 VL 53 IS 10 BP 3363 EP 3365 DI 10.1128/JCM.01351-15 PG 3 WC Microbiology SC Microbiology GA CX3UQ UT WOS:000365625300038 PM 26246485 ER PT J AU Liu, SW Cai, XN Hong, YL Yang, QH Engelgau, M Ge, Z Cai, Y Li, YC Wang, LM Ma, JX Zhou, MG AF Liu, Shiwei Cai, Xiaoning Hong, Yuling Yang, Quanhe Engelgau, Michael Ge, Zeng Cai, Ying Li, Yichong Wang, Limin Ma, Jixiang Zhou, Maigeng TI Cardiovascular disease deaths and high sodium consumption in Shandong province and China: a modelling analysis SO LANCET LA English DT Meeting Abstract CT Lancet - Chinese-Academy-of-Medical-Sciences (CAMS) Health Summit CY OCT 30-31, 2015 CL Beijing, PEOPLES R CHINA SP Lancet, Chinese Acad Med Sc C1 [Liu, Shiwei; Cai, Xiaoning; Ge, Zeng; Li, Yichong; Wang, Limin; Ma, Jixiang; Zhou, Maigeng] Chinese Ctr Dis Control & Prevent, Natl Ctr Chron & Noncommunicable Dis Control & P, Beijing 100050, Peoples R China. [Hong, Yuling; Yang, Quanhe; Engelgau, Michael; Cai, Ying] Ctr Dis Control & Prevent, Atlanta, GA USA. EM majx@163.com; maigengzhou@126.com NR 0 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0140-6736 EI 1474-547X J9 LANCET JI Lancet PD OCT PY 2015 VL 386 SU 1 BP 80 EP 80 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA CX9HR UT WOS:000366016400081 ER PT J AU Jilek, JL Sant, KE Cho, KH Reed, MS Pohl, J Hansen, JM Harris, C AF Jilek, Joseph L. Sant, Karilyn E. Cho, Katherine H. Reed, Matthew S. Pohl, Jan Hansen, Jason M. Harris, Craig TI Ethanol Attenuates Histiotrophic Nutrition Pathways and Alters the Intracellular Redox Environment and Thiol Proteome during Rat Organogenesis SO TOXICOLOGICAL SCIENCES LA English DT Article DE embryo; visceral yolk sac; organogenesis; ethanol; histiotrophic nutrition; glutathione; cysteine; redox potential; redox environment; thiol proteome ID ALCOHOL SPECTRUM DISORDERS; INDUCED OXIDATIVE STRESS; YOLK-SAC DYSFUNCTION; NEURAL CREST CELLS; ACTIN CYTOSKELETON; ANTIOXIDANT RESPONSE; NUCLEAR IMPORT; MOUSE EMBRYOS; IN-VITRO; FETAL AB Ethanol (EtOH) is a reactive oxygen-generating teratogen involved in the etiology of structural and functional developmental defects. Embryonic nutrition, redox environment, and changes in the thiol proteome following EtOH exposures (1.56.0 mg/ml) were studied in rat whole embryo culture. Glutathione (GSH) and cysteine (Cys) concentrations with their respective intracellular redox potentials (E-h) were determined using high-performance liquid chromatography. EtOH reduced GSH and Cys concentrations in embryo (EMB) and visceral yolk sac (VYS) tissues, and also in yolk sac and amniotic fluids. These changes produced greater oxidation as indicated by increasingly positive E-h values. EtOH reduced histiotrophic nutrition pathway activities as measured by the clearance of fluorescin isothiocyanate (FITC)-albumin from culture media. A significant decrease in total FITC clearance was observed at all concentrations, reaching approximately 50% at the highest dose. EtOH-induced changes to the thiol proteome were measured in EMBs and VYSs using isotope-coded affinity tags. Decreased concentrations for specific proteins from cytoskeletal dynamics and endocytosis pathways (alpha-actinin, alpha-tubulin, cubilin, and actin-related protein 2); nuclear translocation (Ran and RanBP1); andmaintenance of receptor-mediated endocytosis (cubilin) were observed. Kyoto encyclopedia of genes and genomes (KEGG) pathway analysis also identified a decrease in ribosomal proteins in both EMB and VYS. Results show that EtOH interferes with nutrient uptake to reduce availability of amino acids and micronutrients required by the conceptus. Intracellular antioxidants such as GSH and Cys are depleted following EtOH and E-h values increase. Thiol proteome analysis in the EMB and VYS show selectively altered actin/cytoskeleton, endocytosis, ribosome biogenesis and function, nuclear transport, and stress-related responses. C1 [Jilek, Joseph L.; Sant, Karilyn E.; Cho, Katherine H.; Harris, Craig] Univ Michigan, Dept Environm Hlth Sci, Ann Arbor, MI 48109 USA. [Reed, Matthew S.; Pohl, Jan] Ctr Dis Control, Biotechnol Core Facil Branch, Atlanta, GA 30333 USA. [Hansen, Jason M.] Brigham Young Univ, Coll Life Sci, Dept Physiol & Dev Biol, Provo, UT 84602 USA. RP Harris, C (reprint author), Univ Michigan, Sch Publ Hlth, Dept Environm Hlth Sci, M6667 SPH 2,1415 Washington Hts, Ann Arbor, MI 48109 USA. EM charris@umich.edu OI Sant, Karilyn/0000-0001-8565-2072 FU Bill and Melinda Gates Foundation, Grand Challenges Explorations, Round 7; University of Michigan National Institute of Environmental Health Sciences (NIEHS) Core Center [P30 ES017885]; Institutional Training Grant from the NIEHS [T32 ES007062] FX This work was supported by the Bill and Melinda Gates Foundation, Grand Challenges Explorations, Round 7; the University of Michigan National Institute of Environmental Health Sciences (NIEHS) Core Center, "Lifestage Exposures and Adult Disease" (P30 ES017885); and from an Institutional Training Grant from the NIEHS to K.E.S. (T32 ES007062). NR 74 TC 2 Z9 2 U1 0 U2 2 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1096-6080 EI 1096-0929 J9 TOXICOL SCI JI Toxicol. Sci. PD OCT PY 2015 VL 147 IS 2 BP 475 EP 489 DI 10.1093/toxsci/kfv145 PG 15 WC Toxicology SC Toxicology GA CX2SO UT WOS:000365547300019 PM 26185205 ER PT J AU Braun, ES Crawford, FW Desai, MM Meek, J Kirley, PD Miller, L Anderson, EJ Oni, O Ryan, P Lynfield, R Bargsten, M Bennett, NM Lung, KL Thomas, A Mermel, E Lindegren, ML Schaffner, W Price, A Chaves, SS AF Braun, Elise S. Crawford, Forrest W. Desai, Mayur M. Meek, James Kirley, Pam Daily Miller, Lisa Anderson, Evan J. Oni, Oluwakemi Ryan, Patricia Lynfield, Ruth Bargsten, Marisa Bennett, Nancy M. Lung, Krista L. Thomas, Ann Mermel, Elizabeth Lindegren, Mary Lou Schaffner, William Price, Andrea Chaves, Sandra S. TI Obesity not associated with severity among hospitalized adults with seasonal influenza virus infection SO INFECTION LA English DT Article DE Influenza; Severe influenza; Influenza hospitalizations; Obesity; BMI; Body mass index ID RISK-FACTOR; PNEUMONIA; A(H1N1); COHORT; IMPACT AB We examined seasonal influenza severity [artificial ventilation, intensive care unit (ICU) admission, and radiographic- confirmed pneumonia] by weight category among adults hospitalized with laboratory-confirmed influenza. Using multivariate logistic regression models, we found no association between obesity or severe obesity and artificial ventilation or ICU admission; however, overweight and obese patients had decreased risk of pneumonia. Underweight was associated with pneumonia (adjusted odds ratio 1.31; 95 % confidence interval 1.04, 1.64). C1 [Braun, Elise S.; Crawford, Forrest W.; Desai, Mayur M.] Yale Univ, Sch Publ Hlth, New Haven, CT USA. [Braun, Elise S.; Chaves, Sandra S.] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA 30329 USA. [Meek, James] Yale Univ, Sch Publ Hlth, Connecticut Emerging Infect Program, New Haven, CT USA. [Kirley, Pam Daily] Calif Emerging Infect Program, Oakland, CA USA. [Miller, Lisa] Colorado Dept Publ Hlth & Environm, Denver, CO USA. [Anderson, Evan J.] Georgia Emerging Infect Program, Atlanta, GA USA. [Oni, Oluwakemi] Iowa Dept Publ Hlth, Des Moines, IA 50319 USA. [Ryan, Patricia] Maryland Dept Hlth & Mental Hyg, Baltimore, MD USA. [Lynfield, Ruth] Minnesota Dept Hlth, St Paul, MN USA. [Bargsten, Marisa] New Mexico Dept Hlth, Santa Fe, NM USA. [Bennett, Nancy M.] Univ Rochester, Sch Med & Dent, Dept Med, Rochester, NY 14642 USA. [Lung, Krista L.] Ohio Dept Hlth, Columbus, OH 43266 USA. [Thomas, Ann] Oregon Publ Hlth Div, Portland, OR USA. [Mermel, Elizabeth] Rhode Isl Dept Hlth, Providence, RI 02908 USA. [Lindegren, Mary Lou; Schaffner, William] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA. [Price, Andrea] Salt Lake Cty Hlth Dept, Salt Lake City, UT USA. RP Chaves, SS (reprint author), Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA 30329 USA. EM bev8@cdc.gov FU NCEZID CDC HHS [CDC-RFA-CK12-1202]; NCHM CDC HHS [5U38HM000414] NR 10 TC 0 Z9 1 U1 0 U2 0 PU SPRINGER HEIDELBERG PI HEIDELBERG PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY SN 0300-8126 EI 1439-0973 J9 INFECTION JI Infection PD OCT PY 2015 VL 43 IS 5 DI 10.1007/s15010-015-0802-x PG 7 WC Infectious Diseases SC Infectious Diseases GA CW4OZ UT WOS:000364972300008 PM 26148927 ER PT J AU Orata, FD Kirchberger, PC Meheust, R Barlow, EJ Tarr, CL Boucher, Y AF Orata, Fabini D. Kirchberger, Paul C. Meheust, Raphael Barlow, E. Jed Tarr, Cheryl L. Boucher, Yan TI The Dynamics of Genetic Interactions between Vibrio metoecus and Vibrio cholerae, Two Close Relatives Co-Occurring in the Environment SO GENOME BIOLOGY AND EVOLUTION LA English DT Article DE Vibrio metoecus; Vibrio cholerae; horizontal gene transfer; genomic islands; integron; comparative genomics ID COMPARATIVE GENOMIC ANALYSIS; PHYLOGENETIC ANALYSIS; PAN-GENOME; NATURAL TRANSFORMATION; PATHOGENICITY ISLAND; NICOTINAMIDASE PNCA; SPECIES DEFINITION; RESISTANCE; INTEGRONS; TOOL AB Vibrio metoecus is the closest relative of Vibrio cholerae, the causative agent of the potent diarrheal disease cholera. Although the pathogenic potential of this new species is yet to be studied in depth, it has been co-isolated with V. cholerae in coastal waters and found in clinical specimens in the United States. We used these two organisms to investigate the genetic interaction between closely related species in their natural environment. The genomes of 20 V. cholerae and 4 V. metoecus strains isolated from a brackish coastal pond on the US east coast, as well as 4 clinical V. metoecus strains were sequenced and compared with reference strains. Whole genome comparison shows 86-87% average nucleotide identity (ANI) in their core genes between the two species. On the other hand, the chromosomal integron, which occupies approximately 3% of their genomes, shows higher conservation in ANI between species than any other region of their genomes. The ANI of 93-94% observed in this region is not significantly greater within than between species, meaning that it does not follow species boundaries. Vibrio metoecus does not encode toxigenic V. cholerae major virulence factors, the cholera toxin and toxin-coregulated pilus. However, some of the pathogenicity islands found in pandemic V. cholerae were either present in the common ancestor it shares with V. metoecus, or acquired by clinical and environmental V. metoecus in partial fragments. The virulence factors of V. cholerae are therefore both more ancient and more widespread than previously believed. There is high interspecies recombination in the core genome, which has been detected in 24% of the single-copy core genes, including genes involved in pathogenicity. Vibrio metoecus was six times more often the recipient of DNA from V. cholerae as it was the donor, indicating a strong bias in the direction of gene transfer in the environment. C1 [Orata, Fabini D.; Kirchberger, Paul C.; Boucher, Yan] Univ Alberta, Dept Biol Sci, Edmonton, AB, Canada. [Meheust, Raphael] Univ Paris 06, Inst Biol Paris Seine, Evolut Paris Seine, Unite Mixte Rech 7138, Paris, France. [Barlow, E. Jed] Univ Alberta, Dept Comp Sci, Edmonton, AB, Canada. [Tarr, Cheryl L.] Ctr Dis Control & Prevent, Enter Dis Lab Branch, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. RP Boucher, Y (reprint author), Univ Alberta, Dept Biol Sci, Edmonton, AB, Canada. EM yboucher@ualberta.ca FU Natural Sciences and Engineering Research Council of Canada; Canadian Institute for Advanced Research; Canadian Foundation for Innovation; Alberta Innovates-Technology Futures FX The authors are grateful for the assistance of Tania Nasreen, Paul Stothard (University of Alberta), Lee Katz, Mike Frace, Maryann Turnsek (Centers for Disease Control and Prevention), Eric Bapteste (Universite Pierre et Marie Curie), Gary Van Domselaar, and Aaron Petkau (National Microbiology Laboratory). They appreciate the helpful discussions with Rebecca Case, Stefan Pukatzki, and David Wishart (University of Alberta). This work was supported by the Natural Sciences and Engineering Research Council of Canada, the Canadian Institute for Advanced Research, the Canadian Foundation for Innovation (to Y.B.), and the Alberta Innovates-Technology Futures (to F.D.O. and P.C.K.). NR 74 TC 7 Z9 7 U1 0 U2 4 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1759-6653 J9 GENOME BIOL EVOL JI Genome Biol. Evol. PD OCT PY 2015 VL 7 IS 10 BP 2941 EP 2954 DI 10.1093/gbe/evv193 PG 14 WC Evolutionary Biology; Genetics & Heredity SC Evolutionary Biology; Genetics & Heredity GA CW4HC UT WOS:000364951100011 PM 26454015 ER PT J AU Shahangian, S Saraiya, M Benard, V AF Shahangian, Shahram Saraiya, Mona Benard, Vicki TI Utilization of Cervical Cytology and Human Papillomavirus DNA Tests by 15-27 Million Privately Insured Women, 2007-2013 SO AMERICAN JOURNAL OF CLINICAL PATHOLOGY LA English DT Meeting Abstract C1 [Shahangian, Shahram; Saraiya, Mona; Benard, Vicki] CDC, Atlanta, GA 30333 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL PATHOLOGY PI CHICAGO PA 2100 W HARRISON ST, CHICAGO, IL 60612 USA SN 0002-9173 EI 1943-7722 J9 AM J CLIN PATHOL JI Am. J. Clin. Pathol. PD OCT PY 2015 VL 144 SU 2 MA 227 BP A227 EP A227 PG 1 WC Pathology SC Pathology GA CV9DJ UT WOS:000364587200228 ER PT J AU Wilson, K AF Wilson, Karlyn TI The Potential to Utilize Mobile Applications to Train Laboratorians on Coagulation Laboratory Testing SO AMERICAN JOURNAL OF CLINICAL PATHOLOGY LA English DT Meeting Abstract C1 [Wilson, Karlyn] CDC, Atlanta, GA 30333 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL PATHOLOGY PI CHICAGO PA 2100 W HARRISON ST, CHICAGO, IL 60612 USA SN 0002-9173 EI 1943-7722 J9 AM J CLIN PATHOL JI Am. J. Clin. Pathol. PD OCT PY 2015 VL 144 SU 2 MA 170 BP A170 EP A170 PG 1 WC Pathology SC Pathology GA CV9DJ UT WOS:000364587200171 ER PT J AU Bauer, KW Marcus, MD El Ghormli, L Ogden, CL Foster, GD AF Bauer, K. W. Marcus, M. D. El Ghormli, L. Ogden, C. L. Foster, G. D. TI Cardio-metabolic risk screening among adolescents: understanding the utility of body mass index, waist circumference and waist to height ratio SO PEDIATRIC OBESITY LA English DT Article DE Adolescents; cardiovascular risk; screening ID OVERWEIGHT CHILDREN; INSULIN-RESISTANCE; OBESITY; DISEASE; PREVALENCE; ADIPOSITY; ADULTHOOD; CHILDHOOD; HEALTHY; BMI AB Background: Few studies have assessed how well body mass index (BMI), waist circumference (WC), or waist to height ratio (WtHR) perform in identifying cardio-metabolic risk among youth. Objective: The objective of this study was to evaluate the utility of BMI and WC percentiles and WtHR to distinguish adolescents with and without cardio-metabolic risk. Methods: A cross-sectional analysis of data from 6097 adolescents aged 10-13 years who participated in the HEALTHY study was conducted. Receiver operating characteristic curves determined the discriminatory ability of BMI and WC percentiles and WtHR. Results: The discriminatory ability of BMI percentile was good (area under the curve [AUC] >= 0.80) for elevated insulin and clustering of >= 3 risk factors, with optimal cut-points of 96 and 95, respectively. BMI percentile performed poor to fair (AUC = 0.57-0.75) in identifying youth with the majority of individual risk factors examined (elevated glucose, total cholesterol, low-density lipoprotein, blood pressure, triglycerides and high-density lipoprotein). WC percentile and WtHR performed similarly to BMI percentile. Conclusions: The current definition of obesity among US children performs well at identifying adolescents with elevated insulin and a clustering of = 3 cardio-metabolic risk factors. Evidence does not support WC percentile or WtHR as superior screening tools compared with BMI percentile for identifying cardio-metabolic risk. C1 [Bauer, K. W.; Foster, G. D.] Temple Univ, Ctr Obes Res & Educ, Philadelphia, PA 19122 USA. [Bauer, K. W.] Temple Univ, Dept Publ Hlth, Philadelphia, PA 19122 USA. [Marcus, M. D.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA. [El Ghormli, L.] George Washington Univ, Ctr Biostat, Rockville, MD USA. [Ogden, C. L.] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. RP Bauer, KW (reprint author), Ctr Obes Res & Educ, 3223 North Broad St,Suite 175, Philadelphia, PA 19140 USA. EM katherine.bauer@temple.edu OI Bauer, Katherine/0000-0003-3512-3994 FU National Institute of Diabetes and Digestive and Kidney Diseases/National Institutes of Health [U01-DK61230, U01-DK61249, U01- DK61231, U01-DK61223] FX This work was completed with funding from the National Institute of Diabetes and Digestive and Kidney Diseases/National Institutes of Health grants U01-DK61230, U01-DK61249, U01- DK61231 and U01-DK61223 to the Studies to Treat Or Prevent Pediatric Type 2 Diabetes (STOPP-T2D) collaborative group. We thank the administration, faculty, staff, students and their families at the middle schools and school districts that participated in the HEALTHY study. All authors made substantial contributions to the conception and design of the study and interpretation of data, and approved the final paper as submitted. KWB drafted the paper and LE carried out the analysis. MDM, CLO and GDF critically revised the paper. NR 30 TC 8 Z9 8 U1 2 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2047-6310 EI 2047-6302 J9 PEDIATR OBES JI Pediatr. Obes. PD OCT PY 2015 VL 10 IS 5 BP 329 EP 337 DI 10.1111/ijpo.267 PG 9 WC Pediatrics SC Pediatrics GA CV9CG UT WOS:000364584300004 PM 25515620 ER PT J AU Anderson, JP Rascoe, LN Levert, K Chastain, HM Reed, MS Rivera, HN McAuliffe, I Zhan, B Wiegand, RE Hotez, PJ Wilkins, PP Pohl, J Handali, S AF Anderson, John P. Rascoe, Lisa N. Levert, Keith Chastain, Holly M. Reed, Matthew S. Rivera, Hilda N. McAuliffe, Isabel Zhan, Bin Wiegand, Ryan E. Hotez, Peter J. Wilkins, Patricia P. Pohl, Jan Handali, Sukwan TI Development of a Luminex Bead Based Assay for Diagnosis of Toxocariasis Using Recombinant Antigens Tc-CTL-1 and Tc-TES-26 SO PLoS Neglected Tropical Diseases LA English DT Article ID EXCRETORY-SECRETORY ANTIGEN; VISCERAL LARVA MIGRANS; CANIS INFECTIVE LARVAE; UNITED-STATES; PARASITIC INFECTIONS; LATIN-AMERICA; TAENIA-SOLIUM; SERODIAGNOSIS; IMMUNODIAGNOSIS; PROTEINS AB The clinical spectrum of human disease caused by the roundworms Toxocara canis and Toxocara cati ranges from visceral and ocular larva migrans to covert toxocariasis. The parasite is not typically recovered in affected tissues, so detection of parasite-specific antibodies is usually necessary for establishing a diagnosis. The most reliable immunodiagnostic methods use the Toxocara excretory-secretory antigens (TES-Ag) in ELISA formats to detect Toxocara-specific antibodies. To eliminate the need for native parasite materials, we identified and purified immunodiagnostic antigens using 2D gel electrophoresis followed by electrospray ionization mass spectrometry. Three predominant immunoreactive proteins were found in the TES; all three had been previously described in the literature: Tc-CTL-1, Tc-TES-26, and Tc-MUC-3. We generated Escherichia coli expressed recombinant proteins for evaluation in Luminex based immunoassays. We were unable to produce a functional assay with the Tc-MUC-3 recombinant protein. Tc-CTL-1 and Tc-TES-26 were successfully coupled and tested using defined serum batteries. The use of both proteins together generated better results than if the proteins were used individually. The sensitivity and specificity of the assay for detecting visceral larval migrans using Tc-CTL-1 plus Tc-TES-26 was 99% and 94%, respectively; the sensitivity for detecting ocular larval migrans was 64%. The combined performance of the new assay was superior to the currently available EIA and could potentially be employed to replace current assays that rely on native TES-Ag. C1 [Anderson, John P.; Rascoe, Lisa N.; Levert, Keith; Chastain, Holly M.; Rivera, Hilda N.; McAuliffe, Isabel; Wiegand, Ryan E.; Wilkins, Patricia P.; Handali, Sukwan] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Atlanta, GA USA. [Reed, Matthew S.; Pohl, Jan] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. [Zhan, Bin; Hotez, Peter J.] Baylor Coll Med, Natl Sch Trop Med, Houston, TX 77030 USA. RP Anderson, JP (reprint author), Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Atlanta, GA USA. EM ahi0@cdc.gov OI Hotez, Peter/0000-0001-8770-1042 FU NIDDK NIH HHS [P30 DK056338] NR 36 TC 1 Z9 1 U1 1 U2 7 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1935-2735 J9 PLOS NEGLECT TROP D JI Plos Neglect. Trop. Dis. PD OCT PY 2015 VL 9 IS 10 AR e0004168 DI 10.1371/journal.pntd.0004168 PG 14 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA CV7NC UT WOS:000364459600066 PM 26485145 ER PT J AU Falendysz, EA Lopera, JG Lorenzsonn, F Salzer, JS Hutson, CL Doty, J Gallardo-Romero, N Carroll, DS Osorio, JE Rocke, TE AF Falendysz, Elizabeth A. Lopera, Juan G. Lorenzsonn, Faye Salzer, Johanna S. Hutson, Christina L. Doty, Jeffrey Gallardo-Romero, Nadia Carroll, Darin S. Osorio, Jorge E. Rocke, Tonie E. TI Further Assessment of Monkeypox Virus Infection in Gambian Pouched Rats (Cricetomys gambianus) Using In Vivo Bioluminescent Imaging SO PLOS NEGLECTED TROPICAL DISEASES LA English DT Article ID ORTHOPOXVIRUS INFECTION; PRAIRIE DOGS; ANIMALS; AFRICAN; DISEASE; MICE; SQUIRRELS; OUTBREAK; STRAINS; FLORIDA AB Monkeypox is a zoonosis clinically similar to smallpox in humans. Recent evidence has shown a potential risk of increased incidence in central Africa. Despite attempts to isolate the virus from wild rodents and other small mammals, no reservoir host has been identified. In 2003, Monkeypox virus (MPXV) was accidentally introduced into the U.S. via the pet trade and was associated with the Gambian pouched rat (Cricetomys gambianus). Therefore, we investigated the potential reservoir competence of the Gambian pouched rat for MPXV by utilizing a combination of in vivo and in vitro methods. We inoculated three animals by the intradermal route and three animals by the intranasal route, with one mock-infected control for each route. Bioluminescent imaging (BLI) was used to track replicating virus in infected animals and virological assays (e.g. real time PCR, cell culture) were used to determine viral load in blood, urine, ocular, nasal, oral, and rectal swabs. Intradermal inoculation resulted in clinical signs of monkeypox infection in two of three animals. One severely ill animal was euthanized and the other affected animal recovered. In contrast, intranasal inoculation resulted in subclinical infection in all three animals. All animals, regardless of apparent or inapparent infection, shed virus in oral and nasal secretions. Additionally, BLI identified viral replication in the skin without grossly visible lesions. These results suggest that Gambian pouched rats may play an important role in transmission of the virus to humans, as they are hunted for consumption and it is possible for MPXV-infected pouched rats to shed infectious virus without displaying overt clinical signs. C1 [Falendysz, Elizabeth A.; Rocke, Tonie E.] US Geol Survey, Natl Wildlife Hlth Ctr, Madison, WI USA. [Lopera, Juan G.; Lorenzsonn, Faye; Osorio, Jorge E.] Univ Wisconsin, Sch Vet Med, Dept Pathobiol Sci, Madison, WI 53706 USA. [Salzer, Johanna S.; Hutson, Christina L.; Doty, Jeffrey; Gallardo-Romero, Nadia; Carroll, Darin S.] Ctr Dis Control & Prevent, Poxvirus & Rabies Branch, Div High Consequence Pathogens & Pathol, Natl Ctr Zoonot & Vector Borne & Enter Dis, Atlanta, GA USA. RP Falendysz, EA (reprint author), US Geol Survey, Natl Wildlife Hlth Ctr, Madison, WI USA. EM trocke@usgs.gov OI Falendysz, Elizabeth/0000-0003-2895-8918; Rocke, Tonie/0000-0003-3933-1563 FU National Institutes of Health [NIH R01 TW 8859-3] FX This study was funded by the National Institutes of Health (www.NIH.gov), grant number NIH R01 TW 8859-3. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 48 TC 0 Z9 0 U1 3 U2 5 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1935-2735 J9 PLOS NEGLECT TROP D JI Plos Neglect. Trop. Dis. PD OCT PY 2015 VL 9 IS 10 AR e0004130 DI 10.1371/journal.pntd.0004130 PG 19 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA CV7NC UT WOS:000364459600035 PM 26517839 ER PT J AU Fan, YC Chiu, HC Chen, LK Chang, GJJ Chiou, SS AF Fan, Yi-Chin Chiu, Hsien-Chung Chen, Li-Kuang Chang, Gwong-Jen J. Chiou, Shyan-Song TI Formalin Inactivation of Japanese Encephalitis Virus Vaccine Alters the Antigenicity and Immunogenicity of a Neutralization Epitope in Envelope Protein Domain III SO PLoS Neglected Tropical Diseases LA English DT Article ID WEST-NILE-VIRUS; CROSS-REACTIVE ANTIBODIES; MONOCLONAL-ANTIBODIES; PROTECTIVE IMMUNITY; DENGUE VIRUS; FREQUENT INTRODUCTIONS; NEPALESE CHILDREN; HUMORAL IMMUNITY; SOUTHEAST-ASIA; TISSUE CULTURE AB Formalin-inactivated Japanese encephalitis virus (JEV) vaccines are widely available, but the effects of formalin inactivation on the antigenic structure of JEV and the profile of antibodies elicited after vaccination are not well understood. We used a panel of monoclonal antibodies (MAbs) to map the antigenic structure of live JEV virus, untreated control virus (UCV), formalin-inactivated commercial vaccine (FICV), and formalin-inactivated virus (FIV). The binding activity of T16 MAb against Nakayama-derived FICV and several strains of FIV was significantly lower compared to live virus and UCV. T16 MAb, a weakly neutralizing JEV serocomplex antibody, was found to inhibit JEV infection at the post-attachment step. The T16 epitope was mapped to amino acids 329, 331, and 389 within domain III (EDIII) of the envelope (E) glycoprotein. When we explored the effect of formalin inactivation on the immunogenicity of JEV, we found that Nakayama-derived FICV, FIV, and UCV all exhibited similar immunogenicity in a mouse model, inducing anti-JEV and anti-EDII 101/ 106/107 epitope-specific antibodies. However, the EDIII 329/331/389 epitope-specific IgG antibody and neutralizing antibody titers were significantly lower for FICV-immunized and FIV-immunized mouse serum than for UCV-immunized. Formalin inactivation seems to alter the antigenic structure of the E protein, which may reduce the potency of commercially available JEV vaccines. Virus inactivation by H2O2, but not by UV or by short-duration and higher temperature formalin treatment, is able to maintain the antigenic structure of the JEV E protein. Thus, an alternative inactivation method, such as H2O2, which is able to maintain the integrity of the E protein may be essential to improving the potency of inactivated JEV vaccines. C1 [Fan, Yi-Chin; Chiou, Shyan-Song] Natl Chung Hsing Univ, Grad Inst Microbiol & Publ Hlth, Taichung 40227, Taiwan. [Chiu, Hsien-Chung] Natl Def Med Ctr, Sch Dent, Dept Periodontol, Taipei, Taiwan. [Chiu, Hsien-Chung] Triserv Gen Hosp, Taipei, Taiwan. [Chen, Li-Kuang] Tzu Chi Univ, Coll Med, Hualien, Taiwan. [Chang, Gwong-Jen J.] Ctr Dis Control & Prevent, Arboviral Dis Branch, Ft Collins, CO USA. RP Fan, YC (reprint author), Natl Chung Hsing Univ, Grad Inst Microbiol & Publ Hlth, Taichung 40227, Taiwan. EM sschiou@dragon.nchu.edu.tw NR 88 TC 1 Z9 1 U1 1 U2 4 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1935-2735 J9 PLOS NEGLECT TROP D JI Plos Neglect. Trop. Dis. PD OCT PY 2015 VL 9 IS 10 AR e0004167 DI 10.1371/journal.pntd.0004167 PG 25 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA CV7NC UT WOS:000364459600065 PM 26495991 ER PT J AU Hutson, CL Nakazawa, YJ Self, J Olson, VA Regnery, RL Braden, Z Weiss, S Malekani, J Jackson, E Tate, M Karem, KL Rocke, TE Osorio, JE Damon, IK Carroll, DS AF Hutson, Christina L. Nakazawa, Yoshinori J. Self, Joshua Olson, Victoria A. Regnery, Russell L. Braden, Zachary Weiss, Sonja Malekani, Jean Jackson, Eddie Tate, Mallory Karem, Kevin L. Rocke, Tonie E. Osorio, Jorge E. Damon, Inger K. Carroll, Darin S. TI Laboratory Investigations of African Pouched Rats (Cricetomys gambianus) as a Potential Reservoir Host Species for Monkeypox Virus SO PLoS Neglected Tropical Diseases LA English DT Article ID TIME PCR ASSAYS; CONGO BASIN; EXPERIMENTAL-INFECTION; WEST-AFRICAN; ORTHOPOXVIRUS; TRANSMISSION; SQUIRRELS; DISEASE; OUTBREAKS; SMALLPOX AB Monkeypox is a zoonotic disease endemic to central and western Africa, where it is a major public health concern. Although Monkeypox virus (MPXV) and monkeypox disease in humans have been well characterized, little is known about its natural history, or its maintenance in animal populations of sylvatic reservoir(s). In 2003, several species of rodents imported from Ghana were involved in a monkeypox outbreak in the United States with individuals of three African rodent genera (Cricetomys, Graphiurus, Funisciurus) shown to be infected with MPXV. Here, we examine the course of MPXV infection in Cricetomys gambianus (pouched Gambian rats) and this rodent species' competence as a host for the virus. We obtained ten Gambian rats from an introduced colony in Grassy Key, Florida and infected eight of these via scarification with a challenge dose of 4X10(4) plaque forming units (pfu) from either of the two primary clades of MPXV: Congo Basin (C-MPXV: n = 4) or West African (W-MPXV: n = 4); an additional 2 animals served as PBS controls. Viral shedding and the effect of infection on activity and physiological aspects of the animals were measured. MPXV challenged animals had significantly higher core body temperatures, reduced activity and increased weight loss than PBS controls. Viable virus was found in samples taken from animals in both experimental groups (C-MPXV and W-MPXV) between 3 and 27 days post infection (p.i.) (up to 1X10(8) pfu/ml), with viral DNA found until day 56 p.i. The results from this work show that Cricetomys gambianus (and by inference, probably the closely related species, Cricetomys emini) can be infected with MPXV and shed viable virus particles; thus suggesting that these animals may be involved in the maintenance of MPXV in wildlife mammalian populations. More research is needed to elucidate the epidemiology of MPXV and the role of Gambian rats and other species. C1 [Hutson, Christina L.; Nakazawa, Yoshinori J.; Self, Joshua; Olson, Victoria A.; Regnery, Russell L.; Braden, Zachary; Weiss, Sonja; Karem, Kevin L.; Damon, Inger K.; Carroll, Darin S.] Ctr Dis Control & Prevent, Poxvirus & Rabies Branch, Atlanta, GA USA. [Malekani, Jean] Univ Kinshasa, Dept Biol, Kinshasa, Congo. [Jackson, Eddie; Tate, Mallory] Ctr Dis Control & Prevent, Anim Resources Branch, Atlanta, GA USA. [Rocke, Tonie E.] US Geol Survey, Natl Wildlife Hlth Ctr, Madison, WI USA. [Osorio, Jorge E.] Univ Wisconsin, Sch Vet Med, Dept Pathobiol Sci, Madison, WI 53706 USA. RP Hutson, CL (reprint author), Ctr Dis Control & Prevent, Poxvirus & Rabies Branch, Atlanta, GA USA. EM zuu6@cdc.gov OI Rocke, Tonie/0000-0003-3933-1563 FU National Institutes of Health (NIH) [1R01TW008859-01] FX This research was supported by the National Institutes of Health (NIH) grant 1R01TW008859-01 ("Sylvatic Reservoirs of Human Monkeypox"). The NIH funders had no role in our study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 52 TC 1 Z9 1 U1 3 U2 4 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1935-2735 J9 PLOS NEGLECT TROP D JI Plos Neglect. Trop. Dis. PD OCT PY 2015 VL 9 IS 10 AR e0004013 DI 10.1371/journal.pntd.0004013 PG 20 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA CV7NC UT WOS:000364459600007 PM 26517724 ER PT J AU Chiang, LF Chen, J Gladden, MR Mercy, JA Kwesigabo, G Mrisho, F Dahlberg, LL Nyunt, MZ Brookmeyer, KA Vagi, K AF Chiang, Laura F. Chen, Jieru Gladden, Matthew R. Mercy, James A. Kwesigabo, Gideon Mrisho, Fatma Dahlberg, Linda L. Nyunt, Myo Zin Brookmeyer, Kate A. Vagi, Kevin TI HTV AND CHILDHOOD SEXUAL VIOLENCE: IMPLICATIONS FOR SEXUAL RISK BEHAVIORS AND HIV TESTING IN TANZANIA SO AIDS EDUCATION AND PREVENTION LA English DT Article ID COGNITIVE PROCESSING THERAPY; INTIMATE PARTNER VIOLENCE; GENDER-BASED VIOLENCE; POSITIVE WOMEN; SOUTH-AFRICA; ABUSE; METAANALYSIS; COUNTRIES; VICTIMS; INFECTION AB Prior research has established an association between sexual violence and HIV. Exposure to sexual violence during childhood can profoundly impact brain architecture and stress regulatory response. As a result, individuals who have experienced such trauma may engage in sexual risk-taking behavior and could benefit from targeted interventions. In 2009, nationally representative data were collected on violence against children in Tanzania from 13-24 year old respondents (n = 3,739). Analyses show that females aged 19-24 (n = 579) who experienced childhood sexual violence, were more likely to report no/infrequent condom use in the past 12 months (AOR = 3.0, CI [1.5, 6.1], p 0.0017) and multiple sex partners in the past 12 months (AOR = 2.3, CI [1.0, 5.1], p = 0.0491), but no more likely to know where to get HIV testing or to have ever been tested. Victims of childhood sexual violence could benefit from targeted interventions to mitigate impacts of violence and prevent HIV. C1 [Chiang, Laura F.; Chen, Jieru; Gladden, Matthew R.; Mercy, James A.; Dahlberg, Linda L.; Brookmeyer, Kate A.; Vagi, Kevin] Ctr Dis Control & Prevent, Atlanta, GA USA. [Kwesigabo, Gideon] Muhimbili Univ, Dar Es Salaam, Tanzania. [Mrisho, Fatma] Tanzania Commiss AIDS, Dar Es Salaam, Tanzania. [Nyunt, Myo Zin] UNICEF Namibia, Windhoek, Namibia. RP Chiang, LF (reprint author), 4770 Buford Highway NE,Mailstop F-64, Atlanta, GA 30341 USA. EM imh6@cdc.gov FU UNICEF-Tanzania FX We would like to acknowledge UNICEF-Tanzania for funding the implementation of the survey in Tanzania. We would like to also acknowledge the Violence against Children Multi-Sectoral Task Force (MSTF) for leadership in the planning and implementation of this study. The authors declare that they have no conflict of interest. NR 58 TC 0 Z9 0 U1 1 U2 4 PU GUILFORD PUBLICATIONS INC PI NEW YORK PA 370 SEVENTH AVE, SUITE 1200, NEW YORK, NY 10001-1020 USA SN 0899-9546 EI 1943-2755 J9 AIDS EDUC PREV JI Aids Educ. Prev. PD OCT PY 2015 VL 27 IS 5 BP 474 EP 487 PG 14 WC Education & Educational Research; Public, Environmental & Occupational Health SC Education & Educational Research; Public, Environmental & Occupational Health GA CV4UF UT WOS:000364261300007 PM 26485236 ER PT J AU Ford, ES AF Ford, Earl S. TI Trends in Mortality From COPD Among Adults in the United States SO CHEST LA English DT Article ID OBSTRUCTIVE PULMONARY-DISEASE; JOINPOINT REGRESSION; GLOBAL BURDEN; DEATH AB BACKGROUND: COPD imposes a large public health burden internationally and in the United States. The objective of this study was to examine trends in mortality from COPD among US adults from 1968 to 2011. METHODS: Data from the National Vital Statistics System from 1968 to 2011 for adults aged > 25 years were accessed, and trends in mortality rates were examined with Joinpoint analysis. RESULTS: Among all adults, age-adjusted mortality rate rose from 29.4 per 100,000 population in 1968 to 67.0 per 100,000 population in 1999 and then declined to 63.7 per 100,000 population in 2011 (annual percentage change [APC] 2000-2011, -0.2%; 95% CI, -0.6 to 0.2). The age-adjusted mortality rate among men peaked in 1999 and then declined (APC 1999-2011, -1.1%; 95% CI, -1.4 to -0.7), whereas the age-adjusted mortality rate among women increased from 2000 to 2011, peaking in 2008 (APC 2000-2011, 0.4%; 95% CI, 0.0-0.9). Despite a narrowing of the sex gap, mortality rates in men continued to exceed those in women. Evidence of a decline in the APC was noted for black men (1999-2011, -1.5%; 95% CI, -2.1 to -1.0) and white men (1999-2011, -0.9%; 95% CI, -1.3 to -0.6), adults aged 55 to 64 years (1989-2011, -1.0%; 95% CI, -1.2 to -0.8), and adults aged 65 to 74 years (1999-2011, -1.2%; 95% CI, -1.6 to -0.9). CONCLUSIONS: In the United States, the mortality rate from COPD has declined since 1999 in men and some age groups but appears to be still rising in women, albeit at a reduced pace. C1 [Ford, Earl S.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Populat Hlth, Atlanta, GA 30341 USA. RP Ford, ES (reprint author), Ctr Dis Control & Prevent, 4770 Buford Hwy,MS F78, Atlanta, GA 30341 USA. EM eford@cdc.gov FU Intramural CDC HHS [CC999999] NR 26 TC 4 Z9 4 U1 0 U2 2 PU AMER COLL CHEST PHYSICIANS PI GLENVIEW PA 2595 PATRIOT BLVD, GLENVIEW, IL 60026 USA SN 0012-3692 J9 CHEST JI Chest PD OCT PY 2015 VL 148 IS 4 BP 962 EP 970 DI 10.1378/chest.14-2311 PG 9 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA CV0QN UT WOS:000363956300036 PM 25411775 ER PT J AU Losby, JL Osuji, TA House, MJ Davis, R Boyce, SP Greenberg, MC Whitehill, JM AF Losby, Jan L. Osuji, Thearis A. House, Marnie J. Davis, Rachel Boyce, Simone Peart Greenberg, Michael Canter Whitehill, John M., Jr. TI Value of a facilitated quality improvement initiative on cardiovascular disease risk: findings from an evaluation of the Aggressively Treating Global Cardiometabolic Risk Factors to Reduce Cardiovascular Events (AT GOAL) SO JOURNAL OF EVALUATION IN CLINICAL PRACTICE LA English DT Article DE cardiovascular outcomes; diabetes mellitus; patient care management; primary health care; programme evaluation; quality improvement ID SOUTHEASTERN UNITED-STATES; CLUSTER-RANDOMIZED-TRIAL; BLOOD-PRESSURE CONTROL; HYPERTENSION MANAGEMENT; EDUCATION; PROGRAM; DYSLIPIDEMIA; CHOLESTEROL; PANEL AB Rationale, aims and objectives In the United States, cardiovascular disease (CVD) is the leading cause of death. The US Centers for Disease Control and Prevention contracted an evaluation of the Aggressively Treating Global Cardiometabolic Risk Factors to Reduce Cardiovascular Events (AT GOAL) programme as part of its effort to identify strategies to address CVD risk factors. Methods This study analysed patient-level data from 7527 patients in 43 primary care practices. The researchers assessed average change in control rates for CVD-related measures across practices, and then across patients between baseline and a patient's last visit during the practice's tenure in the programme (referred to as 'end line') using repeated measures analysis of variance and random effects generalized least squares, respectively. Results Among non-diabetic patients, there were significant increases in control rates for overall blood pressure (74.3% to 78.0%, P = 0.0002), systolic blood pressure (70.3% to 80.6%, P = 0.0099), diastolic blood pressure (90.1% to 92.7%, P = 0.0001) and lowdensity lipoprotein (LDL; 48.6% to 53.1%, P = 0.0001) between baseline and end line. Among diabetic patients, there was a significant increase in diastolic blood pressure control (59.8% to 61.9%, P = 0.0141). While continuous CVD-related outcomes show an overall trend between baseline and end line, patients with uncontrolled measures at baseline showed a decrease between baseline and end line relative to their counterparts who were controlled at baseline. Conclusions Findings from the AT GOAL evaluation support the value of a facilitated quality improvement (QI) initiative on managing CVD risk. C1 [Losby, Jan L.; Davis, Rachel; Whitehill, John M., Jr.] Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, Atlanta, GA 30341 USA. [Osuji, Thearis A.; House, Marnie J.; Boyce, Simone Peart; Greenberg, Michael Canter] ICF Int, Atlanta, GA USA. RP Losby, JL (reprint author), Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, 4770 Buford Hwy NE,MS F72, Atlanta, GA 30341 USA. EM JLosby@cdc.gov FU Centers for Disease Control and Prevention (CDC) [200-2008-27957] FX The authors would like to acknowledge the following individuals from the Consortium for Southeastern Hypertension Control for substantial contributions to the evaluation study: Debra Simmons, RN, MS (Executive Director) and Alex Sheek, BS (Information Technology Director). In addition, Ms. Simmons reviewed earlier drafts of this manuscript. The authors disclosed receipt of the following financial support for the authorships and/or publication of this article: This work was supported in part by a contract (Contract Number 200-2008-27957) from the Centers for Disease Control and Prevention (CDC). NR 21 TC 0 Z9 0 U1 1 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1356-1294 EI 1365-2753 J9 J EVAL CLIN PRACT JI J. Eval. Clin. Pract. PD OCT PY 2015 VL 21 IS 5 BP 963 EP 970 DI 10.1111/jep.12416 PG 8 WC Health Care Sciences & Services; Medical Informatics; Medicine, General & Internal SC Health Care Sciences & Services; Medical Informatics; General & Internal Medicine GA CU9RA UT WOS:000363881200027 PM 26223497 ER PT J AU Caruso, CC AF Caruso, Claire C. TI Reducing Risks to Women Linked to Shift Work, Long Work Hours, and Related Workplace Sleep and Fatigue Issues SO JOURNAL OF WOMENS HEALTH LA English DT Article ID MARITAL INSTABILITY; NONSTANDARD WORK; HEART-DISEASE; METAANALYSIS; DISORDERS; PREGNANCY; SCHEDULES AB In the United States, an estimated 12% to 28% of working women are on shift work schedules, and 12% work more than 48 hours per week. Shift work and long work hours are associated with many health and safety risks, including obesity, injuries, and negative reproductive outcomes. Over time, the worker is at risk for developing a wide range of chronic diseases. These work schedules can also strain personal relationships, owing to fatigue and poor mood from sleep deprivation and reduced quality time to spend with family and friends. Worker errors from fatigue can lead to reduced quality of goods and services, negatively impacting the employer. In addition, mistakes by fatigued workers can have far-reaching negative effects on the community, ranging from medical care errors to motor vehicle crashes and industrial disasters that endanger others. To reduce the many risks that are linked to these demanding work hours, the National Institute for Occupational Safety and Health (NIOSH) conducts research, develops guidance and authoritative recommendations, and translates and disseminates scientific information to protect workers, their families, employers, and the community. The key message to reduce these risks is making sleep a priority in the employer's systems for organizing work and in the worker's personal life. The NIOSH website has freely available online training programs with suggestions for workers and their managers to help them better cope with this workplace hazard. C1 NIOSH, Div Appl Res & Technol, Cincinnati, OH 45226 USA. RP Caruso, CC (reprint author), NIOSH, Div Appl Res & Technol, 1150 Tusculum Ave,MS C-24, Cincinnati, OH 45226 USA. EM ccaruso@cdc.gov NR 48 TC 1 Z9 1 U1 6 U2 16 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-9996 EI 1931-843X J9 J WOMENS HEALTH JI J. Womens Health PD OCT 1 PY 2015 VL 24 IS 10 BP 789 EP 794 DI 10.1089/jwh.2015.5481 PG 6 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies SC Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies GA CV0LF UT WOS:000363941500002 PM 26334800 ER PT J AU Phillips-Howard, PA Otieno, G Burmen, B Otieno, F Odongo, F Odour, C Nyothach, E Amek, N Zielinski-Gutierrez, E Odhiambo, F Zeh, C Kwaro, D Mills, LA Laserson, KF AF Phillips-Howard, Penelope A. Otieno, George Burmen, Barbara Otieno, Frederick Odongo, Frederick Odour, Clifford Nyothach, Elizabeth Amek, Nyanguara Zielinski-Gutierrez, Emily Odhiambo, Frank Zeh, Clement Kwaro, Daniel Mills, Lisa A. Laserson, Kayla F. TI Menstrual Needs and Associations with Sexual and Reproductive Risks in Rural Kenyan Females: A Cross-Sectional Behavioral Survey Linked with HIV Prevalence SO JOURNAL OF WOMENS HEALTH LA English DT Article ID WESTERN KENYA; WOMEN WORKING; YOUNG-PEOPLE; SOUTH-AFRICA; ACCEPTABILITY; SANITATION; HEALTH; IMPACT; MWANZA; GIRLS AB Background: Females in low and middle income countries (LMICs) have difficulty coping with menstrual needs, but few studies have examined the social or health implications of these needs. Methods: Responses from 3418 menstruating females aged 13-29 years were extracted from an HIV and behavioral risks cross-sectional survey conducted in rural western Kenya. We examined sanitary products used, provision of products from sexual partners or from transactional sex, and demographic and sexual exposures. Results: Overall, 75% of females reported using commercial pads and 25% used traditional materials such as cloth or items like paper or tissue, with 10% of girls <15 years old depending on makeshift items. Two-thirds of females with no education relied on traditional items. Having attended secondary school increased the odds of using commercial pads among married (adjusted odds ratios [AOR] 4.8, 95% confidence interval [CI] 3.25-7.12) and single females (AOR 2.17, 95% CI 1.04-4.55). Married females had lower odds of pad use if they reported early (<12 years of age) compared with later (18 years) sexual debut (64% vs. 78%, AOR 0.45, 95% CI 0.21-0.97). Two-thirds of pad users received them from sexual partners. Receipt was lower among married females if partners were violent (AOR 0.67, 95% CI 0.53-0.85). Receipt among single females was higher if they had two or more sexual partners in the past year (AOR 2.11, 95% CI 1.04-4.29). Prevalence of engaging in sex for money to buy pads was low (1.3%); however, 10% of 15-year-olds reported this, with girls 15 having significantly higher odds compared with females over 15 (AOR 2.84, 95% CI 0.89-9.11). The odds of having transactional sex for pads was higher among females having two or more partners in the past 12 months (AOR 4.86, 95% CI 2.06-11.43). Conclusions: Menstrual needs of impoverished females in rural LMICs settings likely leads to increased physical and sexual harms. Studies are required to strengthen knowledge and to evaluate interventions to reduce these harms. C1 [Phillips-Howard, Penelope A.] Univ Liverpool, Liverpool Sch Trop Med, Dept Clin Sci, Liverpool L3 5QA, Merseyside, England. [Phillips-Howard, Penelope A.; Otieno, George; Burmen, Barbara; Otieno, Frederick; Odongo, Frederick; Odour, Clifford; Nyothach, Elizabeth; Amek, Nyanguara; Odhiambo, Frank; Kwaro, Daniel] Kenya Govt Med Res Ctr, Ctr Global Hlth Res, Kisumu, Kenya. [Otieno, Frederick] Nyanza Reprod Hlth Soc, Kisumu, Kenya. [Zielinski-Gutierrez, Emily] Ctr Dis Control & Prevent, Div Global HIV & AIDS, Kisumu, Kenya. [Zeh, Clement; Mills, Lisa A.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Kisumu, Kenya. [Laserson, Kayla F.] Ctr Dis Control & Prevent, Div Global Hlth Protect, Ctr Global Hlth, Atlanta, GA USA. RP Phillips-Howard, PA (reprint author), Univ Liverpool, Liverpool Sch Trop Med, Dept Clin Sci, Pembroke Pl, Liverpool L3 5QA, Merseyside, England. EM Penelope.Phillips-Howard@lstmed.ac.uk FU Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta; Division of Global HIV and Aids through President's Emergency Plan for AIDS Relief (PEPFAR) funds; UK-Joint Global Health Trials award FX Members of Gem community are thanked for their participation. Field staff, data managers, and laboratory and administrative staff are thanked for their assistance. We are very grateful to Deborah Gust, Division of HIV/AIDS Prevention at the Centers for Disease Control and Prevention, Atlanta, for reviewing the manuscript. KEMRI/CDC HDSS is a member of the International Network for the Demographic Evaluation of Populations and Their Health in Developing Countries (IN-DEPTH) Network. Funding for the HIV study came from the Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, and from the Division of Global HIV and Aids through President's Emergency Plan for AIDS Relief (PEPFAR) funds to KEMRI. The Director of KEMRI has approved this manuscript. PPH, EN, CO, and FO were partially funded by a UK-Joint Global Health Trials award for the menstrual feasibility study. The findings and conclusions in this paper are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. NR 43 TC 4 Z9 4 U1 1 U2 2 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-9996 EI 1931-843X J9 J WOMENS HEALTH JI J. Womens Health PD OCT 1 PY 2015 VL 24 IS 10 BP 801 EP 811 DI 10.1089/jwh.2014.5031 PG 11 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies SC Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies GA CV0LF UT WOS:000363941500004 PM 26296186 ER PT J AU Lindsley, MD Ahn, Y McCotter, O Gade, L Hurst, SF Brandt, ME Park, BJ Litvintseva, AP AF Lindsley, Mark D. Ahn, YoonJi McCotter, Orion Gade, Lalitha Hurst, Steven F. Brandt, Mary E. Park, Benjamin J. Litvintseva, Anastasia P. TI Evaluation of the Specificity of Two Enzyme Immunoassays for Coccidioidomycosis by Using Sera from a Region of Endemicity and a Region of Nonendemicity SO CLINICAL AND VACCINE IMMUNOLOGY LA English DT Article ID ANTIBODIES; IMMITIS; SEROLOGY; DISEASE; TESTS AB Coccidioidomycosis (CM), a serious life-threatening fungal infection endemic to arid regions of the western United States and Mexico, can be challenging to diagnose in a timely manner. Commercially developed enzyme immunoassays (EIAs) (from Meridian Biosciences and Immuno-Mycologics [IMMY]) have provided faster, simpler means for serodiagnosis; however, independent evaluations have questioned EIA specificity, particularly IgM-positive/IgG-negative results. This study was conducted to evaluate EIA specificity among persons residing in Puerto Rico (n = 534), where CM is not endemic (who were not likely to have been exposed to Coccidioides spp.), compared to blood bank donors residing in Arizona (n = 1,218), where CM is endemic. Upon comparing serum reactivity between Puerto Rico and Arizona, the Meridian EIA showed a significant difference in IgG reactivity (0.37% versus 3.6%; P < 0.001) but not IgM reactivity (3.4% versus 2.4%; P = 0.31). No IgM-/IgG-reactive sera were detected among sera from Puerto Rico, compared to 7 (0.57%) sera from Arizona. Similar results were observed using the IMMY EIA, although significantly (P = 0.03) fewer IgM-reactive sera from Arizona were observed, compared to the Meridian EIA. EIA-reactive sera were also evaluated by immunodiffusion before and after 3- to 4-fold concentration of the sera. These results demonstrate that elevated IgG EIA reactivity is present in sera from healthy individuals in regions of endemicity and that IgM EIA reactivity observed in sera from individuals residing outside regions of endemicity is most likely nonspecific. Other criteria, including clinical and microbiological evaluations, should be taken into account when interpreting results from surveillance studies and other reporting measures. C1 [Lindsley, Mark D.; Ahn, YoonJi; McCotter, Orion; Gade, Lalitha; Hurst, Steven F.; Brandt, Mary E.; Litvintseva, Anastasia P.] Ctr Dis Control & Prevent, Mycot Dis Branch, Atlanta, GA USA. [Park, Benjamin J.] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA USA. RP Lindsley, MD (reprint author), Ctr Dis Control & Prevent, Mycot Dis Branch, Atlanta, GA USA. EM mlindsley@cdc.gov NR 15 TC 0 Z9 0 U1 5 U2 7 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 1556-6811 EI 1556-679X J9 CLIN VACCINE IMMUNOL JI Clin. Vaccine Immunol. PD OCT PY 2015 VL 22 IS 10 BP 1090 EP 1095 DI 10.1128/CVI.00375-15 PG 6 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA CU8SR UT WOS:000363814100002 PM 26245352 ER PT J AU Roen, EL Wang, Y Calafat, AM Wang, S Margolis, A Herbstman, J Hoepner, LA Rauh, V Perera, FP AF Roen, Emily L. Wang, Ya Calafat, Antonia M. Wang, Shuang Margolis, Amy Herbstman, Julie Hoepner, Lori A. Rauh, Virginia Perera, Frederica P. TI Bisphenol A exposure and behavioral problems among inner city children at 7-9 years of age SO ENVIRONMENTAL RESEARCH LA English DT Article DE Bisphenol A; Child behavior; Sex-specific ID URINARY PHTHALATE METABOLITE; PRENATAL EXPOSURE; PREGNANT-WOMEN; DEVELOPMENTAL EXPOSURE; SEXUAL-DIFFERENTIATION; TEMPORAL VARIABILITY; NEONATAL EXPOSURE; MICE; DISRUPTION; PREDICTORS AB Background: Bisphenol A (BPA) is a ubiquitous endocrine disrupting compound. Several experimental and epidemiological studies suggest that gestational BPA exposure can lead to neurodevelopmental and behavioral problems in early-life, but results have been inconsistent. We previously reported that prenatal BPA exposure may affect child behavior and differently among boys and girls at ages 3-5 years. Objectives: We investigated the association of prenatal and early childhood BPA exposure with behavioral outcomes in 7-9 year old minority children and hypothesized that we would observe the same sex-specific pattern observed at earlier ages. Methods: African-American and Dominican women enrolled in an inner-city prospective cohort study and their children were followed from mother's pregnancy through children's age 7-9 years. Women during the third trimester of pregnancy and children at ages 3 and 5 years provided spot urine samples. BPA exposure was categorized by tertiles of BPA urinary concentrations. The Child Behavioral Checklist (CBCL) was administered at ages 7 and 9 to assess multiple child behavior domains. Associations between behavior and prenatal (maternal) BPA concentrations and behavior and postnatal (child) BPA concentration were assessed via Poisson regression in models stratified by sex. These models accounted for potential confounders including prenatal or postnatal urinary BPA concentrations, child age at CBCL assessment, ethnicity, gestational age, maternal intelligence, maternal education and demoralization, quality of child's home environment, prenatal environmental tobacco smoke exposure, and prenatal mono-n-butyl phthalate concentration. Results: The direction of the associations differed between boys and girls. Among boys (n=115), high prenatal BPA concentration (upper tertile vs. lower two tertiles) was associated with increased internalizing (beta=0.41, p < 0.0001) and externalizing composite scores (beta=0.40, p < 0.0001) and with their corresponding individual syndrome scales. There was a general decrease in scores among girls that was significant for the internalizing composite score (beta= -0.17, p=0.04) (n=135). After accounting for possible selection bias, the results remained consistent for boys. Conversely, high postnatal BPA concentration was associated with increased behaviors on both the internalizing composite (beta=0.30, p=0.0002) and externalizing composite scores (beta=0.33, p < 0.0001) and individual subscores in girls but fewer symptoms in boys. These results remained significant in girls after accounting for selection bias. Conclusion: These results suggest BPA exposure may affect childhood behavioral outcomes in a sex-specific manner and differently depending on timing of exposure. (C) 2015 Elsevier Inc. All rights reserved. C1 [Roen, Emily L.; Herbstman, Julie; Hoepner, Lori A.; Perera, Frederica P.] Columbia Univ, Mailman Sch Publ Hlth, Dept Environm Hlth Sci, New York, NY 10032 USA. [Roen, Emily L.; Wang, Ya; Wang, Shuang; Margolis, Amy; Herbstman, Julie; Hoepner, Lori A.; Rauh, Virginia; Perera, Frederica P.] Columbia Univ, Columbia Ctr Childrens Environm Hlth, New York, NY 10032 USA. [Wang, Ya; Wang, Shuang] Columbia Univ, Mailman Sch Publ Hlth, Dept Biostat, New York, NY 10032 USA. [Calafat, Antonia M.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA. [Margolis, Amy] Columbia Univ, Div Child & Adolescent Psychiat, New York, NY 10032 USA. [Margolis, Amy] Columbia Univ, Ctr Dev Neuropsychiat, Dept Psychiat, New York State Psychiat Inst, New York, NY 10032 USA. [Margolis, Amy] Columbia Univ, Coll Phys & Surg, New York, NY 10032 USA. [Rauh, Virginia] Columbia Univ, Heilbrunn Dept Populat & Family Hlth, New York, NY 10032 USA. RP Perera, FP (reprint author), Columbia Univ, Mailman Sch Publ Hlth, Dept Environm Hlth Sci, 722W 168th St, New York, NY 10032 USA. EM fpp1@columbia.edu FU National Institute for Environmental Health Sciences (NIEHS); U.S. Environmental Protection Agency (US EPA) [NIEHS/EPA P01ES09600/R82702701, NIEHS/EPA P01ES09600/RD832141, NIEHS/EPA P01ES09600/RD834509, NIEHS R01ES08977]; US EPA [RD83209] FX Funding was provided by the National Institute for Environmental Health Sciences (NIEHS) and the U.S. Environmental Protection Agency (US EPA): NIEHS/EPA P01ES09600/R82702701, NIEHS/EPA P01ES09600/RD832141, NIEHS/EPA P01ES09600/RD834509, NIEHS R01ES08977. This publication was also made possible in part by US EPA Grant RD83209, the John and Wendy Neu Family Foundation, the Trustees of the Blanchette Hooker Rockefeller Fund, and the Passport Foundation (Environmental Health Science Innovation Fund). NR 61 TC 14 Z9 15 U1 5 U2 20 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0013-9351 EI 1096-0953 J9 ENVIRON RES JI Environ. Res. PD OCT PY 2015 VL 142 BP 739 EP 745 DI 10.1016/j.envres.2015.01.014 PG 7 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA CU5WN UT WOS:000363602800087 PM 25724466 ER PT J AU Cragan, JD Young, BA Correa, A AF Cragan, Janet D. Young, Bessie A. Correa, Adolfo TI Renin-Angiotensin System Blocker Fetopathy SO JOURNAL OF PEDIATRICS LA English DT Editorial Material ID EARLY-PREGNANCY; MALFORMATIONS; INHIBITION; EXPOSURE C1 [Cragan, Janet D.] Ctr Dis Control & Prevent, Div Birth Defects & Dev Disabil, Atlanta, GA USA. [Young, Bessie A.] Univ Washington, Dept Med, Div Nephrol, Vet Affairs Puget Sound,Kidney Res Inst, Seattle, WA 98195 USA. [Correa, Adolfo] Univ Mississippi, Med Ctr, Dept Med, Jackson, MS 39216 USA. [Correa, Adolfo] Univ Mississippi, Med Ctr, Dept Pediat, Jackson, MS 39216 USA. RP Correa, A (reprint author), Univ Mississippi, Med Ctr, Dept Med, 2500 North State St, Jackson, MS 39216 USA. EM acorrea@umc.edu FU Intramural CDC HHS [CC999999]; NCCIH NIH HHS [U01 AT006239, 1U01AT006239-01]; NHLBI NIH HHS [HHSN268201300049C, HHSN268201300046C]; NIDDK NIH HHS [R01 DK102134, 1R01DK102134-01]; NIMHD NIH HHS [P60MD002249-01, P60 MD002249]; PHS HHS [HHSN268201300047C, HHSN268201300049C, HHSN268201300046C] NR 18 TC 0 Z9 0 U1 0 U2 2 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-3476 EI 1097-6833 J9 J PEDIATR-US JI J. Pediatr. PD OCT PY 2015 VL 167 IS 4 BP 792 EP 794 DI 10.1016/j.jpeds.2015.07.024 PG 3 WC Pediatrics SC Pediatrics GA CU5BE UT WOS:000363545800004 PM 26254838 ER PT J AU Ahn, A Edwards, KM Grijalva, CG Self, WH Zhu, YW Chappell, JD Arnold, SR McCullers, JA Ampofo, K Pavia, AT Bramley, AM Jain, S Williams, DJ AF Ahn, Anna Edwards, Kathryn M. Grijalva, Carlos G. Self, Wesley H. Zhu, Yuwei Chappell, James D. Arnold, Sandra R. McCullers, Jonathan A. Ampofo, Krow Pavia, Andrew T. Bramley, Anna M. Jain, Seema Williams, Derek J. TI Secondhand Smoke Exposure and Illness Severity among Children Hospitalized with Pneumonia SO JOURNAL OF PEDIATRICS LA English DT Article ID ENVIRONMENTAL TOBACCO-SMOKE; NUTRITION EXAMINATION SURVEY; COMMUNITY-ACQUIRED PNEUMONIA; 3RD NATIONAL-HEALTH; PARENTAL SMOKING; UNITED-STATES; RESPIRATORY HEALTH; US POPULATION; ASTHMA; RISK AB Objective To assess the relationship between secondhand smoke (SHS) exposure and disease severity among children hospitalized with community-acquired pneumonia (CAP). Study design Children hospitalized with clinical and radiographic CAP were enrolled between January 1, 2010, and June 30, 2012 at 3 hospitals in Tennessee and Utah as part of the Centers for Disease Control and Prevention's Etiology of Pneumonia in the Community study. Household SHS exposure was defined based on the number of smokers in the child's home. Outcomes included hospital length of stay, intensive care unit admission, and mechanical ventilation. Proportional hazards and logistic regression models were used to assess associations between SHS exposure and outcomes. All models were adjusted for age, sex, race/ethnicity, household education level, government insurance, comorbidities, enrollment site, year, and season. Results Of the 2219 children included in the study, SHS exposure was reported in 785 (35.4%), including 325 (14.8%) with >= 2 smokers in the home. Compared with nonexposed children, the children exposed to >= 2 smokers had longer length of stay (median, 70.4 hours vs 64.4 hours; adjusted hazard ratio, 0.85; 95% CI, 0.75-0.97) and were more likely to receive intensive care (25.2% vs 20.9%; aOR, 1.44; 95% CI, 1.05-1.96), but not mechanical ventilation. Outcomes in children exposed to only 1 household smoker were similar to those in nonexposed children. Conclusion Children hospitalized with CAP from households with >= 2 smokers had a longer length of stay and were more likely to require intensive care compared with children from households with no smokers, suggesting that they experienced greater pneumonia severity. C1 [Ahn, Anna; Edwards, Kathryn M.; Williams, Derek J.] Monroe Carell Jr Childrens Hosp Vanderbilt, Nashville, TN USA. [Ahn, Anna; Edwards, Kathryn M.; Chappell, James D.; Williams, Derek J.] Vanderbilt Univ, Sch Med, Dept Pediat, Nashville, TN 37212 USA. [Grijalva, Carlos G.] Vanderbilt Univ, Sch Med, Dept Hlth Policy, Nashville, TN 37212 USA. [Self, Wesley H.] Vanderbilt Univ, Sch Med, Dept Emergency Med, Nashville, TN 37212 USA. [Zhu, Yuwei] Vanderbilt Univ, Sch Med, Dept Biostat, Nashville, TN 37212 USA. [Chappell, James D.] Vanderbilt Univ, Sch Med, Dept Pathol Microbiol & Immunol, Nashville, TN 37212 USA. [Arnold, Sandra R.; McCullers, Jonathan A.] LeBonheur Childrens Hosp, Dept Pediat, Memphis, TN USA. [Arnold, Sandra R.; McCullers, Jonathan A.] Univ Tennessee, Ctr Hlth Sci, Memphis, TN 38163 USA. [McCullers, Jonathan A.] St Jude Childrens Res Hosp, Dept Pediat, Memphis, TN 38105 USA. [Ampofo, Krow; Pavia, Andrew T.] Primary Childrens Med Ctr, Dept Pediat, Salt Lake City, UT 84103 USA. [Ampofo, Krow; Pavia, Andrew T.] Univ Utah, Sch Med, Salt Lake City, UT USA. [Bramley, Anna M.; Jain, Seema] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. RP Williams, DJ (reprint author), 1161 21st Ave S,S2323 Med Ctr North, Nashville, TN 37232 USA. EM derek.williams@vanderbilt.edu FU National Institute of Allergy and Infectious Diseases/National Institutes of Health (NIH) [K23AI104779]; Influenza Division in the National Center for Immunizations and Respiratory Diseases/Centers for Disease Control and Prevention (CDC) FX Supported by the National Institute of Allergy and Infectious Diseases/National Institutes of Health (NIH; K23AI104779 [to D.W.]). The EPIC study was supported by the Influenza Division in the National Center for Immunizations and Respiratory Diseases/Centers for Disease Control and Prevention (CDC) through cooperative agreements with each study site and was based on a competitive research funding opportunity. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the CDC or the National Institutes of Health. The authors declare no conflicts of interest. NR 33 TC 3 Z9 4 U1 2 U2 3 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-3476 EI 1097-6833 J9 J PEDIATR-US JI J. Pediatr. PD OCT PY 2015 VL 167 IS 4 BP 869 EP + DI 10.1016/j.jpeds.2015.06.049 PG 7 WC Pediatrics SC Pediatrics GA CU5BE UT WOS:000363545800020 PM 26231828 ER PT J AU Spengler, JR Patel, JR Chakrabarti, AK Zivcec, M Garcia-Sastre, A Spiropoulou, CF Bergeron, E AF Spengler, Jessica R. Patel, Jenish R. Chakrabarti, Ayan K. Zivcec, Marko Garcia-Sastre, Adolfo Spiropoulou, Christina F. Bergeron, Eric TI RIG-I Mediates an Antiviral Response to Crimean-Congo Hemorrhagic Fever Virus SO JOURNAL OF VIROLOGY LA English DT Article ID INNATE IMMUNE-RESPONSES; DOUBLE-STRANDED-RNA; SIN-NOMBRE HANTAVIRUS; INDUCIBLE GENE-I; PROTEIN P56; VIRAL-RNA; INTERFERON; RECOGNITION; MDA5; RECEPTORS AB In the cytoplasm, the retinoic acid-inducible gene I (RIG-I) senses the RNA genomes of several RNA viruses. RIG-I binds to viral RNA, eliciting an antiviral response via the cellular adaptor MAVS. Crimean-Congo hemorrhagic fever virus (CCHFV), a negative-sense RNA virus with a 5'-monophosphorylated genome, is a highly pathogenic zoonotic agent with significant public health implications. We found that, during CCHFV infection, RIG-I mediated a type I interferon (IFN) response via MAVS. Interfering with RIG-I signaling reduced IFN production and IFN-stimulated gene expression and increased viral replication. Immunostimulatory RNA was isolated from CCHFV-infected cells and from virion preparations, and RIG-I coimmunoprecipitation of infected cell lysates isolated immunostimulatory CCHFV RNA. This report serves as the first description of a pattern recognition receptor for CCHFV and highlights a critical signaling pathway in the antiviral response to CCHFV. IMPORTANCE CCHFV is a tick-borne virus with a significant public health impact. In order for cells to respond to virus infection, they must recognize the virus as foreign and initiate antiviral signaling. To date, the receptors involved in immune recognition of CCHFV are not known. Here, we investigate and identify RIG-I as a receptor involved in initiating an antiviral response to CCHFV. This receptor initially was not expected to play a role in CCHFV recognition because of characteristics of the viral genome. These findings are important in understanding the antiviral response to CCHFV and support continued investigation into the spectrum of potential viruses recognized by RIG-I. C1 [Spengler, Jessica R.; Chakrabarti, Ayan K.; Zivcec, Marko; Spiropoulou, Christina F.; Bergeron, Eric] Ctr Dis Control & Prevent, Viral Special Pathogens Branch, Div High Consequence Pathogens & Pathol, Atlanta, GA 30333 USA. [Patel, Jenish R.; Garcia-Sastre, Adolfo] Icahn Sch Med Mt Sinai, Dept Microbiol, New York, NY 10029 USA. [Patel, Jenish R.; Garcia-Sastre, Adolfo] Icahn Sch Med Mt Sinai, Global Hlth & Emerging Pathogens Inst, New York, NY 10029 USA. [Garcia-Sastre, Adolfo] Icahn Sch Med Mt Sinai, Dept Med, Div Infect Dis, New York, NY 10029 USA. RP Bergeron, E (reprint author), Ctr Dis Control & Prevent, Viral Special Pathogens Branch, Div High Consequence Pathogens & Pathol, Atlanta, GA 30333 USA. EM ebergeron@cdc.gov OI Spengler, Jessica R./0000-0002-5383-0513; Garcia-Sastre, Adolfo/0000-0002-6551-1827; Zivcec, Marko/0000-0003-4337-8487; Bergeron, Eric/0000-0003-3398-8628 FU CDC; NIAID [R01AI109008]; National Institutes of Health Loan Repayment Award FX These studies were supported by the CDC and a CDC foundation project funded by NIAID grant R01AI109008. This research was supported in part by an appointment to the ASM/CDC Postdoctoral Research Fellowship Program and to the Research Participation Program at the Centers for Disease Control and Prevention, administered by the Oak Ridge Institute for Science and Education through an interagency agreement between the U.S. Department of Energy and the CDC(to J.R.S.), and by a National Institutes of Health Loan Repayment Award (to J.R.S.). NR 49 TC 1 Z9 1 U1 0 U2 1 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0022-538X EI 1098-5514 J9 J VIROL JI J. Virol. PD OCT PY 2015 VL 89 IS 20 BP 10219 EP 10229 DI 10.1128/JVI.01643-15 PG 11 WC Virology SC Virology GA CU3ZG UT WOS:000363464700007 PM 26223644 ER PT J AU Pulit-Penaloza, JA Sun, XJ Creager, HM Zeng, H Belser, JA Maines, TR Tumpey, TM AF Pulit-Penaloza, Joanna A. Sun, Xiangjie Creager, Hannah M. Zeng, Hui Belser, Jessica A. Maines, Taronna R. Tumpey, Terrence M. TI Pathogenesis and Transmission of Novel Highly Pathogenic Avian Influenza H5N2 and H5N8 Viruses in Ferrets and Mice SO JOURNAL OF VIROLOGY LA English DT Article ID BRONCHIAL EPITHELIAL-CELLS; RESPIRATORY-TRACT; SYSTEMIC SPREAD; UNITED-STATES; SOUTH-KOREA; A VIRUSES; HUMANS; RECEPTORS; INFECTION; EVOLUTION AB A novel highly pathogenic avian influenza (HPAI) H5N8 virus, first detected in January 2014 in poultry and wild birds in South Korea, has spread throughout Asia and Europe and caused outbreaks in Canada and the United States by the end of the year. The spread of H5N8 and the novel reassortant viruses, H5N2 and H5N1 (H5Nx), in domestic poultry across multiple states in the United States pose a potential public health risk. To evaluate the potential of cross-species infection, we determined the pathogenicity and transmissibility of two Asian-origin H5Nx viruses in mammalian animal models. The newly isolated H5N2 and H5N8 viruses were able to cause severe disease in mice only at high doses. Both viruses replicated efficiently in the upper and lower respiratory tracts of ferrets; however, the clinical symptoms were generally mild, and there was no evidence of systemic dissemination of virus to multiple organs. Moreover, these influenza H5Nx viruses lacked the ability to transmit between ferrets in a direct contact setting. We further assessed viral replication kinetics of the novel H5Nx viruses in a human bronchial epithelium cell line, Calu-3. Both H5Nx viruses replicated to a level comparable to a human seasonal H1N1 virus, but significantly lower than a virulent Asian-lineage H5N1 HPAI virus. Although the recently isolated H5N2 and H5N8 viruses displayed moderate pathogenicity in mammalian models, their ability to rapidly spread among avian species, reassort, and generate novel strains underscores the need for continued risk assessment in mammals. IMPORTANCE In 2015, highly pathogenic avian influenza (HPAI) H5 viruses have caused outbreaks in domestic poultry in multiple U.S. states. The economic losses incurred with H5N8 and H5N2 subtype virus infection have raised serious concerns for the poultry industry and the general public due to the potential risk of human infection. This recent outbreak underscores the need to better understand the pathogenesis and transmission of these viruses in mammals, which is an essential component of pandemic risk assessment. This study demonstrates that the newly isolated H5N2 and H5N8 viruses lacked the ability to transmit between ferrets and exhibited low to moderate virulence in mammals. In human bronchial epithelial (Calu-3) cells, both H5N8 and H5N2 viruses replicated to a level comparable to a human seasonal virus, but significantly lower than a virulent Asian-lineage H5N1 (A/Thailand/16/2004) virus. The results of this study are important for the evaluation of public health risk. C1 [Pulit-Penaloza, Joanna A.; Sun, Xiangjie; Creager, Hannah M.; Zeng, Hui; Belser, Jessica A.; Maines, Taronna R.; Tumpey, Terrence M.] Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Creager, Hannah M.] Emory Univ, Microbiol & Mol Genet Grad Program, Atlanta, GA 30322 USA. RP Tumpey, TM (reprint author), Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. EM tft9@cdc.gov FU Oak Ridge Institute for Science and Education FX J.A.P.-P., X.S., and H.M.C. are supported by the Oak Ridge Institute for Science and Education. NR 47 TC 11 Z9 11 U1 3 U2 15 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0022-538X EI 1098-5514 J9 J VIROL JI J. Virol. PD OCT PY 2015 VL 89 IS 20 BP 10286 EP 10293 DI 10.1128/JVI.01438-15 PG 8 WC Virology SC Virology GA CU3ZG UT WOS:000363464700012 PM 26223637 ER PT J AU Rocheleau, CM Bertke, SJ Lawson, CC Romitti, PA Sanderson, WT Malik, S Lupo, PJ Desrosiers, TA Bell, E Druschel, C Correa, A Reefhuis, J AF Rocheleau, Carissa M. Bertke, Stephen J. Lawson, Christina C. Romitti, Paul A. Sanderson, Wayne T. Malik, Sadia Lupo, Philip J. Desrosiers, Tania A. Bell, Erin Druschel, Charlotte Correa, Adolfo Reefhuis, Jennita CA Natl Birth Defects Prevention Stud TI Maternal occupational pesticide exposure and risk of congenital heart defects in the national birth defects prevention study SO BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY LA English DT Article DE congenital heart defects; pesticides; occupation; birth defects ID ASSOCIATION; DISEASE; CLASSIFICATION; MALFORMATIONS AB BACKGROUNDCongenital heart defects (CHDs) are common birth defects, affecting approximately 1% of live births. Pesticide exposure has been suggested as an etiologic factor for CHDs, but previous results were inconsistent. METHODSWe examined maternal occupational exposure to fungicides, insecticides, and herbicides for 3328 infants with CHDs and 2988 unaffected control infants of employed mothers using data for 1997 through 2002 births from the National Birth Defects Prevention Study, a population-based multisite case-control study. Potential pesticide exposure from 1 month before conception through the first trimester of pregnancy was assigned by an expert-guided task-exposure matrix and job history details self-reported by mothers. Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated using multivariable logistic regression. RESULTSMaternal occupational exposure to pesticides was not associated with CHDs overall. In examining specific CHD subtypes compared with controls, some novel associations were observed with higher estimated pesticide exposure: insecticides only and secundum atrial septal defect (OR=1.8; 95% CI, 1.3-2.7, 40 exposed cases); both insecticides and herbicides and hypoplastic left heart syndrome (OR=5.1; 95% CI, 1.7-15.3, 4 exposed cases), as well as pulmonary valve stenosis (OR=3.6; 95% CI, 1.3-10.1, 5 exposed cases); and insecticides, herbicides, and fungicides and tetralogy of Fallot (TOF) (OR=2.2; 95% CI, 1.2-4.0, 13 exposed cases). CONCLUSIONBroad pesticide exposure categories were not associated with CHDs overall, but examining specific CHD subtypes revealed some increased odds ratios. These results highlight the importance of examining specific CHDs separately. Because of multiple comparisons, additional work is needed to verify these associations. Birth Defects Research (Part A) 103:823-833, 2015. (c) 2014 Wiley Periodicals, Inc. C1 [Rocheleau, Carissa M.; Bertke, Stephen J.; Lawson, Christina C.] NIOSH, Ctr Dis Control & Prevent, Cincinnati, OH 45226 USA. [Romitti, Paul A.] Univ Iowa, Dept Epidemiol, Coll Publ Hlth, Iowa City, IA USA. [Sanderson, Wayne T.] Univ Kentucky, Dept Epidemiol, Lexington, KY USA. [Malik, Sadia] Univ Arkansas Med Sci, Little Rock, AR 72205 USA. [Lupo, Philip J.] Baylor Coll Med, Dept Pediat, Sect Hematol & Oncol, Houston, TX 77030 USA. [Desrosiers, Tania A.] Univ N Carolina, Dept Epidemiol, Gillings Sch Global Publ Hlth, Chapel Hill, NC USA. [Bell, Erin; Druschel, Charlotte] SUNY Albany, Sch Publ Hlth, Dept Epidemiol & Biostat, Rensselaer, NY USA. [Druschel, Charlotte] New York State Dept Hlth, Ctr Environm Hlth, Albany, NY USA. [Correa, Adolfo] Univ Mississippi, Med Ctr, Dept Med, Jackson, MS 39216 USA. [Correa, Adolfo] Univ Mississippi, Med Ctr, Dept Pediat, Jackson, MS 39216 USA. [Reefhuis, Jennita] Natl Ctr Birth Defects & Dev Disabil, Ctr Dis Control & Prevent, Atlanta, GA USA. RP Rocheleau, CM (reprint author), NIOSH, 1090 Tusculum Ave,MS R-15, Cincinnati, OH 45226 USA. EM crocheleau@cdc.gov OI Lupo, Philip/0000-0003-0978-5863 FU Centers for Disease Control and Prevention [U01/DD000492, U01/DD001035, 200-2000-08018]; National Institute for Occupational Safety and Health FX This work was funded by grants sponsored by the Centers for Disease Control and Prevention (U01/DD000492 and U01/DD001035), and supported in part by contract 200-2000-08018 from the Centers for Disease Control and Prevention and the National Institute for Occupational Safety and Health. NR 27 TC 1 Z9 1 U1 0 U2 9 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1542-0752 EI 1542-0760 J9 BIRTH DEFECTS RES A JI Birth Defects Res. Part A-Clin. Mol. Teratol. PD OCT PY 2015 VL 103 IS 10 BP 823 EP 833 DI 10.1002/bdra.23351 PG 11 WC Developmental Biology; Toxicology SC Developmental Biology; Toxicology GA CU0JP UT WOS:000363202400001 PM 26033688 ER PT J AU Dababneh, F Nichols, EK Asad, M Haddad, Y Notzon, F Anderson, R AF Dababneh, Faris Nichols, Erin K. Asad, Majed Haddad, Yousef Notzon, Francis Anderson, Robert TI Improving mortality data in Jordan: a 10 year review SO BULLETIN OF THE WORLD HEALTH ORGANIZATION LA English DT Article ID DEATH AB Problem Before 2003 there was substantial underreporting of deaths in Jordan. The death notification form did not comply with World Health Organization (WHO) guidelines and information on the cause of death was often missing, incomplete or inaccurate. Approach A new mortality surveillance system to determine the causes of death was implemented in 2003 and a unit for coding causes of death was established at the ministry of health. Local setting Jordan is a middle-income country with a population of 6.4 million people. Approximately 20 000 deaths were registered per year between 2005 and 2011. Relevant changes In 2001, the ministry of health organized the first meeting on Jordan's mortality system, which yielded a five-point plan to improve mortality statistics. Using the recommendations produced from this meeting, in 2003 the ministry of health initiated a mortality statistics improvement project in collaboration with international partners. Jordan has continued to improve its mortality reporting system, with annual reporting since 2004. Reports are based on more than 70% of reported deaths. The quality of cause-of-death information has improved, with only about 6% of deaths allocated to symptoms and ill-defined conditions a substantial decrease from the percentage before 2001 (40%). Mortality information is now submitted to WHO following international standards. Lessons learnt After 10 years of mortality surveillance in Jordan, the reporting has improved and the information has been used by various health programmes throughout Jordan. C1 [Dababneh, Faris; Asad, Majed; Haddad, Yousef] Minist Hlth, Directorate Informat & Res, Amman, Jordan. [Nichols, Erin K.; Notzon, Francis; Anderson, Robert] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, United States Publ Hlth Serv, Hyattsville, MD USA. RP Nichols, EK (reprint author), Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, United States Publ Hlth Serv, Hyattsville, MD USA. EM EKNichols@cdc.gov FU Ministry of Health of Jordan; WHO; CDC; USAID FX Ministry of Health of Jordan, WHO, CDC and USAID. NR 13 TC 0 Z9 0 U1 0 U2 0 PU WORLD HEALTH ORGANIZATION PI GENEVA 27 PA MARKETING AND DISSEMINATION, CH-1211 GENEVA 27, SWITZERLAND SN 0042-9686 EI 1564-0604 J9 B WORLD HEALTH ORGAN JI Bull. World Health Organ. PD OCT PY 2015 VL 93 IS 10 BP 727 EP 731 DI 10.2471/BLT.14.137190 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CU2PE UT WOS:000363364600017 ER PT J AU Decker, SL AF Decker, Sandra L. TI Acceptance of New Medicaid Patients by Primary Care Physicians and Experiences with Physician Availability among Children on Medicaid or the Children's Health Insurance Program SO HEALTH SERVICES RESEARCH LA English DT Article DE State health policies; primary care; access; demand; utilization of services ID FEES; PARTICIPATION; ACCESS; REIMBURSEMENT; SERVICES; BEHAVIOR AB Objective. To estimate the relationship between physicians' acceptance of new Medicaid patients and access to health care. Data Sources. The National Ambulatory Medical Care Survey (NAMCS) Electronic Health Records Survey and the National Health Interview Survey (NHIS) 2011/2012. Study Design. Linear probability models estimated the relationship between measures of experiences with physician availability among children on Medicaid or the Children's Health Insurance Program (CHIP) from the NHIS and state-level estimates of the percent of primary care physicians accepting new Medicaid patients from the NAMCS, controlling for other factors. Principal Findings. Nearly 16 percent of children with a significant health condition or development delay had a doctor's office or clinic indicate that the child's health insurance was not accepted in states with less than 60 percent of physicians accepting new Medicaid patients, compared to less than 4 percent in states with at least 75 percent of physicians accepting new Medicaid patients. Adjusted estimates and estimates for other measures of access to care were similar. Conclusions. Measures of experiences with physician availability for children on Medicaid/CHIP were generally good, though better in states where more primary care physicians accepted new Medicaid patients. C1 Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. RP Decker, SL (reprint author), Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, 3311 Toledo Rd, Hyattsville, MD 20782 USA. EM SDecker@cdc.gov NR 22 TC 4 Z9 4 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0017-9124 EI 1475-6773 J9 HEALTH SERV RES JI Health Serv. Res. PD OCT PY 2015 VL 50 IS 5 BP 1508 EP 1527 DI 10.1111/1475-6773.12288 PG 20 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA CT8JX UT WOS:000363063300008 PM 25683869 ER PT J AU Hahn, RA Truman, BI AF Hahn, Robert A. Truman, Benedict I. TI Education Improves Public Health and Promotes Health Equity SO INTERNATIONAL JOURNAL OF HEALTH SERVICES LA English DT Article DE equity; disparities; social determinant; health in all policies ID SELF-RATED HEALTH; UNITED-STATES; ADULT HEALTH; INTERVENTION; INTELLIGENCE; ASSOCIATION; MORTALITY; INCOME AB This article describes a framework and empirical evidence to support the argument that educational programs and policies are crucial public health interventions. Concepts of education and health are developed and linked, and we review a wide range of empirical studies to clarify pathways of linkage and explore implications. Basic educational expertise and skills, including fundamental knowledge, reasoning ability, emotional self-regulation, and interactional abilities, are critical components of health. Moreover, education is a fundamental social determinant of health - an upstream cause of health. Programs that close gaps in educational outcomes between low-income or racial and ethnic minority populations and higher-income or majority populations are needed to promote health equity. Public health policy makers, health practitioners and educators,and departments of health and education can collaborate to implement educational programs and policies for which systematic evidence indicates clear public health benefits. C1 [Hahn, Robert A.; Truman, Benedict I.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Hahn, RA (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,MS E-69, Atlanta, GA 30333 USA. EM rah1@cdc.gov FU Intramural CDC HHS [CC999999] NR 67 TC 2 Z9 2 U1 0 U2 12 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0020-7314 EI 1541-4469 J9 INT J HEALTH SERV JI Int. J. Health Serv. PD OCT PY 2015 VL 45 IS 4 BP 657 EP 678 DI 10.1177/0020731415585986 PG 22 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA CU1KD UT WOS:000363279200006 PM 25995305 ER PT J AU Dziuban, EJ Raizes, E Koumans, EH AF Dziuban, Eric J. Raizes, Elliot Koumans, Emilia H. TI A farewell to didanosine: harm reduction and cost savings by eliminating use of didanosine SO INTERNATIONAL JOURNAL OF STD & AIDS LA English DT Article DE Didanosine; HIV; AIDS; treatment; antiretroviral therapy; reverse transcriptase inhibitors; drug toxicity; drug interactions ID NONCIRRHOTIC PORTAL-HYPERTENSION; HUMAN-IMMUNODEFICIENCY-VIRUS; HIV-INFECTED PATIENTS; ANTIRETROVIRAL THERAPY; DISCONTINUATION; MUTATIONS; TYPE-1 AB Didanosine (ddI) is a nucleoside reverse transcriptase inhibitor associated with adverse events and public health concerns which have diminished its place in HIV clinical practice, particularly in resource-rich settings. While international guidelines do not contain ddI-containing regimens in preferred first- or second-line antiretroviral therapy (ART), there is no guidance for management of patients currently on ddI. In 2012 at least 20 countries purchased a total of $1-2 million of ddI. Drug purchase data in that year show 3.2-10.3 times higher costs for ddI compared to lamivudine (3TC). Given issues of multiple toxicities, monitoring, drug interactions, inconvenience, and virologic efficacy, as well as cost and formulary concerns, national (including resource-limited setting) ART programmes should consider complete phase-out of ddI. C1 [Dziuban, Eric J.; Raizes, Elliot; Koumans, Emilia H.] Ctr Dis Control & Prevent, Div Global HIV AIDS, Atlanta, GA 30333 USA. RP Dziuban, EJ (reprint author), Ctr Dis Control & Prevent, Div Global HIV AIDS, 1600 Clifton Rd NE,Mailstop E-04, Atlanta, GA 30333 USA. EM esv8@cdc.gov FU Intramural CDC HHS [CC999999] NR 24 TC 1 Z9 1 U1 0 U2 5 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0956-4624 EI 1758-1052 J9 INT J STD AIDS JI Int. J. STD AIDS PD OCT PY 2015 VL 26 IS 12 BP 903 EP 906 DI 10.1177/0956462414554433 PG 4 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CU0PD UT WOS:000363218600009 PM 25281538 ER PT J AU Zhou, H Burkom, H Winston, CA Dey, A Ajani, U AF Zhou, Hong Burkom, Howard Winston, Carla A. Dey, Achintya Ajani, Umed TI Practical comparison of aberration detection algorithms for biosurveillance systems SO JOURNAL OF BIOMEDICAL INFORMATICS LA English DT Article DE Aberration detection; Algorithm; Control chart; Poisson regression; Biosurveillance ID SYNDROMIC SURVEILLANCE; AUTOMATED BIOSURVEILLANCE; INFECTIOUS-DISEASE; OUTBREAK DETECTION; MODELS; EARS AB National syndromic surveillance systems require optimal anomaly detection methods. For method performance comparison, we injected multi-day signals stochastically drawn from lognormal distributions into time series of aggregated daily visit counts from the U.S. Centers for Disease Control and Prevention's BioSense syndromic surveillance system. The time series corresponded to three different syndrome groups: rash, upper respiratory infection, and gastrointestinal illness. We included a sample of facilities with data reported every day and with median daily syndromic counts I over the entire study period. We compared anomaly detection methods of five control chart adaptations, a linear regression model and a Poisson regression model. We assessed sensitivity and timeliness of these methods for detection of multi-day signals. At a daily background alert rate of 1% and 2%, the sensitivities and timeliness ranged from 24 to 77% and 3.3 to 6.1 days, respectively. The overall sensitivity and timeliness increased substantially after stratification by weekday versus weekend and holiday. Adjusting the baseline syndromic count by the total number of facility visits gave consistently improved sensitivity and timeliness without stratification, but it provided better performance when combined with stratification. The daily syndrome/total-visit proportion method did not improve the performance. In general, alerting based on linear regression outperformed control chart based methods. A Poisson regression model obtained the best sensitivity in the series with high-count data. Published by Elsevier Inc. C1 [Zhou, Hong; Dey, Achintya; Ajani, Umed] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Burkom, Howard] Johns Hopkins Appl Phys Lab, Laurel, MD 20723 USA. [Winston, Carla A.] Vet Hlth Adm, Off Publ Hlth Surveillance & Res, Palo Alto, CA 94304 USA. RP Zhou, H (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd, Atlanta, GA 30333 USA. EM fwd6@cdc.gov OI burkom, howard/0000-0003-0667-9467 NR 26 TC 0 Z9 0 U1 2 U2 3 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1532-0464 EI 1532-0480 J9 J BIOMED INFORM JI J. Biomed. Inform. PD OCT PY 2015 VL 57 BP 446 EP 455 DI 10.1016/j.jbi.2015.08.023 PG 10 WC Computer Science, Interdisciplinary Applications; Medical Informatics SC Computer Science; Medical Informatics GA CU3PO UT WOS:000363437500038 PM 26334478 ER PT J AU Laing, KJ Russell, RM Dong, LC Schmid, DS Stern, M Magaret, A Haas, JG Johnston, C Wald, A Koelle, DM AF Laing, Kerry J. Russell, Ronnie M. Dong, Lichun Schmid, D. Scott Stern, Michael Magaret, Amalia Haas, Jurgen G. Johnston, Christine Wald, Anna Koelle, David M. TI Zoster Vaccination Increases the Breadth of CD4(+) T Cells Responsive to Varicella Zoster Virus SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE epitopes; T lymphocytes; vaccine; varicella zoster virus ID SUBUNIT CANDIDATE VACCINE; RECURRENT GENITAL HERPES; OLDER-ADULTS; FUNCTIONAL-CHARACTERIZATION; SAFETY; IMMUNOGENICITY; ANTIGENS; INFECTION; EFFICACY; IMMUNITY AB Background. The live, attenuated varicella vaccine strain (vOka) is the only licensed therapeutic vaccine. Boost of varicella zoster virus (VZV)-specific cellular immunity is a likely mechanism of action. We examined memory CD4(+) T-cell responses to each VZV protein at baseline and after zoster vaccination. Methods. Serial blood samples were collected from 12 subjects vaccinated with Zostavax and immunogenicity confirmed by ex vivo VZV-specific T-cell and antibody assays. CD4(+) T-cell lines enriched for VZV specificity were generated and probed for proliferative responses to every VZV protein and selected peptide sets. Results. Zoster vaccination increased the median magnitude (2.3-fold) and breadth (4.2-fold) of VZV-specific CD4(+) T cells one month post-vaccination. Both measures declined by 6 months. The most prevalent responses at baseline included VZV open reading frames (ORFs) 68, 4, 37, and 63. After vaccination, responses to ORFs 40, 67, 9, 59, 12, 62, and 18 were also prevalent. The immunogenicity of ORF9 and ORF18 were confirmed using peptides, defining a large number of discrete CD4(+) T-cell epitopes. Conclusions. The breadth and magnitude of the VZV-specific CD4(+) T-cell response increase after zoster vaccination. In addition to glycoprotein E (ORF68), we identified antigenic ORFs that may be useful components of subunit vaccines. C1 [Laing, Kerry J.; Russell, Ronnie M.; Dong, Lichun; Johnston, Christine; Wald, Anna; Koelle, David M.] Univ Washington, Dept Med, Seattle, WA 98195 USA. [Schmid, D. Scott] Ctr Dis Control & Prevent, Atlanta, GA USA. [Stern, Michael; Magaret, Amalia; Wald, Anna; Koelle, David M.] Univ Washington, Dept Lab Med, Seattle, WA 98195 USA. [Magaret, Amalia] Univ Washington, Dept Biostat, Seattle, WA 98195 USA. [Magaret, Amalia; Johnston, Christine; Wald, Anna; Koelle, David M.] Fred Hutchinson Canc Res Ctr, Vaccine & Infect Dis Div, Seattle, WA 98104 USA. [Haas, Jurgen G.] Univ Edinburgh, Div Infect & Pathway Med, Edinburgh EH8 9YL, Midlothian, Scotland. [Wald, Anna] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Koelle, David M.] Univ Washington, Dept Global Hlth, Seattle, WA 98195 USA. [Koelle, David M.] Benaroya Res Inst, Seattle, WA USA. RP Laing, KJ (reprint author), Univ Washington, Dept Med, 750 Republican St,Mail Stop 358061, Seattle, WA 98195 USA. EM laingk@u.washington.edu RI Wald, Anna/B-6272-2012; Laing, Kerry/C-2211-2008; Koelle, David/Q-6529-2016 OI Wald, Anna/0000-0003-3486-6438; Laing, Kerry/0000-0001-9245-5325; Koelle, David/0000-0003-1255-9023 FU University of Washington Royalty Research Fund; National Institutes of Health [R01AI094019, P01AI30731, UL1TR000423, HHSN272201400049C] FX This work was supported by the University of Washington Royalty Research Fund and National Institutes of Health grants R01AI094019, P01AI30731, and UL1TR000423, and contract HHSN272201400049C. NR 49 TC 11 Z9 11 U1 1 U2 5 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD OCT 1 PY 2015 VL 212 IS 7 BP 1022 EP 1031 DI 10.1093/infdis/jiv164 PG 10 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA CU0FK UT WOS:000363191300003 PM 25784732 ER PT J AU George, SL Wong, MA Dube, TJT Boroughs, KL Stovall, JL Luy, BE Haller, AA Osorio, JE Eggemeyer, LM Irby-Moore, S Frey, SE Huang, CYH Stinchcomb, DT AF George, Sarah L. Wong, Mimi A. Dube, Tina J. T. Boroughs, Karen L. Stovall, Janae L. Luy, Betty E. Haller, Aurelia A. Osorio, Jorge E. Eggemeyer, Linda M. Irby-Moore, Sharon Frey, Sharon E. Huang, Claire Y. -H. Stinchcomb, Dan T. TI Safety and Immunogenicity of a Live Attenuated Tetravalent Dengue Vaccine Candidate in Flavivirus-Naive Adults: A Randomized, Double-Blinded Phase 1 Clinical Trial SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE Dengue vaccine; live attenuated tetravalent; neutralizing antibody; viremia; clinical trial ID HEMORRHAGIC-FEVER; PDK-53 VIRUS; DENVAX; VOLUNTEERS; EFFICACY; ANTIBODY; FORMULATIONS; PATHOGENESIS; ENHANCEMENT; RECOMBINANT AB Background. Dengue viruses (DENVs) infect > 300 million people annually, causing 96 million cases of dengue disease and 22 000 deaths [ 1]. A safe vaccine that protects against DENV disease is a global health priority [ 2]. Methods. We enrolled 72 flavivirus-naive healthy adults in a phase 1 double-blinded, randomized, placebo-controlled dose-escalation trial (low and high dose) of a live attenuated recombinant tetravalent dengue vaccine candidate (TDV) given in 2 doses 90 days apart. Volunteers were followed for safety, vaccine component viremia, and development of neutralizing antibodies to the 4 DENV serotypes. Results. The majority of adverse events were mild, with no vaccine-related serious adverse events. Vaccinees reported injection site pain (52% vs 17%) and erythema (73% vs 25%) more frequently than placebo recipients. Low levels of TDV-serotype 2 (TDV-2), TDV-3, and TDV-4 viremia were observed after the first but not second administration of vaccine. Overall seroconversion rates and geometric mean neutralization titers after 2 doses were 84.2% and 54.1, respectively, for DENV serotype 1 (DENV-1); 92.1% and 292.8, respectively, for DENV-2; 86.8% and 32.3, respectively, for DENV-3; and 71.1% and 15.0, respectively, for DENV-4. More than 90.0% of high-dose recipients had trivalent or broader responses. Conclusions. TDV was generally well tolerated, induced trivalent or broader neutralizing antibodies to DENV in most flavivirus-naive vaccinees, and is undergoing further development. C1 [George, Sarah L.; Eggemeyer, Linda M.; Irby-Moore, Sharon; Frey, Sharon E.] St Louis Univ, Sch Med, Dept Internal Med, Div Infect Dis Allergy & Immunol, St Louis, MO 63104 USA. [George, Sarah L.] St Louis Vet Adm Med Ctr, St Louis, MO USA. [Wong, Mimi A.; Dube, Tina J. T.] EMMES Corp, Rockville, MD USA. [Boroughs, Karen L.; Stovall, Janae L.; Luy, Betty E.; Haller, Aurelia A.; Huang, Claire Y. -H.] Ctr Dis Control & Prevent, Div Vector Borne Dis, Arboviral Dis Branch, Ft Collins, CO USA. [Osorio, Jorge E.; Stinchcomb, Dan T.] Takeda Vaccines, Deerfield, IL USA. RP George, SL (reprint author), St Louis Univ, Sch Med, Div Infect Dis Allergy & Immunol, Doisy Res Bldg,1100 S Grand Blvd, St Louis, MO 63104 USA. EM georgesl@slu.edu FU Vaccine and Treatment Evaluation Units, NIAID, NIH [N01-AI25464] FX This work was supported by the Vaccine and Treatment Evaluation Units, NIAID, NIH (contract N01-AI25464). NR 38 TC 11 Z9 13 U1 0 U2 5 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD OCT 1 PY 2015 VL 212 IS 7 BP 1032 EP 1041 DI 10.1093/infdis/jiv179 PG 10 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA CU0FK UT WOS:000363191300004 PM 25791116 ER PT J AU Flint, M Goodman, CH Bearden, S Blau, DM Amman, BR Basile, AJ Belser, JA Bergeron, E Bowen, MD Brault, AC Campbell, S Chakrabarti, AK Dodd, KA Erickson, BR Freeman, MM Gibbons, A Guerrero, LW Klena, JD Lash, RR Lo, MK McMullan, LK Momoh, G Massally, JL Goba, A Paddock, CD Priestley, RA Pyle, M Rayfield, M Russell, BJ Salzer, JS Sanchez, AJ Schuh, AJ Sealy, TK Steinau, M Stoddard, RA Taboy, C Turnsek, M Wang, D Zemtsova, GE Zivcec, M Spiropoulou, CF Stroher, U Towner, JS Nichol, ST Bird, BH AF Flint, Mike Goodman, Christin H. Bearden, Scott Blau, Dianna M. Amman, Brian R. Basile, Alison J. Belser, Jessica A. Bergeron, Eric Bowen, Michael D. Brault, Aaron C. Campbell, Shelley Chakrabarti, Ayan K. Dodd, Kimberly A. Erickson, Bobbie R. Freeman, Molly M. Gibbons, Aridth Guerrero, Lisa W. Klena, John D. Lash, R. Ryan Lo, Michael K. McMullan, Laura K. Momoh, Gbetuwa Massally, James L. Goba, Augustine Paddock, Christopher D. Priestley, Rachael A. Pyle, Meredith Rayfield, Mark Russell, Brandy J. Salzer, Johanna S. Sanchez, Angela J. Schuh, Amy J. Sealy, Tara K. Steinau, Martin Stoddard, Robyn A. Taboy, Celine Turnsek, Maryann Wang, David Zemtsova, Galina E. Zivcec, Marko Spiropoulou, Christina F. Stroeher, Ute Towner, Jonathan S. Nichol, Stuart T. Bird, Brian H. TI Ebola Virus Diagnostics: The US Centers for Disease Control and Prevention Laboratory in Sierra Leone, August 2014 to March 2015 SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE Ebola; diagnostics; field laboratory ID REVERSE TRANSCRIPTION-PCR; HEMORRHAGIC-FEVER; MARBURG VIRUSES; CONGO AB In August 2014, the Viral Special Pathogens Branch of the US Centers for Disease Control and Prevention established a field laboratory in Sierra Leone in response to the ongoing Ebola virus outbreak. Through March 2015, this laboratory tested >12 000 specimens from throughout Sierra Leone. We describe the organization and procedures of the laboratory located in Bo, Sierra Leone. C1 [Flint, Mike; Amman, Brian R.; Bergeron, Eric; Campbell, Shelley; Chakrabarti, Ayan K.; Erickson, Bobbie R.; Gibbons, Aridth; Guerrero, Lisa W.; Lo, Michael K.; McMullan, Laura K.; Schuh, Amy J.; Sealy, Tara K.; Taboy, Celine; Zivcec, Marko; Spiropoulou, Christina F.; Stroeher, Ute; Towner, Jonathan S.; Nichol, Stuart T.; Bird, Brian H.] Ctr Dis Control & Prevent, Viral Special Pathogens, Atlanta, GA 30333 USA. [Blau, Dianna M.] Ctr Dis Control & Prevent, Infect Dis Pathol, Atlanta, GA 30333 USA. [Belser, Jessica A.; Wang, David] Ctr Dis Control & Prevent, Influenza Div, Immunol & Pathogenesis, Atlanta, GA 30333 USA. [Bowen, Michael D.] Ctr Dis Control & Prevent, Gastroenteritis & Resp Virus Lab, Atlanta, GA 30333 USA. [Freeman, Molly M.; Turnsek, Maryann] Ctr Dis Control & Prevent, Enter Dis Lab, Atlanta, GA 30333 USA. [Lash, R. Ryan] Ctr Dis Control & Prevent, Travelers Hlth, Atlanta, GA 30333 USA. [Paddock, Christopher D.; Priestley, Rachael A.; Zemtsova, Galina E.] Ctr Dis Control & Prevent, Rickettsial Zoonoses, Atlanta, GA 30333 USA. [Pyle, Meredith] Ctr Dis Control & Prevent, Res Lab, Atlanta, GA 30333 USA. [Rayfield, Mark] Ctr Dis Control & Prevent, Global Dis Detect, Atlanta, GA 30333 USA. [Salzer, Johanna S.] Ctr Dis Control & Prevent, Poxvirus & Rabies, Atlanta, GA 30333 USA. [Steinau, Martin] Ctr Dis Control & Prevent, Chron Viral Dis, Atlanta, GA 30333 USA. [Stoddard, Robyn A.] Ctr Dis Control & Prevent, Bacterial Special Pathogens Branches, Atlanta, GA 30333 USA. [Sanchez, Angela J.] Ctr Dis Control & Prevent, Off Technol & Innovat, Atlanta, GA 30333 USA. [Goodman, Christin H.; Basile, Alison J.; Brault, Aaron C.; Russell, Brandy J.] Ctr Dis Control & Prevent, Arboviral Dis, Ft Collins, CO USA. [Bearden, Scott] Ctr Dis Control & Prevent, Bacterial Dis Branches, Ft Collins, CO USA. [Dodd, Kimberly A.] Univ Calif Davis, Sch Vet Med, Davis, CA USA. [Klena, John D.] Ctr Dis Control & Prevent, Div Global Hlth Protect, Beijing, Peoples R China. [Momoh, Gbetuwa; Massally, James L.; Goba, Augustine] Kenema Govt Hosp, Minist Hlth & Sanitat, Freetown, Sierra Leone. RP Nichol, ST (reprint author), Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Div High Consequence Pathogens & Pathol, Viral Special Pathogens Branch, 1600 Clifton Rd,Mail Stop G-14, Atlanta, GA 30333 USA. EM stn1@cdc.gov OI Lo, Michael/0000-0002-0409-7896; Flint, Michael/0000-0002-5373-787X; Zivcec, Marko/0000-0003-4337-8487 FU International Rescue Committee FX This article is dedicated to all those working to combat the EBOV outbreak, especially the medical technicians and phlebotomists who have risked their lives drawing blood and delivering it to the laboratory. We thank Issah French, Will Pooley, Mambu Momoh, Ian Crozier, Kaci Hickox, Frederique Jacquerioz, Suzanne Donovan, Lewis Rubinson, Darrio Gramuglia, Henry Kyobe, and Monia Sayah; your courage and devotion to helping those afflicted has awed and inspired us. We thank Tanya Klimova for assistance with editing this manuscript. We thank the Sierra Leone Ministry of Health and Sanitation, the World Health Organization and the Global Outbreak Alert and Response Network for organizing the deployment of Centers for Disease Control and Prevention (CDC) scientists to Sierra Leone. We thank the nurses, physicians, and other employees of Kenema Government Hospital and MSF Bo. We also thank the International Rescue Committee for their support of Bo Government Hospital. The laboratory scientist pictured in Figure 3 provided explicit written consent for use of the image. NR 12 TC 9 Z9 9 U1 1 U2 18 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD OCT 1 PY 2015 VL 212 SU 2 BP S350 EP S358 DI 10.1093/infdis/jiv361 PG 9 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA CU0EP UT WOS:000363189100036 PM 26232439 ER PT J AU Knust, B Schafer, IJ Wamala, J Nyakarahuka, L Okot, C Shoemaker, T Dodd, K Gibbons, A Balinandi, S Tumusiime, A Campbell, S Newman, E Lasry, E DeClerck, H Boum, Y Makumbi, I Bosa, HK Mbonye, A Aceng, JR Nichol, ST Stroher, U Rollin, PE AF Knust, Barbara Schafer, Ilana J. Wamala, Joseph Nyakarahuka, Luke Okot, Charles Shoemaker, Trevor Dodd, Kimberly Gibbons, Aridth Balinandi, Stephen Tumusiime, Alex Campbell, Shelley Newman, Edmund Lasry, Estrella DeClerck, Hilde Boum, Yap Makumbi, Issa Bosa, Henry Kyobe Mbonye, Anthony Aceng, Jane Ruth Nichol, Stuart T. Stroeher, Ute Rollin, Pierre E. TI Multidistrict Outbreak of Marburg Virus Disease-Uganda, 2012 SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE Marburg virus; filoviruses; hemorrhagic fever; zoonotic disease; outbreak response ID EBOLA HEMORRHAGIC-FEVER; SANS-FRONTIERES INTERVENTION; RISK-FACTORS; ANGOLA; CONGO; TRANSMISSION; UIGE; INFECTION; EPIDEMIC; FEATURES AB In October 2012, a cluster of illnesses and deaths was reported in Uganda and was confirmed to be an outbreak of Marburg virus disease (MVD). Patients meeting the case criteria were interviewed using a standard investigation form, and blood specimens were tested for evidence of acute or recent Marburg virus infection by reverse transcription-polymerase chain reaction (RT-PCR) and antibody enzyme-linked immunosorbent assay. The total count of confirmed and probable MVD cases was 26, of which 15 (58%) were fatal. Four of 15 laboratory- confirmed cases (27%) were fatal. Case patients were located in 4 different districts in Uganda, although all chains of transmission originated in Ibanda District, and the earliest case detected had an onset in July 2012. No zoonotic exposures were identified. Symptoms significantly associated with being a MVD case included hiccups, anorexia, fatigue, vomiting, sore throat, and difficulty swallowing. Contact with a case patient and attending a funeral were also significantly associated with being a case. Average RT-PCR cycle threshold values for fatal cases during the acute phase of illness were significantly lower than those for nonfatal cases. Following the institution of contact tracing, active case surveillance, care of patients with isolation precautions, community mobilization, and rapid diagnostic testing, the outbreak was successfully contained 14 days after its initial detection. C1 [Knust, Barbara; Schafer, Ilana J.; Dodd, Kimberly; Gibbons, Aridth; Campbell, Shelley; Nichol, Stuart T.; Stroeher, Ute; Rollin, Pierre E.] Ctr Dis Control & Prevent, Viral Special Pathogens Branch, Atlanta, GA USA. [Lasry, Estrella] Med Sans Frontieres, New York, NY USA. [Wamala, Joseph; Makumbi, Issa; Mbonye, Anthony; Aceng, Jane Ruth] Uganda Minist Hlth, Kampala, Uganda. [Okot, Charles] World Hlth Org, Kampala, Uganda. [Bosa, Henry Kyobe] Uganda Minist Hlth, Kampala, Uganda. [Bosa, Henry Kyobe] Uganda People Def Force, Kampala, Uganda. [Nyakarahuka, Luke] Ctr Dis Control & Prevent, Uganda Virus Res Inst, Entebbe, Uganda. [Shoemaker, Trevor; Balinandi, Stephen; Tumusiime, Alex] Ctr Dis Control & Prevent, Viral Special Pathogens Branch, Entebbe, Uganda. [Boum, Yap] EpiCtr, Mbarara, Uganda. [Newman, Edmund] Publ Hlth England, Microbiol Serv Res, Porton Down, England. [DeClerck, Hilde] Publ Hlth England, Microbiol Serv Res, Porton Down, England. RP Knust, B (reprint author), 1600 Clifton Rd NE,MS G-14, Atlanta, GA 30333 USA. EM bknust@cdc.gov FU emergency budgets of CDC; Uganda Ministry of Health; Medecins sans Frontieres; World Health Organization FX The outbreak response was funded through emergency budgets of the CDC, the Uganda Ministry of Health, Medecins sans Frontieres, the World Health Organization, and other relevant responding agencies. NR 30 TC 1 Z9 1 U1 0 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD OCT 1 PY 2015 VL 212 SU 2 BP S119 EP S128 DI 10.1093/infdis/jiv351 PG 10 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA CU0EP UT WOS:000363189100007 PM 26209681 ER PT J AU Spengler, JR McElroy, AK Harmon, JR Stroher, U Nichol, ST Spiropoulou, CF AF Spengler, Jessica R. McElroy, Anita K. Harmon, Jessica R. Stroeher, Ute Nichol, Stuart T. Spiropoulou, Christina F. TI Relationship Between Ebola Virus Real-Time Quantitative Polymerase Chain Reaction-Based Threshold Cycle Value and Virus Isolation From Human Plasma SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE Ebola; qRT-PCR; virus isolation ID HEMORRHAGIC-FEVER; OUTBREAK; PROTECTION; DISEASE; ANGOLA AB We performed a longitudinal analysis of plasma samples obtained from 4 patients with Ebola virus (EBOV) disease (EVD) to determine the relationship between the real-time quantitative reverse transcriptase polymerase chain reaction (qRT-PCR)-based threshold cycle (Ct) value and the presence of infectious EBOV. EBOV was not isolated from plasma samples with a Ct value of >35.5 or >12 days after onset of symptoms. EBOV was not isolated from plasma samples in which anti-EBOV nucleoprotein immunoglobulin G was detected. These data demonstrate the utility of interpreting qRT-PCR results in the context of the course of EBOV infection and associated serological responses for patient-management decisions. C1 [Spengler, Jessica R.; McElroy, Anita K.; Harmon, Jessica R.; Stroeher, Ute; Nichol, Stuart T.; Spiropoulou, Christina F.] Emory Univ, Ctr Dis Control & Prevent, Viral Special Pathogens Branch, Div High Consequence Pathogens & Pathol, Atlanta, GA 30322 USA. [McElroy, Anita K.; Harmon, Jessica R.] Emory Univ, Div Pediat Infect Dis, Atlanta, GA 30322 USA. RP Spiropoulou, CF (reprint author), Ctr Dis Control & Prevent, Viral Special Pathogens Branch, Div High Consequence Pathogens & Pathol, 1600 Clifton Rd NE,MS G14, Atlanta, GA 30333 USA. EM ccs8@cdc.gov OI Spengler, Jessica R./0000-0002-5383-0513 FU National Institutes of Health [K12 HD072245]; Burroughs Wellcome (career award) FX This work was supported by the National Institutes of Health (loan repayment award to J. R. S. and grant K12 HD072245 to A. K. M) and Burroughs Wellcome (career award to A. K. M.). NR 17 TC 11 Z9 11 U1 0 U2 4 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD OCT 1 PY 2015 VL 212 SU 2 BP S346 EP S349 DI 10.1093/infdis/jiv187 PG 4 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA CU0EP UT WOS:000363189100035 PM 25941333 ER PT J AU Sprecher, AG Caluwaerts, A Draper, M Feldmann, H Frey, CP Funk, RH Kobinger, G Le Duc, JW Spiropoulou, C Williams, WJ AF Sprecher, Armand G. Caluwaerts, An Draper, Mike Feldmann, Heinz Frey, Clifford P. Funk, Renee H. Kobinger, Gary Le Duc, James W. Spiropoulou, Christina Williams, Warren Jon TI Personal Protective Equipment for Filovirus Epidemics: A Call for Better Evidence SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE Ebola; heat stress disorders; hemorrhagic fever; protective clothing AB Personal protective equipment (PPE) is an important part of worker protection during filovirus outbreaks. The need to protect against a highly virulent fluid-borne pathogen in the tropical environment imposes a heat stress on the wearer that is itself a safety risk. No evidence supports the choice of PPE employed in recent outbreaks, and standard testing procedures employed by the protective garment industry do not well simulate filovirus exposure. Further research is needed to determine the appropriate PPE for filoviruses and the heat stress that it imposes. C1 [Sprecher, Armand G.; Caluwaerts, An] Med Sans Frontieres, Operat Ctr Brussels, B-1050 Brussels, Belgium. [Draper, Mike] Microgard Ltd, Kingston Upon Hull, Yorks, England. [Feldmann, Heinz] NIAID, Rocky Mt Labs, Virol Lab, Div Intramural Res,NIH, Hamilton, MT 59840 USA. [Frey, Clifford P.] Personal Safety Div, St Paul, MN USA. [Funk, Renee H.] NIOSH, Emergency Preparedness & Response Off, Atlanta, GA USA. [Kobinger, Gary] Publ Hlth Agcy Canada, Natl Microbiol Lab, Special Pathogens, Winnipeg, MB, Canada. [Le Duc, James W.] Univ Texas Med Branch, Galveston Natl Lab, Galveston, TX 77555 USA. [Spiropoulou, Christina] Ctr Dis Control & Prevent, Viral Special Pathogens Branch, Atlanta, GA USA. [Williams, Warren Jon] NIOSH, Human Factors & Ergon Lab, Pittsburgh, PA USA. RP Sprecher, AG (reprint author), Med Sans Frontieres, Dept Med, Rue Arbre Benit 46, B-1050 Brussels, Belgium. EM armand.sprecher@brussels.msf.org FU Intramural Research Program of National Institute of Allergy and Infectious Diseases, National Institutes of Health. FX No financial support was provided from any external agency for this meeting. H. F. is supported by the Intramural Research Program of the National Institute of Allergy and Infectious Diseases, National Institutes of Health. NR 7 TC 9 Z9 9 U1 0 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD OCT 1 PY 2015 VL 212 SU 2 BP S98 EP S100 DI 10.1093/infdis/jiv153 PG 3 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA CU0EP UT WOS:000363189100004 PM 25821225 ER PT J AU Lisko, JG Tran, H Stanfill, SB Blount, BC Watson, CH AF Lisko, Joseph G. Tran, Hang Stanfill, Stephen B. Blount, Benjamin C. Watson, Clifford H. TI Chemical Composition and Evaluation of Nicotine, Tobacco Alkaloids, pH, and Selected Flavors in E-Cigarette Cartridges and Refill Solutions SO NICOTINE & TOBACCO RESEARCH LA English DT Article ID ELECTRONIC CIGARETTES; DELIVERY-SYSTEMS; REPLACEMENT LIQUIDS; MASS-SPECTROMETRY; PRODUCTS; ADULTS AB Introduction: Electronic cigarette (e-cigarette) use is increasing dramatically in developed countries, but little is known about these rapidly evolving products. This study analyzed and evaluated the chemical composition including nicotine, tobacco alkaloids, pH, and flavors in 36 e-liquids brands from 4 manufacturers. Methods: We determined the concentrations of nicotine, alkaloids, and select flavors and measured pH in solutions used in e-cigarettes. E-cigarette products were chosen based upon favorable consumer approval ratings from online review websites. Quantitative analyses were performed using strict quality assurance/quality control validated methods previously established by our lab for the measurement of nicotine, alkaloids, pH, and flavors. Results: Three-quarters of the products contained lower measured nicotine levels than the stated label values (6%-42% by concentration). The pH for e-liquids ranged from 5.1-9.1. Minor tobacco alkaloids were found in all samples containing nicotine, and their relative concentrations varied widely among manufacturers. A number of common flavor compounds were analyzed in all e-liquids. Conclusions: Free nicotine levels calculated from the measurement of pH correlated with total nicotine content. The direct correlation between the total nicotine concentration and pH suggests that the alkalinity of nicotine drives the pH of e-cigarette solutions. A higher percentage of nicotine exists in the more absorbable free form as total nicotine concentration increases. A number of products contained tobacco alkaloids at concentrations that exceed U.S. pharmacopeia limits for impurities in nicotine used in pharmaceutical and food products. C1 [Lisko, Joseph G.; Tran, Hang; Stanfill, Stephen B.; Blount, Benjamin C.; Watson, Clifford H.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Div Sci Lab, Tobacco & Volatiles Branch, Atlanta, GA 30341 USA. RP Lisko, JG (reprint author), Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Div Sci Lab, Tobacco & Volatiles Branch, 4770 Buford Highway, Atlanta, GA 30341 USA. EM jlisko@cdc.gov FU Centers for Disease Control and Prevention FX Funding was provided internally through the Centers for Disease Control and Prevention. NR 45 TC 19 Z9 19 U1 12 U2 37 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1462-2203 EI 1469-994X J9 NICOTINE TOB RES JI Nicotine Tob. Res. PD OCT PY 2015 VL 17 IS 10 BP 1270 EP 1278 DI 10.1093/ntr/ntu279 PG 9 WC Substance Abuse; Public, Environmental & Occupational Health SC Substance Abuse; Public, Environmental & Occupational Health GA CT9ZQ UT WOS:000363175500013 PM 25636907 ER PT J AU Hubbs, AF Cummings, KJ McKernan, LT Dankovic, DA Park, RM Kreiss, K AF Hubbs, Ann F. Cummings, Kristin J. McKernan, Lauralynn Taylor Dankovic, David A. Park, Robert M. Kreiss, Kathleen TI Comment on Farsalinos et al., "Evaluation of Electronic Cigarette Liquids and Aerosol for the Presence of Selected Inhalation Toxins" SO NICOTINE & TOBACCO RESEARCH LA English DT Letter ID OBSTRUCTIVE PULMONARY-DISEASE; 2,3-PENTANEDIONE; RATS C1 [Hubbs, Ann F.] NIOSH, Hlth Effects Lab Div, Morgantown, WV 26505 USA. [Cummings, Kristin J.; Kreiss, Kathleen] NIOSH, Div Resp Dis Studies, Morgantown, WV 26505 USA. [McKernan, Lauralynn Taylor; Dankovic, David A.; Park, Robert M.] NIOSH, Educ & Informat Div, Cincinnati, OH 45226 USA. RP Hubbs, AF (reprint author), NIOSH, Ctr Dis Control, Hlth Effects Lab Div, 1095 Willowdale Rd, Morgantown, WV 26505 USA. EM ahubbs@cdc.gov NR 10 TC 2 Z9 2 U1 2 U2 4 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1462-2203 EI 1469-994X J9 NICOTINE TOB RES JI Nicotine Tob. Res. PD OCT PY 2015 VL 17 IS 10 BP 1288 EP 1289 DI 10.1093/ntr/ntu338 PG 2 WC Substance Abuse; Public, Environmental & Occupational Health SC Substance Abuse; Public, Environmental & Occupational Health GA CT9ZQ UT WOS:000363175500017 PM 25586777 ER PT J AU Ward, BW Martinez, ME AF Ward, Brian W. Martinez, Michael E. TI Health Insurance Status and Psychological Distress among US Adults Aged 18-64Years SO STRESS AND HEALTH LA English DT Article DE psychological distress; health insurance coverage; uninsured; United States ID INTERVIEW SURVEY; UNITED-STATES; STRESS; POPULATION; UNDERINSURANCE; PERSPECTIVES; COVERAGE; DISEASE; SAMPLE; TRENDS AB The purpose of this research was to examine the relationship between psychological distress and aspects of health insurance status, including lack of coverage, types of coverage and disruption in coverage, among US adults. Data from the 2001-2010 National Health Interview Survey were used to conduct analyses representative of the US adult population aged 18-64years. Multivariate analyses regressed psychological distress on health insurance status while controlling for covariates. Adults with private or no health insurance coverage had lower levels of psychological distress than those with public/other coverage. Adults who recently (1year) experienced a change in health insurance status had higher levels of distress than those who had not recently experienced a change. An interaction effect indicated that the relationship between recent change in health insurance status and distress was not dependent on whether an adult had private versus public/other coverage. However, for adults who had not experienced a change in status in the past year, the average absolute level of distress is higher among those with no coverage versus private coverage. Although significant relationships between psychological distress and health insurance status were identified, their strength was modest, with other demographic and health condition covariates also being potential sources of distress. Published 2014. This article is a U.S. Government work and is in the public domain in the USA. C1 [Ward, Brian W.; Martinez, Michael E.] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Div Hlth Interview Stat, Hyattsville, MD 20782 USA. RP Ward, BW (reprint author), Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Div Hlth Interview Stat, 3311 Toledo Rd,Room 2330, Hyattsville, MD 20782 USA. EM bwward@cdc.gov FU Intramural CDC HHS [CC999999] NR 39 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1532-3005 EI 1532-2998 J9 STRESS HEALTH JI Stress Health PD OCT PY 2015 VL 31 IS 4 BP 324 EP 335 DI 10.1002/smi.2559 PG 12 WC Psychology, Applied; Psychiatry; Psychology SC Psychology; Psychiatry GA CT8UC UT WOS:000363091000009 PM 24403273 ER PT J AU Herrenkohl, TI Higgins, DJ Merrick, MT Leeb, RT AF Herrenkohl, Todd I. Higgins, Daryl J. Merrick, Melissa T. Leeb, Rebecca T. TI Positioning a public health framework at the intersection of child maltreatment and intimate partner violence SO CHILD ABUSE & NEGLECT LA English DT Article DE child maltreatment; interpersonal violence; prevention; public health ID ABUSE; NEGLECT C1 [Herrenkohl, Todd I.] Univ Washington, Sch Social Work, Seattle, WA 98105 USA. [Higgins, Daryl J.] Australian Inst Family Studies, Melbourne, Vic, Australia. [Merrick, Melissa T.] Ctr Dis Control & Prevent, Div Violence Prevent, Atlanta, GA USA. [Leeb, Rebecca T.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. RP Herrenkohl, TI (reprint author), Univ Washington, Sch Social Work, 4101 15th Ave NE, Seattle, WA 98105 USA. EM tih@u.washington.edu NR 11 TC 4 Z9 4 U1 0 U2 1 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0145-2134 EI 1873-7757 J9 CHILD ABUSE NEGLECT JI Child Abuse Negl. PD OCT PY 2015 VL 48 BP 22 EP 28 DI 10.1016/j.chiabu.2015.04.013 PG 7 WC Family Studies; Psychology, Social; Social Work SC Family Studies; Psychology; Social Work GA CT6MT UT WOS:000362927800003 PM 25979133 ER PT J AU Tempia, S Walaza, S Cohen, AL von Mollendorf, C Moyes, J McAnerney, JM Cohen, C AF Tempia, Stefano Walaza, Sibongile Cohen, Adam L. von Mollendorf, Claire Moyes, Jocelyn McAnerney, Johanna M. Cohen, Cheryl TI Mortality Associated With Seasonal and Pandemic Influenza Among Pregnant and Nonpregnant Women of Childbearing Age in a High-HIV-Prevalence Setting-South Africa, 1999-2009 SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE influenza; HIV; pregnancy; mortality; South Africa ID ASIAN INFLUENZA; VIRUS; VACCINATION; INFANTS; ADULTS; INFECTION; SEVERITY; EPIDEMIC; DEATHS; YOUNG AB Background. Information on the mortality burden associated with seasonal and pandemic influenza virus infection among pregnant women is scarce in most settings, particularly in sub-Saharan Africa where pregnancy and maternal mortality rates as well as human immunodeficiency virus (HIV) prevalence are elevated. Methods. We used an ecological study design to estimate the seasonal and A(H1N1) pdm09 influenza-associated mortality among pregnant and nonpregnant women of childbearing age (15-49 years) by HIV serostatus during 1999-2009 in South Africa. Mortality rates were expressed per 100 000 person-years. Results. During 1999-2009, the estimated mean annual seasonal influenza-associated mortality rates were 12.6 (123 deaths) and 7.3 (914 deaths) among pregnant and nonpregnant women, respectively. Among pregnant women, the estimated mean annual seasonal influenza-associated mortality rates were 74.9 (109 deaths) among HIV-infected and 1.5 (14 deaths) among HIV-uninfected individuals. Among nonpregnant women, the estimated mean annual seasonal influenza-associated mortality rate was 41.2 (824 deaths) among HIV-infected and 0.9 (90 deaths) among HIV-uninfected individuals. Pregnant women experienced an increased risk of seasonal influenza-associated mortality compared with nonpregnant women (relative risk [RR], 2.8; 95% confidence interval [CI], 1.7-3.9). In 2009, the estimated influenza A(H1N1) pdm09-associated mortality rates were 19.3 (181 deaths) and 9.4 (1189 deaths) among pregnant and nonpregnant women, respectively (RR, 3.2; 95% CI, 2.3-4.1). Conclusions. Among women of childbearing age, the majority of estimated seasonal influenza-associated deaths occurred in HIV-infected individuals. Pregnant women experienced an increased risk of death associated with seasonal and A(H1N1) pdm09 influenza infection compared with nonpregnant women. C1 [Tempia, Stefano; Cohen, Adam L.] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. [Tempia, Stefano; Cohen, Adam L.] Ctr Dis Control & Prevent, Influenza Program, Atlanta, GA USA. [Tempia, Stefano; Walaza, Sibongile; von Mollendorf, Claire; Moyes, Jocelyn; McAnerney, Johanna M.; Cohen, Cheryl] Natl Inst Communicable Dis, Ctr Resp Dis & Meningitis, Natl Hlth Lab Serv, ZA-2131 Johannesburg, Gauteng, South Africa. [Walaza, Sibongile; von Mollendorf, Claire; Moyes, Jocelyn; Cohen, Cheryl] Univ Witwatersrand, Sch Publ Hlth, Fac Hlth Sci, Johannesburg, South Africa. RP Tempia, S (reprint author), Natl Inst Communicable Dis, Ctr Resp Dis & Meningitis, Private Bag X4, ZA-2131 Johannesburg, Gauteng, South Africa. EM stefanot@nicd.ac.za NR 43 TC 3 Z9 3 U1 2 U2 4 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD OCT 1 PY 2015 VL 61 IS 7 BP 1063 EP 1070 DI 10.1093/cid/civ448 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA CT6VZ UT WOS:000362952100006 PM 26060287 ER PT J AU Wong, KK Perdue, CL Malia, J Kenney, JL Peng, S Gwathney, JK Raczniak, GA AF Wong, Karen K. Perdue, Christopher L. Malia, Jennifer Kenney, James L. Peng, Suzette Gwathney, Jamal K. Raczniak, Gregory A. CA Monrovia Medical Unit TI Supportive Care of the First 2 Ebola Virus Disease Patients at the Monrovia Medical Unit SO CLINICAL INFECTIOUS DISEASES LA English DT Editorial Material DE hemorrhagic fever; Ebola; acute kidney injury; point-of-care systems; Liberia ID SIERRA-LEONE; WEST-AFRICA; LIBERIA; OUTCOMES; WORKERS; AUGUST AB We describe the first 2 patients admitted to the Monrovia Medical Unit, a facility established to treat Liberian and international response workers with suspected or known Ebola virus disease (EVD). Their recoveries illustrate the value of local point-of-care diagnostics, parenteral therapies, and electrolyte replacement in EVD supportive care. C1 [Wong, Karen K.; Perdue, Christopher L.; Malia, Jennifer; Kenney, James L.; Peng, Suzette; Gwathney, Jamal K.; Raczniak, Gregory A.; Monrovia Medical Unit] US PHS, Rockville, MD USA. RP Wong, KK (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,MS C-09, Atlanta, GA 30329 USA. EM kwong@cdc.gov NR 21 TC 4 Z9 4 U1 2 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD OCT 1 PY 2015 VL 61 IS 7 BP E47 EP E51 DI 10.1093/cid/civ420 PG 5 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA CT6VZ UT WOS:000362952100001 PM 26021993 ER PT J AU Gargano, JW Freeland, AL Morrison, MA Stevens, K Zajac, L Wolkon, A Hightower, A Miller, MD Brunkard, JM AF Gargano, J. W. Freeland, A. L. Morrison, M. A. Stevens, K. Zajac, L. Wolkon, A. Hightower, A. Miller, M. D. Brunkard, J. M. TI Acute gastrointestinal illness following a prolonged community-wide water emergency SO EPIDEMIOLOGY AND INFECTION LA English DT Article DE Infectious disease epidemiology; investigation; public health; water-borne infections ID NONDISINFECTED DRINKING-WATER; DISTRIBUTION-SYSTEMS; CLIMATE-CHANGE; CONTROLLED-TRIAL; UNITED-STATES; QUALITY; DISEASE; EVENTS; CONSUMPTION; ALABAMA AB The drinking water infrastructure in the United States is ageing; extreme weather events place additional stress on water systems that can lead to interruptions in the delivery of safe drinking water. We investigated the association between household exposures to water service problems and acute gastrointestinal illness (AGI) and acute respiratory illness (ARI) in Alabama communities that experienced a freeze-related community-wide water emergency. Following the water emergency, investigators conducted a household survey. Logistic regression models were used to estimate adjusted prevalence ratios (aPR) and 95% confidence intervals (CI) for self-reported AGI and ARI by water exposures. AGI was higher in households that lost water service for >= 7 days (aPR 2.4, 95% CI 1.1-5.2) and experienced low water pressure for 57 days (aPR 3.6, 95% CI 1.4-9.0) compared to households that experienced normal service and pressure; prevalence of AGI increased with increasing duration of water service interruptions. Investments in the ageing drinking water infrastructure are needed to prevent future low-pressure events and to maintain uninterrupted access to the fundamental public health protection provided by safe water supplies. Households and communities need to increase their awareness of and preparedness for water emergencies to mitigate adverse health impacts. C1 [Gargano, J. W.; Freeland, A. L.] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Gargano, J. W.; Brunkard, J. M.] CDC, Natl Ctr Emerging & Zoonot Dis, Atlanta, GA 30333 USA. [Freeland, A. L.; Zajac, L.; Miller, M. D.] CDC, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA. [Morrison, M. A.] CDC, Off Publ Hlth Preparedness & Response, Atlanta, GA 30333 USA. [Morrison, M. A.; Stevens, K.] Alabama Dept Publ Hlth, Montgomery, AL 36102 USA. [Zajac, L.] Icahn Sch Med Mt Sinai, New York, NY 10029 USA. [Wolkon, A.; Hightower, A.] CDC, Ctr Global Hlth, Atlanta, GA 30333 USA. RP Gargano, JW (reprint author), Ctr Dis Control & Prevent MS C09, Atlanta, GA 30333 USA. EM jgargano@cdc.gov NR 29 TC 0 Z9 0 U1 1 U2 11 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0950-2688 EI 1469-4409 J9 EPIDEMIOL INFECT JI Epidemiol. Infect. PD OCT PY 2015 VL 143 IS 13 BP 2766 EP 2776 DI 10.1017/S0950268814003501 PG 11 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA CT6XA UT WOS:000362955200010 PM 25608522 ER PT J AU Gu, W Vieira, AR Hoekstra, RM Griffin, PM Cole, D AF Gu, W. Vieira, A. R. Hoekstra, R. M. Griffin, P. M. Cole, D. TI Use of random forest to estimate population attributable fractions from a case-control study of Salmonella enterica serotype Enteritidis infections SO EPIDEMIOLOGY AND INFECTION LA English DT Article DE Causality; counterfactual; foodborne diseases; logistic regression; machine learning ID CLASSIFICATION AB To design effective food safety programmes we need to estimate how many sporadic foodborne illnesses are caused by specific food sources based on case-control studies. Logistic regression has substantive limitations for analysing structured questionnaire data with numerous exposures and missing values. We adapted random forest to analyse data of a case-control study of Salmonella enterica serotype Enteritidis illness for source attribution. For estimation of summary population attributable fractions (PAFs) of exposures grouped into transmission routes, we devised a counterfactual estimator to predict reductions in illness associated with removing grouped exposures. For the purpose of comparison, we fitted the data using logistic regression models with stepwise forward and backward variable selection. Our results show that the forward and backward variable selection of logistic regression models were not consistent for parameter estimation, with different significant exposures identified. By contrast, the random forest model produced estimated PAFs of grouped exposures consistent in rank order with results obtained from outbreak data, with egg-related exposures having the highest estimated PAF (22.1%, 95% confidence interval 8.5-31.8). Random forest might be structurally more coherent and efficient than logistic regression models for attributing Salmonella illnesses to sources involving many causal pathways. C1 [Gu, W.; Vieira, A. R.; Griffin, P. M.; Cole, D.] Ctr Dis Control & Prevent, Enter Dis Epidemiol Branch, Atlanta, GA 30333 USA. [Hoekstra, R. M.] Ctr Dis Control, Div Foodborne Waterborne & Environm Dis Atlanta, Atlanta, GA 30333 USA. RP Gu, W (reprint author), Ctr Dis Control & Prevent, Enter Dis Epidemiol Branch, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, 1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM vhg8@cdc.gov NR 27 TC 2 Z9 2 U1 0 U2 4 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0950-2688 EI 1469-4409 J9 EPIDEMIOL INFECT JI Epidemiol. Infect. PD OCT PY 2015 VL 143 IS 13 BP 2786 EP 2794 DI 10.1017/S095026881500014X PG 9 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA CT6XA UT WOS:000362955200012 PM 25672399 ER PT J AU Scallan, E Hoekstra, RM Mahon, BE Jones, TF Griffin, PM AF Scallan, E. Hoekstra, R. M. Mahon, B. E. Jones, T. F. Griffin, P. M. TI An assessment of the human health impact of seven leading foodborne pathogens in the United States using disability adjusted life years SO EPIDEMIOLOGY AND INFECTION LA English DT Article DE Campylobacter; foodborne infections; Salmonella ID IRRITABLE-BOWEL-SYNDROME; GUILLAIN-BARRE-SYNDROME; TOXOPLASMA-GONDII INFECTION; PERFRINGENS TYPE-A; CONGENITAL TOXOPLASMOSIS; REACTIVE ARTHRITIS; DISEASE BURDEN; RISK-FACTORS; GASTROENTERITIS; ILLNESS AB We explored the overall impact of foodborne disease caused by seven leading foodborne pathogens in the United States using the disability adjusted life year (DALY). We defined health states for each pathogen (acute illness and sequelae) and estimated the average annual incidence of each health state using data from public health surveillance and previously published estimates from studies in the United States, Canada and Europe. These pathogens caused about 112 000 DALYs annually due to foodborne illnesses acquired in the United States. Non-typhoidal Salmonella (32 900) and Toxoplasma (32 700) caused the most DALYs, followed by Campylobacter (22 500), norovirus (9900), Listeria monocytogenes (8800), Clostridium perfringens (4000), and Escherichia coli O157 (1200). These estimates can be used to prioritize food safety interventions. Future estimates of the burden of foodborne disease in DALYs would be improved by addressing important data gaps and by the development and validation of US-specific disability weights for foodborne diseases. C1 [Scallan, E.] Univ Colorado Denver, Colorado Sch Publ Hlth, Dept Epidemiol, Aurora, CO 80045 USA. [Hoekstra, R. M.] Ctr Dis Control & Prevent, Biostat & Informat Management Off, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. [Mahon, B. E.; Griffin, P. M.] Ctr Dis Control & Prevent, Enter Dis Epidemiol Branch, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. [Jones, T. F.] Tennessee Dept Hlth, Nashville, TN USA. RP Scallan, E (reprint author), Univ Colorado Denver, Colorado Sch Publ Hlth, UCD AMC Bldg 500,Room W3146,13001 E 17th Pl, Aurora, CO 80045 USA. EM Elaine.Scallan@ucdenver.edu FU NCHM CDC HHS [1U60HM 000803] NR 44 TC 18 Z9 18 U1 10 U2 32 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0950-2688 EI 1469-4409 J9 EPIDEMIOL INFECT JI Epidemiol. Infect. PD OCT PY 2015 VL 143 IS 13 BP 2795 EP 2804 DI 10.1017/S0950268814003185 PG 10 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA CT6XA UT WOS:000362955200013 PM 25633631 ER PT J AU Herman, KM Hall, AJ Gould, LH AF Herman, K. M. Hall, A. J. Gould, L. H. TI Outbreaks attributed to fresh leafy vegetables, United States, 1973-2012 SO EPIDEMIOLOGY AND INFECTION LA English DT Article DE Escherichia coli; food poisoning; food safety; foodborne infections; Norwalk agent and related viruses; Salmonella ID FOODBORNE DISEASE; SURVEILLANCE; NOROVIRUS; ILLNESS AB Leafy vegetables are an essential component of a healthy diet; however, they have been associated with high-profile outbreaks causing severe illnesses. We reviewed leafy vegetable-associated outbreaks reported to the Centers for Disease Control and Prevention between 1973 and 2012. During the study period, 606 leafy vegetable-associated outbreaks, with 20 003 associated illnesses, 1030 hospitalizations, and 19 deaths were reported. On average, leafy vegetable-associated outbreaks were larger than those attributed to other food types. The pathogens that most often caused leafy vegetable-associated outbreaks were norovirus (55% of outbreaks with confirmed aetiology), Shiga toxin-producing Escherichia coli (STEC) (18%), and Salmonella (11%). Most outbreaks were attributed to food prepared in a restaurant or catering facility (85%). An ill food worker was implicated as the source of contamination in 31% of outbreaks. Efforts by local, state, and federal agencies to control leafy vegetable contamination and outbreaks should span from the point of harvest to the point of preparation. C1 [Herman, K. M.; Hall, A. J.; Gould, L. H.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Gould, LH (reprint author), 1600 Clifton Rd,NE MS-C09, Atlanta, GA 30333 USA. EM lgould@cdc.gov FU Intramural CDC HHS [CC999999] NR 25 TC 14 Z9 14 U1 4 U2 39 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0950-2688 EI 1469-4409 J9 EPIDEMIOL INFECT JI Epidemiol. Infect. PD OCT PY 2015 VL 143 IS 14 BP 3011 EP 3021 DI 10.1017/S0950268815000047 PG 11 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA CT6XD UT WOS:000362955500012 PM 25697407 ER PT J AU Hoopes, MJ Dankovchik, J Weiser, T Cheng, T Bigback, K Knaster, ES Sugerman, DE AF Hoopes, Megan J. Dankovchik, Jenine Weiser, Thomas Cheng, Tabitha Bigback, Kristyn Knaster, Elizabeth S. Sugerman, David E. TI Uncovering a missing demographic in trauma registries: epidemiology of trauma among American Indians and Alaska Natives in Washington State SO INJURY PREVENTION LA English DT Article ID UNITED-STATES; RACIAL MISCLASSIFICATION; MORTALITY; SURVEILLANCE; NORTHWEST; INJURIES; CHILDREN; TRENDS AB Background The objectives of this study were to evaluate racial misclassification in a statewide trauma registry and to describe the epidemiology of trauma among the Washington American Indian and Alaska Native (AI/AN) population. Methods We performed probabilistic record linkage between the Washington Trauma Registry (2005-2009) and Northwest Tribal Registry, a dataset of known AI/AN. AI/AN patients were compared with caucasians on demographic, injury and clinical outcome factors. A multivariable model estimated odds of mortality. Results Record linkage increased ascertainment of AI/AN cases in the trauma registry 71%, from 1777 to 3039 cases. Compared with caucasians, AI/AN trauma patients were younger (mean age=36 vs 47 years, p<0.001) and more commonly male (66.5% vs 61.2%, p<0.001). AI/AN experienced more intentional injuries (suicide or homicide: 20.1% vs 6.7%, p<0.001), a higher proportion of severe traumatic brain injury (20.7% vs 16.8%, p=0.004) and were less likely than caucasians to use safety equipment such as seat belts/airbags (53.9% vs 76.7%, p<0.001). ISSs were similar (ISS > 15: 21.4% vs 20.5%, p=0.63), and no difference was observed in mortality after adjustment for covariates (p=0.58). Conclusions Linkage to a state trauma registry improved data quality by correcting racial misclassification, allowing for a comprehensive description of injury patterns for the AI/AN population. AI/AN sustained more severe injuries with similar postinjury outcomes to caucasians. Future efforts should focus on primary prevention for this population, including increased use of seat belts and child safety seats and reduction of interpersonal violence and suicide. C1 [Hoopes, Megan J.; Dankovchik, Jenine; Weiser, Thomas; Bigback, Kristyn] Northwest Portland Area Indian Hlth Board, Northwest Tribal Epidemiol Ctr, Portland, OR 97201 USA. [Weiser, Thomas] Northwest Portland Area Indian Hlth Board, Portland Area Indian Hlth Serv, Portland, OR 97201 USA. [Cheng, Tabitha] Ctr Dis Control & Prevent, Div Sci Educ & Profess Dev, Natl Ctr Injury Prevent & Control, Atlanta, GA USA. [Knaster, Elizabeth S.] Seattle Indian Hlth Board, Urban Indian Hlth Inst, Seattle, WA USA. [Sugerman, David E.] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA USA. RP Dankovchik, J (reprint author), Northwest Portland Area Indian Hlth Board, Northwest Tribal Epidemiol Ctr, 2121 SW Broadway,Suite 300, Portland, OR 97201 USA. EM jdankovchik@npaihb.org FU Agency for Healthcare Research and Quality [R01HS019972]; Office of Minority Health [AIAMP120012]; CDC Foundation External Medical Affairs, Pfizer FX Supported by the grant #R01HS019972 from the Agency for Healthcare Research and Quality Grant #AIAMP120012 from the Office of Minority Health. The CDC Experience is a 1-year fellowship in applied epidemiology at CDC made possible by a public/private partnership supported by a grant to the CDC Foundation from External Medical Affairs, Pfizer. NR 38 TC 0 Z9 0 U1 2 U2 4 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1353-8047 EI 1475-5785 J9 INJURY PREV JI Inj. Prev. PD OCT PY 2015 VL 21 IS 5 BP 335 EP 343 DI 10.1136/injuryprev-2014-041419 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CT4MC UT WOS:000362779600009 PM 25924945 ER PT J AU Rochelle, PA Klonicki, PT Di, GD Hill, VR Akagi, Y Villegas, EN AF Rochelle, Paul A. Klonicki, Patricia T. Di, George D. Hill, Vincent R. Akagi, Yone Villegas, Eric N. TI Conference Report: The 6th International Symposium on Waterborne Pathogens SO JOURNAL AMERICAN WATER WORKS ASSOCIATION LA English DT Article ID DRINKING-WATER; UNITED-STATES; OUTBREAK; DISEASE C1 [Rochelle, Paul A.] MWDSC, La Verne, CA USA. [Klonicki, Patricia T.] CSC, Cincinnati, OH 45242 USA. [Di, George D.] Univ Texas Houston, Sch Publ Hlth, El Paso, TX USA. [Hill, Vincent R.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Akagi, Yone] Portland Water Bur, Portland, OR USA. [Villegas, Eric N.] US Environm Protect Agcy, Cincinnati, OH USA. RP Klonicki, PT (reprint author), CSC, Cincinnati, OH 45242 USA. EM pklonicki@csc.com RI Villegas, Eric/A-7373-2015 OI Villegas, Eric/0000-0002-8059-8588 FU Intramural CDC HHS [CC999999] NR 9 TC 0 Z9 0 U1 0 U2 3 PU AMER WATER WORKS ASSOC PI DENVER PA 6666 W QUINCY AVE, DENVER, CO 80235 USA SN 2164-4535 J9 J AM WATER WORKS ASS JI J. Am. Water Work Assoc. PD OCT PY 2015 VL 107 IS 10 BP 24 EP 32 DI 10.5942/jawwa.2015.107.0156 PG 9 WC Engineering, Civil; Water Resources SC Engineering; Water Resources GA CT3GR UT WOS:000362695700006 PM 26566291 ER PT J AU Shenassa, ED Rossen, LM AF Shenassa, Edmond D. Rossen, Lauren M. TI Telomere length and age-at-menopause in the US SO MATURITAS LA English DT Article DE Menopause; Telomeres; Reproductive aging ID CAUSE-SPECIFIC MORTALITY; BODY-MASS INDEX; NATURAL MENOPAUSE; CANCER-RISK; BLACK-WOMEN; FOLLOW-UP; ALL-CAUSE; HEALTH; SMOKING AB Objectives: Age-at-menopause and leukocyte telomere length (LTL) are both associated with biologic aging. Therefore, it would be reasonable to hypothesize that LTL may also serve as a marker for reproductive aging as shorter LTL may be associated with earlier age-at-menopause. Methods: We analyzed data from 799 post-menopausal (ages 41-85) participants in the National Health and Nutrition Examination Survey (1999-2002), a nationally representative sample of U.S. women. Results: Controlling for behavioral, socio-demographic, and health-related determinants of menopause, we found that among non-Hispanic white women, an increase of one standard deviation in LTL was associated with a 0.43 year higher reported age-at-menopause. Among Mexican Americans, an increase of one standard deviation in LTL was associated with a 1.56 year earlier menopause. There was no significant association between LTL and age-at-menopause among non-Hispanic black women. Conclusions: Our main finding is evidence of a strong interaction by race/ethnicity in the association between LTL and age-at-menopause. This evidence does not support the hypothesis that shorter LTL is a predictor of earlier age-at-menopause, as the magnitude and direction of the associations between LTL and age-at-menopause varied across racial/ethnic groups. (C) 2015 Elsevier Ireland Ltd. All rights reserved. C1 [Shenassa, Edmond D.] Univ Maryland, Maternal & Child Hlth Program, Sch Publ Hlth, College Pk, MD 20742 USA. [Shenassa, Edmond D.] Univ Maryland, Dept Epidemiol Ea Biostat, Sch Publ Hlth, College Pk, MD 20742 USA. [Shenassa, Edmond D.] Brown Univ, Dept Epidemiol, Sch Publ Hlth, Providence, RI 02912 USA. [Shenassa, Edmond D.] Univ Maryland, Dept Epidemiol, Baltimore, MD 21201 USA. [Rossen, Lauren M.] Ctr Dis Control & Prevent, Off Anal & Epidemiol, Natl Ctr Hlth Stat, Washington, DC USA. RP Shenassa, ED (reprint author), Univ Maryland, Maternal & Child Hlth Program, Sch Publ Hlth, College Pk, MD 20742 USA. EM Shenassa@UMD.edu FU Intramural CDC HHS [CC999999]; NICHD NIH HHS [R24 HD041041] NR 33 TC 1 Z9 1 U1 2 U2 8 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0378-5122 EI 1873-4111 J9 MATURITAS JI Maturitas PD OCT PY 2015 VL 82 IS 2 BP 215 EP 221 DI 10.1016/j.maturitas.2015.07.009 PG 7 WC Geriatrics & Gerontology; Obstetrics & Gynecology SC Geriatrics & Gerontology; Obstetrics & Gynecology GA CT7LB UT WOS:000362995100013 PM 26297686 ER PT J AU Skoff, TH Kenyon, C Cocoros, N Liko, J Miller, L Kudish, K Baumbach, J Zansky, S Faulkner, A Martin, SW AF Skoff, Tami H. Kenyon, Cynthia Cocoros, Noelle Liko, Juventila Miller, Lisa Kudish, Kathy Baumbach, Joan Zansky, Shelley Faulkner, Amanda Martin, Stacey W. TI Sources of Infant Pertussis Infection in the United States SO PEDIATRICS LA English DT Article ID IMMUNIZATION PRACTICES ACIP; ADVISORY-COMMITTEE; VACCINE EFFECTIVENESS; PREVENTING TETANUS; YOUNG INFANTS; DIPHTHERIA; RECOMMENDATIONS; ADULTS; TDAP; EPIDEMIOLOGY AB BACKGROUND: Pertussis is poorly controlled, with the highest rates of morbidity and mortality among infants. Although the source of infant pertussis is often unknown, when identified, mothers have historically been the most common reservoir of transmission. Despite high vaccination coverage, disease incidence has been increasing. We examined whether infant source of infection (SOI) has changed in the United States in light of the changing epidemiology. METHODS: Cases <1 year old were identified at Enhanced Pertussis Surveillance sites between January 1, 2006 to December 31, 2013. SOI was collected during patient interview and was defined as a suspected pertussis case in contact with the infant case 7 to 20 days before infant cough onset. RESULTS: A total of 1306 infant cases were identified; 24.2% were <2 months old. An SOI was identified for 569 cases. Infants 0 to 1 months old were more likely to have an SOI identified than 2- to 11-month-olds (54.1% vs 40.2%, respectively; P < . 0001). More than 66% of SOIs were immediate family members, most commonly siblings (35.5%), mothers (20.6%), and fathers (10.0%); mothers predominated until the transition to siblings beginning in 2008. Overall, the SOI median age was 14 years (range: 0-74 years); median age for sibling SOIs was 8 years. CONCLUSIONS: In contrast to previous studies, our data suggest that the most common source of transmission to infants is now siblings. While continued monitoring of SOIs will optimize pertussis prevention strategies, recommendations for vaccination during pregnancy should directly increase protection of infants, regardless of SOI. C1 [Skoff, Tami H.; Faulkner, Amanda; Martin, Stacey W.] Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. [Kenyon, Cynthia] Minnesota Dept Hlth, St Paul, MN USA. [Cocoros, Noelle; Miller, Lisa] Harvard Univ, Sch Med, Dept Populat Med, Boston, MA USA. [Cocoros, Noelle] Harvard Pilgrim Healthcare Inst, Boston, MA USA. [Liko, Juventila] Oregon Hlth Author Portland, Publ Hlth Div, Portland, OR USA. [Miller, Lisa] Colorado Dept Publ Hlth & Environm, Denver, CO USA. [Kudish, Kathy] Connecticut Dept Publ Hlth, Hartford, CT USA. [Baumbach, Joan] New Mexico Dept Hlth, Santa Fe, NM USA. [Zansky, Shelley] New York State Dept Hlth, Albany, NY USA. RP Skoff, TH (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd, Atlanta, GA 30329 USA. EM tlh9@cdc.gov FU Centers for Disease Control and Prevention FX Enhanced Pertussis Surveillance is supported through a Centers for Disease Control and Prevention cooperative agreement. NR 24 TC 25 Z9 25 U1 0 U2 2 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 EI 1098-4275 J9 PEDIATRICS JI Pediatrics PD OCT PY 2015 VL 136 IS 4 BP 635 EP 641 DI 10.1542/peds.2015-1120 PG 7 WC Pediatrics SC Pediatrics GA CT6TC UT WOS:000362944300048 PM 26347437 ER PT J AU Herrick, KA Rossen, LM Nielsen, SJ Branum, AM Ogden, CL AF Herrick, Kirsten A. Rossen, Lauren M. Nielsen, Samara Joy Branum, Amy M. Ogden, Cynthia L. TI Fruit Consumption by Youth in the United States SO PEDIATRICS LA English DT Article ID VEGETABLE CONSUMPTION; DIETARY-INTAKE; BODY-WEIGHT; CHILDREN; ACCULTURATION; METAANALYSIS; MORTALITY; RISK; BIAS AB OBJECTIVES: To describe the contribution of whole fruit, including discrete types of fruit, to total fruit consumption and to investigate differences in consumption by sociodemographic characteristics. METHODS: We analyzed data from 3129 youth aged 2 to 19 years from the National Health and Nutrition Examination Survey, 2011 to 2012. Using the Food Patterns Equivalents Database and the What We Eat in America 150 food groups, we calculated the contribution of whole fruit, 100% fruit juices, mixed fruit dishes, and 12 discrete fruit and fruit juices to total fruit consumption. We examined differences by age, gender, race and Hispanic origin, and poverty status. RESULTS: Nearly 90% of total fruit intake came from whole fruits (53%) and 100% fruit juices (34%) among youth aged 2 to 19 years. Apples, apple juice, citrus juice, and bananas were responsible for almost half of total fruit consumption. Apples accounted for 18.9% of fruit intake. Differences by age were predominately between youth aged 2 to 5 years and 6 to 11 years. For example, apples contributed a larger percentage of total fruit intake among youth 6 to 11 years old (22.4%) than among youth 2 to 5 years old (14.6%), but apple juice contributed a smaller percentage (8.8% vs 16.8%), P < .05. There were differences by race and Hispanic origin in intake of citrus fruits, berries, melons, dried fruit, and citrus juices and other fruit juices. CONCLUSIONS: These findings provide insight into what fruits US youth are consuming and sociodemographic factors that may influence consumption. C1 [Herrick, Kirsten A.; Nielsen, Samara Joy; Ogden, Cynthia L.] Ctr Dis Control & Prevent, Div Hlth & Nutr Examinat Surveys, Hyattsville, MD USA. [Rossen, Lauren M.] Ctr Dis Control & Prevent, Infant Child & Womens Hlth Stat Branch, Off Anal & Epidemiol, Hyattsville, MD USA. [Branum, Amy M.] Ctr Dis Control & Prevent, Reprod Stat Branch, Div Vital Stat, Natl Ctr Hlth Stat, Hyattsville, MD USA. RP Herrick, KA (reprint author), Natl Ctr Hlth Stat, 3311 Toledo Rd, Hyattsville, MD 20782 USA. EM kherrick1@cdc.gov OI Nielsen, Samara Joy/0000-0002-5777-6542 FU Intramural CDC HHS [CC999999] NR 30 TC 2 Z9 2 U1 2 U2 8 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 EI 1098-4275 J9 PEDIATRICS JI Pediatrics PD OCT PY 2015 VL 136 IS 4 BP 664 EP 671 DI 10.1542/peds.2015-1709 PG 8 WC Pediatrics SC Pediatrics GA CT6TC UT WOS:000362944300052 PM 26391940 ER PT J AU Lovegrove, MC Weidle, NJ Budnitz, DS AF Lovegrove, Maribeth C. Weidle, Nina J. Budnitz, Daniel S. TI Trends in Emergency Department Visits for Unsupervised Pediatric Medication Exposures, 2004-2013 SO PEDIATRICS LA English DT Article ID AMERICAN ASSOCIATION; SURVEILLANCE; POISONINGS; INGESTIONS AB BACKGROUND: After reports of increasing emergency department (ED) visits for unsupervised abstract pediatric medication exposures in the 2000s, renewed efforts to improve safety packaging and education were initiated. National data on current trends can help further target interventions. METHODS: We used nationally representative data from the National Electronic Injury Surveillance System-Cooperative Adverse Drug Event Surveillance project (2004-2013) to assess trends in ED visits for unsupervised medication exposures in children aged <6 years. For 2010 through 2013, the dosage form and prescription status of implicated medications were identified. RESULTS: Based on 13 268 cases, there were an estimated 640 161 ED visits (95% confidence interval: 512 885 to 767 436) for unsupervised medication exposures from 2004 through 2013. From 2004 through 2010, ED visits for unsupervised exposures increased by an average of 5.7% annually, peaking at 75 842. After 2010, this trend reversed, and visits decreased by an average of 6.7% annually to 59 092 in 2013. From 2010 through 2013, 91.0% of unsupervised exposure visits involved 1 medication, most commonly an oral prescription solid (45.9%), oral over-the-counter (OTC) solid (22.3%), or oral OTC liquid (12.4%). More than 260 different prescription solids were implicated; opioids (13.8%) and benzodiazepines (12.7%) were the most common classes. Four medications were implicated in 91.2% of OTC liquid exposure visits: acetaminophen (32.9%), cough and cold remedies (27.5%), ibuprofen (15.7%), and diphenhydramine (15.6%). CONCLUSIONS: Targeting prevention efforts based on harm frequency and intervention feasibility can lead to continued reductions in ED visits for pediatric medication exposures. C1 [Lovegrove, Maribeth C.; Budnitz, Daniel S.] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA 30333 USA. [Weidle, Nina J.] Chenega Govt Consulting, Atlanta, GA USA. RP Lovegrove, MC (reprint author), Ctr Dis Control & Prevent, Div Healthcare Qual Promot, 1600 Clifton Rd NE,Mailstop D-26, Atlanta, GA 30333 USA. EM mlovegrove@cdc.gov FU Intramural CDC HHS [CC999999] NR 31 TC 8 Z9 8 U1 0 U2 2 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 EI 1098-4275 J9 PEDIATRICS JI Pediatrics PD OCT PY 2015 VL 136 IS 4 BP E821 EP E829 DI 10.1542/peds.2015-2092 PG 9 WC Pediatrics SC Pediatrics GA CT6TC UT WOS:000362944300006 PM 26347435 ER PT J AU Siffel, C Riehle-Colarusso, T Oster, ME Correa, A AF Siffel, Csaba Riehle-Colarusso, Tiffany Oster, Matthew E. Correa, Adolfo TI Survival of Children With Hypoplastic Left Heart Syndrome SO PEDIATRICS LA English DT Article ID NATIONAL-DEATH-INDEX; METROPOLITAN ATLANTA; SINGLE INSTITUTION; INFANTS BORN; VITAL STATUS; DEFECTS; DISPARITIES; PALLIATION; EXPERIENCE; MANAGEMENT AB OBJECTIVE: To examine the survival of infants with hypoplastic left heart syndrome (HLHS) and potential influence of demographic and clinical characteristics on survival using population-based data. METHODS: Infants with nonsyndromic HLHS (n = 212) born between 1979 and 2005 were identified through the Metropolitan Atlanta Congenital Defects Program. Vital status was ascertained through 2009 based on linkage with vital records. We estimated Kaplan-Meier survival probabilities stratified by select demographic and clinical characteristics. RESULTS: The overall survival probability to 2009 was 24% and significantly improved over time: from 0% in 1979-1984 to 42% in 1999-2005. Survival probability was 66% during the first week, 27% during the first year of life, and 24% during the first 10 years. Survival of very low and low birth weight or preterm infants and those born in high-poverty neighborhoods was significantly poorer. For children with information on surgical intervention (n = 88), the overall survival was 52%, and preterm infants had significantly poorer survival (31%) compared with term infants (56%). For children who survived to 1 year of age, long-term survival was similar to 90%. CONCLUSIONS: Survival to adolescence of children with nonsyndromic HLHS born in metropolitan Atlanta has significantly improved in recent years, with those born full term, with normal birth weight, or in a low-poverty neighborhood having a higher survival probability. Survival beyond infancy to adolescence is high. A better understanding of the growing population of survivors with HLHS is needed to inform resource planning. C1 [Siffel, Csaba; Riehle-Colarusso, Tiffany; Oster, Matthew E.; Correa, Adolfo] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30341 USA. [Siffel, Csaba] Georgia Regents Univ, Coll Allied Hlth Sci, Augusta, GA USA. [Oster, Matthew E.] Emory Univ, Childrens Healthcare Atlanta, Atlanta, GA 30322 USA. [Correa, Adolfo] Univ Mississippi, Med Ctr, Dept Med, Jackson, MS 39216 USA. RP Riehle-Colarusso, T (reprint author), Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Mailstop E-86,4770 Buford Hwy, Atlanta, GA 30341 USA. EM tcolarusso@cdc.gov FU Intramural CDC HHS [CC999999] NR 38 TC 4 Z9 4 U1 0 U2 2 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 EI 1098-4275 J9 PEDIATRICS JI Pediatrics PD OCT PY 2015 VL 136 IS 4 BP E864 EP E870 DI 10.1542/peds.2014-1427 PG 7 WC Pediatrics SC Pediatrics GA CT6TC UT WOS:000362944300011 PM 26391936 ER PT J AU Olsho, LEW Payne, GH Walker, DK Baronberg, S Jernigan, J Abrami, A AF Olsho, Lauren E. W. Payne, Gayle Holmes Walker, Deborah Klein Baronberg, Sabrina Jernigan, Jan Abrami, Alyson TI Impacts of a farmers' market incentive programme on fruit and vegetable access, purchase and consumption SO PUBLIC HEALTH NUTRITION LA English DT Article DE Farmers' markets; Fruits and vegetables; Access; Nutrition incentives ID DIETARY-INTAKE; WAIST CIRCUMFERENCE; UNITED-STATES; WEIGHT; RISK; PHILADELPHIA; OBESITY; ADULTS; TRENDS; GAIN AB ObjectiveThe present study examines the impact of Health Bucks, a farmers' market incentive programme, on awareness of and access to farmers' markets, and fruit and vegetable purchase and consumption in low-income New York City neighbourhoods.DesignThe evaluation used two primary data collection methods: (i) an on-site point-of-purchase survey of farmers' market shoppers; and (ii) a random-digit-dial telephone survey of residents in neighbourhoods where the programme operates. Additionally, we conducted a quasi-experimental analysis examining differential time trends in consumption before and after programme introduction using secondary Community Health Survey (CHS) data.SettingNew York City farmers' markets and communities.SubjectsFarmers' market shoppers (n 2287) completing point-of-purchase surveys in a representative sample of New York City farmers' markets in 2010; residents (n 1025) completing random-digit-dial telephone survey interviews in 2010; and respondents (n 35 606) completing CHS interviews in 2002, 2004, 2008 and 2009.ResultsGreater Health Bucks exposure was associated with: (i) greater awareness of farmers' markets; (ii) increased frequency and amount of farmers' market purchases; and (iii) greater likelihood of a self-reported year-over-year increase in fruit and vegetable consumption. However, our CHS analysis did not detect impacts on consumption.ConclusionsWhile our study provides promising evidence that use of farmers' market incentives is associated with increased awareness and use of farmers' markets, additional research is needed to better understand impacts on fruit and vegetable consumption. C1 [Olsho, Lauren E. W.; Walker, Deborah Klein] ABT Associates Inc, US Hlth Div, Cambridge, MA 02138 USA. [Payne, Gayle Holmes; Jernigan, Jan] Ctr Dis Control & Prevent, Div Nutr Phys Activ & Obes, Atlanta, GA USA. [Baronberg, Sabrina; Abrami, Alyson] NYC Dept Hlth & Mental Hyg, Phys Activ & Nutr Program, New York, NY USA. RP Olsho, LEW (reprint author), ABT Associates Inc, US Hlth Div, 55 Wheeler St, Cambridge, MA 02138 USA. EM lauren_olsho@abtassoc.com OI Olsho, Lauren/0000-0003-4503-9745 FU Centers for Disease Control and Prevention (CDC) [200-2008-27954]; Centers for Disease Control and Prevention (CDC) (TO) [2009-LB-14] FX Financial support: This evaluation study was funded by the Centers for Disease Control and Prevention (CDC) (under contract #200-2008-27954, TO #2009-LB-14). The CDC had no role in the design, analysis or writing of this article. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the CDC. NR 45 TC 4 Z9 4 U1 2 U2 17 PU CAMBRIDGE UNIV PRESS PI CAMBRIDGE PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND SN 1368-9800 EI 1475-2727 J9 PUBLIC HEALTH NUTR JI Public Health Nutr. PD OCT PY 2015 VL 18 IS 15 BP 2712 EP 2721 DI 10.1017/S1368980015001056 PG 10 WC Public, Environmental & Occupational Health; Nutrition & Dietetics SC Public, Environmental & Occupational Health; Nutrition & Dietetics GA CT6WI UT WOS:000362953200003 PM 25919225 ER PT J AU Moorman, AC Stramer, SL Schaefer, MK Collier, MG Suryaprasad, A Kuehnert, MJ Moore, Z Rowan, E Habicht, K Bradley, K Fucci, MC Hopkins, C Xu, FJ AF Moorman, Anne C. Stramer, Susan L. Schaefer, Melissa K. Collier, Melissa G. Suryaprasad, Anil Kuehnert, Matthew J. Moore, Zack Rowan, Elizabeth Habicht, Katherine Bradley, Kristy Fucci, Mei-chien Hopkins, Courtney Xu, Fujie TI Incident hepatitis among repeat blood donors: A sentinel event signaling possible health care-associated infection and need for reporting to public health authorities SO TRANSFUSION LA English DT Editorial Material C1 [Moorman, Anne C.; Collier, Melissa G.; Suryaprasad, Anil; Xu, Fujie] Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA 30329 USA. [Stramer, Susan L.] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA 30329 USA. [Schaefer, Melissa K.; Kuehnert, Matthew J.] Amer Red Cross Sci Support Off, Gaithersburg, MD USA. [Moore, Zack] North Carolina Dept Hlth & Human Serv, Raleigh, NC USA. [Rowan, Elizabeth] Alameda Cty Dept Publ Hlth, Oakland, CA USA. [Habicht, Katherine] S Carolina Dept Hlth & Environm Control, Columbia, SC 29201 USA. [Bradley, Kristy] Oklahoma Dept Hlth, Oklahoma City, OK USA. [Fucci, Mei-chien] Amer Red Cross, West Div Biomed Serv, Tulsa, OK USA. [Hopkins, Courtney] Amer Red Cross, East Div Biomed Serv, Columbia, SC USA. RP Moorman, AC (reprint author), Ctr Dis Control & Prevent, Div Viral Hepatitis, 1600 Clifton Rd, Atlanta, GA 30329 USA. EM amoorman@cdc.gov NR 9 TC 0 Z9 0 U1 2 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0041-1132 EI 1537-2995 J9 TRANSFUSION JI Transfusion PD OCT PY 2015 VL 55 IS 10 BP 2531 EP 2533 DI 10.1111/trf.13132 PG 3 WC Hematology SC Hematology GA CT6HQ UT WOS:000362914500034 PM 25899171 ER PT J AU Miller, CH Rice, AS Boylan, B Payne, AB Kelly, FM Escobar, MA Gill, J Leissinger, C Soucie, JM AF Miller, Connie H. Rice, Anne S. Boylan, Brian Payne, Amanda B. Kelly, Fiona M. Escobar, Miguel A. Gill, Joan Leissinger, Cindy Soucie, J. Michael CA Hemophilia Inhibitor Res Study Inv TI Characteristics of hemophilia patients with factor VIII inhibitors detected by prospective screening SO AMERICAN JOURNAL OF HEMATOLOGY LA English DT Article ID UNITED-STATES; A PATIENTS; SURVEILLANCE; HISTORY AB Characteristics of inhibitors identified by prospective screening may differ from those detected clinically. In a prospective study at 17 hemophilia centers with central inhibitor measurement by Nijmegen-Bethesda assay, 23 (2.8%) of 824 hemophilia A patients had new inhibitors detected: nine high-titer inhibitors (HTI: 7 >= 5.0 NBU plus 2 of 2.6 and 3.4 NBU at immune tolerance induction initiation) and 14 low-titer inhibitors (LTI: 0.5-1.9 NBU). HTI occurred at an earlier age (median 2 years, range 1-18, vs. median 11 years, range 2-61, P = 0.016). Both HTI (22%) and LTI (43%) occurred in non-severe patients. All HTI, but only 64% of LTI, were found to be FVIII-specific by chromogenic Bethesda assay or fluorescence immunoassay (FLI), indicating a high rate of false-positive LTI. Repeat specimens confirmed all HTI, 7/9 LTI, and 7/7 FVIII-specific LTI. FLI results were similar between HTI and FVIII-specific LTI; all included IgG1 and IgG4 subclasses. A comparable prospective study conducted from 1975 to 1979 at 13 U. S. centers found 31 (2.4%) new inhibitors among 1,306 patients. In both studies, one-third of inhibitors occurred in non-severe patients and one-quarter after 150 exposure days (ED). Significant differences were seen in the age at which inhibitors occurred (median 16 years in the older study vs. 5 years currently, P = 0.024) and in ED before inhibitor development, 10% in the older study and 43% currently study occurring within 20 ED, suggesting a temporal change in inhibitor development. Prospective screening detects inhibitors in patients of all severities, ages, and ED. Some LTI, however, are false positives. (C) 2015 Wiley Periodicals, Inc. C1 [Miller, Connie H.; Rice, Anne S.; Boylan, Brian; Payne, Amanda B.; Kelly, Fiona M.; Soucie, J. Michael] Ctr Dis Control & Prevent, Div Blood Disorders, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. [Escobar, Miguel A.] Gulf States Hemophilia & Thrombophilia Ctr, Houston, TX USA. [Gill, Joan] Blood Ctr Wisconsin, Comprehens Ctr Bleeding Disorders, Milwaukee, WI USA. [Gill, Joan] Med Coll Wisconsin, Milwaukee, WI 53226 USA. [Leissinger, Cindy] Louisiana Ctr Bleeding & Clotting Disorders, New Orleans, LA USA. RP Miller, CH (reprint author), Ctr Dis Control & Prevent, Div Blood Disorders, Natl Ctr Birth Defects & Dev Disabil, 1600 Clifton Rd,MS D-02, Atlanta, GA 30333 USA. EM cmiller2@cdc.gov OI Miller, Connie H/0000-0002-3989-7973 FU CDC Foundation through grants from Pfizer Inc.; Baxter Healthcare FX Contract grant sponsor: CDC Foundation through grants from Pfizer Inc. and Baxter Healthcare. NR 16 TC 0 Z9 0 U1 0 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0361-8609 EI 1096-8652 J9 AM J HEMATOL JI Am. J. Hematol. PD OCT PY 2015 VL 90 IS 10 BP 871 EP 876 DI 10.1002/ajh.24104 PG 6 WC Hematology SC Hematology GA CT2VV UT WOS:000362663900010 PM 26147783 ER PT J AU Grohskopf, LA Sokolow, LZ Olsen, SJ Bresee, JS Broder, KR Karron, RA AF Grohskopf, Lisa A. Sokolow, Leslie Z. Olsen, Sonja J. Bresee, Joseph S. Broder, Karen R. Karron, Ruth A. TI Prevention and Control of Influenza With Vaccines: Recommendations of the Advisory Committee on Immunization Practices, United States, 2015-16 Influenza Season SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Article ID 6-TO 23-MONTH-OLD CHILDREN; EGG-ALLERGIC PATIENTS; RELATIVE EFFICACY; YOUNG-CHILDREN; TRIVALENT; IMMUNOGENICITY; VACCINATION; REACTOGENICITY; PERSISTENCE; ANTIBODY C1 [Grohskopf, Lisa A.; Sokolow, Leslie Z.; Olsen, Sonja J.; Bresee, Joseph S.] CDC, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Sokolow, Leslie Z.] Battelle Mem Inst, Atlanta, GA USA. [Broder, Karen R.] CDC, Immunizat Safety Off, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Karron, Ruth A.] Johns Hopkins Univ, Baltimore, MD USA. RP Grohskopf, LA (reprint author), CDC, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. EM lgrohskopf@cdc.gov NR 36 TC 5 Z9 5 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1600-6135 EI 1600-6143 J9 AM J TRANSPLANT JI Am. J. Transplant. PD OCT PY 2015 VL 15 IS 10 BP 2767 EP 2775 DI 10.1111/ajt.13505 PG 9 WC Surgery; Transplantation SC Surgery; Transplantation GA CT2WJ UT WOS:000362665400031 PM 26382204 ER PT J AU McCollum, AM Nakazawa, Y Ndongala, GM Pukuta, E Karhemere, S Lushima, RS Ilunga, BK Kabamba, J Wilkins, K Gao, JX Li, Y Emerson, G Damon, IK Carroll, DS Reynolds, MG Malekani, J Tamfum, JJM AF McCollum, Andrea M. Nakazawa, Yoshinori Ndongala, Guy Mutombo Pukuta, Elisabeth Karhemere, Stomy Lushima, Robert Shongo Ilunga, Benoit Kebela Kabamba, Joelle Wilkins, Kimberly Gao, Jinxin Li, Yu Emerson, Ginny Damon, Inger K. Carroll, Darin S. Reynolds, Mary G. Malekani, Jean Tamfum, Jean-Jacques Muyembe TI Case Report: Human Monkeypox in the Kivus, a Conflict Region of the Democratic Republic of the Congo SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID TIME PCR ASSAYS; SMALLPOX VACCINATION; VIRUS AB Monkeypox (MPX) is a zoonotic Orthopoxvirus infection endemic in central and western Africa. Human MPX cases occur in the central and northern regions of the Democratic Republic of the Congo (DRC), and this is the first report of confirmed MPX cases in the forested areas of North and South Kivu Provinces, with a detailed epidemiological investigation for one case. The location of each case is within areas predicted to be suitable for MPX virus transmission based on an ecological niche model. Phylogenetic analysis places these viruses in the Congo Basin clade. C1 US Ctr Dis Control & Prevent, Poxvirus & Rabies Branch, Div High Consequence Pathogens & Pathol, Atlanta, GA USA. Minist Sante Publ, Div Prov Sante, Goma, Nord Kivu, Zaire. Inst Natl Rech Biomed, Kinshasa, Zaire. Minist Sante Publ, Kinshasa, Zaire. US Ctr Dis Control & Prevent, Kinshasa, Zaire. Univ Kinshasa, Kinshasa, Zaire. RP McCollum, AM (reprint author), 1600 Clifton Rd,MS A-30, Atlanta, GA 30333 USA. EM azv4@cdc.gov NR 17 TC 2 Z9 2 U1 0 U2 5 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 EI 1476-1645 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD OCT PY 2015 VL 93 IS 4 BP 718 EP 721 DI 10.4269/ajtmh.15-0095 PG 4 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA CS8BX UT WOS:000362311800010 PM 26283752 ER PT J AU DeSisto, C Broussard, K Escobedo, M Borntrager, D Alvarado-Ramy, F Waterman, S AF DeSisto, Carla Broussard, Kelly Escobedo, Miguel Borntrager, Denise Alvarado-Ramy, Francisco Waterman, Stephen TI Border Lookout: Enhancing Tuberculosis Control on the United States-Mexico Border SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID RESISTANT TUBERCULOSIS AB We evaluated the use of federal public health intervention tools known as the Do Not Board and Border Lookout (BL) for detecting and referring infectious or potentially infectious land border travelers with tuberculosis (TB) back to treatment. We used data about the issuance of BL from April 2007 to September 2013 to examine demographics and TB laboratory results for persons on the list (N = 66) and time on the list before being located and achieving noninfectious status. The majority of case-patients were Hispanic and male, with a median age of 39 years. Most were citizens of the United States or Mexico, and 30.3% were undocumented migrants. One-fifth had multidrug-resistant TB. Nearly two-thirds of case-patients were located and treated as a result of being placed on the list. However, 25.8% of case-patients, primarily undocumented migrants, remain lost to follow-up and remain on the list. For this highly mobile patient population, the use of this novel federal travel intervention tool facilitated the detection and treatment of infectious TB cases that were lost to follow-up. C1 [DeSisto, Carla] Ctr Dis Control & Prevent, Div Global Migrat & Quarantine, Natl Ctr Emerging & Zoonot Infect Dis, El Paso, TX 79912 USA. Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA. RP DeSisto, C (reprint author), Ctr Dis Control & Prevent, Div Global Migrat & Quarantine, Natl Ctr Emerging & Zoonot Infect Dis, 601 Sunland Pk,Suite 200, El Paso, TX 79912 USA. EM carla.desisto@gmail.com NR 18 TC 1 Z9 1 U1 0 U2 2 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 EI 1476-1645 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD OCT PY 2015 VL 93 IS 4 BP 747 EP 751 DI 10.4269/ajtmh.15-0300 PG 5 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA CS8BX UT WOS:000362311800015 PM 26304917 ER PT J AU Springer, YP Jarnevich, CS Barnett, DT Monaghan, AJ Eisen, RJ AF Springer, Yuri P. Jarnevich, Catherine S. Barnett, David T. Monaghan, Andrew J. Eisen, Rebecca J. TI Modeling the Present and Future Geographic Distribution of the Lone Star Tick, Amblyomma americanum (Ixodida: Ixodidae), in the Continental United States SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID LYME-DISEASE VECTOR; WHITE-TAILED DEER; SPECIES DISTRIBUTION MODELS; IXODES-SCAPULARIS ACARI; CLIMATE-BASED MODEL; RELATIVE-HUMIDITY; BORNE DISEASES; EHRLICHIA-CHAFFEENSIS; RANGE EXPANSION; ODOCOILEUS-VIRGINIANUS AB The Lone star tick (Amblyomma americanum L.) is the primary vector for pathogens of significant public health importance in North America, yet relatively little is known about its current and potential future distribution. Building on a published summary of tick collection records, we used an ensemble modeling approach to predict the present-day and future distribution of climatically suitable habitat for establishment of the Lone star tick within the continental United States. Of the nine climatic predictor variables included in our five present-day models, average vapor pressure in July was by far the most important determinant of suitable habitat. The present-day ensemble model predicted an essentially contiguous distribution of suitable habitat extending to the Atlantic coast east of the 100th western meridian and south of the 40th northern parallel, but excluding a high elevation region associated with the Appalachian Mountains. Future ensemble predictions for 2061-2080 forecasted a stable western range limit, northward expansion of suitable habitat into the Upper Midwest and western Pennsylvania, and range contraction along portions of the Gulf coast and the lower Mississippi river valley. These findings are informative for raising awareness of A. americanttmtransmitted pathogens in areas where the Lone Star tick has recently or may become established. C1 [Springer, Yuri P.] Ctr Dis Control & Prevent, Div Vector Borne Dis, Ft Collins, CO 80521 USA. US Geol Survey, Ft Collins, CO USA. Natl Ecol Observ Network Inc, Boulder, CO USA. Natl Ctr Atmospher Res, Boulder, CO 80307 USA. RP Springer, YP (reprint author), Ctr Dis Control & Prevent, Div Vector Borne Dis, 3150 Rampart Rd, Ft Collins, CO 80521 USA. EM yurispringer@gmail.com OI Monaghan, Andrew/0000-0002-8170-2359 FU U.S. Centers for Disease Control and Prevention; U.S. Geological Survey; National Center for Atmospheric Research; National Science Foundation FX This work was partially supported by the U.S. Centers for Disease Control and Prevention, the U.S. Geological Survey, and the National Center for Atmospheric Research, which is sponsored by the National Science Foundation. NR 121 TC 5 Z9 5 U1 7 U2 32 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 EI 1476-1645 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD OCT PY 2015 VL 93 IS 4 BP 875 EP 890 DI 10.4269/ajtmh.15-0330 PG 16 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA CS8BX UT WOS:000362311800036 PM 26217042 ER PT J AU Storch, EA Hanks, CE Mink, JW McGuire, JF Adams, HR Augustine, EF Vierhile, A Thatcher, A Bitsko, R Lewin, AB Murphy, TK AF Storch, Eric A. Hanks, Camille E. Mink, Jonathan W. McGuire, Joseph F. Adams, Heather R. Augustine, Erika F. Vierhile, Amy Thatcher, Alyssa Bitsko, Rebecca Lewin, Adam B. Murphy, Tanya K. TI SUICIDAL THOUGHTS AND BEHAVIORS IN CHILDREN AND ADOLESCENTS WITH CHRONIC TIC DISORDERS SO DEPRESSION AND ANXIETY LA English DT Article DE Tourette syndrome; tic disorder; suicidal ideation; children; assessment; tics; suicide ID OBSESSIVE-COMPULSIVE SCALE; PSYCHIATRIC RISK-FACTORS; TOURETTE-SYNDROME; SEVERITY-SCALE; INTERVIEW SCHEDULE; PEER VICTIMIZATION; PRACTICE PARAMETER; RELIABILITY; YOUTH; VALIDITY AB ObjectiveDespite evidence of elevated risk factors for suicidal thoughts and behavior in youth with Tourette syndrome and chronic tic disorders (CTD), few studies have actually examined that relationship. This study documented the frequency and clinical correlates of suicidal thoughts and behaviors in a sample of children and adolescents with CTD (N = 196, range 6-18 years old). The content is solely the responsibility of the authors and does not necessarily represent the official views of the Centers for Disease Control. MethodYouth and parents completed a battery of measures that assessed co-occurring psychiatric diagnoses, child emotional and behavioral symptoms, and impairment due to tics or co-occurring conditions. ResultsA structured diagnostic interview identified that 19 youths with CTD (9.7%) experienced suicidal thoughts and/or behaviors, which was elevated compared to 3 youths (3%) who experienced these thoughts in a community control sample (N = 100, range 6-18 years old, P = .03). For youth with CTD, suicidal thoughts and behaviors were frequently endorsed in the context of anger and frustration. The Child Behavior Checklist (CBCL) anxious/depressed, withdrawn, social problems, thought problems, and aggressive behavior subscales, as well as the total internalizing problems scale, were associated with the presence of suicidal thoughts and/or behaviors. Suicidal thoughts and/or behaviors were significantly associated with tic symptom severity; tic-related impairment; and obsessive-compulsive, depressive, anxiety, and attention-deficit/hyperactivity disorders' symptom severity. CBCL anxiety/depression scores mediated the relationship between tic severity and suicidal thoughts and behaviors. ConclusionsFindings suggest that about 1 in 10 youth with CTD experience suicidal thoughts and/or behaviors, which are associated with a more complex clinical presentation and often occur in the presence of anger and frustration. (C) 2015 Wiley Periodicals, Inc. C1 [Storch, Eric A.; Hanks, Camille E.; McGuire, Joseph F.; Lewin, Adam B.; Murphy, Tanya K.] Univ S Florida, Dept Pediat, Rothman Ctr Neuropsychiat, St Petersburg, FL 33701 USA. [Storch, Eric A.; Lewin, Adam B.; Murphy, Tanya K.] Univ S Florida, Dept Psychiat & Behav Neurosci, St Petersburg, FL 33701 USA. [Storch, Eric A.] Univ S Florida, Dept Hlth Policy & Management, St Petersburg, FL 33701 USA. [Storch, Eric A.] Rogers Behav Hlth, Tampa, FL USA. [Storch, Eric A.; Murphy, Tanya K.] Johns Hopkins Med, All Childrens Hosp, Dept Psychiat & Psychol, St Petersburg, FL USA. [Mink, Jonathan W.; Adams, Heather R.; Augustine, Erika F.; Vierhile, Amy; Thatcher, Alyssa] Univ Rochester, Dept Neurol, Rochester, NY USA. [Mink, Jonathan W.; Augustine, Erika F.] Univ Rochester, Dept Pediat, Rochester, NY USA. [Mink, Jonathan W.] Univ Rochester, Dept Neurobiol & Anat, Rochester, NY USA. [Mink, Jonathan W.] Univ Rochester, Dept Brain & Cognit Sci, Rochester, NY USA. [Bitsko, Rebecca] Ctr Dis Control & Prevent, Div Human Dev & Disabil, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. RP Storch, EA (reprint author), Univ S Florida, Dept Pediat, Rothman Ctr Neuropsychiat, Box 7523,880 6th St South, St Petersburg, FL 33701 USA. EM estorch@health.usf.edu RI Murphy, Tanya/J-7079-2013 FU Centers for Disease Control and Prevention [U01DD000509-01] FX Contract grant sponsor: Centers for Disease Control and Prevention; Contract grant number: U01DD000509-01. The content is solely the responsibility of the authors and does not necessarily represent the official views of the Centers for Disease Control. NR 57 TC 3 Z9 4 U1 7 U2 14 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1091-4269 EI 1520-6394 J9 DEPRESS ANXIETY JI Depress. Anxiety PD OCT PY 2015 VL 32 IS 10 BP 744 EP 753 DI 10.1002/da.22357 PG 10 WC Psychology, Clinical; Psychiatry; Psychology SC Psychology; Psychiatry GA CS8WA UT WOS:000362369200005 PM 25711415 ER PT J AU Kobau, R AF Kobau, Rosemarie CA US Ctr Dis Control Prevention Epil TI Nearly one in five adults with active epilepsy lives alone based on findings from the 2010 and 2013 US National Health Interview Surveys. US Centers for Disease Control and Prevention, Epilepsy Program SO EPILEPSY & BEHAVIOR LA English DT Article DE Epilepsy; Surveillance; Epidemiology; Housing; Social support; National Health Interview Survey C1 [Kobau, Rosemarie] CDC, Epilepsy Program, Atlanta, GA 30341 USA. RP Kobau, R (reprint author), CDC, Epilepsy Program, 4770 Buford Highway NE,MS K-78, Atlanta, GA 30341 USA. NR 7 TC 2 Z9 2 U1 0 U2 1 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1525-5050 EI 1525-5069 J9 EPILEPSY BEHAV JI Epilepsy Behav. PD OCT PY 2015 VL 51 BP 259 EP 260 DI 10.1016/j.yebeh.2015.07.034 PG 2 WC Behavioral Sciences; Clinical Neurology; Psychiatry SC Behavioral Sciences; Neurosciences & Neurology; Psychiatry GA CS7TW UT WOS:000362290200039 ER PT J AU Colombo, FA Pereira-Chioccola, VL Meira, CD Motoie, G Gava, R Hiramoto, RM de Almeida, ME da Silva, AJ Cutolo, AA Menz, I AF Colombo, Fabio Antonio Pereira-Chioccola, Vera Lucia Meira, Cristina da Silva Motoie, Gabriela Gava, Ricardo Hiramoto, Roberto M. de Almeida, Marcos E. da Silva, Alexandre J. Cutolo, Andre Antonio Menz, Ingrid TI Performance of a real time PCR for leishmaniasis diagnosis using a L. (L.) infantum hypothetical protein as target in canine samples SO EXPERIMENTAL PARASITOLOGY LA English DT Article DE Subgenus Leishmania; Real time PCR; Canine visceral leishmaniasis; Molecular diagnosis; Leishmania (L.) infantum; Leishmania (L.) amazonensis ID POLYMERASE-CHAIN-REACTION; VISCERAL LEISHMANIASIS; NEW-WORLD; CUTANEOUS LEISHMANIASIS; VIANNIA BRAZILIENSIS; PERIPHERAL-BLOOD; ASSAY; IDENTIFICATION; STATE; QUANTIFICATION AB Visceral leishmaniasis represents an important public health issue in different parts of the world, requiring that measures be put in place to control the spread of the disease worldwide. The canine leishmaniasis diagnosis is not easy based on clinical signs, since dogs may not develop the infection with recognizable signs. Thus, the laboratorial diagnosis is essential to ascertain the incidence and prevalence of canine leishmaniasis especially in areas with major control efforts. Although, the diagnosis can be performed by the use of different approaches, the molecular methods such as PCR have become an indispensable tool for leishmaniases diagnosis. A TaqMan assay for real-time PCR (Linj31-qPCR) was developed to determine the parasite occurrence in clinical cases of leishmaniasis. The assay targets an L. (L.) infantum hypothetical protein region. The specificity of the assay was verified by using Leishmania World Health Organization reference strains including parasites belonging to subgenus L. (Leishmania), subgenus L. (Viannia), other Leishmania species and Trypanosoma cruzi. The sensitivity was verified by using isolates of L. (L.) amazonensis and L. (L.) infantum. The usefulness of the assay for diagnosis was ascertained by testing 277 samples from dogs in regions endemic for visceral and/or cutaneous leishmaniasis and from regions in which leishmaniasis was not endemic in Sao Paulo State, Brazil. Diagnosis of canine visceral leishmaniasis (CVL) was determined on these animals by conventional PCR and three serological tests. The dog samples were divided into four groups. I, dogs with CVL (n = 101); II, dogs with other diseases and without CVL (n = 97); III, dogs with American cutaneous leishmaniasis (n = 7), and, IV, dogs without CVL (n = 72) from areas where leishmaniasis was not endemic as control group. Results indicated that Linj31-qPCR was able to identify parasites belonging to subgenus L. (Leishmania) with no cross-amplification with other parasite subgenera. The Linj31-qPCR detected Leishmania parasites DNA in 98% of samples from Group I. In conclusion this methodology can be used as routine diagnostic tools to detect parasites from subgenus Leishmania. (C) 2015 Elsevier Inc. All rights reserved. C1 [Colombo, Fabio Antonio] Univ Fed Alfenas, Lab Biol Mol Microorganismos, Alfenas, MG, Brazil. [Pereira-Chioccola, Vera Lucia; Meira, Cristina da Silva; Motoie, Gabriela; Gava, Ricardo] Adolfo Lutz Inst, Ctr Parasitol & Micol, Lab Biol Mol Parasitas, BR-01246902 Sao Paulo, SP, Brazil. [Hiramoto, Roberto M.] Adolfo Lutz Inst, Ctr Parasitol & Micol, Nucleo Parasitoses Sistem, BR-01246902 Sao Paulo, SP, Brazil. [de Almeida, Marcos E.; da Silva, Alexandre J.] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Ctr Global Hlth, Publ Hlth Serv, Atlanta, GA USA. [Cutolo, Andre Antonio] Prefeitura Municipal Monte Mor, Setor Controle Zoonoses & Vetores, Monte Mor, SP, Brazil. [Menz, Ingrid] Ingrid Menz Micro Empresa, Campinas, SP, Brazil. RP Pereira-Chioccola, VL (reprint author), Adolfo Lutz Inst, Parasitol Lab, Ave Dr Arnaldo 351,8 Andar, BR-01246902 Sao Paulo, SP, Brazil. EM pchioccola@gmail.com.br RI Motoie, Gabriela/N-8122-2015; Meira-Strejevitch, Cristina /L-8914-2016; OI Meira-Strejevitch, Cristina /0000-0002-2070-8087; Pereira-Chioccola, Vera Lucia/0000-0003-3317-195X FU FAPESP (Fundacao de Amparo a Pesquisa do Estado de Sao Paulo, Brazil); FAPESP [Proc-08/57245-7]; CNPq (Conselho Nacional de Desenvolvimento Cientifico, Brazil) [303489/2012-0] FX We are grateful for Elaine Barbosa de Oliveira for technical support in serological reactions. This study was supported by grants from the FAPESP (Fundacao de Amparo a Pesquisa do Estado de Sao Paulo, Brazil). Procs 08/00520-6 and 2011/13939-8. F.A.C. was supported by fellowship from FAPESP Proc-08/57245-7. V.L.P.C. was supported by a fellowship from CNPq (Conselho Nacional de Desenvolvimento Cientifico, Brazil) Proc 303489/2012-0. NR 45 TC 2 Z9 2 U1 1 U2 7 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0014-4894 EI 1090-2449 J9 EXP PARASITOL JI Exp. Parasitol. PD OCT PY 2015 VL 157 BP 156 EP 162 DI 10.1016/j.exppara.2015.08.014 PG 7 WC Parasitology SC Parasitology GA CS8BH UT WOS:000362310200022 PM 26297683 ER PT J AU Weiser, J Beer, L Frazier, EL Patel, R Dempsey, A Hauck, H Skarbinski, J AF Weiser, John Beer, Linda Frazier, Emma L. Patel, Roshni Dempsey, Antigone Hauck, Heather Skarbinski, Jacek TI Service Delivery and Patient Outcomes in Ryan White HIV/AIDS Program-Funded and -Nonfunded Health Care Facilities in the United States SO JAMA INTERNAL MEDICINE LA English DT Article ID ANTIRETROVIRAL THERAPY; PSYCHIATRIC-DISORDERS; HIV-INFECTION; INTERVENTIONS; METAANALYSIS; ADHERENCE; CENTERS; TRIALS; RISK AB IMPORTANCE Outpatient human immunodeficiency virus (HIV) health care facilities receive funding from the Ryan White HIV/AIDS Program (RWHAP) to provide medical care and essential support services that help patients remain in care and adhere to treatment. Increased access to Medicaid and private insurance for HIV-infected persons may provide coverage for medical care but not all needed support services and may not supplant the need for RWHAP funding. OBJECTIVE To examine differences between RWHAP-funded and non-RWHAP-funded facilities and in patient outcomes between the 2 systems. DESIGN, SETTING, AND PARTICIPANTS The study was conducted from June 1, 2009, to May 31, 2012, using data from the 2009 and 2011 cycles of the Medical Monitoring Project, a national probability sample of 8038 HIV-infected adults receiving medical care at 989 outpatient health care facilities providing HIV medical care. MAIN OUTCOMES AND MEASURES Data were used to compare patient characteristics, service needs, and access to services at RWHAP-funded vs non-RWHAP-funded facilities. Differences in prescribed antiretroviral treatment and viral suppression were assessed. Data analysis was performed between February 2012 and June 2015. RESULTS Overall, 34.4% of facilities received RWHAP funding and 72.8% of patients received care at RWHAP-funded facilities. With results reported as percentage (95% CI), patients attending RWHAP-funded facilities were more likely to be aged 18 to 29 years (8.5% [7.4%-9.5%] vs 5.0%[3.9%-6.2%]), female (29.2%[27.2%-31.2%] vs 20.1%[17.0%-23.1%]), black (47.5%[41.5%-53.5%] vs 25.8% [20.6%-31.0%]) or Hispanic (22.5%[16.4%-28.6%] vs 12.9% [10.6%-15.2%]), have less than a high school education (26.1% [24.0%-28.3%] vs 10.9%[8.7%-13.1%]), income at or below the poverty level (53.6%[50.3%-56.9%] vs 23.9% [19.7%-28.0%]), and lack health care coverage (25.0%[21.9%-28.1%] vs 6.1% [4.1%-8.0%]). The RWHAP-funded facilities were more likely to provide case management (76.1% [69.9%-82.2%] vs 15.4%[10.4%-20.4%]) as well as mental health (64.0%[57.0%-71.0%] vs 18.0%[14.0%-21.9%]), substance abuse (33.6%[27.0%-40.2%] vs 12.0% [8.0%-16.0%]), and other support services; patients attending RWHAP-funded facilities were more likely to receive these services. After adjusting for patient characteristics, the percentage prescribed ART antiretroviral therapy, reported as adjusted prevalence ratio (95% CI), was similar between RWHAP-funded and non-RWHAP-funded facilities (1.01 [0.99-1.03]), but among poor patients, those attending RWHAP-funded facilities were more likely to be virally suppressed (1.09 [1.02-1.16]). CONCLUSIONS AND RELEVANCE A total of 72.8% of HIV-positive patients received care at RWHAP-funded facilities. Many had multiple social determinants of poor health and used services at RWHAP-funded facilities associated with improved outcomes. Without facilities supported by the RWHAP, these patients may have had reduced access to services elsewhere. Poor patients were more likely to achieve viral suppression if they received care at a RWHAP-funded facility. C1 [Weiser, John; Beer, Linda; Frazier, Emma L.; Patel, Roshni] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA 30329 USA. [Patel, Roshni] ICF Int, Hlth Informat & Technol Syst, Atlanta, GA USA. [Dempsey, Antigone; Hauck, Heather] HIV AIDS Bur, Hlth Resources & Serv Adm, Rockville, MD USA. [Skarbinski, Jacek] Ctr Dis Control & Prevent, Div Global HIV AIDS & TB, Atlanta, GA 30329 USA. RP Weiser, J (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, 1600 Clifton Rd NE,Mail Stop E46, Atlanta, GA 30329 USA. EM jweiser@cdc.gov FU Centers for Disease Control and Prevention (CDC) FX Funding for the Medical Monitoring Project is provided by the Centers for Disease Control and Prevention (CDC). NR 28 TC 14 Z9 14 U1 3 U2 9 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD OCT PY 2015 VL 175 IS 10 BP 1650 EP 1659 DI 10.1001/jamainternmed.2015.4095 PG 10 WC Medicine, General & Internal SC General & Internal Medicine GA CT1WY UT WOS:000362594600012 PM 26322677 ER PT J AU Hatzenbuehler, ML Schwab-Reese, L Ranapurwala, SI Hertz, MF Ramirez, MR AF Hatzenbuehler, Mark L. Schwab-Reese, Laura Ranapurwala, Shabbar I. Hertz, Marci F. Ramirez, Marizen R. TI Associations Between Antibullying Policies and Bullying in 25 States SO JAMA PEDIATRICS LA English DT Article ID RISK BEHAVIOR SURVEILLANCE; UNITED-STATES; HEALTH; SCHOOL; YOUTH; FRAMEWORK; LAWS; VICTIMIZATION; CHILDREN; MODEL AB IMPORTANCE Bullying is the most widespread form of peer aggression in schools. In an effort to address school bullying, 49 states have passed antibullying statutes. Despite the ubiquity of these policies, there has been limited empirical examination of their effectiveness in reducing students' risk of being bullied. OBJECTIVE To evaluate the effectiveness of antibullying legislation in reducing students' risk of being bullied and cyberbullied, using data from 25 states in the United States. DESIGN, SETTING, AND PARTICIPANTS A cross-sectional observational study was conducted using a population-based survey of 63 635 adolescents in grades 9 to 12 from 25 states participating in the 2011 Youth Risk Behavior Surveillance System study (September 2010-December 2011). Data on antibullying legislation were obtained from the US Department of Education (DOE), which commissioned a systematic review of state laws in 2011. The report identified 16 key components that were divided into the following 4 broad categories: purpose and definition of the law, district policy development and review, school district policy components (eg, responsibilities for reporting bullying incidents), and additional components (eg, how policies are communicated). Policy variables from 25 states were linked to individual-level data from the Youth Risk Behavior Surveillance System on experiencing bullying and cyberbullying. Analyses were conducted between March 1, 2014, and December 1, 2014. EXPOSURE State antibullying legislation. MAIN OUTCOMES AND MEASURES Exposure to bullying and cyberbullying in the past 12 months. RESULTS There was substantial variation in the rates of bullying and cyberbullying across states. After controlling for relevant state-level confounders, students in states with at least 1 DOE legislative component in the antibullying law had a 24%(95% CI, 15%-32%) reduced odds of reporting bullying and 20%(95% CI, 9%-29%) reduced odds of reporting cyberbullying compared with students in states whose laws had no DOE legislative components. Three individual components of antibullying legislation were consistently associated with decreased odds of exposure to both bullying and cyberbullying: statement of scope, description of prohibited behaviors, and requirements for school districts to develop and implement local policies. CONCLUSIONS AND RELEVANCE Antibullying policies may represent effective intervention strategies for reducing students' risk of being bullied and cyberbullied in schools. C1 [Hatzenbuehler, Mark L.] Columbia Univ, Mailman Sch Publ Hlth, Dept Sociomed Sci, New York, NY 10032 USA. [Schwab-Reese, Laura] Univ Iowa, Coll Publ Hlth, Dept Community & Behav Hlth, Iowa City, IA USA. [Ranapurwala, Shabbar I.; Ramirez, Marizen R.] Univ Iowa, Coll Publ Hlth, Injury Prevent Res Ctr, Dept Occupat & Environm Hlth, Iowa City, IA USA. [Hertz, Marci F.] Ctr Dis Control & Prevent, Div Anal Res & Practice Integrat, Atlanta, GA USA. RP Hatzenbuehler, ML (reprint author), Columbia Univ, Mailman Sch Publ Hlth, Dept Sociomed Sci, 722 W 168th St,Room 549B, New York, NY 10032 USA. EM mlh2101@cumc.columbia.edu FU Center for Injury Epidemiology and Prevention at Columbia University [1 R49 CE002096]; University of Iowa Injury Prevention Research Center [5R49 CE002108]; National Center for Injury Prevention and Control; Centers for Disease Control and Prevention FX This study was supported in part by grant 1 R49 CE002096 from the Center for Injury Epidemiology and Prevention at Columbia University and Research Core grant 5R49 CE002108 from the University of Iowa Injury Prevention Research Center. Both centers were funded by the National Center for Injury Prevention and Control, Centers for Disease Control and Prevention. NR 29 TC 13 Z9 13 U1 10 U2 35 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6203 EI 2168-6211 J9 JAMA PEDIATR JI JAMA Pediatr. PD OCT PY 2015 VL 169 IS 10 AR e152411 DI 10.1001/jamapediatrics.2015.2411 PG 8 WC Pediatrics SC Pediatrics GA CT1XJ UT WOS:000362595700001 PM 26437015 ER PT J AU Raspa, M Levis, DM Kish-Doto, J Wallace, I Rice, C Barger, B Green, KK Wolf, RB AF Raspa, Melissa Levis, Denise M. Kish-Doto, Julia Wallace, Ina Rice, Catherine Barger, Brian Green, Katie K. Wolf, Rebecca B. TI Examining Parents' Experiences and Information Needs Regarding Early Identification of Developmental Delays: Qualitative Research to Inform a Public Health Campaign SO JOURNAL OF DEVELOPMENTAL AND BEHAVIORAL PEDIATRICS LA English DT Article DE early identification; developmental delay or disability; parental concerns; qualitative research; health education campaign ID YOUNG-CHILDREN; EARLY INTERVENTION; SURVEILLANCE; PREVALENCE; CARE; IMPLEMENTATION; PERSPECTIVE; DISORDERS; SERVICES; PROJECT AB Objective:The purpose of this study was to assess the approach and materials of Centers for Disease Control and Prevention's Learn the Signs. Act Early. (LTSAE) health education campaign, which aims to improve awareness of developmental milestones and early warning signs of developmental delay among parents of young children.Methods:We conducted 2 phases of qualitative research. Focus groups assessed the campaign's objectives by exploring the experiences of parents with children who have developmental delays or disabilities to determine facilitators of and barriers to identification. In-depth interviews were conducted with parents of typically developing children, who reviewed campaign materials and provided feedback on appropriateness, appeal, and clarity with regard to the campaign's objectives.Results:Phase 1: Parents were typically the first to express concern about their child's development, and most talked with their child's health care provider. Two categories of health care providers emerged: those who proactively asked about a child's development, used tools to facilitate conversations, and made referrals, and those who did not ask about development, told parents to wait and see, and did not provide information about services and supports. Few parents knew about special education services before identification. Phase 2: Participants found the campaign materials appealing, but were unclear about how to act early and why acting early was important.Conclusions:Results affirmed LTSAE's evidence-based approach to educating parents about child development. Additional campaign considerations include providing more information about how to act early and why acting early is important and enhancing outreach to providers to help them communicate with concerned parents. C1 [Raspa, Melissa; Kish-Doto, Julia; Wallace, Ina] RTI Int, Res Triangle Pk, NC USA. [Levis, Denise M.; Rice, Catherine; Barger, Brian; Green, Katie K.; Wolf, Rebecca B.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. [Barger, Brian] Univ S Carolina, Disabil Res & Disseminat Ctr, Columbia, SC 29208 USA. RP Raspa, M (reprint author), 3040 Cornwallis Rd, Res Triangle Pk, NC 27709 USA. EM mraspa@rti.org FU Centers for Disease Control and Prevention [200-2007-20016/020] FX This investigation was supported by the Centers for Disease Control and Prevention (Contract 200-2007-20016/020). NR 32 TC 1 Z9 1 U1 1 U2 10 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0196-206X EI 1536-7312 J9 J DEV BEHAV PEDIATR JI J. Dev. Behav. Pediatr. PD OCT PY 2015 VL 36 IS 8 BP 575 EP 585 DI 10.1097/DBP.0000000000000205 PG 11 WC Behavioral Sciences; Psychology, Developmental; Pediatrics SC Behavioral Sciences; Psychology; Pediatrics GA CT1FX UT WOS:000362544300004 PM 26414090 ER PT J AU Butler, K Ritter, J Ellis, S Henning, TR Montague, J Zaki, S Garber, D McNicholl, JM Kersh, EN AF Butler, Katherine Ritter, Jana Ellis, Shanon Henning, Tara R. Montague, Jeltley Zaki, Sherif Garber, David McNicholl, Janet M. Kersh, Ellen N. TI Analysis of putative mucosal SHIV susceptibility factors during repeated DMPA treatments in pigtail macaques SO JOURNAL OF MEDICAL PRIMATOLOGY LA English DT Article DE contraception; non-human primates; transmission risk ID DEPOT-MEDROXYPROGESTERONE ACETATE; MENSTRUAL-CYCLE; EPIDEMIOLOGIC EVIDENCE; VAGINAL MICROBIOTA; MACACA-NEMESTRINA; HIV ACQUISITION; ANIMAL-MODELS; CONTRACEPTIVES; PROGESTERONE; EPITHELIUM AB Background Depot-medroxyprogesterone acetate (DMPA) has been associated in some studies with increased HIV susceptibility in women. We used a pigtail macaque model to document the effects of repeated DMPA treatments and their potential contribution to increased SHIV susceptibility. Methods Nine pigtails were administered 2.5, 1.5, or 0.5 mg/kg DMPA in study weeks one and four. Menstrual cycling, vaginal epithelial thickness, and other SHIV susceptibility factors were monitored for a mean of 24 study weeks. Results All DMPA treatments suppressed menstrual cycling and increased vaginal pH. The vaginal epithelium thinned naturally during baseline menstrual cycles (from mean of 351 to 161 pm in late-luteal phase). Following DMPA, the non-nucleated layer was temporarily absent. Two weeks post-second DMPA injection, mean epithelial thickness was 53, 45, and 167 mu m for the descending doses, respectively. Conclusions All animals showed temporal vaginal epithelial thinning with loss of the non-nucleated layer, and vaginal pH changes post-DMPA injections, C1 [Butler, Katherine; Henning, Tara R.; Garber, David; McNicholl, Janet M.; Kersh, Ellen N.] CDC, Branch Lab, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis Sexually Transm, Atlanta, GA 30333 USA. [Ritter, Jana; Montague, Jeltley; Zaki, Sherif] CDC, Infect Dis Pathol Branch, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Ellis, Shanon] Total Solut, Atlanta, GA USA. RP Kersh, EN (reprint author), CDC, Branch Lab, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis Sexually Transm, 1600 Clifton Rd NE MS A25, Atlanta, GA 30333 USA. EM egk6@cdc.gov FU CDC; CDC [Y1-AI-0681-02]; NIH [Y1-AI-0681-02] FX We would like to thank Frank Deyounks, Kristen Kelly, Leecresia Jenkins, Julian Jolly, and the Animal Resources Branch Care staff for all of their help and support with this research project. This work was funded by CDC, and partially supported by Interagency Agreement Y1-AI-0681-02 between CDC and NIH. NR 25 TC 3 Z9 3 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0047-2565 EI 1600-0684 J9 J MED PRIMATOL JI J. Med. Primatol. PD OCT PY 2015 VL 44 IS 5 SI SI BP 286 EP 295 DI 10.1111/jmp.12188 PG 10 WC Veterinary Sciences; Zoology SC Veterinary Sciences; Zoology GA CS3IM UT WOS:000361966000008 PM 26238265 ER PT J AU Morris, MR Byrareddy, SN Villinger, F Henning, TC Butler, K Ansari, AA McNicholl, JM Kersh, EN AF Morris, Monica R. Byrareddy, Siddappa N. Villinger, Francois Henning, Tara C. Butler, Katherine Ansari, Aftab A. McNicholl, Janet M. Kersh, Ellen N. TI Relationship of menstrual cycle and vaginal infection in female rhesus macaques challenged with repeated, low doses of SIVmac251 SO JOURNAL OF MEDICAL PRIMATOLOGY LA English DT Article DE menstrual cycle; progesterone; rhesus macaque; SIV ID SIMIAN IMMUNODEFICIENCY VIRUS; PIGTAIL MACAQUES; TRANSMISSION; SUSCEPTIBILITY; PROTECTS; MONKEYS; HIV; SIV AB Varying susceptibility during menstrual cycling could be a factor for S(H)IV infection risk in female rhesus macaques. We retrospectively determined vaginal SIV infection time points relative to the menstrual cycle in a group of rhesus macaques (n=11) enrolled in an HIV transmission trial. Eight of nine rhesus macaques became infected around menstruation time. C1 [Morris, Monica R.] Total Solut, Atlanta, GA USA. [Byrareddy, Siddappa N.; Villinger, Francois; Ansari, Aftab A.] Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30322 USA. [Henning, Tara C.; Butler, Katherine; McNicholl, Janet M.; Kersh, Ellen N.] Ctr Dis Control, Branch Lab, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. RP Kersh, EN (reprint author), Ctr Dis Control, Branch Lab, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, 1600 Clifton Rd NE,MS A25,Bldg 17,Rm 3229, Atlanta, GA 30333 USA. EM egk6@cdc.gov FU CDC; CDC [Y1-A1-0681-02]; NIH [Y1-A1-0681-02]; NIH-NIAID [AI-098628-01]; [P51 OD11132] FX The authors would like to thank Dr. Ziegler and Dan Wittwer of the University of Wisconsin National Primate Center for progesterone analysis, and the veterinary and technical staff at Emory University for supplying the plasma samples for this study. This work was funded by CDC and an interagency agreement (Y1-A1-0681-02) between CDC and NIH. Also supported by a grant from the NIH-NIAID AI-098628-01 (to A.A.A.) and P51 OD11132 to the Yerkes National Primate Research Center. All authors declare no conflict of interest. NR 14 TC 3 Z9 3 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0047-2565 EI 1600-0684 J9 J MED PRIMATOL JI J. Med. Primatol. PD OCT PY 2015 VL 44 IS 5 SI SI BP 301 EP 305 DI 10.1111/jmp.12177 PG 5 WC Veterinary Sciences; Zoology SC Veterinary Sciences; Zoology GA CS3IM UT WOS:000361966000010 PM 26054016 ER PT J AU Pereira, LE Mesquita, PMM Ham, A Singletary, T McNicholl, J Buckheit, KW Buckheit, RW Smith, J AF Pereira, Lara E. Mesquita, Pedro M. M. Ham, Anthony Singletary, Tyana McNicholl, Janet Buckheit, Karen W. Buckheit, Robert W., Jr. Smith, James TI PHARMACOKINETIC AND PHARMACODYNAMIC EVALUATION OF A DUAL COMPARTMENT DUOGEL (TM) CONTAINING THE NNRTI IQP-0528 IN FEMALE RHESUS MACAQUES SO JOURNAL OF MEDICAL PRIMATOLOGY LA English DT Meeting Abstract C1 [Pereira, Lara E.] LifeSource BioMed LLC, Moffett Field, CA USA. [Mesquita, Pedro M. M.] Albert Einstein Coll Med, Bronx, NY 10467 USA. [Ham, Anthony; Buckheit, Karen W.; Buckheit, Robert W., Jr.] ImQuest BioSci, Frederick, MD USA. [Singletary, Tyana] Anyar Inc, Ft Walton Beach, FL USA. [McNicholl, Janet; Smith, James] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0047-2565 EI 1600-0684 J9 J MED PRIMATOL JI J. Med. Primatol. PD OCT PY 2015 VL 44 IS 5 SI SI MA O5.03 BP 320 EP 320 PG 1 WC Veterinary Sciences; Zoology SC Veterinary Sciences; Zoology GA CS3IM UT WOS:000361966000054 ER PT J AU Butler, K Ritter, J Ellis, S Henning, T Montague, J Zaki, S Garber, D McNicholl, J Kersh, E AF Butler, Katherine Ritter, Jana Ellis, Shanon Henning, Tara Montague, Jeltley Zaki, Sherif Garber, David McNicholl, Janet Kersh, Ellen TI ANALYSIS OF PUTATIVE MUCOSAL SHIV SUSCEPTIBILITY FACTORS DURING REPEATED DMPA TREATMENTS IN PIGTAIL MACAQUES SO JOURNAL OF MEDICAL PRIMATOLOGY LA English DT Meeting Abstract C1 [Butler, Katherine; Ritter, Jana; Henning, Tara; Montague, Jeltley; Zaki, Sherif; Garber, David; McNicholl, Janet; Kersh, Ellen] Ctr Dis Control & Prevent, Atlanta, GA USA. [Ellis, Shanon] Total Solut, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0047-2565 EI 1600-0684 J9 J MED PRIMATOL JI J. Med. Primatol. PD OCT PY 2015 VL 44 IS 5 SI SI MA P1.01 BP 325 EP 325 PG 1 WC Veterinary Sciences; Zoology SC Veterinary Sciences; Zoology GA CS3IM UT WOS:000361966000067 ER PT J AU Kersh, E Morris, M Byrareddy, S Villanger, F Henning, T Butler, K Ansari, A McNicholl, J AF Kersh, Ellen Morris, Monica Byrareddy, Siddappa Villanger, Francois Henning, Tara Butler, Katherine Ansari, Aftab McNicholl, Janet TI RELATIONSHIP OF MENSTRUAL CYCLING AND VAGINAL INFECTION IN FEMALE RHESUS MACAQUES CHALLENGED WITH REPEATED, LOW DOSES OF SIVMAC251 SO JOURNAL OF MEDICAL PRIMATOLOGY LA English DT Meeting Abstract C1 [Kersh, Ellen; Henning, Tara; Butler, Katherine; McNicholl, Janet] Ctr Dis Control & Prevent, Atlanta, GA USA. [Morris, Monica] Total Solut, Atlanta, GA USA. [Byrareddy, Siddappa; Ansari, Aftab] Emory Univ, Atlanta, GA 30322 USA. [Villanger, Francois] Emory Univ, Yerkes Natl Primate Res Ctr, Atlanta, GA 30322 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0047-2565 EI 1600-0684 J9 J MED PRIMATOL JI J. Med. Primatol. PD OCT PY 2015 VL 44 IS 5 SI SI MA P1.02 BP 325 EP 325 PG 1 WC Veterinary Sciences; Zoology SC Veterinary Sciences; Zoology GA CS3IM UT WOS:000361966000068 ER PT J AU Tsegaye, TS Vishwanathan, SA Kennedy, MS Curtis, K Pereira, L Mitchell, J Ellis, SJ Deyounks, F Jenkins, LT Butler, K Garber, D Smith, J McNicholl, JM Kersh, EN AF Tsegaye, Theodros Solomon Vishwanathan, Sundaram Ajay Kennedy, M. Susan Curtis, Kelly Pereira, Lara Mitchell, James Ellis, Shanon J. Deyounks, Frank Jenkins, Leecresia T. Butler, Katherine Garber, David Smith, James McNicholl, Janet M. Kersh, Ellen N. TI SHIV INFECTION FOLLOWING PREVIOUS VACCINATION AND PRE-EXPOSURE PROPHYLAXIS WITH TRUVADA IS ASSOCIATED WITH ALTERED ANTIBODY AVIDITY SO JOURNAL OF MEDICAL PRIMATOLOGY LA English DT Meeting Abstract C1 [Tsegaye, Theodros Solomon; Vishwanathan, Sundaram Ajay; Kennedy, M. Susan; Curtis, Kelly; Mitchell, James; Jenkins, Leecresia T.; Butler, Katherine; Garber, David; Smith, James; McNicholl, Janet M.; Kersh, Ellen N.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Pereira, Lara] LifeSource Biomed LLC, Moffett Field, CA USA. [Ellis, Shanon J.; Deyounks, Frank] Total Solut, Madison, AL USA. NR 0 TC 0 Z9 0 U1 2 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0047-2565 EI 1600-0684 J9 J MED PRIMATOL JI J. Med. Primatol. PD OCT PY 2015 VL 44 IS 5 SI SI MA P3.19 BP 340 EP 340 PG 1 WC Veterinary Sciences; Zoology SC Veterinary Sciences; Zoology GA CS3IM UT WOS:000361966000108 ER PT J AU Srinivasan, P Zhang, JN Martin, A McNicholl, J Buckheit, R Smith, J Ham, A AF Srinivasan, Priya Zhang, Jining Martin, Amy McNicholl, Janet Buckheit, Robert, Jr. Smith, James Ham, Anthony TI PROTECTIVE LEVELS OF THE POTENT ANTIRETROVIRAL COMPOUND IQP-0528 IN MACAQUE VAGINAL FLUID AND TISSUE WHEN DELIVERED WITH QUICK-DISSOLVING VAGINAL FILMS SO JOURNAL OF MEDICAL PRIMATOLOGY LA English DT Meeting Abstract C1 [Srinivasan, Priya; Martin, Amy; McNicholl, Janet; Smith, James] CDC, Atlanta, GA 30333 USA. [Zhang, Jining] Total Solut Inc, Atlanta, GA USA. [Buckheit, Robert, Jr.; Ham, Anthony] ImQuest BioSci, Frederick, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0047-2565 EI 1600-0684 J9 J MED PRIMATOL JI J. Med. Primatol. PD OCT PY 2015 VL 44 IS 5 SI SI MA P5.03 BP 347 EP 347 PG 1 WC Veterinary Sciences; Zoology SC Veterinary Sciences; Zoology GA CS3IM UT WOS:000361966000125 ER PT J AU O'Sullivan, EJ Perrine, CG Rasmussen, KM AF O'Sullivan, Elizabeth J. Perrine, Cria G. Rasmussen, Kathleen M. TI Early Breastfeeding Problems Mediate the Negative Association between Maternal Obesity and Exclusive Breastfeeding at 1 and 2 Months Postpartum SO JOURNAL OF NUTRITION LA English DT Article DE maternal obesity; BMI; early breastfeeding problems; breastfeeding cessation; mediation analysis ID BODY-MASS INDEX; DELAYED-ONSET; INSUFFICIENT MILK; RISK-FACTORS; SELF-EFFICACY; LACTATION; DURATION; INITIATION; SMOKING; WOMEN AB Background: Compared with normal-weight women, women with obesity experience poorer breastfeeding outcomes. Successful breastfeeding among women with obesity is important for achieving national breastfeeding goals. Objectives: The objectives were to determine whether the negative association between obesity and any or exclusive breastfeeding at 1 and 2 mo postpartum is mediated through breastfeeding problems that occur in the first 2 wk postpartum and if this association differs by parity. Methods: Mothers (1151 normal-weight and 580 obese) in the Infant Feeding Practices Study II provided information on sociodemographic and psychosocial characteristics, body mass index, and breastfeeding outcomes. At 1 mo postpartum, participantsyeported the breastfeeding problems they experienced in the first 2 wk postpartum from a predefined list of 17 options. We used factor analysis to condense these problems into 4 explanatory variables; continuous factor scores were computed for use in further analyses. We used maximum likelihood logistic regression to assess mediation of the association between obesity and breastfeeding outcomes through early breastfeeding problems. Results: No significant effect of obesity was found on any breastfeeding at 1 or 2 mo. At 1 mo postpartum, for both primiparous and multiparous women, there was a significant direct effect of obesity on exclusive breastfeeding and a significant indirect effect of obesity through early breastfeeding problems related to the explanatory mediating variable "Insufficient Milk" (throughout the remainder of the Abstract, this factor will be denoted by upper case notation). At 2 mo postpartum both the direct effect of obesity and the indirect effect through Insufficient Milk were significant in primiparous women but only the indirect effect remained significant in multiparous women. Conclusions: Early problems related to Insufficient Milk may partially explain the association between obesity and poor exclusive breastfeeding outcomes. Women who are obese, particularly those reporting breastfeeding problems that grouped in the Insufficient Milk factor in the early postpartum period, may benefit from additional breastfeeding support. C1 [O'Sullivan, Elizabeth J.; Rasmussen, Kathleen M.] Cornell Univ, Div Nutr Sci, Ithaca, NY 14853 USA. [Perrine, Cria G.] CDC, Div Nutr Phys Act & Obes, Atlanta, GA 30333 USA. RP O'Sullivan, EJ (reprint author), Cornell Univ, Div Nutr Sci, Ithaca, NY 14853 USA. EM eo238@cornell.edu FU International Fulbright Science and Technology Award FX Supported by an International Fulbright Science and Technology Award (to EJOS). NR 38 TC 4 Z9 4 U1 5 U2 14 PU AMER SOC NUTRITION-ASN PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-3166 EI 1541-6100 J9 J NUTR JI J. Nutr. PD OCT PY 2015 VL 145 IS 10 BP 2369 EP 2378 DI 10.3945/jn.115.214619 PG 10 WC Nutrition & Dietetics SC Nutrition & Dietetics GA CS9CW UT WOS:000362387700025 PM 26290005 ER PT J AU James, PT Van den Briel, N Rozet, A Israel, AD Fenn, B Navarro-Colorado, C AF James, Philip T. Van den Briel, Natalie Rozet, Aurelie Israel, Anne-Dominique Fenn, Bridget Navarro-Colorado, Carlos TI Low-dose RUTF protocol and improved service delivery lead to good programme outcomes in the treatment of uncomplicated SAM: a programme report from Myanmar SO MATERNAL AND CHILD NUTRITION LA English DT Article DE severe acute malnutrition; health service delivery; community-based; therapeutic feeding; programme evaluation; undernutrition ID CHILD UNDERNUTRITION; MALNUTRITION; CONSEQUENCES; COUNTRIES; HEALTH AB The treatment of uncomplicated severe acute malnutrition (SAM) requires substantial amounts of ready-to-use therapeutic food (RUTF). In 2009, Action Contre la Faim anticipated a shortfall of RUTF for their nutrition programme in Myanmar. A low-dose RUTF protocol to treat children with uncomplicated SAM was adopted. In this protocol, RUTF was dosed according to beneficiary's body weight, until the child reached a Weight-for-Height z-score of -3 and mid-upper arm circumference 110mm. From this point, the child received a fixed quantity of RUTF per day, independent of body weight until discharge. Specific measures were implemented as part of this low-dose RUTF protocol in order to improve service quality and beneficiary support. We analysed individual records of 3083 children treated from July 2009 to January 2010. Up to 90.2% of children recovered, 2.0% defaulted and 0.9% were classified as non-responders. No deaths were recorded. Among children who recovered, median [IQR] length of stay and weight gain were 42 days [28; 56] and 4.0gkg(-1) day(-1) [3.0; 5.7], respectively. Multivariable logistic regression showed that children older than 48 months had higher odds of non-response to treatment than younger children (adjusted odds ratio: 3.51, 95% CI: 1.67-7.42). Our results indicate that a low-dose RUTF protocol, combined with specific measures to ensure good service quality and beneficiary support, was successful in treating uncomplicated SAM in this setting. This programmatic experience should be validated by randomised studies aiming to test, quantify and attribute the effect of the protocol adaptation and programme improvements presented here. C1 [James, Philip T.; Van den Briel, Natalie; Rozet, Aurelie; Israel, Anne-Dominique] ACF, Expertise & Advocacy Dept, F-75854 Paris 17, France. [James, Philip T.; Fenn, Bridget] London Sch Hyg & Trop Med, Fac Epidemiol & Populat Hlth, London WC1, England. [Navarro-Colorado, Carlos] US Ctr Dis Control & Prevent, Emergency Response & Recovery Branch, Div Global Dis Protect, Ctr Global Hlth, Atlanta, GA USA. RP Van den Briel, N (reprint author), ACF, 14-16 Blvd Douaumont, F-75854 Paris 17, France. EM natalievandenbriel@gmail.com OI Navarro Colorado, Carlos/0000-0002-2185-0157 FU European Commission's Humanitarian Aid and Civil Protection Department (ECHO) FX The programme was funded by the European Commission's Humanitarian Aid and Civil Protection Department (ECHO). No additional research funds were used for the study. NR 16 TC 0 Z9 0 U1 2 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1740-8695 EI 1740-8709 J9 MATERN CHILD NUTR JI Matern. Child Nutr. PD OCT PY 2015 VL 11 IS 4 BP 859 EP 869 DI 10.1111/mcn.12192 PG 11 WC Nutrition & Dietetics; Pediatrics SC Nutrition & Dietetics; Pediatrics GA CS6NR UT WOS:000362197100034 PM 25850698 ER PT J AU Keim, SA Branum, AM AF Keim, Sarah A. Branum, Amy M. TI Dietary intake of polyunsaturated fatty acids and fish among US children 12-60 months of age SO MATERNAL AND CHILD NUTRITION LA English DT Article DE polyunsaturated fatty acids; children; fish; race ID GUIDE PYRAMID RECOMMENDATIONS; 1ST YEAR GROWTH; DOCOSAHEXAENOIC ACID; ARACHIDONIC-ACID; PRETERM INFANTS; PRESCHOOL-CHILDREN; MULTIETHNIC COHORT; N-3; BRAIN; ADHERENCE AB This study aimed to estimate intake of individual polyunsaturated fatty acids (PUFAs), identify major dietary sources of PUFAs and estimate the proportion of individuals consuming fish among US children 12-60 months of age, by age and race and ethnicity. The study employed a cross-sectional design using US National Health and Nutrition Examination Survey data. Representative sample of US population based on selected counties. Subjects: 2496 US children aged 12-60 months. Mean daily intake of n-6 PUFAs and eicosapentaenoic acid (EPA) varied by age, with children 12-24 months of age having lower average intakes (mg or gday(-1)) than children 49-60 months of age and the lowest n6:n3 ratio, upon adjustment for energy intake. Docosahexaenoic acid (DHA) intake was low (20mgday(-1)) compared to typical infant intake and did not change with age. Compared to non-Hispanic white children, Mexican American children had higher DHA and arachidonic acid (AA) intake. In the previous 30 days, 53.7% of children ever consumed fish. Non-Hispanic black children were more likely than non-Hispanic white children to have consumed fish (64.0% vs. 53.0%). Results indicate low prevalence of fish intake and key n-3 PUFAs, relative to n-6 fatty acids, which suggests room for improvement in the diets of US children. More research is needed to determine how increasing dietary intakes of n-3 PUFAs like DHA could benefit child health. C1 [Keim, Sarah A.] Nationwide Childrens Hosp, Res Inst, Ctr Biobehav Hlth, Columbus, OH 43205 USA. [Keim, Sarah A.] Ohio State Univ, Coll Med, Dept Pediat, Columbus, OH 43210 USA. [Keim, Sarah A.] Ohio State Univ, Coll Publ Hlth, Div Epidemiol, Columbus, OH 43210 USA. [Branum, Amy M.] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Off Anal & Epidemiol, Infant Children & Womens Hlth Stat Branch, Hyattsville, MD 20782 USA. RP Keim, SA (reprint author), Nationwide Childrens Hosp, Res Inst, Ctr Biobehav Hlth, 700 Childrens Dr, Columbus, OH 43205 USA. EM keim.22@osu.edu OI Keim, Sarah/0000-0003-3490-3649 FU Intramural CDC HHS [CC999999] NR 51 TC 1 Z9 1 U1 0 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1740-8695 EI 1740-8709 J9 MATERN CHILD NUTR JI Matern. Child Nutr. PD OCT PY 2015 VL 11 IS 4 BP 987 EP 998 DI 10.1111/mcn.12077 PG 12 WC Nutrition & Dietetics; Pediatrics SC Nutrition & Dietetics; Pediatrics GA CS6NR UT WOS:000362197100044 PM 24034437 ER PT J AU Benedict, KM AF Benedict, K. M. TI Fungal disease outbreaks and fungal diseases after natural disasters SO MYCOSES LA English DT Meeting Abstract C1 [Benedict, K. M.] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0933-7407 EI 1439-0507 J9 MYCOSES JI Mycoses PD OCT PY 2015 VL 58 SU 4 SI SI MA PS3.2 BP 11 EP 12 PG 2 WC Dermatology; Mycology SC Dermatology; Mycology GA CT4SF UT WOS:000362796800007 ER PT J AU Lockhart, SR AF Lockhart, S. R. TI Azole resistance in the Americas. Not catching up with Europe SO MYCOSES LA English DT Meeting Abstract C1 [Lockhart, S. R.] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0933-7407 EI 1439-0507 J9 MYCOSES JI Mycoses PD OCT PY 2015 VL 58 SU 4 SI SI MA S01.2 BP 20 EP 20 PG 1 WC Dermatology; Mycology SC Dermatology; Mycology GA CT4SF UT WOS:000362796800029 ER PT J AU Chiller, TM AF Chiller, T. M. TI The North American encounter with C. gattii. Where does it stop? Not just an opportunistic infection but an endemic disease! SO MYCOSES LA English DT Meeting Abstract C1 [Chiller, T. M.] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0933-7407 EI 1439-0507 J9 MYCOSES JI Mycoses PD OCT PY 2015 VL 58 SU 4 SI SI MA S10.3 BP 32 EP 32 PG 1 WC Dermatology; Mycology SC Dermatology; Mycology GA CT4SF UT WOS:000362796800062 ER PT J AU Chiller, TM AF Chiller, T. M. TI Fungal Meningitis Caused by Contaminated Steroid Injections USA: Outcome and Treatment SO MYCOSES LA English DT Meeting Abstract C1 [Chiller, T. M.] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0933-7407 EI 1439-0507 J9 MYCOSES JI Mycoses PD OCT PY 2015 VL 58 SU 4 SI SI MA S18.5 BP 40 EP 40 PG 1 WC Dermatology; Mycology SC Dermatology; Mycology GA CT4SF UT WOS:000362796800089 ER PT J AU Healey, KR Lockhart, SR Sobel, JD Farmakiotis, D Kontoyiannis, DP Sanglard, D Shor, E Perlin, DS AF Healey, K. R. Lockhart, S. R. Sobel, J. D. Farmakiotis, D. Kontoyiannis, D. P. Sanglard, D. Shor, E. Perlin, D. S. TI Candida glabrata mutator phenotype promotes resistance to multiple antifungal drugs SO MYCOSES LA English DT Meeting Abstract C1 [Healey, K. R.; Shor, E.] Rutgers, New Jersey Med Sch, Publ Hlth Res Inst, Newark, NJ USA. [Lockhart, S. R.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Sobel, J. D.] Wayne State Univ, Sch Med, Detroit, MI USA. [Farmakiotis, D.; Kontoyiannis, D. P.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Sanglard, D.] Univ Lausanne Hosp, Inst Microbiol, Lausanne, Switzerland. [Perlin, D. S.] New Jersey Med Sch Rutgers, Newark, NJ USA. NR 0 TC 0 Z9 1 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0933-7407 EI 1439-0507 J9 MYCOSES JI Mycoses PD OCT PY 2015 VL 58 SU 4 SI SI MA P017 BP 58 EP 58 PG 1 WC Dermatology; Mycology SC Dermatology; Mycology GA CT4SF UT WOS:000362796800127 ER PT J AU Farooqi, JQ Zafar, A Jabeen, K Mahboob, R Rawala, M Longi, A Deedarali, A Malik, F Lockhart, SR Brandt, M AF Farooqi, J. Q. Zafar, A. Jabeen, K. Mahboob, R. Rawala, M. Longi, A. Deedarali, A. Malik, F. Lockhart, S. R. Brandt, M. TI Invasive candidiasis in Pakistan: Predominant Species and Antifungal Resistance (2010-2014) SO MYCOSES LA English DT Meeting Abstract C1 [Farooqi, J. Q.; Zafar, A.; Jabeen, K.; Mahboob, R.; Rawala, M.; Longi, A.; Deedarali, A.; Malik, F.] Aga Khan Univ, Karachi, Pakistan. [Lockhart, S. R.; Brandt, M.] Ctr Dis Control & Prevent, Atlanta, GA USA. RI Jabeen, Kauser/I-8018-2015 NR 0 TC 1 Z9 1 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0933-7407 EI 1439-0507 J9 MYCOSES JI Mycoses PD OCT PY 2015 VL 58 SU 4 SI SI MA P039 BP 68 EP 69 PG 2 WC Dermatology; Mycology SC Dermatology; Mycology GA CT4SF UT WOS:000362796800149 ER PT J AU Farooqi, JQ Jabeen, K Kumar, H Mahboob, R Brandt, M Zafar, A AF Farooqi, J. Q. Jabeen, K. Kumar, H. Mahboob, R. Brandt, M. Zafar, A. TI Agreement of the direct antifungal susceptibility testing from positive blood culture bottles with conventional method for Candida species SO MYCOSES LA English DT Meeting Abstract C1 [Farooqi, J. Q.; Jabeen, K.; Kumar, H.; Mahboob, R.; Zafar, A.] Aga Khan Univ, Karachi, Pakistan. [Brandt, M.] Ctr Dis Control & Prevent, Atlanta, GA USA. RI Jabeen, Kauser/I-8018-2015 NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0933-7407 EI 1439-0507 J9 MYCOSES JI Mycoses PD OCT PY 2015 VL 58 SU 4 SI SI MA P042 BP 70 EP 70 PG 1 WC Dermatology; Mycology SC Dermatology; Mycology GA CT4SF UT WOS:000362796800152 ER PT J AU Sriruttan, C Naidoo, N Mpembe, R Smith, R Greene, G Adelekan, A Deyde, V Oladoyinbo, S Maotoe, T Chiller, TM Govender, NP AF Sriruttan, C. Naidoo, N. Mpembe, R. Smith, R. Greene, G. Adelekan, A. Deyde, V. Oladoyinbo, S. Maotoe, T. Chiller, T. M. Govender, N. P. TI Reflex Cryptococcal antigen screening among children and adolescents in two districts in Gauteng province, South-Africa SO MYCOSES LA English DT Meeting Abstract C1 [Sriruttan, C.; Naidoo, N.; Mpembe, R.; Govender, N. P.] Natl Inst Communicable Dis, Johannesburg, South Africa. [Smith, R.; Greene, G.; Adelekan, A.; Deyde, V.; Chiller, T. M.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Oladoyinbo, S.; Maotoe, T.] US Agcy Int Dev, Pretoria, South Africa. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0933-7407 EI 1439-0507 J9 MYCOSES JI Mycoses PD OCT PY 2015 VL 58 SU 4 SI SI MA P294 BP 159 EP 159 PG 1 WC Dermatology; Mycology SC Dermatology; Mycology GA CT4SF UT WOS:000362796800344 ER PT J AU Van Handel, M Lyons, B Oraka, E Nasrullah, M DiNenno, E Dietz, P AF Van Handel, Michelle Lyons, Bridget Oraka, Emeka Nasrullah, Muazzam DiNenno, Elizabeth Dietz, Patricia TI Factors Associated with Time Since Last HIV Test Among Persons at High Risk for HIV Infection, National Survey of Family Growth, 2006-2010 SO AIDS PATIENT CARE AND STDS LA English DT Article ID UNITED-STATES; MEN; SEX; JURISDICTIONS; BEHAVIORS; HEALTH; TRENDS; WOMEN; CARE; GAY AB The Centers for Disease Control and Prevention (CDC) recommends annual HIV screening for persons at high risk for HIV infection. We assessed the testing history and factors associated with recent testing (tested in the last 12 months) among persons at high risk for HIV infection. We analyzed 2006-2010 National Survey of Family Growth data and classified respondents aged 15-44 who reported a sexual or drug-use risk behavior in the past year as high-risk'. Logistic regression models estimated prevalence ratios assessing the association between demographic and health-related factors and having been recently tested for HIV compared with never been tested. Among high-risk men, 29.3% had recently tested for HIV, 30.7% tested more than 12 months ago, and 40.0% had never been tested. Among high-risk women, 38.0% had recently tested, 36.9% tested more than 12 months ago, and 26.1% had never been tested. Compared with men who were aged 15-19, white, heterosexual, and had not recently visited a doctor, men who were aged 40-44, black/African American, homosexual/gay or bisexual, and had visited a doctor in the past year were more likely to have recently tested. Compared with women who were white, had not recently visited a doctor, and had never been pregnant, women more likely to have recently tested were black/African American, had visited a doctor in the past year, and had been pregnant. Approximately two-thirds of high-risk men and women had not been recently tested for HIV. CDC recommendations for annual screening are not being implemented for the majority of persons at risk. C1 [Van Handel, Michelle; Lyons, Bridget; Dietz, Patricia] Ctr Dis Control & Prevent, Program Evaluat Branch, Atlanta, GA 30333 USA. [Oraka, Emeka] Ctr Dis Control & Prevent, ICF Int Behav & Clin Surveillance Branch, Atlanta, GA 30333 USA. [Nasrullah, Muazzam; DiNenno, Elizabeth] Ctr Dis Control & Prevent, Behav & Clin Surveillance Branch, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. RP Van Handel, M (reprint author), Ctr Dis Control & Prevent, Program Evaluat Branch, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, 1600 Clifton Rd NE,Mailstop E-59, Atlanta, GA 30333 USA. EM ioq4@cdc.gov FU Intramural CDC HHS [CC999999] NR 29 TC 4 Z9 4 U1 1 U2 2 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1087-2914 EI 1557-7449 J9 AIDS PATIENT CARE ST JI Aids Patient Care STDS PD OCT 1 PY 2015 VL 29 IS 10 BP 533 EP 540 DI 10.1089/apc.2015.0078 PG 8 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA CS6ID UT WOS:000362181100003 PM 26196537 ER PT J AU Baracco, GJ Eisert, S Saavedra, S Hirsch, P Marin, M Ortega-Sanchez, IR AF Baracco, G. J. Eisert, S. Saavedra, S. Hirsch, P. Marin, M. Ortega-Sanchez, I. R. TI Clinical and economic impact of various strategies for varicella immunity screening and vaccination of health care personnel SO AMERICAN JOURNAL OF INFECTION CONTROL LA English DT Article DE Varicella; Occupational health; Screening; Immunization; Occupational exposure; Model ID COST-EFFECTIVENESS; MEASLES OUTBREAK; HERPES-ZOSTER; WORKERS; POPULATION; PREVENTION; STATES AB Background: Exposure to patients with varicella or herpes zoster causes considerable disruption to a health care facility's operations and has a significant health and economic impact. However, practices related to screening for immunity and immunization of health care personnel (HCP) for varicella vary widely. Methods: A decision tree model was built to evaluate the cost-effectiveness of 8 different strategies of screening and vaccinating HCP for varicella. The outcomes are presented as probability of acquiring varicella, economic impact of varicella per employee per year, and cost to prevent additional cases of varicella. Monte Carlo simulations and 1-way sensitivity analyses were performed to address the uncertainties inherent to the model. Alternative epidemiologic and technologic scenarios were also analyzed. Results: Performing a clinical screening followed by serologic testing of HCP with negative history diminished the cost impact of varicella by >99% compared with not having a program. Vaccinating HCP with negative screen cost approximately $50,000 per case of varicella prevented at the current level of U.S. population immunity, but was projected to be cost-saving at 92% or lower immunity prevalence. Improving vaccine acceptance rates and using highly sensitive assays also optimize cost-effectiveness. Conclusion: Strategies relying on screening and vaccinating HCP for varicella on employment were shown to be cost-effective for health care facilities and are consistent with current national guidelines for varicella prevention. Published by Elsevier Inc. on behalf of the Association for Professionals in Infection Control and Epidemiology, Inc. C1 [Baracco, G. J.; Eisert, S.] Vet Hlth Adm, Off Publ Hlth, Natl Ctr Occupat Hlth & Infect Control, Gainesville, FL USA. [Baracco, G. J.] Miami Vet Affairs Healthcare Syst, Miami, FL USA. [Baracco, G. J.] Univ Miami, Miller Sch Med, Miami, FL 33136 USA. [Eisert, S.] Univ S Florida, Coll Publ Hlth, Tampa, FL USA. [Saavedra, S.] Vet Affairs Caribbean Healthcare Syst, San Juan, PR USA. [Hirsch, P.] Vet Hlth Adm, Off Publ Hlth, Occupat Hlth, Washington, DC USA. [Marin, M.; Ortega-Sanchez, I. R.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. RP Baracco, GJ (reprint author), Miami VA Med Ctr, 1201 NW 16th St 111, Miami, FL 33125 USA. EM gio.baracco@va.gov OI Baracco, Gio/0000-0002-7347-7884 FU U.S. Department of Veterans Affairs; Centers for Disease Control and Prevention FX Funding in the form of salary support for the authors was provided by the U.S. Department of Veterans Affairs and the Centers for Disease Control and Prevention. NR 27 TC 2 Z9 2 U1 1 U2 3 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-6553 EI 1527-3296 J9 AM J INFECT CONTROL JI Am. J. Infect. Control PD OCT 1 PY 2015 VL 43 IS 10 BP 1053 EP 1060 DI 10.1016/j.ajic.2015.05.027 PG 8 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA CS5CL UT WOS:000362093600008 PM 26138999 ER PT J AU Allen-Bridson, K Pollock, D Gould, CV AF Allen-Bridson, Katherine Pollock, Daniel Gould, Carolyn V. TI Promoting prevention through meaningful measures: Improving the Centers for Disease Control and Prevention's National Healthcare Safety Network urinary tract infection surveillance definitions SO AMERICAN JOURNAL OF INFECTION CONTROL LA English DT Editorial Material ID CANDIDURIA C1 [Allen-Bridson, Katherine; Pollock, Daniel; Gould, Carolyn V.] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA 30333 USA. RP Allen-Bridson, K (reprint author), Ctr Dis Control & Prevent, Lead Protocol & Training Team, Div Healthcare Qual Promot, 1600 Clifton Rd,Mailstop A-24, Atlanta, GA 30333 USA. EM fsa6@cdc.gov OI Allen-Bridson, Katherine/0000-0002-6578-0832 FU Intramural CDC HHS [CC999999] NR 11 TC 3 Z9 3 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-6553 EI 1527-3296 J9 AM J INFECT CONTROL JI Am. J. Infect. Control PD OCT 1 PY 2015 VL 43 IS 10 BP 1096 EP 1098 DI 10.1016/j.ajic.2015.06.006 PG 3 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA CS5CL UT WOS:000362093600016 PM 26190383 ER PT J AU Allen-Bridson, K Anttila, A Brooks, JE Gross, C Hebden, JN Leaptrot, D Morabit, S Wright, MO AF Allen-Bridson, Katherine Anttila, Angela Brooks, Janet E. Gross, Cindy Hebden, Joan N. Leaptrot, Denise Morabit, Susan Wright, Marc-Oliver TI Health Care-Associated Infections Studies Project Case #2: A 2015 American Journal of Infection Control and National Healthcare Safety Network data quality collaboration SO AMERICAN JOURNAL OF INFECTION CONTROL LA English DT Editorial Material DE CLABSI; NHSN C1 [Allen-Bridson, Katherine] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Natl Healthcare Safety Network, Atlanta, GA USA. [Anttila, Angela; Brooks, Janet E.; Gross, Cindy; Leaptrot, Denise; Morabit, Susan] CACI Inc, Healthcare Solut Grp, Publ Hlth & Surveillance, Atlanta, GA USA. [Hebden, Joan N.] Wolters Kluwer Hlth, Bellevue, WA USA. [Wright, Marc-Oliver] North Shore Univ Hlth Syst, Dept Infect Control, Evanston, IL USA. RP Allen-Bridson, K (reprint author), 1600 Clifton Rd,MS A-24, Atlanta, GA 30333 USA. EM fsa6@cdc.gov OI Allen-Bridson, Katherine/0000-0002-6578-0832; Leaptrot, Denise/0000-0003-2461-208X FU Intramural CDC HHS [CC999999] NR 1 TC 0 Z9 0 U1 0 U2 2 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-6553 EI 1527-3296 J9 AM J INFECT CONTROL JI Am. J. Infect. Control PD OCT 1 PY 2015 VL 43 IS 10 BP 1099 EP 1101 DI 10.1016/j.ajic.2015.05.028 PG 3 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA CS5CL UT WOS:000362093600017 PM 26209337 ER PT J AU Stone, PW Pogorzelska-Maziarz, M Reagan, J Merrill, JA Sperber, B Cairns, C Penn, M Ramanathan, T Mothershed, E Skillen, E AF Stone, Patricia W. Pogorzelska-Maziarz, Monika Reagan, Julie Merrill, Jacqueline A. Sperber, Brad Cairns, Catherine Penn, Matthew Ramanathan, Tara Mothershed, Elizabeth Skillen, Elizabeth TI Impact of laws aimed at healthcare-associated infection reduction: a qualitative study SO BMJ QUALITY & SAFETY LA English DT Article DE Patient safety; Infection control; Healthcare quality improvement; Nosocomial infections; Health policy ID US HOSPITALS; IMPROVEMENT; PREVENTION; EPIDEMIOLOGY; STATEWIDE; PAY AB Background Healthcare-associated infections (HAIs) are preventable. Globally, laws aimed at reducing HAIs have been implemented. In the USA, these laws are at the federal and state levels. It is not known whether the state interventions are more effective than the federal incentives alone. Objective The aims of this study were to explore the impact federal and state HAI laws have on state departments of health and hospital stakeholders in the USA and to explore similarities and differences in perceptions across states. Methods A qualitative study was conducted. In 2012, we conducted semistructured interviews with key stakeholders from states with and without state-level laws to gain multiple perspectives. Interviews were transcribed and open coding was conducted. Data were analysed using content analysis and collected until theoretical saturation was achieved. Results Ninety interviews were conducted with stakeholders from 12 states (6 states with laws and 6 states without laws). We found an increase in state-level collaboration. The publicly reported data helped hospitals benchmark and focus leaders on HAI prevention. There were concerns about the publicly reported data (eg, lack of validation and timeliness). Resource needs were also identified. No major differences were expressed by interviewees from states with and without laws. Conclusions While we could not tease out the impact of specific interventions, increased collaboration between departments of health and their partners is occurring. Harmonisation of HAI definitions and reporting between state and federal laws would minimise reporting burden. Continued monitoring of the progress of HAI prevention is needed. C1 [Stone, Patricia W.; Merrill, Jacqueline A.] Columbia Univ, Ctr Hlth Policy, Sch Nursing, New York, NY 10032 USA. [Pogorzelska-Maziarz, Monika] Thomas Jefferson Univ, Jefferson Sch Nursing, Philadelphia, PA 19107 USA. [Reagan, Julie] Georgia So Univ, Jiann Ping Hsu Coll Publ Hlth, Statesboro, GA 30460 USA. [Sperber, Brad] Keystone Ctr, Ctr Hlth Policy, Washington, DC USA. [Cairns, Catherine] ASTHO, Ctr Hlth Policy, Arlington, VA USA. [Penn, Matthew] Ctr Dis Control & Prevent, Off State Tribal Local & Territorial Support, Atlanta, GA USA. [Penn, Matthew; Ramanathan, Tara] Ctr Dis Control & Prevent, Off State Tribal Local & Territorial Support, Publ Hlth Law Program, Atlanta, GA USA. [Mothershed, Elizabeth] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA USA. [Skillen, Elizabeth] Ctr Dis Control & Prevent, Policy, Atlanta, GA USA. RP Stone, PW (reprint author), Columbia Univ, Ctr Hlth Policy, Sch Nursing, New York, NY 10032 USA. EM ps2024@columbia.edu FU National Institute of Nursing Research [R01NR010107]; Robert Wood Johnson Foundation [270282]; Centers for Disease Control and Prevention [400648] FX National Institute of Nursing Research (R01NR010107), Robert Wood Johnson Foundation (270282), Centers for Disease Control and Prevention (400648). NR 31 TC 2 Z9 2 U1 2 U2 4 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 2044-5415 EI 2044-5423 J9 BMJ QUAL SAF JI BMJ Qual. Saf. PD OCT PY 2015 VL 24 IS 10 BP 637 EP 644 DI 10.1136/bmjqs-2014-003921 PG 8 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA CS0PE UT WOS:000361763300008 PM 26043742 ER PT J AU Heelan, KA Bartee, RT Nihiser, A Sherry, B AF Heelan, Kate A. Bartee, R. Todd Nihiser, Allison Sherry, Bettylou TI Healthier School Environment Leads to Decreases in Childhood Obesity: The Kearney Nebraska Story SO CHILDHOOD OBESITY LA English DT Article ID PHYSICAL-ACTIVITY; UNITED-STATES; CHILDREN; ADOLESCENTS; OVERWEIGHT; PREVENTION; BEHAVIORS; POLICY AB Background: Schools play a role in addressing childhood obesity by implementing healthy eating and physical activity strategies. The primary aim of this case study was to describe prevalence of overweight and obesity among elementary school students in a rural Mid-western community between 2006 and 2012. The secondary aim was to use a novel approach called population dose to retrospectively evaluate the impact dose of each strategy implemented and its estimated potential population level impact on changes in overweight and obesity. Methods: Weight and height were directly measured annually beginning in January 2006 to assess weight status, using BMI (kg/m(2)), for all kindergarten to fifth-grade students (N approximate to 2400 per year). Multiple evidence-based strategies were implemented in nine schools to increase physical activity and healthy eating behaviors. BMI reporting and revised school meal programs were implemented districtwide. Comprehensive school physical activity programs, school food environment, and supportive/promotional strategies were implemented at individual schools. Results: The absolute change in prevalence of obesity (BMI 95th percentile) decreased from 16.4% to 13.9%, indicating a 15.2% relative change in prevalence of obesity in 6 years. There was an inverse relationship between the number of strategies implemented and prevalence of overweight and obesity over time. Conclusions: District and school-level approaches have the potential to impact childhood obesity. Schools can successfully implement strategies to address overweight and obesity, but the extent of implementation between schools may vary. Population dose analysis can be used to estimate impact of clusters of strategies to address overweight/obesity. C1 [Heelan, Kate A.; Bartee, R. Todd] Univ Nebraska, Dept Kinesiol & Sport Sci, Kearney, NE 68849 USA. [Nihiser, Allison] Ctr Dis Control & Prevent, Div Populat Hlth, Atlanta, GA USA. [Sherry, Bettylou] Ctr Dis Control & Prevent, Obes Prevent & Control Branch, Div Nutr Phys Act & Obes, Atlanta, GA USA. RP Heelan, KA (reprint author), Univ Nebraska, Phys Act & Wellness Lab, Kinesiol & Sport Sci Dept, 1410 West 26th St, Kearney, NE 68849 USA. EM heelanka@unk.edu FU Carol M. White Physical Education Program [Q215F080323] FX Funding was provided by a Carol M. White Physical Education Program Grant (no. Q215F080323). The authors acknowledge Carol Renner, Associate Superintendent, and Cari Franzen, Wellness Coordinator, and the students, staff, and administration of Kearney Public Schools, Kearney, Nebraska. The authors also acknowledge Elena Kuo, Evaluation Consultant for the CCHE, for her assistance with using the CCHE approach to measuring population dose. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the CDC. NR 29 TC 2 Z9 2 U1 2 U2 13 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 2153-2168 EI 2153-2176 J9 CHILD OBES JI Child Obes. PD OCT 1 PY 2015 VL 11 IS 5 BP 600 EP 607 DI 10.1089/chi.2015.0005 PG 8 WC Pediatrics SC Pediatrics GA CS7NE UT WOS:000362269500015 PM 26440386 ER PT J AU Green, BL Ayoub, C Bartlett, JD Furrer, C Von Ende, A Chazan-Cohen, R Klevens, J Nygren, P AF Green, Beth L. Ayoub, Catherine Bartlett, Jessica Dym Furrer, Carrie Von Ende, Adam Chazan-Cohen, Rachel Klevens, Joanne Nygren, Peggy TI It's not as simple as it sounds: Problems and solutions in accessing and using administrative child welfare data for evaluating the impact of early childhood interventions SO CHILDREN AND YOUTH SERVICES REVIEW LA English DT Article DE Child maltreatment; Administrative records; Methodology; Evaluation; Early childhood; Randomized control trial ID MALTREATMENT RESEARCH; RISK-FACTORS; ABUSE; NEGLECT; INVOLVEMENT; PREVALENCE; INJURY AB In recent years, there has been increasing interest in using administrative data collected by state child welfare agencies as a source of information for research and evaluation. The challenges of obtaining access to and using these data, however, have not been well documented. This study describes the processes used to access child welfare records in six different states and the approach to combining and using the information gathered to evaluate the impact of the Early Head Start program on children's involvement with the child welfare system from birth through age eleven. We provide "lessons learned" for researchers who are attempting to use this information, including being prepared for long delays in access to information, the need for deep understanding of how child welfare agencies record and code information, and for considerable data management work for translating agency records into analysis-ready datasets. While accessing and using this information is not easy, and the data have a number of limitations, we suggest that the benefits can outweigh the challenges and that these records can be a useful source of information for policy-relevant child welfare research. (C) 2015 Elsevier Ltd. All rights reserved. C1 [Green, Beth L.; Furrer, Carrie; Nygren, Peggy] Portland State Univ, Ctr Improvement Child & Family Studies, Portland, OR 97207 USA. [Ayoub, Catherine; Bartlett, Jessica Dym; Von Ende, Adam] Harvard Univ, Sch Med, Brazelton Touchpoints Ctr BCH3111, Div Dev Med,Boston Childrens Hosp, Boston, MA 02215 USA. [Chazan-Cohen, Rachel] Univ Massachusetts, Coll Educ & Human Dev, Boston, MA 02125 USA. [Klevens, Joanne] Ctr Dis Control & Prevent, Div Violence Prevent, Atlanta, GA 30341 USA. RP Green, BL (reprint author), Portland State Univ, Ctr Improvement Child & Family Studies, POB 751, Portland, OR 97207 USA. EM beth.green@pdx.edu FU Centers for Disease Control and Prevention [200-2010-35155]; Administration for Children and Families (ACF); U.S. Department of Health and Human Services [105-95-1936] FX Support for this study was provided by the Centers for Disease Control and Prevention (Contract #200-2010-35155). The findings and conclusions in this paper are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. The authors would like to offer special thanks to those members of the Early Head Start Research Consortium who attended the Early Head Start-Child Welfare Study (EHS-CWS) Data Camps, and contributed to the development of the study: Judy Carta (University of Kansas), Lori Roggman (Utah State University), and Leanne Whiteside-Mansell (University of Arkansas-Little Rock). We would also like to acknowledge the important roles played by states' child welfare agency research staff in the six EHS-CWS study states that participated in this project, without whose assistance this project would not have been possible: Arkansas, California, Kansas, Michigan, Washington, and Vermont.; Finally, we are indebted to the years of work by the Early Head Start Research Consortium. The findings reported here are based on research conducted as part of the national Early Head Start Research and Evaluation Project funded by the Administration for Children and Families (ACF), U.S. Department of Health and Human Services under Contract 105-95-1936 to Mathematica Policy Research, Princeton, NJ, and Columbia University's National Center for Children and Families, Teachers College, in conjunction with the Early Head Start Research Consortium. The Consortium consists of representatives from 17 programs participating in the evaluation, 15 local research teams, the evaluation contractors, and ACF. Research institutions in the Consortium (and principal researchers for conducting this research through 36 months of age) have included the following: ACF (Rachel Chazan Cohen, Judith Jerald, Esther Kresh, Helen Raikes, and Louisa Tarullo); Catholic University of America (Michaela Farber, Harriet Liebow, Nancy Taylor, Elizabeth Timberlake, and Shavaun Wall); Columbia University (Lisa Berlin, Christy Brady-Smith, and Jeanne Brooks-Gunn); Harvard University (Catherine Ayoub, Barbara Alexander Pan, and Catherine Snow); Iowa State University (Dee Draper, Gayle Luze, Susan McBride, Carla Peterson); Mathematica Policy Research (Kimberly Boller, Jill Constantine, Ellen Eliason Kisker, John M. Love, Diane Paulsell, Christine Ross, Peter Schochet, Susan Sprachman, Cheri Vogel, and Welmoet van Kammen); Medical University of South Carolina (Richard Faldowski, Gui-Young Hong, and Susan Pickrel); Michigan State University (Hiram Fitzgerald, Tom Reischl, and Rachel Schiffman); New York University (Mark Spellmann and Catherine Tamis-LeMonda); University of Arkansas (Robert Bradley, Richard Clubb, Andrea Hart, Mark Swanson, and Leanne Whiteside-Mansell); University of California, Los Angeles (Allison Sidle Fuligni, Carol lee Howes and Claire Hamilton); University of Colorado at Denver (Robert Emde, Jon Korfmacher, JoAnn Robinson, Paul Spicer, and Norman Watt); University of Kansas (Jane Atwater, Judith Carta; and Jean Ann Summers); University of Missouri-Columbia (Mark Fine, Jean Ispa, and Kathy Thornburg); University of Pittsburgh (Beth Green, Carol McAllister, and Robert McCall); University of Washington College of Education (Eduardo Armijo and Joseph Stowitschek); University of Washington School of Nursing (Kathryn Barnard and Susan Spieker), and Utah State University (Lisa Boyce, Gina Cook, Catherine Callow-Heusser, and Lori Roggman). NR 46 TC 3 Z9 3 U1 0 U2 6 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0190-7409 EI 1873-7765 J9 CHILD YOUTH SERV REV JI Child. Youth Serv. Rev. PD OCT PY 2015 VL 57 BP 40 EP 49 DI 10.1016/j.childyouth.2015.07.015 PG 10 WC Family Studies; Social Work SC Family Studies; Social Work GA CS5PU UT WOS:000362131200005 PM 26744551 ER PT J AU Oduyebo, T Zapata, L Whiteman, M Tepper, N Curtis, K D'Angelo, D Marchbanks, P AF Oduyebo, T. Zapata, L. Whiteman, M. Tepper, N. Curtis, K. D'Angelo, D. Marchbanks, P. TI Factors associated with postpartum use of long-acting reversible contraceptive methods: results from the Pregnancy Risk Assessment Monitoring System (PRAMS) - nine states, 2009-2011 SO CONTRACEPTION LA English DT Meeting Abstract C1 [Oduyebo, T.] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 2 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0010-7824 EI 1879-0518 J9 CONTRACEPTION JI Contraception PD OCT PY 2015 VL 92 IS 4 MA P58 BP 380 EP 380 DI 10.1016/j.contraception.2015.06.108 PG 1 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA CS4PC UT WOS:000362057000094 ER PT J AU Vallabhaneni, S Haselow, D Lloyd, S Lockhart, S Moulton-Meissner, H Lester, L Wheeler, G Gladden, L Garner, K Derado, G Park, B Harris, JR AF Vallabhaneni, Snigdha Haselow, Dirk Lloyd, Spencer Lockhart, Shawn Moulton-Meissner, Heather Lester, Laura Wheeler, Gary Gladden, Linda Garner, Kelley Derado, Gordana Park, Benjamin Harris, Julie R. TI Cluster of Cryptococcus neoformans Infections in Intensive Care Unit, Arkansas, USA, 2013 SO EMERGING INFECTIOUS DISEASES LA English DT Article ID GATTII AB We investigated an unusual cluster of 6 patients with Cryptococcus neoformans infection at a community hospital in Arkansas during April December 2013, to determine source of infection. Four patients had bloodstream infection and 2 had respiratory infection; 3 infections occurred within a 10-day period. Five patients had been admitted to the intensive care unit (ICU) with diagnoses other than cryptococcosis; none had HIV infection, and 1 patient had a history of organ transplantation. We then conducted a retrospective cohort study of all patients admitted to the ICU during April December 2013 to determine risk factors for cryptococcosis. Four patients with C. neoformans infection had received a short course of steroids; this short-term use was associated with increased risk for cryptococcosis (rate ratio 19.1; 95% CI 2.1-170.0; p<0.01). Although long-term use of steroids is a known risk factor for cryptococcosis, the relationship between short-term steroid use and disease warrants further study. C1 [Vallabhaneni, Snigdha; Lloyd, Spencer; Lockhart, Shawn; Moulton-Meissner, Heather; Lester, Laura; Derado, Gordana; Park, Benjamin; Harris, Julie R.] Ctr Dis Control & Prevent, Atlanta, GA 30327 USA. [Haselow, Dirk; Lester, Laura; Wheeler, Gary; Gladden, Linda; Garner, Kelley] Arkansas Dept Hlth, Little Rock, AR 72205 USA. RP Vallabhaneni, S (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop C90, Atlanta, GA 30327 USA. EM fco6@cdc.gov NR 17 TC 1 Z9 1 U1 0 U2 1 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD OCT PY 2015 VL 21 IS 10 BP 1719 EP 1724 DI 10.3201/eid2110.150249 PG 6 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CS5ZY UT WOS:000362158000004 PM 26403080 ER PT J AU Johnson, DKH Schiffman, EK Davis, JP Neitzel, DF Sloan, LM Nicholson, WL Fritsche, TR Steward, CR Ray, JA Miller, TK Feist, MA Uphoff, TS Franson, JJ Livermore, AL Deedon, AK Theel, ES Pritt, BS AF Johnson, Diep K. Hoang Schiffman, Elizabeth K. Davis, Jeffrey P. Neitzel, David F. Sloan, Lynne M. Nicholson, William L. Fritsche, Thomas R. Steward, Christopher R. Ray, Julie A. Miller, Tracy K. Feist, Michelle A. Uphoff, Timothy S. Franson, Joni J. Livermore, Amy L. Deedon, Alecia K. Theel, Elitza S. Pritt, Bobbi S. TI Human Infection with Ehrlichia muris-like Pathogen, United States, 2007-2013 SO EMERGING INFECTIOUS DISEASES LA English DT Article ID HUMAN GRANULOCYTIC EHRLICHIOSIS; ANAPLASMA-PHAGOCYTOPHILUM; CHAFFEENSIS AB An Ehrlichia muris-like (EML) pathogen was detected among 4 patients in Minnesota and Wisconsin during 2009. We characterized additional cases clinically and epidemic): logically. During 2004-2013, blood samples from 75,077 patients from all 50 United States were tested by PCR from the groEL gene for Ehrlichia spp. and Anaplasma phagocytophilum. During 2007-2013, samples from 69 (0.1%) patients were positive for the EML pathogen; patients were from 5 states: Indiana (1), Michigan (1), Minnesota (33), North Dakota (3), and Wisconsin (31). Most (64%) patients were male; median age was 63 (range 15-94) years; and all 69 patients reported likely tick exposure in Minnesota or Wisconsin. Fever, malaise, thrombocytopenia, and lymphopenia were the most common symptoms. Sixteen (23%) patients were hospitalized (median 4 days); all recovered, and 96% received doxycycline. Infection with the EML pathogen should be considered for persons reporting tick exposure in Minnesota or Wisconsin. C1 [Johnson, Diep K. Hoang; Davis, Jeffrey P.; Steward, Christopher R.; Deedon, Alecia K.] Wisconsin Dept Hlth Serv, Madison, WI USA. [Schiffman, Elizabeth K.; Neitzel, David F.; Ray, Julie A.] Minnesota Dept Hlth, St Paul, MN USA. [Sloan, Lynne M.; Theel, Elitza S.; Pritt, Bobbi S.] Mayo Clin, Rochester, MN 55905 USA. [Nicholson, William L.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Fritsche, Thomas R.; Uphoff, Timothy S.] Marshfield Clin Fdn Med Res & Educ, Marshfield, WI USA. [Miller, Tracy K.; Feist, Michelle A.] North Dakota Dept Hlth, Bismarck, ND USA. [Franson, Joni J.] Mayo Clin Hlth Syst, Eau Claire, WI USA. [Livermore, Amy L.] Mayo Med Labs, Andover, MA USA. RP Pritt, BS (reprint author), Mayo Clin, 200 1st St SW, Rochester, MN 55905 USA. EM pritt.bobbi@mayo.edu FU Epidemiology Laboratory and Capacity Cooperative Agreement at the Centers for Disease Control and Prevention FX The Epidemiology Laboratory and Capacity Cooperative Agreement at the Centers for Disease Control and Prevention provided support for this study. NR 17 TC 6 Z9 6 U1 0 U2 5 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD OCT PY 2015 VL 21 IS 10 BP 1794 EP 1799 DI 10.3201/eid2110.150143 PG 6 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CS5ZY UT WOS:000362158000013 PM 26402378 ER PT J AU Lindblade, KA Kateh, F Nagbe, TK Neatherlin, JC Pillai, SK Attfield, KR Dweh, E Barradas, DT Williams, SG Blackley, DJ Kirking, HL Patel, MR Dea, M Massoudi, MS Wannemuehler, K Barskey, AE Zarecki, SLM Fomba, M Grube, S Belcher, L Broyles, LN Maxwell, TN Hagan, JE Yeoman, K Westercamp, M Forrester, J Mott, J Mahoney, F Slutsker, L DeCock, KM Nyenswah, T AF Lindblade, Kim A. Kateh, Francis Nagbe, Thomas K. Neatherlin, John C. Pillai, Satish K. Attfield, Kathleen R. Dweh, Emmanuel Barradas, Danielle T. Williams, Seymour G. Blackley, David J. Kirking, Hannah L. Patel, Monita R. Dea, Monica Massoudi, Mehran S. Wannemuehler, Kathleen Barskey, Albert E. Zarecki, Shauna L. Mettee Fomba, Moses Grube, Steven Belcher, Lisa Broyles, Laura N. Maxwell, T. Nikki Hagan, Jose E. Yeoman, Kristin Westercamp, Matthew Forrester, Joseph Mott, Joshua Mahoney, Frank Slutsker, Laurence DeCock, Kevin M. Nyenswah, Tolbert TI Decreased Ebola Transmission after Rapid Response to Outbreaks in Remote Areas, Liberia, 2014 SO EMERGING INFECTIOUS DISEASES LA English DT Article ID HEMORRHAGIC-FEVER; VIRUS DISEASE; WEST-AFRICA; OUTCOMES; CONGO; RISK AB We measured the reproduction number before and after interventions were implemented to reduce Ebola transmission in 9 outbreaks in Liberia during 2014. We evaluated risk factors for secondary cases and the association between patient admission to an Ebola treatment unit (ETU) and survival. The reproduction number declined 94% from 1.7 (95% Cl 1.1-2.6) to 0.1 (95% Cl 0.02-0.6) after interventions began. The risk for secondary infections was 90% lower for patients admitted to an ETU (risk ratio 0.1, 95% Cl 0.04-0.3) than for those who died in the community. The case-fatality rate was 68% (95% Cl 60-74), and ETU admission was associated with a 50% reduction in death (hazard ratio 0.5, 95% Cl 0.4-0.8). Isolation and treatment of Ebola patients had the dual benefit of interrupting community transmission and improving survival. C1 [Lindblade, Kim A.; Neatherlin, John C.; Pillai, Satish K.; Attfield, Kathleen R.; Barradas, Danielle T.; Williams, Seymour G.; Blackley, David J.; Kirking, Hannah L.; Patel, Monita R.; Dea, Monica; Massoudi, Mehran S.; Wannemuehler, Kathleen; Barskey, Albert E.; Zarecki, Shauna L. Mettee; Grube, Steven; Belcher, Lisa; Broyles, Laura N.; Maxwell, T. Nikki; Hagan, Jose E.; Yeoman, Kristin; Westercamp, Matthew; Forrester, Joseph; Mott, Joshua; Mahoney, Frank; Slutsker, Laurence; DeCock, Kevin M.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Kateh, Francis; Nagbe, Thomas K.; Dweh, Emmanuel; Fomba, Moses; Nyenswah, Tolbert] Minist Hlth & Social Welf, Monrovia, CA, Liberia. RP Lindblade, KA (reprint author), Minist Publ Hlth, Dept Dis Control, Thailand US Collaborat, Bldg 7,Soi 4 Tivanon Rd, Nonthaburi 11000, Thailand. EM ki12@cdc.gov FU International Development Office of Foreign Disaster Assistance FX The US Agency for International Development Office of Foreign Disaster Assistance provided leadership and funding. NR 21 TC 12 Z9 12 U1 2 U2 16 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD OCT PY 2015 VL 21 IS 10 BP 1800 EP 1807 DI 10.3201/eid2110.150912 PG 8 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CS5ZY UT WOS:000362158000014 PM 26402477 ER PT J AU Spengler, JR Chakrabarti, AK Coleman-McCray, JD Martin, BE Nichol, ST Spiropoulou, CF Bird, BH AF Spengler, Jessica R. Chakrabarti, Ayan K. Coleman-McCray, JoAnn D. Martin, Brock E. Nichol, Stuart T. Spiropoulou, Christina F. Bird, Brian H. TI Utility of Oral Swab Sampling for Ebola Virus Detection in Guinea Pig Model SO EMERGING INFECTIOUS DISEASES LA English DT Article ID HEMORRHAGIC-FEVER; TRANSMISSION AB To determine the utility of oral swabs for diagnosing infection with Ebola virus, we used a guinea pig model and obtained daily antemortem and postmortem swab samples. According to quantitative reverse transcription PCR analysis, the diagnostic value was poor for antemortem swab samples but excellent for postmortem samples. C1 [Spengler, Jessica R.; Chakrabarti, Ayan K.; Coleman-McCray, JoAnn D.; Martin, Brock E.; Nichol, Stuart T.; Spiropoulou, Christina F.; Bird, Brian H.] Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. RP Bird, BH (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop G14, Atlanta, GA 30329 USA. EM che3@cdc.gov OI Spengler, Jessica R./0000-0002-5383-0513 NR 10 TC 4 Z9 4 U1 0 U2 6 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD OCT PY 2015 VL 21 IS 10 BP 1816 EP 1819 DI 10.3201/eid2110.150840 PG 4 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CS5ZY UT WOS:000362158000016 PM 26401603 ER PT J AU McCleery, EJ Patchanee, P Pongsopawijit, P Chailangkarn, S Tiwananthagorn, S Jongchansittoe, P Dantrakool, A Morakote, N Phyu, H Wilkins, PP Noh, JC Phares, C O'Neal, S Porse, CC AF McCleery, Ellen J. Patchanee, Prapas Pongsopawijit, Pornsawan Chailangkarn, Sasisophin Tiwananthagorn, Saruda Jongchansittoe, Papaspong Dantrakool, Anchalee Morakote, Nimit Phyu, Hnin Wilkins, Patricia P. Noh, John C. Phares, Christina O'Neal, Seth Porse, Charsey Cole TI Taeniasis among Refugees Living on Thailand-Myanmar Border, 2012 SO EMERGING INFECTIOUS DISEASES LA English DT Article ID CHIKUNGUNYA VIRUS; AEDES-AEGYPTI; CALIFORNIA; FEVER AB We tested refugee camp residents on the Thailand Myanmar border for Taenia solium infection. Taeniasis prevalence was consistent with that for other disease-endemic regions, but seropositivity indicating T solium taeniasis was rare. Seropositivity indicating cysticercosis was 5.5% in humans and 3.2% in pigs. Corralling pigs and providing latrines may control transmission of these tapeworms within this camp. C1 [McCleery, Ellen J.; O'Neal, Seth] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Patchanee, Prapas; Pongsopawijit, Pornsawan; Chailangkarn, Sasisophin; Tiwananthagorn, Saruda; Dantrakool, Anchalee; Morakote, Nimit] Chiang Mai Univ, Chiang Mai 50000, Thailand. [Jongchansittoe, Papaspong] Thailand Div Livestock Dev, Mae Hong Son, Thailand. [Phyu, Hnin] Int Rescue Comm, Mae Hong Son, Thailand. [Wilkins, Patricia P.; Noh, John C.; Phares, Christina] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Porse, CC (reprint author), Calif Dept Publ Hlth, 1616 Capitol Ave,MS-7307, Sacramento, CA 95814 USA. EM Charsey.porse@cdph.ca.gov FU NCATS NIH HHS [UL1 TR000128]; NIAID NIH HHS [L30 AI080252] NR 15 TC 1 Z9 1 U1 3 U2 8 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD OCT PY 2015 VL 21 IS 10 BP 1824 EP 1829 DI 10.3201/eid2110.141657 PG 6 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CS5ZY UT WOS:000362158000018 PM 26401787 ER PT J AU Riemersma, KK Komar, N AF Riemersma, Kasen K. Komar, Nicholas TI Heartland Virus Neutralizing Antibodies in Vertebrate Wildlife, United States, 2009-2014 SO EMERGING INFECTIOUS DISEASES LA English DT Article ID BUNYAVIRIDAE PHLEBOVIRUS; AMBLYOMMA-AMERICANUM; MISSOURI; ANIMALS; FEVER; TEXAS AB Since its discovery in 2009, the tickborne Heartland virus (HRTV) has caused human illness in Missouri, Oklahoma, and Tennessee USA. To better assess the geographic distribution of HRTV, we used wildlife serology as an indicator. This retrospective evaluation determined that HRTV is widespread within the central and eastern United States. C1 [Riemersma, Kasen K.; Komar, Nicholas] Ctr Dis Control & Prevent, Ft Collins, CO 80521 USA. RP Komar, N (reprint author), Ctr Dis Control & Prevent, Ft Collins, CO 80521 USA. EM nkomar@cdc.gov FU CDC Epidemiology Elective Program; CDC FX This study was supported by the CDC Epidemiology Elective Program and funded by CDC. NR 13 TC 3 Z9 3 U1 1 U2 8 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD OCT PY 2015 VL 21 IS 10 BP 1830 EP 1833 DI 10.3201/eid2110.150380 PG 4 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CS5ZY UT WOS:000362158000019 PM 26401988 ER PT J AU Wang, DQ Li, SG Cheng, ZB Xiao, N Cotter, C Hwang, J Li, XS Yin, SQ Wang, JZ Bai, L Zheng, Z Wang, SB AF Wang, Duoquan Li, Shengguo Cheng, Zhibin Xiao, Ning Cotter, Chris Hwang, Jimee Li, Xishang Yin, Shouqin Wang, Jiazhi Bai, Liang Zheng, Zhi Wang, Sibao TI Transmission Risk from Imported Plasmodium vivax Malaria in the China-Myanmar Border Region SO EMERGING INFECTIOUS DISEASES LA English DT Article ID FALCIPARUM-MALARIA; ELIMINATION; DELAY AB Malaria importation and local vector susceptibility to imported Plasmodium vivax infection are a continuing risk along the China Myanmar border. Malaria transmission has been prevented in 3 border villages in Tengchong County, Yunnan Province, China, by use of active fever surveillance, integrated vector control measures, and intensified surveillance and response. C1 [Wang, Duoquan; Xiao, Ning] Chinese Ctr Dis Control & Prevent, Shanghai, Peoples R China. [Wang, Duoquan; Xiao, Ning] WHO, Collaborating Ctr Trop Dis, Shanghai, Peoples R China. [Wang, Duoquan; Xiao, Ning] Natl Ctr Int Res Trop Dis, Shanghai, Peoples R China. [Li, Shengguo; Li, Xishang; Yin, Shouqin; Wang, Jiazhi] Tengchong Cty Ctr Dis Control & Prevent, Tengchong, Peoples R China. [Cheng, Zhibin; Zheng, Zhi] Chinese Acad Med Sci, Inst Basic Med Sci, Dept Biochem & Mol Biol, Beijing 100730, Peoples R China. [Cheng, Zhibin; Zheng, Zhi] Peking Union Med Coll, Sch Basic Med, Beijing 100021, Peoples R China. [Cotter, Chris; Hwang, Jimee] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Wang, Jiazhi] Ctr Dis Control & Prevent, Atlanta, GA USA. [Bai, Liang; Wang, Sibao] Chinese Acad Sci, Shanghai, Peoples R China. RP Xiao, N (reprint author), Chinese Ctr Dis Control & Prevent, Natl Inst Parasit Dis, Shanghai, Peoples R China. EM ningxiao116@126.com FU World Health Organization [2012/269948-0]; Laboratory of Parasite and Vector Biology, Ministry of Health [WSBKTKT201403]; National Scientific and Technological Major Program of China [335, 2012ZX10004-220]; National Natural Science Foundation of China [336 81271926]; President's Malaria Initiative; Asia Pacific Malaria Elimination Network fellowship; University of California San Francisco FX The work was supported financially by the World Health Organization (2012/269948-0); the Laboratory of Parasite and Vector Biology, Ministry of Health (WSBKTKT201403); the National Scientific and Technological Major Program of China (grant 335 no. 2012ZX10004-220 to Z.Z.); and the National Natural Science Foundation of China grant no. 336 81271926 to Z.Z.]. J.H. receives salary support from the President's Malaria Initiative. W.D.Q. receives support from a 2014 Asia Pacific Malaria Elimination Network fellowship and the University of California San Francisco. NR 14 TC 9 Z9 14 U1 0 U2 8 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD OCT PY 2015 VL 21 IS 10 BP 1861 EP 1864 DI 10.3201/eid2110.150679 PG 4 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CS5ZY UT WOS:000362158000027 PM 26401843 ER PT J AU Gautret, P Mockenhaupt, FP von Sonnenburg, F Rothe, C Libman, M Van De Winkel, K Bottieau, E Grobusch, MP Hamer, DH Esposito, DH Parola, P Schlagenhauf, P AF Gautret, Philippe Mockenhaupt, Frank P. von Sonnenburg, Frank Rothe, Camilla Libman, Michael Van De Winkel, Kristina Bottieau, Emmanuel Grobusch, Martin P. Hamer, Davidson H. Esposito, Douglas H. Parola, Philippe Schlagenhauf, Patricia CA GeoSentinel Surveillance Network TI Local and International Implications of Schistosomiasis Acquired in Corsica, France SO EMERGING INFECTIOUS DISEASES LA English DT Article ID SURVEILLANCE; DISEASES; EUROPE AB We report 11 cases of schistosomiasis in international travelers who had bathed in rivers in Corsica, France, during 2012-2014. The infections were diagnosed in 2014 and reported to the Geo Sentinel Surveillance Network and European Travel Medicine Network. Travelers can be sentinels for emerging infections; thus, this situation warrants a concerted human and veterinary epidemiologic response. C1 [Gautret, Philippe; Parola, Philippe] Univ Mediterranee Infect, Inst Hosp, Marseille, France. [Gautret, Philippe; Parola, Philippe] Aix Marseille Univ, Marseille, France. [Mockenhaupt, Frank P.] Charite, D-13353 Berlin, Germany. [von Sonnenburg, Frank] Univ Munich, Munich, Germany. [Rothe, Camilla] Univ Clin Hamburg Eppendorf, Hamburg, Germany. [Libman, Michael] McGill Univ, Montreal, PQ, Canada. [Van De Winkel, Kristina] Univ Hosp, Ghent, Belgium. [Bottieau, Emmanuel] Inst Trop Med, B-2000 Antwerp, Belgium. [Grobusch, Martin P.] Univ Amsterdam, Amsterdam, Netherlands. [Hamer, Davidson H.] Boston Med Ctr, Boston, MA USA. [Esposito, Douglas H.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Schlagenhauf, Patricia] Univ Zurich, Ctr Travel Med, Zurich, Switzerland. RP Gautret, P (reprint author), CHU Nord, Chem Bourrely, F-13915 Marseille, France. EM philippe.gautret@club-intemet.fr FU Centers for Disease Control and Prevention [U50/CCU412347]; ISTM FX GeoSentinel, the Global Surveillance Network of the International Society of Travel Medicine (ISTM), is supported by Cooperative Agreement U50/CCU412347 from the Centers for Disease Control and Prevention and by ISTM. NR 15 TC 9 Z9 9 U1 1 U2 6 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD OCT PY 2015 VL 21 IS 10 BP 1865 EP 1868 DI 10.3201/eid2110.150881 PG 4 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CS5ZY UT WOS:000362158000028 PM 26401954 ER PT J AU Cheng, JW Hayden, MK Singh, K Heimler, I Gee, JE Proia, L Sha, BE AF Cheng, Jennifer W. Hayden, Mary K. Singh, Kamaljit Heimler, Ira Gee, Jay E. Proia, Laurie Sha, Beverly E. TI Burkholderia pseudomallei Infection in US Traveler Returning from Mexico, 2014 SO EMERGING INFECTIOUS DISEASES LA English DT Letter ID MELIOIDOSIS C1 [Cheng, Jennifer W.; Hayden, Mary K.; Singh, Kamaljit; Proia, Laurie; Sha, Beverly E.] Rush Univ, Med Ctr, Chicago, IL 60612 USA. [Heimler, Ira] Illinois Dept Publ Hlth Labs, Chicago, IL USA. [Gee, Jay E.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Cheng, JW (reprint author), Rush Univ, Med Ctr, Dept Infect Dis, 600 S Paulina St,Ste 143, Chicago, IL 60612 USA. EM jennifer.w.cheng@gmail.com NR 10 TC 1 Z9 2 U1 0 U2 2 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD OCT PY 2015 VL 21 IS 10 BP 1884 EP 1885 DI 10.3201/eid2110.150815 PG 2 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CS5ZY UT WOS:000362158000037 PM 26401597 ER PT J AU Breedlove, B Arguin, PM AF Breedlove, Byron Arguin, Paul M. TI Don't Lay Your Eggs All in One Basket: Brood Parasitism as a Survival Strategy SO EMERGING INFECTIOUS DISEASES LA English DT Editorial Material C1 [Breedlove, Byron; Arguin, Paul M.] Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. RP Breedlove, B (reprint author), Ctr Dis Control & Prevent, EID Journal, 1600 Clifton Rd NE,Mailstop C19, Atlanta, GA 30329 USA. EM wbbl@cdc.gov OI Breedlove, Byron/0000-0002-1026-1963 NR 6 TC 0 Z9 0 U1 0 U2 9 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD OCT PY 2015 VL 21 IS 10 BP 1891 EP 1892 DI 10.3201/eid2110.AC2110 PG 2 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CS5ZY UT WOS:000362158000041 PM 26672153 ER PT J AU Painter, JA Posey, DL Phares, C AF Painter, John A. Posey, Drew L. Phares, Christina TI Tuberculosis misclassification among immigrants SO INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE LA English DT Letter ID UNITED-STATES; REFUGEES C1 [Painter, John A.; Posey, Drew L.; Phares, Christina] Ctr Dis Control & Prevent, Div Global Migrat & Quarantine, Atlanta, GA 30322 USA. RP Painter, JA (reprint author), Ctr Dis Control & Prevent, Div Global Migrat & Quarantine, Atlanta, GA 30322 USA. EM bzp3@cdc.gov NR 5 TC 0 Z9 0 U1 0 U2 1 PU INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D) PI PARIS PA 68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE SN 1027-3719 EI 1815-7920 J9 INT J TUBERC LUNG D JI Int. J. Tuberc. Lung Dis. PD OCT PY 2015 VL 19 IS 10 BP 1259 EP 1260 DI 10.5588/ijtld.15.0468 PG 2 WC Infectious Diseases; Respiratory System SC Infectious Diseases; Respiratory System GA CS5YR UT WOS:000362154700025 PM 26459545 ER PT J AU Laube, BL Sharpless, G Vikani, AR Harrand, V Zinreich, SJ Sedberry, K Knaus, D Barry, J Papania, M AF Laube, Beth L. Sharpless, Gail Vikani, Ami R. Harrand, Vincent Zinreich, Simeon J. Sedberry, Keith Knaus, Darin Barry, James Papania, Mark TI Intranasal Deposition of Accuspray (TM) Aerosol in Anatomically Correct Models of 2-, 5-, and 12-Year-Old Children SO JOURNAL OF AEROSOL MEDICINE AND PULMONARY DRUG DELIVERY LA English DT Article DE Accuspray delivery in children; 2D gamma scintigraphy; modeling intranasal aerosol deposition in children ID THROAT SAINT MODEL; NASAL DELIVERY-SYSTEMS; UPPER AIRWAY MODEL; PARTICLE DEPOSITION; ULTRAFINE AEROSOLS; DRUG-DELIVERY; NOSE; SPRAY; REPLICAS; INFANTS AB Background: To our knowledge, quantification of intranasal deposition of aerosol generated by Accuspray (AS) in children has never been published. We hypothesized that deposition would vary significantly with age and with placement of the device within, or outside, of the nostril. Methods: We tested these hypotheses in anatomically-correct physical models based on CT scans of 2-, 5-, and 12-year-old children with normal, intranasal airways. Models included a removable anterior nose (AN) with exterior facial features and interior nasal vestibule and nasal valve area and a main nasal airway (MNA), subdivided into upper (superior turbinates and olfactory area), middle (middle turbinates), and lower (inferior turbinates and nasopharynx) thirds. Aerosol was generated from distilled water admixed with (99m)technetium pertechnetate and administered during static airflow by AS inserted inside the right nostril (eight runs/model), or outside the right nostril (six runs/model). Mean aerosol Dv(50)standard deviation was 67.824.7m. Deposition was quantified by 2D gamma scintigraphy and expressed as percentage of the emitted dose. Results: When placed inside the nostril, mean (+/- standard deviation) deposition within the MNA was significantly less in the 2-year-old, compared to the 5- and 12-year-old, averaging 46.8 +/- 33.8% (AN:55.4 +/- 29.9%), 75.4 +/- 26.7% (AN:23.3 +/- 13.6%), and 72.1 +/- 18.5% (AN:25.8 +/- 18.5%), respectively (p<0.05). When placed outside the nostril, MNA was significantly less in the 2- and 5-year-old compared to the 12-year-old, with 1.4 +/- 2.5% (AN:69.7 +/- 40.7%), 7.4 +/- 9.0% (AN:77.8 +/- 32.8%), and 21.1 +/- 29.1% (AN:29.2 +/- 19.3%), respectively (p<0.05). Deposition in the MNA of all age models was highest when AS was placed inside the nostril (p<0.05). Deposition in the lower third was significantly increased for the 5- and 12-year-old and in the middle third of the 5-year-old when AS was placed inside the nostril. Conclusions: These results indicate that age and device placement play important roles in terms of intranasal deposition, when administering aerosol with Accuspray to children. C1 [Laube, Beth L.; Sharpless, Gail; Zinreich, Simeon J.] Johns Hopkins Med Inst, Baltimore, MD 21205 USA. [Vikani, Ami R.] George Washington Univ, Sch Med & Hlth Sci, Washington, DC 20052 USA. [Harrand, Vincent; Sedberry, Keith] CFD Res Corp, Huntsville, AL USA. [Knaus, Darin; Barry, James] Creare LLC, Hanover, NH USA. [Papania, Mark] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Laube, BL (reprint author), Johns Hopkins Hosp Pk David M Rubenstein Bldg, Baltimore, MD 21287 USA. EM blaube@jhmi.edu FU Centers for Disease Control and Prevention FX This work was partially funded by the Centers for Disease Control and Prevention. NR 39 TC 0 Z9 0 U1 0 U2 1 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1941-2711 EI 1941-2703 J9 J AEROSOL MED PULM D JI J. Aerosol Med. Pulm. Drug Deliv. PD OCT 1 PY 2015 VL 28 IS 5 BP 320 EP 333 DI 10.1089/jamp.2014.1174 PG 14 WC Respiratory System SC Respiratory System GA CS5JJ UT WOS:000362114000002 PM 25679810 ER PT J AU Hwang, SS Lu, E Cui, X Diop, H Barfield, WD Manning, SE AF Hwang, S. S. Lu, E. Cui, X. Diop, H. Barfield, W. D. Manning, S. E. TI Home care practices for preterm and term infants after hospital discharge in Massachusetts, 2007 to 2010 SO JOURNAL OF PERINATOLOGY LA English DT Article ID BIRTH-WEIGHT INFANTS; BREAST-MILK; NECROTIZING ENTEROCOLITIS; SLEEPING POSITION; UNIT; RISK; RECOMMENDATIONS; ASPIRATION; OUTCOMES; AGE AB OBJECTIVE: The objective of this study was to compare the prevalence of home care practices in very to moderately preterm (VPT), late preterm (LPT) and term infants born in Massachusetts. STUDY DESIGN: Using 2007 to 2010 Massachusetts Pregnancy Risk Assessment Monitoring System data, births were categorized by gestational age (VPT: 23 to 33 weeks; LPT: 34 to 36 weeks; term: 37 to 42 weeks). Home care practices included breastfeeding initiation and continuation, and infant sleep practices (supine sleep position, sleeping in a crib, cosleeping in an adult bed). We developed multivariate models to examine the association of infant sleep practices and breastfeeding with preterm status, controlling for maternal sociodemographic characteristics. RESULTS: Supine sleep position was more prevalent among term infants compared with VPT and LPT infants (77.1%, 71.5%, 64.4%; P = 0.02). In the adjusted model, LPT infants were less likely to be placed in supine sleep position compared with term infants (adjusted prevalence ratio = 0.86; 95% confidence interval: 0.75 to 0.97). Breastfeeding initiation and continuation did not differ among preterm and term groups. Nearly 16% of VPT and 18% of LPT and term infants were not sleeping in cribs and 14% of LPT and term infants were cosleeping on an adult bed. CONCLUSION: Compared with term infants, LPT infants were less likely to be placed in supine sleep position after hospital discharge. A significant percent of preterm and term infants were cosleeping on an adult bed. Hospitals may consider improving their safe sleep education, particularly to mothers of LPT infants. C1 [Hwang, S. S.] Boston Childrens Hosp, Div Newborn Med, Boston, MA 02115 USA. [Lu, E.; Cui, X.; Diop, H.; Manning, S. E.] Off Data Translat, Massachusetts Dept Publ Hlth, Boston, MA USA. [Barfield, W. D.; Manning, S. E.] Ctr Dis Control & Prevent, Div Reprod Hlth, Boston, MA USA. RP Hwang, SS (reprint author), Boston Childrens Hosp, Div Newborn Med, 300 Longwood Ave,Enders 961, Boston, MA 02115 USA. EM Sunah.hwang@childrens.harvard.edu NR 20 TC 2 Z9 2 U1 1 U2 6 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0743-8346 EI 1476-5543 J9 J PERINATOL JI J. Perinatol. PD OCT PY 2015 VL 35 IS 10 BP 880 EP 884 DI 10.1038/jp.2015.90 PG 5 WC Obstetrics & Gynecology; Pediatrics SC Obstetrics & Gynecology; Pediatrics GA CS2KI UT WOS:000361899100021 PM 26248131 ER PT J AU Schubauer-Berigan, MK Leuraud, K Richardson, DB Cardis, E Daniels, RD Gillies, M O'Hagan, JA Hamra, GB Haylock, R Laurier, D Moissonnier, M Thierry-Chef, I Kesminiene, A AF Schubauer-Berigan, Mary K. Leuraud, Klervi Richardson, David B. Cardis, Elisabeth Daniels, Robert D. Gillies, Michael O'Hagan, Jacqueline A. Hamra, Ghassan B. Haylock, Richard Laurier, Dominique Moissonnier, Monika Thierry-Chef, Isabelle Kesminiene, Ausrele TI INWORKS study: risk of leukaemia from protracted radiation exposure Reply SO LANCET HAEMATOLOGY LA English DT Letter ID NUCLEAR WORKERS; CANCER C1 [Schubauer-Berigan, Mary K.; Daniels, Robert D.] NIOSH, Cincinnati, OH 45226 USA. [Leuraud, Klervi; Laurier, Dominique] Inst Radioprotect & Surete Nucl, Fontenay Aux Roses, France. [Richardson, David B.] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC USA. [Cardis, Elisabeth] Ctr Res Environm Epidemiol, Barcelona, Spain. [Cardis, Elisabeth] Univ Pompeu Fabra, Barcelona, Spain. [Cardis, Elisabeth] CIBER Epidemiol & Salud Publ, Madrid, Spain. [Gillies, Michael; O'Hagan, Jacqueline A.; Haylock, Richard] Publ Hlth England Ctr Radiat Chem & Environm Haza, Chilton, England. [Hamra, Ghassan B.] Drexel Univ, Sch Publ Hlth, Dept Environm & Occupat Hlth, Philadelphia, PA 19104 USA. [Moissonnier, Monika; Thierry-Chef, Isabelle; Kesminiene, Ausrele] Int Agcy Res Canc, F-69372 Lyon, France. RP Schubauer-Berigan, MK (reprint author), NIOSH, Cincinnati, OH 45226 USA. EM klervi.leuraud@irsn.fr RI Cardis, Elisabeth/C-3904-2017 NR 4 TC 0 Z9 1 U1 0 U2 2 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 2352-3026 J9 LANCET HAEMATOL JI Lancet Haematol. PD OCT PY 2015 VL 2 IS 10 BP E405 EP E406 PG 3 WC Hematology SC Hematology GA CS4VY UT WOS:000362075400009 PM 26686041 ER PT J AU Pulliam, JRC Bellan, SE Gambhir, M Meyers, LA Dushoff, J AF Pulliam, Juliet R. C. Bellan, Steve E. Gambhir, Manoj Meyers, Lauren Ancel Dushoff, Jonathan TI Evaluating Ebola vaccine trials: insights from simulation SO LANCET INFECTIOUS DISEASES LA English DT Letter ID DESIGN C1 [Pulliam, Juliet R. C.] Univ Florida, Dept Biol, Gainesville, FL 32610 USA. [Pulliam, Juliet R. C.] Univ Florida, Emerging Pathogens Inst, Gainesville, FL USA. [Bellan, Steve E.] Univ Texas Austin, Ctr Computat Biol & Bioinformat, Austin, TX 78712 USA. [Gambhir, Manoj] Monash Univ, Dept Epidemiol & Prevent Med, Melbourne, Vic 3004, Australia. [Gambhir, Manoj] Ctr Dis Control & Prevent, Div Preparedness & Emerging Infect, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. [Meyers, Lauren Ancel] Univ Texas Austin, Dept Integrat Biol, Austin, TX 78712 USA. [Meyers, Lauren Ancel] Santa Fe Inst, Santa Fe, NM 87501 USA. [Dushoff, Jonathan] McMaster Univ, Dept Biol, Hamilton, ON, Canada. RP Pulliam, JRC (reprint author), Univ Florida, Dept Biol, Gainesville, FL 32610 USA. EM pulliam@ufl.edu OI Pulliam, Juliet/0000-0003-3314-8223 FU Canadian Institutes of Health Research; NIGMS NIH HHS [R25 GM102149, R25GM102149, U01 GM087719, U01GM087719] NR 5 TC 1 Z9 1 U1 1 U2 9 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1473-3099 EI 1474-4457 J9 LANCET INFECT DIS JI Lancet Infect. Dis. PD OCT PY 2015 VL 15 IS 10 BP 1134 EP 1134 PG 1 WC Infectious Diseases SC Infectious Diseases GA CS1UQ UT WOS:000361854300017 PM 26461945 ER PT J AU Iqbal, S Shi, J Seib, K Lewis, P Moro, PL Woo, EJ Shimabukuro, T Orenstein, WA AF Iqbal, Shahed Shi, Jing Seib, Katherine Lewis, Paige Moro, Pedro L. Woo, Emily J. Shimabukuro, Tom Orenstein, Walter A. TI Preparation for global introduction of inactivated poliovirus vaccine: safety evidence from the US Vaccine Adverse Event Reporting System, 2000-12 SO LANCET INFECTIOUS DISEASES LA English DT Article ID SURVEILLANCE; ERADICATION AB Background Safety data from countries with experience in the use of inactivated poliovirus vaccine (IPV) are important for the global polio eradication strategy to introduce IPV into the immunisation schedules of all countries. In the USA, IPV has been included in the routine immunisation schedule since 1997. We aimed to analyse adverse events after IPV administration, reported to the US Vaccine Adverse Event Reporting System (VAERS). Methods We analysed all VAERS data associated with IPV submitted between Jan 1, 2000, and Dec 31, 2012, either as individual or as combination vaccines, for all age and sex groups. We analysed the number and event type (non-serious, non-fatal serious, and death reports) of individual reports, and explored the most commonly coded event terms to describe the adverse event. We classified death reports according to previously published body-system categories (respiratory, cardiovascular, neurological, gastrointestinal, other infectious, and other non-infectious) and reviewed death reports to identify the cause of death. We classified sudden infant death syndrome as a separate cause of death considering previous concerns about sudden infant syndrome after vaccines. We used empirical Bayesian data mining methods to identify disproportionate reporting of adverse events for IPV compared with other vaccines. Additional VAERS data from 1991 to 2000 were analysed to compare the safety profiles of IPV and oral poliovirus vaccine (OPV). Findings Of the 41 792 adverse event reports submitted, 39 568 (95%) were for children younger than 7 years. 38 381 of the reports for children in this age group (97%) were for simultaneous vaccination with IPV and other vaccines (most commonly pneumococcal and acellular pertussis vaccines), whereas standalone IPV vaccines accounted for 0.5% of all reports. 34 880 reports were for non-serious events (88%), 3905 reports were for non-fatal serious events (10%), and 783 reports were death reports (2%). Injection-site erythema was the most commonly coded term for non-serious events (29%), and pyrexia for non-fatal serious events (38%). Most deaths (96%) were in children aged 12 months or younger; most (52%) had sudden infant death syndrome as the reported cause of death. The safely profiles of combined IPV and whole-cell pertussis vaccines, OPV and whole-cell pertussis vaccines, and OPV and acellular pertussis vaccines were similar. We noted no indication of disproportionate reporting of adverse events after immunisation with IPV-containing vaccines compared with other vaccines between 1990 and 2013. Interpretation Fairly few adverse events were reported for the more than 250 million IPV doses distributed between 2000 and 2012. Sudden infant death syndrome reports after IPV were consistent with reporting patterns for other vaccines. No new or unexpected vaccine safety problems were identified for fatal, non-fatal serious, and non-serious reports in this assessment of adverse events after IPV. C1 [Iqbal, Shahed; Shi, Jing; Lewis, Paige; Moro, Pedro L.; Shimabukuro, Tom] Ctr Dis Control & Prevent, Immunizat Safety Off, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Seib, Katherine; Orenstein, Walter A.] Emory Univ, Sch Med, Div Infect Dis, Atlanta, GA USA. [Woo, Emily J.] Food & Drug Adm, Ctr Biol Evaluat & Res, Silver Spring, MD USA. RP Iqbal, S (reprint author), Ctr Dis Control & Prevent, Immunizat Safety Off, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. EM sIqbal@cdc.gov NR 32 TC 2 Z9 2 U1 1 U2 3 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1473-3099 EI 1474-4457 J9 LANCET INFECT DIS JI Lancet Infect. Dis. PD OCT PY 2015 VL 15 IS 10 BP 1175 EP 1182 DI 10.1016/S1473-3099(15)00059-6 PG 8 WC Infectious Diseases SC Infectious Diseases GA CS1UQ UT WOS:000361854300028 PM 26289956 ER PT J AU Marks, M Mitja, O Vestergaard, LS Pillay, A Knauf, S Chen, CY Bassat, Q Martin, DL Fegan, D Taleo, F Kool, J Lukehart, S Emerson, PM Solomon, AW Ye, T Ballard, RC Mabey, DCW Asiedu, KB AF Marks, Michael Mitja, Oriol Vestergaard, Lasse S. Pillay, Allan Knauf, Sascha Chen, Cheng-Yen Bassat, Quique Martin, Diana L. Fegan, David Taleo, Fasihah Kool, Jacob Lukehart, Sheila Emerson, Paul M. Solomon, Anthony W. Ye, Tun Ballard, Ronald C. Mabey, David C. W. Asiedu, Kingsley B. TI Challenges and key research questions for yaws eradication SO LANCET INFECTIOUS DISEASES LA English DT Review ID RESISTANT TREPONEMA-PALLIDUM; SINGLE-DOSE AZITHROMYCIN; TIME MULTIPLEX PCR; RIBOSOMAL-RNA GENE; PAPUA-NEW-GUINEA; HAEMOPHILUS-DUCREYI; MOLECULAR DIFFERENTIATION; MACROLIDE RESISTANCE; RANDOMIZED-TRIAL; SOLOMON-ISLANDS AB Yaws is endemic in west Africa, southeast Asia, and the Pacific region. To eradicate yaws by 2020, WHO has launched a campaign of mass treatment with azithromycin. Progress has been made towards achievement of this ambitious goal, including the validation of point-of-care and molecular diagnostic tests and piloting of the strategy in several countries, including Ghana, Vanuatu, and Papua New Guinea. Gaps in knowledge need to be addressed to allow refinement of the eradication strategy. Studies exploring determinants of the spatial distribution of yaws are needed to help with the completion of baseline mapping. The finding that Haemophilus ducreyi causes lesions similar to yaws is particularly important and further work is needed to assess the effect of azithromycin on these lesions. The integration of diagnostic tests into different stages of the eradication campaign needs investigation. Finally, studies must be done to inform the optimum mass-treatment strategy for sustainable interruption of transmission. C1 [Marks, Michael; Solomon, Anthony W.; Mabey, David C. W.] Univ London London Sch Hyg & Trop Med, Fac Infect & Trop Dis, Dept Clin Res, London WC1E 7HT, England. [Marks, Michael; Solomon, Anthony W.; Mabey, David C. W.] Univ Coll London Hosp NHS Trust, Hosp Trop Dis, London, England. [Mitja, Oriol; Bassat, Quique] Univ Barcelona, Hosp Clin, Barcelona Ctr Int Hlth Res, ISGlobal, Barcelona, Spain. [Mitja, Oriol] Newcrest Min, Int SOS, Lihir Med Ctr, Lihir Isl, Papua, Guinea. [Vestergaard, Lasse S.] WHO, Reg Off Western Pacific, Div Communicable Dis, Manila, Philippines. [Pillay, Allan; Chen, Cheng-Yen] Ctr Dis Control & Prevent, Mol Diagnost & Typing Lab, Lab Reference & Res Branch, Div STD Prevent, Atlanta, GA USA. [Martin, Diana L.] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Atlanta, GA USA. [Ye, Tun; Ballard, Ronald C.] Ctr Dis Control & Prevent, Ctr Global Hlth, Atlanta, GA USA. [Knauf, Sascha] German Primate Ctr, Leibniz Inst Primate Res, Pathol Unit, Working Grp Neglected Trop Dis, Gottingen, Germany. [Bassat, Quique] Ctr Invest Saude Manhica, Maputo, Mozambique. [Fegan, David] WHO, Brisbane, Qld, Australia. [Taleo, Fasihah] Minist Hlth, Port Vila, Vanuatu. [Kool, Jacob] WHO, Vanuatu Country Off, Port Vila, Vanuatu. [Lukehart, Sheila] Univ Washington, Dept Med, Seattle, WA USA. [Lukehart, Sheila] Univ Washington, Dept Global Hlth, Seattle, WA 98195 USA. [Emerson, Paul M.] Int Trachoma Initiat, Decatur, GA USA. [Solomon, Anthony W.; Asiedu, Kingsley B.] WHO, Dept Control Neglected Trop Dis, CH-1211 Geneva, Switzerland. RP Marks, M (reprint author), Univ London London Sch Hyg & Trop Med, Fac Infect & Trop Dis, Dept Clin Res, Keppel St, London WC1E 7HT, England. EM michael.marks@lshtm.ac.uk RI Bassat, Quique/P-2341-2016; Knauf, Sascha/F-1661-2017; OI Bassat, Quique/0000-0003-0875-7596; Knauf, Sascha/0000-0001-5744-4946; Kool, Jacob/0000-0002-9605-2918; Marks, Michael/0000-0002-7585-4743; Mitja, Oriol/0000-0003-3266-8868; Solomon, Anthony/0000-0001-7101-6649 FU Wellcome Trust Clinical Research Fellowship [WT102807]; program Miguel Servet of the ISCIII (Plan Nacional de I+D+I) [CP11/00269] FX MM is supported by a Wellcome Trust Clinical Research Fellowship (WT102807). QB has a fellowship from the program Miguel Servet of the ISCIII (Plan Nacional de I+D+I 2008-2011, grant number: CP11/00269). The funder had no role in the preparation of the manuscript or the decision to submit it for publication. We thank the participants of the WHO yaws eradication and COR-NTD meetings held in 2014 for their valuable contributions to the topics discussed in this manuscript. KBA, AWS, JK, and LSV are employees of the WHO. AP, C-YC, DLM are employees of the Centers for Disease Control and Prevention (CDC). The views expressed in this article are the views of the authors and may not necessarily reflect the views of the WHO or the CDC. NR 49 TC 5 Z9 5 U1 1 U2 1 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1473-3099 EI 1474-4457 J9 LANCET INFECT DIS JI Lancet Infect. Dis. PD OCT PY 2015 VL 15 IS 10 BP 1220 EP 1225 DI 10.1016/S1473-3099(15)00136-X PG 6 WC Infectious Diseases SC Infectious Diseases GA CS1UQ UT WOS:000361854300033 PM 26362174 ER PT J AU Peterson, C Xu, LK Florence, C Grosse, SD Annest, JL AF Peterson, Cora Xu, Likang Florence, Curtis Grosse, Scott D. Annest, Joseph L. TI Professional Fee Ratios for US Hospital Discharge Data SO MEDICAL CARE LA English DT Article DE costs and cost analysis; economics; hospital; hospital charges ID UNITED-STATES; ADMINISTRATIVE DATA; PRICES; COST; CARE AB Background:US hospital discharge datasets typically report facility charges (ie, room and board), excluding professional fees (ie, attending physicians' charges).Objectives:We aimed to estimate professional fee ratios (PFR) by year and clinical diagnosis for use in cost analyses based on hospital discharge data.Subjects:The subjects consisted of a retrospective cohort of Truven Health MarketScan 2004-2012 inpatient admissions (n=23,594,605) and treat-and-release emergency department (ED) visits (n=70,771,576).Measures:PFR per visit was assessed as total payments divided by facility-only payments.Research Design:Using ordinary least squares regression models controlling for selected characteristics (ie, patient age, comorbidities, etc.), we calculated adjusted mean PFR for admissions by health insurance type (commercial or Medicaid) per year overall and by Major Diagnostic Category (MDC), Diagnostic Related Group, Healthcare Cost and Utilization Project Clinical Classification Software, and primary International Classification of Diseases, 9th Edition, Clinical Modification (ICD-9-CM) diagnosis, and for ED visits per year overall and by MDC and primary ICD-9-CM diagnosis.Results:Adjusted mean PFR for 2012 admissions, including preceding ED visits, was 1.264 (95% CI, 1.264, 1.265) for commercially insured admissions (n=2,614,326) and 1.177 (1.176, 1.177) for Medicaid admissions (n=816,503), indicating professional payments increased total per-admission payments by an average 26.4% and 17.7%, respectively, above facility-only payments. Adjusted mean PFR for 2012 ED visits was 1.286 (1.286, 1.286) for commercially insured visits (n=8,808,734) and 1.440 (1.439, 1.440) for Medicaid visits (n=2,994,696). Supplemental tables report 2004-2012 annual PFR estimates by clinical classifications.Conclusions:Adjustments for professional fees are recommended when hospital facility-only financial data from US hospital discharge datasets are used to estimate health care costs. C1 [Peterson, Cora; Xu, Likang; Florence, Curtis; Annest, Joseph L.] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30341 USA. [Grosse, Scott D.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30341 USA. RP Peterson, C (reprint author), Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Mailstop F-62,4770 Buford Highway, Atlanta, GA 30341 USA. EM cora.peterson@cdc.hhs.gov OI Peterson, Cora/0000-0001-7955-0977 FU Intramural CDC HHS [CC999999] NR 33 TC 4 Z9 4 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0025-7079 EI 1537-1948 J9 MED CARE JI Med. Care PD OCT PY 2015 VL 53 IS 10 BP 840 EP 849 DI 10.1097/MLR.0000000000000410 PG 10 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA CS5IL UT WOS:000362111500002 PM 26340662 ER PT J AU Gates, I Olson, V Smith, S Patel, N Damon, I Karem, K AF Gates, Irina Olson, Victoria Smith, Scott Patel, Nishi Damon, Inger Karem, Kevin TI Development of a High-Content Orthopoxvirus Infectivity and Neutralization Assays SO PLOS ONE LA English DT Article ID GREEN FLUORESCENT PROTEIN; SMALLPOX VACCINE AB Currently, a number of assays measure Orthopoxvirus neutralization with serum from individuals, vaccinated against smallpox. In addition to the traditional plaque reduction neutralization test (PRNT), newer higher throughput assays are based on neutralization of recombinant vaccinia virus, expressing reporter genes such as beta-galactosidase or green fluorescent protein. These methods could not be used to evaluate neutralization of variola virus, since genetic manipulations of this virus are prohibited by international agreements. Currently, PRNT is the assay of choice to measure neutralization of variola virus. However, PRNT assays are time consuming, labor intensive, and require considerable volume of serum sample for testing. Here, we describe the development of a high-throughput, cell-based imaging assay that can be used to measure neutralization, and characterize replication kinetics of various Orthopoxviruses, including variola, vaccinia, monkeypox, and cowpox. C1 [Gates, Irina] Atlanta Res & Educ Fdn, Decatur, GA 30033 USA. [Olson, Victoria; Smith, Scott; Patel, Nishi; Damon, Inger; Karem, Kevin] Ctr Dis Control & Prevent, Poxvirus & Rabies Branch, DHCPP, NCEZID, Atlanta, GA USA. RP Gates, I (reprint author), Atlanta Res & Educ Fdn, Decatur, GA 30033 USA. EM irina.gates@gmail.com FU U.S. Department of Health and Human Services (HHS) / The Centers for Disease Control and Prevention (CDC) FX The U.S. Department of Health and Human Services (HHS) / The Centers for Disease Control and Prevention (CDC) approved government funds were used to support this work. NR 16 TC 0 Z9 0 U1 1 U2 1 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD OCT 1 PY 2015 VL 10 IS 10 AR e0138836 DI 10.1371/journal.pone.0138836 PG 20 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CS6GT UT WOS:000362177100022 PM 26426117 ER PT J AU Barile, JP Thompson, WW AF Barile, John P. Thompson, William W. TI Factor structure of the CDC healthy days core and symptoms modules and their association with stress, access to care, and social determinants of health SO QUALITY OF LIFE RESEARCH LA English DT Meeting Abstract C1 [Barile, John P.] Univ Hawaii, Honolulu, HI 96822 USA. [Thompson, William W.] US Ctr Dis Control & Prevent, Atlanta, GA USA. RI Barile, John/F-9456-2015 OI Barile, John/0000-0003-4098-0640 NR 0 TC 0 Z9 0 U1 0 U2 3 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0962-9343 EI 1573-2649 J9 QUAL LIFE RES JI Qual. Life Res. PD OCT PY 2015 VL 24 SU 1 MA 3 BP 2 EP 2 PG 1 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA CS3RA UT WOS:000361991100004 ER PT J AU Jia, HM Zack, MM Thompson, WW AF Jia, Haomiao Zack, Matthew M. Thompson, William W. TI Impact of smoking, physical inactivity, heavy drinking, and obesity on health-related quality of life, life expectancy, and quality-adjusted life expectancy among adults with and without depression in the US SO QUALITY OF LIFE RESEARCH LA English DT Meeting Abstract C1 [Jia, Haomiao] Columbia Univ, New York, NY USA. [Zack, Matthew M.; Thompson, William W.] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 4 U2 5 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0962-9343 EI 1573-2649 J9 QUAL LIFE RES JI Qual. Life Res. PD OCT PY 2015 VL 24 SU 1 MA 109.3 BP 32 EP 32 PG 1 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA CS3RA UT WOS:000361991100079 ER PT J AU Thompson, WW Campbell, V Barile, JP Krahn, GL AF Thompson, William W. Campbell, Vincent Barile, John P. Krahn, Gloria L. TI Examining the association between modifiable health behaviors and health-related quality of life among US adults SO QUALITY OF LIFE RESEARCH LA English DT Meeting Abstract C1 [Thompson, William W.] US Ctr Dis Control & Prevent, Atlanta, GA USA. [Campbell, Vincent] Ctr Dis Control & Prevent, Atlanta, GA USA. [Barile, John P.] Univ Hawaii, Honolulu, HI 96822 USA. [Krahn, Gloria L.] Oregon State Univ, Corvallis, OR 97331 USA. RI Barile, John/F-9456-2015 OI Barile, John/0000-0003-4098-0640 NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0962-9343 EI 1573-2649 J9 QUAL LIFE RES JI Qual. Life Res. PD OCT PY 2015 VL 24 SU 1 MA 303.6 BP 70 EP 70 PG 1 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA CS3RA UT WOS:000361991100156 ER PT J AU Smith, SA Claridy, MD Ansa, BE Damus, F Alema-Mensah, E Thompson, WW AF Smith, Selina A. Claridy, Mechelle D. Ansa, Benjamin E. Damus, Francesca Alema-Mensah, Ernest Thompson, William W. TI Examining the associations between cancer survivorship status and health-related quality of life among African-American female adults SO QUALITY OF LIFE RESEARCH LA English DT Meeting Abstract C1 [Smith, Selina A.; Ansa, Benjamin E.] Georgia Regents Univ, Augusta, GA USA. [Claridy, Mechelle D.; Damus, Francesca; Alema-Mensah, Ernest] Morehouse Sch Med, Atlanta, GA 30310 USA. [Thompson, William W.] US Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0962-9343 EI 1573-2649 J9 QUAL LIFE RES JI Qual. Life Res. PD OCT PY 2015 VL 24 SU 1 MA 2093 BP 134 EP 134 PG 1 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA CS3RA UT WOS:000361991100296 ER PT J AU Tsai, RJ Boiano, JM Steege, AL Sweeney, MH AF Tsai, Rebecca J. Boiano, James M. Steege, Andrea L. Sweeney, Marie H. TI Precautionary Practices of Respiratory Therapists and Other Health-Care Practitioners Who Administer Aerosolized Medications SO RESPIRATORY CARE LA English DT Article DE aerosolized medications; respiratory therapists; exposure controls; pentamidine; antibiotics; web-based survey ID OCCUPATIONAL-EXPOSURE; PENTAMIDINE; WORKERS; TOBRAMYCIN; RIBAVIRIN; ASTHMA AB BACKGROUND: Respiratory therapists (RTs) and other health-care workers are potentially exposed to a variety of aerosolized medications. The National Institute for Occupational Safety and Health (NIOSH) Health and Safety Practices Survey of Healthcare Workers describes current exposure control practices and barriers to using personal protective equipment during administration of selected aerosolized medications. METHODS: An anonymous, multi-module, web-based survey was conducted among members of health-care professional practice organizations representing RTs, nurses, and other health-care practitioners. A module on aerosolized medications included submodules for antibiotics (amikacin, colistin, and tobramycin), pentamidine, and ribavirin. RESULTS: The submodules on antibiotics, pentamidine, and ribavirin were completed by 321, 227, and 50 respondents, respectively, most of whom were RTs. The relatively low number of ribavirin respondents precluded meaningful interpretation of these data and may reflect the rare use of this drug. Consequently, analysis focused on pentamidine, classified by NIOSH as a hazardous drug, and the antibiotics amikacin, colistin, and tobramycin, which currently lack authoritative safe handling guidelines. Respondents who administered pentamidine were more likely to adhere to good work practices compared with those who administered the antibiotics. Examples included training received on safe handling procedures (75% vs 52%), availability of employer standard procedures (82% vs 55%), use of aerosol delivery devices equipped with an expiratory filter (96% vs 53%) or negative-pressure rooms (61% vs 20%), and always using respiratory protection (51% vs 13%). CONCLUSIONS: Despite the availability of safe handling guidelines for pentamidine, implementation was not universal, placing workers, co-workers, and even family members at risk of exposure. Although the antibiotics included in this study lack authoritative safe handling guidelines, prudence dictates that appropriate exposure controls be used to minimize exposure to the antibiotics and other aerosolized medications. Employers and employees share responsibility for ensuring that precautionary measures are taken to keep exposures to all aerosolized medications as low as practicable. C1 [Tsai, Rebecca J.; Boiano, James M.; Steege, Andrea L.; Sweeney, Marie H.] NIOSH, Div Surveillance Hazard Evaluat & Field Studies, Ctr Dis Control & Prevent, Cincinnati, OH 45226 USA. RP Tsai, RJ (reprint author), NIOSH, Div Surveillance Hazard Evaluat & Field Studies, 1090 Tusculum Ave,MS R-17, Cincinnati, OH 45226 USA. EM rtsai@cdc.gov OI Tsai, Rebecca/0000-0001-8656-9836 FU United States Government; National Institute for Occupational Safety and Health FX All authors are federal government employees, and preparation of this manuscript was completely funded by the United States Government. Otherwise, no additional financial disclosures were reported by the authors of this paper. The findings and conclusions in this paper are those of the authors and do not necessarily represent the views of the National Institute for Occupational Safety and Health. Mention of company names or products does not constitute endorsement by the National Institute for Occupational Safety and Health.; This research was supported by the National Institute for Occupational Safety and Health. The authors have disclosed no conflicts of interest. NR 28 TC 2 Z9 2 U1 1 U2 1 PU DAEDALUS ENTERPRISES INC PI IRVING PA 9425 N MAC ARTHUR BLVD, STE 100, IRVING, TX 75063-4706 USA SN 0020-1324 EI 1943-3654 J9 RESP CARE JI Respir. Care PD OCT PY 2015 VL 60 IS 10 BP 1409 EP 1417 DI 10.4187/respcare.03817 PG 9 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA CS7MV UT WOS:000362268600010 PM 26152473 ER PT J AU Ko, JY Tong, VT Callaghan, WM AF Ko, Jean Y. Tong, Van T. Callaghan, William M. TI Screening women for marijuana use does more harm than good Reply SO AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY LA English DT Letter C1 [Ko, Jean Y.; Tong, Van T.; Callaghan, William M.] Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30345 USA. RP Ko, JY (reprint author), Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Hwy, Atlanta, GA 30345 USA. EM FOB1@cdc.gov FU Intramural CDC HHS [CC999999] NR 5 TC 0 Z9 0 U1 1 U2 2 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9378 EI 1097-6868 J9 AM J OBSTET GYNECOL JI Am. J. Obstet. Gynecol. PD OCT PY 2015 VL 213 IS 4 BP 599 EP 599 DI 10.1016/j.ajog.2015.06.023 PG 1 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA CS2EA UT WOS:000361879400055 PM 26071917 ER PT J AU Robbins, CL Farr, SL Zapata, LB D'Angelo, DV Callaghan, WM AF Robbins, Cheryl L. Farr, Sherry L. Zapata, Lauren B. D'Angelo, Denise V. Callaghan, William M. TI Postpartum contraceptive use among women with a recent preterm birth SO AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY LA English DT Article DE contraception effectiveness; insurance; Medicaid; postpartum; preterm birth ID ASSESSMENT MONITORING-SYSTEM; INTERPREGNANCY INTERVALS; RISK; PREGNANCY; HEALTH; INITIATION; STATES; PRAMS; RATES; VISIT AB OBJECTIVE: The objective of the study was to evaluate the associations between postpartum contraception and having a recent preterm birth. STUDY DESIGN: Population-based data from the Pregnancy Risk Assessment Monitoring System in 9 states were used to estimate the postpartum use of highly or moderately effective contraception (sterilization, intrauterine device, implants, shots, pills, patch, and ring) and user-independent contraception (sterilization, implants, and intrauterine device) among women with recent live births (2009-2011). We assessed the differences in contraception by gestational age (<= 27, 28-33, or 34-36 weeks vs term [>= 37 weeks]) and modeled the associations using multivariable logistic regression with weighted data. RESULTS: A higher percentage of women with recent extreme preterm birth (<= 27 weeks) reported using no postpartum method (31%) compared with all other women (15-16%). Women delivering extreme preterm infants had a decreased odds of using highly or moderately effective methods (adjusted odds ratio, 0.5; 95% confidence interval, 0.4-0.6) and user-independent methods (adjusted odds ratio, 0.5; 95% confidence interval, 0.4-0.7) compared with women having term births. Wanting to get pregnant was more frequently reported as a reason for contraceptive nonuse by women with an extreme preterm birth overall (45%) compared with all other women (15-18%, P <.0001). Infant death occurred in 41% of extreme preterm births and more than half of these mothers (54%) reported wanting to become pregnant as the reason for contraceptive nonuse. CONCLUSION: During contraceptive counseling with women who had recent preterm births, providers should address an optimal pregnancy interval and consider that women with recent extreme preterm birth, particularly those whose infants died, may not use contraception because they want to get pregnant. C1 [Robbins, Cheryl L.; Farr, Sherry L.; Zapata, Lauren B.; D'Angelo, Denise V.; Callaghan, William M.] Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30322 USA. RP Robbins, CL (reprint author), Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30322 USA. EM ggf9@cdc.gov FU Intramural CDC HHS [CC999999] NR 31 TC 0 Z9 0 U1 1 U2 4 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9378 EI 1097-6868 J9 AM J OBSTET GYNECOL JI Am. J. Obstet. Gynecol. PD OCT PY 2015 VL 213 IS 4 AR 508.e1 DI 10.1016/j.ajog.2015.05.033 PG 9 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA CS2EA UT WOS:000361879400014 PM 26003062 ER PT J AU Rushmore, J Allison, AB Edwards, EE Bagal, U Altizer, S Cranfield, MR Glenn, TC Liu, H Mudakikwa, A Mugisha, L Muller, MN Stumpf, RM Thompson, ME Wrangham, R Yabsley, MJ AF Rushmore, Julie Allison, Andrew B. Edwards, Erin E. Bagal, Ujwal Altizer, Sonia Cranfield, Mike R. Glenn, Travis C. Liu, Hsi Mudakikwa, Antoine Mugisha, Lawrence Muller, Martin N. Stumpf, Rebecca M. Thompson, Melissa Emery Wrangham, Richard Yabsley, Michael J. TI Screening Wild and Semi-Free Ranging Great Apes for Putative Sexually Transmitted Diseases: Evidence of Trichomonadidae Infections SO AMERICAN JOURNAL OF PRIMATOLOGY LA English DT Article DE Pan troglodytes; Gorilla beringei; papillomavirus; Chlamydia spp.; Tetratrichomonas spp; Treponema pallidum ID IMMUNODEFICIENCY VIRUS-INFECTION; INTERNAL TRANSCRIBED SPACER; MOLECULAR EPIDEMIOLOGY; CHLAMYDIA-TRACHOMATIS; NATIONAL-PARK; CHIMPANZEES; TETRATRICHOMONAS; CONSERVATION; TRANSMISSION; POPULATIONS AB Sexually transmitted diseases (STDs) can persist endemically, are known to cause sterility and infant mortality in humans, and could have similar impacts in wildlife populations. African apes (i.e., chimpanzees, bonobos, and to a lesser extent gorillas) show multi-male mating behavior that could offer opportunities for STD transmission, yet little is known about the prevalence and impact of STDs in this endangered primate group. We used serology and PCR-based detection methods to screen biological samples from wild and orphaned eastern chimpanzees and gorillas (N = 172 individuals, including adults, and juveniles) for four classes of pathogens that either commonly cause human STDs or were previously detected in captive apes: trichomonads, Chlamydia spp., Treponema pallidum (syphilis and yaws), and papillomaviruses. Based on results from prior modeling and comparative research, we expected STD prevalence to be highest in females versus males and in sexually mature versus immature individuals. All samples were negative for Chlamydia, Treponema pallidum, and papillomaviruses; however, a high percentage of wild chimpanzee urine and fecal samples showed evidence of trichomonads (protozoa). Analysis revealed that females were more likely than males to have positive urine-but not fecal-samples; however, there was no evidence of age (sexual maturity) differences in infection status. Sequence analysis of chimpanzee trichomonad samples revealed a close relationship to previously described trichomonads within the genus Tetratrichomonas. Phylogenetic comparisons to archived sequences from multiple vertebrate hosts suggests that many of the chimpanzee parasites from our study are likely transmitted via fecal-oral contact, but the transmission of some Tetratrichomonas sequence-types remains unknown and could include sexual contact. Our work emphasizes that only a fraction of infectious agents affecting wild apes are presently known to science, and that further work on great ape STDs could offer insights for the management of endangered great apes and for understanding human STD origins. (C) 2015 Wiley Periodicals, Inc. C1 [Rushmore, Julie; Altizer, Sonia] Univ Georgia, Odum Sch Ecol, Athens, GA 30602 USA. [Rushmore, Julie; Edwards, Erin E.] Univ Georgia, Coll Vet Med, Athens, GA USA. [Allison, Andrew B.] Cornell Univ, Coll Vet Med, Dept Microbiol & Immunol, Baker Inst Anim Hlth, Ithaca, NY 14853 USA. [Bagal, Ujwal] Univ Georgia, Inst Bioinformat, Athens, GA 30602 USA. [Cranfield, Mike R.] Univ Calif Davis, Wildlife Hlth Ctr, Gorilla Doctors, Davis, CA 95616 USA. [Cranfield, Mike R.] Johns Hopkins Sch Med, Dept Mol & Pathobiol, Baltimore, MD USA. [Glenn, Travis C.] Univ Georgia, Dept Environm Hlth Sci, Athens, GA 30602 USA. [Liu, Hsi] Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Athens, GA USA. [Mudakikwa, Antoine] Rwanda Dev Board, Dept Tourism & Conservat, Kigali, Rwanda. [Mugisha, Lawrence] Conservat & Ecosyst Hlth Alliance, Kampala, Uganda. [Mugisha, Lawrence] Makerere Univ, Coll Vet Med, Anim Resources & Biosecur, Kampala, Uganda. [Muller, Martin N.; Thompson, Melissa Emery] Univ New Mexico, Dept Anthropol, Albuquerque, NM 87131 USA. [Stumpf, Rebecca M.] Univ Illinois, Dept Anthropol, Urbana, IL USA. [Wrangham, Richard] Harvard Univ, Dept Human Evolutionary Biol, Cambridge, MA 02138 USA. [Yabsley, Michael J.] Univ Georgia, Warnell Sch Forestry & Nat Resources, Athens, GA USA. [Yabsley, Michael J.] Univ Georgia, Coll Vet Med, Dept Populat Hlth, Southeastern Cooperat Wildlife Dis Study, Athens, GA USA. RP Rushmore, J (reprint author), Univ Georgia, Coll Vet Med, Odum Sch Ecol, Athens, GA 30602 USA. EM julierushmore@gmail.com OI Edwards, Erin/0000-0001-9447-8395; Allison, Andrew B./0000-0003-0971-1215 FU US Fish and Wildlife Service Research Awards [96200-9-G250, 96200-1-G183]; NSF [BCS 0820709]; Morris Animal Foundation [D10ZO-401]; Fulbright; Margot Marsh Biodiversity Foundation; Graduate Women in Science; Achievement Rewards for College Scientists; Primate Action Fund; Leakey Foundation; National Geographic Society; Getty Foundation; Wenner-Gren Foundation; U.S. National Science Foundation [9807448, 0416125, 1355014] FX Contract grant sponsor: US Fish and Wildlife Service Research Awards; contract grant numbers: 96200-9-G250, 96200-1-G183; contract grant sponsor: NSF; contract grant number: BCS 0820709; contract grant sponsor: Morris Animal Foundation; contract grant number: D10ZO-401; contract grant sponsor: Fulbright; contract grant sponsor: Margot Marsh Biodiversity Foundation; contract grant sponsor: Graduate Women in Science; contract grant sponsor: Achievement Rewards for College Scientists; contract grant sponsor: Primate Action Fund; contract grant sponsor: Leakey Foundation; contract grant sponsor: National Geographic Society; contract grant sponsor: Getty Foundation; contract grant sponsor: Wenner-Gren Foundation; contract grant sponsor: U.S. National Science Foundation; contract grant numbers: 9807448, 0416125, 1355014. NR 71 TC 0 Z9 0 U1 5 U2 28 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0275-2565 EI 1098-2345 J9 AM J PRIMATOL JI Am. J. Primatol. PD OCT PY 2015 VL 77 IS 10 BP 1075 EP 1085 DI 10.1002/ajp.22442 PG 11 WC Zoology SC Zoology GA CS1OS UT WOS:000361836700005 PM 26119266 ER PT J AU Ng, TFF Sachsenroder, J Reuter, G Knowles, NJ Delwart, E Johne, R AF Ng, Terry Fei Fan Sachsenroeder, Jana Reuter, Gabor Knowles, Nick J. Delwart, Eric Johne, Reimar TI Rabovirus: a proposed new picornavirus genus that is phylogenetically basal to enteroviruses and sapeloviruses SO ARCHIVES OF VIROLOGY LA English DT Article ID RIBOSOME ENTRY SITE; ENTERIC VIRUSES; SEQUENCES; REVEALS; ISOLATE; ELF4G AB We have sequenced the genome of a novel picornavirus, rabovirus A (rat-borne virus, RaBoV-A, NC_026314), which was present in the feces of a Norway rat (Rattus norvegicus) from Berlin, Germany. This virus is related to members of the genera Enterovirus and Sapelovirus. RaboV-A contains a type II IRES that is unlike the type I IRES elements of enteroviruses and the type IV elements of sapeloviruses. Its genome is marked by an L protein and a chymotrypsin-like 2A protease. Our analysis of genome organization, pairwise identities, motif, phylogenic and UTR (GIMPU) indicates that RaBoV-A potentially represents a new picornavirus genus, for which we propose the name "Rabovirus". Spread by their rodent hosts and detected in New York and Berlin rats, these viruses may have a wide geographic distribution. C1 [Ng, Terry Fei Fan; Sachsenroeder, Jana; Delwart, Eric] Blood Syst Res Inst, San Francisco, CA USA. [Ng, Terry Fei Fan; Delwart, Eric] Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA. [Sachsenroeder, Jana; Johne, Reimar] Fed Inst Risk Assessment, Berlin, Germany. [Reuter, Gabor] ANTSZ Reg Inst State Publ Hlth Serv, Reg Lab Virol, Pecs, Hungary. [Knowles, Nick J.] Pirbright Inst, Woking, Surrey, England. RP Ng, TFF (reprint author), Ctr Dis Control & Prevent, DVD, NCIRD, 1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM terryfeifan@gmail.com RI Reuter, Gabor/I-7412-2013; Institute, Pirbright/K-4476-2014; OI Reuter, Gabor/0000-0002-5857-4934; Ng, Terry Fei Fan/0000-0002-4815-8697 FU NHLBI [R01 HL105770]; Hungarian Scientific Research Fund [OTKA/NKFIH K111615]; Biotechnology and Biological Sciences Research Council under The Pirbright Institute Livestock Viral Diseases Programme; Deutsche Forschungsgemeinschaft (DFG) [SFB852/1] FX We thank Rainer Ulrich (Friedrich Loeffler Institute, Greifswald-Insel Riems, Germany) for providing the rat sample, and Jaume Jorba for discussion on phylogeny. ELD was supported by NHLBI grant R01 HL105770. GR was supported by a grant from the Hungarian Scientific Research Fund (OTKA/NKFIH K111615). NJK was supported by core funding provided by the Biotechnology and Biological Sciences Research Council under The Pirbright Institute Livestock Viral Diseases Programme. JS was supported by the Deutsche Forschungsgemeinschaft (DFG) through grant SFB852/1. NR 23 TC 3 Z9 3 U1 0 U2 5 PU SPRINGER WIEN PI WIEN PA SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA SN 0304-8608 EI 1432-8798 J9 ARCH VIROL JI Arch. Virol. PD OCT PY 2015 VL 160 IS 10 BP 2569 EP 2575 DI 10.1007/s00705-015-2523-y PG 7 WC Virology SC Virology GA CS1IN UT WOS:000361817600019 PM 26168710 ER PT J AU Sinclair, SM Jones, JK Miller, RK Kwo, PY Greene, MF Thorpe, PG Maddrey, WC AF Sinclair, S. M. Jones, J. K. Miller, R. K. Kwo, P. Y. Greene, M. F. Thorpe, P. G. Maddrey, W. C. TI The Ribavirin Pregnancy Registry: An Interim Analysis at the Mid-Point of Enrollment SO DRUG SAFETY LA English DT Meeting Abstract CT 15th Annual Meeting of the International-Society-of-Pharmacovigilance (ISoP) - Cubism in Pharmacovigilance CY OCT 27-30, 2015 CL Prague, CZECH REPUBLIC SP Int Soc Pharmacovigilance C1 [Sinclair, S. M.] Univ N Carolina, Clin Res, Wilmington, NC 28401 USA. [Jones, J. K.] Degge Grp Ltd, Fairfax, VA USA. [Miller, R. K.] Univ Rochester, Sch Med & Dent, Dept Obstet Gynecol, Rochester, NY USA. [Kwo, P. Y.] Indiana Univ, Gastroenterol, Indianapolis, IN 46204 USA. [Greene, M. F.] Harvard Univ, Sch Med, Obstet Gynecol & Reprod Biol, Boston, MA USA. [Thorpe, P. G.] Ctr Dis Control & Prevent, Div Birth Defects & Dev Disabil, Atlanta, GA USA. [Maddrey, W. C.] Univ Texas Southwestern, Internal Med, Dallas, TX USA. NR 4 TC 0 Z9 0 U1 4 U2 4 PU ADIS INT LTD PI NORTHCOTE PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND SN 0114-5916 EI 1179-1942 J9 DRUG SAFETY JI Drug Saf. PD OCT PY 2015 VL 38 IS 10 MA P 149 BP 1027 EP 1027 PG 1 WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy; Toxicology SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy; Toxicology GA CS0PK UT WOS:000361764000212 ER PT J AU Taylor, MM Newman, DR Schillinger, JA Lewis, FMT Furness, B Braunstein, S Mickey, T Skinner, J Eberhart, M Opoku, J Blank, S Peterman, TA AF Taylor, Melanie M. Newman, Daniel R. Schillinger, Julia A. Lewis, Felicia M. T. Furness, Bruce Braunstein, Sarah Mickey, Tom Skinner, Julia Eberhart, Michael Opoku, Jenevieve Blank, Susan Peterman, Thomas A. TI Viral Loads Among HIV-Infected Persons Diagnosed With Primary and Secondary Syphilis in 4 US Cities: New York City, Philadelphia, PA, Washington, DC, and Phoenix, AZ SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article DE syphilis; HIV; viral load; STD; HIV coinfection; HIV transmission; men who have sex with men; HIV treatment ID SEXUALLY-TRANSMITTED-DISEASES; ACTIVE ANTIRETROVIRAL THERAPY; MULTICLINIC ASSESSMENT; UNITED-STATES; SAFER-SEX; MEN; PREVENTION; CARE; RISK; TRANSMISSION AB Background:Incident syphilis among HIV-infected persons indicates the ongoing behavioral risk for HIV transmission. Detectable viral loads (VLs) among coinfected cases may amplify this risk.Methods:Primary and secondary cases reported during 2009-2010 from 4 US sites were crossmatched with local HIV surveillance registries to identify syphilis case-persons infected with HIV before or shortly after the syphilis diagnosis. We examined HIV VL and CD4 results collected within 6 months before or after syphilis diagnosis for the coinfected cases identified. Independent correlates of detectable VLs (200 copies/mL) were determined.Results:We identified 1675 cases of incident primary or secondary syphilis among persons with HIV. Median age was 37 years; 99.5% were men, 41.1% were African American, 24.5% were Hispanics, and 79.9% of the HIV diagnoses were made at least 1 year before syphilis diagnosis. Among those coinfected, there were no VL results reported for 188 (11.2%); of the 1487 (88.8%) with reported VL results, 809 (54.4%) had a detectable VL (median, 25,101 copies/mL; range, 206-3,590,000 copies/mL). Detectable VLs independently correlated with syphilis diagnosed at younger age, at an sexually transmitted disease clinic, and closer in time to HIV diagnosis.Conclusions:More than half of syphilis case-persons identified with HIV had a detectable VL collected within 6 months of the syphilis diagnosis. This suggests virologic and active behavioral risk for transmitting HIV. C1 [Taylor, Melanie M.; Newman, Daniel R.; Schillinger, Julia A.; Lewis, Felicia M. T.; Furness, Bruce; Blank, Susan; Peterman, Thomas A.] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA USA. [Taylor, Melanie M.; Skinner, Julia] Arizona Dept Hlth Serv, STD Program, Phoenix, AZ 85007 USA. [Taylor, Melanie M.] Maricopa Cty Dept Publ Hlth, STD Program, Phoenix, AZ USA. [Schillinger, Julia A.; Braunstein, Sarah; Mickey, Tom; Blank, Susan] New York City Dept Hlth & Mental Hyg, Long Isl City, NY USA. [Lewis, Felicia M. T.; Eberhart, Michael] Philadelphia Dept Publ Hlth, Philadelphia, PA USA. [Furness, Bruce; Opoku, Jenevieve] Dist Columbia Dept Hlth, HIV AIDS Hepatitis STD & TB Adm, Washington, DC USA. RP Taylor, MM (reprint author), CDC, NCHHSTP, DSTDP, 1645 East Roosevelt, Phoenix, AZ 85006 USA. EM mdt7@cdc.gov NR 45 TC 1 Z9 1 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1525-4135 EI 1077-9450 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD OCT 1 PY 2015 VL 70 IS 2 BP 179 EP 185 DI 10.1097/QAI.0000000000000730 PG 7 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CR8OC UT WOS:000361612600010 PM 26090756 ER PT J AU Curtiss, EL AF Curtiss, Elaine L. TI DIRECT FROM CDC ENVIRONMENTAL HEALTH SERVICES BRANCH EHSB's Free Resources for Environmental Health Practitioners SO JOURNAL OF ENVIRONMENTAL HEALTH LA English DT Editorial Material ID UNITED-STATES; FOODBORNE ILLNESS C1 Carter Consulting Inc, Natl Ctr Environm Hlth, Div Emergency & Environm Hlth Serv, Atlanta, GA 30341 USA. RP Curtiss, EL (reprint author), Carter Consulting Inc, Natl Ctr Environm Hlth, Div Emergency & Environm Hlth Serv, 4770 Buford Hwy,MS F-58, Atlanta, GA 30341 USA. EM ECurtiss@cdc.gov NR 6 TC 0 Z9 0 U1 0 U2 0 PU NATL ENVIRON HEALTH ASSOC PI DENVER PA 720 S COLORADO BLVD SUITE 970, SOUTH TOWER, DENVER, CO 80246 USA SN 0022-0892 J9 J ENVIRON HEALTH JI J. Environ. Health PD OCT PY 2015 VL 78 IS 3 BP 30 EP 32 PG 3 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA CS1VF UT WOS:000361855900005 PM 26591335 ER PT J AU Wall, PA AF Wall, Patrick A. TI DIRECT FROM CDC ENVIRONMENTAL PUBLIC HEALTH TRACKING NETWORK Together at Last: Exploring Health and Environmental Information on the National Environmental Health Tracking Network SO JOURNAL OF ENVIRONMENTAL HEALTH LA English DT Editorial Material C1 CDC, Environm Hlth Tracking Branch, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA. RP Wall, PA (reprint author), CDC, Environm Hlth Tracking Branch, Natl Ctr Environm Hlth, 4770 Buford Hwy,MS F-57, Atlanta, GA 30341 USA. EM pwall@cdc.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATL ENVIRON HEALTH ASSOC PI DENVER PA 720 S COLORADO BLVD SUITE 970, SOUTH TOWER, DENVER, CO 80246 USA SN 0022-0892 J9 J ENVIRON HEALTH JI J. Environ. Health PD OCT PY 2015 VL 78 IS 3 BP 34 EP 36 PG 3 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA CS1VF UT WOS:000361855900006 PM 26591336 ER PT J AU Hays, RD Spritzer, KL Thompson, WW Cella, D AF Hays, Ron D. Spritzer, Karen L. Thompson, William W. Cella, David TI US General Population Estimate for "Excellent" to "Poor" Self-Rated Health Item SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE health status; quality of life; survey research; outcomes ID PATIENT; MORTALITY; SCORES AB The most commonly used self-reported health question asks people to rate their general health from excellent to poor. This is one of the Patient-Reported Outcomes Measurement Information System (PROMIS) global health items. Four other items are used for scoring on the PROMIS global physical health scale. Because the single item is used on the majority of large national health surveys in the U.S., it is useful to construct scores that can be compared to U.S. general population norms. To estimate the PROMIS global physical health scale score from the responses to the single excellent to poor self-rated health question for use in public health surveillance, research, and clinical assessment. A cross-sectional survey of 21,133 individuals, weighted to be representative of the U.S. general population. The PROMIS items were administered via a Web-based survey to 19,601 persons in a national panel and 1,532 subjects from PROMIS research sites. The average age of individuals in the sample was 53 years, 52 % were female, 80 % were non-Hispanic white, and 19 % had a high school degree or lower level of education. PROMIS global physical health scale. The product-moment correlation of the single item with the PROMIS global physical health scale score was 0.81. The estimated scale score based on responses to the single item ranged from 29 (poor self-rated health, 2.1 SDs worse than the general population mean) to 62 (excellent self-rated health, 1.2 SDs better than the general population mean) on a T-score metric (mean of 50). This item can be used to estimate scores for the PROMIS global physical health scale for use in monitoring population health and achieving public health objectives. The item may also be used for individual assessment, but its reliability (0.52) is lower than that of the PROMIS global health scale (0.81). C1 [Hays, Ron D.; Spritzer, Karen L.] Univ Calif Los Angeles, Dept Med, Div Gen Internal Med, Los Angeles, CA 90024 USA. [Thompson, William W.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. [Cella, David] Northwestern Univ, Feinberg Sch Med, Dept Med Social Sci, Chicago, IL 60611 USA. RP Hays, RD (reprint author), Univ Calif Los Angeles, Dept Med, Div Gen Internal Med, 911 Broxton Ave, Los Angeles, CA 90024 USA. EM drhays@g.ucla.edu FU National Institute on Aging [P30AG028748, P30AG021684]; National Center on Minority Health and Health Disparities [P20MD000182]; National Cancer Institute (NCI) [1U2-CCA186878-01]; National Institutes of Health (NIH) Common Fund Initiative (Northwestern University) [U54AR057951, U01AR052177, U54AR057943]; National Institutes of Health (NIH) Common Fund Initiative (American Institutes for Research) [U54AR057926]; National Institutes of Health (NIH) Common Fund Initiative (State University of New York) [U01AR057948, U01AR052170]; National Institutes of Health (NIH) Common Fund Initiative (University of Washington, Seattle) [U01AR057954, U01AR052171]; National Institutes of Health (NIH) Common Fund Initiative (University of North Carolina, Chapel Hill) [U01AR052181]; National Institutes of Health (NIH) Common Fund Initiative (Children's Hospital of Philadelphia) [U01AR057956]; National Institutes of Health (NIH) Common Fund Initiative (Stanford University) [U01AR052158]; National Institutes of Health (NIH) Common Fund Initiative (Boston University) [U01AR057929]; National Institutes of Health (NIH) Common Fund Initiative (University of California, Los Angeles) [U01AR057936]; National Institutes of Health (NIH) Common Fund Initiative (University of Pittsburgh) [U01AR052155]; National Institutes of Health (NIH) Common Fund Initiative (Georgetown University) [U01AR057971]; National Institutes of Health (NIH) Common Fund Initiative (Children's Hospital Medical Center, Cincinnati) [U01AR057940]; National Institutes of Health (NIH) Common Fund Initiative (University of Maryland, Baltimore) [U01AR057967]; National Institutes of Health (NIH) Common Fund Initiative (Duke University) [U01AR052186] FX Dr. Hays was supported in part by grants P30AG028748 and P30AG021684 from the National Institute on Aging and grant P20MD000182 from the National Center on Minority Health and Health Disparities. Dr. Hays and Dr. Cella were also supported by a grant from the National Cancer Institute (NCI; 1U2-CCA186878-01).; PROMIS (R) was funded with cooperative agreements from the National Institutes of Health (NIH) Common Fund Initiative (Northwestern University, PI: David Cella, PhD, U54AR057951, U01AR052177; Northwestern University, PI: Richard C. Gershon, PhD, U54AR057943; American Institutes for Research, PI: Susan (San) D. Keller, PhD, U54AR057926; State University of New York, Stony Brook, PIs: Joan E. Broderick, PhD and Arthur A. Stone, PhD, U01AR057948, U01AR052170; University of Washington, Seattle, PIs: Heidi M. Crane, MD, MPH, Paul K. Crane, MD, MPH, and Donald L. Patrick, PhD, U01AR057954; University of Washington, Seattle, PI: Dagmar Amtmann, PhD, U01AR052171; University of North Carolina, Chapel Hill, PI: Harry A. Guess, MD, PhD (deceased), Darren A. DeWalt, MD, MPH, U01AR052181; Children's Hospital of Philadelphia, PI: Christopher B. Forrest, MD, PhD, U01AR057956; Stanford University, PI: James F. Fries, MD, U01AR052158; Boston University, PIs: Alan Jette, PT, PhD, Stephen M. Haley, PhD (deceased), and David Scott Tulsky, PhD (University of Michigan, Ann Arbor), U01AR057929; University of California, Los Angeles, PIs: Dinesh Khanna, MD (University of Michigan, Ann Arbor) and Brennan Spiegel, MD, MSHS, U01AR057936; University of Pittsburgh, PI: Paul A. Pilkonis, PhD, U01AR052155; Georgetown University, PIs: Carol. M. Moinpour, PhD (Fred Hutchinson Cancer Research Center, Seattle) and Arnold L. Potosky, PhD, U01AR057971; Children's Hospital Medical Center, Cincinnati, PI: Esi M. Morgan DeWitt, MD, MSCE, U01AR057940; University of Maryland, Baltimore, PI: Lisa M. Shulman, MD, U01AR057967; and Duke University, PI: Kevin P. Weinfurt, PhD, U01AR052186). NIH Science Officers on this project have included Deborah Ader, PhD, Vanessa Ameen, MD (deceased), Susan Czajkowski, PhD, Basil Eldadah, MD, PhD, Lawrence Fine, MD, DrPH, Lawrence Fox, MD, PhD, Lynne Haverkos, MD, MPH, Thomas Hilton, PhD, Laura Lee Johnson, PhD, Michael Kozak, PhD, Peter Lyster, PhD, Donald Mattison, MD, Claudia Moy, PhD, Louis Quatrano, PhD, Bryce Reeve, PhD, William Riley, PhD, Peter Scheidt, MD, Ashley Wilder Smith, PhD, MPH, Susana Serrate-Sztein, MD, William Phillip Tonkins, DrPH, Ellen Werner, PhD, Tisha Wiley, PhD, and James Witter, MD, PhD. NR 23 TC 4 Z9 4 U1 1 U2 5 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD OCT PY 2015 VL 30 IS 10 BP 1511 EP 1516 DI 10.1007/s11606-015-3290-x PG 6 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA CS0MR UT WOS:000361755000028 PM 25832617 ER PT J AU Allison, RD Tong, X Moorman, AC Ly, KN Rupp, L Xu, FJ Gordon, SC Holmberg, SD AF Allison, Robert D. Tong, Xin Moorman, Anne C. Ly, Kathleen N. Rupp, Loralee Xu, Fujie Gordon, Stuart C. Holmberg, Scott D. CA Chronic Hepatitis Cohort Study TI Increased incidence of cancer and cancer-related mortality among persons with chronic hepatitis C infection, 2006-2010 SO JOURNAL OF HEPATOLOGY LA English DT Article DE Hepatitis C virus; SEER; Cancer; Incidence; Mortality ID NON-HODGKIN-LYMPHOMA; CHRONIC VIRAL-HEPATITIS; ORAL LICHEN-PLANUS; VIRUS-INFECTION; UNITED-STATES; HIGH PREVALENCE; CELL CARCINOMA; RISK; RNA; EPIDEMIOLOGY AB Background & Aims: Persons chronically infected with the hepatitis C virus (HCV) may be at higher risk for developing and dying from non-liver cancers than the general population. Methods: 12,126 chronic HCV-infected persons in the Chronic Hepatitis Cohort Study (CHeCS) contributed 39,984 person-years of follow-up from 2006 to 2010 and were compared to 133,795,010 records from 13 Surveillance, Epidemiology and End Results Program (SEER) cancer registries, and approximately 12 million U.S. death certificates from Multiple Cause of Death (MCOD) data. Measurements included standardized rate ratios (SRR) and relative risk (RR). Results: The incidence of the following cancers was significantly higher among patients with chronic HCV infection: liver (SRR, 48.6 [95% CI, 44.4-52.7]), pancreas (2.5 [1.7-3.2]), rectum (2.1 [1.3-2.8]), kidney (1.7 [1.1-2.2]), non-Hodgkin lymphoma (NHL) (1.6 [1.2-2.1]), and lung (1.6 [1.3-1.9]). Age-adjusted mortality was significantly higher among patients with: liver (RR, 29.6 [95% CI, 29.1-30.1]), oral (5.2 [5.1-5.4]), rectum (2.6 [2.5-2.7]), NHL (2.3 [2.2-2.31]), and pancreatic (1.63 [1.6-1.7]) cancers. The mean ages of cancer diagnosis and cancer-related death were significantly younger among CHeCS HCV cohort patients compared to the general population for many cancers. Conclusions: Incidence and mortality of many types of non-liver cancers were higher, and age at diagnosis and death younger, in patients with chronic HCV infection compared to the general population. Published by Elsevier B.V. on behalf of the European Association for the Study of the Liver. C1 [Allison, Robert D.; Tong, Xin; Moorman, Anne C.; Ly, Kathleen N.; Xu, Fujie; Holmberg, Scott D.] Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. [Rupp, Loralee; Gordon, Stuart C.] Henry Ford Hlth Syst, Detroit, MI USA. RP Allison, RD (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Bldg 24,MS-A04, Atlanta, GA 30329 USA. EM rallison@cdc.gov OI Allison, Robert/0000-0001-8458-5250 FU CDC Foundation (CDCF); CDCF; AbbVie; Gilead Sciences; Janssen Pharmaceuticals, Inc.; Vertex Pharmaceuticals; Genentech, a member of the Roche Group FX Dr. Allison was hired as a Guest Researcher from the Johns Hopkins Bloomberg School of Public Health and funded by the CDC Foundation (CDCF) to complete this study. CHeCS was funded by the CDCF, which currently receives grants from AbbVie, Gilead Sciences, Janssen Pharmaceuticals, Inc., and Vertex Pharmaceuticals. Past funders include Genentech, a member of the Roche Group. Current and past partial funders include Bristol-Myers Squibb. Granting corporations do not have access to CHeCS data and do not contribute to data analysis or writing of manuscripts. NR 42 TC 16 Z9 16 U1 2 U2 5 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0168-8278 EI 1600-0641 J9 J HEPATOL JI J. Hepatol. PD OCT PY 2015 VL 63 IS 4 BP 822 EP 828 PG 7 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA CS0EG UT WOS:000361729900010 PM 25937437 ER PT J AU Zhu, WM Sieradzki, K Albrecht, V McAllister, S Lin, W Stuchlik, O Limbago, B Pohl, J Rasheed, JK AF Zhu, Wenming Sieradzki, Krzysztof Albrecht, Valerie McAllister, Sigrid Lin, Wen Stuchlik, Olga Limbago, Brandi Pohl, Jan Rasheed, J. Kamile TI Evaluation of the Biotyper MALDI-TOF MS system for identification of Staphylococcus species SO JOURNAL OF MICROBIOLOGICAL METHODS LA English DT Article DE MALDI-TOF MS; Staphylococcus; Biochemical identification ID FLIGHT MASS-SPECTROMETRY; DESORPTION IONIZATION-TIME; ASSISTED-LASER-DESORPTION/IONIZATION; COAGULASE-NEGATIVE STAPHYLOCOCCI; SCORE CUTOFF VALUES; CLINICAL MICROBIOLOGY; EXTRACTION METHOD; BLOOD CULTURES; BACTERIA; AUREUS AB The Bruker Biotyper MALDI-TOF MS (Biotyper) system, with a modified 30 minute formic acid extraction method, was evaluated by its ability to identify 216 clinical Staphylococcus isolates from the CDC reference collection comprising 23 species previously identified by conventional biochemical tests. 16S rDNA sequence analysis was used to resolve discrepancies. Of these, 209 (96.8%) isolates were correctly identified: 177 (84.7%) isolates had scores >= 2.0, while 32 (15.3%) had scores between 1.70 and 1.99. The Biotyper identification was inconsistent with the biochemical identification for seven (3.2%) isolates, but the Biotyper identifications were confirmed by 16S rDNA analysis. The distribution of low scores was strongly species-dependent, e.g. only 5% of Staphylococcus epidermidis and 4.8% of Staphylococcus aureus isolates scored below 2.0, while 100% of Staphylococcus cohnii, 75% of Staphylococcus sciuri, and 60% of Staphylococcus caprae produced low but accurate Biotyper scores. Our results demonstrate that the Biotyper can reliably identify Staphylococcus species with greater accuracy than conventional biochemicals. Broadening of the reference database by inclusion of additional examples of under-represented species could further optimize Biotyper results. Published by Elsevier B.V. C1 [Zhu, Wenming; Sieradzki, Krzysztof; Albrecht, Valerie; McAllister, Sigrid; Lin, Wen; Limbago, Brandi; Rasheed, J. Kamile] Ctr Dis Control Prevent, Div Healthcare Qual Promot, Atlanta, GA USA. [Stuchlik, Olga; Pohl, Jan] Ctr Dis Control & Prevent, Div Sci Resources, Atlanta, GA 30333 USA. RP Zhu, WM (reprint author), Ctr Dis Control & Prevent, Div Healthcare Qual Promot, 1600 Clifton Rd,MS-C16, Atlanta, GA 30333 USA. EM waz7@cdc.gov NR 26 TC 3 Z9 4 U1 2 U2 18 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0167-7012 EI 1872-8359 J9 J MICROBIOL METH JI J. Microbiol. Methods PD OCT PY 2015 VL 117 BP 14 EP 17 DI 10.1016/j.mimet.2015.07.014 PG 4 WC Biochemical Research Methods; Microbiology SC Biochemistry & Molecular Biology; Microbiology GA CS1XA UT WOS:000361861000004 PM 26183765 ER PT J AU Rosenthal, J Lopez-Pazos, E Dowling, NF Pfeiffer, CM Mulinare, J Vellozzi, C Zhang, MD Lavoie, DJ Molina, R Ramirez, N Reeve, ME AF Rosenthal, Jorge Lopez-Pazos, Eunice Dowling, Nicole F. Pfeiffer, Christine M. Mulinare, Joe Vellozzi, Claudia Zhang, Mindy Lavoie, Donna J. Molina, Roberto Ramirez, Nicte Reeve, Mary-Elizabeth TI Folate and Vitamin B12 Deficiency Among Non-pregnant Women of Childbearing-Age in Guatemala 2009-2010: Prevalence and Identification of Vulnerable Populations SO MATERNAL AND CHILD HEALTH JOURNAL LA English DT Article DE Prevalence; Serum and red blood cell folate; Vitamin B12; Deficiency; Women of childbearing age; Guatemala ID NEURAL-TUBE DEFECTS; FOLIC-ACID; CARDIOVASCULAR-DISEASE; BLOOD FOLATE; FORTIFICATION; RISK; HEALTH; SERUM; FOOD; HOMOCYSTEINE AB Information on folate and vitamin B12 deficiency rates in Guatemala is essential to evaluate the current fortification program. The objectives of this study were to describe the prevalence of folate and vitamin B12 deficiencies among women of childbearing age (WCBA) in Guatemala and to identify vulnerable populations at greater risk for nutrient deficiency. A multistage cluster probability study was designed with national and regional representation of nonpregnant WCBA (15-49 years of age). Primary data collection was carried out in 2009-2010. Demographic and health information was collected through face-to-face interviews. Blood samples were collected from 1473 WCBA for serum and red blood cell (RBC) folate and serum vitamin B12. Biochemical concentrations were normalized using geometric means. Prevalence rate ratios were estimated to assess relative differences among different socioeconomic and cultural groups including ethnicity, age, education level, wealth index and rural versus urban locality. National prevalence estimates for deficient serum [< 10 nmol per liter (nmol/L)] and RBC folate (< 340 nmol/L) concentrations were 5.1 % (95 % CI 3.8, 6.4) and 8.9 % (95 % CI 6.7, 11.7), respectively; for vitamin B12 deficiency (< 148 pmol/L) 18.5 % (95 % CI 15.6, 21.3). Serum and RBC folate deficiency prevalences were higher for rural areas than for urban areas (8.0 vs. 2.0 % and 13.5 vs. 3.9 %, respectively). The prevalence of RBC folate deficiency showed wide variation by geographic region (3.2-24.9 %) and by wealth index (4.1-15.1 %). The prevalence of vitamin B12 deficiency also varied among regions (12.3-26.1 %). In Guatemala, folate deficiency was more prevalent among indigenous rural and urban poor populations. Vitamin B12 deficiency was widespread among WCBA. Our results suggest the ongoing need to monitor existing fortification programs, in particular regarding its reach to vulnerable populations. C1 [Rosenthal, Jorge; Dowling, Nicole F.; Mulinare, Joe; Vellozzi, Claudia] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. [Lopez-Pazos, Eunice] Guatemala Minist Salud Publ & Asistencia Publ, Guatemala City, Guatemala. [Pfeiffer, Christine M.; Zhang, Mindy; Lavoie, Donna J.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA. [Molina, Roberto] Univ Valle Guatemala, Guatemala City, Guatemala. [Ramirez, Nicte] Fdn Alimentos & Nutr Ctr Amer & Panama, Guatemala City, Guatemala. RP Rosenthal, J (reprint author), Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, MS-86, Atlanta, GA 30333 USA. EM jyr4@cdc.gov FU Intramural CDC HHS [CC999999] NR 35 TC 1 Z9 1 U1 0 U2 4 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1092-7875 EI 1573-6628 J9 MATERN CHILD HLTH J JI Matern. Child Health J. PD OCT PY 2015 VL 19 IS 10 BP 2272 EP 2285 DI 10.1007/s10995-015-1746-6 PG 14 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CR8SV UT WOS:000361625100021 PM 26002178 ER PT J AU England, L Kotelchuck, M Wilson, HG Diop, H Oppedisano, P Kim, SY Cui, XH Shapiro-Mendoza, CK AF England, Lucinda Kotelchuck, Milton Wilson, Hoyt G. Diop, Hafsatou Oppedisano, Paul Kim, Shin Y. Cui, Xiaohui Shapiro-Mendoza, Carrie K. TI Estimating the Recurrence Rate of Gestational Diabetes Mellitus (GDM) in Massachusetts 1998-2007: Methods and Findings SO MATERNAL AND CHILD HEALTH JOURNAL LA English DT Article DE Diabetes; Gestational diabetes mellitus; Diabetes recurrence; Sequential pregnancies; Pregnancy ID LIFE-STYLE INTERVENTION; PREPREGNANCY OBESITY; PREGNANT-WOMEN; HIGH-RISK; TRENDS; PREVALENCE; OUTCOMES; PRESERVATION; POPULATION; PROGRAM AB Women with gestational diabetes mellitus (GDM) may be able to reduce their risk of recurrent GDM and progression to type 2 diabetes mellitus through lifestyle change; however, there is limited population-based information on GDM recurrence rates. We used data from a population of women delivering two sequential live singleton infants in Massachusetts (1998-2007) to estimate the prevalence of chronic diabetes mellitus (CDM) and GDM in parity one pregnancies and recurrence of GDM and progression from GDM to CDM in parity two pregnancies. We examined four diabetes classification approaches; birth certificate (BC) data alone, hospital discharge (HD) data alone, both sources hierarchically combined with a diagnosis of CDM from either source taking priority over a diagnosis of GDM, and both sources combined including only pregnancies with full agreement in diagnosis. Descriptive statistics were used to describe population characteristics, prevalence of CDM and GDM, and recurrence of diabetes in successive pregnancies. Diabetes classification agreement was assessed using the Kappa statistic. Associated maternal characteristics were examined through adjusted model-based t tests and Chi square tests. A total of 134,670 women with two sequential deliveries of parities one and two were identified. While there was only slight agreement on GDM classification across HD and BC records, estimates of GDM recurrence were fairly consistent; nearly half of women with GDM in their parity one pregnancy developed GDM in their subsequent pregnancy. While estimates of progression from GDM to CDM across sequential pregnancies were more variable, all approaches yielded estimates of a parts per thousand currency sign5 %. The development of either GDM or CDM following a parity one pregnancy with no diagnosis of diabetes was < 3 % across approaches. Women with recurrent GDM were disproportionately older and foreign born. Recurrent GDM is a serious life course public health issue; the inter-pregnancy interval provides an important window for diabetes prevention. C1 [England, Lucinda; Kim, Shin Y.] Ctr Dis Control & Prevent, Atlanta, GA 30341 USA. [Kotelchuck, Milton] Harvard Univ, MassGen Hosp Children, MGH Ctr Child & Adolescent Hlth Res & Policy, Sch Med, Boston, MA 02115 USA. [Wilson, Hoyt G.] DB Consulting Grp Inc, Silver Spring, MD 20910 USA. [Diop, Hafsatou; Cui, Xiaohui] Massachusetts Dept Publ Hlth, Bur Family Hlth & Nutr, Boston, MA 02108 USA. [Oppedisano, Paul] Massachusetts Dept Publ Hlth, Boston, MA 02108 USA. [Shapiro-Mendoza, Carrie K.] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA 30341 USA. RP Kotelchuck, M (reprint author), Harvard Univ, MassGen Hosp Children, MGH Ctr Child & Adolescent Hlth Res & Policy, Sch Med, 100 Cambridge St,Room 15-1545, Boston, MA 02115 USA. EM lbe@cdc.gov; mkotelchuck@partners.org; hgw0@att.net; hafsatou.diop@state.ma.us; paul.oppedisano@state.ma.us; skim1@cdc.gov; xiaohui.cui@state.ma.usa; ayn9@cdc.gov FU Intramural CDC HHS [CC999999] NR 35 TC 3 Z9 3 U1 0 U2 3 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1092-7875 EI 1573-6628 J9 MATERN CHILD HLTH J JI Matern. Child Health J. PD OCT PY 2015 VL 19 IS 10 BP 2303 EP 2313 DI 10.1007/s10995-015-1750-x PG 11 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CR8SV UT WOS:000361625100024 PM 26045058 ER PT J AU Rogers, M Johnson, K Yu, J Cuoco, L Blank, S AF Rogers, Meighan Johnson, Kimberly Yu, Jiang Cuoco, Louis Blank, Susan TI Impact of a Brief Intervention for Substance Use on Acquisition of Sexually Transmitted Diseases Including HIV: Findings From an Urban Sexually Transmitted Disease Clinic Population SO SEXUALLY TRANSMITTED DISEASES LA English DT Article ID BEHAVIORAL-COUNSELING INTERVENTIONS; PRIMARY-CARE; ALCOHOL-USE; DRUG-USE; SERVICES; EFFICACY; METAANALYSIS; ASSOCIATION; CONSUMPTION; PREVENTION AB Background Unhealthy substance use is associated with increased rates of sexually transmitted diseases (STDs), including HIV. The screening, brief intervention, and referral to treatment strategy is effective at reducing substance use over time. We investigated whether STD clinic patients who received a brief intervention (BI) had lower rates of STD/HIV acquisition over time than those who did not. Methods A retrospective sample of 7665 patients who screened positive for substance abuse or dependence between May 1, 2008, and December 31, 2010, was matched with STD and HIV surveillance registries for a 1-year follow-up period to determine incidence of STD and HIV infection. Results Overall, 44.6% (n = 3420) received BI; 7.0% of this population acquired a bacterial STD compared with 8.8% of persons who did not receive BI (P < 0.005). In multivariate analysis, BI had a protective effect against STD infection for men (odds ratio, 0.774; 95% confidence interval [CI], 0.63-0.96), after controlling for age, race/ethnicity, and sex of partner. There were 61 new HIV infections over the follow-up period; however, we found no significant association between BI and subsequent HIV diagnosis. Conclusions Brief intervention is associated with a reduction in STD incidence among men who screen positive for substance abuse and should be considered as an STD prevention strategy. Further study is needed to identify mechanisms through which BI may impact STD outcomes. C1 [Rogers, Meighan; Blank, Susan] New York City Dept Hlth & Mental Hyg, Bur STD Control, New York, NY 10013 USA. [Johnson, Kimberly] New York City Dept Hlth & Mental Hyg, Bur Environm Dis & Injury Prevent, New York, NY 10013 USA. [Yu, Jiang] SUNY Albany, Sch Social Welf, Albany, NY 12222 USA. [Cuoco, Louis] New York City Dept Hlth & Mental Hyg, Bur Mental Hlth, New York, NY 10013 USA. [Blank, Susan] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA USA. RP Johnson, K (reprint author), New York City Dept Hlth & Mental Hyg, 125 Worth St,Room 620, New York, NY 10013 USA. EM Kjohnson5@health.nyc.gov FU federal grant from the Substance Abuse and Mental Health Services Administration [TI018746] FX This program was supported by a federal grant from the Substance Abuse and Mental Health Services Administration that was awarded to New York State Office of Alcoholism and Substance Abuse Services (Grant No. TI018746). NR 33 TC 1 Z9 1 U1 1 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2015 VL 42 IS 10 BP 569 EP 574 DI 10.1097/OLQ.0000000000000339 PG 6 WC Infectious Diseases SC Infectious Diseases GA CR8LZ UT WOS:000361605700007 PM 26372929 ER PT J AU Patel, CG Tao, GY AF Patel, Chirag G. Tao, Guoyu TI The Significant Impact of Different Insurance Enrollment Criteria on the HEDIS Chlamydia Screening Measure for Young Women Enrolled in Medicaid and Commercial Insurance Plans SO SEXUALLY TRANSMITTED DISEASES LA English DT Article ID UNITED-STATES; ELIGIBILITY; COVERAGE; CHILDREN AB Objective The impact of length of enrollment in a health plan on eligibility of women under the Healthcare Effectiveness Data and Information Set (HEDIS) chlamydia screening measure is not fully understood. We assessed the representativeness of the measure among the proportion of women aged 15 to 24 years with a gap in coverage for Medicaid and commercial health insurance. Methods Truven Health Marketscan Medicaid and commercial health insurance data from 2006 to 2012 were used to make comparisons between proportions of women with a gap in coverage to those enrolled in insurance plans for different numbers of months. Results Approximately 48% of Medicaid-insured women and 31% of commercially insured women had an at least 2-month gap that disqualified them from eligibility for inclusion in the HEDIS chlamydia screening measure. Extending eligibility to women with at least 6 months of coverage, regardless of gap, would increase the proportion of insured women included in the HEDIS measure to 76% (from 52%) for Medicaid and 83% (from 69%) for commercial insurance, without much effect on chlamydia testing rate. This would make the measure more representative of all insured women. Conclusions The large proportion of young women who had a 2-month or greater gap in coverage in Medicaid had a significant impact on the overall representativeness of the current HEDIS chlamydia screening measure. C1 [Patel, Chirag G.; Tao, Guoyu] Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Div STD Prevent, Atlanta, GA USA. [Patel, Chirag G.] Oak Ridge Inst Sci & Educ, Oak Ridge, TN USA. RP Patel, CG (reprint author), Ctr Dis Control & Prevent, Div STD Prevent, 1600 Clifton Rd,MS-2016, Atlanta, GA 30316 USA. EM wyp3@cdc.gov NR 21 TC 1 Z9 1 U1 1 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2015 VL 42 IS 10 BP 575 EP 579 DI 10.1097/OLQ.0000000000000338 PG 5 WC Infectious Diseases SC Infectious Diseases GA CR8LZ UT WOS:000361605700008 PM 26372930 ER PT J AU Cramer, R Martinez, N Roberts, C Habel, MA Leino, EV Leichliter, JS AF Cramer, Ryan Martinez, Nina Roberts, Craig Habel, Melissa A. Leino, E. Victor Leichliter, Jami S. TI Use of Expedited Partner Therapy for Sexually Transmitted Diseases in College and University Health Centers in the United States, 2011-2012 SO SEXUALLY TRANSMITTED DISEASES LA English DT Article ID CHLAMYDIAL INFECTIONS; LEGAL STATUS; PERSONS 14; ATTITUDES; PROVIDERS; STUDENTS; AGE AB We examined expedited partner therapy for chlamydia and gonorrhea in college and university health centers by institutional and policy characteristics. Expedited partner therapy awareness and use was low (44.1% used), did not differ by institutional characteristics, and differed by policy environment. Our findings suggest missed opportunities for sexually transmitted disease prevention in college and university health centers. C1 [Cramer, Ryan; Martinez, Nina; Habel, Melissa A.; Leichliter, Jami S.] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA 30329 USA. [Roberts, Craig] Univ Wisconsin, Madison, WI USA. [Leino, E. Victor] Amer Coll Hlth Assoc, Baltimore, MD USA. RP Cramer, R (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd,MS E-02, Atlanta, GA 30329 USA. EM rcramer@cdc.gov NR 25 TC 0 Z9 0 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2015 VL 42 IS 10 BP 580 EP 584 DI 10.1097/OLQ.0000000000000347 PG 5 WC Infectious Diseases SC Infectious Diseases GA CR8LZ UT WOS:000361605700009 PM 26366508 ER PT J AU Owusu-Edusei, K Gift, TL Patton, ME Johnson, DB Valentine, JA AF Owusu-Edusei, Kwame, Jr. Gift, Thomas L. Patton, Monica E. Johnson, David B. Valentine, Jo A. TI Estimating the Total Annual Direct Cost of Providing Sexually Transmitted Infection and HIV Testing and Counseling for Men Who Have SexWith Men in the United States SO SEXUALLY TRANSMITTED DISEASES LA English DT Article ID LIGASE CHAIN-REACTION; URINE SAMPLES; SEX; CHLAMYDIA; GONORRHEA; PREVENTION; PREVALENCE; HEALTH; WOMEN AB Background The Centers for Disease Control and Prevention recommends annual sexually transmitted infection (STI) and HIV testing and counseling for men who have sex with men (MSM) in the United States. We estimated the annual total direct medical cost of providing recommended STI and HIV testing and counseling services for MSM in the United States. Methods We included costs for 9 STI (including anatomic site-specific) tests recommended by the Centers for Disease Control and Prevention (HIV, syphilis, gonorrhea, chlamydia, hepatitis B viral infection, and herpes simplex virus type 2), office visits, and counseling. We included nongenital tests for MSM with exposure at nongenital sites. All cost data were obtained from the 2012 MarketScan outpatient claims database. Men were defined as MSM if they had a male sex partner within the last 12 months, which was estimated at 2.9% (2.6%-3.2%) of the male population in a 2012 study. All costs were updated to 2014 US dollars. Results The estimated average costs were as follows: HIV ($18 [$9-$27]), hepatitis B viral infection ($23 [$12-$35]), syphilis ($8 [$4-$11]), gonorrhea and chlamydia ($45 [$22-$67]) per anatomic site), herpes simplex virus type 2 ($27 [$14-$41]), office visit ($100 [$50-$149]), and counseling ($29 [$15-$44]). We estimated that the total annual direct cost of a universal STI and HIV testing and counseling program was $1.1 billion ($473 million-$1.7 billion) for all MSM and $756 (range, $338-$1.2 billion) when excluding office visit cost. Conclusions These estimates provide the potential costs associated with universal STI and HIV testing and counseling for MSM in the United States. This information may be useful in future cost and/or cost-effectiveness analyses that can be used to evaluate STI and HIV prevention efforts. C1 [Owusu-Edusei, Kwame, Jr.; Gift, Thomas L.; Patton, Monica E.; Johnson, David B.; Valentine, Jo A.] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA 30333 USA. RP Owusu-Edusei, K (reprint author), Ctr Dis Control & Prevent, Div STD Prevent, 1600 Clifton Rd,MS E-80, Atlanta, GA 30333 USA. EM Kowusuedusei@cdc.gov NR 21 TC 0 Z9 0 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2015 VL 42 IS 10 BP 586 EP 589 DI 10.1097/OLQ.0000000000000341 PG 4 WC Infectious Diseases SC Infectious Diseases GA CR8LZ UT WOS:000361605700011 PM 26366510 ER PT J AU Bernstein, KT AF Bernstein, Kyle T. TI Systems Approaches to Improving Rates of Extragenital Chlamydia and Gonorrhea Screening Among Men Who Have Sex With Men Engaged in Human Immunodeficiency Virus Care SO SEXUALLY TRANSMITTED DISEASES LA English DT Editorial Material ID IMPROVEMENT INTERVENTION; UNITED-STATES; HIV; INCREASES C1 Ctr Dis Control & Prevent, Div Sexually Transmitted Dis Prevent, Atlanta, GA 30333 USA. RP Bernstein, KT (reprint author), Ctr Dis Control & Prevent, Div Sexually Transmitted Dis Prevent, 1600 Clifton Rd,SE-02, Atlanta, GA 30333 USA. EM Kio8@cdc.gov NR 20 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2015 VL 42 IS 10 BP 599 EP 600 DI 10.1097/OLQ.0000000000000354 PG 2 WC Infectious Diseases SC Infectious Diseases GA CR8LZ UT WOS:000361605700014 PM 26366511 ER PT J AU Schein, CH Ye, MY Paul, AV Oberste, MS Chapman, N van Noort, GJV Filippov, DV Choi, KH AF Schein, Catherine H. Ye, Mengyi Paul, Aniko V. Oberste, M. Steven Chapman, Nora van Noort, Gerbrand J. van der Heden Filippov, Dmitri V. Choi, Kyung H. TI Sequence specificity for uridylylation of the viral peptide linked to the genome (VPg) of enteroviruses SO VIROLOGY LA English DT Article DE Peptide priming; Nucleotide transfer reaction; RNA polymerase; Coxsackie virus; EV-71; Poliovirus; PCP-consensus sequence; Metal ion dependent phosphotransfer ID DEPENDENT RNA-POLYMERASE; PROTEIN PRIMER; POLIOVIRUS RNA; COXSACKIEVIRUS B3; CRYSTAL-STRUCTURE; REPLICATION; INFECTION; MECHANISM; COMPLEX; IDENTIFICATION AB Enteroviruses (EV) uridylylate a peptide, VPg, as the first step in their replication. VPgpUpU, found free in infected cells, serves as the primer for RNA elongation. The abilities of four polymerases (3D(Pol)), from EV-species A-C, to uridylylate VPgs that varied by up to 60% of their residues were compared. Each 3D(Pol) was able to uridylylate all five VPgs using polyA RNA as template, while showing specificity for its own genome encoded peptide. All 3D(Pol) uridylylated a consensus VPg representing the physical chemical properties of 31 different VPgs. Thus the residues required for uridylylation and the enzymatic mechanism must be similar in diverse EV. As VPg-binding sites differ in co-crystal structures, the reaction is probably done by a second 3D(Pol) molecule. The conservation of polymerase residues whose mutation reduces uridylylation but not RNA elongation is compared. (C) 2015 Elsevier Inc. All rights reserved. C1 [Schein, Catherine H.] FfAME, Alachua, FL 32616 USA. [Ye, Mengyi; Choi, Kyung H.] Univ Texas Med Branch, Dept Biochem & Mol Biol, Galveston, TX 77555 USA. [Paul, Aniko V.] SUNY Stony Brook, Dept Mol Genet & Microbiol, Stony Brook, NY 11790 USA. [Oberste, M. Steven] Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA 30333 USA. [Chapman, Nora] Univ Nebraska Med Ctr, Dept Pathol & Microbiol, Omaha, NE 68198 USA. [van Noort, Gerbrand J. van der Heden; Filippov, Dmitri V.] Leiden Univ, Leiden Inst Chem, NL-2300 RA Leiden, Netherlands. RP Schein, CH (reprint author), FfAME, 13709 Progress Blvd, Alachua, FL 32616 USA. EM chschein@ffame.org OI Schein, Catherine/0000-0002-8290-2109 FU NIH [1R21AI105985]; VIDI grand from the Netherlands Organisation for Scientific Research (NWO); [RO1AI0152235] FX Special appreciation and thanks are due to Kaija Maher, CDC, for obtaining the genes for CVA24 and EV-A71 3DPol and staff at FfAME, particularly Ryan Shaw, Lucy Glushacova, Ozlem Yaren, Jennifer Moses, Nicole Leal, Nidhi Sharma, Andrea Bradley and Dianne Rowold for help in establishing the assay methods and Steve Benner for helpful discussions. This work was supported by grants from the NIH to CHS (1R21AI105985), and in part by grant RO1AI0152235 (PI: Eckard Wimmer). Synthesis of VPgs and VPg-pUs was supported by a VIDI grand from the Netherlands Organisation for Scientific Research (NWO). NR 55 TC 1 Z9 1 U1 0 U2 2 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0042-6822 J9 VIROLOGY JI Virology PD OCT PY 2015 VL 484 BP 80 EP 85 DI 10.1016/j.virol.2015.05.016 PG 6 WC Virology SC Virology GA CR8CG UT WOS:000361578100009 PM 26074065 ER PT J AU Albarino, CG Guerrero, LW Lo, MK Nichol, ST Towner, JS AF Albarino, Cesar G. Guerrero, Lisa Wiggleton Lo, Michael K. Nichol, Stuart T. Towner, Jonathan S. TI Development of a reverse genetics system to generate a recombinant Ebola virus Makona expressing a green fluorescent protein SO VIROLOGY LA English DT Article ID SPECTRUM ANTIVIRAL ACTIVITY; HEMORRHAGIC-FEVER VIRUSES; DEPENDENT RNA-POLYMERASE; MARBURG VIRUS; WEST-AFRICA; REPLICATION CYCLE; IRF-3 ACTIVATION; DISEASE OUTBREAK; HIGH-THROUGHPUT; IN-VITRO AB Previous studies have demonstrated the potential application of reverse genetics technology in studying a broad range of aspects of viral biology, including gene regulation, protein function, cell entry, and pathogenesis. Here, we describe a highly efficient reverse genetics system used to generate recombinant Ebola virus (EBOV) based on a recent isolate from a human patient infected during the 2014-2015 outbreak in Western Africa. We also rescued a recombinant EBOV expressing a fluorescent reporter protein from a cleaved VP40 protein fusion. Using this virus and an inexpensive method to quantitate the expression of the foreign gene, we demonstrate its potential usefulness as a tool for screening antiviral compounds and measuring neutralizing antibodies. Published by Elsevier Inc. C1 [Albarino, Cesar G.; Guerrero, Lisa Wiggleton; Lo, Michael K.; Nichol, Stuart T.; Towner, Jonathan S.] Ctr Dis Control & Prevent, Atlanta, GA 30322 USA. RP Albarino, CG (reprint author), Ctr Dis Control & Prevent, Atlanta, GA 30322 USA. EM calbarino@cdc.gov OI Lo, Michael/0000-0002-0409-7896 NR 47 TC 9 Z9 10 U1 1 U2 11 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0042-6822 J9 VIROLOGY JI Virology PD OCT PY 2015 VL 484 BP 259 EP 264 DI 10.1016/j.virol.2015.06.013 PG 6 WC Virology SC Virology GA CR8CG UT WOS:000361578100028 PM 26122472 ER PT J AU Belser, JA Maines, TR Creager, HM Katz, JM Tumpey, TM AF Belser, Jessica A. Maines, Taronna R. Creager, Hannah M. Katz, Jacqueline M. Tumpey, Terrence M. TI Oseltamivir inhibits influenza virus replication and transmission following ocular-only aerosol inoculation of ferrets SO VIROLOGY LA English DT Article DE Influenza virus; Oseltamivir (Tamiflu); Ferret model; Antiviral; Aerosol; Transmission ID A VIRUSES; EPITHELIAL-CELLS; INFECTION; H5N1; MODEL; MICE; TROPISM; PATHOGENESIS; VIRULENCE; REGIMENS AB Ocular exposure to influenza virus represents an alternate route of virus entry capable of establishing a respiratory infection in mammals, but the effectiveness of currently available antiviral treatments to limit virus replication within ocular tissue or inhibit virus spread from ocular sites to the respiratory tract is poorly understood. Using an inoculation method that delivers an aerosol inoculum exclusively to the ocular surface, we demonstrate that oral oseltamivir administration following ocular-only aerosol inoculation with multiple avian and human influenza viruses protected ferrets from a fatal and systemic infection, reduced clinical signs and symptoms of illness, and decreased virus transmissibility to susceptible contacts when a respiratory infection was initiated. The presence of oseltamivir further inhibited influenza virus replication in primary human corneal epithelial cells. These findings provide critical experimental evidence supporting the use of neuraminidase inhibitors during outbreaks of influenza virus resulting in ocular disease or following ocular exposure. Published by Elsevier Inc. C1 [Belser, Jessica A.; Maines, Taronna R.; Creager, Hannah M.; Katz, Jacqueline M.; Tumpey, Terrence M.] Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Creager, Hannah M.] Emory Univ, Microbiol & Mol Genet Grad Program, Atlanta, GA 30322 USA. RP Belser, JA (reprint author), Influenza Div, MS G-16 1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM jax6@cdc.gov NR 41 TC 1 Z9 1 U1 1 U2 5 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0042-6822 J9 VIROLOGY JI Virology PD OCT PY 2015 VL 484 BP 305 EP 312 DI 10.1016/j.virol.2015.06.020 PG 8 WC Virology SC Virology GA CR8CG UT WOS:000361578100032 PM 26142497 ER PT J AU Dawson, AL Riehle-Colarusso, T Reefhuis, J Arena, JF AF Dawson, April L. Riehle-Colarusso, Tiffany Reefhuis, Jennita Arena, J. Fernando CA Natl Birth Defects Prevention Stud TI In response to "In utero exposure to methotrexate and risk of congenital malformations" SO AMERICAN JOURNAL OF MEDICAL GENETICS PART A LA English DT Letter C1 [Dawson, April L.; Riehle-Colarusso, Tiffany; Reefhuis, Jennita; Arena, J. Fernando; Natl Birth Defects Prevention Stud] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. RP Dawson, AL (reprint author), Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, CDC, 1600 Clifton Rd MS-E86, Atlanta, GA 30333 USA. EM isp3@cdc.gov FU Intramural CDC HHS [CC999999] NR 3 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1552-4825 EI 1552-4833 J9 AM J MED GENET A JI Am. J. Med. Genet. A PD OCT PY 2015 VL 167 IS 10 BP 2490 EP 2490 DI 10.1002/ajmg.a.37151 PG 1 WC Genetics & Heredity SC Genetics & Heredity GA CR2TS UT WOS:000361184100046 PM 25959112 ER PT J AU King, BA Jama, AO Marynak, KL Promoff, GR AF King, Brian A. Jama, Amal O. Marynak, Kristy L. Promoff, Gabbi R. TI Attitudes Toward Raising the Minimum Age of Sale for Tobacco Among US Adults SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID CIGARETTE-SMOKING; YOUTH ACCESS; INITIATION AB Introduction: Efforts to disrupt tobacco sales to minors through age of sale restrictions can contribute to reductions in youth tobacco use. The objective of this study was to assess attitudes toward raising the minimum tobacco age of sale to 21 years among U.S. adults. Methods: Data from the 2014 Summer Styles, an Internet survey of U.S. adults aged >= 18 years (N=4,219), were analyzed in 2014. Respondents were asked: Do you favor or oppose raising the legal minimum age to purchase all tobacco products from 18 to 21? Responses included: strongly favor, somewhat favor, somewhat oppose, and strongly oppose. ORs and 95% CIs were calculated using logistic regression; covariates included sex, age, race/ethnicity, education, income, region, and cigarette smoking status. Results: Among all adults, 50.4% strongly and 24.6% somewhat favored raising the age to 21 years; 77.5% of never smokers, 74.6% of former smokers, and 69.9% of current smokers strongly or somewhat favored it. Adjusted odds of strongly or somewhat favoring raising the age were higher among adults aged 25-44 (OR=1.8, 95% CI=1.3, 2.5), 45-64 (OR=2.3, 95% CI=1.7, 3.2), and >= 65 (OR=3.1, 95% CI=2.2, 4.5) years, and lower among former (OR=0.7, 95% CI=0.6, 0.9) and current (OR=0.7, 95% CI=0.5, 0.8) smokers. Conclusions: Three quarters of adults favor raising the minimum tobacco age of sale to 21 years, including seven in ten smokers. Raising the minimum age of sale, along with proven tobacco control strategies, could prevent youth tobacco use. Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine C1 [King, Brian A.; Marynak, Kristy L.; Promoff, Gabbi R.] CDC, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. [Jama, Amal O.] CDC, DB Consulting Grp, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. RP King, BA (reprint author), CDC, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway,MS F-79, Atlanta, GA 30341 USA. EM baking@cdc.gov FU Intramural CDC HHS [CC999999] NR 16 TC 4 Z9 4 U1 0 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD OCT PY 2015 VL 49 IS 4 BP 583 EP 588 DI 10.1016/j.amepre.2015.05.012 PG 6 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA CR5YV UT WOS:000361421200011 PM 26163165 ER PT J AU Pate, RR McIver, KL Colabianchi, N Troiano, RP Reis, JP Carroll, DD Fulton, JE AF Pate, Russell R. McIver, Kerry L. Colabianchi, Natalie Troiano, Richard P. Reis, Jared P. Carroll, Dianna D. Fulton, Janet E. TI Physical Activity Measures in the Healthy Communities Study SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID MIDDLE SCHOOL GIRLS; ADOLESCENT GIRLS; ENVIRONMENTS; CHILDREN; YOUTH; PARENT; BOYS AB The risk of obesity is reduced when youth engage in recommended levels of physical. activity (PA). For that reason, public health organizations in the U.S. have encouraged communities to implement programs and policies designed to increase PA in youth, and many communities have taken on that challenge. However, the long-term effects of those programs and policies on obesity are largely unknown. The Healthy Communities Study is a large-scale observational study of U.S. communities that is examining the characteristics of programs and policies designed to promote healthy behaviors (e.g., increase PA and improve diet) and determining their association with obesity-related outcomes. The purpose of this paper is to describe the methods used to measure PA in children and the personal and community factors that may influence it. The study used both self-reported and objective measures of PA, and measured personal, family, and home influences on PA via three constructs: (1) PA self-schema; (2) parental support; and (3) parental rules regarding PA. Neighborhood and community factors related to PA were assessed using three measures: (1) child perceptions of the neighborhood environment; (2) availability of PA equipment; and (3) attributes of the child's street segment via direct observation. School influences on children's PA were assessed via three constructs: (1) school PA policies; (2) child perceptions of the school PA environment; and (3) school outdoor PA environment. These measures will enable examination of the associations between characteristics of community PA programs and policies and obesity-related outcomes in children and youth. C1 [Pate, Russell R.; McIver, Kerry L.] Univ S Carolina, Dept Exercise Sci, Arnold Sch Publ Hlth, Columbia, SC 29208 USA. [Colabianchi, Natalie] Univ Michigan, Inst Social Res, Ann Arbor, MI USA. [Troiano, Richard P.] NCI, Div Canc Control & Populat Sci, Bethesda, MD 20892 USA. [Reis, Jared P.] NHLBI, Div Cardiovasc Sci, Bethesda, MD 20892 USA. [Carroll, Dianna D.; Fulton, Janet E.] Ctr Dis Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Nutr Phys Act & Obes, Atlanta, GA 30333 USA. RP Pate, RR (reprint author), Publ Hlth Res Ctr, 921 Assembly St,Suite 212, Columbia, SC 29208 USA. EM rpate@mailbox.sc.edu OI Troiano, Richard/0000-0002-6807-989X FU National Heart, Lung, and Blood Institute; Eunice Kennedy Shriver National Institute of Child Health and Development, National Institute of Diabetes and Digestive and Kidney Disorders, National Cancer Institute; NIH Office of Behavioral and Social Sciences Research; DHHS [HHSN268201000041C] FX The Healthy Communities Study was funded with federal funds from the National Heart, Lung, and Blood Institute, in collaboration with the Eunice Kennedy Shriver National Institute of Child Health and Development, National Institute of Diabetes and Digestive and Kidney Disorders, National Cancer Institute, and NIH Office of Behavioral and Social Sciences Research; DHHS, under Contract No. HHSN268201000041C. NR 42 TC 6 Z9 6 U1 2 U2 13 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD OCT PY 2015 VL 49 IS 4 BP 653 EP 659 DI 10.1016/j.amepre.2015.06.020 PG 7 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA CR5YV UT WOS:000361421200022 PM 26384937 ER PT J AU Wiggins, LD Levy, SE Daniels, J Schieve, L Croen, LA DiGuiseppi, C Blaskey, L Giarelli, E Lee, LC Pinto-Martin, J Reynolds, A Rice, C Rosenberg, CR Thompson, P Yeargin-Allsopp, M Young, L Schendel, D AF Wiggins, Lisa D. Levy, Susan E. Daniels, Julie Schieve, Laura Croen, Lisa A. DiGuiseppi, Carolyn Blaskey, Lisa Giarelli, Ellen Lee, Li-Ching Pinto-Martin, Jennifer Reynolds, Ann Rice, Catherine Rosenberg, Cordelia Robinson Thompson, Patrick Yeargin-Allsopp, Marshalyn Young, Lisa Schendel, Diana TI Autism Spectrum Disorder Symptoms Among Children Enrolled in the Study to Explore Early Development (SEED) SO JOURNAL OF AUTISM AND DEVELOPMENTAL DISORDERS LA English DT Article DE Autism; Etiology; Symptoms; Phenotype; Study to Explore Early Development ID ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; SOCIAL COMMUNICATION QUESTIONNAIRE; DIAGNOSTIC OBSERVATION SCHEDULE; PREVALENCE; DISABILITIES; COMORBIDITY; GENETICS; VALIDITY; SAMPLE; TWIN AB This study examined the phenotypic profiles of children aged 30-68 months in the Study to Explore Early Development (SEED). Children classified as autism spectrum disorder (ASD), developmental delay (DD) with ASD symptoms, DD without ASD symptoms, and population comparison (POP) differed significantly from each other on cognitive, adaptive, behavioral, and social functioning and the presence of parent-reported conditions. Children with ASD and DD with ASD symptoms had mild to severe ASD risk on several measures compared to children with other DD and POP who had little ASD risk across measures. We conclude that children in SEED have varying degrees of ASD impairment and associated deficits. SEED thus provides a valuable sample to explore ASD phenotypes and inform risk factor analyses. C1 [Wiggins, Lisa D.; Schieve, Laura; Rice, Catherine; Yeargin-Allsopp, Marshalyn; Schendel, Diana] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. [Levy, Susan E.; Blaskey, Lisa; Giarelli, Ellen] Childrens Hosp Philadelphia, Ctr Autism Res, Philadelphia, PA 19104 USA. [Daniels, Julie] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC USA. [Croen, Lisa A.] Kaiser Permanente No Calif, Div Res, Autism Res Program, Oakland, CA USA. [DiGuiseppi, Carolyn] Univ Colorado, Colorado Sch Publ Hlth, Aurora, CO USA. [Reynolds, Ann; Rosenberg, Cordelia Robinson] Univ Colorado, JFK Partners, Aurora, CO USA. [Lee, Li-Ching] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA. [Pinto-Martin, Jennifer; Young, Lisa] Univ Penn, Sch Nursing, Philadelphia, PA 19104 USA. [Thompson, Patrick] Michigan State Univ, Clin & Translat Sci Inst, E Lansing, MI 48824 USA. [Levy, Susan E.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Schendel, Diana] Aarhus Univ, Dept Econ & Business, Natl Ctr Register Based Res, Aarhus, Denmark. [Schendel, Diana] Lundbeck Fdn Initiat Integrat Psychiat Res, iPSYCH, Copenhagen, Denmark. RP Wiggins, LD (reprint author), Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, 1600 Clifton Rd MS E-86, Atlanta, GA 30333 USA. EM lwiggins@cdc.gov RI Rice, Catherine/D-6305-2016; OI Reynolds, Ann/0000-0002-0836-746X FU Colorado Department of Public Health [U10DD000180]; Kaiser Foundation Research Institute (CA) [U10DD000181]; University of Pennsylvania [U10DD000182]; Johns Hopkins University [U10DD000183]; University of North Carolina at Chapel Hill [U10DD000184]; Michigan State University [U10DD000498] FX We would like to thank Aimee Alexander for her assistance with data cleaning and the SEED principal investigators, co-principal investigators, project coordinators, project staff, and children and families who participated in this research. This publication was supported by six cooperative agreements from the Centers for Disease Control and Prevention: Cooperative Agreement Number U10DD000180, Colorado Department of Public Health; Cooperative Agreement Number U10DD000181, Kaiser Foundation Research Institute (CA); Cooperative Agreement Number U10DD000182, University of Pennsylvania; Cooperative Agreement Number U10DD000183, Johns Hopkins University; Cooperative Agreement Number U10DD000184, University of North Carolina at Chapel Hill; and Cooperative Agreement Number U10DD000498, Michigan State University. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. NR 43 TC 2 Z9 2 U1 3 U2 11 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0162-3257 EI 1573-3432 J9 J AUTISM DEV DISORD JI J. Autism Dev. Disord. PD OCT PY 2015 VL 45 IS 10 BP 3183 EP 3194 DI 10.1007/s10803-015-2476-8 PG 12 WC Psychology, Developmental SC Psychology GA CR6CF UT WOS:000361430200010 PM 26048040 ER PT J AU Yasmin, S Adams, L Briggs, G Weiss, J Bisgard, K Anderson, S Tsang, C Henke, E Vasiq, M Komatsu, K AF Yasmin, Seema Adams, Laura Briggs, Graham Weiss, Joli Bisgard, Kris Anderson, Shoana Tsang, Clarisse Henke, Evan Vasiq, Muhammad Komatsu, Ken TI Outbreak of Botulism After Consumption of Illicit Prison-Brewed Alcohol in a Maximum Security PrisonArizona, 2012 SO JOURNAL OF CORRECTIONAL HEALTH CARE LA English DT Article DE botulism; botulinum; outbreak; prison ID FOODBORNE BOTULISM; UNITED-STATES AB The authors investigated the second botulism outbreak to occur in a maximum security prison in Arizona within a 4-month period. Botulism was confirmed in eight men aged 20 to 35 years who reported sharing a single batch of pruno made with potatoes. Initial symptoms included blurred vision, slurred speech, muscle weakness, ptosis, and dysphagia. All patients received heptavalent botulinum antitoxin, seven required mechanical ventilation, and all survived. The median incubation period was 29 hours. Sera from all patients and leftover pruno tested positive for botulinum toxin type A. Botulism should be considered among prisoners with cranial nerve palsies and descending, symmetric flaccid paralysis. Prison-brewed alcohol, particularly when made with potatoes, can be a vehicle for botulism and is associated with outbreaks of botulism in prisons. C1 [Yasmin, Seema; Adams, Laura] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA. [Yasmin, Seema; Adams, Laura; Weiss, Joli; Anderson, Shoana; Tsang, Clarisse; Henke, Evan; Komatsu, Ken] Arizona Dept Hlth Serv, Phoenix, AZ 85007 USA. [Briggs, Graham] Pinal Cty Publ Hlth Serv, Florence, AZ USA. [Bisgard, Kris] Ctr Dis Control & Prevent, Div Sci Educ & Profess Dev, Ctr Surveillance Epidemiol & Lab Serv, Atlanta, GA USA. [Anderson, Shoana] Metro Publ Hlth Dept, Nashville, TN USA. [Henke, Evan] 3M Food Safety, Ctr 3M, St Paul, MN 55144 USA. [Vasiq, Muhammad] Mt Vista Med Ctr, Mesa, AZ USA. RP Yasmin, S (reprint author), Univ Texas Dallas, Sch Nat Sci & Math, 800 West Campbell Rd, Richardson, TX 75080 USA. EM seemayasmin@gmail.com FU Centers for Disease Control and Prevention; Arizona Department of Health Services; Pinal County Public Health Services FX The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the Centers for Disease Control and Prevention, Arizona Department of Health Services, and Pinal County Public Health Services. NR 10 TC 0 Z9 0 U1 3 U2 5 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1078-3458 EI 1940-5200 J9 J CORRECT HEALTH CAR JI J. Correct. Health Care PD OCT PY 2015 VL 21 IS 4 BP 327 EP 334 DI 10.1177/1078345815604752 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CR6VQ UT WOS:000361486400002 PM 26377381 ER PT J AU Adams, LE Yasmin, S Briggs, G Redden, K Silvas, S Anderson, S Weiss, J Tsang, CA Henke, E Francies, J Herrick, K Lira, R Livar, E Thompson, G Sunenshine, R Robinson, BF Bisgard, KM Komatsu, KK AF Adams, Laura E. Yasmin, Seema Briggs, Graham Redden, Kore Silvas, Suzanne Anderson, Shoana Weiss, Joli Tsang, Clarisse A. Henke, Evan Francies, Jessica Herrick, Kristen Lira, Rosa Livar, Eugene Thompson, Gerald Sunenshine, Rebecca Robinson, Byron F. Bisgard, Kristine M. Komatsu, Kenneth K. TI Alcohol Production, Prevention Strategies, and Inmate Knowledge About the Risk for Botulism From Pruno Consumption in a Correctional FacilityArizona, 2013 SO JOURNAL OF CORRECTIONAL HEALTH CARE LA English DT Article DE botulism; alcohol drinking; drinking behavior; prisons; health education ID MADE ILLICIT ALCOHOL AB During July to November 2012, two botulism outbreaks (12 cases total) occurred in one all-male prison; both were associated with illicitly brewed alcohol (pruno) consumption. Inmate surveys were conducted to evaluate and develop prevention and education strategies. Qualitative surveys with open-ended questions were performed among inmates from rooms where outbreaks occurred to learn about pruno consumption. Quantitative surveys assessed knowledge gained after the outbreaks and preferred information sources. For the quantitative surveys, 250 inmates were randomly selected by bed from across the correctional facility and 164 inmates were interviewed. Only 24% of inmates reported any botulism knowledge before the outbreaks and education outreach, whereas 73% reported knowledge after the outbreaks (p < .01). Preferred information sources included handouts/fliers (52%) and the prison television channel (32%). C1 [Adams, Laura E.; Yasmin, Seema] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA. [Adams, Laura E.; Yasmin, Seema; Anderson, Shoana; Weiss, Joli; Tsang, Clarisse A.; Henke, Evan; Francies, Jessica; Herrick, Kristen; Lira, Rosa; Livar, Eugene; Komatsu, Kenneth K.] Arizona Dept Hlth Serv, Phoenix, AZ 85007 USA. [Adams, Laura E.; Yasmin, Seema; Sunenshine, Rebecca] Maricopa Cty Dept Publ Hlth, Phoenix, AZ 85007 USA. [Briggs, Graham; Redden, Kore; Silvas, Suzanne] Pinal Cty Publ Hlth Serv Dist, Florence, AZ USA. [Francies, Jessica; Lira, Rosa] Ctr Dis Control & Prevent, Publ Hlth Associate Program, Atlanta, GA USA. [Thompson, Gerald] Arizona Dept Correct, Florence, AZ USA. [Sunenshine, Rebecca] Ctr Dis Control & Prevent, Off Publ Hlth Preparedness & Response, Atlanta, GA USA. [Robinson, Byron F.; Bisgard, Kristine M.] Ctr Dis Control & Prevent, Epidemiol Workforce Branch, Atlanta, GA USA. RP Adams, LE (reprint author), Maricopa Cty Dept Publ Hlth, 150 N 18th Ave,Ste 100, Phoenix, AZ 85007 USA. EM laura.adams@azdhs.gov NR 11 TC 0 Z9 0 U1 4 U2 8 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1078-3458 EI 1940-5200 J9 J CORRECT HEALTH CAR JI J. Correct. Health Care PD OCT PY 2015 VL 21 IS 4 BP 335 EP 342 DI 10.1177/1078345815599763 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CR6VQ UT WOS:000361486400003 PM 26285594 ER PT J AU Goodman, CH Russell, BJ Velez, JO Laven, JJ Bagarozzi, DA Moon, JL Bedi, K Johnson, BW AF Goodman, C. H. Russell, B. J. Velez, J. O. Laven, J. J. Bagarozzi, D. A., Jr. Moon, J. L. Bedi, K. Johnson, B. W. TI Production of a Sindbis/Eastern Equine Encephalitis chimeric virus inactivated cell culture antigen SO JOURNAL OF VIROLOGICAL METHODS LA English DT Article DE Sindbis/Eastern Equine Encephalitis chimeric virus; Antigen; Immunoglobulin M antibody-capture enzyme-linked immunosorbent assay (MAC-ELISA); Beta-propiolactone Gamma-irradiation ID BETA-PROPIOLACTONE; VACCINE CANDIDATES; EASTERN; INFECTION; ASSAYS; NORTH AB Eastern Equine Encephalitis virus (EEEV) is a medically important pathogen that can cause severe encephalitis in humans, with mortality rates ranging from 30 to 80%. Unfortunately there are no antivirals or licensed vaccines available for human use, and laboratory diagnosis is essential to differentiate EEEV infection from other pathogens with similar clinical manifestations. The Arboviral Diseases Branch (ADB) reference laboratory at the CDC Division of Vector-Borne Diseases (DVBD) produces reference antigens used in serological assays such as the EEEV immunoglobulin M antibody-capture enzyme-linked immunosorbent assay (MAC-ELISA). However, EEEV is classified as a HHS select agent and requires biosafety level (BSL) three containment, limiting EEEV antigen production in non-select agent and BSL-2 laboratories. A recombinant Sindbis virus (SINV)/EEEV has been constructed for use under BSL-2 conditions and is not regulated as a select agent. Cell culture production of inactivated EEEV antigen from SINV/EEEV for use in the EEEV MAC-ELISA is reported here. Cell culture conditions and inactivation procedures were analyzed for SINV/EEEV using a recently developed antigen production algorithm, with the MAC-ELISA as the performance indicator. Published by Elsevier B.V. C1 [Goodman, C. H.; Russell, B. J.; Velez, J. O.; Laven, J. J.; Johnson, B. W.] Ctr Dis Control & Prevent, Arboviral Dis Branch, Div Vector Borne Dis, Ft Collins, CO 80521 USA. [Bagarozzi, D. A., Jr.; Moon, J. L.; Bedi, K.] CDC, Div Sci Resources, Atlanta, GA 30333 USA. RP Goodman, CH (reprint author), Ctr Dis Control & Prevent, Arboviral Dis Branch, Div Vector Borne Dis, 3156 Rampart Rd, Ft Collins, CO 80521 USA. EM bvv0@cdc.gov OI Moon, Jonathan/0000-0001-6533-507X FU Intramural CDC HHS [CC999999] NR 20 TC 0 Z9 0 U1 0 U2 5 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0166-0934 EI 1879-0984 J9 J VIROL METHODS JI J. Virol. Methods PD OCT PY 2015 VL 223 BP 19 EP 24 DI 10.1016/j.jviromet.2015.07.007 PG 6 WC Biochemical Research Methods; Biotechnology & Applied Microbiology; Virology SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Virology GA CR3UN UT WOS:000361258700004 PM 26205552 ER PT J AU Esona, MD Gautam, R Tam, KI Williams, A Mijatovic-Rustempasic, S Bowen, MD AF Esona, Mathew D. Gautam, Rashi Tam, Ka Ian Williams, Alice Mijatovic-Rustempasic, Slavica Bowen, Michael D. TI Multiplexed one-step RT-PCR VP7 and VP4 genotyping assays for rotaviruses using updated primers SO JOURNAL OF VIROLOGICAL METHODS LA English DT Article DE Rotavirus; VP7 and VP4 genes multiplexed gel-based genotyping; Updated primers ID GROUP-A ROTAVIRUS; POLYMERASE-CHAIN-REACTION; LINKED-IMMUNOSORBENT-ASSAY; REVERSE-TRANSCRIPTASE PCR; PLACEBO-CONTROLLED TRIAL; WHOLE-GENOME ANALYSES; 1ST 2 YEARS; MONOCLONAL-ANTIBODIES; DOUBLE-BLIND; ENZYME-IMMUNOASSAY AB The current two-step VP7 and VP4genotyping RT-PCR assays for rotaviruses have been linked consistently to genotyping failure in an estimated 30% of RVA positive samples worldwide. We have developed a VP7 and VP4 multiplexed one-step genotyping assays using updated primers generated from contemporary VP7 and VP4 sequences. To determine assay specificity and sensitivity, 17 reference virus strains, 6 nontarget gastroenteritis viruses and 725 clinical samples carrying the most common VP7 (G1, G2, G3, G4, G9, and G12) and VP4 (P[4], P[6], P[8], P[9] and P[10]) genotypes were tested in this study. All reference RVA strain targets yielded amplicons of the expected sizes and non-target genotypes and gastroenteritis viruses were not detected by either assay. Out of the 725 clinical samples tested, the VP7 and VP4 assays were able to assigned specific genotypes to 711 (98.1%) and 714 (98.5%), respectively. The remaining unassigned samples were re-tested for RVA antigen using EIA and qRT-PCR assays and all were found to be negative. The overall specificity, sensitivity and limit of detection of the VP7 assay were in the ranges of 99.0-100%, 94.0-100% and 8.6 x 10(1) to 8.6 x 10(2) copies of RNA/reaction, respectively. For the VP4 assay, the overall specificity, sensitivity and limit of detection assay were in the ranges of 100%, 94.0-100% and <= 1 to 8.6 x 10(2) copies of RNA/reaction, respectively. Here we report two highly robust, accurate, efficient, affordable and documentable gel-based genotyping systems which are capable of genotyping 97.8% of the six common VP7 and 98.3% of the five common VP4 genotypes of RVA strains which are responsible for approximately 88.2% of all RVA infections worldwide. Published by Elsevier B.V. C1 [Esona, Mathew D.; Gautam, Rashi; Tam, Ka Ian; Mijatovic-Rustempasic, Slavica; Bowen, Michael D.] Ctr Dis Control & Prevent, Gastroenteritis & Resp Viruses Lab Branch, Div Viral Dis, NCIRD, Atlanta, GA 30329 USA. [Williams, Alice] Furman Univ, Greenville, SC 29613 USA. RP Esona, MD (reprint author), 1600 Clifton Rd NE,MSG 04, Atlanta, GA 30333 USA. EM mdi4@cdc.gov FU Pan American Health Organization (PAHO); World Health Organization (WHO); Centers for Disease Control and Prevention (CDC) FX We thank the staff of the Gastroenteritis and Respiratory Viruses Laboratory Branch at the Centers for Disease Control and Prevention for invaluable assistance. We also wish to thank the Pan American Health Organization (PAHO), the World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC) for their support of this study. NR 74 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0166-0934 EI 1879-0984 J9 J VIROL METHODS JI J. Virol. Methods PD OCT PY 2015 VL 223 BP 96 EP 104 DI 10.1016/j.jviromet.2015.07.012 PG 9 WC Biochemical Research Methods; Biotechnology & Applied Microbiology; Virology SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Virology GA CR3UN UT WOS:000361258700017 PM 26231786 ER PT J AU Sweeney, LM MacCalman, L Haber, LT Kuempel, ED Tran, CL AF Sweeney, Lisa M. MacCalman, Laura Haber, Lynne T. Kuempel, Eileen D. Lang Tran, C. TI Bayesian evaluation of a physiologically-based pharmacokinetic (PBPK) model of long-term kinetics of metal nanoparticles in rats SO REGULATORY TOXICOLOGY AND PHARMACOLOGY LA English DT Article DE Nanoparticles; Physiologically-based pharmacokinetic model; Bayesian analysis; Markov chain Monte Carlo ID INSOLUBLE IRIDIUM PARTICLES; TISSUE DISTRIBUTION; SILVER NANOPARTICLES; TOXICODYNAMIC MODELS; RISK-ASSESSMENT; TRANSLOCATION; CLEARANCE; LUNG; TRICHLOROETHYLENE; BIODISTRIBUTION AB Biomathematical modeling quantitatively describes the disposition of metal nanoparticles in lungs and other organs of rats. In a preliminary model, adjustable parameters were calibrated to each of three data sets using a deterministic approach, with optimal values varying among the different data sets. In the current effort, Bayesian population analysis using Markov chain Monte Carlo (MCMC) simulation was used to recalibrate the model while improving assessments of parameter variability and uncertainty. The previously-developed model structure and some physiological parameter values were modified to improve physiological realism. The data from one of the three previously-identified studies and from two other studies were used for model calibration. The data from the one study that adequately characterized mass balance were used to generate parameter distributions. When data from a second study of the same nanomaterial (iridium) were added, the level of agreement was still acceptable. Addition of another data set (for silver nanoparticles) led to substantially lower precision in parameter estimates and large discrepancies between the model predictions and experimental data for silver nanoparticles. Additional toxicokinetic data are needed to further evaluate the model structure and performance and to reduce uncertainty in the kinetic processes governing in vivo disposition of metal nanoparticles. (C) 2015 Elsevier Inc. All rights reserved. C1 [Sweeney, Lisa M.] Henry M Jackson Fdn Adv Mil Med, Naval Med Res Unit Dayton NAMRU Dayton, Wright Patterson AFB, OH 45433 USA. [Sweeney, Lisa M.; Haber, Lynne T.] Toxicol Excellence Risk Assessment, Cincinnati, OH 45211 USA. [MacCalman, Laura; Lang Tran, C.] Inst Occupat Med, Edinburgh EH14 4AP, Midlothian, Scotland. [Kuempel, Eileen D.] NIOSH, Cincinnati, OH 45226 USA. RP Sweeney, LM (reprint author), Henry M Jackson Fdn Adv Mil Med, Naval Med Res Unit Dayton, 2729 R St,Bldg 837, Wright Patterson AFB, OH 45433 USA. EM LMS29@cwru.edu FU Intramural CDC HHS [CC999999]; PHS HHS [13FED1313358] NR 46 TC 5 Z9 5 U1 6 U2 18 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0273-2300 EI 1096-0295 J9 REGUL TOXICOL PHARM JI Regul. Toxicol. Pharmacol. PD OCT PY 2015 VL 73 IS 1 BP 151 EP 163 DI 10.1016/j.yrtph.2015.06.019 PG 13 WC Medicine, Legal; Pharmacology & Pharmacy; Toxicology SC Legal Medicine; Pharmacology & Pharmacy; Toxicology GA CR5UU UT WOS:000361410700016 PM 26145831 ER PT J AU McNeil, MM Weintraub, ES Duffy, J Sukumaran, L Jacobsen, SJ Klein, NP Hambidge, SJ Lee, GM Jackson, LA Irving, SA King, JP Kharbanda, EO Bednarczyk, RA DeStefano, F AF McNeil, Michael M. Weintraub, Eric S. Duffy, Jonathan Sukumaran, Lakshmi Jacobsen, Steven J. Klein, Nicola P. Hambidge, Simon J. Lee, Grace M. Jackson, Lisa A. Irving, Stephanie A. King, Jennifer P. Kharbanda, Elyse O. Bednarczyk, Robert A. DeStefano, Frank TI Risk of anaphylaxis after vaccination in children and adults SO ALERGOLOGIA POLSKA-POLISH JOURNAL OF ALLERGOLOGY LA Polish DT Article C1 [McNeil, Michael M.; Weintraub, Eric S.; Duffy, Jonathan; Sukumaran, Lakshmi; DeStefano, Frank] Ctr Dis Control & Prevent, Immunizat Safety Off, Div Healthcare Qual Promot, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. [Jacobsen, Steven J.] Southern Calif Kaiser Permanente, Pasadena, CA USA. [Klein, Nicola P.] Kaiser Permanente, Vaccine Study Ctr, Oakland, CA USA. [Hambidge, Simon J.] Kaiser Permanente, Inst Hlth Res, Denver, CO USA. [Lee, Grace M.] Harvard Med Sch, Oraz Harvard Pilgrim Hlth Care Inst, Dept Populat Med, Boston, MA USA. [Jackson, Lisa A.] Grp Hlth Res Inst, Seattle, WA USA. [Irving, Stephanie A.] Kaiser Permanente Northwest, Ctr Hlth Res, Portland, OR USA. [King, Jennifer P.] Marshfield Clin Res Fdn, Marshfield, WI USA. [Kharbanda, Elyse O.] HealthPartners Inst Educ & Res, Minneapolis, MN USA. [Bednarczyk, Robert A.] Emory Univ, Kaiser Permanente, Ctr Hlth Res, Oraz Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. RP McNeil, MM (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,MS D-26, Atlanta, GA 30333 USA. EM mmm2@cdc.gov NR 48 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER URBAN & PARTNER SP Z O O PI WROCLAW PA UL MIGDALOWA 4, LOK 59, WROCLAW, 02-796, POLAND SN 2353-3854 J9 ALERGOL POL JI Alergol. Pol. PD OCT-DEC PY 2015 VL 2 IS 4 BP T37 EP T52 DI 10.1016/j.jaci.2015.07.048 PG 16 WC Allergy SC Allergy GA V46XZ UT WOS:000209918200001 ER PT J AU O'Leary, A Jemmott, JB Jemmott, LS Bellamy, S Icard, LD Ngwane, Z AF O'Leary, Ann Jemmott, John B., III Jemmott, Loretta S. Bellamy, Scarlett Icard, Larry D. Ngwane, Zolani TI Mediation of an Efficacious HIV Risk Reduction Intervention for South African Men SO AIDS AND BEHAVIOR LA English DT Article DE HIV prevention; Cluster-randomized trial; South Africa; Men; Behavioral intervention; Mediation ID RANDOMIZED CONTROLLED-TRIAL; BEHAVIOR-CHANGE; AMERICAN ADOLESCENTS; CONDOM USE; MODERATION; INFECTION; WOMEN AB "Men, Together Making a Difference!" is an HIV/STD risk-reduction intervention that significantly increased self-reported consistent condom use during vaginal intercourse compared with a health-promotion attention-control intervention among men (N = 1181) in Eastern Cape Province, South Africa. The present analyses were designed to identify mediators of the intervention's efficacy. The potential mediators were Social Cognitive Theory (SCT) constructs that the intervention targeted, including several aspects of condom-use self-efficacy, outcome expectancies, and knowledge. Mediation was assessed using a product-of-coefficients approach where an alpha path (the intervention's effect on the potential mediator) and a beta path (the potential mediator's effect on the outcome of interest, adjusting for intervention) were estimated independently in a generalized estimating equations framework. Condom-use negotiation self-efficacy, technical-skill self-efficacy, and impulse-control self-efficacy were significant mediators. Although not mediators, descriptive norm and expected friends' approval of condom use predicted subsequent self-reported condom use, whereas the expected approval of sexual partner did not. The present results suggest that HIV/STD risk-reduction interventions that draw upon SCT and that address self-efficacy to negotiate condom use, to apply condoms correctly, and to exercise sufficient control when sexually aroused to use condoms may contribute to efforts to reduce sexual risk behavior among South African men. Future research must examine whether approaches that build normative support for condom use among men's friends are also efficacious. C1 [O'Leary, Ann] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA 30329 USA. [Jemmott, John B., III; Jemmott, Loretta S.; Bellamy, Scarlett] Univ Penn, Philadelphia, PA 19104 USA. [Icard, Larry D.] Temple Univ, Philadelphia, PA 19122 USA. [Ngwane, Zolani] Haverford Coll, Haverford, PA 19041 USA. RP O'Leary, A (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, 8 Corp Sq Blvd, Atlanta, GA 30329 USA. EM aoleary@cdc.gov FU National Institutes of Health [1 R01 HD053270] FX The authors wish to thank Craig Carty, Dr. Xoliswa Mtose, and Dr. Anita Heeren for their contributions to this study. The findings and conclusions are those of the authors and do not represent the views of the Centers for Disease Control and Prevention. This study was funded by a Research Grant 1 R01 HD053270 from the National Institutes of Health. NR 29 TC 1 Z9 1 U1 0 U2 4 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1090-7165 EI 1573-3254 J9 AIDS BEHAV JI AIDS Behav. PD OCT PY 2015 VL 19 IS 10 BP 1842 EP 1849 DI 10.1007/s10461-015-1042-x PG 8 WC Public, Environmental & Occupational Health; Social Sciences, Biomedical SC Public, Environmental & Occupational Health; Biomedical Social Sciences GA CR0HK UT WOS:000360999000012 PM 25969177 ER PT J AU Bauermeister, JA Pingel, ES Jadwin-Cakmak, L Harper, GW Horvath, K Weiss, G Dittus, P AF Bauermeister, Jose A. Pingel, Emily S. Jadwin-Cakmak, Laura Harper, Gary W. Horvath, Keith Weiss, Gretchen Dittus, Patricia TI Acceptability and Preliminary Efficacy of a Tailored Online HIV/STI Testing Intervention for Young Men who have Sex with Men: The Get Connected! Program SO AIDS AND BEHAVIOR LA English DT Article DE Prevention; eHealth; Youth; Linkage to care ID HIV PREVENTION INTERVENTION; PERSONS AWARE; HEALTH; RISK; GAY; YOUTH; METAANALYSIS; PERCEPTIONS; UNAWARE; CARE AB Southeast Michigan accounts for over 70 % of all HIV/STI cases in the state, with young men who have sex with men (YMSM) between the ages of 13 and 24 encumbering the largest burden in HIV/STI incidence. Using community-based participatory research principles, we developed and pilot tested a web-based, randomized control trial seeking to promote HIV/STI testing ("Get Connected!") among YMSM (N = 130; ages 15-24). Randomized participants completed a baseline assessment and shown a test-locator condition (control) or a tailored, personalized site (treatment). At 30-day follow-up, we found high acceptability among YMSM in both conditions, yet higher credibility of intervention content among YMSM in the treatment group (d = .55). Furthermore, 30 participants reported testing by following, with the majority of these participants (73.3 %; n = 22) completing the treatment condition, a clinically meaningful effect (d = .34) suggesting preliminary efficacy for the intervention. These results demonstrate the potential of the intervention, and suggest that a larger efficacy trial may be warranted. C1 [Bauermeister, Jose A.; Pingel, Emily S.; Jadwin-Cakmak, Laura; Harper, Gary W.] Univ Michigan, Sch Publ Hlth, Dept Hlth Behav & Hlth Educ, Ctr Sexual & Hlth Dispar, Ann Arbor, MI 48109 USA. [Horvath, Keith] Univ Minnesota, Minneapolis, MN USA. [Weiss, Gretchen] Natl Assoc Cty & City Hlth Officials, Washington, DC USA. [Dittus, Patricia] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Bauermeister, JA (reprint author), Univ Michigan, Sch Publ Hlth, Dept Hlth Behav & Hlth Educ, Ctr Sexual & Hlth Dispar, 1415 Washington Hts,SPH I Room 3822, Ann Arbor, MI 48109 USA. EM jbauerme@umich.edu OI Bauermeister, Jose/0000-0002-9276-2306 FU National Association of County and City Health Officials (NACHHO); MAC AIDS Fund; NIH Career Development Award [K01-MH087242] FX This research was supported by an award from the National Association of County and City Health Officials (NACHHO) and the MAC AIDS Fund to Dr. Bauermeister. Dr. Bauermeister was supported through a NIH Career Development Award (K01-MH087242). We thank our CAB and YAB for their contributions during the development and implementation of the intervention. NR 37 TC 7 Z9 7 U1 1 U2 6 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1090-7165 EI 1573-3254 J9 AIDS BEHAV JI AIDS Behav. PD OCT PY 2015 VL 19 IS 10 BP 1860 EP 1874 DI 10.1007/s10461-015-1009-y PG 15 WC Public, Environmental & Occupational Health; Social Sciences, Biomedical SC Public, Environmental & Occupational Health; Biomedical Social Sciences GA CR0HK UT WOS:000360999000014 PM 25638038 ER PT J AU Clark, SJ Reeves, SL Gebremariam, A Stokley, S Dombkowski, KJ AF Clark, Sarah J. Reeves, Sarah L. Gebremariam, Acham Stokley, Shannon Dombkowski, Kevin J. TI Communication From Primary Care Practices Regarding Adolescent Immunization SO CLINICAL PEDIATRICS LA English DT Article ID FEASIBILITY; REMINDERS C1 [Clark, Sarah J.; Reeves, Sarah L.; Gebremariam, Acham; Dombkowski, Kevin J.] Univ Michigan, Ann Arbor, MI 48109 USA. [Stokley, Shannon] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. RP Clark, SJ (reprint author), Univ Michigan, Child Hlth Evaluat & Res Unit, 300 North Ingalls,6E06, Ann Arbor, MI 48109 USA. EM saclark@umich.edu FU Centers for Disease Control and Prevention [U01 IP000316] FX The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the Centers for Disease Control and Prevention (U01 IP000316). NR 9 TC 2 Z9 2 U1 0 U2 0 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0009-9228 EI 1938-2707 J9 CLIN PEDIATR JI Clin. Pediatr. PD OCT PY 2015 VL 54 IS 11 BP 1107 EP 1109 DI 10.1177/0009922814557787 PG 3 WC Pediatrics SC Pediatrics GA CR1XW UT WOS:000361119600013 PM 25385931 ER PT J AU Alterman, T Gabbard, S Grzywacz, JG Shen, R Li, J Nakamoto, J Carroll, DJ Muntaner, C AF Alterman, Toni Gabbard, Susan Grzywacz, Joseph G. Shen, Rui Li, Jia Nakamoto, Jorge Carroll, Daniel J. Muntaner, Carles TI Evaluating Job Demands and Control Measures for Use in Farm Worker Health Surveillance SO JOURNAL OF IMMIGRANT AND MINORITY HEALTH LA English DT Article DE Farm workers; Immigrant; Decision latitude; Job demands; Job control; Job stress ID CONTROL SUPPORT MODEL; MENTAL-HEALTH; LATINO FARMWORKERS; CARDIOVASCULAR-DISEASE; STRAIN; STRESS AB Workplace stress likely plays a role in health disparities; however, applying standard measures to studies of immigrants requires thoughtful consideration. The goal of this study was to determine the appropriateness of two measures of occupational stressors ('decision latitude' and 'job demands') for use with mostly immigrant Latino farm workers. Cross-sectional data from a pilot module containing a four-item measure of decision latitude and a two-item measure of job demands were obtained from a subsample (N = 409) of farm workers participating in the National Agricultural Workers Survey. Responses to items for both constructs were clustered toward the low end of the structured response-set. Percentages of responses of 'very often' and 'always' for each of the items were examined by educational attainment, birth country, dominant language spoken, task, and crop. Cronbach's alpha, when stratified by subgroups of workers, for the decision latitude items were (0.65-0.90), but were less robust for the job demands items (0.25-0.72). The four-item decision latitude scale can be applied to occupational stress research with immigrant farm workers, and potentially other immigrant Latino worker groups. The short job demands scale requires further investigation and evaluation before suggesting widespread use. C1 [Alterman, Toni; Li, Jia] NIOSH, Div Surveillance Hazard Evaluat & Field Studies, Ctr Dis Control & Prevent, Cincinnati, OH 45226 USA. [Gabbard, Susan; Nakamoto, Jorge] JBS Int, Aguirre Div, Burlingame, CA USA. [Grzywacz, Joseph G.] Oklahoma State Univ, Dept Human Dev & Family Sci, Tulsa, OK USA. [Grzywacz, Joseph G.] Oklahoma State Univ, Ctr Family Resilience, Tulsa, OK USA. [Shen, Rui] Emergint Technol, Cincinnati, OH USA. [Carroll, Daniel J.] US Dept Labor, Employment & Training Adm, Washington, DC 20210 USA. [Muntaner, Carles] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada. [Muntaner, Carles] Univ Toronto, Bloomberg Coll Nursing, Toronto, ON, Canada. RP Alterman, T (reprint author), NIOSH, Div Surveillance Hazard Evaluat & Field Studies, Ctr Dis Control & Prevent, 4676 Columbia Pkwy NIOSH R-17, Cincinnati, OH 45226 USA. EM talterman@cdc.gov OI Alterman, Toni/0000-0003-1512-4367 FU National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention; U.S., Department of Labor, Employment and Training Administration FX We would like to thank the farm workers and interviewers for their participation. We would also like to thank Dr. Thomas A. Arcury, Dr. Sara A. Quandt, and Dr. Annie Georges for their careful review of this paper. Funding was provided by the National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention, and by the U.S., Department of Labor, Employment and Training Administration. NR 23 TC 0 Z9 0 U1 1 U2 5 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1557-1912 EI 1557-1920 J9 J IMMIGR MINOR HEALT JI J. Immigr. Minor. Health PD OCT PY 2015 VL 17 IS 5 BP 1364 EP 1373 DI 10.1007/s10903-014-0090-z PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CQ9DL UT WOS:000360911300010 PM 25138138 ER PT J AU Howley, MM Rouse, CD Katz, DJ Colson, PW Hirsch-Moverman, Y Royce, RA AF Howley, Meredith M. Rouse, Chaturia D. Katz, Dolores J. Colson, Paul W. Hirsch-Moverman, Yael Royce, Rachel A. CA TB Epidemiologic Studies TI Knowledge and Attitudes About Tuberculosis Among US-Born Blacks and Whites with Tuberculosis SO JOURNAL OF IMMIGRANT AND MINORITY HEALTH LA English DT Article DE Health knowledge; Attitudes; Practice; Tuberculosis; US-born; Race ID PERCEIVED RISK; UNITED-STATES; PULMONARY TUBERCULOSIS; HOMELESS ADULTS; FOREIGN-BORN; TB PATIENTS; BELIEFS; DISPARITIES; INFECTION; PAKISTAN AB Non-Hispanic blacks represent 13 % of the U.S.-born population but account for 37 % of tuberculosis (TB) cases reported in U.S.-born persons. Few studies have explored whether this disparity is associated with differences in TB-related knowledge and attitudes. Interviews were conducted with U.S.-born, non-Hispanic blacks and whites diagnosed with TB from August 2009 to December 2010 in cities and states that accounted for 27 % of all TB cases diagnosed in these racial groups in the U.S. during that time period. Of 477 participants, 368 (77 %) were non-Hispanic black and 109 (23 %) were non-Hispanic white. Blacks had significantly less knowledge and more misconceptions about TB transmission and latent TB infection than whites. Most TB patients in both groups recalled being given TB information; having received such information was strongly correlated with TB knowledge. Providing information to U.S.-born TB patients significantly increased their knowledge and understanding of TB. More focused efforts are needed to provide TB information to U.S.-born black TB patients. C1 [Howley, Meredith M.] New York State Dept Hlth, Albany, NY 12203 USA. [Rouse, Chaturia D.] Case Western Reserve Univ, Sch Med, Cleveland, OH USA. [Katz, Dolores J.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Colson, Paul W.; Hirsch-Moverman, Yael] Columbia Univ, Charles P Felton Natl TB Ctr, Mailman Sch Publ Hlth, New York, NY USA. [Royce, Rachel A.] RTI Int, Res Triangle Pk, NC USA. RP Howley, MM (reprint author), New York State Dept Hlth, Albany, NY 12203 USA. EM meredith.howley@health.ny.gov FU Intramural CDC HHS [CC999999] NR 39 TC 0 Z9 0 U1 0 U2 8 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1557-1912 EI 1557-1920 J9 J IMMIGR MINOR HEALT JI J. Immigr. Minor. Health PD OCT PY 2015 VL 17 IS 5 BP 1487 EP 1495 DI 10.1007/s10903-014-0105-9 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CQ9DL UT WOS:000360911300025 PM 25432148 ER PT J AU Rasberry, CN Morris, E Lesesne, CA Kroupa, E Topete, P Carver, LH Robin, L AF Rasberry, Catherine N. Morris, Elana Lesesne, Catherine A. Kroupa, Elizabeth Topete, Pablo Carver, Lisa H. Robin, Leah TI Communicating With School Nurses About Sexual Orientation and Sexual Health: Perspectives of Teen Young Men Who Have Sex With Men SO JOURNAL OF SCHOOL NURSING LA English DT Article DE adolescent; men who have sex with men; lesbian; gay; bisexual; and transgender (LGBT); communication; school health; HIV; STD; condoms; school nurses ID UNITED-STATES; HIV-INFECTION; RECOMMENDATIONS; PREVALENCE; STUDENTS; YOUTHS; WOMEN; GAY AB Black and Latino young men who have sex with men (YMSM) are at disproportionate risk for sexually transmitted diseases (STDs), including HIV. This study informs school-centered strategies for connecting YMSM to health services by describing their willingness, perceived safety, and experiences in talking to school staff about sexual health. Cross-sectional data were collected from Black and Latino YMSM aged 13-19 through web-based questionnaires (N = 415) and interviews (N = 32). School nurses were the staff members youth most often reported willingness to talk to about HIV testing (37.8%), STD testing (37.1%), or condoms (37.3%), but least often reported as safe to talk to about attraction to other guys (11.4%). Interviews revealed youth reluctance to talk with school staff including nurses when uncertain of staff members' perceptions of lesbian, gay, bisexual, transgender, and questioning (LGBTQ) people or perceiving staff to lack knowledge of LGBTQ issues, communities, or resources. Nurses may need additional training to effectively reach Black and Latino YMSM. C1 [Rasberry, Catherine N.; Morris, Elana; Robin, Leah] Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Div Adolescent & Sch Hlth, Atlanta, GA 30329 USA. [Lesesne, Catherine A.; Kroupa, Elizabeth; Topete, Pablo; Carver, Lisa H.] ICF Int, Atlanta, GA USA. RP Rasberry, CN (reprint author), Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Div Adolescent & Sch Hlth, 1600 Clifton Rd,MS E-75, Atlanta, GA 30329 USA. EM crasberry@cdc.gov RI Rasberry, Catherine/P-1984-2016 OI Rasberry, Catherine/0000-0001-8256-6961 FU Centers for Disease Control and Prevention, Division of Adolescent and School Health [200-2009-30503] FX The author(s) disclosed the following financial support for the research, authorship, and/or publication of this article: This formative evaluation was supported by contract number 200-2009-30503 from the Centers for Disease Control and Prevention, Division of Adolescent and School Health as technical assistance to Advocates for Youth. NR 28 TC 3 Z9 3 U1 1 U2 17 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1059-8405 EI 1546-8364 J9 J SCH NURS JI J. Sch. Nurs. PD OCT PY 2015 VL 31 IS 5 BP 334 EP 344 DI 10.1177/1059840514557160 PG 11 WC Nursing SC Nursing GA CR2EW UT WOS:000361139600004 PM 25519713 ER PT J AU Ehrenreich, H Nahapetyan, L Orpinas, P Song, X AF Ehrenreich, Heidi Nahapetyan, Lusine Orpinas, Pamela Song, Xiao TI Marijuana Use from Middle to High School: Co-occurring Problem Behaviors, Teacher-Rated Academic Skills and Sixth-Grade Predictors SO JOURNAL OF YOUTH AND ADOLESCENCE LA English DT Article DE Adolescent marijuana use; Problem behaviors; Teacher ratings; Group-based modeling; Academic performance; Marijuana trajectories; Early adolescence ID ADOLESCENT PROBLEM BEHAVIOR; CANNABIS USE; DRUG-USE; DEVELOPMENTAL TRAJECTORIES; UNITED-STATES; AFRICAN-AMERICAN; YOUNG ADULTHOOD; SUBSTANCE USE; EARLY-ONSET; ALCOHOL AB Rising marijuana use and its lowered perceived risk among adolescents highlight the importance of examining patterns of marijuana use over time. This study identified trajectories of marijuana use among adolescents followed from middle through high school, characterized these by co-occurring problem behaviors and teacher-rated academic skills (study skills, attention problems, and learning problems), and tested sixth-grade predictors of trajectory membership. The sample consisted of a randomly-selected cohort of 619 students assessed annually from sixth to twelfth grade. Using group-based modeling, we identified four trajectories of marijuana use: Abstainer (65.6 %), Sporadic (13.9 %), Experimental (11.5 %), and Increasing (9.0 %). Compared to Abstainers, students in the Sporadic, Experimental and Increasing trajectories reported significantly more co-occurring problem behaviors of alcohol use, cigarette smoking, and physical aggression. Sporadic and Experimental users reported significantly less smoking and physical aggression, but not alcohol use, than Increasing users. Teachers consistently rated Abstainers as having better study skills and less attention and learning problems than the three marijuana use groups. Compared to Abstainers, the odds of dropping out of high school was at least 2.7 times higher for students in the marijuana use trajectories. Dropout rates did not vary significantly between marijuana use groups. In sixth grade, being male, cigarette smoking, physical aggression and attention problems increased the odds of being in the marijuana use trajectories. Multiple indicators-student self-reports, teacher ratings and high school dropout records-showed that marijuana was not an isolated or benign event in the life of adolescents but part of an overall problem behavior syndrome. C1 [Ehrenreich, Heidi] CDC, Div Violence Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30341 USA. [Nahapetyan, Lusine] SE Louisiana Univ, Kinesiol & Hlth Studies, Hammond, LA 70402 USA. [Orpinas, Pamela] Univ Georgia, Dept Hlth Promot & Behav, Coll Publ Hlth, Athens, GA 30605 USA. [Song, Xiao] Univ Georgia, Dept Epidemiol & Biostat, Coll Publ Hlth, Athens, GA 30602 USA. RP Ehrenreich, H (reprint author), CDC, Div Violence Prevent, Natl Ctr Injury Prevent & Control, 4770 Buford Highway,NE, Atlanta, GA 30341 USA. EM vza7@cdc.gov; Lusine.Nahapetyan@selu.edu; porpinas@uga.edu; xsong@uga.edu NR 49 TC 7 Z9 7 U1 4 U2 19 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0047-2891 EI 1573-6601 J9 J YOUTH ADOLESCENCE JI J. Youth Adolesc. PD OCT PY 2015 VL 44 IS 10 SI SI BP 1929 EP 1940 DI 10.1007/s10964-014-0216-6 PG 12 WC Psychology, Developmental SC Psychology GA CQ9DO UT WOS:000360911700007 PM 25376473 ER PT J AU Fowler, KA Dahlberg, LL Haileyesus, T Annest, JL AF Fowler, Katherine A. Dahlberg, Linda L. Haileyesus, Tadesse Annest, Joseph L. TI Firearm injuries in the United States SO PREVENTIVE MEDICINE LA English DT Article DE Violence; Firearms; Epidemiology ID GUNSHOT INJURY; SUICIDE RATES; PREVENTION; OUTCOMES; CHILDREN; VIOLENCE; TRENDS AB Objective. This paper examines the epidemiology of fatal and nonfatal firearm violence in the United States. Trends over two decades in homicide, assault, self-directed and unintentional firearm injuries are described along with current demographic characteristics of victimization and health impact. Method. Fatal firearm injury data were obtained from the National Vital Statistics System (NVSS). Nonfatal firearm injury data were obtained from the National Electronic Injury Surveillance System (NEISS). Trends were tested using Joinpoint regression analyses. CDC Cost of Injury modules were used to estimate costs associated with firearm deaths and injuries. Results. More than 32,000 persons die and over 67,000 persons are injured by firearms each year. Case fatality rates are highest for self-harm related firearm injuries, followed by assault-related injuries. Males, racial/ethnic minority populations, and young Americans (with the exception of firearm suicide) are disproportionately affected. The severity of such injuries is distributed relatively evenly across outcomes from outpatient treatment to hospitalization to death. Firearm injuries result in over $48 billion in medical and work loss costs annually, particularly fatal firearm injuries. From 1993 to 1999, rates of firearm violence declined significantly. Declines were seen in both fatal and nonfatal firearm violence and across all types of intent. While unintentional firearm deaths continued to decline from 2000 to 2012, firearm suicides increased and nonfatal firearm assaults increased to their highest level since 1995. Conclusion. Firearm injuries are an important public health problem in the United States, contributing substantially each year to premature death, illness, and disability. Understanding the nature and impact of the problem is only a first step toward preventing firearm violence. A science-driven approach to understand risk and protective factors and identify effective solutions is key to achieving measurable reductions in firearm violence. Published by Elsevier Inc. C1 [Fowler, Katherine A.; Dahlberg, Linda L.] Ctr Dis Control & Prevent, Div Violence Prevent, Natl Ctr Injury Prevent, Atlanta, GA 30341 USA. [Haileyesus, Tadesse; Annest, Joseph L.] Ctr Dis Control & Prevent, Div Anal Res & Practice Integrat, Natl Ctr Injury Prevent, Atlanta, GA 30341 USA. RP Fowler, KA (reprint author), Ctr Dis Control & Prevent, Div Violence Prevent, 4770 Buford Hwy NE,MS F-64, Atlanta, GA 30341 USA. EM kafowler@cdc.gov FU Intramural CDC HHS [CC999999] NR 47 TC 16 Z9 18 U1 2 U2 17 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0091-7435 EI 1096-0260 J9 PREV MED JI Prev. Med. PD OCT PY 2015 VL 79 SI SI BP 5 EP 14 DI 10.1016/j.ypmed.2015.06.002 PG 10 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA CR1IK UT WOS:000361078200003 PM 26116133 ER PT J AU Bittl, JA Tamis-Holland, JE Lang, CD He, YL AF Bittl, John A. Tamis-Holland, Jacqueline E. Lang, Christopher D. He, Yulei TI Outcomes after multivessel or culprit-Vessel intervention for ST-elevation myocardial infarction in patients with multivessel coronary disease: A Bayesian cross-design meta-analysis SO CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS LA English DT Article DE myocardial infarction; randomized trials; percutaneous coronary intervention ID ASSOCIATION TASK-FORCE; PRACTICE GUIDELINES; RANDOMIZED-TRIAL; REVASCULARIZATION; REGISTRY; IMPACT; ANGIOPLASTY; REPERFUSION; IMMEDIATE; INSIGHTS AB IntroductionDuring primary percutaneous coronary intervention (PCI), patients with ST-elevation myocardial infarction (STEMI) and multivessel coronary disease can undergo either multivessel intervention (MVI) or culprit-vessel intervention (CVI) only. BackgroundRandomized controlled trials (RCTs) support the use of MVI, but cohort studies support the use of CVI. MethodsWe developed Bayesian models that incorporated parameters for study type and study outcome after MVI or CVI. ResultsA total of 18 studies (4 RCTs, 3 matched cohort studies, and 11 unmatched observational studies) enrolled 48,398 patients with STEMI and multivessel CAD and reported outcomes after MVI or CVI-only at the time of primary PCI. Using a Bayesian hierarchical model, we found that the point estimates replicated previously reported trends, but the wide Bayesian credible intervals (BCI) excluded any plausible mortality difference between MVI versus CVI in all three study types: RCTs (odds ratio [OR] 0.60, 95% BCI 0.31-1.20), matched cohort studies (OR 1.37, 95% BCI 0.86-2.24), or unmatched cohort studies (OR 1.16, 95% BCI 0.70-1.89). Both the global summary (OR 1.10, 95% BCI 0.74-1.51) and a sensitivity analysis that weighted the RCTs 1-5 times as much as observational studies revealed no credible advantage of one PCI strategy over the other (OR 1.05, 95% BCI 0.64-1.48). ConclusionsBayesian approaches contextualize the comparison of different strategies by study type and suggest that neither MVI nor CVI emerges as a preferred strategy in an analysis that accounts mortality differences. (c) 2015 Wiley Periodicals, Inc. C1 [Bittl, John A.] Munroe Reg Med Ctr, Ocala, FL USA. [Tamis-Holland, Jacqueline E.] Mt Sinai St Lukes Hosp, New York, NY USA. [Tamis-Holland, Jacqueline E.] Icahn Sch Med Mt Sinai, New York, NY 10029 USA. [Lang, Christopher D.] Brown Univ, Alpert Sch Med, Providence, RI 02912 USA. [He, Yulei] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Off Res & Methodol, Hyattsville, MD 20782 USA. RP Bittl, JA (reprint author), 1221 SE 5th St, Ocala, FL 34471 USA. EM jabittl@mac.com NR 39 TC 4 Z9 4 U1 2 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1522-1946 EI 1522-726X J9 CATHETER CARDIO INTE JI Catheter. Cardiovasc. Interv. PD OCT 1 PY 2015 VL 86 SU 1 BP S15 EP S22 DI 10.1002/ccd.26025 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA CQ7RX UT WOS:000360802700003 PM 26011638 ER PT J AU Machado-Ferreira, E Balsemao-Pires, E Dietrich, G Hojgaard, A Vizzoni, VF Scoles, G Bell-Sakyi, L Piesman, J Zeidner, NS Soares, CAG AF Machado-Ferreira, Erik Balsemao-Pires, Emilia Dietrich, Gabrielle Hojgaard, Andrias Vizzoni, Vinicius F. Scoles, Glen Bell-Sakyi, Lesley Piesman, Joseph Zeidner, Nordin S. Soares, Carlos A. G. TI Transgene expression in tick cells using Agrobacterium tumefaciens SO EXPERIMENTAL AND APPLIED ACAROLOGY LA English DT Article DE Transgene expression; Tick cells; Agrobacterium tumefaciens; Rhipicephalus microplus; Ixodes scapularis ID IXODES-SCAPULARIS TICKS; T-DNA; BORRELIA-BURGDORFERI; GENETIC-TRANSFORMATION; ANAPLASMA-MARGINALE; BOOPHILUS-MICROPLUS; HOST IMMUNITY; MODEL SYSTEM; PLANT-CELLS; INFECTION AB Ticks transmit infectious agents to humans and other animals. Genetic manipulation of vectors like ticks could enhance the development of alternative disease control strategies. Transgene expression using the phytopathogen Agrobacterium tumefaciens has been shown to promote the genetic modification of non-plant cells. In the present work we developed T-DNA constructs for A. tumefaciens to mediate transgene expression in HeLa cells as well as Rhipicephalus microplus tick cells. Translational fusions eGfp:eGfp or Salp15:eGfp, including the enhanced-green fluorescent protein and the Ixodes scapularis salivary factor SALP15 genes, were constructed using the CaMV 35S (cauliflower mosaic virus) promoter, "PBm" tick promoter (R. microplus pyrethroid metabolizing esterase gene) or the Simian Virus SV40 promoter. Confocal microscopy, RT-PCR and Western-blot assays demonstrated transgene(s) expression in both cell lines. Transgene expression was also achieved in vivo, in both R. microplus and I. scapularis larvae utilizing a soaking method including the A. tumefaciens donor cells and confirmed by nested-RT-PCR showing eGfp or Salp15 poly-A-mRNA(s). This strategy opens up a new avenue to express exogenous genes in ticks and represents a potential breakthrough for the study of tick-host pathophysiology. C1 [Machado-Ferreira, Erik; Balsemao-Pires, Emilia; Vizzoni, Vinicius F.; Soares, Carlos A. G.] Univ Fed Rio de Janeiro, Ilha Fundao, CCS, Inst Biol,Dept Genet,Lab Genet Mol Eucariontes &, BR-21941617 Rio De Janeiro, RJ, Brazil. [Machado-Ferreira, Erik; Dietrich, Gabrielle; Hojgaard, Andrias; Piesman, Joseph; Zeidner, Nordin S.] Ctr Dis Control & Prevent, Div Vector Borne Infect Dis, Bacterial Zoonoses Branch, Ft Collins, CO USA. [Scoles, Glen] Washington State Univ, USDA ARS, Pullman, WA 99164 USA. [Bell-Sakyi, Lesley] Pirbright Inst, Surrey, England. RP Soares, CAG (reprint author), Univ Fed Rio de Janeiro, Ilha Fundao, CCS, Inst Biol,Dept Genet,Lab Genet Mol Eucariontes &, Bloco A,Sala A2-120, BR-21941617 Rio De Janeiro, RJ, Brazil. EM soares@biologia.ufrj.br RI Soares, Carlos/H-9464-2016; Institute, Pirbright/K-4476-2014 OI Soares, Carlos/0000-0001-9058-9266; FU CDC; Brazilian agency CAPES in the Departamento de Genetica-Instituto de Biologia (Universidade Federal do Rio de Janeiro); CAPES/Brazil; CNPq/Brazil FX Erik Machado-Ferreira's fellowship was supported by CDC and the Brazilian agency CAPES in the Departamento de Genetica-Instituto de Biologia (Universidade Federal do Rio de Janeiro). E. Balsemao-Pires was supported by a PhD fellowship from CAPES/Brazil and a SWE fellowship from CNPq/Brazil. The BME/CTVM2 cell line was provided by the Tick Cell Biobank. The anti-Salp15 antibody was supplied by Dr. Amy Ullmann-Moore of the CDC. NR 56 TC 2 Z9 2 U1 0 U2 12 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0168-8162 EI 1572-9702 J9 EXP APPL ACAROL JI Exp. Appl. Acarol. PD OCT PY 2015 VL 67 IS 2 BP 269 EP 287 DI 10.1007/s10493-015-9949-5 PG 19 WC Entomology SC Entomology GA CQ6HG UT WOS:000360704600007 PM 26188857 ER PT J AU Hayek, S Heitgerd, JL Williams, WO Krueger, AL Dietz, PM AF Hayek, Samah Heitgerd, Janet L. Williams, Weston O. Krueger, Amy L. Dietz, Patricia M. TI County-Level Correlates of CDC-Funded HIV Testing Events, United States, 2012 SO JOURNAL OF COMMUNITY HEALTH LA English DT Article DE HIV testing; Social determinants of health; County level; Race/ethnicity ID PREVALENCE; DIAGNOSIS; CARE AB HIV prevalence and socio-demographic data were analyzed to assess the alignment of CDC-funded HIV testing activity in 2012 with its high-impact prevention approach. CDC-funded HIV-testing was conducted in counties with high HIV prevalence and in places potentially more affected by HIV as measured by urbanicity, percent black, percent poverty, and percent uninsured. The percent Hispanic/Latino was associated with a lower probability of HIV testing activity. Higher percentages of black and Hispanic/Latino in the population was positively associated with new HIV diagnoses. Analyzing county-level data confirmed the appropriateness of CDC-funded HIV testing activities under a high-impact prevention approach but also suggested areas for possible improvement. C1 [Hayek, Samah; Heitgerd, Janet L.; Krueger, Amy L.; Dietz, Patricia M.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV AIDS, Viral Hepatitis STD & TB Prevent, Atlanta, GA 30333 USA. [Williams, Weston O.] MANILA Consulting Grp Inc, Mclean, VA 22101 USA. RP Heitgerd, JL (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV AIDS, Viral Hepatitis STD & TB Prevent, 1600 Clifton Rd,MS-E59, Atlanta, GA 30333 USA. EM jbh0@cdc.gov NR 21 TC 0 Z9 0 U1 1 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0094-5145 EI 1573-3610 J9 J COMMUN HEALTH JI J. Community Health PD OCT PY 2015 VL 40 IS 5 BP 1031 EP 1036 DI 10.1007/s10900-015-0028-y PG 6 WC Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA CQ5VC UT WOS:000360672800024 PM 25903300 ER PT J AU Andersen, L Myers, L O'Malley, K Mundorf, AR Harris, DM Johnson, CC AF Andersen, Lori Myers, Leann O'Malley, Keelia Mundorf, Adrienne R. Harris, Diane M. Johnson, Carolyn C. TI Adolescent Student Use of School-Based Salad Bars SO JOURNAL OF SCHOOL HEALTH LA English DT Article DE childhood obesity; fruit; vegetable access; school salad bars; adolescents; minority health ID BODY-MASS INDEX; VEGETABLE CONSUMPTION; UNITED-STATES; PHYSICAL-ACTIVITY; FRUIT; OBESITY; PREVALENCE; ADULTS; CHILDREN; OVERWEIGHT AB BACKGROUNDChildhood obesity continues to be a public health problem in the United States. Increasing consumption of fruits and vegetables (F/V) is one strategy for decreasing high consumption of energy-dense, high-fat foods, thereby improving weight status. Many Orleans Parish public schools were provided with salad bars (SBs) to augment school lunch with increased access to F/V. This study identified factors associated with student use of SBs. METHODSSurveys examining SB use, demographics, food preference, nutrition knowledge, and social support were administered to students in the 7th to 12th grades (N=702) in Orleans Parish (New Orleans, Louisiana). Generalized estimating equations, which incorporate clustering at the school level, helped to determine associations between independent variables and SB use. RESULTSSixty percent of participants were SB users. Non-African-American students were more likely to be SB users than African-American students (odds ratio [OR]=2.35, confidence interval [CI]: 1.35-4.07) and students who had high preference for healthy food were more likely to use the SB than those who had low preference (OR=2.41, CI: 1.44-4.01). Students who encouraged others to consume F/V were more likely to use the SB than those who did not (p=.015). CONCLUSIONSIndividual and interpersonal factors related to SB use can provide guidance in the development of school-based interventions to increase SB use and F/V consumption. C1 [Andersen, Lori] Utah State Univ, Hlth Educ & Promot, Emma Eccles Jones Coll Educ & Human Serv, Dept Hlth Phys Educ & Recreat, Logan, UT 84322 USA. [Myers, Leann] Tulane Univ, Sch Publ Hlth & Trop Med, Dept Biostat & Bioinformat, New Orleans, LA 70112 USA. [O'Malley, Keelia; Mundorf, Adrienne R.] Tulane Prevent Res Ctr, Sch Publ Hlth & Trop Med, Dept Global Community Hlth & Behav Sci, New Orleans, LA 70112 USA. [Harris, Diane M.] Ctr Dis Control & Prevent, Hlth Food Environm, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Nutr Phys Act & Obes, Atlanta, GA 30341 USA. [Johnson, Carolyn C.] Tulane Univ, Prevent Res Ctr, Sch Publ Hlth & Trop Med, Dept Global Community Hlth & Behav Sci, New Orleans, LA 70112 USA. RP Andersen, L (reprint author), Utah State Univ, Hlth Educ & Promot, Emma Eccles Jones Coll Educ & Human Serv, Dept Hlth Phys Educ & Recreat, 7000 Old Main Hill, Logan, UT 84322 USA. EM lori.andersen@usu.edu; myersl@tulane.edu; komalley@tulane.edu; arathert@tulane.edu; dmharris@cdc.gov; cjohnso5@tulane.edu OI O'Malley, Keelia/0000-0002-3309-6833 FU Centers for Disease Control and Prevention (CDC), Atlanta, GA, through the Tulane Prevention Research Center (PRC) [U48DP001948]; [12-063] FX This work was supported by the Centers for Disease Control and Prevention (CDC), Atlanta, GA, through the Tulane Prevention Research Center (PRC) Cooperative Agreement #U48DP001948 and including Special Interest Project #12-063. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. The authors thank the school partnerships for their support for the project and the many Tulane University School of Public Health and Tropical Medicine graduate research assistants who worked on the project. NR 33 TC 0 Z9 0 U1 3 U2 28 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0022-4391 EI 1746-1561 J9 J SCHOOL HEALTH JI J. Sch. Health PD OCT PY 2015 VL 85 IS 10 BP 722 EP 727 DI 10.1111/josh.12302 PG 6 WC Education & Educational Research; Education, Scientific Disciplines; Health Care Sciences & Services; Public, Environmental & Occupational Health SC Education & Educational Research; Health Care Sciences & Services; Public, Environmental & Occupational Health GA CQ7RS UT WOS:000360802100009 PM 26331755 ER PT J AU Pollara, J McGuire, E Fouda, GG Rountree, W Eudailey, J Overman, RG Seaton, KE Deal, A Edwards, RW Tegha, G Kamwendo, D Kumwenda, J Nelson, JAE Liao, HX Brinkley, C Denny, TN Ochsenbauer, C Ellington, S King, CC Jamieson, DJ van der Horst, C Kourtis, AP Tomaras, GD Ferrari, G Permar, SR AF Pollara, Justin McGuire, Erin Fouda, Genevieve G. Rountree, Wes Eudailey, Josh Overman, R. Glenn Seaton, Kelly E. Deal, Aaron Edwards, R. Whitney Tegha, Gerald Kamwendo, Deborah Kumwenda, Jacob Nelson, Julie A. E. Liao, Hua-Xin Brinkley, Christie Denny, Thomas N. Ochsenbauer, Christina Ellington, Sascha King, Caroline C. Jamieson, Denise J. van der Horst, Charles Kourtis, Athena P. Tomaras, Georgia D. Ferrari, Guido Permar, Sallie R. TI Association of HIV-1 Envelope-Specific Breast Milk IgA Responses with Reduced Risk of Postnatal Mother-to-Child Transmission of HIV-1 SO JOURNAL OF VIROLOGY LA English DT Article ID IMMUNODEFICIENCY-VIRUS TYPE-1; VACCINE EFFICACY TRIAL; ANTIBODY-RESPONSES; SECRETORY IGA; NEUTRALIZATION; TRANSMITTED/FOUNDER; PROTECTION; CONSENSUS; MORTALITY; EPITOPES AB Infants born to HIV-1-infected mothers in resource-limited areas where replacement feeding is unsafe and impractical are repeatedly exposed to HIV-1 throughout breastfeeding. Despite this, the majority of infants do not contract HIV-1 postnatally, even in the absence of maternal antiretroviral therapy. This suggests that immune factors in breast milk of HIV-1-infected mothers help to limit vertical transmission. We compared the HIV-1 envelope-specific breast milk and plasma antibody responses of clade C HIV-1-infected postnatally transmitting and nontransmitting mothers in the control arm of the Malawi-based Breastfeeding Antiretrovirals and Nutrition Study using multivariable logistic regression modeling. We found no association between milk or plasma neutralization activity, antibody-dependent cell-mediated cytotoxicity, or HIV-1 envelope-specific IgG responses and postnatal transmission risk. While the envelope-specific breast milk and plasma IgA responses also did not reach significance in predicting postnatal transmission risk in the primary model after correction for multiple comparisons, subsequent exploratory analysis using two distinct assay methodologies demonstrated that the magnitudes of breast milk total and secretory IgA responses against a consensus HIV-1 envelope gp140 (B.con env03) were associated with reduced postnatal transmission risk. These results suggest a protective role for mucosal HIV-1 envelope-specific IgA responses in the context of postnatal virus transmission. This finding supports further investigations into the mechanisms by which mucosal IgA reduces risk of HIV-1 transmission via breast milk and into immune interventions aimed at enhancing this response. IMPORTANCE Infants born to HIV-1-infected mothers are repeatedly exposed to the virus in breast milk. Remarkably, the transmission rate is low, suggesting that immune factors in the breast milk of HIV-1-infected mothers help to limit transmission. We compared the antibody responses in plasma and breast milk of HIV-1-transmitting and -nontransmitting mothers to identify responses that correlated with reduced risk of postnatal HIV-1 transmission. We found that neither plasma nor breast milk IgG antibody responses were associated with risk of HIV-1 transmission. In contrast, the magnitudes of the breast milk IgA and secretory IgA responses against HIV-1 envelope proteins were associated with reduced risk of postnatal HIV-1 transmission. The results of this study support further investigations of the mechanisms by which mucosal IgA may reduce the risk of HIV-1 transmission via breastfeeding and the development of strategies to enhance milk envelope-specific IgA responses to reduce mother-to-child HIV transmission and promote an HIV-free generation. C1 [Pollara, Justin; Edwards, R. Whitney; Ferrari, Guido] Duke Univ, Sch Med, Dept Surg, Durham, NC USA. [McGuire, Erin; Fouda, Genevieve G.; Rountree, Wes; Eudailey, Josh; Overman, R. Glenn; Seaton, Kelly E.; Deal, Aaron; Liao, Hua-Xin; Brinkley, Christie; Denny, Thomas N.; Tomaras, Georgia D.; Permar, Sallie R.] Duke Univ, Sch Med, Human Vaccine Inst, Durham, NC 27708 USA. [Tegha, Gerald; Kamwendo, Deborah; Kumwenda, Jacob] Univ North Carolina Project, Lilongwe, Malawi. [Nelson, Julie A. E.] Univ N Carolina, Sch Med, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA. [Ochsenbauer, Christina] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA. [Ellington, Sascha; King, Caroline C.; Jamieson, Denise J.; Kourtis, Athena P.] Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. [van der Horst, Charles] Univ N Carolina, Sch Med, Div Infect Dis, Chapel Hill, NC USA. RP Permar, SR (reprint author), Duke Univ, Sch Med, Human Vaccine Inst, Durham, NC 27708 USA. EM sallie.permar@dm.duke.edu RI Tomaras, Georgia/J-5041-2016 FU Doris Duke Charitable Foundation; National Institute of Allergy and Infectious Diseases [AI06380]; Duke Center for HIV/AIDS Vaccine Immunology-Immunogen Discovery [AI100645]; Bill and Melinda Gates Foundation's Collaboration for Vaccine Discovery; Duke University Center for AIDS Research (CFAR), a National Institutes of Health (NIH) [5P30 AI064518]; University of North Carolina CFAR [5P30 AI050410, P30-AI50410]; Prevention Research Centers Special Interest Project of the Centers for Disease Control and Prevention [SIP 13-01 U48-CCU409660-09, SIP 26-04 U48-DP000059-01, SIP 22-09 U48-DP001944-01]; National Institute of Allergy and Infectious Diseases; NIH Fogarty AIDS International Training and Research Program [DHHS/NIH/FIC 2-D43 Tw01039-06]; Fogarty International Clinical Research Scholars Program [R24 Tw00798]; American Recovery and Reinvestment Act; Bill and Melinda Gates Foundation [OPP5310]; Elizabeth Glaser Pediatric AIDS Foundation; United Nations Children's Fund; World Food Program; Malawi Ministry of Health and Population; Johnson Johnson; U.S. Agency for International Development FX This work was supported by the Doris Duke Charitable Foundation; the National Institute of Allergy and Infectious Diseases (AI06380); the Duke Center for HIV/AIDS Vaccine Immunology-Immunogen Discovery (AI100645); the Bill and Melinda Gates Foundation's Collaboration for Vaccine Discovery; the Duke University Center for AIDS Research (CFAR), a National Institutes of Health (NIH)-funded program (5P30 AI064518); and the University of North Carolina CFAR (5P30 AI050410).; The Breastfeeding Antiretrovirals and Nutrition (BAN) Study was supported by grants from the Prevention Research Centers Special Interest Project of the Centers for Disease Control and Prevention (SIP 13-01 U48-CCU409660-09, SIP 26-04 U48-DP000059-01, and SIP 22-09 U48-DP001944-01), the National Institute of Allergy and Infectious Diseases, the University of North Carolina CFAR (P30-AI50410), the NIH Fogarty AIDS International Training and Research Program (DHHS/NIH/FIC 2-D43 Tw01039-06), the Fogarty International Clinical Research Scholars Program (R24 Tw00798), the American Recovery and Reinvestment Act, and the Bill and Melinda Gates Foundation (OPP5310). The antiretrovirals used in the BAN study were donated by Abbott Laboratories, GlaxoSmithKline, Boehringer Ingelheim, Roche Pharmaceuticals, and Bristol-Myers Squibb. The Call to Action PMTCT program was supported by the Elizabeth Glaser Pediatric AIDS Foundation, the United Nations Children's Fund, the World Food Program, the Malawi Ministry of Health and Population, Johnson & Johnson, and the U.S. Agency for International Development. NR 44 TC 4 Z9 4 U1 0 U2 9 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0022-538X EI 1098-5514 J9 J VIROL JI J. Virol. PD OCT PY 2015 VL 89 IS 19 BP 9952 EP 9961 DI 10.1128/JVI.01560-15 PG 10 WC Virology SC Virology GA CQ6HJ UT WOS:000360704900025 PM 26202232 ER PT J AU Johnson, MG Adams, J McDonald-Hamm, C Wendelboe, A Bradley, KK AF Johnson, Matthew G. Adams, Jaymes McDonald-Hamm, Christie Wendelboe, Aaron Bradley, Kristy K. TI Seasonality and survival associated with three outbreak seasons of West Nile virus disease in Oklahoma-2003, 2007, and 2012 SO JOURNAL OF MEDICAL VIROLOGY LA English DT Article DE encephalitis; fever; West Nile virus ID TRANSMISSION DYNAMICS; NEW-YORK; TEMPERATURE; INFECTION; EPIDEMIOLOGY; PROGNOSIS; CULICIDAE; DIPTERA AB West Nile virus (WNV) activity has fluctuated in the south-central United States since its introduction. Seasonal outbreaks are common, with three in Oklahoma during 2003, 2007, and 2012. Morbidity and mortality rates vary during each outbreak. Long-term neurologic sequelae in association with West Nile virus disease (WNVD) are well-described, but limited information is available about delayed mortality among acute WNV infection survivors. A retrospective cohort analysis of all confirmed and probable WNVD cases reported to the Oklahoma State Department of Health (OSDH) during 2003, 2007, and 2012 was performed. OSDH surveillance data and mortality data from Oklahoma's vital statistics database were used to construct a descriptive epidemiologic analysis of the geography, temporality, severity, and associated mortality for each outbreak season. A Kaplan-Meier survival curve and standardized mortality ratios (SMRs) were calculated to measure survival of the 2003 and 2007 WNVD cohorts. Seventy-nine cases during 2003, 107 cases during 2007, and 180 cases during 2012 met inclusion criteria. Median ages of the 2003, 2007, and 2012 cohorts were 48, 58, and 59 years, respectively; race, sex, and symptom information were not substantially different. Each outbreak season had a different severity, temporality, and geography. Age- and sex-adjusted SMRs for the combined 2003 and 2007 cohorts censored at 5 years was 0.9 (95% confidence interval 0.51-1.75); no substantial difference was observed between the survival curves. Although similar patterns of long-term mortality were evident on the survival curves, SMRs did not demonstrate increased 5-year cumulative risk for death for patients surviving acute WNV infection. J. Med. Virol. 87:1633-1640, 2015. (c) 2015 Wiley Periodicals, Inc. C1 [Johnson, Matthew G.] Ctr Dis Control & Prevent, Oklahoma State Dept Hlth, Epidem Intelligence Serv, Oklahoma City, OK 73117 USA. [Adams, Jaymes] Univ Oklahoma, Hlth Sci Ctr, Coll Publ Hlth, Oklahoma City, OK 73126 USA. [McDonald-Hamm, Christie] Oklahoma Dept Hlth, Acute Dis Serv, Oklahoma City, OK 73117 USA. [Wendelboe, Aaron] Univ Oklahoma, Hlth Sci Ctr, Coll Publ Hlth, Oklahoma City, OK 73126 USA. [Bradley, Kristy K.] Oklahoma Dept Hlth, Off State Epidemiologist, Oklahoma City, OK 73117 USA. RP Johnson, MG (reprint author), Duke Univ, Med Ctr, 315 Trent Dr, Durham, NC 27710 USA. EM mgjohnson33@gmail.com NR 22 TC 2 Z9 2 U1 1 U2 10 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0146-6615 EI 1096-9071 J9 J MED VIROL JI J. Med. Virol. PD OCT PY 2015 VL 87 IS 10 BP 1633 EP 1640 DI 10.1002/jmv.24235 PG 8 WC Virology SC Virology GA CO3VP UT WOS:000359089500002 PM 25946680 ER PT J AU Ludwig, A Lucero-Obusan, C Schirmer, P Winston, C Holodniy, M AF Ludwig, Alison Lucero-Obusan, Cynthia Schirmer, Patricia Winston, Carla Holodniy, Mark TI Acute cardiac injury events <= 30 days after laboratory-confirmed influenza virus infection among US veterans, 2010-2012 SO BMC CARDIOVASCULAR DISORDERS LA English DT Article DE Influenza; Human; Myocardial ischemia; Cardiovascular disease; Veterans health ID ACUTE MYOCARDIAL-INFARCTION; UNITED-STATES; CARDIOVASCULAR-DISEASE; HEART-DISEASE; TROPONIN-I; VACCINATION; MORTALITY; RISK; HOSPITALIZATIONS; ASSOCIATION AB Background: Cardiac injury is a known potential complication of influenza infection. Because U.S. veterans cared for at the U.S. Department of Veterans Affairs are older and have more cardiovascular disease (CVD) risk factors than the general U.S. population, veterans are at risk for cardiac complications of influenza infection. We investigated biomarkers of cardiac injury characteristics and associated cardiac events among veterans who received cardiac biomarker testing <= 30 days after laboratory-confirmed influenza virus infection. Methods: Laboratory-confirmed influenza cases among veterans cared for at U.S. Department of Veterans Affairs' facilities for October 2010-December 2012 were identified using electronic medical records (EMRs). Influenza confirmation was based on respiratory specimen viral culture or antigen or nucleic acid detection. Acute cardiac injury (ACI) was defined as an elevated cardiac biomarker (troponin I or creatinine kinase isoenzyme MB) >99 % of the upper reference limit occurring <= 30 days after influenza specimen collection. EMRs were reviewed for demographics, CVD history and risk factors, and ACI-associated cardiac events. Results: Among 38,197 patients with influenza testing results, 4,469 (12 %) had a positive result; 600 of those patients had cardiac biomarker testing performed <= 30 days after influenza testing, and 143 (24 %) had one or more elevated cardiac biomarkers. Among these 143, median age was 73 years (range 44-98 years), and 98 (69 %) were non-Hispanic white. All patients had one or more CVD risk factors, and 98 (69 %) had a history of CVD. Eighty-six percent of ACI-associated events occurred within 3 days of influenza specimen collection date. Seventy patients (49 %) had documented or probable acute myocardial infarction, 8 (6 %) acute congestive heart failure, 6 (4 %) myocarditis, and 4 (3 %) atrial fibrillation. Eleven (8 %) had non-cardiac explanations for elevated cardiac biomarkers, and 44 (31 %) had no documented explanation. Sixty-eight (48 %) patients had received influenza vaccination during the related influenza season. Conclusion: Among veterans with laboratory-confirmed influenza infection and cardiac biomarker testing <= 30 days after influenza testing, approximately 25 % had evidence of ACI, the majority within 3 days. Approximately half were myocardial infarctions. Our findings emphasize the importance of considering ACI associated with influenza infection among patients at high risk, including this older population with prevalent CVD risk factors. C1 [Ludwig, Alison] Ctr Dis Control & Prevent, Vet Affairs Off Publ Hlth Surveillance & Res, Palo Alto, CA 94304 USA. [Ludwig, Alison; Lucero-Obusan, Cynthia; Schirmer, Patricia; Winston, Carla; Holodniy, Mark] Vet Affairs Off Publ Hlth Surveillance & Res, Palo Alto, CA 94304 USA. [Holodniy, Mark] Stanford Univ, Div Infect Dis & Geog Med, Palo Alto, CA 94303 USA. RP Ludwig, A (reprint author), Ctr Dis Control & Prevent, Vet Affairs Off Publ Hlth Surveillance & Res, 3801 Miranda Ave 132, Palo Alto, CA 94304 USA. EM Alison.Ludwig@va.gov NR 44 TC 2 Z9 2 U1 0 U2 2 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2261 J9 BMC CARDIOVASC DISOR JI BMC Cardiovasc. Disord. PD SEP 30 PY 2015 VL 15 AR 109 DI 10.1186/s12872-015-0095-0 PG 9 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA CS4RF UT WOS:000362062900002 PM 26423142 ER PT J AU D'Elia, G Hanson, JD Mauldin, MR Teta, P Pardinas, UFJ AF D'Elia, Guillermo Hanson, J. Delton Mauldin, Matthew R. Teta, Pablo Pardinas, Ulyses F. J. TI Molecular systematics of South American marsh rats of the genus Holochilus (Muroidea, Cricetidae, Sigmodontinae) SO JOURNAL OF MAMMALOGY LA English DT Article DE Holochilomys; Oryzomyini; Rodentia; South America; taxonomy ID DNA-SEQUENCES; EVOLUTIONARY TREES; MAXIMUM-LIKELIHOOD; CYTOCHROME-B; RODENTS; ARGENTINA; PHYLOGENY; BRASILIENSIS; HANTAVIRUS; PROVINCE AB We present a comprehensive systematic study of Holochilus, a sigmodontine genus of large, herbivorous, and semiaquatic rodents widely distributed in South America. Remarkably, given its complex taxonomic history and large economic as well as epidemiological importance, the alpha taxonomy of Holochilus has not benefited from a molecular-based approach. The study is based on sequences of 1 mitochondrial and 3 nuclear loci that were analyzed by maximum likelihood and Bayesian inference. Analyses include sequences of specimens from localities from Argentina, Bolivia, Brazil, Colombia, Paraguay, Peru, Suriname, and Uruguay, representing all but 2 of the species currently recognized in the genus. Of the 4 data matrices, the mitochondrial data set contains the largest geographic coverage and recovered 6 species-level lineages that form 2 well-supported species groups: the brasiliensis species group formed by H. brasiliensis and H. vulpinus and the sciureus species group composed by H. chacarius, H. sciureus, and 2 currently unnamed forms. Surprisingly, in the cytochrome b gene analyses, the 2 species groups are not sister to each other; i.e., Holochilus is not monophyletic, although these topologies lack significant support. However, the monophyly of Holochilus was supported by the 3 nuclear loci as well as by the combined analysis of all 4 loci. These genealogical results are the basis of taxonomic and biogeographic considerations. (C) 2015 American Society of Mammalogists, www.mammalogy.org C1 [D'Elia, Guillermo] Univ Austral Chile, Fac Ciencias, Inst Ciencias Ambientales & Evolut, Valdivia, Chile. [Hanson, J. Delton] RTL Genom, Lubbock, TX 79407 USA. [Mauldin, Matthew R.] Texas Tech Univ, Dept Biol Sci, Lubbock, TX 79409 USA. [Mauldin, Matthew R.] Ctr Dis Control & Prevent, Poxvirus & Rabies Branch, Atlanta, GA 30333 USA. [Teta, Pablo] Museo Argentino Ciencias Nat Bernardino Rivadavia, Div Mastozool, Buenos Aires, DF, Argentina. [Pardinas, Ulyses F. J.] Ctr Nacl Patagon, Unidad Invest Diversidad Sistemat & Evoluc, RA-9120 Puerto Madryn, Chubut, Argentina. RP D'Elia, G (reprint author), Univ Austral Chile, Fac Ciencias, Inst Ciencias Ambientales & Evolut, Campus Isla Teja S-N, Valdivia, Chile. EM guille.delia@gmail.com RI D'Elia, Guillermo/G-2253-2011 OI D'Elia, Guillermo/0000-0001-7173-2709 FU FONDECYT [1141055]; Agencia (PICT) [2008-0547]; CONICET [PIP 6179] FX Assistance during field works carried out by the authors was provided by C. Galliari, J. Notarnicola, M. Lareschi, J. Sanchez, G. Navone, D. Voglino, D. Podesta, S. Cirignoli, P. Jayat, C. Manchini, and I. Mora. Logistics and resources provided by CEPAVE-CONICET, L. Aquino, and R. D. Owen to conduct field work in Argentina and Paraguay are greatly appreciated. N. de la Sancha, P. Perez, E. M. Gonzalez, and J. A. Martinez-Lanfranco provided some of the tissue samples. J. Patton kindly provided some sequences generated by him. P. Myers and C. Galliari shared with us their knowledge on the taxonomy of Holochilus. J. Oliveira, L. Machado, and Y. Leite assisted us with information on Brazilian specimens. B. K. Lim (Royal Ontario Museum), J. Dunn (MSB), G. Lessa (MZUFV), and N. Martins (MZUFV) sent photographs of specimens housed at their institutions. S. Jansa, M. Weksler, and an anonymous reviewer made comments that helped to improve the originally submitted version of this paper. Economic support was provided by FONDECYT 1141055 (to GD), Agencia (PICT 2008-0547 to UFJP), and CONICET (PIP 6179 to UFJP). NR 68 TC 1 Z9 1 U1 0 U2 13 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-2372 EI 1545-1542 J9 J MAMMAL JI J. Mammal. PD SEP 29 PY 2015 VL 96 IS 5 BP 1081 EP 1094 DI 10.1093/jmammal/gyv115 PG 14 WC Zoology SC Zoology GA CT0PD UT WOS:000362497700020 ER PT J AU Ley, B Luter, N Espino, FE Devine, A Kalnoky, M Lubell, Y Thriemer, K Baird, JK Poirot, E Conan, N Kheong, CC Dysoley, L Khan, WA Dion-Berboso, AG Bancone, G Hwang, J Kumar, R Price, RN von Seidlein, L Domingo, GJ AF Ley, Benedikt Luter, Nick Espino, Fe Esperanza Devine, Angela Kalnoky, Michael Lubell, Yoel Thriemer, Kamala Baird, J. Kevin Poirot, Eugenie Conan, Nolwenn Kheong, Chong Chee Dysoley, Lek Khan, Wasif Ali Dion-Berboso, April G. Bancone, Germana Hwang, Jimee Kumar, Ritu Price, Ric N. von Seidlein, Lorenz Domingo, Gonzalo J. TI The challenges of introducing routine G6PD testing into radical cure: a workshop report SO MALARIA JOURNAL LA English DT Article DE G6PD; Point of care test; Plasmodium vivax; Primaquine; Malaria ID PLASMODIUM-VIVAX MALARIA; GLUCOSE-6-PHOSPHATE-DEHYDROGENASE DEFICIENCY; PRIMAQUINE; ASSOCIATION; PERFORMANCE; MUTATIONS; KNOWLEDGE; BENEFITS; DISEASE; ASSAY AB The only currently available drug that effectively removes malaria hypnozoites from the human host is primaquine. The use of 8-aminoquinolines is hampered by haemolytic side effects in glucose-6-phosphate dehydrogenase (G6PD) deficient individuals. Recently a number of qualitative and a quantitative rapid diagnostic test (RDT) format have been developed that provide an alternative to the current standard G6PD activity assays. The WHO has recently recommended routine testing of G6PD status prior to primaquine radical cure whenever possible. A workshop was held in the Philippines in early 2015 to discuss key challenges and knowledge gaps that hinder the introduction of routine G6PD testing. Two point-of-care (PoC) test formats for the measurement of G6PD activity are currently available: qualitative tests comparable to malaria RDT as well as biosensors that provide a quantitative reading. Qualitative G6PD PoC tests provide a binomial test result, are easy to use and some products are comparable in price to the widely used fluorescent spot test. Qualitative test results can accurately classify hemizygous males, heterozygous females, but may misclassify females with intermediate G6PD activity. Biosensors provide a more complex quantitative readout and are better suited to identify heterozygous females. While associated with higher costs per sample tested biosensors have the potential for broader use in other scenarios where knowledge of G6PD activity is relevant as well. The introduction of routine G6PD testing is associated with additional costs on top of routine treatment that will vary by setting and will need to be assessed prior to test introduction. Reliable G6PD PoC tests have the potential to play an essential role in future malaria elimination programmes, however require an improved understanding on how to best integrate routine G6PD testing into different health settings. C1 [Ley, Benedikt; Thriemer, Kamala; Price, Ric N.] Charles Darwin Univ, Menzies Sch Hlth Res, Global & Trop Hlth Div, Darwin, NT 0811, Australia. [Luter, Nick; Kalnoky, Michael; Kumar, Ritu; Domingo, Gonzalo J.] PATH, Diagnost Program, Seattle, WA USA. [Espino, Fe Esperanza; Lubell, Yoel] Res Inst Trop Med, Manila, Philippines. [Devine, Angela; von Seidlein, Lorenz] Mahidol Univ, Mahidol Oxford Trop Med Res Unit, Bangkok 10700, Thailand. [Baird, J. Kevin] Eijkman Oxford Clin Res Unit, Jakarta, Indonesia. [Devine, Angela; Lubell, Yoel; Baird, J. Kevin; Price, Ric N.; von Seidlein, Lorenz] Univ Oxford, Ctr Trop Med & Global Hlth, Nuffield Dept Med, Oxford, England. [Poirot, Eugenie; Hwang, Jimee] Univ Calif San Francisco, Global Hlth Grp, Malaria Eliminat Initiat, San Francisco, CA 94143 USA. [Conan, Nolwenn] Malaria Consortium, Bangkok, Thailand. [Kheong, Chong Chee] Minist Hlth Malaysia, Dis Control Div, Kuala Lumpur, Malaysia. [Dysoley, Lek] Natl Ctr Parasitol Entomol & Malaria Control, Phnom Penh, Cambodia. [Dysoley, Lek] Natl Inst Publ Hlth, Sch Publ Hlth, Phnom Penh, Cambodia. [Khan, Wasif Ali] Bangladesh Icddr B, Int Ctr Diarrheal Dis Res, Dhaka, Bangladesh. [Dion-Berboso, April G.] Univ Philippines, Natl Inst Hlth, Newborn Screening Ctr, Inst Human Genet, Manila, Philippines. [Bancone, Germana] Shoklo Malaria Res Unit, Mae Sot, Tak Province, Thailand. [Hwang, Jimee] Ctr Dis Control & Prevent, Malaria Branch, Div Parasit Dis & Malaria, Atlanta, GA USA. RP Ley, B (reprint author), Charles Darwin Univ, Menzies Sch Hlth Res, Global & Trop Hlth Div, POB 41096, Darwin, NT 0811, Australia. EM benedikt.ley@menzies.edu.au OI Price, Richard/0000-0003-2000-2874; Thriemer, Kamala/0000-0001-7536-7497; Lubell, Yoel/0000-0002-0237-1070; Bancone, Germana/0000-0003-4550-0431 FU Asia Pacifica Malaria Elimination Network (APMEN); PATH FX We would like to thank all participants of the workshop and RITM for hosting this event and Ms. Kylie Mannion for logistic support. The workshop has been funded by the Asia Pacifica Malaria Elimination Network (APMEN) and PATH. NR 52 TC 6 Z9 6 U1 0 U2 7 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1475-2875 J9 MALARIA J JI Malar. J. PD SEP 29 PY 2015 VL 14 AR 377 DI 10.1186/s12936-015-0896-8 PG 12 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA CS2ZL UT WOS:000361940600001 PM 26416229 ER PT J AU Wu, H Hightow-Weidman, LB Gay, CL Zhang, XJ Beagle, S Hall, L Jackson, T Marmorino, J Do, AN Peters, PJ AF Wu, Hsiu Hightow-Weidman, Lisa B. Gay, Cynthia L. Zhang, Xinjian Beagle, Steve Hall, Laura Jackson, Tonyka Marmorino, Jenni Do, Ann N. Peters, Philip J. TI Unreported Male Sex Partners Among Men with Newly Diagnosed HIV Infection - North Carolina, 2011-2013 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID HEALTH-CARE PROVIDERS; BLACK-MEN; DISCLOSURE; WOMEN C1 [Wu, Hsiu; Zhang, Xinjian; Hall, Laura; Jackson, Tonyka; Do, Ann N.; Peters, Philip J.] CDC, Chapel Hill, NC 27517 USA. [Hightow-Weidman, Lisa B.; Gay, Cynthia L.; Beagle, Steve; Marmorino, Jenni] Univ N Carolina, Chapel Hill, NC USA. [Hall, Laura; Jackson, Tonyka] ICF Int, Atlanta, GA USA. RP Peters, PJ (reprint author), CDC, Chapel Hill, NC 27517 USA. EM pjpeters@cdc.gov NR 10 TC 0 Z9 0 U1 2 U2 2 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD SEP 25 PY 2015 VL 64 IS 37 BP 1037 EP 1041 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CS5DD UT WOS:000362095700001 PM 26401589 ER PT J AU Tan, CH Denny, CH Cheal, NE Sniezek, JE Kanny, D AF Tan, Cheryl H. Denny, Clark H. Cheal, Nancy E. Sniezek, Joseph E. Kanny, Dafna TI Alcohol Use and Binge Drinking Among Women of Childbearing Age - United States, 2011-2013 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID PREVALENCE C1 [Tan, Cheryl H.; Denny, Clark H.; Cheal, Nancy E.; Sniezek, Joseph E.] Natl Ctr Birth Defects & Dev Disabil, Div Birth Defects & Dev Disabil, Iowa City, IA 52242 USA. [Kanny, Dafna] CDC, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Populat Hlth, Atlanta, GA 30333 USA. RP Tan, CH (reprint author), Natl Ctr Birth Defects & Dev Disabil, Div Birth Defects & Dev Disabil, Iowa City, IA 52242 USA. EM ctan1@cdc.gov NR 10 TC 18 Z9 18 U1 1 U2 4 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD SEP 25 PY 2015 VL 64 IS 37 BP 1042 EP 1046 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CS5DD UT WOS:000362095700002 PM 26401713 ER PT J AU Omura, JD Carlson, SA Paul, P Watson, KB Loustalot, F Foltz, JL Fulton, JE AF Omura, John D. Carlson, Susan A. Paul, Prabasaj Watson, Kathleen B. Loustalot, Fleetwood Foltz, Jennifer L. Fulton, Janet E. TI Adults Eligible for Cardiovascular Disease Prevention Counseling and Participation in Aerobic Physical Activity - United States, 2013 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Omura, John D.] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Omura, John D.; Carlson, Susan A.; Paul, Prabasaj; Watson, Kathleen B.; Fulton, Janet E.] CDC, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Nutr Phys Act & Obes, Atlanta, GA 30333 USA. [Loustalot, Fleetwood; Foltz, Jennifer L.] CDC, Div Heart Dis & Stroke Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. RP Omura, JD (reprint author), CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. EM ydk8@cdc.gov NR 10 TC 3 Z9 3 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD SEP 25 PY 2015 VL 64 IS 37 BP 1047 EP 1051 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CS5DD UT WOS:000362095700003 PM 26401758 ER PT J AU Grant, GB Reef, SE Dabbagh, A Gacic-Dobo, M Strebel, PM AF Grant, Gavin B. Reef, Susan E. Dabbagh, Alya Gacic-Dobo, Marta Strebel, Peter M. TI Global Progress Toward Rubella and Congenital Rubella Syndrome Control and Elimination-2000-2014 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Grant, Gavin B.; Reef, Susan E.] CDC, Ctr Global Hlth, Global Immunizat Div, Atlanta, GA 30333 USA. [Gacic-Dobo, Marta; Strebel, Peter M.] WHO, Dept Immunizat Vaccines & Biol, Geneva, Switzerland. RP Grant, GB (reprint author), CDC, Ctr Global Hlth, Global Immunizat Div, Atlanta, GA 30333 USA. EM gbgrant@cdc.gov NR 2 TC 7 Z9 7 U1 1 U2 8 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD SEP 25 PY 2015 VL 64 IS 37 BP 1052 EP 1055 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CS5DD UT WOS:000362095700004 PM 26401958 ER PT J AU Walters, MS Eggers, P Albrecht, V Travis, T Lonsway, D Hovan, G Taylor, D Rasheed, K Limbago, B Kallen, A AF Walters, Maroya Spalding Eggers, Paula Albrecht, Valerie Travis, Tatiana Lonsway, David Hovan, Greg Taylor, Debra Rasheed, Kamile Limbago, Brandi Kallen, Alexander TI Vancomycin-Resistant Staphylococcus aureus - Delaware, 2015 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Walters, Maroya Spalding; Albrecht, Valerie; Travis, Tatiana; Lonsway, David; Taylor, Debra; Rasheed, Kamile; Limbago, Brandi; Kallen, Alexander] CDC, Natl Ctr Emerging & Zoonot Infect Dis, Div Healthcare Qual Promot, Atlanta, GA 30333 USA. [Eggers, Paula] CDC, Delaware Div Publ Health, Atlanta, GA 30333 USA. [Hovan, Greg] CDC, Delaware Publ Hlth Lab, Atlanta, GA 30333 USA. RP Walters, MS (reprint author), CDC, Natl Ctr Emerging & Zoonot Infect Dis, Div Healthcare Qual Promot, Atlanta, GA 30333 USA. EM vii0@cdc.gov NR 2 TC 6 Z9 6 U1 0 U2 5 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD SEP 25 PY 2015 VL 64 IS 37 BP 1056 EP 1056 PG 1 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CS5DD UT WOS:000362095700006 PM 26402026 ER PT J AU Shcherbik, S Pearce, N Balish, A Jones, J Thor, S Davis, CT Pearce, M Tumpey, T Cureton, D Chen, LM Villanueva, J Bousse, TL AF Shcherbik, Svetlana Pearce, Nicholas Balish, Amanda Jones, Joyce Thor, Sharmi Davis, Charles Todd Pearce, Melissa Tumpey, Terrence Cureton, David Chen, Li-Mei Villanueva, Julie Bousse, Tatiana L. TI Generation and Characterization of Live Attenuated Influenza A(H7N9) Candidate Vaccine Virus Based on Russian Donor of Attenuation SO PLOS ONE LA English DT Article ID A H7N9 VIRUS; PROTECTION; COUNTRIES; TECHNOLOGY; INFECTIONS; STABILITY; FERRETS; YIELD; EGGS; MICE AB Background Avian influenza A (H7N9) virus has emerged recently and continues to cause severe disease with a high mortality rate in humans prompting the development of candidate vaccine viruses. Live attenuated influenza vaccines (LAIV) are 6: 2 reassortant viruses containing the HA and NA gene segments from wild type influenza viruses to induce protective immune responses and the six internal genes from Master Donor Viruses (MDV) to provide temperature sensitive, cold-adapted and attenuated phenotypes. Methodology/Principal Findings LAIV candidate A/Anhui/1/2013(H7N9)-CDC-LV7A (abbreviated as CDC-LV7A), based on the Russian MDV, A/Leningrad/134/17/57 (H2N2), was generated by classical reassortment in eggs and retained MDV temperature-sensitive and cold-adapted phenotypes. CDC-LV7A had two amino acid substitutions N123D and N149D (H7 numbering) in HA and one substitution T10I in NA. To evaluate the role of these mutations on the replication capacity of the reassortants in eggs, the recombinant viruses A(H7N9) RG-LV1 and A (H7N9) RG-LV2 were generated by reverse genetics. These changes did not alter virus antigenicity as ferret antiserum to CDC-LV7A vaccine candidate inhibited hemagglutination by homologous A(H7N9) virus efficiently. Safety studies in ferrets confirmed that CDC-LV7A was attenuated compared to wild-type A/Anhui/1/2013. In addition, the genetic stability of this vaccine candidate was examined in eggs and ferrets by monitoring sequence changes acquired during virus replication in the two host models. No changes in the viral genome were detected after five passages in eggs. However, after ten passages additional mutations were detected in the HA gene. The vaccine candidate was shown to be stable in the ferret model; post-vaccination sequence data analysis showed no changes in viruses collected in nasal washes present at day 5 or day 7. Conclusions/Significance Our data indicate that the A/Anhui/1/2013(H7N9)-CDC-LV7A reassortant virus is a safe and genetically stable candidate vaccine virus that is now available for distribution by WHO to vaccine manufacturers. C1 [Shcherbik, Svetlana; Pearce, Nicholas; Balish, Amanda; Jones, Joyce; Thor, Sharmi; Davis, Charles Todd; Pearce, Melissa; Tumpey, Terrence; Cureton, David; Chen, Li-Mei; Villanueva, Julie; Bousse, Tatiana L.] Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30329 USA. [Shcherbik, Svetlana; Pearce, Nicholas] Battelle Mem Inst, Atlanta, GA USA. [Cureton, David] Atlanta Res & Educ Fdn, Atlanta, GA USA. RP Bousse, TL (reprint author), Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30329 USA. EM tbousse@cdc.gov FU WHO; BARDA FX We thank the Chinese Center for Disease Control and Prevention, Beijing, China; Centre for Health Protection, Hong Kong, SAR; Centers for Disease Control, Taiwan; and the National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Canada for providing wild type A(H7N9) viruses used in this study. We thank IEM, St Petersburg, Russia and Bio-Diem (Australia) for providing MDV and serum to MDV. We thank WHO and BARDA for special contribution funds to support LAIV seed strains generation and quality control at CDC. We thank Nancy Cox for support of LAIV development at CDC and David Wentworth for constructive suggestions for the paper. The findings and conclusions in this report are those of the authors and do not necessarily reflect the views of the funding agency. NR 46 TC 2 Z9 3 U1 1 U2 5 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD SEP 25 PY 2015 VL 10 IS 9 AR e0138951 DI 10.1371/journal.pone.0138951 PG 16 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CS1CR UT WOS:000361800700127 PM 26405798 ER PT J AU King, CC Kourtis, AP Persaud, D Nelson, JAE Ziemniak, C Hudgens, MG Tegha, G Chasela, CS Jamieson, DJ van der Horst, CM AF King, Caroline C. Kourtis, Athena P. Persaud, Deborah Nelson, Julie A. E. Ziemniak, Carrie Hudgens, Michael G. Tegha, Gerald Chasela, Charles S. Jamieson, Denise J. van der Horst, Charles M. TI Delayed HIV detection among infants exposed to postnatal antiretroviral prophylaxis during breastfeeding SO AIDS LA English DT Article DE antiretroviral; breastfeeding; detection; HIV; infant ID POLYMERASE-CHAIN-REACTION; IMMUNE-RESPONSES; VIRAL RESERVOIRS; PLASMA VIREMIA; THERAPY; TYPE-1; DNA; TRANSMISSION; DIAGNOSIS; PREVENT AB Objective:The objective of this study is to determine whether detection of HIV infection was delayed in infants exposed to antiretroviral prophylaxis to prevent HIV transmission during breastfeeding.Design:The Breastfeeding, Antiretrovirals and Nutrition (BAN) study was a randomized trial of 2369 mother-infant pairs conducted from 2004 to 2010. In addition to an intrapartum regimen, all mother-infant pairs were randomly assigned to three antiretroviral intervention arms during 28 weeks of breastfeeding: no further antiretroviral prophylaxis (control arm); infant-daily nevirapine (nevirapine arm); and maternal zidovudine, lamivudine and either nevirapine, nelfinavir or lopinavir-ritonavir (maternal arm). After breastfeeding cessation counselling and stopping the antiretroviral interventions by 28 weeks, 28 infant HIV infections occurred.Methods:To determine whether these infections occurred during the breastfeeding and antiretroviral intervention phase but had delayed detection on the antiretroviral arms, we performed ultrasensitive (droplet digital PCR) HIV testing on infants with stored peripheral blood mononuclear cell (PBMC) specimens at 24 weeks (n=9).Results:Of the nine infants, all three on the infant nevirapine arm had detectable HIV DNA at 24 weeks, compared with two of four on the maternal antiretroviral arm and one of two on the control arm. For infants with detectable HIV at 24 weeks, the median delay in detection between the ultrasensitive and standard assays was 18.3 weeks for the nevirapine arm, 15.4 weeks for the maternal arm and 9.4 weeks for the control arm.Conclusion:The prolonged inability to detect HIV with standard assays in the context of postnatal antiretroviral prophylaxis suggests that early antiretrovirals may restrict HIV replication sufficiently to lead to missed diagnosis among infected infants. Therefore, repeat virologic testing is warranted beyond the WHO-recommended point of testing at 6 weeks after breastfeeding cessation. C1 [King, Caroline C.; Kourtis, Athena P.; Jamieson, Denise J.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Reprod Hlth, Atlanta, GA 30341 USA. [Persaud, Deborah; Ziemniak, Carrie] Johns Hopkins Univ, Dept Pediat, Baltimore, MD 21218 USA. [Nelson, Julie A. E.] Univ N Carolina, Sch Med, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA. [Hudgens, Michael G.] Univ N Carolina, Gillings Sch Global Hlth, Dept Biostat, Chapel Hill, NC 27599 USA. [Tegha, Gerald] UNC Project Malawi, Lilongwe, Malawi. [Chasela, Charles S.] Univ Witwatersrand, Dept Epidemiol & Biostat, Johannesburg, South Africa. [van der Horst, Charles M.] Univ N Carolina, Sch Med, Div Infect Dis, Chapel Hill, NC USA. RP Kourtis, AP (reprint author), Ctr Dis Control & Prevent, 4770 Buford Highway NE,MS F-74, Atlanta, GA 30341 USA. EM apk3@cdc.gov FU Prevention Research Centers Special Interest Project of the CDC [SIP 13-01 U48-CCU409660-09, SIP 26-04 U48-DP000059-01, SIP 22-09 U48-DP001944-01]; National Institute of Allergy and Infectious Diseases; University of North Carolina Center for AIDS Research [P30-AI50410]; Carolina Population Center [R24 HD050924]; National Institutes for Health Fogarty International Center (AIDS International Training and Research Program and Scholars and Fellows Program) [D43 TW001039, R24 TW007988]; American Recovery and Reinvestment Act; Bill & Melinda Gates Foundation [OPP53107]; Elizabeth Glaser Pediatric AIDS Foundation; United Nations Children's Fund; World Food Programme; Malawi Ministry of Health and Population; Johnson Johnson; U.S. Agency for International Development; National Institutes of Health [R01 HD080474, P30 AI094189] FX The Breastfeeding, Antiretrovirals, and Nutrition Study was supported by grants from the Prevention Research Centers Special Interest Project of the CDC [SIP 13-01 U48-CCU409660-09, SIP 26-04 U48-DP000059-01 and SIP 22-09 U48-DP001944-01], the National Institute of Allergy and Infectious Diseases, the University of North Carolina Center for AIDS Research [P30-AI50410], the Carolina Population Center [R24 HD050924], the National Institutes for Health Fogarty International Center (AIDS International Training and Research Program [D43 TW001039] and Scholars and Fellows Program [R24 TW007988]; the American Recovery and Reinvestment Act, and the Bill & Melinda Gates Foundation [OPP53107]. The antiretrovirals used in the BAN study were donated by Abbott Laboratories, GlaxoSmithKline, Boehringer Ingelheim, Roche Pharmaceuticals and Bristol-Myers Squibb. The Call to Action PMTCT programme, from which BAN mothers were recruited, was supported by the Elizabeth Glaser Pediatric AIDS Foundation, the United Nations Children's Fund, the World Food Programme, the Malawi Ministry of Health and Population, Johnson & Johnson and the U.S. Agency for International Development. The ultrasensitive testing was supported by the National Institutes of Health [R01 HD080474 and P30 AI094189]. NR 27 TC 3 Z9 3 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0269-9370 EI 1473-5571 J9 AIDS JI Aids PD SEP 24 PY 2015 VL 29 IS 15 BP 1953 EP 1961 DI 10.1097/QAD.0000000000000794 PG 9 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA DB4OR UT WOS:000368493200001 PM 26153671 ER PT J AU Kassim, AA Payne, AB Rodeghier, M Macklin, EA Strunk, RC DeBaun, MR AF Kassim, Adetola A. Payne, Amanda B. Rodeghier, Mark Macklin, Eric A. Strunk, Robert C. DeBaun, Michael R. TI Low forced expiratory volume is associated with earlier death in sickle cell anemia SO BLOOD LA English DT Article ID LUNG-FUNCTION; PULMONARY-FUNCTION; CYSTIC-FIBROSIS; REFERENCE VALUES; FUNCTION TESTS; FOLLOW-UP; DISEASE; MORTALITY; RISK; ADULTS AB Pulmonary complications result in mortality in adults with sickle cell anemia (SCA). We tested the hypothesis that abnormal pulmonary function was associated with earlier death. A prospective cohort of adults with SCA, followed in the Cooperative Study for Sickle Cell Disease, was constructed using the first pulmonary function test at >21 years of age. Spirometry measures: forced expiratory volume in 1 second (FEV1), forced vital capacity, and total lung capacity were categorized based on age, gender, height, and race. Pulmonary function patterns were categorized based on the American Thoracic Society guidelines using both spirometry and lung volumes. A cohort of 430 adults with SCA, mean age 32.6 +/- 9.5 (range, 21.0-67.8) years at time of first pulmonary function test, and a median follow-up of 5.5 years, was evaluated. A total of 63 deaths occurred. At baseline, 47% had normal, 29% restrictive, 8% obstructive, 2% mixed, and 14% nonspecific lung function patterns. In the final multivariable model, lower FEV1 percent predicted was associated with increased hazard ratio of death (HRper% predicted 1.02; 95% confidence interval [CI] 1.00-1.04; P=.037), as was older age(HR 1.07; 95% CI 1.04-1.10; P<.001), male sex (HR 2.09; 95% CI 1.20-3.65; P=.010), higher lactate dehydrogenase levels (HR per mg/dL 1.002; 95% CI 1.00-1.003; P=.015), and higher acute chest syndrome incidence rate (HR per event/year 10.4; 95% CI 3.11-34.8; P < .001). Presence of obstructive (HR 1.18; 95% CI: 0.44-3.20; P=.740) and restrictive (HR 1.31; 95% CI: 0.64-2.32; P = .557) pulmonary function patterns were not associated with earlier death. Understanding the pathophysiology of a low FEV1 percent predicted in individuals with SCA is warranted, enabling early intervention for those at risk. C1 [Kassim, Adetola A.] Vanderbilt Univ, Sch Med, Dept Med, Div Hematol Oncol, Nashville, TN 37232 USA. [Kassim, Adetola A.; DeBaun, Michael R.] Vanderbilt Univ, Sch Med, Vanderbilt Meharry Ctr Excellence Sickle Cell Dis, Nashville, TN 37232 USA. [Payne, Amanda B.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. [Rodeghier, Mark] Rodeghier Consultants, Chicago, IL USA. [Macklin, Eric A.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Macklin, Eric A.] Harvard Univ, Sch Med, Boston, MA 02115 USA. [Strunk, Robert C.] Washington Univ, Sch Med, Dept Pediat, Div Allergy Immunol & Pulm Med, St Louis, MO 63110 USA. [DeBaun, Michael R.] Vanderbilt Univ, Sch Med, Dept Pediat & Med, Div Hematol Oncol, Nashville, TN 37232 USA. RP DeBaun, MR (reprint author), Vanderbilt Univ, Sch Med, Vanderbilt Meharry Ctr Excellence Sickle Cell Dis, Dept Pediat, 2200 Childrens Way,11206DOT, Nashville, TN 37232 USA. EM m.debaun@vanderbilt.edu OI Macklin, Eric/0000-0003-1618-3502 FU National Institutes of Health, National Heart, Lung, and Blood Institute [5R01-HL079937-07]; Burroughs Wellcome Foundation FX This work was supported in part by the National Institutes of Health, National Heart, Lung, and Blood Institute (grant 5R01-HL079937-07) (R.C.S. and M.R.D.) and the Burroughs Wellcome Foundation (M.R.D.). The funding sources provided the financial resources to conduct the research. M.R.D. confirms that he had full access to all of the data in this study and had the final responsibility for the decision to submit for publication. NR 33 TC 7 Z9 7 U1 0 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD SEP 24 PY 2015 VL 126 IS 13 BP 1544 EP 1550 DI 10.1182/blood-2015-05-644435 PG 7 WC Hematology SC Hematology GA CU4EX UT WOS:000363481000008 PM 26261241 ER PT J AU Tebbens, RJD Pallansch, MA Cochi, SL Wassilak, SGF Thompson, KM AF Tebbens, Radboud J. Duintjer Pallansch, Mark A. Cochi, Stephen L. Wassilak, Steven G. F. Thompson, Kimberly M. TI An economic analysis of poliovirus risk management policy options for 2013-2052 SO BMC INFECTIOUS DISEASES LA English DT Article ID VACCINE-DERIVED POLIOVIRUS; WILD POLIOVIRUS; POPULATION IMMUNITY; COST-EFFECTIVENESS; POLIOMYELITIS OUTBREAKS; SENSITIVITY ANALYSES; GLOBAL ERADICATION; TRANSMISSION; CIRCULATION; DISEASE AB Background: The Global Polio Eradication Initiative plans for coordinated cessation of oral poliovirus vaccine (OPV) after interrupting all wild poliovirus (WPV) transmission, but many questions remain related to long-term poliovirus risk management policies. Methods: We used an integrated dynamic poliovirus transmission and stochastic risk model to simulate possible futures and estimate the health and economic outcomes of maintaining the 2013 status quo of continued OPV use in most developing countries compared with OPV cessation policies with various assumptions about global inactivated poliovirus vaccine (IPV) adoption. Results: Continued OPV use after global WPV eradication leads to continued high costs and/or high cases. Global OPV cessation comes with a high probability of at least one outbreak, which aggressive outbreak response can successfully control in most instances. A low but non-zero probability exists of uncontrolled outbreaks following a poliovirus reintroduction long after OPV cessation in a population in which IPV-alone cannot prevent poliovirus transmission. We estimate global incremental net benefits during 2013-2052 of approximately $16 billion (US$2013) for OPV cessation with at least one IPV routine immunization dose in all countries until 2024 compared to continued OPV use, although significant uncertainty remains associated with the frequency of exportations between populations and the implementation of long term risk management policies. Conclusions: Global OPV cessation offers the possibility of large future health and economic benefits compared to continued OPV use. Long-term poliovirus risk management interventions matter (e.g., IPV use duration, outbreak response, containment, continued surveillance, stockpile size and contents, vaccine production site requirements, potential antiviral drugs, and potential safer vaccines) and require careful consideration. Risk management activities can help to ensure a low risk of uncontrolled outbreaks and preserve or further increase the positive net benefits of OPV cessation. Important uncertainties will require more research, including characterizing immunodeficient longterm poliovirus excretor risks, containment risks, and the kinetics of outbreaks and response in an unprecedented world without widespread live poliovirus exposure. C1 [Tebbens, Radboud J. Duintjer; Thompson, Kimberly M.] Kid Risk Inc, Orlando, FL 32832 USA. [Pallansch, Mark A.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Div Viral Dis, Atlanta, GA USA. [Cochi, Stephen L.; Wassilak, Steven G. F.] Ctr Dis Control & Prevent, Ctr Global Hlth, Global Immunizat Div, Atlanta, GA USA. RP Tebbens, RJD (reprint author), Kid Risk Inc, 10524 Moss Pk Rd,Ste 204-364, Orlando, FL 32832 USA. EM rdt@kidrisk.org FU US Centers for Disease Control and Prevention [U66IP000519] FX RJDT and KMT acknowledge support for this work from the US Centers for Disease Control and Prevention under Contract U66IP000519. The contents of this article are solely the responsibility of the authors and do not represent the official views of the US Centers for Disease Control and Prevention. NR 73 TC 10 Z9 10 U1 0 U2 4 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2334 J9 BMC INFECT DIS JI BMC Infect. Dis. PD SEP 24 PY 2015 VL 15 AR 389 DI 10.1186/s12879-015-1112-8 PG 21 WC Infectious Diseases SC Infectious Diseases GA CS0YM UT WOS:000361788100003 ER PT J AU Osaki, H Mshana, G Wambura, M Grund, J Neke, N Kuringe, E Plotkin, M Mahler, H Terris-Prestholt, F Weiss, H Changalucha, J AF Osaki, Haika Mshana, Gerry Wambura, Mwita Grund, Jonathan Neke, Nyasule Kuringe, Evodius Plotkin, Marya Mahler, Hally Terris-Prestholt, Fern Weiss, Helen Changalucha, John TI "If You Are Not Circumcised, I Cannot Say Yes": The Role of Women in Promoting the Uptake of Voluntary Medical Male Circumcision in Tanzania SO PLOS ONE LA English DT Article ID HIV PREVENTION; CONDOM USE; SOUTH-AFRICA; ACCEPTABILITY; UGANDA; TRIAL; MEN; INTERVENTION; COUNTRIES; KISUMU AB Voluntary Medical Male Circumcision (VMMC) for HIV prevention in Tanzania was introduced by the Ministry of Health and Social Welfare in 2010 as part of the national HIV prevention strategy. A qualitative study was conducted prior to a cluster randomized trial which tested effective strategies to increase VMMC up take among men aged >= 20 years. During the formative qualitative study, we conducted in-depth interviews with circumcised males (n = 14), uncircumcised males (n = 16), and participatory group discussions (n = 20) with men and women aged 20-49 years in Njombe and Tabora regions of Tanzania. Participants reported that mothers and female partners have an important influence on men's decisions to seek VMMC both directly by denying sex, and indirectly through discussion, advice and providing information on VMMC to uncircumcised partners and sons. Our findings suggest that in Tanzania and potentially other settings, an expanded role for women in VMMC communication strategies could increase adult male uptake of VMMC services. C1 [Osaki, Haika; Mshana, Gerry; Wambura, Mwita; Neke, Nyasule; Kuringe, Evodius; Changalucha, John] Natl Inst Med Res, Mwanza, Tanzania. [Grund, Jonathan] Ctr Dis Control & Prevent, Atlanta, GA USA. [Plotkin, Marya; Mahler, Hally] Jhpiego, Dar Es Salaam, Tanzania. [Terris-Prestholt, Fern; Weiss, Helen] London Sch Hyg & Trop Med, MRC, Trop Epidemiol Grp, London WC1, England. RP Mshana, G (reprint author), Natl Inst Med Res, Mwanza, Tanzania. EM gmshana@nimr.or.tz FU President's Emergency Plan for AIDS Relief (PEPFAR) through the Centers for Disease Control and Prevention (CDC) [5U01GH00513] FX This research has been supported by the President's Emergency Plan for AIDS Relief (PEPFAR) through the Centers for Disease Control and Prevention (CDC) under the terms of the Cooperative Agreement Number 5U01GH00513. The findings and conclusions in this manuscript are those of the authors and do not necessarily represent the official position of the funding agencies. NR 29 TC 1 Z9 1 U1 0 U2 4 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD SEP 24 PY 2015 VL 10 IS 9 AR e0139009 DI 10.1371/journal.pone.0139009 PG 11 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CS1BS UT WOS:000361798100050 PM 26402231 ER PT J AU Sonzogni-Desautels, K Renteria, AE Camargo, FV Di Lenardo, TZ Mikhail, A Arrowood, MJ Fortin, A Ndao, M AF Sonzogni-Desautels, Karine Renteria, Axel E. Camargo, Fabio V. Di Lenardo, Thomas Z. Mikhail, Alexandre Arrowood, Michael J. Fortin, Anny Ndao, Momar TI Oleylphosphocholine (OIPC) arrests Cryptosporidium parvum growth in vitro and prevents lethal infection in interferon gamma receptor knock-out mice SO FRONTIERS IN MICROBIOLOGY LA English DT Article DE Cryptosporidium parvum; cryptosporidiosis; oleylphosphocholine; OIPC; miltefosine; interferon gamma receptor knockout mice; oocysts; parasite burden ID SCID MOUSE MODEL; THERAPEUTIC-EFFICACY; DIARRHEAL DISEASE; ADULT MICE; LEISHMANIASIS; OLPC; EPIDEMIOLOGY; TOLERABILITY; MILTEFOSINE; PAROMOMYCIN AB Cryptosporidium parvum is a species of protozoa that causes cryptosporidiosis, an intestinal disease affecting many mammals including humans. Typically, in healthy individuals, cryptosporidiosis is a self-limiting disease. However, C. parvum can cause a severe and persistent infection that can be life-threatening for immunocompromised individuals, such as AIDS patients. As there are no available treatments for these patients that can cure the disease, there is an urgent need to identify treatment options. We tested the anti-parasitic activity of the alkylphosphocholine oleylphosphocholine (OIPC), an analog of miltefosine, against C. parvum in in vitro and in vivo studies. In vitro experiments using C. parvum infected human ileocecal adenocarcinoma cells (HCT-8 cells) showed that OIPC has an EC50 of 18.84 nM. Moreover, no cell toxicity has been seen at concentrations <= 50 mu M. C57BL/6 interferon gamma receptor knock-out mice, were infected by gavage with 4000 C. parvum oocysts on Day 0. Oral treatments, with OIPC, miltefosine, paromomycin or PBS, began on Day 3 post-infection for 10 days. Treatment with OIPC, at 40 mg/kg/day resulted in 100% survival, complete clearance of parasite in stools and a 99.9% parasite burden reduction in the intestines at Day 30. Doses of 30 and 20 mg/kg/day also demonstrated an increased survival rate and a dose-dependent parasite burden reduction. Mice treated with 10 mg/kg/day of miltefosine resulted in 50% survival at Day 30. In contrast, control mice, treated with PBS or 100 mg/kg/day of paromomycin, died or had to be euthanized between Days 6 and 13 due to severe illness. Results of parasite burden were obtained by qPCR and cross-validated by both flow cytometry of stool oocysts and histological sections of the ileum. Together, our results strongly support that OIPC represents a potential candidate for the treatment of C. parvum infections in immunocompromised patients. C1 [Sonzogni-Desautels, Karine; Renteria, Axel E.; Camargo, Fabio V.; Mikhail, Alexandre; Ndao, Momar] McGill Univ, Ctr Hlth, Res Inst, Natl Reference Ctr Parasitol, Montreal, PQ H4A 3J1, Canada. [Sonzogni-Desautels, Karine; Ndao, Momar] McGill Univ, Inst Parasitol, Montreal, PQ, Canada. [Renteria, Axel E.; Di Lenardo, Thomas Z.; Ndao, Momar] McGill Univ, Dept Expt Med, Montreal, PQ, Canada. [Arrowood, Michael J.] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Atlanta, GA USA. [Fortin, Anny] McGill Univ, Dept Biochem, Montreal, PQ, Canada. [Fortin, Anny] Dafra Pharma R&D, Turnhout, Belgium. RP Ndao, M (reprint author), McGill Univ, Ctr Hlth, Res Inst, Natl Reference Ctr Parasitol, 1001 Decarie Blvd,Room EM3 3244, Montreal, PQ H4A 3J1, Canada. EM momar.ndao@mcgill.ca FU Public Health Agency of Canada/National Microbiology Laboratory grant [MOA 4500299739]; Foundation of the Montreal General Hospital; Research Institute of the McGill University Health Centre; Dafra Pharma R&D through grant from IWT, Flanders, Belgium (Innovatie door Wetenschap en Technologie) [110402] FX The National Reference Centre for Parasitology is supported by Public Health Agency of Canada/National Microbiology Laboratory grant MOA 4500299739, the Foundation of the Montreal General Hospital and the Research Institute of the McGill University Health Centre. This study would not have been possible without the valuable help of Nathalie Martel for mouse colony management and the technical help of Annie Beauchamp for mouse procedures. Part of the in vitro testing of OIPC was funded by Dafra Pharma R&D through grant #110402 from IWT, Flanders, Belgium (Innovatie door Wetenschap en Technologie) to AF. NR 49 TC 1 Z9 1 U1 1 U2 2 PU FRONTIERS MEDIA SA PI LAUSANNE PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND SN 1664-302X J9 FRONT MICROBIOL JI Front. Microbiol. PD SEP 23 PY 2015 VL 6 AR 973 DI 10.3389/fmicb.2015.00973 PG 14 WC Microbiology SC Microbiology GA CS2PS UT WOS:000361914000001 PM 26441906 ER PT J AU Emukule, GO Paget, J van der Velden, K Mott, JA AF Emukule, Gideon O. Paget, John van der Velden, Koos Mott, Joshua A. TI Influenza-Associated Disease Burden in Kenya: A Systematic Review of Literature SO PLOS ONE LA English DT Article ID RESPIRATORY SYNCYTIAL VIRUS; YOUNG-CHILDREN; PEDIATRIC INFLUENZA; SEVERE PNEUMONIA; WESTERN KENYA; UNITED-STATES; SOUTH-AFRICA; RURAL KENYA; ILLNESS; INFECTIONS AB Background In Kenya data on the burden of influenza disease are needed to inform influenza control policies. Methods We conducted a systematic review of published data describing the influenza disease burden in Kenya using surveillance data collected until December 2013. We included studies with laboratory confirmation of influenza, well-defined catchment populations, case definitions used to sample patients for testing and a description of the laboratory methods used for influenza testing. Studies with or without any adjustments on the incidence rates were included. Results Ten studies reporting the incidence of medically-attended and non-medically attended influenza were reviewed. For all age groups, the influenza positive proportion ranged from 5-10% among hospitalized patients, and 5-27% among all medically-attended patients (a combination of in-and outpatients). The adjusted incidence rate of hospitalizations with influenza among children < 5 years ranged from 2.7-4.7 per 1,000 [5.7 per 1,000 in children < 6 months old], and were 7-10 times higher compared to persons aged >= 5 years. The adjusted incidence of all medically-attended influenza among children aged < 5 years ranged from 13.0-58.0 per 1,000 compared to 4.3-26.0 per 1,000 among persons aged >= 5 years. Conclusions Our review shows an expanding set of literature on disease burden associated with influenza in Kenya, with a substantial burden in children under five years of age. Hospitalizations with influenza in these children were 2-3 times higher than reported in the United States. These findings highlight the possible value of an influenza vaccination program in Kenya, with children < 5 years and pregnant women being potentially important targets. C1 [Emukule, Gideon O.; Mott, Joshua A.] Ctr Dis Control & Prevent, Kenya Country Off, Nairobi, Kenya. [Paget, John] NIVEL, Netherlands Inst Hlth Serv Res, Utrecht, Netherlands. [Paget, John; van der Velden, Koos] Radboud Univ Nijmegen, Med Ctr, Dept Primary & Community Care, NL-6525 ED Nijmegen, Netherlands. [Mott, Joshua A.] US Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [Mott, Joshua A.] US PHS, Rockville, MD USA. RP Emukule, GO (reprint author), Ctr Dis Control & Prevent, Kenya Country Off, Nairobi, Kenya. EM uyr9@cdc.gov FU Centers for Disease Control and Prevention FX This work was supported by the Centers for Disease Control and Prevention. The funder had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 53 TC 1 Z9 1 U1 0 U2 2 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD SEP 23 PY 2015 VL 10 IS 9 AR e0138708 DI 10.1371/journal.pone.0138708 PG 14 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CS1BM UT WOS:000361797500096 PM 26398196 ER PT J AU Fernandes, CG Placido, D Lousa, D Brito, JA Isidro, A Soares, CM Pohl, J Carrondo, MA Archer, M Henriques, AO AF Fernandes, Catarina G. Placido, Diana Lousa, Diana Brito, Jose A. Isidro, Anabela Soares, Claudio M. Pohl, Jan Carrondo, Maria A. Archer, Margarida Henriques, Adriano O. TI Structural and Functional Characterization of an Ancient Bacterial Transglutaminase Sheds Light on the Minimal Requirements for Protein Cross-Linking SO BIOCHEMISTRY LA English DT Article ID BACILLUS-SUBTILIS SPORES; TISSUE TRANSGLUTAMINASE; CATALYTIC TRIAD; STREPTOVERTICILLIUM-MOBARAENSE; MICROBIAL TRANSGLUTAMINASE; STREPTOMYCES-MOBARAENSIS; 3-DIMENSIONAL STRUCTURE; STRUCTURE VALIDATION; ESCHERICHIA-COLI; CALCIUM-IONS AB Transglutaminases are best known for their ability to catalyze protein cross-linking reactions that impart chemical and physical resilience to cellular structures. Here, we report the crystal structure and characterization of Tgl, a transglutaminase from the bacterium Bacillus subtilis. Tgl is produced during sporulation and cross-links the surface of the highly resilient spore. Tgl-like proteins are found only in spore-forming bacteria of the Bacillus and Clostridia classes, indicating an ancient origin. Tgl is a single-domain protein, produced in active form, and the smallest transglutaminase characterized to date. We show that Tgl is structurally similar to bacterial cell wall endopeptidases and has an NlpC/P60 catalytic core, thought to represent the ancestral unit of the cysteine protease fold. We show that Tgl functions through a unique partially redundant catalytic dyad formed by Cys116 and Glu187 or Glu115. Strikingly, the catalytic Cys is insulated within a hydrophobic tunnel that traverses the molecule from side to side. The lack of similarity of Tgl to other transglutaminases together with its small size suggests that an NlpC/P60 catalytic core and insulation of the active site during catalysis may be essential requirements for protein cross-linking. C1 [Fernandes, Catarina G.; Isidro, Anabela; Henriques, Adriano O.] Univ Nova Lisboa, ITQB, Microbial Dev Grp, P-2780157 Oeiras, Portugal. [Placido, Diana; Brito, Jose A.; Carrondo, Maria A.; Archer, Margarida] Univ Nova Lisboa, ITQB, Membrane Prot Crystallog, P-2780157 Oeiras, Portugal. [Lousa, Diana; Soares, Claudio M.] Univ Nova Lisboa, ITQB, Prot Modelling Grp, Inst Tecnol Quim & Biol Antonio Xavier, P-2780157 Oeiras, Portugal. [Pohl, Jan] Ctr Dis Control & Prevent, Biotechnol Branch, Atlanta, GA 30333 USA. RP Archer, M (reprint author), Univ Nova Lisboa, ITQB, Membrane Prot Crystallog, P-2780157 Oeiras, Portugal. EM archer@itqb.unl.pt; aoh@itqb.unl.pt RI Soares, Claudio/E-2675-2012; Lousa, Diana/S-7808-2016; OI Soares, Claudio/0000-0003-1154-556X; Lousa, Diana/0000-0002-2309-0980; Brito, Jose A./0000-0002-8307-2282 FU "Fundacao para a Ciencia e a Tecnologia" (FCT) [SFRH/BD/43200/2008, SFRH/BD/14384/2003, SFRH/BD/28269/2006, SFRH/BPD/8967/2002, SFRH/BPD/79224/2011]; FCT [Pest-E/EQB/LA0004/2011, POCI/BIA-BCM/60855/2004, POCTI/BCI/48647/2002, PTDC/BIA-PRO/118535/2010]; European Commission [RII3-CT-2004-506008] FX This work was funded by "Fundacao para a Ciencia e a Tecnologia" (FCT) trough Ph.D. (SFRH/BD/43200/2008, SFRH/BD/14384/2003, and SFRH/BD/28269/2006) and postdoctoral (SFRH/BPD/8967/2002 and SFRH/BPD/79224/2011) fellowships and FCT Grants (Pest-E/EQB/LA0004/2011, POCI/BIA-BCM/60855/2004, POCTI/BCI/48647/2002, and PTDC/BIA-PRO/118535/2010). Support from the European Commission under the sixth Framework Programme through the Key Action "Strengthening the European Research Area Programme" (Contract no RII3-CT-2004-506008) was provided to collect X-ray data at EMBL/DESY (Hamburg, Germany) and SLS (Villigen, Switzerland). NR 56 TC 3 Z9 3 U1 2 U2 17 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 0006-2960 J9 BIOCHEMISTRY-US JI Biochemistry PD SEP 22 PY 2015 VL 54 IS 37 BP 5723 EP 5734 DI 10.1021/acs.biochem.5b00661 PG 12 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA CS2XL UT WOS:000361935200007 PM 26322858 ER PT J AU Jackson, ML Jackson, LA Kieke, B McClure, D Gaglani, M Murthy, K Malosh, R Monto, A Zimmerman, RK Foppa, IM Flannery, B Thompson, MG AF Jackson, Michael L. Jackson, Lisa A. Kieke, Burney McClure, David Gaglani, Manjusha Murthy, Kempapura Malosh, Ryan Monto, Arnold Zimmerman, Richard K. Foppa, Ivo M. Flannery, Brendan Thompson, Mark G. TI Incidence of medically attended influenza infection and cases averted by vaccination, 2011/2012 and 2012/2013 influenza seasons SO VACCINE LA English DT Article DE Influenza, human; Influenza vaccines; Incidence ID UNITED-STATES; METAANALYSIS; PNEUMONIA; MORTALITY; BURDEN AB Background: We estimated the burden of outpatient influenza and cases prevented by vaccination during the 2011/2012 and 2012/2013 influenza seasons using data from the United States Influenza Vaccine Effectiveness (US Flu VE) Network. Methods: We defined source populations of persons who could seek care for acute respiratory illness (ARI) at each of the five US Flu VE Network sites. We identified all members of the source population who were tested for influenza during US Flu VE influenza surveillance. Each influenza-positive subject received a sampling weight based on the proportion of source population members who were tested for influenza, stratified by site, age, and other factors. We used the sampling weights to estimate the cumulative incidence of medically attended influenza in the source populations. We estimated cases averted by vaccination using estimates of cumulative incidence, vaccine coverage, and vaccine effectiveness. Results: Cumulative incidence of medically attended influenza ranged from 0.8% to 2.8% across sites during 2011/2012 and from 2.6% to 6.5% during the 2012/2013 season. Stratified by age, incidence ranged from 1.2% among adults 50 years of age and older in 2011/2012 to 10.9% among children 6 months to 8 years of age in 2012/2013. Cases averted by vaccination ranged from 4 to 41 per 1000 vaccinees, depending on the study site and year. Conclusions: The incidence of medically attended influenza varies greatly by year and even by geographic region within the same year. The number of cases averted by vaccination varies greatly based on overall incidence and on vaccine coverage. (C) 2015 Elsevier Ltd. All rights reserved. C1 [Jackson, Michael L.; Jackson, Lisa A.] Grp Hlth Res Inst, Seattle, WA 98101 USA. [Kieke, Burney; McClure, David] Marshfield Clin Res Fdn, Marshfield, WI USA. [Gaglani, Manjusha; Murthy, Kempapura] Baylor Scott & White Hlth, Temple, TX USA. [Gaglani, Manjusha; Murthy, Kempapura] Texas A&M Univ, Coll Med, Hlth Sci Ctr, Temple, TX 76508 USA. [Malosh, Ryan; Monto, Arnold] Univ Michigan, Sch Publ Hlth, Ann Arbor, MI 48109 USA. [Zimmerman, Richard K.] Univ Pittsburgh, Pittsburgh, PA USA. [Foppa, Ivo M.; Flannery, Brendan; Thompson, Mark G.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Foppa, Ivo M.] Batelle, Atlanta, GA USA. RP Jackson, ML (reprint author), Grp Hlth Res Inst, Seattle, WA 98101 USA. EM jackson.ml@ghc.org OI Zimmerman, Richard/0000-0001-5941-6092 FU Centers for Disease Control and Prevention [U01 IP000466] FX This work was supported by the Centers for Disease Control and Prevention [U01 IP000466]. NR 37 TC 0 Z9 0 U1 3 U2 7 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD SEP 22 PY 2015 VL 33 IS 39 BP 5181 EP 5187 DI 10.1016/j.vaccine.2015.07.098 PG 7 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA CS1XT UT WOS:000361862900022 PM 26271827 ER PT J AU Kahn, KE Santibanez, TA Zhai, YS Singleton, JA AF Kahn, Katherine E. Santibanez, Tammy A. Zhai, Yusheng Singleton, James A. TI Influenza vaccination type, live, attenuated influenza vaccine (LAIV) versus inactivated influenza vaccine (IIV), received by children, United States, 2011-12 through 2013-14 influenza seasons SO VACCINE LA English DT Article DE Influenza vaccines; Vaccination; Child; LAIV vaccine; Health surveys ID NATIONAL IMMUNIZATION SURVEY; YOUNG-CHILDREN; HOSPITALIZATIONS; ADOLESCENTS; COVERAGE; RECOMMENDATIONS; TRIVALENT; EFFICACY; INFANTS; ILLNESS AB Background: Influenza vaccines available for children in the United States include inactivated influenza vaccine (IIV) and live, attenuated influenza vaccine (LAIV). Objectives of this study were to quantify proportions of IIV and LAIV received by vaccinated children, and examine associations between vaccine type received and demographic characteristics. Methods: National Immunization Survey-Flu (NIS-Flu) parental reported data for the 2011-12 through 2013-14 influenza seasons were used to estimate proportions of vaccinated children 2-17 years who received IIV and LAIV. Tests of association between vaccination type and demographic variables were conducted using Wald chi-square tests and pair-wise comparison t-tests. Multivariable logistic regression was used to determine variables independently associated with receipt of LAIV versus IIV. Results: In the 2013-14 season, 33.3% of vaccinated children received LAIV, similar to the proportion in the 2011-12 (32.2%) and 2012-13 (32.1%) seasons. Across all seasons studied, the strongest observed association was between vaccination type and child's age, with children 2-8 years (Adjusted Prevalence Ratio (95% confidence interval) [APR(95% CI)] 1.41(1.27-1.56), 1.46(1.34-1.59), and 1.50(1.38-1.63) for 2011-12,2012-13, and 2013-14) and 9-12 years (APR(95% CI) 1.37(1.23-1.54), 1.38(1.26-1.51), and 1.50(1.38-1.63) for 2011-12, 2012-13, and 2013-14) being more likely to have received LAIV than children 13-17 years. Among those vaccinated, whites were more likely to have received LAIV compared with blacks (APR(95% Cl) 1.19(1.05-1.35), 1.24(1.10-1.39), and 1.22(1.11-1.34) for 2011-12,2012-13, and 2013-14), and children living above poverty (annual income >$75,000) were more likely to have received LAIV than those living at or below poverty (APR(95% CI) 1.43(1.23-1.67), 1.13(1.02-1.26), and 1.16(1.06-1.28) for 2011-12,2012-13, and 2013-14). Conclusions: This study provides a baseline of the extent and patterns of LAIV uptake that can be used to measure the impact of relevant public health policy. Additional research is needed to investigate parental and provider preferences and barriers regarding LAIV. Published by Elsevier Ltd. C1 [Kahn, Katherine E.; Zhai, Yusheng] Leidos Inc, Atlanta, GA USA. [Kahn, Katherine E.; Santibanez, Tammy A.; Zhai, Yusheng; Singleton, James A.] Ctr Dis Control & Prevent CDC, NCIRD, Atlanta, GA 30333 USA. RP Kahn, KE (reprint author), Ctr Dis Control & Prevent CDC, NCIRD, 1600 Clifton Rd NE,Mail Stop A-19, Atlanta, GA 30333 USA. EM xdo9@cdc.gov FU Intramural CDC HHS [CC999999] NR 37 TC 1 Z9 1 U1 1 U2 6 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD SEP 22 PY 2015 VL 33 IS 39 BP 5196 EP 5203 DI 10.1016/j.vaccine.2015.07.064 PG 8 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA CS1XT UT WOS:000361862900024 PM 26238724 ER PT J AU Allen, NB Badon, S Greenlund, KJ Huffman, M Hong, YL Lloyd-Jones, DM AF Allen, Norrina B. Badon, Sylvia Greenlund, Kurt J. Huffman, Mark Hong, Yuling Lloyd-Jones, Donald M. TI The association between cardiovascular health and health-related quality of life and health status measures among US adults: a cross-sectional study of the National Health and Nutrition Examination Surveys, 2001-2010 SO HEALTH AND QUALITY OF LIFE OUTCOMES LA English DT Article DE Quality of Life; Cardiovascular diseases; Risk factors ID AMERICAN-HEART-ASSOCIATION; DISEASE RISK-FACTORS; PHYSICAL-ACTIVITY; FACTOR PROFILE; MIDDLE-AGE; MORTALITY; POPULATION; COUNTRIES; STROKE; SYSTEM AB Background: This study was conducted to examine the association between ideal cardiovascular health (CVH) and health-related quality of life and health status indicators. Methods: This cross-sectional study included adult NHANES participants from 2001 to 2010 without CVD (N = 7115). CVH was defined according to AHA definitions with poor, intermediate and ideal levels of the seven factors (diet, BMI, physical activity, smoking, blood pressure, glucose, and cholesterol) assigned scores of 0, 1, and 2, respectively. A CVH score (CVHS) was calculated as the sum of the scores from each individual health factor (range 0-14; higher score indicating greater CVH). CVHS was categorized as poor (0-7), intermediate (8-10), and ideal (11-14). Linear regression models examined the association between CVHS category with health status and number of unhealthy days per month, adjusted for socio-demographic characteristics and disability. Results: Among US adults 20-79 years, 14, 46 and 40 % had ideal, intermediate and poor CVHS, respectively. Compared to those with poor CVH, individuals in intermediate and ideal CVH were 44 and 71 % less likely to report being in fair/poor health. Participants with ideal CVH scores reported a mean of 2.4 fewer unhealthy days over the past month, including one less day in which their physical health was not good and two fewer days in which their mental health was not good. Conclusions: Ideal CVH is associated with greater overall health status and fewer physically and mentally unhealthy days. C1 [Allen, Norrina B.; Badon, Sylvia; Huffman, Mark; Lloyd-Jones, Donald M.] Northwestern Univ, Feinberg Sch Med, Dept Prevent Med, Chicago, IL 60611 USA. [Greenlund, Kurt J.] Ctr Dis Control & Prevent, Div Populat Hlth, Atlanta, GA USA. [Hong, Yuling] Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, Atlanta, GA USA. RP Allen, NB (reprint author), Northwestern Univ, Feinberg Sch Med, Dept Prevent Med, 680 North Lake Shore Dr,Suite 1400, Chicago, IL 60611 USA. EM Norrina-allen@northwestern.edu OI Huffman, Mark/0000-0001-7412-2519 FU NCATS NIH HHS [UL1 TR001422] NR 26 TC 1 Z9 1 U1 0 U2 5 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1477-7525 J9 HEALTH QUAL LIFE OUT JI Health Qual. Life Outcomes PD SEP 22 PY 2015 VL 13 AR 152 DI 10.1186/s12955-015-0352-z PG 7 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA CR9YC UT WOS:000361712400001 PM 26396070 ER PT J AU Akram, M Fatima, Z Purdy, MA Sue, A Saleem, S Amin, I Shahid, M Idrees, M Nawaz, R AF Akram, Madiha Fatima, Zareen Purdy, Mike A. Sue, Amanda Saleem, Sana Amin, Irum Shahid, Muhammad Idrees, Muhammad Nawaz, Rabia TI Introduction and evolution of dengue virus type 2 in Pakistan: a phylogeographic analysis SO VIROLOGY JOURNAL LA English DT Article ID FEVER; FLAVIVIRUSES; SEROTYPES; SELECTION; PRESSURE; DYNAMICS; OUTBREAK; KARACHI; INDIA; RNA AB Background: Pattern of Dengue periodic epidemics through the years along with sporadic cases of Dengue hemorrhagic fever followed by a severe 2011 epidemic of Dengue fever in Pakistan make Pakistan a Dengue endemic country. To study the entry and evolution of dengue virus serotype 2 (DENV-2) in Pakistan, we sequenced three full length genomes and 24 complete envelope sequences of DENV-2 from the years 2010, 2011 and 2013 collected from Punjab province of Pakistan. Methods: Phylogenetic and Bayesian phylogeographic analyses was applied to three full genome sequences as well as 24 envelope sequences to study the spatiotemporal dynamics of DENV-2 in Pakistan. Results: Most of the DENV-2 viruses from the years 2008 to 2013 formed a monophyletic Pakistani clade in IVb sublineage of cosmopolitan genotype except one 2008 DENV-2 strain. Phylogeographic analysis revealed that this 2008 DENV-2 strain was rooted to India 25.4 years ago with a location probability of 0.88. However Pakistani clade rooted back to Sri Lanka 12.6 years ago with a location probability of 0.57. Conclusion: DENV-2 genotype IV was introduced in Pakistan in two time events. First event was introduction from India to Pakistan in the late 1980s (around 1986), and second event was introduction from Sri Lanka to Pakistan around 2000. The later introduction event was responsible for major outbreaks in the Punjab region of Pakistan, including major 2011 outbreak. After the second Introduction event, DENV-2 circulated locally in the region forming a distinct Sublineage within the IVb cosmopolitan genotype of DENV-2. C1 [Akram, Madiha; Fatima, Zareen; Saleem, Sana; Amin, Irum; Shahid, Muhammad; Nawaz, Rabia] Univ Punjab, Div Mol Virol, Ctr Excellence Mol Biol, Lahore, Pakistan. [Purdy, Mike A.; Sue, Amanda] Ctr Dis Control & Prevent, Atlanta, GA USA. [Idrees, Muhammad] Univ Punjab, CAMB, Lahore, Pakistan. RP Idrees, M (reprint author), Univ Punjab, CAMB, 87 West Canal Bank Rd Thokar Niaz Baig Lahore, Lahore, Pakistan. EM directorcamb@yahoo.com NR 32 TC 0 Z9 0 U1 1 U2 4 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1743-422X J9 VIROL J JI Virol. J. PD SEP 22 PY 2015 VL 12 AR 148 DI 10.1186/s12985-015-0371-8 PG 11 WC Virology SC Virology GA CR9IU UT WOS:000361669000001 PM 26395339 ER PT J AU Cantillo-Barraza, O Garces, E Gomez-Palacio, A Cortes, LA Pereira, A Marcet, PL Jansen, AM Triana-Chavez, O AF Cantillo-Barraza, Omar Garces, Edilson Gomez-Palacio, Andres Cortes, Luis A. Pereira, Andre Marcet, Paula L. Jansen, Ana M. Triana-Chavez, Omar TI Eco-epidemiological study of an endemic Chagas disease region in northern Colombia reveals the importance of Triatoma maculata (Hemiptera: Reduviidae), dogs and Didelphis marsupialis in Trypanosoma cruzi maintenance SO PARASITES & VECTORS LA English DT Article DE Colombia; Risk factors for Chagas disease; Trypanosoma cruzi; Seroprevalence; Dogs; Non-domiciliated vectors ID BLOOD-MEAL SOURCES; DOMESTIC MAMMALS; TRANSMISSION; VECTORS; BRAZIL; WILD; IDENTIFICATION; AREAS; RESERVOIRS; INFECTION AB Background: In Colombia, Rhodnius prolixus and Triatoma dimidiata are the main domestic triatomine species known to transmit T. cruzi. However, there are multiple reports of T. cruzi transmission involving secondary vectors. In this work, we carried out an eco-epidemiological study on Margarita Island, located in the Caribbean region of Colombia, where Chagas disease is associated with non-domiciliated vectors. Methods: To understand the transmission dynamics of Trypanosoma cruzi in this area, we designed a comprehensive, multi-faceted study including the following: (i) entomological evaluation through a community-based insect-surveillance campaign, blood meal source determination and T. cruzi infection rate estimation in triatomine insects; (ii) serological determination of T. cruzi prevalence in children under 15 years old, as well as in domestic dogs and synanthropic mammals; (iii) evaluation of T. cruzi transmission capacity in dogs and Didelphis marsupialis, and (iv) genetic characterization of T. cruzi isolates targeting spliced-leader intergene region (SL-IR) genotypes. Results: Out of the 124 triatomines collected, 94 % were Triatoma maculata, and 71.6 % of them were infected with T. cruzi. Blood-meal source analysis showed that T. maculata feeds on multiple hosts, including humans and domestic dogs. Serological analysis indicated 2 of 803 children were infected, representing a prevalence of 0.25 %. The prevalence in domestic dogs was 71.6 % (171/224). Domestic dogs might not be competent reservoir hosts, as inferred from negative T. cruzi xenodiagnosis and haemoculture tests. However, 61.5 % (8/13) of D. marsupialis, the most abundant synanthropic mammal captured, were T. cruzi-positive on xenodiagnosis and haemocultures. Conclusions: This study reveals the role of peridomestic T. maculata and dogs in T. cruzi persistence in this region and presents evidence that D. marsupialis are a reservoir mediating peridomestic-zoonotic cycles. This picture reflects the complexity of the transmission dynamics of T. cruzi in an endemic area with non-domiciliated vectors where active human infection exists. There is an ongoing need to control peridomestic T. maculata populations and to implement continuous reservoir surveillance strategies with community participation. C1 [Cantillo-Barraza, Omar; Garces, Edilson; Gomez-Palacio, Andres; Triana-Chavez, Omar] Univ Antioquia UdeA, Grp BCEI, Medellin, Colombia. [Cortes, Luis A.] Secretaria Salud Dept Bolivar, Unidad Entomol Med, Cartagena, Colombia. [Pereira, Andre; Jansen, Ana M.] Fiocruz MS, Inst Oswaldo Cruz, Lab Trypanosomatid Biol, BR-21040360 Rio De Janeiro, RJ, Brazil. [Marcet, Paula L.] Ctr Dis Control & Prevent CDC, Div Parasit Dis & Malaria, Entomol Branch, Atlanta, GA USA. RP Triana-Chavez, O (reprint author), Univ Antioquia UdeA, Grp BCEI, Calle 70 52-21, Medellin, Colombia. EM omar.triana@udea.edu.co RI GOMEZ, PERLA/F-4969-2016; OI GOMEZ, PERLA/0000-0002-8535-6887; Triana, Omar/0000-0001-8031-0225; Marcet, Paula/0000-0002-0676-3020; Gomez-Palacio, Andres/0000-0002-1069-9199 FU Universidad de Antioquia-UdeA; COLCIENCIAS [111549326149] FX This study was financed by Universidad de Antioquia-UdeA and COLCIENCIAS project No. 111549326149. NR 59 TC 3 Z9 3 U1 3 U2 5 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1756-3305 J9 PARASITE VECTOR JI Parasites Vectors PD SEP 22 PY 2015 VL 8 AR 482 DI 10.1186/s13071-015-1100-2 PG 10 WC Parasitology SC Parasitology GA CR7HL UT WOS:000361519200003 PM 26394766 ER PT J AU Nichols, EK Giles, D Kang'oma, S Mwalwanda, L Onaka, A Notzon, F AF Nichols, E. K. Giles, D. Kang'oma, S. Mwalwanda, L. Onaka, A. Notzon, F. TI Rapid assessment of Malawi's civil registration and vital statistics system SO PUBLIC HEALTH ACTION LA English DT Article DE mortality; natality; quality improvement AB In 2010, Malawi adopted a National Registration Act, making the registration of births and deaths compulsory, and efforts to improve Malawi's civil registration and vital statistics (CRVS) system are underway. During a participatory-style workshop, stakeholders completed a rapid assessment of the national civil registration and vital statistics systems. While participants discussed and scored each item in a standard tool, the workshop focused on sharing of partners' roles and challenges. The workshop has enhanced receptiveness in collaboration, and an inter-ministerial technical working group has now been formed to develop a strategic plan and conduct a comprehensive assessment to guide future improvements. C1 [Nichols, E. K.; Notzon, F.] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Rm 2423 MS P08 3311 Toledo Rd, Hyattsville, MD 20782 USA. [Nichols, E. K.] US PHS, Washington, DC 20201 USA. [Giles, D.; Mwalwanda, L.] Ctr Dis Control & Prevent Malawi, Lilongwe, Malawi. [Kang'oma, S.] Natl Registrat Bur, Lilongwe, Malawi. [Onaka, A.] Hawaii State Dept Hlth, Off Hlth Status Monitoring, Honolulu, HI USA. RP Nichols, EK (reprint author), Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Rm 2423 MS P08 3311 Toledo Rd, Hyattsville, MD 20782 USA. EM EKNichols@cdc.gov NR 5 TC 0 Z9 0 U1 1 U2 1 PU INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D) PI PARIS PA 68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE SN 2220-8372 J9 PUBLIC HEALTH ACTION JI PUBLIC HEALTH ACTION PD SEP 21 PY 2015 VL 5 IS 3 BP 162 EP 164 DI 10.5588/pha.15.0021 PG 3 WC Respiratory System SC Respiratory System GA DL2FZ UT WOS:000375450100004 PM 26399284 ER PT J AU Yeole, RD Khillare, K Chadha, VK Lo, T Kumar, AMV AF Yeole, R. D. Khillare, K. Chadha, V. K. Lo, T. Kumar, A. M. V. TI Tuberculosis case notification by private practitioners in Pune, India: how well are we doing? SO PUBLIC HEALTH ACTION LA English DT Article DE tuberculosis; notification; private practitioners; challenges; India AB Setting: Pimpri Chinchwad Municipal Corporation area, Pune, India. Objective: To assess the proportion of private practitioners (PPs) who notified tuberculosis (TB) patients during February-April 2013 and their contribution to the overall number notified, and to determine their perceived challenges in reporting TB cases. Design: Mixed-method study including an analysis of notification data, followed by in-depth interviews with PPs. Interviews were transcribed and inductive content analysis was performed to derive themes. Results: Of 831 PPs, 533 (64%) participated in case notification; of these 87 (16%) notified at least one TB case during the study period. In all, 138 TB cases were notified by PPs, accounting for 20% of the total TB cases notified. Emerging themes among perceived challenges and barriers were lack of complete knowledge about TB notification, fear of a breach of patient confidentiality, lack of a simplified operational mechanism of notification, and lack of trust and coordination with the government health system. Conclusion: About two thirds of PPs participated in case notification and contributed significantly to the overall TB cases notified. India's national TB programme should focus on training PPs and targeted media communication campaigns, and establish alternative mechanisms for notification, such as the internet and mobile telephones, to overcome perceived barriers. C1 [Yeole, R. D.] WHO, Country Off India, New Delhi, India. [Khillare, K.] Pimpri Chinchwad Municipal Corp, City TB Off, Pune, Maharashtra, India. [Chadha, V. K.] Natl TB Inst, Epidemiol & Res Div, Bangalore, Karnataka, India. [Lo, T.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Int Res & Programs Branch, Atlanta, GA USA. [Kumar, A. M. V.] Int Union TB & Lung Dis, South East Asia Reg Off, New Delhi, India. RP Yeole, RD (reprint author), State TB Off, Vishrantwadi Alandi Rd, Pune 411006, Maharashtra, India. EM yeoler@rntcp.org FU World Health Organization [001] NR 19 TC 1 Z9 1 U1 0 U2 0 PU INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D) PI PARIS PA 68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE SN 2220-8372 J9 PUBLIC HEALTH ACTION JI PUBLIC HEALTH ACTION PD SEP 21 PY 2015 VL 5 IS 3 BP 173 EP 179 DI 10.5588/pha.15.0031 PG 7 WC Respiratory System SC Respiratory System GA DL2FZ UT WOS:000375450100007 PM 26399287 ER PT J AU Anderka, M Mai, CT Romitti, PA Copeland, G Isenburg, J Feldkamp, ML Krikov, S Rickard, R Olney, RS Canfield, MA Stanton, C Mosley, B Kirby, RS AF Anderka, Marlene Mai, Cara T. Romitti, Paul A. Copeland, Glenn Isenburg, Jennifer Feldkamp, Marcia L. Krikov, Sergey Rickard, Russel Olney, Richard S. Canfield, Mark A. Stanton, Carol Mosley, Bridget Kirby, Russell S. TI Development and implementation of the first national data quality standards for population-based birth defects surveillance programs in the United States SO BMC PUBLIC HEALTH LA English DT Article ID CERTIFICATE AB Background: Population-based birth defects surveillance is a core public health activity in the United States (U.S.); however, the lack of national data quality standards has limited the use of birth defects surveillance data across state programs. Development of national standards will facilitate data aggregation and utilization across birth defects surveillance programs in the U.S. Methods: Based on national standards for other U.S. public health surveillance programs, existing National Birth Defects Prevention Network (NBDPN) guidelines for conducting birth defects surveillance, and information from birth defects surveillance programs regarding their current data quality practices, we developed 11 data quality measures that focused on data completeness (n = 5 measures), timeliness (n = 2), and accuracy (n = 4). For each measure, we established tri-level performance criteria (1 = rudimentary, 2 = essential, 3 = optimal). In January 2014, we sent birth defects surveillance programs in each state, District of Columbia, Puerto Rico, Centers for Disease Control and Prevention (CDC), and the U.S. Department of Defense Birth and Infant Health Registry an invitation to complete a self-administered NBDPN Standards Data Quality Assessment Tool. The completed forms were electronically submitted to the CDC for analyses. Results: Of 47 eligible population-based surveillance programs, 45 submitted a completed assessment tool. Two of the 45 programs did not meet minimum inclusion criteria and were excluded; thus, the final analysis included information from 43 programs. Average scores for four of the five completeness performance measures were above level 2. Conversely, the average scores for both timeliness measures and three of the four accuracy measures were below level 2. Surveillance programs using an active case-finding approach scored higher than programs using passive case-finding approaches for the completeness and accuracy measures, whereas their average scores were lower for timeliness measures. Conclusions: This initial, nation-wide assessment of data quality across U.S. population-based birth defects surveillance programs highlights areas for improvement. Using this information to identify strengths and weaknesses, the birth defects surveillance community, working through the NBDPN, can enhance and implement a consistent set of standards that can promote uniformity and enable surveillance programs to work towards improving the potential of these programs. C1 [Anderka, Marlene] Massachusetts Dept Publ Hlth, Boston, MA 02108 USA. [Mai, Cara T.; Isenburg, Jennifer; Olney, Richard S.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. [Romitti, Paul A.] Univ Iowa, Coll Publ Hlth, Dept Epidemiol, Iowa City, IA USA. [Copeland, Glenn] Michigan Dept Community Hlth, Lansing, MI USA. [Isenburg, Jennifer] Carter Consulting, Atlanta, GA USA. [Feldkamp, Marcia L.; Krikov, Sergey] Univ Utah, Sch Med, Dept Pediat, Div Med Genet, Salt Lake City, UT USA. [Rickard, Russel] Natl Birth Defects Prevent Network, Houston, TX USA. [Canfield, Mark A.] Texas Dept State Hlth Serv, Birth Defects Epidemiol & Surveillance Branch, Austin, TX USA. [Stanton, Carol] Colorado Dept Publ Hlth & Environm, Denver, CO USA. [Mosley, Bridget] Univ Arkansas Med Sci, Arkansas Childrens Hosp, Coll Med, Res Inst, Little Rock, AR 72205 USA. [Kirby, Russell S.] Univ S Florida, Coll Publ Hlth, Dept Community & Family Hlth, Tampa, FL USA. RP Anderka, M (reprint author), Massachusetts Dept Publ Hlth, 250 Washington St 5th floor, Boston, MA 02108 USA. EM manderka@live.com NR 12 TC 4 Z9 4 U1 0 U2 3 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2458 J9 BMC PUBLIC HEALTH JI BMC Public Health PD SEP 19 PY 2015 VL 15 AR 925 DI 10.1186/s12889-015-2223-2 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CR6GL UT WOS:000361442800006 PM 26386816 ER PT J AU Black, CL Yue, X Ball, SW Donahue, SMA Izrael, D de Perio, MA Laney, AS Williams, WW Lindley, MC Graitcer, SB Lu, PJ Bridges, CB DiSogra, C Sokolowski, J Walker, DK Greby, SM AF Black, Carla L. Yue, Xin Ball, Sarah W. Donahue, Sara M. A. Izrael, David de Perio, Marie A. Laney, A. Scott Williams, Walter W. Lindley, Megan C. Graitcer, Samuel B. Lu, Peng-jun Bridges, Carolyn B. DiSogra, Charles Sokolowski, John Walker, Deborah K. Greby, Stacie M. TI Influenza Vaccination Coverage Among Health Care Personnel - United States, 2014-15 Influenza Season SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID RANDOMIZED CONTROLLED-TRIAL; HOME STAFF; WORKERS; RESIDENTS; MORTALITY C1 [Black, Carla L.; Yue, Xin; Williams, Walter W.; Lindley, Megan C.; Graitcer, Samuel B.; Lu, Peng-jun; Bridges, Carolyn B.; Greby, Stacie M.] CDC, Immunizat Serv Div, Natl Ctr Immunizat & Resp Dis, Cambridge, MA 02141 USA. [Ball, Sarah W.; Donahue, Sara M. A.; Izrael, David; Walker, Deborah K.] ABT Associates Inc, Cambridge, MA 02138 USA. [de Perio, Marie A.] CDC, Div Surveillance Hazard Evaluat & Field Studies, Natl Inst Occupat Safety & Hlth, New York, NY USA. [Laney, A. Scott] CDC, Div Resp Dis Studies, Natl Inst Occupat Safety & Hlth, New York, NY USA. [DiSogra, Charles; Sokolowski, John] Abt SRBI, New York, NY USA. RP Black, CL (reprint author), CDC, Immunizat Serv Div, Natl Ctr Immunizat & Resp Dis, Cambridge, MA 02141 USA. EM cblack2@cdc.gov NR 10 TC 11 Z9 11 U1 1 U2 3 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD SEP 18 PY 2015 VL 64 IS 36 BP 993 EP 999 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CS5DB UT WOS:000362095400001 PM 26389743 ER PT J AU Ding, HL Black, CL Ball, S Donahue, S Fink, RV Williams, WW Kennedy, ED Bridges, CB Lu, PJ Kahn, KE Dean, AK Grohskopf, LA Ahluwalia, IB Devlin, R DiSogra, C Walker, DK Greby, SM AF Ding, Helen Black, Carla L. Ball, Sarah Donahue, Sara Fink, Rebecca V. Williams, Walter W. Kennedy, Erin D. Bridges, Carolyn B. Lu, Peng-Jun Kahn, Katherine E. Dean, Anna K. Grohskopf, Lisa A. Ahluwalia, Indu B. Devlin, Rebecca DiSogra, Charles Walker, Deborah K. Greby, Stacie M. TI Influenza Vaccination Coverage Among Pregnant Women - United States, 2014-15 Influenza Season SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Ding, Helen] LLC, Eagle Med Serv, San Antonio, TX 78248 USA. [Black, Carla L.; Williams, Walter W.; Kennedy, Erin D.; Bridges, Carolyn B.; Lu, Peng-Jun; Dean, Anna K.; Greby, Stacie M.] CDC, Immunizat Serv Div, Natl Ctr Immunizat & Resp Dis, Cambridge, MA USA. [Ball, Sarah; Donahue, Sara; Fink, Rebecca V.; Walker, Deborah K.] ABT Associates Inc, Cambridge, MA 02138 USA. [Kahn, Katherine E.] Leidos, Atlanta, GA USA. [Dean, Anna K.] CDC, Oak Ridge Inst Sci & Educ, New York, NY USA. [Grohskopf, Lisa A.] CDC, Influenza Div, Natl Ctr Immunizat & Resp Dis, New York, NY USA. [Ahluwalia, Indu B.] CDC, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, New York, NY USA. [Devlin, Rebecca; DiSogra, Charles] Abt SRBI, New York, NY USA. RP Ding, HL (reprint author), LLC, Eagle Med Serv, San Antonio, TX 78248 USA. EM hding@cdc.gov NR 9 TC 11 Z9 11 U1 1 U2 3 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD SEP 18 PY 2015 VL 64 IS 36 BP 1000 EP 1005 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CS5DB UT WOS:000362095400002 PM 26390253 ER PT J AU Goodman, AB Meites, E Anstey, EH Fullerton, KE Jayatilleke, A Ruben, W Koumans, E Oster, AM Karwowski, MP Dziuban, E Kirkcaldy, RD Glover, M Lowe, L Peacock, G Mahon, B Griese, SE AF Goodman, Alyson B. Meites, Elissa Anstey, Erica H. Fullerton, Kathleen E. Jayatilleke, Achala Ruben, Wendy Koumans, Emily Oster, Alexandra M. Karwowski, Mateusz P. Dziuban, Eric Kirkcaldy, Robert D. Glover, Maleeka Lowe, Luis Peacock, Georgina Mahon, Barbara Griese, Stephanie E. TI Clinical Inquiries Received by CDC Regarding Suspected Ebola Virus Disease in Children - United States, July 9, 2014-January 4, 2015 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Goodman, Alyson B.; Meites, Elissa; Anstey, Erica H.; Fullerton, Kathleen E.; Jayatilleke, Achala; Ruben, Wendy; Koumans, Emily; Oster, Alexandra M.; Karwowski, Mateusz P.; Dziuban, Eric; Kirkcaldy, Robert D.; Glover, Maleeka; Lowe, Luis; Peacock, Georgina; Mahon, Barbara; Griese, Stephanie E.] CDC, Ebola Response 2014 2015, Atlanta, GA 30333 USA. [Goodman, Alyson B.; Ruben, Wendy; Peacock, Georgina] CDC, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. [Meites, Elissa; Oster, Alexandra M.; Kirkcaldy, Robert D.] CDC, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. [Anstey, Erica H.] CDC, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. [Fullerton, Kathleen E.; Jayatilleke, Achala] CDC, Ctr Surveillance Epidemiol & Lab Serv, Atlanta, GA 30333 USA. [Koumans, Emily; Dziuban, Eric] CDC, Ctr Global Hlth, Atlanta, GA 30333 USA. [Karwowski, Mateusz P.] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Karwowski, Mateusz P.] CDC, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA. [Glover, Maleeka] CDC, Off Infect Dis, Atlanta, GA 30333 USA. [Lowe, Luis; Mahon, Barbara] CDC, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Griese, Stephanie E.] CDC, Off Publ Hlth Preparedness & Response, Atlanta, GA 30333 USA. RP Goodman, AB (reprint author), CDC, Ebola Response 2014 2015, Atlanta, GA 30333 USA. EM iym3@cdc.gov OI Meites, Elissa/0000-0002-0077-2591 NR 9 TC 2 Z9 2 U1 0 U2 3 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD SEP 18 PY 2015 VL 64 IS 36 BP 1006 EP 1010 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CS5DB UT WOS:000362095400003 PM 26390343 ER PT J AU Blanton, L Kniss, K Smith, S Mustaquim, D Steffens, C Flannery, B Fry, AM Bresee, J Wallis, T Garten, R Xu, XY Abd Elal, AI Gubareva, L Wentworth, DE Burns, E Katz, J Jernigan, D Brammer, L AF Blanton, Lenee Kniss, Krista Smith, Sophie Mustaquim, Desiree Steffens, Craig Flannery, Brendan Fry, Alicia M. Bresee, Joseph Wallis, Teresa Garten, Rebecca Xu, Xiyan Abd Elal, Anwar Isa Gubareva, Larisa Wentworth, David E. Burns, Erin Katz, Jacqueline Jernigan, Daniel Brammer, Lynnette TI Update: Influenza Activity - United States and Worldwide, May 24-September 5, 2015 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID IMMUNIZATION PRACTICES; ADVISORY-COMMITTEE; HOSPITALIZATIONS; RECOMMENDATIONS; VACCINATION; SEASON C1 [Blanton, Lenee; Kniss, Krista; Smith, Sophie; Mustaquim, Desiree; Steffens, Craig; Flannery, Brendan; Fry, Alicia M.; Bresee, Joseph; Wallis, Teresa; Garten, Rebecca; Xu, Xiyan; Abd Elal, Anwar Isa; Gubareva, Larisa; Wentworth, David E.; Burns, Erin; Katz, Jacqueline; Jernigan, Daniel; Brammer, Lynnette] CDC, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP Blanton, L (reprint author), CDC, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. EM lblanton@cdc.gov OI Wentworth, David/0000-0002-5190-980X NR 8 TC 1 Z9 1 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD SEP 18 PY 2015 VL 64 IS 36 BP 1011 EP 1016 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CS5DB UT WOS:000362095400004 PM 26390411 ER PT J AU Das, S Rundell, MS Mirza, AH Pingle, MR Shigyo, K Garrison, AR Paragas, J Smith, SK Olson, VA Larone, DH Spitzer, ED Barany, F Golightly, LM AF Das, Sanchita Rundell, Mark S. Mirza, Aashiq H. Pingle, Maneesh R. Shigyo, Kristi Garrison, Aura R. Paragas, Jason Smith, Scott K. Olson, Victoria A. Larone, Davise H. Spitzer, Eric D. Barany, Francis Golightly, Linnie M. TI A Multiplex PCR/LDR Assay for the Simultaneous Identification of Category A Infectious Pathogens: Agents of Viral Hemorrhagic Fever and Variola Virus SO PLOS ONE LA English DT Article ID LIGASE DETECTION REACTION; REVERSE-TRANSCRIPTASE PCR; POLYMERASE-CHAIN-REACTION; EBOLA-VIRUS; BIOTERRORISM AGENTS; SMALLPOX-VIRUS; DIAGNOSIS; DISEASE; DNA; OUTBREAK AB CDC designated category A infectious agents pose a major risk to national security and require special action for public health preparedness. They include viruses that cause viral hemorrhagic fever (VHF) syndrome as well as variola virus, the agent of smallpox. VHF is characterized by hemorrhage and fever with multi-organ failure leading to high morbidity and mortality. Smallpox, a prior scourge, has been eradicated for decades, making it a particularly serious threat if released nefariously in the essentially non-immune world population. Early detection of the causative agents, and the ability to distinguish them from other pathogens, is essential to contain outbreaks, implement proper control measures, and prevent morbidity and mortality. We have developed a multiplex detection assay that uses several species-specific PCR primers to generate amplicons from multiple pathogens; these are then targeted in a ligase detection reaction (LDR). The resultant fluorescently-labeled ligation products are detected on a universal array enabling simultaneous identification of the pathogens. The assay was evaluated on 32 different isolates associated with VHF (ebolavirus, marburgvirus, Crimean Congo hemorrhagic fever virus, Lassa fever virus, Rift Valley fever virus, Dengue virus, and Yellow fever virus) as well as variola virus and vaccinia virus (the agent of smallpox and its vaccine strain, respectively). The assay was able to detect all viruses tested, including 8 sequences representative of different variola virus strains from the CDC repository. It does not cross react with other emerging zoonoses such as monkeypox virus or cowpox virus, or six flaviviruses tested (St. Louis encephalitis virus, Murray Valley encephalitis virus, Powassan virus, Tick-borne encephalitis virus, West Nile virus and Japanese encephalitis virus). C1 [Das, Sanchita; Shigyo, Kristi; Golightly, Linnie M.] Cornell Univ, Dept Med, Div Infect Dis, Weill Med Coll, New York, NY 10021 USA. [Rundell, Mark S.; Mirza, Aashiq H.; Pingle, Maneesh R.; Larone, Davise H.; Barany, Francis; Golightly, Linnie M.] Cornell Univ, Dept Microbiol & Immunol, Weill Med Coll, New York, NY 10021 USA. [Garrison, Aura R.] US Army Med Res Inst Infect Dis, Frederick, MD USA. [Paragas, Jason] NIAID, Integrated Res Facil, Div Clin Res, NIH, Ft Detrick, MD USA. [Smith, Scott K.; Olson, Victoria A.] Ctr Dis Control & Prevent, Poxvirus Team, Poxvirus & Rabies Branch,Natl Ctr Emerging Zoonot, Div High Consequence Pathogens & Pathol, Atlanta, GA USA. [Larone, Davise H.] Cornell Univ, Weill Med Coll, Dept Pathol & Lab Med, New York, NY 10021 USA. [Spitzer, Eric D.] SUNY Stony Brook, Dept Pathol, Med Ctr, Stony Brook, NY 11794 USA. RP Golightly, LM (reprint author), Cornell Univ, Dept Med, Div Infect Dis, Weill Med Coll, New York, NY 10021 USA. EM lgolight@med.cornell.edu FU National Institute of Allergy and Infectious Diseases of the National Institute of Health [UC1-AI062579] FX This work was supported by contract UC1-AI062579 awarded to FB by the National Institute of Allergy and Infectious Diseases of the National Institute of Health (http://www.niaid.nih.gov/Pages/default.aspx). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. At no time during the study did they receive salary support, other funds, or research materials from Beckman Coulter or Coferon Inc. to support the study, nor do either of these entities have any commercial rights or interest in developing a product from the current study. NR 57 TC 2 Z9 3 U1 1 U2 13 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD SEP 18 PY 2015 VL 10 IS 9 AR e0138484 DI 10.1371/journal.pone.0138484 PG 16 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CS0ZE UT WOS:000361790200113 PM 26381398 ER PT J AU Katzelnick, LC Fonville, JM Gromowski, GD Arriaga, JB Green, A James, SL Lau, L Montoya, M Wang, CL VanBlargan, LA Russell, CA Thu, HM Pierson, TC Buchy, P Aaskov, JG Munoz-Jordan, JL Vasilakis, N Gibbons, RV Tesh, RB Osterhaus, ADME Fouchier, RAM Durbin, A Simmons, CP Holmes, EC Harris, E Whitehead, SS Smith, DJ AF Katzelnick, Leah C. Fonville, Judith M. Gromowski, Gregory D. Arriaga, Jose Bustos Green, Angela James, Sarah L. Lau, Louis Montoya, Magelda Wang, Chunling VanBlargan, Laura A. Russell, Colin A. Thu, Hlaing Myat Pierson, Theodore C. Buchy, Philippe Aaskov, John G. Munoz-Jordan, Jorge L. Vasilakis, Nikos Gibbons, Robert V. Tesh, Robert B. Osterhaus, Albert D. M. E. Fouchier, Ron A. M. Durbin, Anna Simmons, Cameron P. Holmes, Edward C. Harris, Eva Whitehead, Stephen S. Smith, Derek J. TI Dengue viruses cluster antigenically but not as discrete serotypes SO SCIENCE LA English DT Article ID REDUCTION NEUTRALIZATION TEST; HEMORRHAGIC-FEVER; INFLUENZA-VIRUS; ANTIBODY-LEVELS; INFECTION; EVOLUTION; THAILAND; VACCINE; IDENTIFICATION; FLAVIVIRUSES AB The four genetically divergent dengue virus (DENV) types are traditionally classified as serotypes. Antigenic and genetic differences among the DENV types influence disease outcome, vaccine-induced protection, epidemic magnitude, and viral evolution. We characterized antigenic diversity in the DENV types by antigenic maps constructed from neutralizing antibody titers obtained from African green monkeys and after human vaccination and natural infections. Genetically, geographically, and temporally, diverse DENV isolates clustered loosely by type, but we found that many are as similar antigenically to a virus of a different type as to some viruses of the same type. Primary infection antisera did not neutralize all viruses of the same DENV type any better than other types did up to 2 years after infection and did not show improved neutralization to homologous type isolates. That the canonical DENV types are not antigenically homogeneous has implications for vaccination and research on the dynamics of immunity, disease, and the evolution of DENV. C1 [Katzelnick, Leah C.; Fonville, Judith M.; James, Sarah L.; Smith, Derek J.] Univ Cambridge, Dept Zool, Ctr Pathogen Evolut, Cambridge CB2 3EJ, England. [Katzelnick, Leah C.; Fonville, Judith M.; James, Sarah L.; Smith, Derek J.] World Hlth Org WHO Collaborating Ctr Modeling Evo, Cambridge CB2 3EJ, England. [Katzelnick, Leah C.; Gromowski, Gregory D.; Arriaga, Jose Bustos; VanBlargan, Laura A.; Pierson, Theodore C.; Whitehead, Stephen S.] NIAID, NIH, Bethesda, MD 20892 USA. [Katzelnick, Leah C.; Green, Angela; Lau, Louis; Montoya, Magelda; Wang, Chunling; Harris, Eva] Univ Calif Berkeley, Sch Publ Hlth, Div Infect Dis & Vaccinol, Berkeley, CA 94720 USA. [Fonville, Judith M.; Osterhaus, Albert D. M. E.; Fouchier, Ron A. M.; Smith, Derek J.] Erasmus MC, Dept Virosci, NL-3015 GE Rotterdam, Netherlands. [Russell, Colin A.] Univ Cambridge, Dept Vet Med, Cambridge CB3 0ES, England. [Thu, Hlaing Myat] Dept Med Res, Yangon, Myanmar. [Buchy, Philippe] Reseau Int Inst Pasteur, Inst Pasteur Cambodia, Phnom Penh 12201, Cambodia. [Aaskov, John G.] Queensland Univ Technol, Inst Hlth & Biomed Innovat, Brisbane, Qld 4001, Australia. [Aaskov, John G.] Australian Army Malaria Inst, Brisbane, Qld 4051, Australia. [Munoz-Jordan, Jorge L.] Ctr Dis Control & Prevent, Dengue Branch, Div Vector Borne Dis, San Juan, PR 00971 USA. [Vasilakis, Nikos; Tesh, Robert B.] Univ Texas Med Branch, Dept Pathol, Galveston, TX 77555 USA. [Vasilakis, Nikos; Tesh, Robert B.] Univ Texas Med Branch, Ctr Biodef & Emerging Infect Dis, Galveston, TX 77555 USA. [Vasilakis, Nikos; Tesh, Robert B.] Univ Texas Med Branch, Ctr Trop Dis, Galveston, TX 77555 USA. [Vasilakis, Nikos; Tesh, Robert B.] Univ Texas Med Branch, Inst Human Infect & Immun, Galveston, TX 77555 USA. [Gibbons, Robert V.] Armed Forces Res Inst Med Sci, Dept Virol, Bangkok 10400, Thailand. [Durbin, Anna] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Ctr Immunizat Res, Baltimore, MD 21205 USA. [Simmons, Cameron P.] Univ Oxford, Clin Res Unit, Wellcome Trust Major Overseas Programme, Ho Chi Minh City, Vietnam. [Simmons, Cameron P.] Univ Oxford, Nuffield Dept Clin Med, Ctr Trop Med, Oxford OX3 7LJ, England. [Simmons, Cameron P.] Univ Melbourne, Dept Microbiol & Immunol, Parkville, Vic 3010, Australia. [Holmes, Edward C.] Univ Sydney, Sch Biol Sci, Charles Perkins Ctr, Marie Bashir Inst Infect Dis & Biosecur, Sydney, NSW 2006, Australia. [Holmes, Edward C.] Univ Sydney, Sydney Med Sch, Sydney, NSW 2006, Australia. RP Smith, DJ (reprint author), Univ Cambridge, Dept Zool, Ctr Pathogen Evolut, Downing St, Cambridge CB2 3EJ, England. EM djs200@cam.ac.uk RI Fouchier, Ron/A-1911-2014; OI Fouchier, Ron/0000-0001-8095-2869; Simmons, Cameron P./0000-0002-9039-7392; Holmes, Edward/0000-0001-9596-3552 FU Intramural Research Program of the U.S. NIH; National Institute of Allergy and Infectious Diseases (NIAID); European Union (EU) [223498, 278976]; Human Frontier Science Program (HFSP) program grant [P0050/2008]; NIH Director's Pioneer Award [DP1-OD000490-01]; FIRST program from the Bill and Melinda Gates Foundation; Instituto Carlos Slim de la Salud; NIAID-NIH Centers of Excellence for Influenza Research and Surveillance [HHSN266200700010C, HHSN272201400008C]; Gates Cambridge Scholarship; NIH Oxford Cambridge Scholars Program; Medical Research Council Fellowship [MR/K021885/1]; Junior Research Fellowship from Homerton College Cambridge; National Health and Medical Research Council Australia Fellowship; NIH [HHSN272201000040I/HHSN27200004/D04]; GSK Pharma; GSK Vaccines; Merck FX We express our gratitude to the members of the Dengue Antigenic Cartography Consortium, named in the supplementary materials, for their advice and contributions to the Consortium to date. We thank D. Burke, N. Lewis, E. Selkov, E. Skepner, A. Mosterin, R. Mogling, S. Wilks, T. Kotarba, and V. Duong for their technical expertise. M. Melendrez, J. Hang, R. Jarman, S. M. Cave, S. G. Widen, T. G. Wood, and V. Duong assisted with virus sequencing. C. Firestone and M. Galvez assisted with neutralization assay titrations. This research was supported in part by the Intramural Research Program of the U.S. NIH, National Institute of Allergy and Infectious Diseases (NIAID), European Union (EU) FP7 programs EMPERIE (223498) and ANTIGONE (278976), Human Frontier Science Program (HFSP) program grant P0050/2008, the NIH Director's Pioneer Award DP1-OD000490-01, the FIRST program from the Bill and Melinda Gates Foundation, and the Instituto Carlos Slim de la Salud (E.H.). The antigenic cartography toolkit was in part supported by NIAID-NIH Centers of Excellence for Influenza Research and Surveillance contracts HHSN266200700010C and HHSN272201400008C for use on influenza virus. L.C.K. was supported by the Gates Cambridge Scholarship and the NIH Oxford Cambridge Scholars Program. J.M.F. was supported by a Medical Research Council Fellowship (MR/K021885/1) and a Junior Research Fellowship from Homerton College Cambridge. E.C.H. was supported by an National Health and Medical Research Council Australia Fellowship. N.V. and R.B.T were supported by NIH contract HHSN272201000040I/HHSN27200004/D04. The viruses and sera used in this study are covered by standard material transfer agreements at the home institutions of S.S.W., C.P.S., E.H., P.B., J.G.A., J.L.M.J., N.V., and R.B.T. A.D.M.E.O. is a professor and director of Artemis One Health Utrecht, The Netherlands; Chief Scientific Officer Viroclinics Biosciences BV, the Netherlands; and a Board Member of Protein Sciences USA. P.B. performed this work while at the Institut Pasteur in Cambodia, but since June 2015, is with GlaxoSmithKline vaccines in Singapore, and has stock options with GSK. C.P.S. is a paid consultant to GSK Pharma, GSK Vaccines, and Merck and has received a grant and consulting payments to his institution from Sanofi Pasteur. The sequences used in this study are available from GenBank (http://www.ncbi.nlm.nih.gov/genbank/) and are listed in table S1. Files used for genetic analyses are available as supplementary data files. The NIH monovalent DENV vaccines trials (ClinicalTrials.gov identifiers: NCT00473135 NCT00920517, NCT00831012, NCT00831012) were performed under an investigational new drug application reviewed by the U.S. Food and Drug Administration and approved by the Institutional Review Board at the University of Vermont and Johns Hopkins University. Informed consent was obtained in accordance federal and international regulations (21CFR50, ICHE6). The Pediatric Dengue Cohort Study in Managua, Nicaragua, was approved by the Institutional Review Boards of the Nicaraguan Ministry of Health and the University of California, Berkeley. Parents or legal guardians of all subjects provided written informed consent, and subjects 6 years of age and older provided assent. NR 41 TC 18 Z9 18 U1 4 U2 22 PU AMER ASSOC ADVANCEMENT SCIENCE PI WASHINGTON PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA SN 0036-8075 EI 1095-9203 J9 SCIENCE JI Science PD SEP 18 PY 2015 VL 349 IS 6254 BP 1338 EP 1343 DI 10.1126/science.aac5017 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CR5CR UT WOS:000361357700049 PM 26383952 ER PT J AU McMorrow, ML Emukule, GO Njuguna, HN Bigogo, G Montgomeryz, JM Nyawanda, B Audi, A Breiman, RF Katz, MA Cosmas, L Waiboci, LW Duque, J Widdowson, MA Mott, JA AF McMorrow, Meredith L. Emukule, Gideon O. Njuguna, Henry N. Bigogo, Godfrey Montgomeryz, Joel M. Nyawanda, Bryan Audi, Allan Breiman, Robert F. Katz, Mark A. Cosmas, Leonard Waiboci, Lilian W. Duque, Jazmin Widdowson, Marc-Alain Mott, Joshua A. TI The Unrecognized Burden of Influenza in Young Kenyan Children, 2008-2012 SO PLOS ONE LA English DT Article ID LABORATORY-CONFIRMED INFLUENZA; WESTERN KENYA; RESPIRATORY-INFECTIONS; HOSPITALIZED CHILDREN; SEASONAL INFLUENZA; EPIDEMIOLOGY; AFRICA; SURVEILLANCE; PNEUMONIA; ETIOLOGY AB Influenza-associated disease burden among children in tropical sub-Saharan Africa is not well established, particularly outside of the 2009 pandemic period. We estimated the burden of influenza in children aged 0-4 years through population-based surveillance for influenza-like illness (ILI) and acute lower respiratory tract illness (ALRI). Household members meeting ILI or ALRI case definitions were referred to health facilities for evaluation and collection of nasopharyngeal and oropharyngeal swabs for influenza testing by real-time reverse transcription polymerase chain reaction. Estimates were adjusted for health-seeking behavior and those with ILI and ALRI who were not tested. During 2008-2012, there were 9,652 person-years of surveillance among children aged 0-4 years. The average adjusted rate of influenza-associated hospitalization was 4.3 (95% Cl 3.0-6.0) per 1,000 person-years in children aged 0-4 years. Hospitalization rates were highest in the 0-5 month and 6-23 month age groups, at 7.6 (95% Cl 3.2-18.2) and 8.4 (95% Cl 5.4-13.0) per 1,000 personyears, respectively. The average adjusted rate of influenza-associated medically attended (inpatient or outpatient) ALRI in children aged 0-4 years was 17.4 (95% Cl 14.2-19.7) per 1,000 person-years. Few children who had severe laboratory-confirmed influenza were clinically diagnosed with influenza by the treating clinician in the inpatient (0/33, 0%) or outpatient (1/109, 0.9%) settings. Influenza-associated hospitalization rates from 2008-2012 were 5-10 times higher than contemporaneous U.S. estimates. Many children with danger signs were not hospitalized; thus, influenza-associated severe disease rates in Kenyan children are likely higher than hospital-based estimates suggest. C1 [McMorrow, Meredith L.; Widdowson, Marc-Alain; Mott, Joshua A.] Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [McMorrow, Meredith L.; Montgomeryz, Joel M.; Mott, Joshua A.] US PHS, Rockville, MD USA. [Emukule, Gideon O.; Njuguna, Henry N.; Montgomeryz, Joel M.; Breiman, Robert F.; Katz, Mark A.; Cosmas, Leonard; Waiboci, Lilian W.; Mott, Joshua A.] Kenya Country Off, Ctr Dis Control & Prevent, Nairobi, Kenya. [Bigogo, Godfrey; Nyawanda, Bryan; Audi, Allan] Kenya Med Res Inst KEMRI, Nairobi, Kenya. [Bigogo, Godfrey; Nyawanda, Bryan; Audi, Allan] Kenya Med Res Inst KEMRI, Kisumu, Kenya. [Montgomeryz, Joel M.] Ctr Dis Control & Prevent, Div Global Hlth Protect, Ctr Global Hlth, Atlanta, GA USA. [Breiman, Robert F.] Emory Univ, Emory Global Hlth Inst, Atlanta, GA 30322 USA. [Duque, Jazmin] Battelle Mem Inst, Atlanta, GA USA. RP McMorrow, ML (reprint author), Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. EM mmcmorrow@cdc.gov OI Duque, Jazmin/0000-0003-3484-276X FU Centers for Disease Control and Prevention (CDC) Cooperative Agreement; Kenya Medical Research Institute (KEMRI) [1U01 GH000048] FX The work was supported by Centers for Disease Control and Prevention (CDC) Cooperative Agreement with Kenya Medical Research Institute (KEMRI) 1U01 GH000048. NR 45 TC 0 Z9 0 U1 0 U2 1 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD SEP 17 PY 2015 VL 10 IS 9 AR e0138272 DI 10.1371/journal.pone.0138272 PG 14 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CS0RH UT WOS:000361769400079 PM 26379030 ER PT J AU Tebbens, RJD Pallansch, MA Thompson, KM AF Tebbens, Radboud J. Duintjer Pallansch, Mark A. Thompson, Kimberly M. TI Modeling the prevalence of immunodeficiency-associated long-term vaccine-derived poliovirus excretors and the potential benefits of antiviral drugs SO BMC INFECTIOUS DISEASES LA English DT Article ID COMMON VARIABLE IMMUNODEFICIENCY; IMMUNE-DEFICIENCY DISORDERS; UNITED-STATES; PARALYTIC POLIOMYELITIS; VIRUS EXCRETION; ERADICATION; PATIENT; INFECTION; DISEASES; POLICY AB Background: A small number of individuals with B-cell-related primary immunodeficiency diseases (PIDs) may exhibit long-term (prolonged or chronic) excretion of immunodeficiency-associated vaccine-derived polioviruses (iVDPVs) following infection with oral poliovirus vaccine (OPV). These individuals pose a risk of live poliovirus reintroduction into the population after global wild poliovirus eradication and subsequent OPV cessation. Treatment with polio antiviral drugs may potentially stop excretion in some of these individuals and thus may reduce the future population risk. Methods: We developed a discrete event simulation model to characterize the global prevalence of long-term iVDPV excretors based on the best available evidence. We explored the impact of different assumptions about the effectiveness of polio antiviral drugs and the fraction of long-term excretors identified and treated. Results: Due to the rarity of long-term iVDPV excretion and limited data on the survival of PID patients in developing countries, uncertainty remains about the current and future prevalence of long-term iVDPV excretors. While the model suggests only approximately 30 current excretors globally and a rapid decrease after OPV cessation, most of these excrete asymptomatically and remain undetected. The possibility that one or more PID patients may continue to excrete iVDPVs for several years after OPV cessation represents a risk for reintroduction of live polioviruses after OPV cessation, particularly for middle-income countries. With the effectiveness of a single polio antiviral drug possibly as low as 40 % and no system in place to identify and treat asymptomatic excretors, the impact of passive use of a single polio antiviral drug to treat identified excretors appears limited. Higher drug effectiveness and active efforts to identify long-term excretors will dramatically increase the benefits of polio antiviral drugs. Conclusions: Efforts to develop a second polio antiviral compound to increase polio antiviral effectiveness and/or to maximize the identification and treatment of affected individuals represent important risk management opportunities for the polio endgame. Better data on the survival of PID patients in developing countries and more longitudinal data on their exposure to and recovery from OPV infections would improve our understanding of the risks associated with iVDPV excretors and the benefits of further investments in polio antiviral drugs. C1 [Tebbens, Radboud J. Duintjer; Thompson, Kimberly M.] Kid Risk Inc, Orlando, FL 32832 USA. [Pallansch, Mark A.] Ctr Dis Control & Prevent, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. RP Tebbens, RJD (reprint author), Kid Risk Inc, 10524 Moss Pk Rd,Ste 204-364, Orlando, FL 32832 USA. EM rdt@kidrisk.org FU US Centers for Disease Control and Prevention [U66IP000519] FX RJDT and KMT acknowledge support for this work from the US Centers for Disease Control and Prevention under Contract U66IP000519. The authors thank Drs. Stephen Cochi and Steven Wassilak for helpful discussions. The contents of this article are solely the responsibility of the authors and do not represent the official views of the US Centers for Disease Control and Prevention. NR 66 TC 7 Z9 7 U1 1 U2 7 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2334 J9 BMC INFECT DIS JI BMC Infect. Dis. PD SEP 17 PY 2015 VL 15 AR 379 DI 10.1186/s12879-015-1115-5 PG 18 WC Infectious Diseases SC Infectious Diseases GA CR5BU UT WOS:000361355100006 ER PT J AU Gray, AM Arguin, PM Hamed, K AF Gray, Alyson M. Arguin, Paul M. Hamed, Kamal TI Surveillance for the safety and effectiveness of artemether-lumefantrine in patients with uncomplicated Plasmodium falciparum malaria in the USA: a descriptive analysis SO MALARIA JOURNAL LA English DT Article DE Artemether-lumefantrine; Effectiveness; Malaria; Safety ID PLUS SULFADOXINE-PYRIMETHAMINE; RANDOMIZED-TRIAL; 6-DOSE REGIMEN; UGANDAN CHILDREN; AFRICAN INFANTS; EFFICACY; ARTESUNATE; ANTIMALARIAL; AMODIAQUINE; QUININE AB Background: Data from clinical studies show that artemether-lumefantrine (AL) is effective and well tolerated in adults and children with uncomplicated Plasmodium falciparum malaria. However, data on effectiveness and safety of AL in patients in non-endemic settings are limited. Methods: A 5-year surveillance plan included all AL-treated adult and paediatric patients with confirmed or suspected P. falciparum malaria in the USA, as reported to the National Malaria Surveillance System at the Centers for Disease Control and Prevention. Descriptive analyses included demographics, baseline characteristics, clinical effectiveness, and safety. From May 2010 to April 2015, demographics and baseline characteristics were collected for 203 patients and safety data for 108 patients. Treatment effectiveness data at day 7 were collected for 117 patients and at day 28 for 98 patients. Results: The majority of patients were male (58.6 %), Black (62.6 %), non-Hispanic (92.6 %), and likely malaria non-immune (80.8 %). The median age was 32 (range 1-88) years and the median body mass index was 25.5 (range 13.8-42.4) kg/m(2). All patients with effectiveness data had confirmed (n = 116) or suspected (n = 1) malaria. The overall cure rate for patients treated with AL was 91.5 % (95 % CI 84.8-95.8 %) at day 7 and 96.9 % (95 % CI 91.3-99.4 %) at day 28. Adverse events were reported in four (3.7 %) patients, and there were no new or unexpected safety signals. Conclusion: AL was effective and well tolerated in the treatment of likely non-immune patients with P. falciparum malaria. C1 [Gray, Alyson M.; Arguin, Paul M.] Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. [Hamed, Kamal] Novartis Pharmaceut, E Hanover, NJ 07936 USA. RP Hamed, K (reprint author), Novartis Pharmaceut, One Hlth Plaza, E Hanover, NJ 07936 USA. EM kamal.hamed@novartis.com OI Hamed, Kamal/0000-0003-1896-9736 FU Novartis Pharmaceuticals Corporation FX The sponsors of the project were involved in study design, data analysis, data interpretation, and writing of the report. Sonja Mali and Karen Cullen at CDC were involved in tracking all AL-treated cases that were reported in the NMSS. This surveillance effort was a five-year project made possible by a public-private partnership supported by a grant to the CDC Foundation from Novartis Pharmaceuticals Corporation. The findings and conclusions in this study are those of the authors and do not necessarily represent the official views of CDC. NR 29 TC 3 Z9 3 U1 1 U2 4 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1475-2875 J9 MALARIA J JI Malar. J. PD SEP 17 PY 2015 VL 14 AR 349 DI 10.1186/s12936-015-0881-2 PG 6 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA CR5DB UT WOS:000361358800005 PM 26377423 ER PT J AU Gomes, B Wilding, CS Weetman, D Sousa, CA Novo, MT Savage, HM Almeida, APG Pinto, J Donnelly, MJ AF Gomes, Bruno Wilding, Craig S. Weetman, David Sousa, Carla A. Novo, Maria T. Savage, Harry M. Almeida, Antonio P. G. Pinto, Joao Donnelly, Martin J. TI Limited genomic divergence between intraspecific forms of Culex pipiens under different ecological pressures SO BMC EVOLUTIONARY BIOLOGY LA English DT Article ID WEST NILE VIRUS; MOLESTUS FORSKAL DIPTERA; ANOPHELES-GAMBIAE; REPRODUCTIVE ISOLATION; POPULATION-STRUCTURE; MOLECULAR-FORMS; AFLP MARKERS; CULICIDAE; SPECIATION; INTROGRESSION AB Background: Divergent selection can be a major driver of ecological speciation. In insects of medical importance, understanding the speciation process is both of academic interest and public health importance. In the West Nile virus vector Culex pipiens, intraspecific pipiens and molestus forms vary in ecological and physiological traits. Populations of each form appear to share recent common ancestry but patterns of genetic differentiation across the genome remain unknown. Here, we undertook an AFLP genome scan on samples collected from both sympatric and allopatric populations from Europe and the USA to quantify the extent of genomic differentiation between the two forms. Results: The forms were clearly differentiated but each exhibited major population sub-structuring between continents. Divergence between pipiens and molestus forms from USA was higher than in both inter- and intra-continental comparisons with European samples. The proportion of outlier loci between pipiens and molestus (approximate to 3 %) was low but consistent in both continents, and similar to those observed between sibling species of other mosquito species which exhibit contemporary gene flow. Only two of the outlier loci were shared between inter-form comparisons made within Europe and USA. Conclusion: This study supports the molestus and pipiens status as distinct evolutionary entities with low genomic divergence. The low number of shared divergent loci between continents suggests a relatively limited number of genomic regions determining key typological traits likely to be driving incipient speciation and/or adaptation of molestus to anthropogenic habitats. C1 [Gomes, Bruno; Sousa, Carla A.; Novo, Maria T.; Almeida, Antonio P. G.; Pinto, Joao] Univ Nova Lisboa, Inst Higiene & Med Trop, Global Hlth & Trop Med, P-1349008 Lisbon, Portugal. [Gomes, Bruno; Wilding, Craig S.; Weetman, David; Donnelly, Martin J.] Univ Liverpool, Liverpool Sch Trop Med, Dept Vector Biol, Liverpool L3 5QA, Merseyside, England. [Wilding, Craig S.] Liverpool John Moores Univ, Sch Nat Sci & Psychol, Liverpool L3 3AF, Merseyside, England. [Savage, Harry M.] Ctr Dis Control & Prevent, Ft Collins, CO 80521 USA. RP Gomes, B (reprint author), Univ Nova Lisboa, Inst Higiene & Med Trop, Global Hlth & Trop Med, Rua Junqueira 100, P-1349008 Lisbon, Portugal. EM Bruno.GomesdaSilva@lstmed.ac.uk RI Pinto, Joao/C-2208-2012; Almeida, Antonio Paulo Gouvei/I-2541-2012; Sousa, Carla /G-6531-2012; Wilding, Craig/C-5500-2012; Weetman, David/M-1261-2014 OI Pinto, Joao/0000-0001-8572-7708; Almeida, Antonio Paulo Gouvei/0000-0003-0751-4488; Sousa, Carla /0000-0002-2386-7577; Wilding, Craig/0000-0001-5818-2706; Gomes, Bruno/0000-0003-3877-2359; Weetman, David/0000-0002-5820-1388 FU Fundacao para a Ciencia e a Tecnologia/, Portugal [POCI/BIA-BDE/57650/2004, PPCDT/BIA-BDE/57650/2004]; PhD fellowship of Fundacao para a Ciencia e Tecnologia/MCTES [SFRH/BD/36410/2007] FX We thank Tiago Antao for the technical support given to the data analysis. This study was funded by Fundacao para a Ciencia e a Tecnologia/, Portugal (POCI/BIA-BDE/57650/2004 and PPCDT/BIA-BDE/57650/2004). Bruno Gomes was funded by a PhD fellowship of Fundacao para a Ciencia e Tecnologia/MCTES (SFRH/BD/36410/2007). NR 55 TC 2 Z9 2 U1 3 U2 22 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2148 J9 BMC EVOL BIOL JI BMC Evol. Biol. PD SEP 16 PY 2015 VL 15 AR 197 DI 10.1186/s12862-015-0477-z PG 11 WC Evolutionary Biology; Genetics & Heredity SC Evolutionary Biology; Genetics & Heredity GA CR4BC UT WOS:000361275800007 PM 26377220 ER PT J AU Ruckart, PZ Bove, FJ Shanley, E Maslia, M AF Ruckart, Perri Zeitz Bove, Frank J. Shanley, Edwin, III Maslia, Morris TI Evaluation of contaminated drinking water and male breast cancer at Marine Corps Base Camp Lejeune, North Carolina: a case control study SO ENVIRONMENTAL HEALTH LA English DT Article DE Male breast cancer; Volatile organic compounds; Solvents; Drinking water; Military exposures ID OCCUPATIONAL-EXPOSURE; CASE-COHORT; COX MODEL; RISK; WORKERS; MORTALITY; SOLVENTS; BENZENE AB Background: Solvents contaminated drinking water supplies at Marine Corps Base Camp Lejeune during 1950s-1985. Methods: We conducted a case-control study among Marines to evaluate associations between residential exposure to contaminated drinking water at Camp Lejeune and male breast cancer risk. The study included 71 male breast cancer cases and 373 controls identified from the Department of Veteran's Affairs (VA) cancer registry whose military personnel records were available. Controls were selected from cancers not known to be associated with solvent exposure and included 270 skin cancers, 71 mesotheliomas, and 32 bone cancers. Base assignment and risk factor information came from military personnel and VA records. Groundwater contaminant fate/transport and distribution system models provided monthly estimated residential contaminant levels. We conducted exact logistic regression using the 50th percentile level among exposed controls to create low and high exposure categories. We calculated 95 % confidence intervals (CIs) to indicate precision of effect estimates. Exploratory analyses used proportional hazards methods to evaluate associations between exposures and age at diagnosis. Results: After adjusting for age at diagnosis, race, and service in Vietnam, the odds ratio (OR) for ever stationed at Camp Lejeune was 1.14 (95 % CI: 0.65, 1.97). Adjusted ORs for high residential cumulative exposures to tetrachloroethylene (PCE), t-1,2 dichloroethylene (DCE), and vinyl chloride were 1.20 [95 % CI: 0.16-5.89], 1.50 [95 % CI: 0.30-6.11], 1.19 [95 % CI: 0.16-5.89], respectively, with a monotonic exposure response relationship for PCE only. However these results were based on two or three cases in the high cumulative exposure categories. Ever stationed at Camp Lejeune and high cumulative exposures to trichloroethylene (TCE), PCE, DCE and vinyl chloride were associated with earlier age at onset for male breast cancer; hazard ratios ranged from 1.4-2.7 with wide confidence intervals for cumulative exposure variables. Conclusion: Findings suggested possible associations between male breast cancer and being stationed at Camp Lejeune and cumulative exposure to PCE, DCE, and vinyl chloride. TCE, PCE, DCE and vinyl chloride cumulative exposures showed possible associations with earlier age at onset of male breast cancer. However, this study was limited by small numbers of cases in high exposure categories. C1 [Ruckart, Perri Zeitz; Bove, Frank J.] Agcy Tox Subst & Dis Registry, Div Toxicol & Human Hlth Sci, Atlanta, GA 30341 USA. [Shanley, Edwin, III] Agcy Tox Subst & Dis Registry, Natl Ctr Environm Hlth, Off Director, Atlanta, GA 30341 USA. [Maslia, Morris] Agcy Tox Subst & Dis Registry, Div Community Hlth Invest, Atlanta, GA 30341 USA. RP Ruckart, PZ (reprint author), Agcy Tox Subst & Dis Registry, Div Toxicol & Human Hlth Sci, Atlanta, GA 30341 USA. EM pruckart@cdc.gov NR 38 TC 2 Z9 2 U1 3 U2 9 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1476-069X J9 ENVIRON HEALTH-GLOB JI Environ. Health PD SEP 16 PY 2015 VL 14 AR 74 DI 10.1186/s12940-015-0061-4 PG 16 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA CR4DT UT WOS:000361282700001 PM 26376727 ER PT J AU Chen, AC Donovan, A Ned-Sykes, R Andrews, NC AF Chen, Alan C. Donovan, Adriana Ned-Sykes, Renee Andrews, Nancy C. TI Noncanonical role of transferrin receptor 1 is essential for intestinal homeostasis SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article DE transferrin receptor; intestinal epithelium; epithelial-mesenchymal transition; homeostasis; stem cell ID EPITHELIAL-MESENCHYMAL TRANSITION; MOLECULAR-MECHANISMS; IRON-METABOLISM; BREAST-CANCER; EXPRESSION; CELLS; PHOSPHORYLATION; NOTCH; MICE; WNT AB Transferrin receptor 1 (Tfr1) facilitates cellular iron uptake through receptor-mediated endocytosis of iron-loaded transferrin. It is expressed in the intestinal epithelium but not involved in dietary iron absorption. To investigate its role, we inactivated the Tfr1 gene selectively in murine intestinal epithelial cells. The mutant mice had severe disruption of the epithelial barrier and early death. There was impaired proliferation of intestinal epithelial cell progenitors, aberrant lipid handling, increased mRNA expression of stem cell markers, and striking induction of many genes associated with epithelial-to-mesenchymal transition. Administration of parenteral iron did not improve the phenotype. Surprisingly, however, enforced expression of a mutant allele of Tfr1 that is unable to serve as a receptor for iron-loaded transferrin appeared to fully rescue most animals. Our results implicate Tfr1 in homeostatic maintenance of the intestinal epithelium, acting through a role that is independent of its iron-uptake function. C1 [Chen, Alan C.; Andrews, Nancy C.] Duke Univ, Sch Med, Dept Pharmacol & Canc Biol, Durham, NC 27705 USA. [Donovan, Adriana] Scholar Rock, Div Pharmacol & Preclin Biol, Cambridge, MA 02142 USA. [Ned-Sykes, Renee] Ctr Dis Control & Prevent, Div Lab Syst, Ctr Surveillance Epidemiol & Lab Serv, Atlanta, GA 30333 USA. [Andrews, Nancy C.] Duke Univ, Sch Med, Dept Pediat, Durham, NC 27705 USA. RP Andrews, NC (reprint author), Duke Univ, Sch Med, Dept Pharmacol & Canc Biol, Durham, NC 27705 USA. EM nancy.andrews@duke.edu FU Roche Foundation for Anemia Research; National Institutes of Health [R01 DK089705] FX We thank the Duke Microarray Shared Resource for performing microarray experiments and statistical analysis; Zhengzheng Wei for developing heat maps; and the N.C.A. laboratory for helpful discussions. This work was supported by the Roche Foundation for Anemia Research and National Institutes of Health Grant R01 DK089705 (to N.C.A.). NR 42 TC 11 Z9 11 U1 1 U2 5 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD SEP 15 PY 2015 VL 112 IS 37 BP 11714 EP 11719 DI 10.1073/pnas.1511701112 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CR5OW UT WOS:000361393700073 PM 26324903 ER PT J AU Wilmot, KA O'Flaherty, M Capewell, S Ford, ES Vaccarino, V AF Wilmot, Kobina A. O'Flaherty, Martin Capewell, Simon Ford, Earl S. Vaccarino, Viola TI Coronary Heart Disease Mortality Declines in the United States From 1979 Through 2011 Evidence for Stagnation in Young Adults, Especially Women SO CIRCULATION LA English DT Article DE coronary disease; epidemiology; mortality; sex ID ACUTE MYOCARDIAL-INFARCTION; DEATH CERTIFICATE DIAGNOSIS; PANEL III GUIDELINES; SEX-SPECIFIC TRENDS; ELDERLY-PATIENTS; CARDIOVASCULAR-DISEASE; ATHEROSCLEROSIS RISK; US ADULTS; RATES; AGE AB Background Coronary heart disease (CHD) mortality rates have fallen dramatically over the past 4 decades in the Western world. However, recent data from the United States and elsewhere suggest a plateauing of CHD incidence and mortality among young women. We therefore examined recent trends in CHD mortality rates in the United States according to age and sex. Methods and Results We analyzed mortality data between 1979 and 2011 for US adults 25 years of age. We calculated age-specific CHD mortality rates and compared estimated annual percentage changes during 3 approximate decades of data (1979-1989, 1990-1999, and 2000-2011). We then used Joinpoint regression modeling to assess changes in trends over time on the basis of inflection points of the mortality rates. Adults 65 years of age showed consistent mortality declines, which became even steeper after 2000 (women, -5.0%; men, -4.4%). In contrast, young men and women (<55 years of age) initially showed a clear decline in CHD mortality from 1979 until 1989 (estimated annual percentage change, -5.5% in men and -4.6% in women). However, the 2 subsequent decades saw stagnation with minimal improvement. Notably, young women demonstrated no improvements between 1990 and 1999 (estimated annual percentage change, 0.1%) and only -1% estimated annual percentage change since 2000. Joinpoint analyses provided consistent results. Conclusions The dramatic decline in CHD mortality since 1979 conceals major heterogeneities. CHD death rates in older groups are now falling steeply. However, young adults have experienced frustratingly small decreases in CHD mortality rates since 1990. The drivers of these major differences in CHD mortality trends by age and sex merit urgent study. C1 [Wilmot, Kobina A.; Vaccarino, Viola] Emory Univ, Sch Med, Dept Med, Div Cardiol, Atlanta, GA USA. [Vaccarino, Viola] Emory Univ, Sch Med, Rollins Sch Publ Hlth, Dept Epidemiol, Atlanta, GA USA. [O'Flaherty, Martin; Capewell, Simon] Univ Liverpool, Inst Psychol Hlth & Soc, Dept Publ Hlth & Policy, Liverpool L69 3BX, Merseyside, England. [Ford, Earl S.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Vaccarino, V (reprint author), Rollins Sch Publ Hlth, 1518 Clifton Rd,Room 3011, Atlanta, GA 30322 USA. EM viola.vaccarino@emory.edu OI O'Flaherty, Martin/0000-0001-8944-4131 FU [2K24 HL077506]; [R01 HL109413]; [R01HL109413-02S1] FX This work was supported by grants 2K24 HL077506, R01 HL109413, and R01HL109413-02S1. NR 50 TC 39 Z9 39 U1 6 U2 16 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD SEP 15 PY 2015 VL 132 IS 11 BP 997 EP 1002 DI 10.1161/CIRCULATIONAHA.115.015293 PG 6 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA CR4HW UT WOS:000361293800004 PM 26302759 ER PT J AU Baker, MA Kaelber, DC Bar-Shain, DS Moro, PL Zambarano, B Mazza, M Garcia, C Henry, A Platt, R Klompas, M AF Baker, Meghan A. Kaelber, David C. Bar-Shain, David S. Moro, Pedro L. Zambarano, Bob Mazza, Megan Garcia, Crystal Henry, Adam Platt, Richard Klompas, Michael TI Advanced Clinical Decision Support for Vaccine Adverse Event Detection and Reporting SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE vaccine; immunization; adverse reaction; reporting; adverse event ID IMMUNIZATION SAFETY; SYSTEM; DISEASES AB Rigorous postmarketing vaccine safety surveillance is critical to building public and professional trust in vaccines. An open-source, electronic health record-based clinical decision support system with advanced predictive algorithms can increase adverse event detection and reporting.Methods.aEuro integral ESP-VAERS monitors patients' electronic health records for new diagnoses, changes in laboratory values, and new allergies following vaccinations. When suggestive events are found, ESP-VAERS sends the patient's clinician a secure electronic message with an invitation to affirm or refute the message, add comments, and submit an automated, prepopulated electronic report to VAERS. High-probability AEs are reported automatically if the clinician does not respond. We implemented ESP-VAERS in December 2012 throughout the MetroHealth System, an integrated healthcare system in Ohio. We queried the VAERS database to determine MetroHealth's baseline reporting rates from January 2009 to March 2012 and then assessed changes in reporting rates with ESP-VAERS. Results.aEuro integral In the 8 months following implementation, 91 622 vaccinations were given. ESP-VAERS sent 1385 messages to responsible clinicians describing potential AEs. Clinicians opened 1304 (94.2%) messages, responded to 209 (15.1%), and confirmed 16 for transmission to VAERS. An additional 16 high-probability AEs were sent automatically. Reported events included seizure, pleural effusion, and lymphocytopenia. The odds of a VAERS report submission during the implementation period were 30.2 (95% confidence interval, 9.52-95.5) times greater than the odds during the comparable preimplementation period. Conclusions.aEuro integral An open-source, electronic health record-based clinical decision support system can increase AE detection and reporting rates in VAERS. C1 [Baker, Meghan A.; Mazza, Megan; Garcia, Crystal; Henry, Adam; Platt, Richard; Klompas, Michael] Harvard Univ, Sch Med, Dept Populat Med, Boston, MA USA. [Baker, Meghan A.; Mazza, Megan; Garcia, Crystal; Henry, Adam; Platt, Richard; Klompas, Michael] Harvard Pilgrim Hlth Care Inst, Boston, MA 02215 USA. [Baker, Meghan A.; Klompas, Michael] Brigham & Womens Hosp, Dept Med, Div Infect Dis, Boston, MA 02115 USA. [Kaelber, David C.; Bar-Shain, David S.] Case Western Reserve Univ, MetroHlth Syst, Ctr Clin Informat Res & Educ, Cleveland, OH 44106 USA. [Kaelber, David C.; Bar-Shain, David S.] Case Western Reserve Univ, Sch Med, Cleveland, OH 44106 USA. [Moro, Pedro L.] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Immunizat Safety Off, Atlanta, GA USA. [Zambarano, Bob] Commonwealth Informat Inc, Waltham, MA USA. RP Baker, MA (reprint author), Harvard Pilgrim Hlth Care Inst, Dept Populat Med, 133 Brookline Ave,6th Flr, Boston, MA 02215 USA. EM meghan_baker@harvardpilgrim.org FU Centers for Disease Control and Prevention's SHEPheRD Program [200-2011-42037] FX This work was supported by the Centers for Disease Control and Prevention's SHEPheRD Program (contract number 200-2011-42037). NR 17 TC 3 Z9 3 U1 0 U2 3 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD SEP 15 PY 2015 VL 61 IS 6 BP 864 EP 870 DI 10.1093/cid/civ430 PG 7 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA CR6OY UT WOS:000361468200003 PM 26060294 ER PT J AU Florescu, DF Kalil, AC Hewlett, AL Schuh, AJ Stroher, U Uyeki, TM Smith, PW AF Florescu, Diana F. Kalil, Andre C. Hewlett, Angela L. Schuh, Amy J. Stroher, Ute Uyeki, Timothy M. Smith, Philip W. TI Administration of Brincidofovir and Convalescent Plasma in a Patient With Ebola Virus Disease SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE Ebola; investigational therapies; trials ID HUMORAL IMMUNE-RESPONSE; HEMORRHAGIC-FEVER; CMX001; SUDAN; INFECTIONS; OUTBREAK; GULU AB From 2014 to May 2015, >26 000 Ebola virus disease (EVD) cases were reported from West Africa. We present a patient with EVD who received brincidofovir and convalescent plasma. The relative contributions of supportive care, investigational therapies, and patient's immune-response on survival could not be determined. Randomized trials are needed. C1 [Florescu, Diana F.; Kalil, Andre C.; Hewlett, Angela L.; Smith, Philip W.] Univ Nebraska, Med Ctr, Div Infect Dis, Omaha, NE 68182 USA. [Florescu, Diana F.] Univ Nebraska, Med Ctr, Transplant Surg Program, Omaha, NE 68182 USA. [Schuh, Amy J.; Stroher, Ute] Ctr Dis Control & Prevent, Viral Special Pathogens Branch, Div High Consequence Pathogens, Atlanta, GA USA. [Schuh, Amy J.; Stroher, Ute] Ctr Dis Control & Prevent, Pathol Natl Ctr Emerging & Zoonot, Atlanta, GA USA. [Uyeki, Timothy M.] Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. RP Florescu, DF (reprint author), Div Infect Dis, 985400 Nebraska Med Ctr, Omaha, NE 68198 USA. EM dflorescu@unmc.edu NR 21 TC 24 Z9 24 U1 0 U2 11 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD SEP 15 PY 2015 VL 61 IS 6 BP 969 EP 973 DI 10.1093/cid/civ395 PG 5 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA CR6OY UT WOS:000361468200020 PM 25991468 ER PT J AU Moro, PL Arana, J Cano, M Lewis, P Shimabukuro, TT AF Moro, Pedro L. Arana, Jorge Cano, Maria Lewis, Paige Shimabukuro, Tom T. TI Deaths Reported to the Vaccine Adverse Event Reporting System, United States, 1997-2013 SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE death; vaccines; epidemiology; surveillance; vaccine safety ID IMMUNIZATION; RISK; SAFETY; RATES; SIDS AB Background. Vaccines are among the safest medical products in use today. Hundreds of millions of vaccinations are administered in the United States each year. Serious adverse reactions are uncommon. However, temporally associated deaths can occur following vaccination. Our aim was to characterize main causes of death among reports submitted to the US Vaccine Adverse Event Reporting System (VAERS), a spontaneous vaccine safety surveillance system. Methods. We searched VAERS for US reports of death after any vaccination from 1 July 1997 through 31 December 2013. Available medical records, autopsy reports, and death certificates were reviewed to identify cause of death. Results. VAERS received 2149 death reports, most (n = 1469 [68.4%]) in children. Median age was 0.5 years (range, 0-100 years); males accounted for 1226 (57%) reports. The total annual number of death reports generally decreased during the latter part of the study period. Most common causes of death among 1244 child reports with available death certificates/autopsy reports included sudden infant death syndrome (n = 544 [44%]), asphyxia (n = 74 [6.0%]), septicemia (n = 61 [4.9%]), and pneumonia (n = 57 [4.6%]). Among 526 adult reports, most common causes of death included diseases of the circulatory (n = 247 [46.9%]) and respiratory systems (n = 77 [14.6%]), certain infections and parasitic diseases (n = 62 [11.8%]), and malignant neoplasms (n = 20 [3.8%]). For child death reports, 79.4% received > 1 vaccine on the same day. Inactivated influenza vaccine given alone was most commonly associated with death reports in adults (51.4%). Conclusions. No concerning pattern was noted among death reports submitted to VAERS during 1997-2013. The main causes of death were consistent with the most common causes of death in the US population. C1 [Moro, Pedro L.; Arana, Jorge; Cano, Maria; Lewis, Paige; Shimabukuro, Tom T.] Ctr Dis Control & Prevent, Immunizat Safety Off, Atlanta, GA 30333 USA. RP Moro, PL (reprint author), Ctr Dis Control & Prevent, Immunizat Safety Off, Div Healthcare Qual Promot, 1600 Clifton Rd NE,MS D26, Atlanta, GA 30333 USA. EM pmoro@cdc.gov NR 28 TC 6 Z9 6 U1 1 U2 10 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD SEP 15 PY 2015 VL 61 IS 6 BP 980 EP 987 DI 10.1093/cid/civ423 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA CR6OY UT WOS:000361468200023 PM 26021988 ER PT J AU Siberry, GK Patel, K Bellini, WJ Karalius, B Purswani, MU Burchett, SK Meyer, WA Sowers, SB Ellis, A Van Dyke, RB AF Siberry, George K. Patel, Kunjal Bellini, William J. Karalius, Brad Purswani, Murli U. Burchett, Sandra K. Meyer, William A., III Sowers, Sun Bae Ellis, Angela Van Dyke, Russell B. CA Pediat HIV AIDS Cohort Study PHACS TI Immunity to Measles, Mumps, and Rubella in US Children With Perinatal HIV Infection or Perinatal HIV Exposure Without Infection SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE perinatal HIV; measles; mumps; rubella; immunity ID ACTIVE ANTIRETROVIRAL THERAPY; IMMUNIZATION STATUS; UNINFECTED INFANTS; CONJUGATE VACCINE; ZAMBIAN CHILDREN; IMMUNOGENICITY; RESPONSES; ANTIBODY; POPULATION; REVACCINATION AB Background. Children with perinatal human immunodeficiency virus (HIV) infection (PHIV) may not be protected against measles, mumps, and rubella (MMR) because of impaired initial vaccine response or waning immunity. Our objectives were to estimate seroimmunity in PHIV-infected and perinatally HIV-exposed but uninfected (HEU) children and identify predictors of immunity in the PHIV cohort. Methods. PHIV and HEU children were enrolled in the Pediatric HIV/AIDS Cohort Study (PHACS) at ages 7-15 years from 2007 to 2009. At annual visits, demographic, laboratory, immunization, and clinical data were abstracted and serologic specimens collected. Most recent serologic specimen was used to determine measles seroprotection by plaque reduction neutralization assay and rubella seroprotection and mumps seropositivity by enzyme immunoassay. Sustained combination antiretroviral therapy (cART) was defined as taking cART for at least 3 months. Results. Among 428 PHIV and 221 HEU PHACS participants, the prevalence was significantly lower in PHIV children for measles seroprotection (57% [95% confidence interval {CI}, 52%-62%] vs 99% [95% CI, 96%-100%]), rubella seroprotection (65% [95% CI, 60%-70%] vs 98% [95% CI, 95%-100%]), and mumps seropositivity (59% [95% CI, 55%-64%] vs 97% [95% CI, 94%-99%]). On multivariable analysis, greater number of vaccine doses while receiving sustained cART and higher nadir CD4 percentage between last vaccine dose and serologic testing independently improved the cumulative prediction of measles seroprotection in PHIV. Predictors of rubella seroprotection and mumps seropositivity were similar. Conclusions. High proportions of PHIV-infected children, but not HEU children, lack serologic evidence of immunity to MMR, despite documented immunization and current cART. Effective cART before immunization is a strong predictor of current seroimmunity. C1 [Siberry, George K.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Maternal & Pediat Infect Dis Branch, NIH, Bethesda, MD 20892 USA. [Patel, Kunjal; Karalius, Brad] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Ctr Biostat AIDS Res, Boston, MA USA. [Bellini, William J.; Sowers, Sun Bae] Ctr Dis Control & Prevent, Measles Mumps Rubella & Herpesviruses Lab Branch, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [Purswani, Murli U.] Bronx Lebanon Hosp Ctr, Albert Einstein Coll Med, New York, NY USA. [Burchett, Sandra K.] Boston Childrens Hosp, Boston, MA USA. [Burchett, Sandra K.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA. [Bellini, William J.] Quest Diagnost, Baltimore, MD USA. [Ellis, Angela] Frontier Sci & Technol Res Fdn Inc, Buffalo, NY USA. [Van Dyke, Russell B.] Tulane Univ, Sch Med, New Orleans, LA 70118 USA. RP Siberry, GK (reprint author), Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Maternal & Pediat Infect Dis Branch, NIH, 6100 Executive Blvd,Rm 4B11H, Bethesda, MD 20892 USA. EM siberryg@mail.nih.gov FU Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute on Drug Abuse; National Institute of Allergy and Infectious Diseases; Office of AIDS Research; National Institute of Mental Health; National Institute of Neurological Disorders and Stroke; National Institute on Deafness and Other Communication Disorders; National Heart, Lung, and Blood Institute; National Institute of Dental and Craniofacial Research; National Institute on Alcohol Abuse and Alcoholism; Harvard University School of Public Health [U01 HD052102]; Tulane University School of Medicine [U01 HD052104] FX The PHACS was supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development with co-funding from the National Institute on Drug Abuse, the National Institute of Allergy and Infectious Diseases, the Office of AIDS Research, the National Institute of Mental Health, the National Institute of Neurological Disorders and Stroke, the National Institute on Deafness and Other Communication Disorders, the National Heart, Lung, and Blood Institute, the National Institute of Dental and Craniofacial Research, and the National Institute on Alcohol Abuse and Alcoholism, through cooperative agreements with the Harvard University School of Public Health (U01 HD052102; PI: George Seage; Project Director: Julie Alperen) and the Tulane University School of Medicine (U01 HD052104; PI: Russell Van Dyke; Co-PI: Kenneth Rich; Project Director: Patrick Davis). Serologic assays were performed in a US federal government (CDC) laboratory. NR 37 TC 5 Z9 5 U1 0 U2 12 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD SEP 15 PY 2015 VL 61 IS 6 BP 988 EP 995 DI 10.1093/cid/civ440 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA CR6OY UT WOS:000361468200024 PM 26060291 ER PT J AU McMorrow, ML Wemakoy, EO Tshilobo, JK Emukule, GO Mott, JA Njuguna, H Waiboci, L Heraud, JM Rajatonirina, S Razanajatovo, NH Chilombe, M Everett, D Heyderman, RS Barakat, A Nyatanyi, T Rukelibuga, J Cohen, AL Cohen, C Tempia, S Thomas, J Venter, M Mwakapeje, E Mponela, M Lutwama, J Duque, J Lafond, K Nzussouo, NT Williams, T Widdowson, MA AF McMorrow, Meredith L. Wemakoy, Emile Okitolonda Tshilobo, Joelle Kabamba Emukule, Gideon O. Mott, Joshua A. Njuguna, Henry Waiboci, Lilian Heraud, Jean-Michel Rajatonirina, Soatianana Razanajatovo, Norosoa H. Chilombe, Moses Everett, Dean Heyderman, Robert S. Barakat, Amal Nyatanyi, Thierry Rukelibuga, Joseph Cohen, Adam L. Cohen, Cheryl Tempia, Stefano Thomas, Juno Venter, Marietjie Mwakapeje, Elibariki Mponela, Marcelina Lutwama, Julius Duque, Jazmin Lafond, Kathryn Nzussouo, Ndahwouh Talla Williams, Thelma Widdowson, Marc-Alain TI Severe Acute Respiratory Illness Deaths in Sub-Saharan Africa and the Role of Influenza: A Case Series From 8 Countries SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE influenza; human; mortality; Africa South of the Sahara ID UNITED-STATES; BACTERIAL PNEUMONIA; SEASONAL INFLUENZA; EXCESS MORTALITY; YOUNG-CHILDREN; GLOBAL BURDEN; SOUTH-AFRICA; DISEASE; EPIDEMIOLOGY; METAANALYSIS AB Background. Data on causes of death due to respiratory illness in Africa are limited. Methods.aEuro integral From January to April 2013, 28 African countries were invited to participate in a review of severe acute respiratory illness (SARI)-associated deaths identified from influenza surveillance during 2009-2012. Results.aEuro integral Twenty-three countries (82%) responded, 11 (48%) collect mortality data, and 8 provided data. Data were collected from 37 714 SARI cases, and 3091 (8.2%; range by country, 5.1%-25.9%) tested positive for influenza virus. There were 1073 deaths (2.8%; range by country, 0.1%-5.3%) reported, among which influenza virus was detected in 57 (5.3%). Case-fatality proportion (CFP) was higher among countries with systematic death reporting than among those with sporadic reporting. The influenza-associated CFP was 1.8% (57 of 3091), compared with 2.9% (1016 of 34 623) for influenza virus-negative cases (P < .001). Among 834 deaths (77.7%) tested for other respiratory pathogens, rhinovirus (107 [12.8%]), adenovirus (64 [6.0%]), respiratory syncytial virus (60 [5.6%]), and Streptococcus pneumoniae (57 [5.3%]) were most commonly identified. Among 1073 deaths, 402 (37.5%) involved people aged 0-4 years, 462 (43.1%) involved people aged 5-49 years, and 209 (19.5%) involved people aged a parts per thousand yen50 years. Conclusions.aEuro integral Few African countries systematically collect data on outcomes of people hospitalized with respiratory illness. Stronger surveillance for deaths due to respiratory illness may identify risk groups for targeted vaccine use and other prevention strategies. C1 [McMorrow, Meredith L.; Mott, Joshua A.; Tempia, Stefano; Lafond, Kathryn; Nzussouo, Ndahwouh Talla; Williams, Thelma; Widdowson, Marc-Alain] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Influenza Div, Atlanta, GA 30329 USA. [Duque, Jazmin] Battelle Mem Inst, Atlanta, GA USA. [McMorrow, Meredith L.; Mott, Joshua A.; Cohen, Adam L.] US PHS, Rockville, MD USA. [Wemakoy, Emile Okitolonda] Kinshasa Sch Publ Hlth, Kinshasa, Zaire. [Tshilobo, Joelle Kabamba] Ctr Dis Control & Prevent Democrat Republ Congo, Kinshasa, Zaire. [Emukule, Gideon O.; Mott, Joshua A.; Njuguna, Henry; Waiboci, Lilian] Ctr Dis Control & Prevent Kenya, Nairobi, Kenya. [Heraud, Jean-Michel; Rajatonirina, Soatianana; Razanajatovo, Norosoa H.] Inst Pasteur Madagascar, Natl Influenza Ctr, Antananarivo, Madagascar. [Chilombe, Moses; Everett, Dean; Heyderman, Robert S.] Univ Malawi, Coll Med, Malawi Liverpool Wellcome Trust Clin Res Program, Blantyre, Malawi. [Barakat, Amal] Natl Inst Hyg, Rabat, Morocco. [Nyatanyi, Thierry] Rwanda Biomed Ctr, Div Epidem Infect Dis, Kigali, Rwanda. [Rukelibuga, Joseph] Ctr Dis Control & Prevent Rwanda, Kigali, Rwanda. [Cohen, Adam L.; Tempia, Stefano; Venter, Marietjie] Ctr Dis Control & Prevent, Durban, South Africa. [Venter, Marietjie] Univ Pretoria, Dept Med Virol, Zoonoses Res Unit, ZA-0002 Pretoria, South Africa. [Venter, Marietjie] Ctr Resp Dis & Meningitis, Atlanta, GA USA. [Thomas, Juno] Natl Inst Communicable Dis, Outbreak Response Unit, New Delhi, India. [Mwakapeje, Elibariki] Univ Witwatersrand, Fac Hlth Sci, Sch Publ Hlth, Johannesburg, South Africa. [Mwakapeje, Elibariki; Mponela, Marcelina] Minist Hlth & Social Welfare Tanzania, Dar Es Salaam, Tanzania. [Mponela, Marcelina; Lutwama, Julius] Ctr Dis Control & Prevent Tanzania, Dar Es Salaam, Tanzania. [Mponela, Marcelina] Uganda Virus Res Inst, Entebbe, Uganda. RP McMorrow, ML (reprint author), Ctr Dis Control & Prevent, Influenza Div, 1600 Clifton Rd NE,Mailstop A32, Atlanta, GA 30329 USA. EM mmcmorrow@cdc.gov RI HERAUD, Jean-Michel/O-1464-2013; Venter, Marietjie/P-9604-2016; OI HERAUD, Jean-Michel/0000-0003-1107-0859; Venter, Marietjie/0000-0003-2696-824X; Duque, Jazmin/0000-0003-3484-276X FU CDC; Institut Pasteur; Wellcome Trust FX This work was supported by the CDC (all countries that provided data for this analysis are supported via a cooperative agreement for influenza surveillance), Institut Pasteur (core funding to Madagascar), and the Wellcome Trust (core funding to the Malawi-Liverpool-Wellcome Trust Clinical Research Programme). NR 39 TC 2 Z9 2 U1 1 U2 4 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD SEP 15 PY 2015 VL 212 IS 6 BP 853 EP 860 DI 10.1093/infdis/jiv100 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA CR4EW UT WOS:000361285600003 PM 25712970 ER PT J AU Ly, KN Klevens, RM Jiles, RB AF Ly, Kathleen N. Klevens, R. Monina Jiles, Ruth B. TI Letter to the Editor in Response to the Editorial Commentary by Dr Kenrad E. Nelson Entitled, "The Changing Epidemiology of Hepatitis A Virus Infections in the United States" SO JOURNAL OF INFECTIOUS DISEASES LA English DT Letter C1 [Ly, Kathleen N.; Klevens, R. Monina; Jiles, Ruth B.] Ctr Dis Control & Prevent, NCHHSTP, Div Viral Hepatitis, Atlanta, GA 30333 USA. RP Ly, KN (reprint author), Ctr Dis Control & Prevent, NCHHSTP, Div Viral Hepatitis, Atlanta, GA 30333 USA. EM kathleenly@cdc.gov NR 4 TC 2 Z9 2 U1 0 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD SEP 15 PY 2015 VL 212 IS 6 BP 1009 EP 1010 DI 10.1093/infdis/jiv151 PG 2 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA CR4EW UT WOS:000361285600021 PM 25784730 ER PT J AU Li, R Qu, SL Zhang, P Chattopadhyay, S Gregg, EW Albright, A Hopkins, D Pronk, NP AF Li, Rui Qu, Shuli Zhang, Ping Chattopadhyay, Sajal Gregg, Edward W. Albright, Ann Hopkins, David Pronk, Nicolaas P. TI Economic Evaluation of Combined Diet and Physical Activity Promotion Programs to Prevent Type 2 Diabetes Among Persons at Increased Risk: A Systematic Review for the Community Preventive Services Task Force SO ANNALS OF INTERNAL MEDICINE LA English DT Review ID LIFE-STYLE INTERVENTION; IMPAIRED GLUCOSE-TOLERANCE; COST-EFFECTIVENESS ANALYSIS; CARDIOVASCULAR-DISEASE; METFORMIN; MELLITUS; STRATEGIES; PEOPLE; ADULTS; CARE AB Background: Diabetes is a highly prevalent and costly disease. Studies indicate that combined diet and physical activity promotion programs can prevent type 2 diabetes among persons at increased risk. Purpose: To systematically evaluate the evidence on cost, cost-effectiveness, and cost-benefit estimates of diet and physical activity promotion programs. Data Sources: Cochrane Library, EMBASE, MEDLINE, PsycINFO, Sociological Abstracts, Web of Science, EconLit, and CINAHL through 7 April 2015. Study Selection: English-language studies from high-income countries that provided data on cost, cost-effectiveness, or cost-benefit ratios of diet and physical activity promotion programs with at least 2 sessions over at least 3 months delivered to persons at increased risk for type 2 diabetes. Data Extraction: Dual abstraction and assessment of relevant study details. Data Synthesis: Twenty-eight studies were included. Costs were expressed in 2013 U.S. dollars. The median program cost per participant was $653. Costs were lower for group-based pro-grams (median, $417) and programs implemented in community or primary care settings (median, $424) than for the U.S. DPP (Diabetes Prevention Program) trial and the DPP Outcomes Study ($5881). Twenty-two studies assessed the incremental cost-effectiveness ratios (ICERs) of the programs. From a health system perspective, 16 studies reported a median ICER of $13 761 per quality-adjusted life-year (QALY) saved. Group-based programs were more cost-effective (median, $1819 per QALY) than those that used individual sessions (median, $15 846 per QALY). No cost-benefit studies were identified. Limitation: Information on recruitment costs and cost-effectiveness of translational programs implemented in community and primary care settings was limited. Conclusion: Diet and physical activity promotion programs to prevent type 2 diabetes are cost-effective among persons at increased risk. Costs are lower when programs are delivered to groups in community or primary care settings. C1 [Li, Rui; Qu, Shuli; Zhang, Ping; Chattopadhyay, Sajal; Gregg, Edward W.; Albright, Ann; Hopkins, David] Ctr Dis Control & Prevent, Atlanta, GA 30341 USA. [Pronk, Nicolaas P.] HealthPartners Res Fdn, Minneapolis, MN 55425 USA. RP Li, R (reprint author), Ctr Dis Control & Prevent, Div Diabet Translat, 4770 Buford Highway Northeast,MS F-75, Atlanta, GA 30341 USA. EM eok8@cdc.gov RI kiaie, robabeh/I-2157-2016; kiaie, fatemeh/I-6083-2016 OI kiaie, robabeh/0000-0001-5251-3201; FU Intramural CDC HHS [CC999999] NR 54 TC 17 Z9 18 U1 2 U2 22 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD SEP 15 PY 2015 VL 163 IS 6 BP 452 EP + DI 10.7326/M15-0469 PG 16 WC Medicine, General & Internal SC General & Internal Medicine GA CR5FL UT WOS:000361365900019 PM 26167962 ER PT J AU Tam, KI Esona, MD Williams, A Ndze, VN Boula, A Bowen, MD AF Tam, Ka Ian Esona, Mathew D. Williams, Alice Ndze, Valantine N. Boula, Angeline Bowen, Michael D. TI Evaluation of BBL (TM) Sensi-Discs (TM) and FTA (R) cards as sampling devices for detection of rotavirus in stool samples SO JOURNAL OF VIROLOGICAL METHODS LA English DT Article DE Rotavirus; Stool; Storage; Shipment; Ambient; Virus isolation; Enzyme immunoassay; Genotyping ID UNITED-STATES; CELL-CULTURE; VACCINE; PCR; RNA; METAANALYSIS; COLLECTION; SEROTYPES; STORAGE AB Rotavirus is the most important cause of severe childhood gastroenteritis worldwide. Rotavirus vaccines are available and rotavirus surveillance is carried out to assess vaccination impact. In surveillance studies, stool samples are stored typically at 4 degrees C or frozen to maintain sample quality. Uninterrupted cold storage is a problem in developing countries because of power interruptions. Cold-chain transportation of samples from collection sites to testing laboratories is costly. In this study, we evaluated the use of BBL (TM) Sensi-Discs (TM) and FTA (R) cards for storage and transportation of samples for virus isolation, EIA, and RT-PCR testing. Infectious rotavirus was recovered after 30 days of storage on Sensi-Discs (TM) at room temperature. We were able to genotype 98-99% of samples stored on Sensi-Discs (TM) and FTA (R) cards at temperatures ranging from -80 degrees C to 37 degrees C up to 180 days. A field sampling test using samples prepared and shipped from Cameroon, showed that both matrices yielded 100% genotyping success compared with whole stool and Sensi-Discs (TM) demonstrated 95% concordance with whole stool in EIA testing. The utilization of BBL (TM) Sensi-Discs (TM) and FTA (R) cards for stool sample storage and shipment has the potential to have great impact on global public health by facilitating surveillance and epidemiological investigations of rotavirus strains worldwide at a reduced cost. Published by Elsevier B.V. C1 [Tam, Ka Ian; Esona, Mathew D.; Bowen, Michael D.] Ctr Dis Control & Prevent, Gastroenteritis & Resp Viruses Lab Branch, Div Viral Dis, NCIRD, Atlanta, GA 30329 USA. [Ndze, Valantine N.] Univ Yaounde, Fac Med & Biomed Sci, Yaounde, Cameroon. [Ndze, Valantine N.; Boula, Angeline] Chantal Biya Fdn, Mother & Child Ctr, Yaounde, Cameroon. [Williams, Alice] Furman Univ, Greenville, SC 29613 USA. RP Bowen, MD (reprint author), Ctr Dis Control & Prevent, Gastroenteritis & Resp Viruses Lab Branch, Div Viral Dis, NCIRD, Atlanta, GA 30329 USA. EM mkb6@cdc.gov FU CDC Office of Science Quality, Office of the Associate Director for Science for Innovation Fund award FX We would like to thank the CDC Office of Science Quality, Office of the Associate Director for Science for the 2012 Innovation Fund award. We thank the staff of the Gastroenteritis and Respiratory Viruses Laboratory Branch, Centers for Disease Control and Prevention for invaluable assistance. NR 23 TC 0 Z9 0 U1 0 U2 5 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0166-0934 EI 1879-0984 J9 J VIROL METHODS JI J. Virol. Methods PD SEP 15 PY 2015 VL 222 BP 41 EP 46 DI 10.1016/j.jviromet.2015.05.007 PG 6 WC Biochemical Research Methods; Biotechnology & Applied Microbiology; Virology SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Virology GA CP4TC UT WOS:000359874500007 PM 26022083 ER PT J AU Gelanew, T Poole-Smith, BK Hunsperger, E AF Gelanew, Tesfaye Poole-Smith, B. Katherine Hunsperger, Elizabeth TI Development and characterization of mouse monoclonal antibodies against monomeric dengue virus non-structural glycoprotein 1 (NS1) SO JOURNAL OF VIROLOGICAL METHODS LA English DT Article DE Dengue virus; Nonstructural protein 1; Monoclonal antibody; ELISA; Epitope; Serotype; Immunecomplex ID PROTEIN NS1; ANTIGEN-DETECTION; INFECTION; DIAGNOSIS; ASSAY; ELISA; DISEASE; SENSITIVITY; PERFORMANCE; ILLNESS AB Dengue virus (DENV) nonstructural-1 (NS1) glycoprotein is useful for diagnosis of DENV infections in the first 8 days of illness with any of the four serotypes (DENV-1, DENV-2, DENV-3 and DENV-4). However, NS1 diagnostics are less sensitive for secondary DENV infections so the utility of NS1 diagnostics in dengue endemic countries where there is predominantly secondary infections is being questioned. Heat-mediated immunecomplex dissociation (ICD) prior to testing serum samples can significantly improve NS1 test sensitivity in secondary infections but requires monoclonal antibodies (MAbs) reactive to heat-denatured NS1. In order to incorporate a simple heat-mediated ICD step, a crucial step was to develop new MAbs with high affinity and specificity to heat-denatured DENV NS1 protein. In the present study, six new MAbs were isolated from BALB/c mice immunized with recombinant monomeric NS1 of DENV-1 and DENV-2. Characterization using three different methods: indirect ELISA, fixed cell ELISA and western blot revealed that all six MAbs are serotype-cross-reactive and capable of recognizing dimeric and hexameric isoforms as well as heat-denatured NS1 from all four DENV serotypes. No cross-reactivity to NS1 of West Nile virus and Yellow fever virus was observed on western blot and indirect ELISA. Five of the six MAbs mapped to the DENV NS1 region of 105-119 amino acids. The remaining MAb mapped to DENV NS1 region of 25-39 amino acids. These two NS1 regions were found to be highly conserved among all four DENV serotypes by sequences analysis and database comparison. These MAbs were used to develop an NS1 capture ELISA and tested using a small panel of clinical specimens. The results from the NS1 capture ELISA indicated at least a three-fold increase in NS1 antigen detection in heat-denatured samples compared to untreated specimens. Furthermore, artificial immunecomplexed results also demonstrated the binding efficiency of these MAbs to heat denatured NS1. Taken together, these MAbs allow for the incorporation of a heat dissociation step to improve the sensitivity of DENV NS1 antigen detection in secondary infections. (C) 2015 Elsevier B.V. All rights reserved. C1 [Gelanew, Tesfaye; Poole-Smith, B. Katherine; Hunsperger, Elizabeth] Ctr Dis Control & Prevent, Div Vector Borne Dis, Dengue Branch, San Juan, PR USA. RP Gelanew, T (reprint author), 1324 Calle Canada, San Juan, PR 00920 USA. EM Vsx5@cdc.gov FU Oak Ridge Institute for Science and Education (ORISE) Postdoctoral fellowship; Biomedical Advanced Research and Development Authority, of the Office of the Assistant Secretary of Preparedness and Response, US Health and Human Services [IAA - CI 10-039] FX We wish to thank all members of Immunodiagnostic, Development and Research Lab, Dengue Branch, specifically Manuela Beltran and Jessica Carrion for their help with production of DENV seeds and Vero cell culture. We thank Dr. Margolis for critical review of the manuscript. TG is supported by Oak Ridge Institute for Science and Education (ORISE) Postdoctoral fellowship. Production of anti-DENV NS1 antibodies was funded by Biomedical Advanced Research and Development Authority, of the Office of the Assistant Secretary of Preparedness and Response, US Health and Human Services, IAA - CI 10-039 grant. The funding agency has no role in study design, collection, analysis and interpretation of data, in writing of the report; and in the decision where to publish. The findings and conclusions in this report are those of authors and not necessarily represent the views of Centers for Diseases Control and Prevention. NR 36 TC 2 Z9 3 U1 0 U2 16 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0166-0934 EI 1879-0984 J9 J VIROL METHODS JI J. Virol. Methods PD SEP 15 PY 2015 VL 222 BP 214 EP 223 DI 10.1016/j.jviromet.2015.06.003 PG 10 WC Biochemical Research Methods; Biotechnology & Applied Microbiology; Virology SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Virology GA CP4TC UT WOS:000359874500034 PM 26070890 ER PT J AU Turkevich, LA Dastidar, AG Hachmeister, Z Lim, M AF Turkevich, Leonid A. Dastidar, Ashok G. Hachmeister, Zachary Lim, Michael TI Potential explosion hazard of carbonaceous nanoparticles: Explosion parameters of selected materials SO JOURNAL OF HAZARDOUS MATERIALS LA English DT Article DE Explosion hazard; Dust; Carbon; Nanoparticle; Nanomaterials ID MINIMUM IGNITION ENERGY; ELEMENTAL DUST CLOUDS; PARTICLE-SIZE; EXPLOSIBILITY; 20-L; TITANIUM; CHAMBER; METALS; IRON AB Following a previous explosion screening study, we have conducted concentration and ignition energy scans on several carbonaceous nanopowders: fullerene, SWCNT, carbon black, MWCNT, graphene, CNF, and graphite. We have measured minimum explosive concentration (MEC), minimum ignition energy (MIE), and minimum ignition temperature (MITcloud) for these materials. The nanocarbons exhibit MEC 10(1)-10(2) g/m(3), comparable to the MEC for coals and for fine particle carbon blacks and graphites. The nanocarbons are confirmed mainly to be in the St-1 explosion class, with fullerene, at K-St 200 bar-m/s, borderline St-1/St-2. We estimate MIE 10(2)-10(3) J, an order of magnitude higher than the MIE for coals but an order of magnitude lower than the MIE for fine particle graphites. While the explosion severity of the nanocarbons is comparable to that of the coals, their explosion susceptibility (ease of ignition) is significantly less (i.e., the nanocarbons have higher MIEs than do the coals); by contrast, the nanocarbons exhibit similar explosion severity to the graphites but enhanced explosion susceptibility (i.e., the nanocarbons have lower MIEs than do the graphites). MITcloud > 550 degrees C, comparable to that of the coals and carbon blacks. Published by Elsevier B.V. C1 [Turkevich, Leonid A.] NIOSH, Ctr Dis Control & Prevent, Div Appl Res & Technol, Cincinnati, OH 45226 USA. [Dastidar, Ashok G.; Hachmeister, Zachary; Lim, Michael] Fauske & Associates LLC, Burr Ridge, IL 60527 USA. RP Turkevich, LA (reprint author), NIOSH, Ctr Dis Control & Prevent, Div Appl Res & Technol, 1090 Tusculum Ave,MS-R7, Cincinnati, OH 45226 USA. EM LLT0@cdc.gov FU NIOSH Nanotechnology Research Center FX This work was supported through the NIOSH Nanotechnology Research Center. We especially thank Paul Schulte (NIOSH) for the prescient recognition of the potential explosion hazard posed by these materials and for the encouragement of this research. NR 43 TC 2 Z9 2 U1 4 U2 63 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0304-3894 EI 1873-3336 J9 J HAZARD MATER JI J. Hazard. Mater. PD SEP 15 PY 2015 VL 295 BP 97 EP 103 DI 10.1016/j.jhazmat.2015.03.069 PG 7 WC Engineering, Environmental; Engineering, Civil; Environmental Sciences SC Engineering; Environmental Sciences & Ecology GA CK3PG UT WOS:000356127400013 PM 25913651 ER PT J AU Geraci, C Heidel, D Sayes, C Hodson, L Schulte, P Eastlake, A Brenner, S AF Geraci, Charles Heidel, Donna Sayes, Christie Hodson, Laura Schulte, Paul Eastlake, Adrienne Brenner, Sara TI Perspectives on the design of safer nanomaterials and manufacturing processes SO JOURNAL OF NANOPARTICLE RESEARCH LA English DT Editorial Material DE Nanomaterial; Prevention through design; Responsible development; Environmental and health effects ID ENGINEERED NANOPARTICLES; IN-VITRO; EXPOSURE; TOXICITY; INHALATION; RELEASE; SIZE AB A concerted effort is being made to insert Prevention through Design principles into discussions of sustainability, occupational safety and health, and green chemistry related to nanotechnology. Prevention through Design is a set of principles, which includes solutions to design out potential hazards in nanomanufacturing including the design of nanomaterials, and strategies to eliminate exposures and minimize risks that may be related to the manufacturing processes and equipment at various stages of the lifecycle of an engineered nanomaterial. C1 [Geraci, Charles; Hodson, Laura; Schulte, Paul; Eastlake, Adrienne] NIOSH, Cincinnati, OH 45226 USA. [Heidel, Donna] Bur Veritas North Amer Inc, Edison, NJ USA. [Sayes, Christie] Baylor Univ, Waco, TX 76798 USA. [Brenner, Sara] State Univ New York Polytech Inst SUNY Poly, Coll Nanoscale Sci, Albany, NY USA. [Brenner, Sara] State Univ New York Polytech Inst SUNY Poly, Coll Engn, Albany, NY USA. RP Hodson, L (reprint author), NIOSH, Cincinnati, OH 45226 USA. EM lhodson@cdc.gov RI Sayes, Christie/C-1333-2016 OI Sayes, Christie/0000-0002-5529-4101 FU Intramural CDC HHS [CC999999] NR 49 TC 3 Z9 3 U1 1 U2 11 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 1388-0764 EI 1572-896X J9 J NANOPART RES JI J. Nanopart. Res. PD SEP 14 PY 2015 VL 17 IS 9 AR 366 DI 10.1007/s11051-015-3152-9 PG 13 WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials Science, Multidisciplinary SC Chemistry; Science & Technology - Other Topics; Materials Science GA DA5NE UT WOS:000367849000001 PM 26435688 ER PT J AU Thomas, TN Leander-Griffith, M Harp, V Cioffi, JP AF Thomas, Tracy N. Leander-Griffith, Michelle Harp, Victoria Cioffi, Joan P. TI Influences of Preparedness Knowledge and Beliefs on Household Disaster Preparedness SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Thomas, Tracy N.; Leander-Griffith, Michelle; Harp, Victoria; Cioffi, Joan P.] CDC, Off Publ Hlth Preparedness & Response, Learning Off, Atlanta, GA 30333 USA. RP Thomas, TN (reprint author), CDC, Off Publ Hlth Preparedness & Response, Learning Off, Atlanta, GA 30333 USA. EM tct5@cdc.gov NR 7 TC 1 Z9 1 U1 4 U2 5 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD SEP 11 PY 2015 VL 64 IS 35 BP 965 EP 971 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CS5CB UT WOS:000362092500001 PM 26356729 ER PT J AU Hinton, CF Griese, SE Anderson, MR Chernak, E Peacock, G Thorpe, PG Lurie, N AF Hinton, Cynthia F. Griese, Stephanie E. Anderson, Michael R. Chernak, Esther Peacock, Georgina Thorpe, Phoebe G. Lurie, Nicole TI CDC Grand Rounds: Addressing Preparedness Challenges for Children in Public Health Emergencies SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID DISASTER C1 [Hinton, Cynthia F.; Peacock, Georgina] CDC, Natl Ctr Birth Defects & Dev Disabil, Div Human Dev & Disabil, Atlanta, GA 30333 USA. [Griese, Stephanie E.] CDC, Off Director, Off Publ Hlth Preparedness & Response, Atlanta, GA 30333 USA. [Anderson, Michael R.] Case Western Reserve Univ, Rainbow Babies & Childrens Hosp, Cleveland, OH 44106 USA. [Chernak, Esther] Drexel Univ, Sch Publ Hlth, Ctr Publ Hlth Readiness & Commun, Philadelphia, PA 19104 USA. [Thorpe, Phoebe G.] CDC, Off Associate Director Sci, Atlanta, GA 30333 USA. [Lurie, Nicole] US Dept HHS, Off Assistant Secretary Preparedness & Response, Washington, DC 20201 USA. RP Hinton, CF (reprint author), CDC, Natl Ctr Birth Defects & Dev Disabil, Div Human Dev & Disabil, Atlanta, GA 30333 USA. EM chinton@cdc.gov NR 19 TC 2 Z9 2 U1 0 U2 3 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD SEP 11 PY 2015 VL 64 IS 35 BP 972 EP 974 PG 3 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CS5CB UT WOS:000362092500002 PM 26356838 ER PT J AU Attfield, KR Dobson, CB Henn, JB Acosta, M Smorodinsky, S Wilken, JA Barreau, T Schreiber, M Windham, GC Materna, BL Roisman, R AF Attfield, Kathleen R. Dobson, Christine B. Henn, Jennifer B. Acosta, Meileen Smorodinsky, Svetlana Wilken, Jason A. Barreau, Tracy Schreiber, Merritt Windham, Gayle C. Materna, Barbara L. Roisman, Rachel TI Injuries and Traumatic Psychological Exposures Associated with the South Napa Earthquake - California, 2014 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID DISASTERS C1 [Attfield, Kathleen R.] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Attfield, Kathleen R.; Dobson, Christine B.; Smorodinsky, Svetlana; Wilken, Jason A.; Barreau, Tracy; Windham, Gayle C.; Materna, Barbara L.; Roisman, Rachel] Calif Dept Publ Hlth, Bakersfield, CA USA. [Dobson, Christine B.] CDC CSTE Appl Epidemiol Fellowship Program, Atlanta, GA USA. [Henn, Jennifer B.] Napa Cty Publ Hlth, Napa, CA 94559 USA. [Acosta, Meileen] Solano Cty Publ Hlth, Fairfield, CA USA. [Wilken, Jason A.] CDC, Off Publ Hlth Preparedness & Response, Atlanta, GA 30333 USA. [Schreiber, Merritt] Univ Calif Irvine, Irvine, CA USA. RP Attfield, KR (reprint author), CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. EM wby4@cdc.gov NR 10 TC 0 Z9 0 U1 1 U2 2 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD SEP 11 PY 2015 VL 64 IS 35 BP 975 EP 978 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CS5CB UT WOS:000362092500003 PM 26355257 ER PT J AU Bawo, L Fallah, M Kateh, F Nagbe, T Clement, P Gasasira, A Mahmoud, N Musa, E Lo, TQ Pillai, SK Seeman, S Sunshine, BJ Weidle, PJ Nyensweh, T AF Bawo, Luke Fallah, Mosoka Kateh, Francis Nagbe, Thomas Clement, Peter Gasasira, Alex Mahmoud, Nuha Musa, Emmanuel Lo, Terrence Q. Pillai, Satish K. Seeman, Sara Sunshine, Brittany J. Weidle, Paul J. Nyensweh, Tolbert CA Liberia Minist Hlth World Hlth Org CDC Ebola Response Teams TI Elimination of Ebola Virus Transmission in Liberia - September 3, 2015 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID JANUARY-FEBRUARY 2015; DISEASE C1 [Bawo, Luke; Fallah, Mosoka; Kateh, Francis; Nagbe, Thomas; Nyensweh, Tolbert] Liberia Minist Hlth, Greater Monrovia, Liberia. [Clement, Peter; Gasasira, Alex; Mahmoud, Nuha; Musa, Emmanuel] WHO, Geneva, Switzerland. [Lo, Terrence Q.; Pillai, Satish K.; Seeman, Sara; Sunshine, Brittany J.; Weidle, Paul J.] CDC, Atlanta, GA 30333 USA. RP Sunshine, BJ (reprint author), CDC, Atlanta, GA 30333 USA. EM ymz6@cdc.gov NR 10 TC 2 Z9 2 U1 1 U2 7 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD SEP 11 PY 2015 VL 64 IS 35 BP 979 EP 980 PG 2 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CS5CB UT WOS:000362092500004 PM 26355323 ER PT J AU Jordan, JG Pritchard, S Nicholson, G Winston, T Gumke, M Rubino, H Watkins, S Heberlein-Larson, LA Likos, A AF Jordan, John G. Pritchard, Scott Nicholson, Garik Winston, Tiffany Gumke, Megan Rubino, Heather Watkins, Sharon Heberlein-Larson, Lea A. Likos, Anna TI Pneumonia Associated with an Influenza A H3 Outbreak at a Skilled Nursing Facility - Florida, 2014 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID UNITED-STATES; SEASONAL INFLUENZA; VACCINE C1 [Jordan, John G.] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Jordan, John G.; Pritchard, Scott; Winston, Tiffany; Gumke, Megan; Rubino, Heather; Watkins, Sharon; Likos, Anna] Florida Dept Hlth, Div Dis Control & Hlth Protect, Lakeland, FL USA. [Nicholson, Garik] Florida Dept Hlth Pasco County, Lakeland, FL USA. [Heberlein-Larson, Lea A.] Bur Publ Hlth Labs Tampa, Florida Dept Hlth, Tampa, FL USA. RP Jordan, JG (reprint author), CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. EM jgjordan@cdc.gov NR 4 TC 0 Z9 0 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD SEP 11 PY 2015 VL 64 IS 35 BP 985 EP 986 PG 2 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CS5CB UT WOS:000362092500006 PM 26355557 ER PT J AU Bruce, MG Singleton, R Bulkow, L Rudolph, K Zulz, T Gounder, P Hurlburt, D Bruden, D Hennessy, T AF Bruce, Michael G. Singleton, Rosalyn Bulkow, Lisa Rudolph, Karen Zulz, Tammy Gounder, Prabhu Hurlburt, Debby Bruden, Dana Hennessy, Thomas TI Impact of the 13-valent pneumococcal conjugate vaccine (pcv13) on invasive pneumococcal disease and carriage in Alaska SO VACCINE LA English DT Article DE Streptococcus pneumoniae; Invasive pneumococcal disease; Carriage; Vaccine; Serotype; Alaska; US ID STREPTOCOCCUS-PNEUMONIAE; NASOPHARYNGEAL COLONIZATION; ANTIMICROBIAL RESISTANCE; SEROTYPE DISTRIBUTION; CHILDREN AB Background: Alaska Native (AN) children have experienced high rates of invasive pneumococcal disease (IPD). In March 2010, PCV13 was introduced statewide in Alaska. We evaluated the impact of PCV13 on IPD in children and adults, 45 months after introduction. Methods: Pneumococcal sterile site isolates, reported through state-wide surveillance, were serotyped using standard methods. We defined a pre-PCV13 time period 2005-2008 and post-PCV13 time period April 2010-December 2013; excluding Jan 2009-March 2010 because PCV13 was introduced pre-licensure in one high-risk region in 2009. Results: Among Alaska children <5 years, PCV13 serotypes comprised 65% of IPD in the pre-PCV13 period and 26% in the PCV13 period. Among all Alaska children <5 years, IPD rates decreased from 60.9 (pre) to 25.4 (post) per 100,000/year (P<0.001); PCV13 serotype IPD decreased from 37.7 to 6.4 (P<0.001). Among AN children <5 years, IPD rates decreased from 149.2 to 60.8 (P<0.001); PCV13 serotype IPD decreased from 87.0 to 17.4 (P<0.001); non-PCV13 serotype IPD did not change significantly. Among persons 5-17 and >= 45 years, the post-vaccine IPD rate was similar to the baseline period, but declined in persons 18-44 years (39%, P<0.001); this decline was similar in AN and non-AN persons (38%, P=0.016,43%, P=0.014, respectively). Conclusions: Forty-five months after PCV13 introduction, overall IPD and PCV13-serotype IPD rates had decreased 58% and 83%, respectively, in Alaska children <5 years of age when compared with 2005-2008. We observed evidence of indirect effect among adults with a 39% reduction in IPD among persons 18-44 years. Published by Elsevier Ltd. C1 [Bruce, Michael G.; Bulkow, Lisa; Rudolph, Karen; Zulz, Tammy; Gounder, Prabhu; Hurlburt, Debby; Bruden, Dana; Hennessy, Thomas] Ctr Dis Control & Prevent, Arctic Invest Program, Natl Ctr Emerging Zoonot & Infect Dis, Anchorage, AK USA. [Singleton, Rosalyn] Alaska Native Med Ctr, Anchorage, AK USA. RP Bruce, MG (reprint author), Ctr Dis Control & Prevent, Arctic Invest Program, Natl Ctr Emerging Zoonot & Infect Dis, Anchorage, AK USA. EM zwa8@cdc.gov FU Centers for Disease Control and Prevention; Investigator Originated Project grant from Pfizer pharmaceuticals [0887X1-4409] FX The impact of PCV13 on IPD in Alaska was funded by the Centers for Disease Control and Prevention. The carriage study was supported by an Investigator Originated Project grant (protocol #: 0887X1-4409) from Pfizer pharmaceuticals and through in-kind support from CDC. NR 32 TC 8 Z9 8 U1 0 U2 1 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD SEP 11 PY 2015 VL 33 IS 38 BP 4813 EP 4819 DI 10.1016/j.vaccine.2015.07.080 PG 7 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA CR8EE UT WOS:000361583100013 PM 26247901 ER PT J AU Haber, P Parashar, UD Haber, M DeStefano, F AF Haber, Penina Parashar, Umesh D. Haber, Michael DeStefano, Frank TI Intussusception after monovalent rotavirus vaccine-United States, Vaccine Adverse Event Reporting System (VAERS), 2008-2014 SO VACCINE LA English DT Article DE Rotarix vaccines; Intussusception; Safety monitoring; Vaccine adverse event ID CASE-SERIES METHOD; IMMUNIZATION PRACTICES ACIP; ADVISORY-COMMITTEE; US INFANTS; SAFETY; RISK; RECOMMENDATIONS; GASTROENTERITIS; SURVEILLANCE; PREVENTION AB Background: In 2006 and 2008, two new rotavirus vaccines (RotaTeq [RV5] and Rotarix [RV1]) were introduced in the United States. US data on intussusception have been mostly related to RV5, with limited data on RV1. Methods: We assessed intussusception events following RV1 reported to the Vaccine Adverse Event Reporting System (VAERS), a US national passive surveillance system, during February 2008-December 2014. We conducted a self-controlled risk interval analysis using Poisson regression to estimate the daily reporting ratio (DRR) of intussusception after the first 2 doses of RV1 comparing average daily reports 3-6 versus 0-2 days after vaccination. We calculated the excess risk of intussusception per 100,000 vaccinations based on DRRs and background rates of intussusception. Sensitivity analyses were conducted to assess effects of differential reporting completeness and inaccuracy of baseline rates. Results: VAERS received 108 confirmed insusceptible reports after RV1. A significant clustering was observed on days 3-8 after does1 (p = 0.001) and days 2-7 after dose 2 (p = 0.001). The DRR comparing the 3-6 day and the 0-2 day periods after RV1 dose 1 was 7.5 (95% CI = 2.3, 24.6), translating to an excess risk of 1.6(9% CI = 0.3, 5.8) per 100,000 vaccinations. The DRR was elevated but not significant after dose 2 (2.4 [95% CI = 0.8,7.5]). The excess risk ranged from 1.2 to 2.8 per 100,000 in sensitivity analysis. Conclusions: We observed a significant increased risk of intussusception 3-6 days after dose 1 of RV1. The estimated small number of intussusception cases attributable to RV1 is outweighed by the benefits of rotavirus vaccination. Published by Elsevier Ltd. C1 [Haber, Penina; DeStefano, Frank] Ctr Dis Control & Prevent CDC, Immunizat Safety Off, Div Healthcare Qual Promot, NCEZID, Anchorage, AK USA. [Parashar, Umesh D.] CDC, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Haber, Michael] Emory Univ, Rollins Sch Publ Hlth Biostat & Bioinfomat, Atlanta, GA 30322 USA. RP Haber, P (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,MS D-26, Atlanta, GA 30333 USA. EM phaber@cdc.gov NR 32 TC 6 Z9 6 U1 0 U2 6 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD SEP 11 PY 2015 VL 33 IS 38 BP 4873 EP 4877 DI 10.1016/j.vaccine.2015.07.054 PG 5 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA CR8EE UT WOS:000361583100021 PM 26276687 ER PT J AU Pushko, P Pujanauski, LM Sun, XJ Pearce, M Hidajat, R Kort, T Schwartzman, LM Tretyakova, I Liu, CQ Taubenberger, JK Tumpey, TM AF Pushko, Peter Pujanauski, Lindsey M. Sun, Xiangjie Pearce, Melissa Hidajat, Rachmat Kort, Thomas Schwartzman, Louis M. Tretyakova, Irina Liu Chunqing Taubenberger, Jeffery K. Tumpey, Terrence M. TI Recombinant H7 hemagglutinin forms subviral particles that protect mice and ferrets from challenge with H7N9 influenza virus SO VACCINE LA English DT Article DE Influenza; H7N9; Influenza vaccine; Virus-like particles; VLP ID AVIAN INFLUENZA; IMMUNE-RESPONSES; H5N1 VIRUSES; INTRANASAL VACCINATION; CONFERS PROTECTION; CANDIDATE VACCINE; CONTROLLED-TRIAL; HEALTHY-ADULTS; A(H7N9) VIRUS; INFECTION AB A novel avian-origin influenza A H7N9 virus emerged in China in 2013 and continues to cause sporadic human infections with mortality rates approaching 35%. Currently there are no approved human vaccines for H7N9 virus. Recombinant approaches including hemagglutinin (HA) and virus-like particles (VLPs) have resulted in experimental vaccines with advantageous safety and manufacturing characteristics. While high immunogenicity of VLP vaccines has been attributed to the native conformation of HA arranged in the regular repeated patterns within virus-like structures, there is limited data regarding molecular organization of HA within recombinant HA vaccine preparations. In this study, the full-length recombinant H7 protein (rH7) of A/Anhui/1/2013 (H7N9) virus was expressed in Sf9 cells. We showed that purified full-length rH7 retained functional ability to agglutinate red blood cells and formed oligomeric pleomorphic subviral particles (SVPs) of similar to 20 nm in diameter composed of approximately 10 HAO molecules. No significant quantities of free monomeric HAO were observed in rH7 preparation by size exclusion chromatography. Immunogenicity and protective efficacy of rH7 SVPs was confirmed in the mouse and ferret challenge models suggesting that SVPs can be used for vaccination against H7N9 virus. (C) 2015 Elsevier Ltd. All rights reserved. C1 [Pushko, Peter; Hidajat, Rachmat; Kort, Thomas; Tretyakova, Irina] Medigen Inc, Frederick, MD 21701 USA. [Liu Chunqing] Wuhan Siqiyuan Ltd, Wuhan, Peoples R China. [Pujanauski, Lindsey M.; Schwartzman, Louis M.; Taubenberger, Jeffery K.] NIAID, Viral Pathogenesis & Evolut Sect, NIH, Bethesda, MD 20892 USA. [Sun, Xiangjie; Pearce, Melissa; Tumpey, Terrence M.] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. RP Pushko, P (reprint author), Medigen Inc, 8420 Gas House Pike,Suite S, Frederick, MD 21701 USA. EM ppushko@medigen-usa.com OI Pujanandez, Lindsey/0000-0002-2982-3700 FU NIH NIAID [1R01AI111532]; USDA NIFA [2013-33610-21041]; Intramural Research Program of the National Institute of Allergy and Infectious Diseases, National Institutes of Health FX We thank Darrell Kapczynski (SEPRL, USDA) for H7-specific antiserum. We also thank Noah Horn, Raphael Prather, Brian Nickols, Xia Lei, and Xiaohui Li for valuable contributions and discussions. LMP current address is The American Association of Immunologists, 9650 Rockville Pike, Bethesda, MD, USA. This research was supported in part by grants 1R01AI111532 (NIH NIAID) and 2013-33610-21041 (USDA NIFA) to P.P., and in part by the Intramural Research Program of the National Institute of Allergy and Infectious Diseases, National Institutes of Health. We thank the Comparative Medicine Branch (NIAID, NIH) for assistance with the mouse studies. The findings and conclusions in this report are those of the authors and do not necessarily reflect the views of the funding agencies. NR 52 TC 8 Z9 8 U1 0 U2 3 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD SEP 11 PY 2015 VL 33 IS 38 BP 4975 EP 4982 DI 10.1016/j.vaccine.2015.07.026 PG 8 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA CR8EE UT WOS:000361583100035 PM 26207590 ER PT J AU Nishizawa, M Matsuda, M Hattori, J Shiino, T Matano, T Heneine, W Johnson, JA Sugiura, W AF Nishizawa, Masako Matsuda, Masakazu Hattori, Junko Shiino, Teiichiro Matano, Tetsuro Heneine, Walid Johnson, Jeffrey A. Sugiura, Wataru TI Longitudinal Detection and Persistence of Minority Drug-Resistant Populations and Their Effect on Salvage Therapy SO PLOS ONE LA English DT Article ID TREATMENT-NAIVE PATIENTS; HIV-1 REVERSE-TRANSCRIPTASE; SINGLE-DOSE NEVIRAPINE; ANTIRETROVIRAL THERAPY; VIROLOGICAL FAILURE; INFECTED PATIENTS; VIRAL VARIANTS; TYPE-1 POL; MUTATIONS; TRANSMISSION AB Background Drug-resistant HIV are more prevalent and persist longer than previously demonstrated by bulk sequencing due to the ability to detect low-frequency variants. To clarify a clinical benefit to monitoring minority-level drug resistance populations as a guide to select active drugs for salvage therapy, we retrospectively analyzed the dynamics of low-frequency drug-resistant population in antiretroviral (ARV)-exposed drug resistant individuals. Materials and Methods Six HIV-infected individuals treated with ARV for more than five years were analyzed. These individuals had difficulty in controlling viremia, and treatment regimens were switched multiple times guided by standard drug resistance testing using bulk sequencing. To detect minority variant populations with drug resistance, we used a highly sensitive allele-specific PCR (AS-PCR) with detection thresholds of 0.3-2%. According to ARV used in these individuals, we focused on the following seven reverse transcriptase inhibitor-resistant mutations: M41L, K65R, K70R, K103N, Y181C, M184V, and T215F/Y. Results of AS-PCR were compared with bulk sequencing data for concordance and presence of additional mutations. To clarify the genetic relationship between low-frequency and high-frequency populations, AS-PCR amplicon sequences were compared with bulk sequences in phylogenetic analysis. Results The use of AS-PCR enabled detection of the drug-resistant mutations, M41L, K103N, Y181C, M184V and T215Y, present as low-frequency populations in five of the six individuals. These drug resistant variants persisted for several years without ARV pressure. Phylogenetic analysis indicated that pre-existing K103N and T215I variants had close genetic relationships with high-frequency K103N and T215I observed during treatment. Discussion and Conclusion Our results demonstrate the long-term persistence of drug-resistant viruses in the absence of drug pressure. The rapid virologic failures with pre-existing mutant viruses detectable by AS-PCR highlight the clinical importance of low-frequency drug-resistant viruses. Thus, our results highlight the usefulness of AS-PCR and support its expanded evaluation in ART clinical management. C1 [Nishizawa, Masako; Matano, Tetsuro; Sugiura, Wataru] Natl Inst Infect Dis, AIDS Res Ctr, Tokyo, Japan. [Matsuda, Masakazu; Hattori, Junko; Sugiura, Wataru] Natl Hosp Org, Clin Res Ctr, Nagoya Med Ctr, Nagoya, Aichi, Japan. [Shiino, Teiichiro] Natl Inst Infect Dis, Infect Dis Surveillance Ctr, Tokyo, Japan. [Heneine, Walid; Johnson, Jeffrey A.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. [Sugiura, Wataru] Nagoya Univ, Grad Sch Med, Dept AIDS Res, Nagoya, Aichi 4648601, Japan. RP Sugiura, W (reprint author), Natl Inst Infect Dis, AIDS Res Ctr, Tokyo, Japan. EM taru1600@me.com FU Ministry of Health, Labour, and Welfare of Japan [H25-AIDS-004] FX This work was supported by a Grant-in-Aid for AIDS research from the Ministry of Health, Labour, and Welfare of Japan (H25-AIDS-004) http://www.mhlw.go.jp/ to WS. NR 48 TC 2 Z9 2 U1 0 U2 1 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD SEP 11 PY 2015 VL 10 IS 9 AR e0135941 DI 10.1371/journal.pone.0135941 PG 13 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CR0WB UT WOS:000361043100006 PM 26360259 ER PT J AU Kourtis, AP King, CC Nelson, J Jamieson, DJ van der Horst, C AF Kourtis, Athena P. King, Caroline C. Nelson, Julie Jamieson, Denise J. van der Horst, Charles TI Time of HIV diagnosis in infants after weaning from breast milk SO AIDS LA English DT Letter ID TRANSMISSION AB Of 28 infants diagnosed with HIV infections after the recommended time of breastfeeding cessation in a large clinical trial (the Breastfeeding, Antiretrovirals and Nutrition Study), 19 (68%) were first detected more than 6 weeks (and up to 168 days) after recommended weaning. The current WHO recommendation for HIV testing of infants is at 6 weeks or more after weaning; these data argue for repeat HIV testing of infants up to 6 months after breastfeeding cessation, so that no infant HIV infections are missed. C1 [Kourtis, Athena P.; King, Caroline C.; Jamieson, Denise J.] Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. [Nelson, Julie] Univ N Carolina, Sch Med, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA. [van der Horst, Charles] Univ N Carolina, Sch Med, Div Infect Dis, Chapel Hill, NC USA. EM apk3@cdc.gov FU FIC NIH HHS [R24 TW007988, D43 TW001039]; NIAID NIH HHS [P30 AI050410]; NICHD NIH HHS [R24 HD050924] NR 4 TC 0 Z9 0 U1 1 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0269-9370 EI 1473-5571 J9 AIDS JI Aids PD SEP 10 PY 2015 VL 29 IS 14 BP 1897 EP 1898 DI 10.1097/QAD.0000000000000796 PG 2 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA CV6KF UT WOS:000364378400003 PM 26153670 ER PT J AU Edens, C Dybdahl-Sissoko, NC Weldon, WC Oberste, MS Prausnitz, MR AF Edens, Chris Dybdahl-Sissoko, Naomi C. Weldon, William C. Oberste, M. Steven Prausnitz, Mark R. TI Inactivated polio vaccination using a microneedle patch is immunogenic in the rhesus macaque SO VACCINE LA English DT Article DE Inactivated polio vaccine; Microneedle patch; Poliomyelitis; Rhesus macaque; Sharps waste; Vaccination ID DISSOLVING POLYMER MICRONEEDLES; INTRADERMAL DELIVERY; INFLUENZA VACCINE; ERADICATION; PROTECTION; DRUG; POLIOVIRUSES; IMMUNIZATION; EXPERIENCES; EVOLUTION AB The phased replacement of oral polio vaccine (OPV) with inactivated polio vaccine (IPV) is expected to significantly complicate mass vaccination campaigns, which are an important component of the global polio eradication endgame strategy. To simplify mass vaccination with IPV, we developed microneedle patches that are easy to administer, have a small package size, generate no sharps waste and are inexpensive to manufacture. When administered to rhesus macaques, neutralizing antibody titers were equivalent among monkeys vaccinated using microneedle patches and conventional intramuscular injection for IPV types 1 and 2. Serologic response to IPV type 3 vaccination was weaker after microneedle patch vaccination compared to intramuscular injection; however, we suspect the administered type 3 dose was lower due to a flawed pre-production IPV type 3 analytical method. IPV vaccination using microneedle patches was well tolerated by the monkeys. We conclude that IPV vaccination using a microneedle patch is immunogenic in rhesus macaques and may offer a simpler method of IPV vaccination of people to facilitate polio eradication. (C) 2015 Elsevier Ltd. All rights reserved. C1 [Edens, Chris; Prausnitz, Mark R.] Georgia Tech, Coulter Dept Biomed Engn, Atlanta, GA 30332 USA. [Edens, Chris; Prausnitz, Mark R.] Emory Univ, Georgia Inst Technol, Atlanta, GA 30332 USA. [Dybdahl-Sissoko, Naomi C.; Weldon, William C.; Oberste, M. Steven] Ctr Dis Control & Prevent, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Prausnitz, Mark R.] Georgia Inst Technol, Sch Chem & Biomol Engn, Atlanta, GA 30332 USA. RP Prausnitz, MR (reprint author), Georgia Inst Technol, Sch Chem & Biomol Engn, Atlanta, GA 30332 USA. EM prausnitz@gatech.edu OI Edens, William/0000-0002-7563-6201 FU Bill and Melinda Gates Foundation; World Health Organization; Centers for Disease Control and Prevention's Global Immunization Division FX This work was funded in part by the Bill and Melinda Gates Foundation, the World Health Organization, and the Centers for Disease Control and Prevention's Global Immunization Division. NR 43 TC 13 Z9 13 U1 1 U2 22 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD SEP 8 PY 2015 VL 33 IS 37 SI SI BP 4683 EP 4690 DI 10.1016/j.vaccine.2015.01.089 PG 8 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA CR3WK UT WOS:000361263600004 PM 25749246 ER PT J AU Tsals, I Jarrahian, C Snyder, FE Saganic, L Saxon, E Zehrung, D Zimmerman, G Papania, M Klaff, L AF Tsals, Izrail Jarrahian, Courtney Snyder, Fred E. Saganic, Laura Saxon, Eugene Zehrung, Darin Zimmerman, Glen Papania, Mark Klaff, Leslie TI Clinical performance and safety of adapters for intradermal delivery with conventional and autodisable syringes SO VACCINE LA English DT Article DE Intradermal; Mantoux; Vaccination; Delivery technology ID VACCINATION; VACCINES; IMMUNOGENICITY; BEVEL AB Although the number of vaccines and diagnostic tests currently delivered intradermally is limited, this route of administration offers potential advantages due to the high concentration of antigen-presenting cells in the skin. One factor which may in part be limiting development and use of intradermal (ID) administration is concern about the ease and reliability of the needle and syringe-based Mantoux technique. A phase I clinical study was conducted to evaluate two ID adapters that have been developed as injection-delivery aids to increase the safety, simplicity, and reliability of ID injection: a prototype autodisable, intradermal (ADID) adapter for autodisable (AD) syringes, and a marketed side-merge adapter (SMA). Thirty healthy adult volunteers each received six injections of 0.1 mL of sterile saline solution. Each adapter was used to give injections into the upper deltoid, forearm, and suprascapular regions of each volunteer. The needle-bevel orientation during injection was random. Injection performance was determined by measuring wheal size and fluid leakage. Wheals were similar in size for the ADID adapter (mean 9.9 +/- 0.17 mm) and SMA (mean 9.8 +/- 0.15 mm). In all of the injections completed with the SMA, and 98% of those completed with the ADID, fluid leakage was less than 10% of the intended injection volume. Minor skin abrasions were the only adverse events. Based on self-reporting of pain, injections were well tolerated (mean pain score of 2 on a 0-10 scale). ID delivery using the SMA and ADID adapters appears safe and effective. (C) 2015 Elsevier Ltd. All rights reserved. C1 [Tsals, Izrail; Snyder, Fred E.] SID Technol, Newtown, PA 18940 USA. [Jarrahian, Courtney; Saganic, Laura; Saxon, Eugene; Zehrung, Darin] PATH, Seattle, WA 98121 USA. [Zimmerman, Glen] West Pharmaceut Serv Inc, Exton, PA 19341 USA. [Papania, Mark] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Klaff, Leslie] Rainier Clin Res Ctr, Renton, WA 98057 USA. RP Tsals, I (reprint author), SID Technol, 51 Rittenhouse Cir, Newtown, PA 18940 USA. EM izzy.tsals@gmail.com FU US Centers for Disease Control and Prevention [200-2011-41645] FX The authors would like to thank Pamela Martin of Rainier Clinical Research Center for assistance with the study. The development of the ADID adapter and this study were performed under contract No. 200-2011-41645, "Development of a New Disabling Device for Intradermal Vaccination," granted by the US Centers for Disease Control and Prevention to SID Technologies. NR 28 TC 2 Z9 2 U1 0 U2 3 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD SEP 8 PY 2015 VL 33 IS 37 SI SI BP 4705 EP 4711 DI 10.1016/j.vaccine.2015.04.095 PG 7 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA CR3WK UT WOS:000361263600007 PM 25964169 ER PT J AU Edens, C Collins, ML Goodson, JL Rota, PA Prausnitz, MR AF Edens, Chris Collins, Marcus L. Goodson, James L. Rota, Paul A. Prausnitz, Mark R. TI A microneedle patch containing measles vaccine is immunogenic in non-human primates SO VACCINE LA English DT Article DE Measles; Vaccination; Microneedle; Stability; Non-human primate ID TRANSDERMAL DRUG-DELIVERY; RHESUS MACAQUES; POLYMER MICRONEEDLES; UNSAFE INJECTIONS; VIRUS-INFECTION; IMMUNIZATION; ANTIBODY; ERADICATION; INFLUENZA; FABRICATION AB Very high vaccination coverage is required to eliminate measles, but achieving high coverage can be constrained by the logistical challenges associated with subcutaneous injection. To simplify the logistics of vaccine delivery, a patch containing micron-scale polymeric needles was formulated to encapsulate the standard dose of measles vaccine (1000 TCID50) and the immunogenicity of the microneedle patch was compared with subcutaneous injection in rhesus macaques. The microneedle patch was administered without reconstitution with diluent, dissolved in skin within 10 min, and caused only mild, transient skin erythema. Both groups of rhesus macaques generated neutralizing antibody responses to measles that were consistent with protection and the neutralizing antibody titers were equivalent. In addition, the microneedle patches maintained an acceptable level of potency after storage at elevated temperature suggesting improved thermostability compared to standard lyophilized vaccine. In conclusion, a measles microneedle patch vaccine was immunogenic in non-human primates, and this approach offers a promising delivery method that could help increase vaccination coverage. (C) 2015 Elsevier Ltd. All rights reserved. C1 [Edens, Chris; Prausnitz, Mark R.] Georgia Tech, Coulter Dept Biomed Engn, Atlanta, GA 30332 USA. [Edens, Chris; Prausnitz, Mark R.] Emory Univ, Georgia Inst Technol, Atlanta, GA 30332 USA. [Collins, Marcus L.; Rota, Paul A.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Div Viral Dis, Atlanta, GA 30329 USA. [Goodson, James L.] Ctr Dis Control & Prevent, Ctr Global Hlth, Global Immunizat Div, Atlanta, GA 30329 USA. [Prausnitz, Mark R.] Georgia Inst Technol, Sch Chem & Biomol Engn, Atlanta, GA 30332 USA. RP Rota, PA (reprint author), Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Div Viral Dis, Atlanta, GA 30329 USA. EM par1@cdc.gov; prausnitz@gatech.edu OI Edens, William/0000-0002-7563-6201 FU National Institutes of Health [U01EB012495]; Global Immunization Division of the Centers for Disease Control and Prevention FX We thank Brianna Skinner, Robin Engel and Ryan Johnson for veterinary care and advice; Devin McAllister, Winston Pewin and Xin Dong Guo for helpful discussions of microneedle patch design and fabrication; Donna Bondy for administrative support; Susan Chu for help with obtaining financial support, Nobia Williams for help with the ELISAs, and NCHHSTP/CDC for assistance with rhesus macaques. This work was funded in part by the National Institutes of Health (grant number U01EB012495) and the Global Immunization Division of the Centers for Disease Control and Prevention. Mark Prausnitz is an inventor of patents that have been licensed to companies developing microneedle-based products, is a paid advisor to companies developing microneedle-based products, and is a founder/shareholder of companies developing microneedle-based products. The resulting potential conflict of interest has been disclosed and is managed by Georgia Tech and Emory University. NR 47 TC 19 Z9 19 U1 8 U2 42 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD SEP 8 PY 2015 VL 33 IS 37 SI SI BP 4712 EP 4718 DI 10.1016/j.vaccine.2015.02.074 PG 7 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA CR3WK UT WOS:000361263600008 PM 25770786 ER PT J AU Menke, A Casagrande, S Geiss, L Cowie, CC AF Menke, Andy Casagrande, Sarah Geiss, Linda Cowie, Catherine C. TI Prevalence of and Trends in Diabetes Among Adults in the United States, 1988-2012 SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Article ID BODY-MASS INDEX; HEALTH-INSURANCE COVERAGE; FASTING PLASMA-GLUCOSE; NATIONAL-HEALTH; US ADULTS; OBESITY; POPULATION; PARTICIPANTS; CUTOFFS AB IMPORTANCE Previous studies have shown increasing prevalence of diabetes in the United States. New US data are available to estimate prevalence of and trends in diabetes. OBJECTIVE To estimate the recent prevalence and update US trends in total diabetes, diagnosed diabetes, and undiagnosed diabetes using National Health and Nutrition Examination Survey (NHANES) data. DESIGN, SETTING, AND PARTICIPANTS Cross-sectional surveys conducted between 1988-1994 and 1999-2012 of nationally representative samples of the civilian, noninstitutionalized US population; 2781 adults from 2011-2012 were used to estimate recent prevalence and an additional 23 634 adults from 1988-2010 were used to estimate trends. MAIN OUTCOMES AND MEASURES The prevalence of diabetes was defined using a previous diagnosis of diabetes or, if diabetes was not previously diagnosed, by (1) a hemoglobin A(1c) level of 6.5% or greater or a fasting plasma glucose (FPG) level of 126 mg/dL or greater (hemoglobin A1c or FPG definition) or (2) additionally including 2-hour plasma glucose (2-hour PG) level of 200mg/dL or greater (hemoglobin A1c, FPG, or 2-hour PG definition). Prediabetes was defined as a hemoglobin A1c level of 5.7% to 6.4%, an FPG level of 100 mg/dL to 125 mg/dL, or a 2-hour PG level of 140 mg/dL to 199 mg/dL. RESULTS In the overall 2011-2012 population, the unadjusted prevalence (using the hemoglobin A1c, FPG, or 2-hour PG definitions for diabetes and prediabetes) was 14.3%(95% CI, 12.2%-16.8%) for total diabetes, 9.1% (95% CI, 7.8%-10.6%) for diagnosed diabetes, 5.2% (95% CI, 4.0%-6.9%) for undiagnosed diabetes, and 38.0%(95% CI, 34.7%-41.3%) for prediabetes; among those with diabetes, 36.4%(95% CI, 30.5%-42.7%) were undiagnosed. The unadjusted prevalence of total diabetes (using the hemoglobin A1c or FPG definition) was 12.3%(95% CI, 10.8%-14.1%); among those with diabetes, 25.2%(95% CI, 21.1%-29.8%) were undiagnosed. Compared with non-Hispanic white participants (11.3%[95% CI, 9.0%-14.1%]), the age-standardized prevalence of total diabetes (using the hemoglobin A1c, FPG, or 2-hour PG definition) was higher among non-Hispanic black participants (21.8%[95% CI, 17.7%-26.7%]; P < .001), non-Hispanic Asian participants (20.6%[95% CI, 15.0%-27.6%]; P = .007), and Hispanic participants (22.6%[95% CI, 18.4%-27.5%]; P < .001). The age-standardized percentage of cases that were undiagnosed was higher among non-Hispanic Asian participants (50.9%[95% CI, 38.3%-63.4%]; P = .004) and Hispanic participants (49.0% [95% CI, 40.8%-57.2%]; P = .02) than all other racial/ethnic groups. The age-standardized prevalence of total diabetes (using the hemoglobin A1c or FPG definition) increased from 9.8%(95% CI, 8.9%-10.6%) in 1988-1994 to 10.8%(95% CI, 9.5%-12.0%) in 2001-2002 to 12.4%(95% CI, 10.8%-14.2%) in 2011-2012 (P < .001 for trend) and increased significantly in every age group, in both sexes, in every racial/ethnic group, by all education levels, and in all poverty income ratio tertiles. CONCLUSIONS AND RELEVANCE In 2011-2012, the estimated prevalence of diabetes was 12% to 14% among US adults, depending on the criteria used, with a higher prevalence among participants who were non-Hispanic black, non-Hispanic Asian, and Hispanic. Between 1988-1994 and 2011-2012, the prevalence of diabetes increased in the overall population and in all subgroups evaluated. C1 [Menke, Andy; Casagrande, Sarah] Social & Sci Syst Inc, Silver Spring, MD 20910 USA. [Geiss, Linda] US Ctr Dis Control & Prevent, Div Diabet Translat, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. [Cowie, Catherine C.] NIDDK, NIH, Bethesda, MD USA. RP Menke, A (reprint author), Social & Sci Syst Inc, 8757 Georgia Ave, Silver Spring, MD 20910 USA. EM amenke@s-3.com FU National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) [GS10F0381L] FX This work was supported by contract GS10F0381L from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). NR 23 TC 138 Z9 139 U1 4 U2 24 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD SEP 8 PY 2015 VL 314 IS 10 BP 1021 EP 1029 DI 10.1001/jama.2015.10029 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA CQ8FA UT WOS:000360840700014 PM 26348752 ER PT J AU Abdulla, S Adam, I Adjei, GO Adjuik, MA Alemayehu, B Allan, R Arinaitwe, E Ashley, EA Ba, MS Barennes, H Barnes, KI Bassat, Q Baudin, E Berens-Riha, N Bjorkman, A Bompart, F Bonnet, M Borrmann, S Bousema, T Brasseur, P Bukirwa, H Checchi, F Dahal, P D'Alessandro, U Desai, M Dicko, A Djimde, AA Dorsey, G Doumbo, OK Drakeley, CJ Duparc, S Eshetu, T Espie, E Etard, JF Faiz, AM Falade, CO Fanello, CI Faucher, JF Faye, B Faye, O Filler, S Flegg, JA Fofana, B Fogg, C Gadalla, NB Gaye, O Genton, B Gething, PW Gil, JP Gonzalez, R Grandesso, F Greenhouse, B Greenwood, B Grivoyannis, A Guerin, PJ Guthmann, JP Hamed, K Hamour, S Hay, SI Hodel, EM Humphreys, GS Hwang, J Ibrahim, ML Jima, D Jones, JJ Jullien, V Juma, E Kachur, PS Kager, PA Kamugisha, E Kamya, MR Karema, C Kayentao, K Kiechel, JR Kironde, F Kofoed, PE Kremsner, PG Krishna, S Lameyre, V Lell, B Lima, A Makanga, M Malik, EM Marsh, K Martensson, A Massougbodji, A Menan, H Menard, D Menendez, C Mens, PF Meremikwu, M Moreira, C Nabasumba, C Nambozi, M Ndiaye, JL Ngasala, BE Nikiema, F Nsanzabana, C Ntoumi, F Oguike, M Ogutu, BR Olliaro, P Omar, SA Ouedraogo, JB Owusu-Agyei, S Penali, LK Pene, M Peshu, J Piola, P Plowe, CV Premji, Z Price, RN Randrianarivelojosia, M Rombo, L Roper, C Rosenthal, PJ Sagara, I Same-Ekobo, A Sawa, P Schallig, HDFH Schramm, B Seck, A Shekalaghe, SA Sibley, CH Sinou, V Sirima, SB Som, FA Sow, D Staedke, SG Stepniewska, K Sutherland, CJ Swarthout, TD Sylla, K Talisuna, AO Taylor, WRJ Temu, EA Thwing, JI Tine, RCK Tinto, H Tommasini, S Toure, OA Ursing, J Vaillant, MT Valentini, G Van den Broek, I Van Vugt, M Ward, SA Winstanley, PA Yavo, W Yeka, A Zolia, YM Zongo, I AF Abdulla, Salim Adam, Ishag Adjei, George O. Adjuik, Martin A. Alemayehu, Bereket Allan, Richard Arinaitwe, Emmanuel Ashley, Elizabeth A. Ba, Mamadou S. Barennes, Hubert Barnes, Karen I. Bassat, Quique Baudin, Elisabeth Berens-Riha, Nicole Bjoerkman, Anders Bompart, Francois Bonnet, Maryline Borrmann, Steffen Bousema, Teun Brasseur, Philippe Bukirwa, Hasifa Checchi, Francesco Dahal, Prabin D'Alessandro, Umberto Desai, Meghna Dicko, Alassane Djimde, Abdoulaye A. Dorsey, Grant Doumbo, Ogobara K. Drakeley, Chris J. Duparc, Stephan Eshetu, Teferi Espie, Emmanuelle Etard, Jean-Francois Faiz, Abul M. Falade, Catherine O. Fanello, Caterina I. Faucher, Jean-Francois Faye, Babacar Faye, Oumar Filler, Scott Flegg, Jennifer A. Fofana, Bakary Fogg, Carole Gadalla, Nahla B. Gaye, Oumar Genton, Blaise Gething, Peter W. Gil, Jose P. Gonzalez, Raquel Grandesso, Francesco Greenhouse, Bryan Greenwood, Brian Grivoyannis, Anastasia Guerin, Philippe J. Guthmann, Jean-Paul Hamed, Kamal Hamour, Sally Hay, Simon I. Hodel, Eva Maria Humphreys, Georgina S. Hwang, Jimee Ibrahim, Maman L. Jima, Daddi Jones, Joel J. Jullien, Vincent Juma, Elizabeth Kachur, Patrick S. Kager, Piet A. Kamugisha, Erasmus Kamya, Moses R. Karema, Corine Kayentao, Kassoum Kiechel, Jean-Rene Kironde, Fred Kofoed, Poul-Erik Kremsner, Peter G. Krishna, Sanjeev Lameyre, Valerie Lell, Bertrand Lima, Angeles Makanga, Michael Malik, ElFatih M. Marsh, Kevin Martensson, Andreas Massougbodji, Achille Menan, Herve Menard, Didier Menendez, Clara Mens, Petra F. Meremikwu, Martin Moreira, Clarissa Nabasumba, Carolyn Nambozi, Michael Ndiaye, Jean-Louis Ngasala, Billy E. Nikiema, Frederic Nsanzabana, Christian Ntoumi, Francine Oguike, Mary Ogutu, Bernhards R. Olliaro, Piero Omar, Sabah A. Ouedraogo, Jean-Bosco Owusu-Agyei, Seth Penali, Louis K. Pene, Mbaye Peshu, Judy Piola, Patrice Plowe, Christopher V. Premji, Zul Price, Ric N. Randrianarivelojosia, Milijaona Rombo, Lars Roper, Cally Rosenthal, Philip J. Sagara, Issaka Same-Ekobo, Albert Sawa, Patrick Schallig, Henk D. F. H. Schramm, Birgit Seck, Amadou Shekalaghe, Seif A. Sibley, Carol H. Sinou, Vronique Sirima, Sodiomon B. Som, Fabrice A. Sow, Doudou Staedke, Sarah G. Stepniewska, Kasia Sutherland, Colin J. Swarthout, Todd D. Sylla, Khadime Talisuna, Ambrose O. Taylor, Walter R. J. Temu, Emmanuel A. Thwing, Julie I. Tine, Roger C. K. Tinto, Halidou Tommasini, Silva Toure, Offianan A. Ursing, Johan Vaillant, Michel T. Valentini, Giovanni Van den Broek, Ingrid Van Vugt, Michele Ward, Stephen A. Winstanley, Peter A. Yavo, William Yeka, Adoke Zolia, Yah M. Zongo, Issaka CA WWARN Artemisinin Based TI Clinical determinants of early parasitological response to ACTs in African patients with uncomplicated falciparum malaria: a literature review and meta-analysis of individual patient data SO BMC MEDICINE LA English DT Review ID RESISTANT PLASMODIUM-FALCIPARUM; PARASITE CLEARANCE; ARTEMETHER-LUMEFANTRINE; ARTEMISININ RESISTANCE; COMBINATION THERAPY; IN-VIVO; EFFICACY; ARTESUNATE; CHILDREN; CAMBODIA AB Background: Artemisinin-resistant Plasmodium falciparum has emerged in the Greater Mekong sub-region and poses a major global public health threat. Slow parasite clearance is a key clinical manifestation of reduced susceptibility to artemisinin. This study was designed to establish the baseline values for clearance in patients from Sub-Saharan African countries with uncomplicated malaria treated with artemisinin-based combination therapies (ACTs). Methods: A literature review in PubMed was conducted in March 2013 to identify all prospective clinical trials (uncontrolled trials, controlled trials and randomized controlled trials), including ACTs conducted in Sub-Saharan Africa, between 1960 and 2012. Individual patient data from these studies were shared with the WorldWide Antimalarial Resistance Network (WWARN) and pooled using an a priori statistical analytical plan. Factors affecting early parasitological response were investigated using logistic regression with study sites fitted as a random effect. The risk of bias in included studies was evaluated based on study design, methodology and missing data. Results: In total, 29,493 patients from 84 clinical trials were included in the analysis, treated with artemether-lumefantrine (n = 13,664), artesunate-amodiaquine (n = 11,337) and dihydroartemisinin-piperaquine (n = 4,492). The overall parasite clearance rate was rapid. The parasite positivity rate (PPR) decreased from 59.7 % (95 % CI: 54.5-64.9) on day 1 to 6.7 % (95 % CI: 4.8-8.7) on day 2 and 0.9 % (95 % CI: 0.5-1.2) on day 3. The 95th percentile of observed day 3 PPR was 5.3 %. Independent risk factors predictive of day 3 positivity were: high baseline parasitaemia (adjusted odds ratio (AOR) = 1.16 (95 % CI: 1.08-1.25); per 2-fold increase in parasite density, P <0.001); fever (>37.5 degrees C) (AOR = 1.50 (95 % CI: 1.06-2.13), P = 0.022); severe anaemia (AOR = 2.04 (95 % CI: 1.21-3.44), P = 0.008); areas of low/moderate transmission setting (AOR = 2.71 (95 % CI: 1.38-5.36), P = 0.004); and treatment with the loose formulation of artesunate-amodiaquine (AOR = 2.27 (95 % CI: 1.14-4.51), P = 0.020, compared to dihydroartemisinin-piperaquine). Conclusions: The three ACTs assessed in this analysis continue to achieve rapid early parasitological clearance across the sites assessed in Sub-Saharan Africa. A threshold of 5 % day 3 parasite positivity from a minimum sample size of 50 patients provides a more sensitive benchmark in Sub-Saharan Africa compared to the current recommended threshold of 10 % to trigger further investigation of artemisinin susceptibility. C1 [Abdulla, Salim; Shekalaghe, Seif A.] Ifakara Hlth Inst, Dar Es Salaam, Tanzania. [Adam, Ishag] Univ Khartoum, Fac Med, Khartoum, Sudan. [Adjei, George O.] Univ Ghana, Sch Med, Ctr Trop Clin Pharmacol & Therapeut, Accra, Ghana. [Adjuik, Martin A.] INDEPTH Network Secretariat, Accra, Ghana. [Alemayehu, Bereket] Int Ctr AIDS Care & Treatment Programs, Addis Ababa, Ethiopia. [Allan, Richard; Baudin, Elisabeth; Temu, Emmanuel A.] MENTOR Initiat, Crawley, England. [Arinaitwe, Emmanuel; Staedke, Sarah G.] Infect Dis Res Collaborat, Kampala, Uganda. [Ashley, Elizabeth A.; Checchi, Francesco; Espie, Emmanuelle; Etard, Jean-Francois; Grandesso, Francesco; Nabasumba, Carolyn; Schramm, Birgit] Epictr, Paris, France. [Ba, Mamadou S.; Faye, Babacar; Faye, Oumar; Gaye, Oumar; Ndiaye, Jean-Louis; Pene, Mbaye; Sow, Doudou; Sylla, Khadime; Tine, Roger C. K.] Univ Cheikh Anta Diop, Dept Parasitol & Mycol, Fac Med, Dakar, Senegal. [Barennes, Hubert; Ouedraogo, Jean-Bosco; Tinto, Halidou] Ctr Muraz, Bobo Dioulasso, Burkina Faso. [Barennes, Hubert] French Foreign Affairs, Biarritz, France. [Barnes, Karen I.] WorldWide Antimalarial Resistance Network WWARN, Cape Town, South Africa. [Barnes, Karen I.] Univ Cape Town, Dept Med, Div Clin Pharmacol, ZA-7925 Cape Town, South Africa. [Bassat, Quique; Gonzalez, Raquel; Menendez, Clara] Ctr Invest Saude Manhica, Manhica, Mozambique. [Bassat, Quique; Eshetu, Teferi; Gonzalez, Raquel; Menendez, Clara] Univ Barcelona, Barcelona Ctr Int Hlth Res CRESIB, ISGlobal, Hosp Clin, Barcelona, Spain. [Berens-Riha, Nicole] Univ Munich LMU, Med Ctr, Div Infect Dis & Trop Med, Munich, Germany. [Berens-Riha, Nicole] LMU, German Ctr Infect Res DZIF, Munich, Germany. [Bjoerkman, Anders; Martensson, Andreas] Karolinska Inst, Dept Microbiol Tumour & Cell Biol, Stockholm, Sweden. [Bompart, Francois; Lameyre, Valerie] Sanofi Aventis, Direct Acces Med Access Med, Gentilly, France. [Bonnet, Maryline] Epictr, Geneva, Switzerland. [Borrmann, Steffen; Marsh, Kevin; Peshu, Judy] Wellcome Trust Res Programme, Kenya Med Res Inst, Kilifi, Kenya. [Borrmann, Steffen; Kremsner, Peter G.; Lell, Bertrand; Ntoumi, Francine] Univ Tubingen, Inst Trop Med, Tubingen, Germany. [Borrmann, Steffen; Drakeley, Chris J.] German Ctr Infect Res, Tubingen, Germany. [Bousema, Teun; Gadalla, Nahla B.; Oguike, Mary; Sutherland, Colin J.] London Sch Hyg & Trop Med, Fac Infect & Trop Dis, Dept Infect & Immun, London WC1, England. [Bousema, Teun] Radboud Univ Nijmegen, Med Ctr, Dept Med Microbiol, Njimegen, Netherlands. [Brasseur, Philippe] IRD, Dakar, Senegal. [Bukirwa, Hasifa; Yeka, Adoke] Uganda Malaria Surveillance Project, Kampala, Uganda. [Dahal, Prabin; Flegg, Jennifer A.; Guerin, Philippe J.; Humphreys, Georgina S.; Moreira, Clarissa; Nsanzabana, Christian; Price, Ric N.; Sibley, Carol H.; Stepniewska, Kasia] WorldWide Antimalarial Resistance Network WWARN, Oxford, England. [Dahal, Prabin; Guerin, Philippe J.; Humphreys, Georgina S.; Marsh, Kevin; Moreira, Clarissa; Nsanzabana, Christian; Olliaro, Piero; Price, Ric N.; Stepniewska, Kasia] Univ Oxford, Nuffield Dept Clin Med, Ctr Trop Med & Global Hlth, Oxford, England. [D'Alessandro, Umberto] Inst Trop Med, Unit Malariol, B-2000 Antwerp, Belgium. [D'Alessandro, Umberto] MRC Unit, Fajara, Gambia. [D'Alessandro, Umberto; Greenwood, Brian] London Sch Hyg & Trop Med, Fac Infect & Trop Dis, Dept Dis Control, London WC1, England. [Desai, Meghna; Hwang, Jimee; Kachur, Patrick S.; Thwing, Julie I.] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Malaria Branch, Atlanta, GA USA. [Dicko, Alassane; Djimde, Abdoulaye A.; Doumbo, Ogobara K.; Fofana, Bakary; Kayentao, Kassoum; Sagara, Issaka] Univ Bamako, Fac Med Pharm & Dent, Malaria Res & Training Ctr, Bamako, Mali. [Dicko, Alassane] Univ Bamako, Fac Med Pharm & Dent, Dept Publ Hlth, Bamako, Mali. [Dorsey, Grant; Greenhouse, Bryan; Rosenthal, Philip J.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. [Duparc, Stephan] Med Malaria Venture, Geneva, Switzerland. [Eshetu, Teferi] Jimma Univ, Dept Med Lab Sci & Pathol, Jimma, Ethiopia. [Etard, Jean-Francois] IRD, Montpellier, France. [Faiz, Abul M.] Mahidol Univ, Fac Trop Med, Bangkok, Thailand. [Falade, Catherine O.] Univ Ibadan, Coll Med, Dept Pharmacol & Therapeut, Ibadan, Nigeria. [Fanello, Caterina I.] Mahidol Univ, Fac Trop Med, Mahidol Oxford Res Unit, Bangkok, Thailand. [Faucher, Jean-Francois] IRD, Mother & Child Hlth Trop Res Unit, Paris, France. [Faucher, Jean-Francois] Univ Paris 05, PRES Sorbonne Paris Cite, Paris, France. [Faucher, Jean-Francois] Univ Besancon, Med Ctr, Dept Infect Dis, F-25030 Besancon, France. [Filler, Scott] Global Fund Fight AIDS TB & Malaria, Geneva, Switzerland. [Flegg, Jennifer A.] Monash Univ, Sch Math Sci, Melbourne, Vic 3004, Australia. [Flegg, Jennifer A.] Monash Univ, Monash Acad Cross & Interdisciplinary Math Applic, Melbourne, Vic 3004, Australia. [Fogg, Carole] Univ Portsmouth, Portsmouth Hosp NHS Trust, Portsmouth, Hants, England. [Gadalla, Nahla B.] Natl Res Ctr, Res Inst Trop Med, Dept Epidemiol, Khartoum, Sudan. [Gadalla, Nahla B.] NIAID, Rockville, MD USA. [Genton, Blaise; Hodel, Eva Maria; Temu, Emmanuel A.] Swiss Trop & Publ Hlth Inst, Dept Epidemiol & Publ Hlth, Basel, Switzerland. [Genton, Blaise] Univ Lausanne Hosp, Div Infect Dis, Lausanne, Switzerland. [Genton, Blaise] Univ Lausanne Hosp, Dept Ambulatory Care & Community Med, Lausanne, Switzerland. [Gething, Peter W.] Univ Oxford, Dept Zool, Spatial Ecol & Epidemiol Grp, Oxford OX1 3PS, England. [Gil, Jose P.] Karolinska Inst, Pharmacogenet Sect, Drug Resistance Unit, Dept Physiol & Pharmacol, Stockholm, Sweden. [Gil, Jose P.] Univ Lisbon, Fac Sci, Biosyst & Integrat Sci Inst BioISI, P-1699 Lisbon, Portugal. [Gil, Jose P.] SUNY Binghamton, Harpur Coll Arts & Sci, Binghamton, NY USA. [Grivoyannis, Anastasia] Univ Washington, Div Emergency Med, Seattle, WA 98195 USA. [Guthmann, Jean-Paul] Inst Veille Sanit, Dept Malad Infect, St Maurice, France. [Hamed, Kamal] Novartis Pharmaceut, E Hanover, NJ USA. [Hamour, Sally] Royal Free Hosp, UCL Ctr Nephrol, London NW3 2QG, England. [Hay, Simon I.; Lima, Angeles] Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford, England. [Hay, Simon I.] Univ Washington, Inst Hlth Metr & Evaluat, Seattle, WA 98195 USA. [Hay, Simon I.] NIH, Fogarty Int Ctr, Bethesda, MD 20892 USA. [Hodel, Eva Maria] Univ Liverpool, Liverpool Sch Trop Med, Dept Parasitol, Liverpool L3 5QA, Merseyside, England. [Hwang, Jimee] Univ Calif San Francisco, Global Hlth Grp, San Francisco, CA 94143 USA. [Ibrahim, Maman L.] Ctr Rech Med & Sanit, Niamey, Niger. [Jima, Daddi] Fed Minist Hlth, Addis Ababa, Ethiopia. [Jones, Joel J.; Zolia, Yah M.] Minist Hlth & Social Welf, Natl Malaria Control Programme, Monrovia, Liberia. [Jullien, Vincent] Univ Paris 05, AP HP, Paris, France. [Juma, Elizabeth] Kenya Govt Med Res Ctr, Nairobi, Kenya. [Kager, Piet A.; Mens, Petra F.] Univ Amsterdam, Acad Med Ctr, Ctr Infect & Immun Amsterdam CINIMA, Div Infect Dis Trop Med & AIDS, NL-1105 AZ Amsterdam, Netherlands. [Kamugisha, Erasmus] Catholic Univ Hlth & Allied Sci, Mwanza, Tanzania. [Kamya, Moses R.] Makerere Univ, Coll Hlth Sci, Kampala, Uganda. [Karema, Corine] Minist Hlth, Malaria & Other Parasit Dis Div RBC, Kigali, Rwanda. [Kiechel, Jean-Rene] Drugs Neglected Dis initiat, Geneva, Switzerland. [Kironde, Fred] Makerere Univ, Dept Biochem, Kampala, Uganda. [Kofoed, Poul-Erik; Ursing, Johan] Projecto Saude Bandim, Bissau, Guinea Bissau. [Kofoed, Poul-Erik] Kolding Cty Hosp, Dept Paediat, Kolding, Denmark. [Kremsner, Peter G.; Lell, Bertrand] Ctr Rech Med Lambarene, Lambarene, Gabon. [Krishna, Sanjeev] Univ London, Inst Infect & Immun, London, England. Operat Ctr Barcelona Athens, Med Sans Frontieres, Barcelona, Spain. [Makanga, Michael] European & Dev Countries Clin Trials Partnership, Cape Town, South Africa. [Malik, ElFatih M.] Fed Minist Hlth, Khartoum, Sudan. [Martensson, Andreas] Karolinska Inst, Dept Publ Hlth Sci, Stockholm, Sweden. [Martensson, Andreas] Uppsala Univ, Ctr Clin Res Sormland, Uppsala, Sweden. [Massougbodji, Achille] Univ Abomey Calavi, FSS, CERPAGE, Cotonou, Benin. [Menan, Herve] Univ Cocody, Fac Pharm, Dept Parasitol, Abidjan, Cote Ivoire. [Menard, Didier] Inst Pasteur Cambodia, Malaria Mol Epidemiol Unit, Phnom Penh, Cambodia. [Mens, Petra F.; Schallig, Henk D. F. H.] KIT Biomed Res, Royal Trop Inst, Amsterdam, Netherlands. [Meremikwu, Martin] Univ Calabar, Dept Paediat, Calabar, Nigeria. [Meremikwu, Martin] Inst Trop Dis Res & Prevent, Calabar, Nigeria. [Nabasumba, Carolyn] Mbarara Univ Sci & Technol, Fac Med, Mbarara, Uganda. [Nambozi, Michael] Trop Dis Res Ctr, Ndola, Zambia. [Ngasala, Billy E.; Premji, Zul] Muhimbili Univ Hlth & Allied Sci, Dept Parasitol, Dar Es Salaam, Tanzania. [Ngasala, Billy E.; Ursing, Johan] Karolinska Inst, Dept Med Solna, Infect Dis Unit, Malaria Res, Stockholm, Sweden. [Nikiema, Frederic; Ouedraogo, Jean-Bosco; Som, Fabrice A.; Tinto, Halidou; Zongo, Issaka] Inst Rech Sci Sante, Bobo Dioulasso, Burkina Faso. [Ntoumi, Francine] Univ Marien Ngouabi, FCRM, Fac Sci Sante, Brazzaville, Congo. [Ogutu, Bernhards R.] United States Army Med Res Unit, Kenya Med Res Inst, Kisumu, Kenya. [Olliaro, Piero; Taylor, Walter R. J.] UNICEF UNDP World Bank WHO Special Programme Res, Geneva, Switzerland. [Omar, Sabah A.] Kenya Govt Med Res Ctr, Ctr Biotechnol Res & Dev, Nairobi, Kenya. [Owusu-Agyei, Seth] Kintampo Hlth Res Ctr, Kintampo, Ghana. [Penali, Louis K.; Seck, Amadou] WorldWide Antimalarial Resistance Network WWARN W, Dakar, Senegal. [Piola, Patrice] Inst Pasteur Madagascar, Epidemiol Unit, Antananarivo, Madagascar. [Plowe, Christopher V.] Univ Maryland, Sch Med, Howard Hughes Med Inst, Ctr Vaccine Dev, Baltimore, MD 21201 USA. [Price, Ric N.] Menzies Sch Hlth Res, Darwin, NT, Australia. [Price, Ric N.] Charles Darwin Univ, Darwin, NT 0909, Australia. [Randrianarivelojosia, Milijaona] Inst Pasteur Madagascar, Malaria Res Unit, Antananarivo, Madagascar. [Rombo, Lars] Karolinska Inst, Karolinska Univ Hosp, Infect Dis Unit, Malaria Res Lab,Dept Med, Stockholm, Sweden. [Rombo, Lars] Malarsjukhuset, Dept Infect Dis, S-63188 Eskilstuna, Sweden. [Rombo, Lars] Clin Res Ctr, Uppsala, Sweden. [Roper, Cally] London Sch Hyg & Trop Med, Fac Infect & Trop Dis, Dept Pathogen Mol Biol, London WC1, England. [Same-Ekobo, Albert] Ctr Hosp Univ Yaounde, Fac Med & Sci Biomed, Yaounde, Cameroon. [Sawa, Patrick] Int Ctr Insect Physiol & Ecol, Human Hlth Div, Mbita, Kenya. [Shekalaghe, Seif A.] Kilimanjaro Christian Med Ctr, Kilimanjaro Clin Med Res Inst, Moshi, Tanzania. [Sibley, Carol H.] Univ Washington, Dept Genome Sci, Seattle, WA 98195 USA. [Sinou, Vronique] Aix Marseille Univ, Fac Pharm, UMR MD3, Marseille, France. [Sirima, Sodiomon B.] CNRFP, Ouagadougou, Burkina Faso. [Staedke, Sarah G.] London Sch Hyg & Trop Med, Fac Infect & Trop Dis, Dept Clin Res, London WC1, England. [Swarthout, Todd D.; Van den Broek, Ingrid] Med Sans Frontieres, London, England. [Talisuna, Ambrose O.] East Africa Reg Ctr, WorldWide Antimalarial Resistance Network WWARN, Nairobi, Kenya. [Talisuna, Ambrose O.] Univ Oxford, KEMRI, Wellcome Trust Res Programme, Nairobi, Kenya. [Taylor, Walter R. J.] Hop Cantonal Univ Geneva, Serv Med Int & Humanitaire, Geneva, Switzerland. [Temu, Emmanuel A.] Univ Basel, Basel, Switzerland. [Tommasini, Silva; Valentini, Giovanni] Sigma Tau Ind Farmaceut Riunite SpA, Rome, Italy. [Toure, Offianan A.] Inst Pasteur Cote Ivoire, Malariol Dept, Abidjan, Cote Ivoire. [Vaillant, Michel T.] CRP Sante, Ctr Hlth Studies, Methodol & Stat Unit, Luxembourg, Luxembourg. [Vaillant, Michel T.] Univ Bordeaux 2, Unite Bases Therapeut Inflammat & Infect 3677, F-33076 Bordeaux, France. [Van den Broek, Ingrid] Natl Inst Publ Hlth & Environm, Ctr Infect Dis Control, NL-3720 BA Bilthoven, Netherlands. [Van Vugt, Michele] Univ Amsterdam, Acad Med Ctr, Ctr Trop Med & Travel Med, Div Infect Dis, NL-1012 WX Amsterdam, Netherlands. [Ward, Stephen A.] Univ Liverpool, Liverpool Sch Trop Med, Dept Parasitol, Liverpool L3 5QA, Merseyside, England. [Winstanley, Peter A.] Univ Warwick, Warwick Med Sch, Coventry CV4 7AL, W Midlands, England. [Yavo, William] Univ Cocody, Fac Pharmaceut & Biol Sci, Dept Parasitol & Mycol, Abidjan, Cote Ivoire. [Yavo, William] Natl Inst Publ Hlth, Malaria Res & Control Ctr, Abidjan, Cote Ivoire. RP Abdulla, S (reprint author), Univ Oxford, Ctr Trop Med & Global Hlth, Nuffield Dept Clin Med WorldWide Antimalarial Res, Oxford, England. RI Bousema, Teun/N-3574-2014; Ward, Steve/G-6003-2015; Roper, Cally/K-2989-2013; Hay, Simon/F-8967-2015; OI Gething, Peter/0000-0001-6759-5449; Guerin, Philippe/0000-0002-6008-2963; Hamed, Kamal/0000-0003-1896-9736; Humphreys, Georgina/0000-0001-9947-0034; Ward, Steve/0000-0003-2331-3192; Roper, Cally/0000-0002-6545-309X; Hay, Simon/0000-0002-0611-7272; GADALLA, NAHLA/0000-0002-6177-6705; Price, Richard/0000-0003-2000-2874; Flegg, Jennifer/0000-0002-8809-726X; Dahal, Prabin/0000-0002-2158-846X; Sutherland, Colin/0000-0003-1592-6407 FU Bill & Melinda Gates Foundation FX WWARN is funded by a Bill & Melinda Gates Foundation grant. The funder did not participate in the study protocol development or the writing of the paper. NR 59 TC 0 Z9 0 U1 0 U2 21 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1741-7015 J9 BMC MED JI BMC Med. PD SEP 7 PY 2015 VL 13 AR 212 DI 10.1186/s12916-015-0445-x PG 16 WC Medicine, General & Internal SC General & Internal Medicine GA CQ7SO UT WOS:000360804700001 ER PT J AU Lindsey, NP Lehman, JA Staples, JE Fischer, M AF Lindsey, Nicole P. Lehman, Jennifer A. Staples, J. Erin Fischer, Marc TI West Nile Virus and Other Nationally Notifiable Arboviral Diseases - United States, 2014 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID ENCEPHALITIS; USA C1 [Lindsey, Nicole P.; Lehman, Jennifer A.; Staples, J. Erin; Fischer, Marc] CDC, Div Vector Borne Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. RP Lindsey, NP (reprint author), CDC, Div Vector Borne Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. EM nplindsey@cdc.gov NR 10 TC 11 Z9 11 U1 0 U2 7 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD SEP 4 PY 2015 VL 64 IS 34 BP 929 EP 934 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CS5BZ UT WOS:000362092300001 PM 26334477 ER PT J AU Agaku, IT Singh, T Jones, SE King, BA Jamal, A Neff, L Caraballo, RS AF Agaku, Israel T. Singh, Tushar Jones, Sherry Everett King, Brian A. Jamal, Ahmed Neff, Linda Caraballo, Ralph S. TI Combustible and Smokeless Tobacco Use Among High School Athletes - United States, 2001-2013 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Agaku, Israel T.; Singh, Tushar; King, Brian A.; Jamal, Ahmed; Neff, Linda; Caraballo, Ralph S.] CDC, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. [Singh, Tushar] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Jones, Sherry Everett] CDC, Div Adolescent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. [Jones, Sherry Everett] CDC, Sch Hlth, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. RP Agaku, IT (reprint author), CDC, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. EM IAgaku@cdc.gov NR 10 TC 1 Z9 1 U1 1 U2 2 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD SEP 4 PY 2015 VL 64 IS 34 BP 935 EP 939 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CS5BZ UT WOS:000362092300002 PM 26334565 ER PT J AU Abedi, GR Watson, JT Pham, H Nix, WA Oberste, MS Gerber, SI AF Abedi, Glen R. Watson, John T. Pham, Huong Nix, W. Allan Oberste, M. Steven Gerber, Susan I. TI Enterovirus and Human Parechovirus Surveillance - United States, 2009-2013 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID FOOT; HAND; A6 C1 [Abedi, Glen R.; Watson, John T.; Pham, Huong; Nix, W. Allan; Oberste, M. Steven; Gerber, Susan I.] CDC, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP Abedi, GR (reprint author), CDC, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. EM gabedi@cdc.gov NR 9 TC 8 Z9 9 U1 0 U2 6 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD SEP 4 PY 2015 VL 64 IS 34 BP 940 EP 943 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CS5BZ UT WOS:000362092300003 PM 26334674 ER PT J AU Kobayashi, M Bennett, NM Gierke, R Almendares, O Moore, MR Whitney, CG Pilishvili, T AF Kobayashi, Miwako Bennett, Nancy M. Gierke, Ryan Almendares, Olivia Moore, Matthew R. Whitney, Cynthia G. Pilishvili, Tamara TI Intervals Between PCV13 and PPSV23 Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP) SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID PNEUMOCOCCAL POLYSACCHARIDE VACCINE; IMMUNOCOMPROMISING CONDITIONS RECOMMENDATIONS; HIV-INFECTED ADULTS; CONJUGATE VACCINE; RESPONSES; CHILDREN; AGE C1 [Kobayashi, Miwako; Gierke, Ryan; Almendares, Olivia; Moore, Matthew R.; Whitney, Cynthia G.; Pilishvili, Tamara] CDC, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Kobayashi, Miwako] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Bennett, Nancy M.] Advisory Comm Immunizat Practices, Pneumococcal Vaccines Working Grp Chair, Chicago, IL USA. [Bennett, Nancy M.] Univ Rochester, Sch Med & Dent, Dept Med, Rochester, NY 14642 USA. RP Pilishvili, T (reprint author), CDC, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. EM tpilishvili@cdc.gov NR 18 TC 40 Z9 43 U1 0 U2 1 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD SEP 4 PY 2015 VL 64 IS 34 BP 944 EP 947 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CS5BZ UT WOS:000362092300004 PM 26334788 ER PT J AU Liang, J Wallace, G Mootrey, G AF Liang, Jennifer Wallace, Greg Mootrey, Gina TI Licensure of a Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine and Guidance for Use as a Booster Dose SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Liang, Jennifer; Mootrey, Gina] CDC, Div Bacterial Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Wallace, Greg] CDC, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP Liang, J (reprint author), CDC, Div Bacterial Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. EM JLiang@cdc.gov NR 6 TC 1 Z9 1 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD SEP 4 PY 2015 VL 64 IS 34 BP 948 EP 949 PG 2 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CS5BZ UT WOS:000362092300005 PM 26334944 ER PT J AU Yang, QH Zhong, YA Ritchey, M Cobain, M Gillespie, C Merritt, R Hong, YL George, MG Bowman, BA AF Yang, Quanhe Zhong, Yuna Ritchey, Matthew Cobain, Mark Gillespie, Cathleen Merritt, Robert Hong, Yuling George, Mary G. Bowman, Barbara A. TI Vital Signs: Predicted Heart Age and Racial Disparities in Heart Age Among US Adults at the State Level SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID DISEASE RISK-FACTORS; CARDIOVASCULAR-DISEASE; UNITED-STATES; HEALTH; MORTALITY; PREVALENCE; PROFILE; UPDATE; SYSTEM; TERM AB Introduction: Cardiovascular disease is a leading cause of morbidity and mortality in the United States. Heart age (the predicted age of a person's vascular system based on their cardiovascular risk factor profile) and its comparison with chronological age represent a new way to express risk for developing cardiovascular disease. This study estimates heart age and differences between heart age and chronological age (excess heart age) and examines racial, sociodemographic, and regional disparities in heart age among U.S. adults aged 30-74 years. Methods: Weighted 2011 and 2013 Behavioral Risk Factor Surveillance System data were applied to the sex-specific non-laboratory-based Framingham risk score models, stratifying the results by age and race/ethnic group, educational and income level, and state. These results were then translated into age-standardized heart age values, mean excess heart age was calculated, and the findings were compared across groups. Results: Overall, average predicted heart age for adult men and women was 7.8 and 5.4 years older than their chronological age, respectively. Statistically significant (p<0.05) racial/ethnic, sociodemographic, and regional differences in heart age were observed: heart age among non-Hispanic black men (58.7 years) and women (58.9 years) was greater than other racial/ethnic groups, including non-Hispanic white men (55.3 years) and women (52.5 years). Excess heart age was lowest for men and women in Utah (5.8 and 2.8 years, respectively) and highest in Mississippi (10.1 and 9.1 years, respectively). Conclusions and Implications for Public Health Practice: The predicted heart age among U.S. adults aged 30-74 years was significantly higher than their chronological age. Use of predicted heart age might 1) simplify risk communication and motivate more persons to live heart-healthy lifestyles and better comply with recommended therapeutic interventions, and 2) motivate communities to implement programs and policies that support cardiovascular health. C1 [Yang, Quanhe; Zhong, Yuna; Ritchey, Matthew; Gillespie, Cathleen; Merritt, Robert; Hong, Yuling; George, Mary G.; Bowman, Barbara A.] CDC, Div Heart Dis & Stroke Prevent, Atlanta, GA 30333 USA. [Cobain, Mark] Habit Partners Community Interest Co, London, England. RP Yang, QH (reprint author), CDC, Div Heart Dis & Stroke Prevent, Atlanta, GA 30333 USA. EM qay0@cdc.gov NR 22 TC 3 Z9 3 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD SEP 4 PY 2015 VL 64 IS 34 BP 950 EP 958 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CS5BZ UT WOS:000362092300006 PM 26335037 ER PT J AU Peacock, G Iezzoni, LI Harkin, TR AF Peacock, Georgina Iezzoni, Lisa I. Harkin, Thomas R. TI Health Care for Americans with Disabilities-25 Years after the ADA SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Editorial Material C1 [Peacock, Georgina] CDC, Natl Ctr Birth Defects & Dev Disabil, Div Human Dev & Disabil, Atlanta, GA 30333 USA. [Iezzoni, Lisa I.] Massachusetts Gen Hosp, Mongan Inst Hlth Policy, Boston, MA 02114 USA. [Iezzoni, Lisa I.] Harvard Univ, Sch Med, Med, Boston, MA USA. [Harkin, Thomas R.] US Senator, Ames, IA USA. RP Peacock, G (reprint author), CDC, Natl Ctr Birth Defects & Dev Disabil, Div Human Dev & Disabil, Atlanta, GA 30333 USA. FU Intramural CDC HHS [CC999999] NR 5 TC 2 Z9 2 U1 0 U2 1 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 EI 1533-4406 J9 NEW ENGL J MED JI N. Engl. J. Med. PD SEP 3 PY 2015 VL 373 IS 10 BP 892 EP 893 DI 10.1056/NEJMp1508854 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA CQ2OB UT WOS:000360439500004 PM 26225616 ER PT J AU Styles, T Przysiecki, P Archambault, G Sosa, L Toal, B Magri, J Cartter, M AF Styles, Timothy Przysiecki, Patricia Archambault, Gary Sosa, Lynn Toal, Brian Magri, Julie Cartter, Matthew TI Two Storm-Related Carbon Monoxide Poisoning Outbreaks-Connecticut, October 2011 and October 2012 SO ARCHIVES OF ENVIRONMENTAL & OCCUPATIONAL HEALTH LA English DT Article DE carbon monoxide poisoning; disaster medicine; environmental exposure; communications media; hazardous substances ID UNITED-STATES; ICE STORM; EXPOSURES AB Storm-related carbon monoxide (CO) poisoning outbreaks occurred in Connecticut in 2011 and 2012, despite efforts to improve public messaging. We describe the cases and incidents and identify possible preventive interventions. We defined cases as blood carboxyhemoglobin 9.0% among persons exposed to alternative power or heat sources because of storm-related losses. We identified 133 cases, including 3 deaths, in 2011 and 30 in 2012, associated with 72 and 11 incidents, respectively. Racial/ethnic minorities were overrepresented (60% of 2011 patients; 48% in 2012), compared with Connecticut's minority population (29%). Generator or charcoal misuse (83% in 2011; 100% in 2012) caused the majority of incidents. Few CO-source operators recalled media or product CO warnings. Incorrect generator and charcoal use, racial/ethnic disparities, and incomplete penetration of warning messages characterized both outbreaks. A multifaceted approach is needed to decrease postdisaster CO poisonings. C1 [Styles, Timothy] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA 30341 USA. [Styles, Timothy; Sosa, Lynn; Cartter, Matthew] Connecticut Dept Publ Hlth, Div Infect Dis, Hartford, CT USA. [Przysiecki, Patricia; Archambault, Gary; Toal, Brian] Connecticut Dept Publ Hlth, Environm & Occupat Hlth Assessment Program, Hartford, CT USA. [Magri, Julie] Ctr Dis Control & Prevent, Sci Educ & Profess Dev Program Off, Atlanta, GA 30341 USA. RP Styles, T (reprint author), Ctr Dis Control & Prevent, Div Canc Prevent & Control, 4770 Buford Highway NE,MS F-76, Atlanta, GA 30341 USA. EM vii6@cdc.gov FU Intramural CDC HHS [CC999999] NR 25 TC 0 Z9 0 U1 0 U2 2 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 1933-8244 EI 2154-4700 J9 ARCH ENVIRON OCCUP H JI Arch. Environ. Occup. Health PD SEP 3 PY 2015 VL 70 IS 5 BP 291 EP 296 DI 10.1080/19338244.2014.904267 PG 6 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA CP1OL UT WOS:000359645000009 PM 24971904 ER PT J AU Buhnerkempe, MG Gostic, K Park, M Ahsan, P Belser, JA Lloyd-Smith, JO AF Buhnerkempe, Michael G. Gostic, Katelyn Park, Miran Ahsan, Prianna Belser, Jessica A. Lloyd-Smith, James O. TI Mapping influenza transmission in the ferret model to transmission in humans SO ELIFE LA English DT Article ID A H7N9 VIRUS; AIRBORNE TRANSMISSION; RECEPTOR SPECIFICITY; A/H5N1 VIRUS; OSELTAMIVIR; RESISTANT; INFECTION; PATHOGENESIS; ADAPTATION; HOUSEHOLD AB The controversy surrounding 'gain-of-function' experiments on high-consequence avian influenza viruses has highlighted the role of ferret transmission experiments in studying the transmission potential of novel influenza strains. However, the mapping between influenza transmission in ferrets and in humans is unsubstantiated. We address this gap by compiling and analyzing 240 estimates of influenza transmission in ferrets and humans. We demonstrate that estimates of ferret secondary attack rate (SAR) explain 66% of the variation in human SAR estimates at the subtype level. Further analysis shows that ferret transmission experiments have potential to identify influenza viruses of concern for epidemic spread in humans, though small sample sizes and biological uncertainties prevent definitive classification of human transmissibility. Thus, ferret transmission experiments provide valid predictions of pandemic potential of novel influenza strains, though results should continue to be corroborated by targeted virological and epidemiological research. C1 [Buhnerkempe, Michael G.; Gostic, Katelyn; Park, Miran; Ahsan, Prianna; Lloyd-Smith, James O.] Univ Calif Los Angeles, Dept Ecol & Evolutionary Biol, Los Angeles, CA 90095 USA. [Buhnerkempe, Michael G.; Lloyd-Smith, James O.] NIH, Fogarty Int Ctr, Bethesda, MD 20892 USA. [Belser, Jessica A.] Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. RP Buhnerkempe, MG (reprint author), Univ Calif Los Angeles, Dept Ecol & Evolutionary Biol, Los Angeles, CA 90095 USA. EM michael.buhnerkempe@ucla.edu RI Lloyd-Smith, James/K-4080-2012 OI Lloyd-Smith, James/0000-0001-7941-502X FU National Institutes of Health (NIH)/Fogarty International Center (FIC) Research and Policy for Infectious Disease Dynamics (RAPIDD); National Institutes of Health (NIH) [T32-GM008185]; National Science Foundation (NSF) [DGE-1144087, EF-0928690]; University of California, Los Angeles (UCLA) FX National Institutes of Health (NIH)/Fogarty International Center (FIC) Research and Policy for Infectious Disease Dynamics (RAPIDD) Michael G Buhnerkempe, James O Lloyd-Smith; National Institutes of Health (NIH) Ruth L. Kirschstein National Research Service Award (T32-GM008185) Katelyn Gostic; National Science Foundation (NSF) DGE-1144087 Miran Park; National Science Foundation (NSF) EF-0928690 James O Lloyd-Smith; University of California, Los Angeles (UCLA) De Logi Chair in Biological Sciences James O Lloyd-Smith NR 56 TC 8 Z9 8 U1 2 U2 9 PU ELIFE SCIENCES PUBLICATIONS LTD PI CAMBRIDGE PA SHERATON HOUSE, CASTLE PARK, CAMBRIDGE, CB3 0AX, ENGLAND SN 2050-084X J9 ELIFE JI eLife PD SEP 2 PY 2015 VL 4 AR e07969 DI 10.7554/eLife.07969 PG 15 WC Biology SC Life Sciences & Biomedicine - Other Topics GA CS5GM UT WOS:000362105700001 ER PT J AU Boiano, JM Steege, AL Sweeney, MH AF Boiano, James M. Steege, Andrea L. Sweeney, Marie H. TI Adherence to Precautionary Guidelines for Compounding Antineoplastic Drugs: A Survey of Nurses and Pharmacy Practitioners SO JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL HYGIENE LA English DT Article DE pharmacy technicians; hazardous drugs; pharmacists; compounding antineoplastic drugs; web-based survey; chemotherapy; nurses; safe handling practices ID HOSPITAL MEDICATION SYSTEM; HEALTH-CARE WORKERS; SURFACE CONTAMINATION; OCCUPATIONAL-EXPOSURE; TRANSFER DEVICE; AWARENESS; PERSONNEL; AGENTS; CYCLOPHOSPHAMIDE; SETTINGS AB Precautionary guidelines detailing standards of practice and equipment to eliminate or minimize exposure to antineoplastic drugs during handling activities have been available for nearly three decades. To evaluate practices for compounding antineoplastic drugs, the NIOSH Health and Safety Practices Survey of Healthcare Workers was conducted among members of professional practice organizations representing primarily oncology nurses, pharmacists, and pharmacy technicians. This national survey is the first in over 20years to examine self-reported use of engineering, administrative, and work practice controls and PPE by pharmacy practitioners for minimizing exposure to antineoplastic drugs. The survey was completed by 241 nurses and 183 pharmacy practitioners who compounded antineoplastic drugs in the seven days prior to the survey. They reported: not always wearing two pairs of chemotherapy gloves (85%, 47%, respectively) or even a single pair (8%, 10%); not always using closed system drug-transfer devices (75%, 53%); not always wearing recommended gown (38%, 20%); I.V. lines sometimes/always primed with antineoplastic drug (19%, 30%); and not always using either a biological safety cabinet or isolator (9%, 15%). They also reported lack of: hazard awareness training (9%, 13%); safe handling procedures (20%, 11%); and medical surveillance programs (61%, 45%). Both employers and healthcare workers share responsibility for adhering to precautionary guidelines and other best practices. Employers can ensure that: workers are trained regularly; facility safe-handling procedures reflecting national guidelines are in place and support for their implementation is understood; engineering controls and PPE are available and workers know how to use them; and medical surveillance, exposure monitoring, and other administrative controls are in place. Workers can seek out training, understand and follow facility procedures, be role models for junior staff, ask questions, and report any safety concerns. C1 [Boiano, James M.; Steege, Andrea L.; Sweeney, Marie H.] NIOSH, Div Surveillance Hazard Evaluat & Field Studies, Ctr Dis Control & Prevent, Cincinnati, OH 45226 USA. RP Boiano, JM (reprint author), NIOSH, Div Surveillance Hazard Evaluat & Field Studies, 1090 Tusculum Ave,MS R-17, Cincinnati, OH 45226 USA. EM jboiano@cdc.gov RI Steege, Andrea/H-8900-2016 OI Steege, Andrea/0000-0001-5665-2559 FU National Institute for Occupational Safety and Health FX This project was supported by the National Institute for Occupational Safety and Health. NR 42 TC 0 Z9 0 U1 5 U2 13 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 1545-9624 EI 1545-9632 J9 J OCCUP ENVIRON HYG JI J. Occup. Environ. Hyg. PD SEP 2 PY 2015 VL 12 IS 9 BP 588 EP 602 DI 10.1080/15459624.2015.1029610 PG 15 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA CQ0YW UT WOS:000360325500001 PM 25897702 ER PT J AU Ceballos, D Mead, K Ramsey, J AF Ceballos, Diana Mead, Kenneth Ramsey, Jessica TI Recommendations to Improve Employee Thermal Comfort When Working in 40 degrees F Refrigerated Cold Rooms SO JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL HYGIENE LA English DT Article DE airline catering; cold rooms; food service; thermal comfort AB Cold rooms are commonly used for food storage and preparation, and are usually kept around 40 degrees F following food safety guidelines. Some food preparation employees may spend 8 or more hours inside cold rooms. These employees may not be aware of the risks associated with mildly cold temperatures, dampness, and limited ventilation. We performed an evaluation of cold rooms at an airline catering facility because of concerns with exposure to cold temperatures. We spoke with and observed employees in two cold rooms, reviewed daily temperature logs, evaluated employee's physical activity, work/rest schedule, and protective clothing. We measured temperature, percent relative humidity, and air velocities at different work stations inside the cold rooms. We concluded that thermal comfort concerns perceived by cold room employees may have been the result of air drafts at their workstations, insufficient use of personal protective equipment due to dexterity concerns, work practices, and lack of knowledge about good health and safety practices in cold rooms. These moderately cold work conditions with low air velocities are not well covered in current occupational health and safety guidelines, and wind chill calculations do not apply. We provide practical recommendations to improve thermal comfort of cold room employees. Engineering control recommendations include the redesigning of air deflectors and installing of suspended baffles. Administrative controls include the changing out of wet clothing, providing hand warmers outside of cold rooms, and educating employees on cold stress. We also recommended providing more options on personal protective equipment. However, there is a need for guidelines and educational materials tailored to employees in moderately cold environments to improve thermal comfort and minimize health and safety problems. C1 [Ceballos, Diana; Mead, Kenneth; Ramsey, Jessica] NIOSH, Cincinnati, OH 45226 USA. RP Ceballos, D (reprint author), NIOSH, 1090 Tusculum Ave,MS 11, Cincinnati, OH 45226 USA. EM DCeballos@cdc.gov FU Intramural CDC HHS [CC999999] NR 10 TC 0 Z9 0 U1 2 U2 10 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 1545-9624 EI 1545-9632 J9 J OCCUP ENVIRON HYG JI J. Occup. Environ. Hyg. PD SEP 2 PY 2015 VL 12 IS 9 BP D216 EP D221 DI 10.1080/15459624.2015.1047023 PG 6 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA CQ0YX UT WOS:000360325600004 PM 25961447 ER PT J AU Reynolds, JA Peng, Y Vaidya, N Dumitru, CG Hopkins, DP AF Reynolds, Jeffrey A. Peng, Yinan Vaidya, Namita Dumitru, Cristian G. Hopkins, David P. TI Comprehensive Tobacco Control Programs Reduce Tobacco Use and Secondhand Smoke Exposure: A Systematic Review SO JOURNAL OF THORACIC ONCOLOGY LA English DT Meeting Abstract DE interventions; tobacco; control; prevention C1 [Reynolds, Jeffrey A.; Peng, Yinan; Vaidya, Namita; Dumitru, Cristian G.; Hopkins, David P.] Ctr Dis Control & Prevent, Community Guide Branch, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1556-0864 EI 1556-1380 J9 J THORAC ONCOL JI J. Thorac. Oncol. PD SEP PY 2015 VL 10 IS 9 SU 2 MA MINI11.06 BP S302 EP S302 PG 1 WC Oncology; Respiratory System SC Oncology; Respiratory System GA DE1CX UT WOS:000370365101117 ER PT J AU Smith, J Gangadharan, D Weyant, R AF Smith, Jacinta Gangadharan, Denise Weyant, Robbin TI REVIEW OF RESTRICTED EXPERIMENT REQUESTS, DIVISION OF SELECT AGENTS AND TOXINS, CENTERS FOR DISEASE CONTROL AND PREVENTION, 2006-2013 SO HEALTH SECURITY LA English DT Review AB The Centers for Disease Control and Prevention (CDC) Division of Select Agents and Toxins (DSAT) regulates laboratories that possess, use, or transfer select agents and toxins in the United States. DSAT also mitigates biosafety risks through the review of "restricted experiments,'' which under the select agent regulations are experiments that pose heightened biosafety risks. From January 2006 through December 2013, DSAT received 618 requests from 109 entities to perform potentially restricted experiments. Of these requests, 85% were determined not to meet the regulatory definition of a restricted experiment, while 15% of the requests met the definition of a restricted experiment. Of the 91 restricted experiments proposed, DSAT approved 31 (34%) requests because the biosafety conditions proposed were commensurate with the experiments' biosafety risk. All 31 approved restricted experiments were for work with select toxins. DSAT did not approve 60 restricted experiment requests due to potentially serious biosafety risks to public health and safety. All 60 denied restricted experiments proposed inserting drug resistance traits into select agents that could compromise the control of disease. The select agents and toxins associated most frequently with requests that met the regulatory definition of a restricted experiment are Shiga toxin (n = 16), Burkholderia mallei (n = 15), Botulinum neurotoxin (n = 14), and Brucella abortus (n = 14). In general, all restricted experiment decisions are determined on a case-by-case basis. This article describes the trends and characteristics of the data associated with restricted experiment requests among select agents that have an impact on public health and safety (HHS only agents) or both public health and safety and animal health or products (overlap agents). The information presented here, coupled with the information published in the restricted experiment guidance document (www.selectagents.gov), is intended to promote awareness among the research community of the type of experiments that meet the regulatory definition of a restricted experiment as well as to provide a greater understanding of the restricted experiment review process. C1 [Smith, Jacinta; Gangadharan, Denise; Weyant, Robbin] Ctr Dis Control & Prevent, Div Select Agents & Toxins, Atlanta, GA USA. RP Gangadharan, D (reprint author), DSAT OPHPR CDC, Sci, 1600 Clifton Rd,MS A46, Atlanta, GA 30329 USA. EM ghz7@cdc.gov NR 12 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 2326-5094 EI 2326-5108 J9 HEALTH SECUR JI Health Secur. PD SEP-OCT PY 2015 VL 13 IS 5 BP 307 EP 316 DI 10.1089/hs.2015.0021 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DD1OQ UT WOS:000369691400002 PM 26347984 ER PT J AU DeBastiani, SD Strine, TW Vagi, SJ Barnett, DJ Kahn, EB AF DeBastiani, Summer D. Strine, Tara W. Vagi, Sara J. Barnett, Daniel J. Kahn, Emily B. TI PREPAREDNESS PERCEPTIONS, SOCIODEMOGRAPHIC CHARACTERISTICS, AND LEVEL OF HOUSEHOLD PREPAREDNESS FOR PUBLIC HEALTH EMERGENCIES: BEHAVIORAL RISK FACTOR SURVEILLANCE SYSTEM, 2006-2010 SO HEALTH SECURITY LA English DT Article ID OF-THE-LITERATURE; DISASTER PREPAREDNESS; UNITED-STATES; VULNERABILITY; EXPERIENCE; AFTERMATH; TERRORISM; HAZARDS; FLORIDA; COUNTY AB Our objective was to inform state and community interventions focused on increasing household preparedness by examining the association between self-reported possession of household disaster preparedness items (ie, a 3-day supply of food and water, a written evacuation plan, and a working radio and flashlight) and perceptions of household preparedness on a 3-point scale from "well prepared'' to "not at all prepared.'' Data were analyzed from 14 states participating in a large state-based telephone survey: the 2006-2010 Behavioral Risk Factor Surveillance System (BRFSS) (n = 104,654). Only 25.3% of the population felt they were well prepared, and only 12.3% had all 5 of the recommended items. Fewer than half the households surveyed had 4 or more of the recommended preparedness items (34.1%). Respondents were more likely to report their households were well prepared as the number of preparedness items possessed by their household increased. Risk factors for having no preparedness items were: younger age, being female, lower levels of education, and requesting the survey to be conducted in Spanish. To increase household disaster preparedness, more community-based preparedness education campaigns targeting vulnerable populations, such as those with limited English abilities and lower reading levels, are needed. C1 [DeBastiani, Summer D.] Univ Miami, Sch Nursing & Hlth Studies, POB 248153, Coral Gables, FL 33124 USA. [Strine, Tara W.] Ctr Dis Control & Prevent, Div State & Local Readiness, Off Publ Hlth Preparedness & Response, Atlanta, GA USA. [Vagi, Sara J.] Ctr Dis Control & Prevent, US Publ Hlth Serv, Off Publ Hlth Preparedness & Response, Atlanta, GA USA. [Kahn, Emily B.] Ctr Dis Control & Prevent, Sci Integrat & Appl Res Team, Appl Sci & Evaluat Branch, Div State & Local Readiness,Off Publ Hlth Prepare, Atlanta, GA USA. [Barnett, Daniel J.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Environm Hlth Sci, Baltimore, MD USA. RP DeBastiani, SD (reprint author), Univ Miami, Sch Nursing & Hlth Studies, POB 248153, Coral Gables, FL 33124 USA. EM SXD308@miami.edu NR 55 TC 0 Z9 0 U1 7 U2 9 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 2326-5094 EI 2326-5108 J9 HEALTH SECUR JI Health Secur. PD SEP-OCT PY 2015 VL 13 IS 5 BP 317 EP 326 DI 10.1089/hs.2014.0093 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DD1OQ UT WOS:000369691400003 PM 26348094 ER PT J AU Escoffery, C Fernandez, ME Vernon, SW Liang, ST Maxwell, AE Allen, JD Dwyer, A Hannon, PA Kohn, M DeGroff, A AF Escoffery, Cam Fernandez, Maria E. Vernon, Sally W. Liang, Shuting Maxwell, Annette E. Allen, Jennifer D. Dwyer, Andrea Hannon, Peggy A. Kohn, Marlana DeGroff, Amy TI Patient Navigation in a Colorectal Cancer Screening Program SO JOURNAL OF PUBLIC HEALTH MANAGEMENT AND PRACTICE LA English DT Article DE colorectal cancer neoplasms; early detection of cancer; health promotion; patient navigation; uninsured ID RANDOMIZED-CONTROLLED-TRIAL; COLONOSCOPY; BARRIERS; BREAST; INCOME; CARE; INTERVENTION; SCIENCE; METRICS; POLICY AB Context: Colorectal cancer (CRC) is the second leading cause of cancer death among cancers affecting both men and women in the United States. The Centers for Disease Control and Prevention's Colorectal Cancer Control Program (CRCCP) supports both direct clinical screening services (screening provision) and activities to promote screening at the population level (screening promotion). Objective: The purpose of this study was to characterize patient navigation (PN) programs for screening provision and promotion for the first 1 to 2 years of program funding. Participants: We conducted a cross-sectional survey of the 29 CRCCP grantees (25 states and 4 tribal organizations) and 14 in-depth interviews to assess program implementation. Main Outcome Measures: The survey and interview guide collected information on CRC screening provision and promotion activities and PN, including the structure of the PN program, characteristics of the navigators, funding mechanism, and navigators' activities. Results: Twenty-four of 28 CRCCP grantees of the survey used PN for screening provision whereas 18 grantees used navigation for screening promotion. Navigators were often trained in nursing or public health. Navigation activities were similar for both screening provision and promotion, and common tasks included assessing and responding to patient barriers to screening, providing patient education, and scheduling appointments. For screening provision, activities centered on making reminder calls, educating patients on bowel preparation for colonoscopies, and tracking patients for completion of the tests. Navigation may influence screening quality by improving patients' bowel preparation for colonoscopies. Conclusions: Our study provides insights into PN across a federally funded CRC program. Results suggest that PN activities may be instrumental in recruiting people into cancer screening and ensuring completed screening and follow-up. C1 [Escoffery, Cam; Liang, Shuting] Emory Univ, Rollins Sch Publ Hlth, Behav Sci & Hlth Educ, Atlanta, GA 30322 USA. [Fernandez, Maria E.; Vernon, Sally W.] Univ Texas Houston, Ctr Hlth Promot & Prevent Res, Houston, TX USA. [Maxwell, Annette E.] Univ Calif Los Angeles, Ctr Canc Prevent & Control Res, Los Angeles, CA 90024 USA. [Allen, Jennifer D.] Tufts Univ, Community Hlth Program, Boston, MA 02111 USA. [Dwyer, Andrea] Univ Colorado, Ctr Canc, Denver, CO 80262 USA. [Hannon, Peggy A.; Kohn, Marlana] Univ Washington, Hlth Promot Res Ctr, Seattle, WA 98195 USA. [DeGroff, Amy] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Atlanta, GA USA. RP Escoffery, C (reprint author), Emory Univ, Rollins Sch Publ Hlth, 1518 Clifton Rd,5th Floor, Atlanta, GA 30322 USA. EM cescoff@emory.edu RI Allen, Jennifer/M-2113-2015 FU National Cancer Institute; Centers for Disease Control and Prevention; Centers for Disease Control and Prevention (CDC) through the Cancer Prevention and Control Research Network, a network within the CDC's Prevention Research Centers Program (Emory University) [U48DP001909]; Centers for Disease Control and Prevention (CDC) through the Cancer Prevention and Control Research Network, a network within the CDC's Prevention Research Centers Program (Harvard University) [U48D001946]; Centers for Disease Control and Prevention (CDC) through the Cancer Prevention and Control Research Network, a network within the CDC's Prevention Research Centers Program (University of California at Los Angeles) [U48DP001934]; Centers for Disease Control and Prevention (CDC) through the Cancer Prevention and Control Research Network, a network within the CDC's Prevention Research Centers Program (University of Colorado) [U48DP001938]; Centers for Disease Control and Prevention (CDC) through the Cancer Prevention and Control Research Network, a network within the CDC's Prevention Research Centers Program (University of Texas at Houston) [U48DP001949]; Centers for Disease Control and Prevention (CDC) through the Cancer Prevention and Control Research Network, a network within the CDC's Prevention Research Centers Program (University of Washington) [U48DP001911] FX We have more than 6 authors as a result of a national workgroup of collaborating researchers from different universities as part of the Cancer Prevention and Control Research Network funded by the National Cancer Institute and Centers for Disease Control and Prevention.; This publication was supported by the Centers for Disease Control and Prevention (CDC) through the Cancer Prevention and Control Research Network, a network within the CDC's Prevention Research Centers Program (Emory University, U48DP001909; Harvard University, U48D001946; University of California at Los Angeles, U48DP001934; University of Colorado, U48DP001938; University of Texas at Houston, U48DP001949; University of Washington, U48DP001911). The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the CDC. NR 33 TC 4 Z9 4 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1078-4659 EI 1550-5022 J9 J PUBLIC HEALTH MAN JI J. Public Health Manag. Pract. PD SEP-OCT PY 2015 VL 21 IS 5 BP 433 EP 440 DI 10.1097/PHH.0000000000000132 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DD1TI UT WOS:000369704300008 PM 25140407 ER PT J AU Steele, CB Rose, JM Chovnick, G Townsend, JS Stockmyer, CK Fonseka, J Richardson, LC AF Steele, C. Brooke Rose, John M. Chovnick, Gary Townsend, Julie S. Stockmyer, Chrisandra K. Fonseka, Jamila Richardson, Lisa C. TI Use of Evidence-Based Practices and Resources Among Comprehensive Cancer Control Programs SO JOURNAL OF PUBLIC HEALTH MANAGEMENT AND PRACTICE LA English DT Article DE cancer; comprehensive cancer control; evidence-based practices ID EVIDENCE-BASED INTERVENTIONS; DISSEMINATION RESEARCH; COLORECTAL-CANCER; HEALTH; RECOMMENDATIONS; IMPLEMENTATION; PERSPECTIVE; TRANSLATION; PREVENTION; DIFFUSION AB Context: While efforts to promote use of evidence-based practices (EBPs) for cancer control have increased, questions remain whether this will result in widespread adoption of EBPs (eg, Guide to Community Preventive Services interventions) by comprehensive cancer control (CCC) programs. Objective: To examine use of EBPs among CCC programs to develop cancer control plans and select interventions. Design: Conducted Web-based surveys of and telephone interviews with CCC program staff between March and July 2012. Setting: CCC programs funded by the Centers for Disease Control and Prevention's National Comprehensive Cancer Control Program (NCCCP). Participants: Sixty-one CCC program directors. Main Outcome Measures: 1) Use of and knowledge/attitudes about EBPs and related resources and 2) EBP-related technical assistance needs. Results: Seventy-five percent of eligible program directors reported use of EBPs to a moderate or great extent to address program objectives. Benefits of using EBPS included their effectiveness has been proven, they are an efficient use of resources, and they lend credibility to an intervention. Challenges to using EBPs included resource limitations, lack of culturally appropriate interventions, and limited skills adapting EBPs for local use. Most respondents had heard of and used Web sites for The Guide to Community Preventive Services (95% and 91%, respectively) and Cancer Control P.L.A.N.E.T. (98% and 75%, respectively). Training needs included how to adapt an EBP and its materials for cultural appropriateness (state 78%, tribe 86%, territory 80%) and how to maintain the fidelity of an EBP (state 75%, tribe 86%, territory 60%). Conclusions: While awareness, knowledge, and use of EBPs and related resources are high, respondents identified numerous challenges and training needs. The findings from this study may be used to enhance technical assistance provided to NCCCP grantees related to selecting and implementing EBPs. C1 [Steele, C. Brooke; Townsend, Julie S.; Fonseka, Jamila] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Atlanta, GA USA. [Stockmyer, Chrisandra K.] Ctr Dis Control & Prevent, Div Populat Hlth, Atlanta, GA USA. [Richardson, Lisa C.] Ctr Dis Control & Prevent, Div Blood Disorders, Atlanta, GA USA. [Rose, John M.; Chovnick, Gary] Battelle Mem Inst, Hlth & Analyt Grp, Columbus, OH 43201 USA. RP Steele, CB (reprint author), 4770 Buford Highway NE,Chamblee Bldg,MS F-76, Atlanta, GA 30341 USA. EM BSteele1@cdc.gov FU Intramural CDC HHS [CC999999] NR 24 TC 2 Z9 2 U1 1 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1078-4659 EI 1550-5022 J9 J PUBLIC HEALTH MAN JI J. Public Health Manag. Pract. PD SEP-OCT PY 2015 VL 21 IS 5 BP 441 EP 448 DI 10.1097/PHH.0000000000000053 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DD1TI UT WOS:000369704300009 PM 24402431 ER PT J AU Townsend, JS Moore, AR Mulder, TN Boyd, M AF Townsend, Julie S. Moore, Angela R. Mulder, Tiffani N. Boyd, Mary TI What Does a Performance Measurement System Tell Us About the National Comprehensive Cancer Control Program? SO JOURNAL OF PUBLIC HEALTH MANAGEMENT AND PRACTICE LA English DT Article DE cancer control; neoplasms/prevention and control; performance measurement; program evaluation/standards; program evaluation/utilization; Public Health Practice/prevention and control ID PUBLIC-HEALTH; QUALITY IMPROVEMENT; UNITED-STATES; SURVIVORS; COALITIONS AB Context: The National Comprehensive Cancer Control Program (NCCCP) performance measurement system seeks to understand both the processes that funded programs undertake with their respective coalitions to implement the objectives of their cancer plans and the outcomes of those efforts. Objective: To identify areas of achievement and technical assistance needs of NCCCP awardees. Design: Program performance was assessed through surveys completed by program directors on performance indicators in 2009 and 2010 and queries from a Web-based management information system in 2011 and 2012. Setting: Programs funded by the Centers for Disease Control and Prevention's NCCCP. Participants: Sixty-nine programs. Main Outcome Measure(s): The key performance measures assessed were inclusion of diverse partners and key sectors in cancer coalitions, partners' involvement in activities, receiving in-kind resources from partners, using evidence-based interventions and data for setting priorities, conducting program evaluation, using community-or organization-level strategies to address cancer control efforts, and demonstrating progress toward achieving health outcomes. Results: Most programs reported having active coalitions that represent diverse organizational sectors. Nearly all programs routinely assess the burden of cancer. In-kind resources to implement activities peaked at $64 716 in the second year of a 5-year funding cycle and declined in subsequent project years. By year 3, more than 70% of programs reported having an evaluation plan. While programs reported that nearly two-thirds of their interventions were evidence-based, some programs implemented non-evidence-based interventions. A majority of programs successfully used at least 1 community-or organization-level change strategy. However, many programs did not incorporate objectives linked to health outcomes as they reported progress in implementing interventions. Conclusions: While NCCCP programs were strong at building and maintaining infrastructure, some programs may need additional technical assistance to increase the adoption of evidence-based interventions, develop solid and responsive evaluation plans, and better link efforts to population-based measures that demonstrate impact toward reducing the burden of cancer. C1 [Townsend, Julie S.; Moore, Angela R.; Mulder, Tiffani N.; Boyd, Mary] Ctr Dis Control & Prevent, Div Canc Prevent & Control, 4770 Buford Hwy NE,MS F76, Atlanta, GA 30341 USA. RP Townsend, JS (reprint author), Ctr Dis Control & Prevent, Div Canc Prevent & Control, 4770 Buford Hwy NE,MS F76, Atlanta, GA 30341 USA. EM jtownsend@cdc.gov FU Intramural CDC HHS [CC999999] NR 34 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1078-4659 EI 1550-5022 J9 J PUBLIC HEALTH MAN JI J. Public Health Manag. Pract. PD SEP-OCT PY 2015 VL 21 IS 5 BP 449 EP 458 DI 10.1097/PHH.0000000000000124 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DD1TI UT WOS:000369704300010 PM 25136936 ER PT J AU Duffy, J Johnsen, P Ferris, M Miller, M Leighton, K McGilvray, M McNamara, L Breakwell, L Yu, Y Bhavsar, T Briere, E Patel, M AF Duffy, Jonathan Johnsen, Peter Ferris, Mary Miller, Mary Leighton, Kevin McGilvray, Mark McNamara, Lucy Breakwell, Lucy Yu, Yon Bhavsar, Tina Briere, Elizabeth Patel, Manisha TI Safety of a novel meningococcal group B vaccine used in response to two outbreaks in the US SO PHARMACOEPIDEMIOLOGY AND DRUG SAFETY LA English DT Meeting Abstract C1 [Duffy, Jonathan; McNamara, Lucy; Breakwell, Lucy; Yu, Yon; Bhavsar, Tina; Briere, Elizabeth; Patel, Manisha] Ctr Dis Control & Prevent, Atlanta, GA USA. [Johnsen, Peter; Leighton, Kevin] Princeton Univ, Princeton, NJ 08544 USA. [Ferris, Mary; Miller, Mary; McGilvray, Mark] Univ Calif Santa Barbara, Santa Barbara, CA 93106 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1053-8569 EI 1099-1557 J9 PHARMACOEPIDEM DR S JI Pharmacoepidemiol. Drug Saf. PD SEP PY 2015 VL 24 SU 1 SI SI MA 310 BP 173 EP 174 PG 2 WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy GA DD5QW UT WOS:000369980200301 ER PT J AU McNeil, MM Weintraub, E Duffy, J Sukumaran, L Jacobsen, SJ Klein, NP Hambidge, SJ Lee, GM Jackson, LA Irving, SA King, JP Kharbanda, EO Bednarczyk, RA DeStefano, F AF McNeil, Michael M. Weintraub, Eric Duffy, Jonathan Sukumaran, Lakshmi Jacobsen, Steven J. Klein, Nicola P. Hambidge, Simon J. Lee, Grace M. Jackson, Lisa A. Irving, Stephanie A. King, Jennifer P. Kharbanda, Elyse O. Bednarczyk, Robert A. DeStefano, Frank TI Risk of anaphylaxis following vaccination in children and adults SO PHARMACOEPIDEMIOLOGY AND DRUG SAFETY LA English DT Meeting Abstract C1 [McNeil, Michael M.; Weintraub, Eric; Duffy, Jonathan; Sukumaran, Lakshmi; DeStefano, Frank] CDC, Atlanta, GA 30333 USA. [Jacobsen, Steven J.] Kaiser Permanente So Calif, Pasadena, CA 91101 USA. [Klein, Nicola P.] Kaiser Permanente, Vaccine Study Ctr, Oakland, CA USA. [Hambidge, Simon J.] Kaiser Permanente, Inst Hlth Res, Denver, CO USA. [Lee, Grace M.] Harvard Univ, Sch Med, Boston, MA USA. [Lee, Grace M.] Harvard Pilgrim Hlth Care Inst, Boston, MA USA. [Jackson, Lisa A.] Grp Hlth Res Inst, Seattle, WA USA. [Irving, Stephanie A.] Kaiser Permanente Northwest, Ctr Hlth Res, Portland, OR USA. [King, Jennifer P.] Marshfield Clin Res Fdn, Marshfield, WI USA. [Kharbanda, Elyse O.] HealthPartners Inst Educ & Res, Minneapolis, MN USA. [Bednarczyk, Robert A.] Kaiser Permanente, Ctr Hlth Res, Atlanta, GA USA. [Bednarczyk, Robert A.] Emory Univ, Atlanta, GA 30322 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1053-8569 EI 1099-1557 J9 PHARMACOEPIDEM DR S JI Pharmacoepidemiol. Drug Saf. PD SEP PY 2015 VL 24 SU 1 SI SI MA 314 BP 176 EP 176 PG 1 WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy GA DD5QW UT WOS:000369980200305 ER PT J AU Haber, P Moro, PL Cano, M Lewis, P Stweart, B Shimabukuro, TT AF Haber, Penina Moro, Pedro L. Cano, Maria Lewis, Paige Stweart, Brock Shimabukuro, Tom T. TI Post-licensure surveillance of quadrivalent live attenuated influenza vaccine United States, vaccine adverse event reporting system (VAERS), July 2013-June 2014 SO PHARMACOEPIDEMIOLOGY AND DRUG SAFETY LA English DT Meeting Abstract C1 [Haber, Penina; Moro, Pedro L.; Cano, Maria; Lewis, Paige; Stweart, Brock; Shimabukuro, Tom T.] CDC, Atlanta, GA 30333 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1053-8569 EI 1099-1557 J9 PHARMACOEPIDEM DR S JI Pharmacoepidemiol. Drug Saf. PD SEP PY 2015 VL 24 SU 1 SI SI MA 322 BP 180 EP 180 PG 1 WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy GA DD5QW UT WOS:000369980200313 ER PT J AU Moro, PL Lewis, P Cragan, J Tepper, N AF Moro, Pedro L. Lewis, Paige Cragan, Janet Tepper, Naomi TI Safety of seasonal influenza vaccines in pregnancy in the vaccine adverse event reporting system, 2010-2014 SO PHARMACOEPIDEMIOLOGY AND DRUG SAFETY LA English DT Meeting Abstract C1 [Moro, Pedro L.; Lewis, Paige] Ctr Dis Control & Prevent, Immunizat Safety Off, Atlanta, GA USA. [Cragan, Janet] Ctr Dis Control & Prevent, Birth Defects Branch, Div Birth Defects & Dev Disabil, Atlanta, GA USA. [Tepper, Naomi] Ctr Dis Control & Prevent, Womens Hlth & Fertil Branch, Div Reprod Hlth, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1053-8569 EI 1099-1557 J9 PHARMACOEPIDEM DR S JI Pharmacoepidemiol. Drug Saf. PD SEP PY 2015 VL 24 SU 1 SI SI MA 323 BP 180 EP 181 PG 2 WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy GA DD5QW UT WOS:000369980200314 ER PT J AU Haber, P Parashar, UD Weintraub, ES Haber, MJ DeStefano, F AF Haber, Penina Parashar, Umesh D. Weintraub, Eric S. Haber, Michael J. DeStefano, Frank TI Intussuception after Rotarix Vaccien Adverse Event Reporting System (VAERS0, 04/2008-12/2014) SO PHARMACOEPIDEMIOLOGY AND DRUG SAFETY LA English DT Meeting Abstract C1 CDC, ISO, Atlanta, GA 30333 USA. Emory Univ, Bio Stat, Atlanta, GA 30322 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1053-8569 EI 1099-1557 J9 PHARMACOEPIDEM DR S JI Pharmacoepidemiol. Drug Saf. PD SEP PY 2015 VL 24 SU 1 SI SI MA 327 BP 183 EP 183 PG 1 WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy GA DD5QW UT WOS:000369980200318 ER PT J AU Lind, JN Reefhuis, J Friedman, JM Louik, C Riehle-Colarusso, T Honein, MA AF Lind, Jennifer N. Reefhuis, Jennita Friedman, Jan M. Louik, Carol Riehle-Colarusso, Tiffany Honein, Margaret A. TI Maternal Use of Specific Selective Serotonin-reuptake Inhibitors in Early Pregnancy and the Risk of Birth Defects SO PHARMACOEPIDEMIOLOGY AND DRUG SAFETY LA English DT Meeting Abstract C1 [Lind, Jennifer N.; Reefhuis, Jennita; Riehle-Colarusso, Tiffany; Honein, Margaret A.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. [Lind, Jennifer N.] US Public Hlth Serv Commissioned Corp, Atlanta, GA USA. [Friedman, Jan M.] Univ British Columbia, Dept Med Genet, Vancouver, BC, Canada. [Louik, Carol] Boston Univ, Slone Epidemiol Grp, Boston, MA 02215 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1053-8569 EI 1099-1557 J9 PHARMACOEPIDEM DR S JI Pharmacoepidemiol. Drug Saf. PD SEP PY 2015 VL 24 SU 1 SI SI MA 430 BP 243 EP 244 PG 2 WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy GA DD5QW UT WOS:000369980200421 ER PT J AU Tinker, S Reefhuis, J Broussard, C Gilboa, S Bitsko, R Werler, M Mitchell, A AF Tinker, Sarah Reefhuis, Jennita Broussard, Cheryl Gilboa, Suzanne Bitsko, Rebecca Werler, Martha Mitchell, Allen TI Periconceptional Benzodiazepine Use and the Risk for Birth Defects: Data from the National Birth Defects Prevention Study SO PHARMACOEPIDEMIOLOGY AND DRUG SAFETY LA English DT Meeting Abstract C1 [Tinker, Sarah; Reefhuis, Jennita; Broussard, Cheryl; Gilboa, Suzanne; Bitsko, Rebecca] CDC, NCBDDD, Atlanta, GA 30333 USA. [Werler, Martha; Mitchell, Allen] Boston Univ, Sch Publ Hlth, Boston, MA USA. [Werler, Martha; Mitchell, Allen] Boston Univ, Sch Med, Boston, MA 02118 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1053-8569 EI 1099-1557 J9 PHARMACOEPIDEM DR S JI Pharmacoepidemiol. Drug Saf. PD SEP PY 2015 VL 24 SU 1 SI SI MA 451 BP 256 EP 257 PG 2 WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy GA DD5QW UT WOS:000369980200442 ER PT J AU Moro, RN Johnson, JL Leung, CC Chang, KC Martinson, N Borisov, A Goldberg, SV AF Moro, Ruth N. Johnson, John L. Leung, Chi-Chiu Chang, Kwok-Chiu Martinson, Neil Borisov, Andrey Goldberg, Stefan V. TI Ethnic and Regional Differences in Neutrophil Counts and Neutropenia Reporting in Two International Clinical Trials of Rifapentine and Rifampicin for Tuberculosis Treatment SO PHARMACOEPIDEMIOLOGY AND DRUG SAFETY LA English DT Meeting Abstract C1 [Moro, Ruth N.; Borisov, Andrey; Goldberg, Stefan V.] Ctr Dis Control & Prevent, Clin Res Branch, Div TB Eliminat, Atlanta, GA USA. [Johnson, John L.] Uganda Case Western Reserve Univ, Res Collaborat, Kampala, Uganda. [Johnson, John L.] Case Western Reserve Univ, Sch Med, Cleveland, OH USA. [Leung, Chi-Chiu; Chang, Kwok-Chiu] TB & Chest Serv, Dept Hlth, Hong Kong, Hong Kong, Peoples R China. [Martinson, Neil] Univ Witwatersrand & Baragwanath, Soweto, South Africa. [Moro, Ruth N.] CDC Fdn, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1053-8569 EI 1099-1557 J9 PHARMACOEPIDEM DR S JI Pharmacoepidemiol. Drug Saf. PD SEP PY 2015 VL 24 SU 1 SI SI MA 589 BP 336 EP 337 PG 2 WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy GA DD5QW UT WOS:000369980200580 ER PT J AU DeStefano, F Weintraub, E Duffy, J Sukumaran, L Jacobsen, SJ Klein, NP Hambidge, SJ Lee, GM Jackson, LA Irving, SA King, JP Kharbanda, EO Bednarczyk, RA McNeil, MM AF DeStefano, Frank Weintraub, Eric Duffy, Jonathan Sukumaran, Lakshmi Jacobsen, Steven J. Klein, Nicola P. Hambidge, Simon J. Lee, Grace M. Jackson, Lisa A. Irving, Stephanie A. King, Jennifer P. Kharbanda, Elyse O. Bednarczyk, Robert A. McNeil, Michael M. TI Risk of Anaphylaxis Following Influenza Vaccination: Results from the Vaccine Safety Datalink SO PHARMACOEPIDEMIOLOGY AND DRUG SAFETY LA English DT Meeting Abstract C1 [DeStefano, Frank; Weintraub, Eric; Duffy, Jonathan; Sukumaran, Lakshmi; McNeil, Michael M.] CDC, Atlanta, GA 30333 USA. [Jacobsen, Steven J.] Kaiser Permanente So Calif, Pasadena, CA 91101 USA. [Klein, Nicola P.] Kaiser Permanente, Vaccine Study Ctr, Oakland, CA USA. [Hambidge, Simon J.] Kaiser Permanente Colorado, Inst Hlth Res, Denver, CO USA. [Lee, Grace M.] Harvard Univ, Sch Med, Harvard Pilgrim Hlth Care Inst, Boston, MA USA. [Jackson, Lisa A.] Grp Hlth Res Inst, Seattle, WA USA. [Irving, Stephanie A.] Kaiser Permanente Northwest, Ctr Hlth Res, Portland, OR USA. [King, Jennifer P.] Marshfield Clin Res Fdn, Marshfield, WI USA. [Kharbanda, Elyse O.] HealthPartners Inst Educ & Res, Minneapolis, MN USA. [Bednarczyk, Robert A.] Emory Univ, Sch Publ Hlth, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1053-8569 EI 1099-1557 J9 PHARMACOEPIDEM DR S JI Pharmacoepidemiol. Drug Saf. PD SEP PY 2015 VL 24 SU 1 SI SI MA 714 BP 407 EP 407 PG 1 WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy GA DD5QW UT WOS:000369980201006 ER PT J AU Hansen, C Interrante, JD Ailes, EC Frey, MT Broussard, CS Godoshian, VJ Lewis, C Polen, KN Polen, KN Garcia, AP Gilboa, SM AF Hansen, Craig Interrante, Julia D. Ailes, Elizabeth C. Frey, Meghan T. Broussard, Cheryl S. Godoshian, Valerie J. Lewis, Courtney Polen, Kara N. Polen, Kara N. Garcia, Amanda P. Gilboa, Suzanne M. TI Assessment of YouTube Videos as a Source of Information on Medication Use in Pregnancy SO PHARMACOEPIDEMIOLOGY AND DRUG SAFETY LA English DT Meeting Abstract C1 [Hansen, Craig; Interrante, Julia D.; Ailes, Elizabeth C.; Frey, Meghan T.; Broussard, Cheryl S.; Godoshian, Valerie J.; Lewis, Courtney; Polen, Kara N.; Polen, Kara N.; Garcia, Amanda P.; Gilboa, Suzanne M.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1053-8569 EI 1099-1557 J9 PHARMACOEPIDEM DR S JI Pharmacoepidemiol. Drug Saf. PD SEP PY 2015 VL 24 SU 1 SI SI MA 761 BP 435 EP 435 PG 1 WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy GA DD5QW UT WOS:000369980201053 ER PT J AU Williamson, PC Custer, B Lanciotti, R Biggerstaff, BJ Sayers, M Eason, S Winkelman, V Lanteri, MC Petersen, LR Busch, MP AF Williamson, P. C. Custer, B. Lanciotti, R. Biggerstaff, B. J. Sayers, M. Eason, S. Winkelman, V. Lanteri, M. C. Petersen, L. R. Busch, M. P. TI Incidence of West Nile Virus Infection in the Dallas-Fort Worth Metropolitan Area During the 2012 Epidemic SO TRANSFUSION LA English DT Meeting Abstract CT AABB Annual Meeting CY OCT 24-27, 2015 CL Anaheim, CA SP AABB C1 [Williamson, P. C.; Winkelman, V.] Creat Testing Solut, Tempe, AZ USA. [Williamson, P. C.; Custer, B.; Lanteri, M. C.; Busch, M. P.] Blood Syst Res Inst, San Francisco, CA USA. [Sayers, M.; Eason, S.] Carter BloodCare, Bedford, TX USA. [Lanciotti, R.; Biggerstaff, B. J.; Petersen, L. R.] Ctr Dis Control & Prevent, Ft Collins, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0041-1132 EI 1537-2995 J9 TRANSFUSION JI Transfusion PD SEP PY 2015 VL 55 SU 3 SI SI MA S23-020B BP 15A EP 16A PG 2 WC Hematology SC Hematology GA DD5GS UT WOS:000369951500030 ER PT J AU Soyseth, V Johnsen, HL Henneberger, PK Kongerud, J AF Soyseth, Vidar Johnsen, Helle Laier Henneberger, Paul K. Kongerud, Johny TI Increased Decline in Pulmonary Function Among Employees in Norwegian Smelters Reporting Work-Related Asthma-Like Symptoms SO JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE LA English DT Article ID ALUMINUM POTROOM WORKERS; SILICON-CARBIDE INDUSTRY; LUNG-FUNCTION; OCCUPATIONAL ASTHMA; DUST EXPOSURE; FEV1 DECLINE; DISEASE; RESPONSIVENESS; COPD AB Objective: To investigate associations between work-related asthma-like symptoms (WASTH) and annual pulmonary function decline among employees of 18 Norwegian smelters. Methods: A 5-year longitudinal study in which WASTH was defined as a combination of dyspnea and wheezing that improved on rest days and vacation. Results: A total of 12,966 spirometry examinations were performed in 3084 employees. Crude annual decline in forced expiratory volume in 1 second (FEV1) (dFEV(1)) was 32.9 mL/yr (95% confidence interval, 30.5 to 35.3), and crude annual decline in forced vital capacity (FVC) (dFVC) was 40.9 mL/yr (37.8 to 43.9). After adjustment for relevant covariates, employees reporting WASTH showed higher dFEV(1) by 16.0 m:/yr (3.4 to 28.6) and higher dFVC by 20.5 mL/yr (6.0 to 35.0) compared with employees not reporting WASTH. Conclusion: Work-related asthma-like symptom was associated with greater annual declines in FEV1 and FVC, indicating a restrictive pattern. C1 [Soyseth, Vidar; Johnsen, Helle Laier; Kongerud, Johny] Univ Oslo, Akershus Univ Hosp, Fac Div, Dept Med, N-1478 Lorenskog, Norway. [Soyseth, Vidar] Univ Oslo, Fac Med, Oslo, Norway. [Johnsen, Helle Laier] Natl Inst Occupat Hlth, Oslo, Norway. [Henneberger, Paul K.] NIOSH, Ctr Dis Control & Prevent, Morgantown, WV USA. [Kongerud, Johny] Univ Oslo, Rikshosp, Radiumhosp, Dept Resp Med,Fac Div, N-0027 Oslo, Norway. RP Soyseth, V (reprint author), Univ Oslo, Akershus Univ Hosp, Fac Div, Dept Med, N-1478 Lorenskog, Norway. EM vidar.soyseth@medisin.uio.no FU Norwegian Industries, Confederation of Norwegian Business and Industry Working Environment Fund; Norwegian smelting industry; Federation of Norwegian Industries; Confederation of Norwegian Business and Industry Working Environment Fund FX Supported by Norwegian Industries, Confederation of Norwegian Business and Industry Working Environment Fund, and the Norwegian smelting industry.; Dr Soyseth received US$6000 annually from the Federation of Norwegian Industries during 1998 to 2003. Dr Johnsen had been a research fellow from 2003 to 2008, salary covered by the Confederation of Norwegian Business and Industry Working Environment Fund and the Norwegian smelting industry. Dr Kongerud totally received US$8000 from the Federation of Norwegian Industries. Dr Henneberger has conflict of interest to declare. NR 21 TC 3 Z9 3 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1076-2752 EI 1536-5948 J9 J OCCUP ENVIRON MED JI J. Occup. Environ. Med. PD SEP PY 2015 VL 57 IS 9 BP 1004 EP 1008 DI 10.1097/JOM.0000000000000518 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DC8AH UT WOS:000369441800012 PM 26340289 ER PT J AU McLellan, DL Caban-Martinez, AJ Nelson, CC Pronk, NP Katz, JN Allen, JD Davis, KL Wagner, GR Sorensen, G AF McLellan, Deborah L. Caban-Martinez, Alberto J. Nelson, Candace C. Pronk, Nicolaas P. Katz, Jeffrey N. Allen, Jennifer D. Davis, Kia L. Wagner, Gregory R. Sorensen, Glorian TI Organizational Characteristics Influence Implementation of Worksite Health Protection and Promotion Programs Evidence From Smaller Businesses SO JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE LA English DT Article ID OCCUPATIONAL-SAFETY; UNITED-STATES; WORKPLACE; READINESS; EMPLOYERS; SECTOR; SITE AB Objective: We explored associations between organizational factors (size, sector, leadership support, and organizational capacity) and implementation of occupational safety and health (OSH) and worksite health promotion (WHP) programs in smaller businesses. Methods: We conducted a webbased survey of human resource managers of 117 smaller businesses (<750 employees) and analyzed factors associated with implementation of OSH and WHP among these sites using multivariate analyses. Results: Imple-Implementation of OSH, but not WHP activities, was related to industry sector (P = 0.003). Leadership support was positively associated with OSH activities (P < 0.001), but negatively associated with WHP implementation. Organizational capacity (budgets, staffing, and committee involvement) was associated with implementation of both OSH and WHP. Size was related to neither. Conclusions: Leadership support and specifically allocated resources reflecting that support are important factors for implementing OSH and WHP in smaller organizations. C1 [McLellan, Deborah L.; Nelson, Candace C.; Allen, Jennifer D.; Davis, Kia L.; Sorensen, Glorian] Dana Farber Canc Inst, Boston, MA 02215 USA. [McLellan, Deborah L.; Caban-Martinez, Alberto J.; Nelson, Candace C.; Pronk, Nicolaas P.; Katz, Jeffrey N.; Allen, Jennifer D.; Davis, Kia L.; Wagner, Gregory R.; Sorensen, Glorian] Harvard Univ, TH Chan Sch Publ Hlth, Boston, MA 02115 USA. [Caban-Martinez, Alberto J.] Univ Miami, Sch Med, Miami, FL USA. [Pronk, Nicolaas P.] HealthPartners Inc, Minneapolis, MN USA. [Katz, Jeffrey N.] Brigham & Womens Hosp, Boston, MA USA. [Allen, Jennifer D.] Tufts Univ, Medford, MA 02155 USA. [Wagner, Gregory R.] NIOSH, CDC, Washington, DC USA. RP McLellan, DL (reprint author), Dana Farber Canc Inst, Ctr Community Based Res, 450 Brookline Ave,LW715, Boston, MA 02215 USA. EM deborah_mclellan@dfci.harvard.edu RI Allen, Jennifer/M-2113-2015; OI Davis, Kia/0000-0002-1338-3018 FU National Institute for Occupational Safety and Health [U19 OH008861]; National Institutes of Health [K05 CA108663, R25 CA057711, 5R25 GM055353] FX This work was supported by a grant from the National Institute for Occupational Safety and Health (U19 OH008861) for the Harvard School of Public Health Center for Work, Health and Well-being, and grants from the National Institutes of Health (K05 CA108663 to GS; R25 CA057711 and 5R25 GM055353 to KD). NR 42 TC 6 Z9 6 U1 2 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1076-2752 EI 1536-5948 J9 J OCCUP ENVIRON MED JI J. Occup. Environ. Med. PD SEP PY 2015 VL 57 IS 9 BP 1009 EP 1016 DI 10.1097/JOM.0000000000000517 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DC8AH UT WOS:000369441800013 PM 26340290 ER PT J AU Kim, SA Blanck, HM Cradock, A Gortmaker, S AF Kim, Sonia A. Blanck, Heidi M. Cradock, Angie Gortmaker, Steven TI Networking to Improve Nutrition Policy Research SO PREVENTING CHRONIC DISEASE LA English DT Article ID OBESITY PREVENTION; ENVIRONMENTS; PREVALENCE; FOOD AB Effective nutrition and obesity policies that improve the food environments in which Americans live, work, and play can have positive effects on the quality of human diets. The Centers for Disease Control and Prevention's (CDC's) Nutrition and Obesity Policy Research and Evaluation Network (NOPREN) conducts transdisciplinary practice-based policy research and evaluation to foster understanding of the effectiveness of nutrition policies. The articles in this special collection bring to light a set of policies that are being used across the United States. They add to the larger picture of policies that can work together over time to improve diet and health. C1 [Kim, Sonia A.; Blanck, Heidi M.] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Atlanta, GA USA. [Cradock, Angie; Gortmaker, Steven] Harvard Univ, TH Chan Sch Publ Hlth, Boston, MA 02115 USA. RP Kim, SA (reprint author), 4770 Buford Hwy NE,MS F-77, Atlanta, GA 30341 USA. EM Skim@cdc.gov FU CDC (Prevention Research Center) [U48DP001946]; NOPREN FX No author has any financial disclosures. The authors thank Linda Barnes, Suzianne Garner, and Paulette Murphy for their support. Funding for this project was provided in part by cooperative agreement with CDC (Prevention Research Center U48DP001946, including NOPREN). The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of CDC. NR 19 TC 1 Z9 1 U1 2 U2 2 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD SEP PY 2015 VL 12 AR 150329 DI 10.5888/pcd12.150329 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DB6ZV UT WOS:000368665100010 ER PT J AU Mbulo, L Palipudi, KM Nelson-Blutcher, G Murty, KS Asma, S AF Mbulo, Lazarous Palipudi, Krishna M. Nelson-Blutcher, Glenda Murty, Komanduri S. Asma, Samira CA Global Adult Tobacco Survey TI The Process of Cessation Among Current Tobacco Smokers: A Cross-Sectional Data Analysis From 21 Countries, Global Adult Tobacco Survey, 2009-2013 SO PREVENTING CHRONIC DISEASE LA English DT Article ID SMOKING CESSATION AB We analyzed data from the Global Adult Tobacco Survey (GATS) from 21 countries to categorize smokers by stages of cessation and highlight interventions that could be tailored to each stage. GATS is a nationally representative household survey that measures tobacco use and other key indicators by using a standardized protocol. The distribution of smokers into precontemplation, contemplation, and preparation stages varied by country. Using the stages of change model, each country can design and implement effective interventions suitable to its cultural, social, and economic situations to help smokers advance successfully through the stages of cessation. C1 [Mbulo, Lazarous; Palipudi, Krishna M.; Nelson-Blutcher, Glenda; Asma, Samira] Ctr Dis Control & Prevent, Global Tobacco Control Branch, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway NE,MS F-79, Atlanta, GA 30341 USA. [Murty, Komanduri S.] Ft Valley State Univ, Dept Behav Sci, Ft Valley, GA USA. RP Mbulo, L (reprint author), Ctr Dis Control & Prevent, Global Tobacco Control Branch, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway NE,MS F-79, Atlanta, GA 30341 USA. EM vyp7@cdc.gov FU Bloomberg Philanthropies' Initiative to Reduce Tobacco Use; Bill and Melinda Gates Foundation; Indian government FX The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or GATS partner organizations. The authors received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. However, GATS was supported by the Bloomberg Philanthropies' Initiative to Reduce Tobacco Use, the Bill and Melinda Gates Foundation, and the Indian government. NR 13 TC 2 Z9 2 U1 0 U2 1 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD SEP PY 2015 VL 12 AR 15014G DI 10.5888/pcd12.150146 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DB6ZV UT WOS:000368665100013 ER PT J AU Trogdon, JG Murphy, LB Khavjou, OA Li, R Maylahn, CM Tangka, FK Nurmagambetov, TA Ekwueme, DU Nwaise, I Chapman, DP Orenstein, D AF Trogdon, Justin G. Murphy, Louise B. Khavjou, Olga A. Li, Rui Maylahn, Christopher M. Tangka, Florence K. Nurmagambetov, Tursynbek A. Ekwueme, Donatus U. Nwaise, Isaac Chapman, Daniel P. Orenstein, Diane TI Costs of Chronic Diseases at the State Level: The Chronic Disease Cost Calculator SO PREVENTING CHRONIC DISEASE LA English DT Article ID HEALTH; US AB Introduction Many studies have estimated national chronic disease costs, but state-level estimates are limited. The Centers for Disease Control and Prevention developed the Chronic Disease Cost Calculator (CDCC), which estimates state -level costs for arthritis, asthma, cancer, congestive heart failure, coronary heart disease, hypertension, stroke, other heart diseases, depression, and diabetes. Methods Using publicly available and restricted secondary data from multiple national data sets from 2004 through 2008, disease-attributable annual per-person medical and absenteeism costs were estimated. Total state medical and absenteeism costs were derived by multiplying per person costs from regressions by the number of people in the state treated for each disease. Medical costs were estimated for all payers and separately for Medicaid, Medicare, and private insurers. Projected medical costs for all payers (2010 through 2020) were calculated using medical costs and projected state population counts. Results Median state-specific medical costs ranged from $410 million (asthma) to $1.8 billion (diabetes); median absenteeism costs ranged from $5 million (congestive heart failure) to $217 million (arthritis). Conclusion CDCC provides methodologically rigorous chronic disease cost estimates. These estimates highlight possible areas of cost savings achievable through targeted prevention efforts or research into new interventions and treatments. C1 [Trogdon, Justin G.] Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Hlth Policy & Management, 1101-B McGavran Greenberg Bldg,135 Dauer Dr, Chapel Hill, NC 27599 USA. [Murphy, Louise B.; Chapman, Daniel P.] Ctr Dis Control & Prevent, Div Populat Hlth, Atlanta, GA USA. [Khavjou, Olga A.] RTI Int, Res Triangle Pk, NC USA. [Li, Rui] Ctr Dis Control & Prevent, Div Diabet Translat, Atlanta, GA USA. [Maylahn, Christopher M.] New York State Dept Hlth, Albany, NY USA. [Tangka, Florence K.; Ekwueme, Donatus U.] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Atlanta, GA USA. [Nurmagambetov, Tursynbek A.] Ctr Dis Control & Prevent, Div Environm Hazards & Hlth Effects, Atlanta, GA USA. [Nwaise, Isaac] Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, Atlanta, GA USA. [Orenstein, Diane] Ctr Dis Control & Prevent, Div Community Hlth, Atlanta, GA USA. RP Trogdon, JG (reprint author), Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Hlth Policy & Management, 1101-B McGavran Greenberg Bldg,135 Dauer Dr, Chapel Hill, NC 27599 USA. EM justintrogdon@unc.edu FU CDC [200-2008-27958, 002] FX This research was funding by CDC (contract no. 200-2008-27958, task order 002). The findings and conclusions in this paper are those of the authors and do not necessarily represent the official position of CDC. NR 23 TC 6 Z9 6 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD SEP PY 2015 VL 12 AR 150131 DI 10.5888/pcd12.150131 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DB6ZV UT WOS:000368665100002 ER PT J AU Hing, E Hsiao, CJ AF Hing, Esther Hsiao, Chun-Ju TI In which states are physician assistants or nurse practitioners more likely to work in primary care? SO JAAPA-JOURNAL OF THE AMERICAN ACADEMY OF PHYSICIAN ASSISTANTS LA English DT Article DE physician assistant; nurse practitioner; primary care practice; scope of practice; multispecialty; metropolitan AB Objective: Examine availability of physician assistants (PAs) or nurse practitioners (NPs) in primary care physician practices by state and by state PA and NP scope-of-practice laws. Methods: Availability of PAs and NPs in primary care practices was examined in multivariate analysis using a 2012 state-based, nationally representative survey of office-based physicians. Covariates included practice characteristics, state, and in a separate model, PA and NP scope-of-practice variables. Results: After controlling for practice characteristics, higher use of PAs and NPs was found in three states (Minnesota, Montana, and South Dakota). In a separate model, higher use of PAs or NPs was associated with favorable PA scope-of-practice laws, but not with NP scope-of-practice laws. Conclusions: Higher availability of PAs or NPs was associated with favorable PA scope-of-practice laws. Lack of association between PA or NP availability and NP scope-of-practice laws requires further investigation. C1 [Hing, Esther] CDC, Natl Ctr Hlth Stat, Div Hlth Care Stat, Hyattsville, MD USA. [Hsiao, Chun-Ju] Natl Ctr Hlth Stat, Hyattsville, MD USA. RP Hing, E (reprint author), CDC, Natl Ctr Hlth Stat, Div Hlth Care Stat, Hyattsville, MD USA. FU Office of the National Coordinator for Health Information Technology FX The authors would like to thank the Office of the National Coordinator for Health Information Technology for funding the National Ambulatory Medical Care Survey-Electronic Medical Records Survey. NR 21 TC 2 Z9 2 U1 1 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1547-1896 EI 0893-7400 J9 JAAPA-J AM ACAD PHYS JI JAAPA-J. Am. Acad. Physician Assist. PD SEP PY 2015 VL 28 IS 9 BP 46 EP 53 DI 10.1097/01.JAA.0000470436.69199.45 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA DB7EM UT WOS:000368677500011 PM 26302324 ER PT J AU Mork, N Griffin, S AF Mork, Nathan Griffin, Susan TI Perceived safety and benefit of community water fluoridation: 2009 HealthStyles survey SO JOURNAL OF PUBLIC HEALTH DENTISTRY LA English DT Article DE community water fluoridation; fluoride; dental public health; effectiveness; safety ID CHILDREN; RISK; PERCEPTIONS; OPPOSITION; AMBIGUITY; AUSTRALIA; OPINIONS; SUPPORT; ADULTS; CARIES AB Objectives: To describe perceived benefits and safety of community water fluoridation (CWF) and investigate factors associated with those perceptions of CWF among respondents to a proprietary survey in the United States. Methods: We obtained data from the 2009 HealthStyles survey, a convenience sample of 4,556 respondents. Pearson's chi-squared and logistic regression were used to determine the associations between certain socio-demographic factors and perceptions regarding the safety and health benefits of CWF. Results: The majority of respondents (55.3 percent) strongly agreed/agreed that CWF was safe, while 31.5 percent were neutral, and 13.2 percent disagreed/strongly disagreed. Twenty-seven percent of respondents reported CWF had no health benefit, 57.3 percent reported some benefit, and 15.5 percent reported great benefit. Perceived CWF safety and benefit in the bivariate analyses were associated with gender, age, race/ethnicity, education, marital status, income, sealant knowledge, CWF knowledge, past year dental utilization, and perceived vaccine safety. Respondents with knowledge of CWF (47.9 percent) were more likely to agree that it was safe (69.8 percent) than those who reported no knowledge (41.3 percent). Among respondents who said childhood vaccines were not safe (4.0 percent), almost half disagreed that CWF was safe. Logistic regression results indicated that perceived CWF safety and benefits increased with CWF knowledge, perceived vaccine safety, and income. Conclusions: Although only a minority of the US population perceived CWF as unsafe or providing no benefit to health, perceptions regarding CWF varied by knowledge of CWF and socio-demographic factors. Oral health promotion activities should consider these differing perceptions of CWF among groups to tailor oral health messaging appropriately. C1 [Mork, Nathan; Griffin, Susan] Ctr Dis Control & Prevent, Div Oral Hlth, Mail Stop F-80 4770 Buford Highway NE, Atlanta, GA 30341 USA. RP Griffin, S (reprint author), Ctr Dis Control & Prevent, Div Oral Hlth, Mail Stop F-80 4770 Buford Highway NE, Atlanta, GA 30341 USA. EM sig1@CDC.GOV FU Intramural CDC HHS [CC999999] NR 31 TC 1 Z9 1 U1 3 U2 8 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0022-4006 EI 1752-7325 J9 J PUBLIC HEALTH DENT JI J. Public Health Dent. PD FAL PY 2015 VL 75 IS 4 BP 327 EP 336 DI 10.1111/jphd.12104 PG 10 WC Dentistry, Oral Surgery & Medicine; Public, Environmental & Occupational Health SC Dentistry, Oral Surgery & Medicine; Public, Environmental & Occupational Health GA DB3TX UT WOS:000368435900010 PM 26147330 ER PT J AU Wong-McClure, RA Gregg, EW Barcelo, A Lee, K Abarca-Gomez, L Sanabria-Lopez, L Tortos-Guzman, J AF Wong-McClure, Roy A. Gregg, Edward W. Barcelo, Alberto Lee, Kahye Abarca-Gomez, Leandra Sanabria-Lopez, Laura Tortos-Guzman, Jaime TI Prevalence of metabolic syndrome in Central America: a cross-sectional population-based study SO REVISTA PANAMERICANA DE SALUD PUBLICA-PAN AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article DE Metabolic syndrome X; Belize; Costa Rica; Guatemala; Honduras; Nicaragua; Central America ID CARDIOVASCULAR-DISEASE; ASSOCIATION; COUNTRIES; GENDER; ADULTS; RISK AB Objective. To report the prevalence of metabolic syndrome (MetS) as found by the Central American Diabetes Initiative (CAMDI) study for five major Central American populations: Belize (national); Costa Rica (San Jose); Guatemala (Guatemala City); Honduras (Tegucigalpa); and Nicaragua (Managua). Methods. Study data on 6 185 adults aged 20 years or older with anthropometric and laboratory determination of MetS from population-based surveys were analyzed. Overall, the survey response rate was 82.0%. MetS prevalence was determined according to criteria from the Adult Treatment Panel III of the National Cholesterol Education Program. The study's protocol was reviewed and approved by the bioethical committee of each country studied. Results. The overall standardized prevalence of MetS in the Central American region was 30.3% (95% confidence interval (CI): 27.1-33.4). There was wide variability by gender and work conditions, with higher prevalence among females and unpaid workers. The standardized percentage of the population free of any component of MetS was lowest in Costa Rica (9.0%; CI: 6.5-11.4) and highest in Honduras (21.1%; CI: 16.4-25.9). Conclusions. Overall prevalence of MetS in Central America is high. Strengthening surveillance of chronic diseases and establishing effective programs for preventing cardiovascular diseases might reduce the risk of MetS in Central America. C1 [Wong-McClure, Roy A.; Abarca-Gomez, Leandra; Sanabria-Lopez, Laura] Caja Costarricense Seguro Social, Off Epidemiol & Surveillance, San Jose, Costa Rica. [Gregg, Edward W.] US Ctr Dis Control & Prevent, Epidemiol & Stat Branch, Div Diabet Translat, Atlanta, GA USA. [Barcelo, Alberto] Pan Amer Hlth Org, Chron Dis, Washington, DC USA. [Lee, Kahye; Tortos-Guzman, Jaime] Caja Costarricense Seguro Social, Hosp San Juan de Dios, Div Cardiol, San Jose, Costa Rica. RP Wong-McClure, RA (reprint author), Caja Costarricense Seguro Social, Off Epidemiol & Surveillance, San Jose, Costa Rica. EM rwong@ccss.sa.cr FU Central American governments of the participant countries; PAHO; CDC FX The CAMDI project was supported by funds from the Central American governments of the participant countries, PAHO, and the CDC. NR 20 TC 1 Z9 1 U1 2 U2 3 PU PAN AMER HEALTH ORGANIZATION PI WASHINGTON PA 525 23RD ST NW, WASHINGTON, DC 20037 USA SN 1020-4989 J9 REV PANAM SALUD PUBL JI Rev. Panam. Salud Publica PD SEP PY 2015 VL 38 IS 3 BP 202 EP 208 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CZ9DF UT WOS:000367397300004 PM 26757998 ER PT J AU Weinbaum, CM Cano, M AF Weinbaum, Cindy M. Cano, Maria TI HPV Vaccination and Complex Regional Pain Syndrome: Lack of Evidence SO EBIOMEDICINE LA English DT Editorial Material ID HUMAN-PAPILLOMAVIRUS VACCINATION; IMMUNIZATION C1 [Weinbaum, Cindy M.] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA 30329 USA. [Cano, Maria] Ctr Dis Control & Prevent, Immunizat Safety Off, Div Healthcare Qual Promot, Atlanta, GA 30329 USA. RP Weinbaum, CM (reprint author), Ctr Dis Control & Prevent, Div Healthcare Qual Promot, 1600 Clifton Rd, Atlanta, GA 30329 USA. EM cweinbaum@cdc.gov; mcano@cdc.gov NR 8 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 2352-3964 J9 EBIOMEDICINE JI EBioMedicine PD SEP PY 2015 VL 2 IS 9 BP 1014 EP 1015 DI 10.1016/j.ebiom.2015.08.030 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA CX8MK UT WOS:000365957600006 PM 26779563 ER PT J AU Lecher, SL Shrestha, RK Botts, LW Alvarez, J Moore, JH Thomas, V Weidle, PJ AF Lecher, Shirley Lee Shrestha, Ram K. Botts, Linda W. Alvarez, Jorge Moore, James H. Thomas, Vasavi Weidle, Paul J. TI Cost analysis of a novel HIV testing strategy in community pharmacies and retail clinics SO JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION LA English DT Article ID HUMAN-IMMUNODEFICIENCY-VIRUS; HEALTH-CARE SETTINGS; RECOMMENDATIONS; INFECTION; ACCESS AB Objective: To document the cost of implementing point-of-care (POC) human immunodeficiency virus (HIV) rapid testing in busy community pharmacies and retail clinics. Providing HIV testing services in community pharmacies and retail clinics is an innovative way to expand HIV testing. The cost of implementing POC HIV rapid testing in a busy retail environment needs to be documented to provide program and policy leaders with adequate information for planning and budgeting. Design: Cost analysis from a pilot project that provided confidential POC HIV rapid testing services in community pharmacies and retail clinics. Setting: The pharmacy sites were operated under several different ownership structures (for-profit, nonprofit, sole proprietorship, corporation, public, and private) in urban and rural areas. We included data from the initial six sites that participated in the project. We collected the time spent by pharmacy and retail clinic staff for pretest and posttest counseling in an activity log for time-in-motion for each interaction. Participants: Pharmacists and retail clinic staff. Intervention: HIV rapid testing. Main outcome measures: The total cost was calculated to include costs of test kits, control kits, shipping, test supplies, training, reporting, program administration, and advertising. Results: The six sites trained 22 staff to implement HIV testing. A total of 939 HIV rapid tests were conducted over a median time of 12 months, of which 17 were reactive. Median pretest counseling time was 2 minutes. Median posttest counseling time was 2 minutes for clients with a nonreactive test and 10 minutes for clients with a reactive test. The average cost per person tested was an estimated $47.21. When we considered only recurrent costs, the average cost per person tested was $32.17. Conclusions: Providing POC HIV rapid testing services required a modest amount of staff time and costs that are comparable to other services offered in these settings. HIV testing in pharmacies and retail clinics can provide an additional alternative venue for increasing the availability and accessibility of HIV testing services in the United States. C1 [Lecher, Shirley Lee; Shrestha, Ram K.; Alvarez, Jorge; Thomas, Vasavi; Weidle, Paul J.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. [Botts, Linda W.] ASHLIN Management Grp Inc, Greenbelt, MD USA. [Moore, James H.] IMPAQ Int LLC, Labor Div, Columbia, MD USA. RP Lecher, SL (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, 1600 Clifton Rd,MS G-45, Atlanta, GA 30333 USA. EM slecher@cdc.gov FU Centers for Disease Control and Prevention [200-2009-30908-00004] FX Provided by the Centers for Disease Control and Prevention, Contract 200-2009-30908-00004, to ASHLIN Management Group, Inc., Atlanta, GA. NR 16 TC 0 Z9 0 U1 1 U2 6 PU AMER PHARMACEUTICAL ASSOC PI WASHINGTON PA 2215 CONSTITUTION AVE NW, WASHINGTON, DC 20037 USA SN 1544-3191 EI 1544-3450 J9 J AM PHARM ASSOC JI J. Am. Pharm. Assoc. PD SEP-OCT PY 2015 VL 55 IS 5 BP 488 EP 492 DI 10.1331/JAPhA.2015.150630 PG 5 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA CX2FJ UT WOS:000365511000007 PM 26359959 ER PT J AU Cohen, AL Sahr, PK Treurnicht, F Walaza, S Groome, MJ Kahn, K Dawood, H Variava, E Tempia, S Pretorius, M Moyes, J Olorunju, SAS Malope-Kgokong, B Kuonza, L Wolter, N von Gottberg, A Madhi, SA Venter, M Cohen, C AF Cohen, Adam L. Sahr, Philip K. Treurnicht, Florette Walaza, Sibongile Groome, Michelle J. Kahn, Kathleen Dawood, Halima Variava, Ebrahim Tempia, Stefano Pretorius, Marthi Moyes, Jocelyn Olorunju, Steven A. S. Malope-Kgokong, Babatyi Kuonza, Lazarus Wolter, Nicole von Gottberg, Anne Madhi, Shabir A. Venter, Marietjie Cohen, Cheryl CA South African Severe Acute Resp TI Parainfluenza Virus Infection Among Human Immunodeficiency Virus (HIV)-Infected and HIV-Uninfected Children and Adults Hospitalized for Severe Acute Respiratory Illness in South Africa, 2009-2014 SO OPEN FORUM INFECTIOUS DISEASES LA English DT Article DE HIV; parainfluenza virus; severe acute respiratory illness; South Africa ID COMMUNITY-ACQUIRED PNEUMONIA; TRACT INFECTIONS; RURAL THAILAND; UNITED-STATES; PREVALENCE; ETIOLOGY; EPIDEMIOLOGY; AGE AB Background. Parainfluenza virus (PIV) is a common cause of acute respiratory tract infections, but little is known about PIV infection in children and adults in Africa, especially in settings where human immunodeficiency virus (HIV) prevalence is high. Methods. We conducted active, prospective sentinel surveillance for children and adults hospitalized with severe acute respiratory illness (SARI) from 2009 to 2014 in South Africa. We enrolled controls (outpatients without febrile or respiratory illness) to calculate the attributable fraction for PIV infection. Respiratory specimens were tested by multiplex real-time reverse-transcription polymerase chain reaction assay for parainfluenza types 1, 2, and 3. Results. Of 18 282 SARI cases enrolled, 1188 (6.5%) tested positive for any PIV type: 230 (19.4%) were type 1; 168 (14.1%) were type 2; 762 (64.1%) were type 3; and 28 (2.4%) had coinfection with 2 PIV types. After adjusting for age, HIV serostatus, and respiratory viral coinfection, the attributable fraction for PIV was 65.6% (95% CI [ confidence interval], 47.1-77.7); PIV contributed to SARI among HIV-infected and -uninfected children < 5 years of age and among individuals infected with PIV types 1 and 3. The observed overall incidence of PIV-associated SARI was 38 (95% CI, 36-39) cases per 100 000 population and was highest in children < 1 year of age (925 [ 95% CI, 864-989] cases per 100 000 population). Compared with persons without HIV, persons with HIV had an increased relative risk of PIV hospitalization (9.4; 95% CI, 8.5-10.3). Conclusions. Parainfluenza virus causes substantial severe respiratory disease in South Africa among children < 5 years of age, especially those that are infected with HIV. C1 [Cohen, Adam L.; Tempia, Stefano; Venter, Marietjie] Ctr Dis Control & Prevent South Africa, ZA-0001 Pretoria, South Africa. [Cohen, Adam L.; Tempia, Stefano] Ctr Dis Control & Prevent, Atlanta, GA USA. [Cohen, Adam L.] US PHS, Rockville, MD USA. [Sahr, Philip K.; Kuonza, Lazarus] South African Field Epidemiol Training Program, Johannesburg, South Africa. [Sahr, Philip K.] Univ Pretoria, Fac Hlth Sci, Sch Hlth Syst & Publ Hlth, ZA-0002 Pretoria, South Africa. [Treurnicht, Florette; Walaza, Sibongile; Tempia, Stefano; Moyes, Jocelyn; Malope-Kgokong, Babatyi; Wolter, Nicole; von Gottberg, Anne; Madhi, Shabir A.; Cohen, Cheryl] Natl Inst Communicable Dis, Ctr Resp Dis & Meningitis, Johannesburg, South Africa. [Walaza, Sibongile; Moyes, Jocelyn; Cohen, Cheryl] Univ Witwatersrand, Sch Publ Hlth, Johannesburg, South Africa. [Groome, Michelle J.] Univ Witwatersrand, Resp & Meningeal Pathogens Res Unit, Med Res Council, Fac Hlth Sci, Johannesburg, South Africa. [Groome, Michelle J.; Madhi, Shabir A.] Univ Witwatersrand, Dept Sci & Technol, Natl Res Fdn Vaccine Preventable Dis, Johannesburg, South Africa. [Kahn, Kathleen] Univ Witwatersrand, Sch Publ Hlth, MRC Wits Rural Publ Hlth & Hlth Transit Res Unit, Johannesburg, South Africa. [Variava, Ebrahim] Univ Witwatersrand, Fac Hlth Sci, Dept Internal Med, Johannesburg, South Africa. [Wolter, Nicole; von Gottberg, Anne] Univ Witwatersrand, Fac Hlth Sci, Sch Pathol, Johannesburg, South Africa. [Kahn, Kathleen] Umea Univ, Ctr Global Hlth Res, S-90187 Umea, Sweden. [Kahn, Kathleen] INDEPTH Network, Accra, Ghana. [Dawood, Halima] Pietermaritzburg Metropolitan Hosp Complex, Durban, South Africa. [Dawood, Halima] Univ KwaZulu Natal, Durban, South Africa. [Variava, Ebrahim] Klerksdorp Tshepong Hosp Complex, Dept Internal Med, Durban, South Africa. [Pretorius, Marthi; Venter, Marietjie] Univ Pretoria, Zoonoses Res Unit, Dept Med Virol, ZA-0002 Pretoria, South Africa. [Pretorius, Marthi] Natl Hlth Lab Serv, Tshwane Acad Div, Pretoria, South Africa. [Olorunju, Steven A. S.] MRC, Pretoria, South Africa. RP Cohen, AL (reprint author), Ctr Dis Control & Prevent South Africa, POB 9536, ZA-0001 Pretoria, South Africa. EM dvj1@cdc.gov RI Venter, Marietjie/P-9604-2016 OI Venter, Marietjie/0000-0003-2696-824X NR 30 TC 1 Z9 1 U1 0 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 2328-8957 J9 OPEN FORUM INFECT DI JI Open Forum Infect. Dis. PD FAL PY 2015 VL 2 IS 4 DI 10.1093/ofid/ofv139 PG 9 WC Infectious Diseases SC Infectious Diseases GA CX6BY UT WOS:000365787400006 ER PT J AU Grant, RM Smith, DK AF Grant, Robert M. Smith, Dawn K. TI Integrating Antiretroviral Strategies for Human Immunodeficiency Virus Prevention: Post- and Pre-Exposure Prophylaxis and Early Treatment SO OPEN FORUM INFECTIOUS DISEASES LA English DT Review DE early treatment; HIV; postexposure prophylaxis; pre-exposure prophylaxis; prevention ID POSTEXPOSURE PROPHYLAXIS; DRUG-RESISTANCE; HIV PREVENTION; CARE SETTINGS; INFECTION; MEN; RECOMMENDATIONS; SEROCONVERSION; WOMEN; TRIAL AB Best practices for integrating human immunodeficiency virus (HIV) testing and antiretroviral interventions for prevention and treatment are suggested based on research evidence and existing normative guidance. The goal is to provide high-impact prevention services during periods of substantial risk. Antiretroviral medications are recommended for postexposure prophylaxis (PEP), pre-exposure prophylaxis (PrEP), and treatment of HIV infection. We reviewed research evidence and current normative guidelines to identify best practices for integrating these high-impact prevention strategies. More sensitive HIV tests used for screening enable earlier diagnosis and treatment of HIV infection, more appropriate counseling, and help limit drug resistance. A fully suppressive PEP regimen should be initiated based on exposure history or physical findings when sensitive diagnostic testing is delayed or not available and antibody tests are negative. Transitions from PEP to PrEP are often warranted because HIV exposure events may continue to occur. This algorithmic approach to integrating PEP, PrEP, and early treatment decisions may increase the uptake of these interventions by a greater number and diversity of knowledgeable healthcare providers. C1 [Grant, Robert M.] Gladstone Inst, San Francisco, CA 94158 USA. [Grant, Robert M.] Univ Calif San Francisco, San Francisco, CA 94158 USA. [Grant, Robert M.] San Francisco AIDS Fdn, San Francisco, CA USA. [Smith, Dawn K.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. RP Grant, RM (reprint author), Gladstone Inst, 1650 Owens St, San Francisco, CA 94158 USA. EM robert.grant@ucsf.edu NR 51 TC 5 Z9 5 U1 2 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 2328-8957 J9 OPEN FORUM INFECT DI JI Open Forum Infect. Dis. PD FAL PY 2015 VL 2 IS 4 DI 10.1093/ofid/ofv126 PG 7 WC Infectious Diseases SC Infectious Diseases GA CX6BY UT WOS:000365787400010 ER PT J AU Grijalva, CG Wunderink, RG Zhu, YW Williams, DJ Balk, R Fakhran, S Courtney, DM Anderson, EJ Qi, C Trabue, C Pavia, AT Moore, MR Jain, S Edwards, KM Self, WH AF Grijalva, Carlos G. Wunderink, Richard G. Zhu, Yuwei Williams, Derek J. Balk, Robert Fakhran, Sherene Courtney, D. Mark Anderson, Evan J. Qi, Chao Trabue, Christopher Pavia, Andrew T. Moore, Matthew R. Jain, Seema Edwards, Kathryn M. Self, Wesley H. TI In-Hospital Pneumococcal Polysaccharide Vaccination Is Associated With Detection of Pneumococcal Vaccine Serotypes in Adults Hospitalized for Community-Acquired Pneumonia SO OPEN FORUM INFECTIOUS DISEASES LA English DT Article DE antigen; pneumococcal conjugate vaccine; pneumonia; serotype; urine ID CONJUGATE VACCINE; ANTIGEN TEST; US ADULTS; IMMUNIZATION AB During an etiology study of adults hospitalized for pneumonia, in which urine specimens were examined for serotype-specific pneumococcal antigen detection, we observed that some patients received 23-valent pneumococcal polysaccharide vaccine before urine collection. Some urine samples became positive for specific vaccine pneumococcal serotypes shortly after vaccination, suggesting false-positive test results. C1 [Grijalva, Carlos G.; Zhu, Yuwei; Williams, Derek J.; Edwards, Kathryn M.; Self, Wesley H.] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA. [Grijalva, Carlos G.] VA Tennessee Valley, Geriatr Res Educ Clin Ctr, Nashville, TN USA. [Wunderink, Richard G.; Courtney, D. Mark; Qi, Chao] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. [Balk, Robert] Rush Univ, Sch Med, Chicago, IL 60612 USA. [Fakhran, Sherene] John H Stroger Jr Hosp Cook Cty, Chicago, IL USA. [Anderson, Evan J.] Emory Univ, Sch Med, Atlanta, GA USA. [Trabue, Christopher] Vanderbilt Univ, St Thomas Hlth, Hlth Sci Ctr, Nashville, TN 37212 USA. [Pavia, Andrew T.] Univ Utah, Sch Med, Salt Lake City, UT USA. [Moore, Matthew R.; Jain, Seema] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Grijalva, CG (reprint author), Vanderbilt Univ, Sch Med, Dept Hlth Policy, 1500 21st Ave South,Village Vanderbilt Suite 2600, Nashville, TN 37212 USA. EM carlos.grijalva@vanderbilt.edu OI Wunderink, Richard/0000-0002-8527-4195 NR 15 TC 1 Z9 1 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 2328-8957 J9 OPEN FORUM INFECT DI JI Open Forum Infect. Dis. PD FAL PY 2015 VL 2 IS 4 DI 10.1093/ofid/ofv135 PG 5 WC Infectious Diseases SC Infectious Diseases GA CX6BY UT WOS:000365787400013 ER PT J AU Mullins, J Kudish, K Sosa, L Hadler, J AF Mullins, Jocelyn Kudish, Kathy Sosa, Lynn Hadler, Jim TI Continuing Decline in Varicella Incidence After the 2-Dose Vaccination Recommendation-Connecticut, 2009-2014 SO OPEN FORUM INFECTIOUS DISEASES LA English DT Article DE immunization; vaccine; varicella ID AGED 19-35 MONTHS; UNITED-STATES; SCHOOL YEAR; COVERAGE; CHILDREN; EPIDEMIOLOGY; KINDERGARTEN; ADOLESCENTS; IMPACT AB Background. Varicella is a highly contagious vaccine-preventable illness. In 1996, the Advisory Committee for Immunization Practices recommended 1 dose of vaccine for children, and in 2006 it recommended 2 doses; Connecticut required 1 dose for school entry in 2000 and 2 doses for school entry starting in 2011. Connecticut varicella incidence overall and among persons aged 1-14 years declined during 2005-2008. We analyzed varicella surveillance data for 2009-2014 to characterize overall and age group-specific trends in the setting of the 2-dose requirement. Methods. Passive surveillance was used to collect data and identify incidence trends and changes in proportions, and these were assessed by chi(2) tests for trend and proportion, respectively. Results. Varicella incidence decreased from 13.8 cases/100 000 persons during 2009 to 5.1 cases/100 000 persons during 2014 (P < .001); significant declines in incidence occurred among children aged 1-4, 5-9, and 10-14 years (P < .01 for each age group). Cases classified as preventable decreased from 44% during 2009 to 25% during 2014 (P < .01); significant declines in percentages of preventable cases occurred only among those aged 5-9 years (P < .05) and 10-14 (P < .01) years. Conclusions. Varicella incidence continued to decline in Connecticut in the setting of the 2-dose school-entry program. Continued surveillance is needed to assess the full influence of the 2-dose recommendation. C1 [Mullins, Jocelyn] Ctr Dis Control & Prevent, Div Sci Educ & Profess Dev, Epidem Intelligence Serv, Atlanta, GA USA. [Mullins, Jocelyn; Kudish, Kathy; Sosa, Lynn] Connecticut Dept Publ Hlth, Hartford, CT 06134 USA. [Hadler, Jim] Connecticut Emerging Infect Program, Hartford, CT USA. RP Mullins, J (reprint author), Connecticut Dept Publ Hlth, Epidemiol & Emerging Infect Program, 410 Capitol Ave,MS 11FDS,POB 340308, Hartford, CT 06134 USA. EM jocelyn.mullins@ct.gov NR 18 TC 1 Z9 1 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 2328-8957 J9 OPEN FORUM INFECT DI JI Open Forum Infect. Dis. PD FAL PY 2015 VL 2 IS 4 DI 10.1093/ofid/ofv150 PG 6 WC Infectious Diseases SC Infectious Diseases GA CX6BY UT WOS:000365787400024 ER PT J AU Faiz, AS Khan, I Beckman, MG Bockenstedt, P Heit, JA Kulkarni, R Manco-Johnson, M Moll, S Ortel, TL Philipp, CS AF Faiz, Ambarina S. Khan, Imran Beckman, Michele G. Bockenstedt, Paula Heit, John A. Kulkarni, Roshni Manco-Johnson, Marilyn Moll, Stephan Ortel, Thomas L. Philipp, Claire S. TI Characteristics and Risk Factors of Cancer Associated Venous Thromboembolism SO THROMBOSIS RESEARCH LA English DT Article DE Cancer; Malignancy; Venous Thromboembolism; Pulmonary Embolism; Deep Vein Thrombosis; Thrombophilia ID DEEP-VEIN THROMBOSIS; PULMONARY-EMBOLISM; COMPLICATIONS; METAANALYSIS; PROPHYLAXIS; MANAGEMENT; FREQUENCY; MUTATION; DISEASE; SURGERY AB Introduction: The objective of this study was to examine the differences in commonly associated characteristics and risk factors of venous thromboembolism(VTE) between patients with and without cancer in a VTE population. Materials and Methods: Uniform data were collected for patients with a diagnosis of VTE obtaining care at CDC funded Thrombosis Network Centers. Patient characteristics and risk factors were compared in VTE patients with and without cancer. Logistic regression was used to calculate the unadjusted and adjusted odds ratios (ORs) and 95% confidence intervals (CIs) to assess patient characteristics and thrombotic risk factors more frequently identified among VTE patients with cancer compared to those without cancer. Results: Between August 2003 and April 2011, 3,115 adult patients with a diagnosis of VTE including 189 (6.1%) patients with active cancer participated in the multi-site thrombosis registry. VTE patients with cancer had a higher prevalence of PE and DVT in unusual sites compared to those without cancer. Thrombophilia was more common among VTE patients without cancer than those with cancer (25.1% vs 10.6%, p < 0.001). In adjusted analysis, age group >= 45 years (OR = 5.20, 95% CI, 3.30, 8.18), surgery (OR = 1.86, 95% CI, 1.19, 2.91), and hypertension (OR = 1.66, 95% CI, 1.15, 2.40) were the VTE risk factors more commonly found among VTE patients with cancer. Conclusion: The study identified several thrombotic risk factors more likely to be found with cancer associated VTE, which may help to characterize at risk cancer patients and to develop prevention and management strategies in this population. (C) 2015 Elsevier Ltd. All rights reserved. C1 [Faiz, Ambarina S.; Khan, Imran; Philipp, Claire S.] Rutgers Robert Wood Johnson Med Sch, Div Hematol, New Brunswick, NJ 08901 USA. [Beckman, Michele G.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Bockenstedt, Paula] Univ Michigan, Div Hematol Oncol, Ann Arbor, MI 48109 USA. [Heit, John A.] Mayo Clin, Div Cardiovasc Dis, Rochester, MN USA. [Kulkarni, Roshni] Michigan State Univ, Div Pediat, E Lansing, MI 48824 USA. [Manco-Johnson, Marilyn] Univ Colorado, Aurora, CO USA. [Manco-Johnson, Marilyn] Childrens Hosp, Aurora, CO USA. [Moll, Stephan] Univ N Carolina, Chapel Hill, NC USA. [Ortel, Thomas L.] Duke Univ, Med Ctr, Div Hematol, Durham, NC USA. RP Faiz, AS (reprint author), Rutgers Robert Wood Johnson Med Sch, MEB Room 378,51 French St, New Brunswick, NJ 08901 USA. EM faizas@rutgers.edu FU Centers for Disease Control and Prevention [DD000017, DD000235, DD000016, DD000292, DD000014, DD000015] FX This work was supported by grants from the Centers for Disease Control and Prevention (DD000017 to CP, DD000235 to JAH, DD000016 to MMJ, DD000292 to SM, DD000014 to TLO, and DD000015 to the Hemophilia Foundation of Michigan [PLB, RK]). NR 46 TC 1 Z9 2 U1 0 U2 1 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0049-3848 J9 THROMB RES JI Thromb. Res. PD SEP PY 2015 VL 136 IS 3 BP 535 EP 541 DI 10.1016/j.thromres.2015.06.036 PG 7 WC Hematology; Peripheral Vascular Disease SC Hematology; Cardiovascular System & Cardiology GA CX6GT UT WOS:000365799900008 PM 26168693 ER PT J AU Southern, TR Racsa, LD Albarino, CG Fey, PD Hinrichs, SH Murphy, CN Herrera, VL Sambol, AR Hill, CE Ryan, EL Kraft, CS Campbell, S Sealy, TK Schuh, A Ritchie, JC Lyon, GM Mehta, AK Varkey, JB Ribner, BS Brantly, KP Stroher, U Iwen, PC Burd, EM AF Southern, Timothy R. Racsa, Lori D. Albarino, Cesar G. Fey, Paul D. Hinrichs, Steven H. Murphy, Caitlin N. Herrera, Vicki L. Sambol, Anthony R. Hill, Charles E. Ryan, Emily L. Kraft, Colleen S. Campbell, Shelley Sealy, Tara K. Schuh, Amy Ritchie, James C. Lyon, G. Marshall, III Mehta, Aneesh K. Varkey, Jay B. Ribner, Bruce S. Brantly, Kent P. Stroeher, Ute Iwen, Peter C. Burd, Eileen M. TI Comparison of FilmArray and Quantitative Real-Time Reverse Transcriptase PCR for Detection of Zaire Ebolavirus from Contrived and Clinical Specimens SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID UNITED-STATES; VIRUS DISEASE AB Rapid, reliable, and easy-to-use diagnostic assays for detection of Zaire ebolavirus (ZEBOV) are urgently needed. The goal of this study was to examine the agreement among emergency use authorization (EUA) tests for the detection of ZEBOV nucleic acids, including the BioFire FilmArray BioThreat (BT) panel, the FilmArray BT-E panel, and the NP2 and VP40 quantitative real-time reverse transcriptase (qRT) PCR assays from the Centers for Disease Control and Prevention (CDC). Specimens used in this study included whole blood spiked with inactivated ZEBOV at known titers and whole-blood, plasma, and urine clinical specimens collected from persons diagnosed with Ebola virus disease (EVD). The agreement for FilmArray and qRT-PCR results using contrived whole-blood specimens was 100% (6/6 specimens) for each ZEBOV dilution from 4 x 10(7) to 4 x 10(2) 50% tissue culture infective dose (TCID50)/ml, as well as the no-virus negative-control sample. The limit of detection for FilmArray and qRT-PCR assays with inactivated ZEBOV, based on duplicate positive results, was determined to be 4 x 10(2) TCID50/ml. Rates of agreement between FilmArray and qRT-PCR results for clinical specimens from patients with EVD were 85% (23/27 specimens) for whole-blood specimens, 90% (18/20 specimens) for whole-blood specimens tested by FilmArray testing and matched plasma specimens tested by qRT-PCR testing, and 85% (11/13 specimens) for urine specimens. Among 60 specimens, eight discordant results were noted, with ZEBOV nucleic acids being detected only by FilmArray testing in four specimens and only by qRT-PCR testing in the remaining four specimens. These findings demonstrate that the rapid and easy-to-use FilmArray panels are effective tests for evaluating patients with EVD. C1 [Southern, Timothy R.; Fey, Paul D.; Hinrichs, Steven H.; Murphy, Caitlin N.; Iwen, Peter C.] Univ Nebraska Med Ctr, Dept Pathol & Microbiol, Omaha, NE USA. [Southern, Timothy R.; Murphy, Caitlin N.; Herrera, Vicki L.; Sambol, Anthony R.; Iwen, Peter C.] Nebraska Publ Hlth Lab, Omaha, NE USA. [Racsa, Lori D.; Hill, Charles E.; Ryan, Emily L.; Kraft, Colleen S.; Ritchie, James C.; Burd, Eileen M.] Emory Univ, Dept Pathol & Lab Med, Atlanta, GA 30322 USA. [Albarino, Cesar G.; Campbell, Shelley; Sealy, Tara K.; Schuh, Amy; Stroeher, Ute] Ctr Dis Control & Prevent, Atlanta, GA USA. [Kraft, Colleen S.; Lyon, G. Marshall, III; Mehta, Aneesh K.; Varkey, Jay B.; Ribner, Bruce S.; Burd, Eileen M.] Emory Univ, Sch Med, Dept Med, Div Infect Dis, Atlanta, GA USA. [Brantly, Kent P.] Samaritans Purse, Boone, NC USA. RP Burd, EM (reprint author), Emory Univ, Dept Pathol & Lab Med, Atlanta, GA 30322 USA. EM eburd@emory.edu RI Mehta, Aneesh/B-8054-2012 OI Mehta, Aneesh/0000-0002-6552-9162 FU BioFire FX P.D.F. previously received grant support from BioFire to support clinical validation studies of the FilmArray respiratory and gastrointestinal panels. NR 14 TC 11 Z9 12 U1 1 U2 3 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 EI 1098-660X J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD SEP PY 2015 VL 53 IS 9 BP 2956 EP 2960 DI 10.1128/JCM.01317-15 PG 5 WC Microbiology SC Microbiology GA CW6TE UT WOS:000365129900024 PM 26157148 ER PT J AU Petrone, BL Wolff, BJ DeLaney, AA Diaz, MH Winchell, JM AF Petrone, Brianna L. Wolff, Bernard J. DeLaney, Alexandra A. Diaz, Maureen H. Winchell, Jonas M. TI Isothermal Detection of Mycoplasma pneumoniae Directly from Respiratory Clinical Specimens SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID COMMUNITY-ACQUIRED PNEUMONIA; RAPID DETECTION; AMPLIFICATION ASSAY; DNA AMPLIFICATION; VISUAL DETECTION; CULTURE-MEDIUM; PCR ASSAY; DIAGNOSIS; INFECTION; CHILDREN AB Mycoplasma pneumoniae is a leading cause of community-acquired pneumonia (CAP) across patient populations of all ages. We have developed a loop-mediated isothermal amplification (LAMP) assay that enables rapid, low-cost detection of M. pneumoniae from nucleic acid extracts and directly from various respiratory specimen types. The assay implements calcein to facilitate simple visual readout of positive results in approximately 1 h, making it ideal for use in primary care facilities and resource-poor settings. The analytical sensitivity of the assay was determined to be 100 fg by testing serial dilutions of target DNA ranging from 1 ng to 1 fg per reaction, and no cross-reactivity was observed against 17 other Mycoplasma species, 27 common respiratory agents, or human DNA. We demonstrated the utility of this assay by testing nucleic acid extracts (n = 252) and unextracted respiratory specimens (n = 72) collected during M. pneumoniae outbreaks and sporadic cases occurring in the United States from February 2010 to January 2014. The sensitivity of the LAMP assay was 88.5% tested on extracted nucleic acid and 82.1% evaluated on unextracted clinical specimens compared to a validated real-time PCR test. Further optimization and improvements to this method may lead to the availability of a rapid, cost-efficient laboratory test for M. pneumoniae detection that is more widely available to primary care facilities, ultimately facilitating prompt detection and appropriate responses to potential M. pneumoniae outbreaks and clusters within the community. C1 [Petrone, Brianna L.; Wolff, Bernard J.; DeLaney, Alexandra A.; Diaz, Maureen H.; Winchell, Jonas M.] US Ctr Dis Control & Prevent, Pneumonia Response & Surveillance Lab, Resp Dis Branch, Div Bacterial Dis,Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30322 USA. RP Winchell, JM (reprint author), US Ctr Dis Control & Prevent, Pneumonia Response & Surveillance Lab, Resp Dis Branch, Div Bacterial Dis,Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30322 USA. EM zdx2@cdc.gov NR 37 TC 3 Z9 3 U1 2 U2 10 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 EI 1098-660X J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD SEP PY 2015 VL 53 IS 9 BP 2970 EP 2976 DI 10.1128/JCM.01431-15 PG 7 WC Microbiology SC Microbiology GA CW6TE UT WOS:000365129900026 PM 26179304 ER PT J AU Schafer, KR Shah, N Almira-Suarez, MI Reese, JM Hoke, GM Mandell, JW Roy, SL Visvesvara, G AF Schafer, Katherine R. Shah, Neil Almira-Suarez, M. I. Reese, Jennifer M. Hoke, George M. Mandell, James W. Roy, Sharon L. Visvesvara, Govinda TI Disseminated Balamuthia mandrillaris Infection SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID GRANULOMATOUS AMEBIC ENCEPHALITIS; FREE-LIVING AMEBAE; ORGAN-TRANSPLANTATION; PATIENT; BRAIN; MENINGOENCEPHALITIS; CYTOPATHOGENICITY; AGENT AB Balamuthia mandrillaris is a rare cause of human infection, but when infections do occur, they result in high rates of morbidity and mortality. A case of disseminated Balamuthia infection is presented. Early diagnosis and initiation of recommended therapy are essential for increased chances of successful outcomes. C1 [Schafer, Katherine R.] Wake Forest Univ Hlth Sci, Winston Salem, NC 27103 USA. [Shah, Neil] Univ N Carolina, Chapel Hill, NC USA. [Almira-Suarez, M. I.] George Washington Univ Hosp, Washington, DC USA. [Reese, Jennifer M.] Midatlantic Pathol Serv Inc, Sterling, VA USA. [Hoke, George M.; Mandell, James W.] Univ Virginia Hlth Sci, Charlottesville, VA USA. [Roy, Sharon L.; Visvesvara, Govinda] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Schafer, KR (reprint author), Wake Forest Univ Hlth Sci, Winston Salem, NC 27103 USA. EM kschafer@wakehealth.edu NR 17 TC 0 Z9 0 U1 0 U2 2 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 EI 1098-660X J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD SEP PY 2015 VL 53 IS 9 BP 3072 EP 3076 DI 10.1128/JCM.01549-15 PG 5 WC Microbiology SC Microbiology GA CW6TE UT WOS:000365129900045 PM 26135864 ER PT J AU Reidy, DE Kearns, MC Degue, S Lilienfeld, SO Massetti, G Kiehl, KA AF Reidy, Dennis E. Kearns, Megan C. Degue, Sarah Lilienfeld, Scott O. Massetti, Greta Kiehl, Kent A. TI Why psychopathy matters: Implications for public health and violence prevention SO AGGRESSION AND VIOLENT BEHAVIOR LA English DT Article DE Psychopathy; Callous-unemotional traits; Violence; Violence prevention; Public health; Primary prevention ID CALLOUS-UNEMOTIONAL TRAITS; ANTISOCIAL-BEHAVIOR; CONDUCT PROBLEMS; FOLLOW-UP; JUVENILE PSYCHOPATHY; ADOLESCENT OFFENDERS; FLEDGLING PSYCHOPATH; TEMPORAL STABILITY; PERSONALITY-TRAITS; COMMUNITY SAMPLE AB Psychopathy is an early-appearing risk factor for severe and chronic violence. The violence largely attributable to psychopathy constitutes a substantial portion of the societal burden to the public health and criminal justice systems, and thus necessitates significant attention from prevention experts. Yet, despite a vast base of research in psychology and criminology, the public health approach to violence has generally neglected to consider this key variable. Fundamentally, the public health approach to violence prevention is focused on achieving change at the population level to provide the most benefit to the maximum number of people. Increasing attention to the individual-level factor of psychopathy in public health could improve our ability to reduce violence at the community and societal levels. We conclude that the research literature on psychopathy points to a pressing need for a broad-based public health approach with a focus on primary prevention. Further, we consider how measuring psychopathy in public health research may benefit violence prevention, and ultimately society, in general. Published by Elsevier Ltd. C1 [Reidy, Dennis E.; Kearns, Megan C.; Degue, Sarah; Massetti, Greta] Ctr Dis Control & Prevent, Div Violence Prevent, Atlanta, GA 30322 USA. [Lilienfeld, Scott O.] Emory Univ, Atlanta, GA 30322 USA. [Kiehl, Kent A.] Univ New Mexico, Albuquerque, NM 87131 USA. [Kiehl, Kent A.] Mind Res Network Nonprofit, Albuquerque, NM USA. RP Reidy, DE (reprint author), Ctr Dis Control & Prevent, Div Violence Prevent, Atlanta, GA 30322 USA. EM dreidy@cdc.gov OI Massetti, Greta/0000-0002-3813-9839 NR 154 TC 1 Z9 1 U1 5 U2 24 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 1359-1789 EI 1873-6335 J9 AGGRESS VIOLENT BEH JI Aggress. Violent Behav. PD SEP-OCT PY 2015 VL 24 BP 214 EP 225 DI 10.1016/j.avb.2015.05.018 PG 12 WC Criminology & Penology; Psychology, Multidisciplinary SC Criminology & Penology; Psychology GA CW3HJ UT WOS:000364882300015 ER PT J AU Huang, JD King, BA Babb, SD Xu, X Hallett, C Hopkins, M AF Huang, Jidong King, Brian A. Babb, Stephen D. Xu, Xin Hallett, Cynthia Hopkins, Maggie TI Sociodemographic Disparities in Local Smoke-Free Law Coverage in 10 States SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID MULTIUNIT HOUSING RESIDENTS; UNITED-STATES; HEALTH PROTECTION; SECONDHAND SMOKE; MASSACHUSETTS; REGULATIONS; POLICIES AB Objectives. We assessed sociodemographic disparities in local 100% smoke-free laws prohibiting smoking in all indoor areas of nonhospitality worksites, restaurants, and bars in 10 states. Methods. We obtained data on local 100% smoke-free laws (US Tobacco Control Laws Database) and subcounty characteristics (2006-2010 American Community Survey) for Alabama, Alaska, Indiana, Kentucky, Mississippi, Missouri, North Dakota, South Carolina, Texas, and West Virginia. Outcomes included (1) 100% smoke-free law covering restaurants, bars, and workplaces; (2) 100% smoke-free law covering restaurants, bars, or workplaces; and (3) number of venue types covered by 100% smoke-free laws (0-3). Sociodemographics included total population, urban status, percentage racial/ethnic minority, per capita income, percentage with high-school diploma, percentage with blue-collar jobs, and percentage of workers who live and work in the same locality. Results. Across states, localities with less-educated residents, smaller proportions of workers living and working in the same locality, or both generally had lower odds of being covered by 100% smoke-free laws. Coverage varied across states for other sociodemographics. Conclusions. Disparities exist in local smoke-free law coverage. Identifying patterns in coverage can inform state efforts to address related disparities. C1 [Huang, Jidong] Univ Illinois, Inst Hlth Res & Policy, Chicago, IL USA. [King, Brian A.; Babb, Stephen D.; Xu, Xin] Ctr Dis Control & Prevent, Off Smoking & Hlth, Atlanta, GA 30341 USA. [Hallett, Cynthia; Hopkins, Maggie] Amer Nonsmokers Rights Fdn, Berkeley, CA USA. RP King, BA (reprint author), Ctr Dis Control & Prevent, Off Smoking & Hlth, 4770 Buford Highway NE,MS F79, Atlanta, GA 30341 USA. EM baking@cdc.gov NR 25 TC 3 Z9 3 U1 1 U2 1 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 EI 1541-0048 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD SEP PY 2015 VL 105 IS 9 BP 1806 EP 1813 DI 10.2105/AJPH.2015.302655 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CV5PG UT WOS:000364322600036 PM 26180972 ER PT J AU Hirshfield, S Schrimshaw, EW Stall, RD Margolis, AD Downing, MJ Chiasson, MA AF Hirshfield, Sabina Schrimshaw, Eric W. Stall, Ronald D. Margolis, Andrew D. Downing, Martin J., Jr. Chiasson, Mary Ann TI Drug Use, Sexual Risk, and Syndemic Production Among Men Who Have Sex With Men Who Engage in Group Sexual Encounters SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID PSYCHOSOCIAL HEALTH-PROBLEMS; HIV RISK; GAY MEN; NATIONAL ONLINE; UNITED-STATES; BISEXUAL MEN; PARTIES; MSM; INFECTION; ASSOCIATION AB Objectives. We surveyed men who have sex with men (MSM) to determine whether sexual risk behaviors, recent drug use, and other psychosocial problems differed between men who engaged in one-on-one and group sexual encounters. Methods. We conducted an Internet-based cross-sectional survey of 7158 MSM aged 18 years or older in the United States recruited from a gay-oriented sexual networking Web site in 2008. Among MSM who engaged in group sexual encounters, we compared their past-60-day sexual behaviors in one-on-one encounters and group sexual encounters. We also compared risk profiles and syndemic production between men who did and did not participate in group sex. Results. Men reporting a group-sex encounter had significantly higher poly-drug use and sexual risk than did the men not reporting group sex in the past 60 days. The odds of engaging in group sex with 4 or more sexual partners significantly increased with the number of psychosocial problems, supporting evidence of syndemic production. Conclusions. We identified a particularly high-risk subgroup in the MSM population with considerable psychosocial problems that may be reached online. Research is needed on how to engage these high-risk men in combination prevention interventions. C1 [Hirshfield, Sabina; Downing, Martin J., Jr.; Chiasson, Mary Ann] Publ Hlth Solut, New York, NY 10013 USA. [Schrimshaw, Eric W.] Columbia Univ, Mailman Sch Publ Hlth, Dept Sociomed Sci, New York, NY USA. [Stall, Ronald D.] Univ Pittsburgh, Sch Publ Hlth, Dept Behav & Community Hlth Sci, Pittsburgh, PA 15260 USA. [Margolis, Andrew D.] Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Div HIV AIDS Prevent, Prevent Res Branch, Atlanta, GA USA. RP Hirshfield, S (reprint author), Publ Hlth Solut, 40 Worth St,5th Floor, New York, NY 10013 USA. EM shirshfield@healthsolutions.org FU NCHHSTP CDC HHS [UR6 PS000415] NR 43 TC 5 Z9 5 U1 5 U2 6 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 EI 1541-0048 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD SEP PY 2015 VL 105 IS 9 BP 1849 EP 1858 DI 10.2105/AJPH.2014.302346 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CV5PG UT WOS:000364322600041 PM 25713951 ER EF